<SEC-DOCUMENT>0000950123-11-076776.txt : 20110812
<SEC-HEADER>0000950123-11-076776.hdr.sgml : 20110812
<ACCEPTANCE-DATETIME>20110812152456
ACCESSION NUMBER:		0000950123-11-076776
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20110630
FILED AS OF DATE:		20110812
DATE AS OF CHANGE:		20110812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		111031110

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>c17919e10vq.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 10-Q</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 10pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 10pt"><B>FORM 10-Q</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>(Mark One)</B>
</DIV>


<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%" style="font-size: 12pt">
<TR style="font-size: 10pt">
    <TD width="7%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="88%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center"><FONT style="font-family: Wingdings">&#254;</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD>
</TR>
</TABLE>
</DIV>


<!-- xbrl,dc -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 12%"><B>For the quarterly period ended June&nbsp;30, 2011</B></DIV>
<!-- /xbrl,dc -->

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>OR</B></DIV>


<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%" style="font-size: 12pt">
<TR style="font-size: 10pt">
    <TD width="7%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="88%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center"><FONT style="font-family: Wingdings">&#111;</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD>
</TR>
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Commission files number 0-50626</B>
</DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>91-1707622</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or Other Jurisdiction
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(I.R.S. Employer</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">of Incorporation or Organization)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>200 Connell Drive, Suite&nbsp;1500</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>Berkeley Heights, New Jersey</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>07922</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(Address of principal executive offices)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 10pt">Registrant&#146;s telephone number, including area code: (<B>908) 517-7330</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by
Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&nbsp;months (or for
such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been
subject to such filing requirements for the past 90&nbsp;days. Yes <FONT style="font-family: Wingdings">&#254;</FONT> No <FONT style="font-family: Wingdings">&#111;</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Indicate by check mark whether the registrant has submitted electronically and posted on its
corporate Web site, if any, every Interactive Data File required to be submitted and posted
pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T (&#167;232.405 of this chapter) during the preceding 12&nbsp;months
(or for such shorter period that the registrant was required to submit and post such files).
Yes <FONT style="font-family: Wingdings">&#254;</FONT> No <FONT style="font-family: Wingdings">&#111;</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer, or a smaller reporting company. See definitions of &#147;large accelerated
filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule&nbsp;12b-2 of the Exchange Act.
</DIV>



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="22%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
<TD width="22%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
</TR>
<!-- End Table Head -->

<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">Large accelerated filer <FONT face="Wingdings">&#111;</FONT></TD>   <TD>&nbsp;</TD>
    <TD align="center" valign="top">Accelerated filer <FONT face="Wingdings">&#111;</FONT></TD><TD>&nbsp;</TD>
    <TD align="center" valign="top">Non-accelerated filer <FONT face="Wingdings">&#111;</FONT></TD><TD>&nbsp;</TD>
    <TD align="right" valign="top"  NOWRAP>Smaller reporting filer <FONT face="Wingdings">&#254;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" nowrap>(Do not check if a smaller
reporting company)</TD>
    <TD>&nbsp;</TD>
<TD align="right" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE></DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Indicate by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2 of the
Exchange Act). Yes <FONT style="font-family: Wingdings">&#111;</FONT> No <FONT style="font-family: Wingdings">&#254;</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">As of August&nbsp;12, 2011 there were 54,224,093 shares of the registrant&#146;s common stock outstanding.
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>






<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="left">
<!-- TOC -->
</DIV>
<DIV align="left">
<A name="C17919tocpage"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 10pt"><B>INDEX</B>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="86%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">Page</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#C17919101">Part I. Financial Information</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#C17919102">Item&nbsp;1. Financial Statements (Unaudited)</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#C17919103">Item&nbsp;2. Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#C17919104">Item&nbsp;3. Quantitative and Qualitative Disclosures About Market Risk</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">41</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#C17919105">Item&nbsp;4. Controls and Procedures</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">42</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#C17919106">Part II. Other Information</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#C17919107">Item&nbsp;1. Legal Proceedings</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">44</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#C17919108">Item&nbsp;1A. Risk Factors</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">44</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#C17919109">Item&nbsp;2. Unregistered Sales of Equity Securities and Use of Proceeds</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">69</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#C17919110">Item&nbsp;3. Defaults upon Senior Securities</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">69</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#C17919111">Item&nbsp;4. (Removed and Reserved)</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">69</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#C17919112">Item&nbsp;5. Other Information</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">69</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#C17919113">Item&nbsp;6. Exhibits</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">69</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#C17919114">SIGNATURE PAGE</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="c17919exv10w1.htm">Exhibit 10.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="c17919exv10w2.htm">Exhibit 10.2</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="c17919exv31w1.htm">Exhibit 31.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="c17919exv31w2.htm">Exhibit 31.2</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="c17919exv32w1.htm">Exhibit 32.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="c17919exv32w2.htm">Exhibit 32.2</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="cycc-20110630.xml">EX-101 INSTANCE DOCUMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="cycc-20110630.xsd">EX-101 SCHEMA DOCUMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="cycc-20110630_cal.xml">EX-101 CALCULATION LINKBASE DOCUMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="cycc-20110630_lab.xml">EX-101 LABELS LINKBASE DOCUMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="cycc-20110630_pre.xml">EX-101 PRESENTATION LINKBASE DOCUMENT</A></FONT></TD></TR>
</TABLE>
</DIV>
<DIV align="left">
<!-- /TOC -->
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="left">
<A name="C17919101"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>PART I. FINANCIAL INFORMATION</B>
</DIV>

<DIV align="left">
<A name="C17919102"></A>
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;1.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Financial Statements.</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.<BR>
(A Development Stage Company)<BR>
<!-- xbrl,bs -->
CONDENSED CONSOLIDATED BALANCE SHEETS<BR>
<!-- xbrl,body -->
(In $000s, except share amounts)</B>
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>December 31,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>(Unaudited)</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>ASSETS</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Current assets:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">29,495</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">20,614</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Inventory</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">174</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">147</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Prepaid expenses and other current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,382</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,688</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><B>Total current assets</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31,051</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22,449</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Property, plant and equipment (net)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">408</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">246</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Total assets</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">31,459</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">22,695</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>LIABILITIES AND STOCKHOLDERS&#146; EQUITY</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Current liabilities:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accounts payable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,723</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,104</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accrued liabilities and other current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,132</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,459</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Warrant liability</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">680</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">477</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><B>Total current liabilities</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,535</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,040</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Total liabilities</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,535</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,040</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Stockholders&#146; equity:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Preferred stock, $0.001 par value; 5,000,000 shares
authorized at December&nbsp;31, 2010 and June&nbsp;30, 2011;
1,213,142 shares issued and outstanding at December
31, 2010 and June&nbsp;30, 2011. Aggregate preference in
liquidation (including undeclared cumulative
dividends) of $13,344,562 at December&nbsp;31, 2010 and
June&nbsp;30, 2011</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Common stock, $0.001 par value; 100,000,000 shares
authorized at December&nbsp;31, 2010 and June&nbsp;30, 2011;
46,564,914 and 46,587,182 shares issued and
outstanding at December&nbsp;31, 2010 and June&nbsp;30, 2011,
respectively</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Additional paid-in capital</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">266,666</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">266,529</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Accumulated other comprehensive loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Deficit accumulated during the development stage</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(241,821</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(249,961</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><B>Total stockholders&#146; equity</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24,924</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16,655</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Total liabilities and stockholders&#146; equity</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">31,459</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">22,695</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 10pt">The accompanying notes are an integral part of these consolidated financial statements.
</DIV>
<!-- /xbrl,bs -->

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.<BR>
(A Development Stage Company)<BR>
<!-- xbrl,op -->
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS<BR>
<!-- xbrl,body -->
(In $000s, except share and per share amounts)<BR>
(Unaudited)</B>
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Period from</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>August 13, 1996</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Six Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>(inception) to</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Revenues:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Collaboration and research and
development revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,100</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Product revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">168</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">273</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">360</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,682</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Grant revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,648</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">119</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">168</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">389</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">360</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,430</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Operating expenses</B>:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Cost of goods sold</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">92</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">72</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">234</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">178</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,570</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,322</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,859</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,497</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,939</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">181,532</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Selling, general and administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,091</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,034</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,491</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,840</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">85,806</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Goodwill and intangible impairment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,934</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Restructuring costs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,634</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Total operating expenses</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,505</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,965</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,222</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,957</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">279,476</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(4,386</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,797</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(8,833</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(8,597</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(270,046</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other income (expense):</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>

<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Costs associated with aborted 2004 IPO</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,550</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Payment under guarantee</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,652</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Change in valuation of derivative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(308</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Change in valuation of warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">273</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">125</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(516</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">203</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,273</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Warrant re-pricing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(44</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Foreign exchange (losses)/gains</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(49</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(19</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(38</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(87</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(4,342</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Interest income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13,704</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Interest expense</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(9</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(33</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(4,677</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total other income (expense)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">223</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">119</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(570</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">140</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,404</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Loss before taxes</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(4,163</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,678</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(9,403</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(8,457</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(264,642</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Income tax benefit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">230</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">126</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">363</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">317</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18,196</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Net loss</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,933</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,552</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(9,040</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(8,140</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(246,446</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Dividends on preferred ordinary shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(38,123</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Deemed dividend on convertible
exchangeable preferred shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2,496</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2,915</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,515</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Dividend on convertible exchangeable
preferred shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(114</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(182</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(403</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(364</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,293</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Net loss applicable to common shareholders</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(6,543</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(3,734</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(12,358</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(8,504</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(291,377</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss per share &#151; Basic and diluted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.18</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.08</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.36</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.18</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Weighted average common shares outstanding</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>36,565,972</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>46,582,915</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>34,157,279</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>46,577,577</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 10pt">The accompanying notes are an integral part of these consolidated financial statements.
</DIV>
<!-- /xbrl,op -->

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.<BR>
(A Development Stage Company)<BR>
<!-- xbrl,cf -->
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS<BR>
<!-- xbrl,body -->
(In $000s)<BR>
(Unaudited)</B>
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="58%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Period from</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>August 13,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>1996</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>(inception)</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Six Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>to</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Cash flows from operating activities:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(9,040</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(8,140</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(246,446</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Adjustments to reconcile net loss to net cash used in
operating activities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accretion of interest on notes payable, net of
amortization of debt premium </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Amortization of investment premiums, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2,297</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Change in valuation of derivative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">308</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Change in valuation of warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">516</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(203</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(6,273</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Warrant re-pricing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">44</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Depreciation and amortization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">240</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">172</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,486</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Amortization of intangible assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">886</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Fixed asset impairment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">221</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Goodwill and intangibles impairment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,934</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Unrealized foreign exchange loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,768</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Deferred revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(98</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Compensation for warrants issued to non-employees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,215</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Shares issued for IP rights</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">446</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">(Gain) loss on disposal of property, plant and equipment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(9</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">99</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Stock based compensation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">786</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">455</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18,596</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Provision for restructuring</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,779</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Amortization of issuance costs of Preferred Ordinary
&#147;C&#148; shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,517</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Changes in operating assets and liabilities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Prepaid expenses, inventory and other current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(88</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(279</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(511</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Accounts payable, accrued liabilities and other
current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2,183</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(482</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(6,372</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Net cash used in operating activities</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(9,776</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(8,456</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(207,598</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Investing activities:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Purchase of ALIGN </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,763</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Purchase of property, plant and equipment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(8</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(8,831</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Proceeds from sale of property, plant and equipment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">35</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">158</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Purchase of short-term investments </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(156,657</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Redemptions of short-term investments, net of maturities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">162,729</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net cash provided by (used in) investing activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(6,364</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Financing activities:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Payment of capital lease obligations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,719</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Proceeds from issuance of ordinary and preferred ordinary
shares, net of issuance costs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">121,678</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Proceeds from issuance of common stock and warrants, net
of issuance costs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,155</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(80</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">82,324</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net proceeds from stock options and warrants exercised</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,700</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">173</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<!-- /xbrl,cf -->

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.<BR>
(A Development Stage Company)<BR>

<!-- xbrl,cf -->
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS<BR>
<!-- xbrl,body -->
(In $000s)<BR>
(Unaudited)</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="58%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Period from</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>August 13,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>1996</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>(inception)</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Six Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>to</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Payment of preferred stock dividend</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(364</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,898</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Repayment of government loan</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(455</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Government loan received</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">414</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Loan received from Cyclacel Group Plc</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,103</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Proceeds of committable loan notes issued from shareholders</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,883</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Loans received from shareholders</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,645</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash and cash equivalents assumed on stock purchase</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17,915</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Costs associated with stock purchase</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,951</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net cash provided by (used in) financing activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17,855</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(441</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">234,112</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Effect of exchange rate changes on cash and cash
equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(56</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">464</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net increase (decrease)&nbsp;in cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,050</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(8,881</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20,614</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash and cash equivalents at beginning of period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,493</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29,495</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Cash and cash equivalents at end of period</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">19,543</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">20,614</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">20,614</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Supplemental disclosure of cash flows information:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash received during the period for:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Interest</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,726</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">110</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17,522</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash paid during the period for:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Interest</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(187</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,914</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Schedule of non-cash transactions:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Acquisitions of equipment purchased through capital
leases</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,470</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Issuance of common shares in connection with license
agreements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">592</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Issuance of ordinary shares on conversion of bridging
loan</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,638</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Issuance of preferred ordinary &#147;C&#148; shares on conversion
of
secured convertible loan notes and accrued interest</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,893</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Issuance of ordinary shares in lieu of cash bonus</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">164</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Issuance of other long term payable on ALIGN acquisition</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,122</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 10pt">The accompanying notes are an integral part of these consolidated financial statements.
</DIV>
<!-- /xbrl,cf -->



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>
<!-- xbrl,ns -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B>
</DIV>


<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Nature of Operations</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Cyclacel Pharmaceuticals, Inc. (''Cyclacel&#146;&#146; or the ''Company&#146;&#146;) is a development-stage
biopharmaceutical company dedicated to the development and commercialization of novel,
mechanism-targeted drugs to treat human cancers and other serious diseases. Cyclacel&#146;s strategy is
to build a diversified biopharmaceutical business focused in hematology and oncology based on a
portfolio of commercial products and a development pipeline of novel drug candidates.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Cyclacel&#146;s clinical development priorities are focused on sapacitabine in the following
indications:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Acute myeloid leukemia, or AML, in the elderly;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Myelodysplastic syndromes, or MDS; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Non-small cell lung cancer, or NSCLC.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On January&nbsp;11, 2011, the Company opened enrollment of the SEAMLESS pivotal Phase 3 trial for
the Company&#146;s sapacitabine oral capsules as a front-line treatment of elderly patients aged 70
years or older with newly diagnosed AML who are not candidates for intensive induction chemotherapy
under a Special Protocol Assessment, or SPA, reached with the U.S. Food &#038; Drug Administration, or
FDA.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company has advanced two additional product candidates, seliciclib in Phase 2 for NSCLC
and nasopharyngeal cancer or NPC, and CYC116 in Phase 1 clinical development. The combination of
sapacitabine with seliciclib is also being evaluated in a Phase 1 clinical trial. The Company will
determine the feasibility of pursuing further development and/or partnering these assets depending
on the availability of funding and further clinical data. In addition, the Company markets directly
in the United States Xclair<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Cream for radiation dermatitis and Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Liquid and Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>
Lozenges for xerostomia.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As a development stage enterprise, substantially all efforts of the Company to date have been
devoted to performing research and development, conducting clinical trials, developing and
acquiring intellectual property and raising capital.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Basis of Presentation</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The condensed consolidated balance sheet as of June&nbsp;30, 2011, the condensed consolidated
statements of operations for the three and six months ended June&nbsp;30, 2011 and 2010 and the
condensed consolidated statements of cash flows for the six months ended June&nbsp;30, 2011 and 2010,
and related disclosures contained in the accompanying notes are unaudited. The condensed
consolidated balance sheet as of December&nbsp;31, 2010 is derived from the audited consolidated
financial statements included in the Annual Report on Form 10-K for the year ended December&nbsp;31,
2010 filed with the Securities and Exchange Commission (&#147;SEC&#148;). The condensed consolidated
financial statements are presented on the basis of accounting principles that are generally
accepted in the United States (&#147;GAAP&#148;) for interim financial information and in accordance with the
rules and regulations of the SEC; accordingly, they do not include all the information and
footnotes required by accounting principles generally accepted in the United States for a complete
set of financial statements. In the opinion of management, all adjustments, which include only
normal recurring adjustments, necessary to present fairly the condensed consolidated balance sheet
as of June&nbsp;30, 2011, the results of operations for the three and six months ended June&nbsp;30, 2011 and
2010 and the consolidated statements of cash flows for the six months ended June&nbsp;30, 2011 and 2010
have been made. The interim results for the three and six months ended June&nbsp;30, 2011 are not
necessarily indicative of the results to be expected for the year ending December&nbsp;31, 2011 or for
any other year. The condensed consolidated financial statements should be read in conjunction with
the audited consolidated financial statements and the
accompanying notes included in the Company&#146;s Annual Report on Form 10-K for the year ended
December&nbsp;31, 2010 filed with the SEC.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Subsequent Developments</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Preferred Stock Dividend</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On July&nbsp;8, 2011, the Board of Directors (the &#147;Board&#148;) decided not to declare the quarterly
cash dividend on the Company&#146;s 6% Convertible Exchangeable Preferred Stock (&#147;Preferred Stock&#148;) with
respect to the second quarter of 2011 that would have otherwise been payable on August&nbsp;1, 2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Board also did not declare the quarterly cash dividend with respect to each of the four
quarters of fiscal year 2009 and the first, second and third quarters of 2010. To the extent that
any dividends payable on the Preferred Stock are not paid, such unpaid dividends are added to the
liquidity preference of the Preferred Stock. As the Company failed to pay in an aggregate amount
equal to at least six quarterly dividends (whether or not consecutive) on the Preferred Stock, the
size of the Company&#146;s Board was increased by two members and the holders of the Preferred Stock,
voting separately as a class, voted on May&nbsp;24, 2011 and elected two directors to fill the vacancies
created thereby, which directorships shall terminate when the Company pays all accrued but unpaid
dividends.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>License Agreement</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On July&nbsp;11, 2011, the Company entered into an amendment to its license agreement with Daiichi
Sankyo Company, Limited (&#147;Daiichi Sankyo&#148;), dated September&nbsp;10, 2003, relating to certain rights
which the Company has licensed from Daiichi Sankyo with regard to the Company&#146;s sapacitabine drug.
Effective July&nbsp;11, 2011, the license agreement was amended to irrevocably waive a termination right
Daiichi Sankyo possessed under a provision of the agreement that required the Company to obtain
regulatory approval to sell sapacitabine in at least one country by September&nbsp;2011, and releases
the Company from all claims and liability of any kind arising under such provision. The amendment
further provides that the royalty due from the Company to Daiichi Sankyo on future net sales of
sapacitabine be increased by a percentage between 1.25% and 1.50% depending on the level of net
sales of sapacitabine realized.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Financing</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On July&nbsp;7, 2011, the Company closed an underwritten offering for an aggregate of 7,617,646
units, at an offering price of $1.36 per unit, for gross proceeds of approximately $10.4&nbsp;million.
Each unit consists of (i)&nbsp;one share of common stock and (ii)&nbsp;a five-year warrant to purchase 0.5 of
a share of common stock at an exercise price of $1.36 per share, exercisable beginning six months
after the date of issuance. The shares of common stock and warrants were immediately separable and
were issued separately such that no units were issued. The net proceeds, after underwriting
discounts and commissions and other fees and expenses payable by the Company, were approximately
$9.3&nbsp;million.
</DIV>

<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Consolidation</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The accompanying condensed consolidated financial statements include the accounts of the
Company and its wholly-owned subsidiaries for the indicated periods. All significant intercompany
transactions and balances have been eliminated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Use of Estimates</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The preparation of financial statements in accordance with GAAP requires management to make
estimates and assumptions that affect the reported amounts of assets, liabilities and related
disclosures of contingent assets and liabilities at the date of the financial statements and the
reported amounts of income and expenses during the reporting period. The Company reviews its
estimates on an ongoing basis. The estimates are based on historical experience and on various
other assumptions that the Company believes to be reasonable under the circumstances. Actual
results may differ from these estimates.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Cash and Cash Equivalents</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Cash and cash equivalents are stated at cost, which is substantially the same as fair value.
The Company considers all highly liquid investments with an original maturity of three months or
less at the time of purchase to be cash equivalents. The Company&#146;s cash equivalents generally
include investments in money market funds and corporate commercial paper.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Trade Accounts Receivable and Allowance for Doubtful Accounts</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">An allowance for doubtful accounts is provided, as necessary, on trade receivables based on
their respective aging categories and historical collection experience, taking into consideration
the type of payer, historical and projected collection outcomes, and current economic and business
conditions that could affect the collectability of the Company&#146;s receivables. The allowance for
doubtful accounts is reviewed, at a minimum, on a quarterly basis. Changes in the allowance for
doubtful accounts are recorded as an adjustment to bad debt expense within general and
administrative expenses. Material revisions to reserve estimates may result from adverse changes in
collection experience. The Company writes off accounts against the allowance for doubtful accounts
when reasonable collection efforts have been unsuccessful and it is likely the receivable will not
be recovered. At December&nbsp;31, 2010 and June&nbsp;30, 2011, all receivables were deemed collectible.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">For the three months ended June&nbsp;30, 2010 and 2011, approximately 87% and 92%, respectively, of
the Company&#146;s product sales in the United States were to three wholesalers. For the six months
ended June&nbsp;30, 2010 and 2011, approximately 83% and 91%, respectively, of the Company&#146;s product
sales in the United States were to three wholesalers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Inventory</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Cyclacel values inventories at the lower of cost or market value. The Company determines cost
using the first-in, first-out method. As of December&nbsp;31, 2010 and June&nbsp;30, 2011, all inventories
were classified as finished goods. The Company analyzes its inventory levels at least quarterly to
identify any items that may expire prior to sale, inventory that has a cost basis in excess of net
realizable value, or inventory in excess of expected sales requirements. The determination of
whether or not inventory costs will be realizable requires estimates by the Company&#146;s management.
A critical input is future sales forecasts. The Company writes down the value of inventory to the
extent that inventory is expected to expire before being sold or if the cost basis is in excess of net realizable value. If actual market conditions are less
favorable than those projected by management, additional inventory write-downs may be required in
future periods.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Revenue Recognition</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Product sales</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company recognizes revenue from product sales when persuasive evidence of an arrangement
exists; delivery has occurred or services have been rendered; the selling price is fixed or
determinable; and collectability is reasonably assured.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The Company offers a general right of return on these product sales, and has considered the
guidance in ASC 605-15, &#147;<I>Revenue Recognition -Products</I>&#148; (&#147;ASC 605-15&#148;) and ASC 605 -10 &#147;<I>Revenue
Recognition &#151; Overall</I>&#148; (&#147;ASC 605-10&#148;). Under these guidelines, the Company accounts for all product
sales using the &#147;sell-through&#148; method. Under the sell-through method, revenue is not recognized
upon shipment of product to distributors. Instead, the Company records deferred revenue at gross
invoice sales price and deferred cost of sales at the cost at which those goods were held in
inventory. The Company recognizes revenue when such inventory is sold through to pharmacies. To
estimate product sold through to pharmacies, the Company relies on third-party information,
including information obtained from significant distributors with respect to their inventory levels
and sell-through to pharmacies. The Company estimates product returns based on historical returns
experience and other factors that affect demand for the Company&#146;s products as well as the amount of
product subject to return.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 8%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Deferred revenue was $0.1&nbsp;million at June&nbsp;30, 2010 and 2011. Deferred cost of goods sold was
approximately $58,000 and $11,000&nbsp;million at June&nbsp;30, 2010 and 2011, respectively.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Collaboration, research and development, and grant revenue</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Certain of the Company&#146;s revenues are earned from collaborative agreements. The Company
recognizes revenue when persuasive evidence of an arrangement exists; delivery has occurred or
services have been rendered; the fee is fixed or determinable; and collectability is reasonably
assured. Determination of whether these criteria have been met is based on management&#146;s judgments
regarding the nature of the research performed, the substance of the milestones met relative to
those the Company must still perform, and the collectability of any related fees. Should changes in
conditions cause management to determine these criteria are not met for certain future
transactions, revenue recognized for any reporting period could be adversely affected.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Research and development revenues, which are earned under agreements with third parties for
contract research and development activities, are recorded as the related services are performed.
Milestone payments are non-refundable and recognized as revenue when earned, as evidenced by
achievement of the specified milestones and the absence of ongoing performance obligations. Any
amounts received in advance of performance are recorded as deferred revenue. None of the revenues
recognized to date are refundable if the relevant research effort is not successful.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Grant revenues from government agencies and private research foundations are recognized as the
related qualified research and development costs are incurred, up to the limit of the prior
approval funding amounts. All grants received are not refundable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Clinical Trial Accounting</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Data management and monitoring of all of the Company&#146;s clinical trials are performed by
contract research organizations (''CROs&#146;&#146;) or clinical research associates (''CRAs&#146;&#146;) in accordance
with the Company&#146;s standard operating procedures. Typically, CROs and some CRAs bill monthly for
services performed, and others bill based upon milestones achieved. The Company accrues unbilled clinical trial expenses based on estimates of the level of services
performed each period. Costs of setting up investigational sites for participation in the Company&#146;s
clinical trials are expensed immediately as research and development expenses. Clinical trial site
costs related to patient enrollment are accrued as patients are entered into the trial. Any initial
payment made to the clinical trial site is recognized upon execution of the clinical trial
agreements and expensed as research and development expenses.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Research and Development Expenditures</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Research and development expenses consist primarily of costs associated with the Company&#146;s
product candidates, upfront fees, milestones, compensation and other expenses for research and
development personnel, supplies and development materials, costs for consultants and related
contract research, facility costs, amortization of purchased technology and depreciation.
Expenditures relating to research and development are expensed as incurred.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Foreign currency and currency translation</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Transactions that are denominated in a foreign currency are re-measured into the functional
currency at the current exchange rate on the date of the transaction. Any foreign
currency-denominated monetary assets and liabilities are subsequently re-measured at current
exchange rates, with gains or losses recognized as foreign exchange (losses)/gains in the statement
of operations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The assets and liabilities of the Company&#146;s international subsidiary are translated from its
functional currency into United States dollars at exchange rates prevailing at the balance sheet
date. Average rates of exchange during the period are used to translate the statement of
operations, while historical rates of exchange are used to translate any equity transactions.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Translation adjustments arising on consolidation due to differences between average rates and
balance sheet rates, as well as unrealized foreign exchange gains or losses arising from
translation of intercompany loans that are of a long-term-investment nature, are recorded in other
comprehensive income.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Derivative Instruments</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Derivative financial instruments are measured at fair value. Significant judgments and
estimates are necessary in determining the fair value in the absence of quoted market values. These
estimates are based on valuation methodologies and assumptions deemed appropriate in the
circumstances. The use of different assumptions may have a material effect on the estimated fair
value amount and the Company&#146;s results of operations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Fair Value Measurements</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Inputs used to determine fair value of financial and non-financial assets and liabilities are
categorized using a fair value hierarchy that prioritizes observable and unobservable inputs into
three broad levels, from Level 1, which is the most reliable, to Level 3, which is the least
reliable (see &#147;Note 3 &#151; Fair Value Measurements&#148;). Management reviews the categorization of fair
value inputs on a periodic basis and may determine that it is necessary to transfer an input from
one level of the fair value hierarchy to another based on changes in events or circumstances, such
as a change in the observability of an input. Any such transfer will be recognized at the end of
the reporting period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Income Taxes</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company accounts for income taxes under the liability method. Under this method, deferred
tax assets and liabilities are determined based on the difference between the financial statement
and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the
differences are expected to affect taxable income. Valuation allowances are established when
necessary to reduce deferred tax assets to the amounts expected to be realized. The Company&#146;s
management has established a full valuation allowance against its deferred tax assets based on the
determination that it is not more likely than not that the Company will recognize the benefits of
those assets.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company adopted the guidance related to accounting for uncertainty in income taxes,
primarily codified in ASC 740, <I>&#147;Income taxes&#148; </I>(&#147;ASC 740&#148;). ASC 740 specifies the accounting for
uncertainty in income taxes recognized in a company&#146;s financial statements by prescribing a minimum
probability threshold a tax position is required to meet before being recognized in the financial
statements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company records income tax benefits related to research and development tax credits, which
will be claimed from H. M. Revenue &#038; Customs, the United Kingdom&#146;s taxation and customs authority,
with respect to qualifying research and development costs incurred in the same accounting period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Stock-based Compensation</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company grants stock options, restricted stock units and restricted stock to officers,
employees and directors under the 2006 Amended and Restated Equity Incentive Plan (&#147;2006 Plan&#148;),
which was approved on March&nbsp;16, 2006 and subsequently amended and restated on April&nbsp;14, 2008. The
Company also has outstanding options under various stock-based compensation plans for employees and
directors. These plans are described more fully in &#147;Note 6 &#151; Stock-Based Compensation&#148;. The
Company accounts for these plans under ASC 718, &#147;<I>Compensation &#151; Stock Compensation</I>&#148; (&#147;ASC 718&#148;).
</DIV>

<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>


<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">ASC 718 requires measurement of compensation cost for all stock-based awards at fair value on
date of grant and recognition of compensation over the requisite service period for awards expected
to vest. The fair value of restricted stock and restricted stock units is determined based on the
number of shares granted and the quoted price of the Company&#146;s common stock on the date of grant.
The determination of grant-date fair value for stock option awards is estimated using the
Black-Scholes model, which includes variables such as the expected volatility of our share price,
the anticipated exercise behavior of our employees, interest rates, and dividend yields. These
variables are projected based on our historical data, experience, and other
factors. Changes in any of these variables could result in material adjustments to the expense
recognized for share-based payments. Such value is recognized as expense over the requisite service
period, net of estimated forfeitures, using the straight-line attribution method. The estimation of
stock awards that will ultimately vest requires judgment, and to the extent actual results or
updated estimates differ from current estimates, such amounts are recorded as a cumulative
adjustment in the period estimates are revised. The Company considers many factors when estimating
expected forfeitures, including type of awards granted employee class, and historical experience.
Actual results and future estimates may differ substantially from current estimates.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Segments</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company has determined its reportable segments in accordance with ASC 280, &#147;<I>Segment
Reporting</I>&#148; (&#147;ASC 280&#148;) and related disclosures about products, services, geographic areas and major
customers. After considering its business activities and geographic reach, the Company has
concluded that it operates in just one operating segment being the discovery, development and
commercialization of novel, mechanism-targeted drugs to treat cancer and other serious disorders,
with development operations in two geographic areas, namely the United States and the United
Kingdom.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Net Loss per Common Share</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company calculates net loss per common share in accordance with ASC 260, &#147;<I>Earnings Per
Share</I>&#148; (&#147;ASC 260&#148;). Basic and diluted net loss per common share were determined by dividing net loss
applicable to common stockholders by the weighted average number of common shares outstanding
during the period. The Company&#146;s potentially dilutive shares, which include outstanding common
stock options, restricted stock, restricted stock units, convertible preferred stock, and common
stock warrants, have not been included in the computation of diluted net loss per share for all
periods as the result would be anti-dilutive.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Stock options</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,187,291</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,543,529</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Restricted stock and restricted stock units </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">75,515</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">44,255</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Convertible preferred stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">516,228</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">516,228</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Options to purchase common stock and common
stock warrants issued in connection with the
October&nbsp;2010 financing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,242,398</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Common stock warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,843,597</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,005,192</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total shares excluded from calculation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,622,631</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20,351,602</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Comprehensive Income (Loss)</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In accordance with ASC 220, &#147;<I>Comprehensive Income</I>&#148; (&#147;ASC 220&#148;) all components of comprehensive
income (loss), including net income (loss), are reported in the financial statements in the period
in which they are recognized. ASC 220 defines comprehensive income (loss)&nbsp;as the change in equity
during a period from transactions and other events and circumstances from nonowner sources. Net
income (loss)&nbsp;and other comprehensive income (loss), including foreign currency translation
adjustments, are reported, net of any related tax effect, to arrive at comprehensive income (loss).
No taxes were recorded on items of other comprehensive income.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Period from</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>August 13, 1996</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Six Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>(inception) to</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" colspan="18">$000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,933</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,552</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(9,040</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(8,140</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(246,446</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Translation adjustment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(19</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">139</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,001</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2,826</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,952</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Unrealized foreign
exchange (loss)&nbsp;gain
on intercompany loans</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(108</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,979</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,834</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(5,913</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Comprehensive loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,943</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,521</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(9,018</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(8,132</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(246,407</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>3. FAIR VALUE MEASUREMENTS</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As defined in ASC 820, fair value is based on the price that would be received to sell an
asset or paid to transfer a liability in an orderly transaction between market participants at the
measurement date. In order to increase consistency and comparability in fair value measurements,
ASC 820 establishes a fair value hierarchy that prioritizes observable and unobservable inputs used
to measure fair value into three broad levels, which are described below:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Level 1: Quoted prices (unadjusted)&nbsp;in active markets that are accessible at the
measurement date for assets or liabilities. The fair value hierarchy gives the highest
priority to Level 1 inputs.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Level 2: Inputs other than quoted prices within Level 1 that are observable for the
asset or liability, either directly or indirectly.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Level 3: Unobservable inputs that are used when little or no market data is available.
The fair value hierarchy gives the lowest priority to Level 3 inputs.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In determining fair value, the Company utilizes valuation techniques that maximize the use of
observable inputs and minimize the use of unobservable inputs to the extent possible as well as
considers counterparty credit risk in its assessment of fair value. Financial assets and
liabilities carried at fair value on a recurring basis as of December&nbsp;31, 2010 are classified in
the table below in one of the three categories described above:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Level 1</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Level 2</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Level 3</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Total</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>$000</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>$000</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>$000</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>$000</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29,066</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29,066</TD>
    <TD>&nbsp;</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">680</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">680</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29,066</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">680</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29,746</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Financial assets and liabilities carried at fair value on a recurring basis as of June&nbsp;30,
2011 are classified in the table below in one of the three categories described above:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Level 1</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Level 2</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Level 3</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Total</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>$000</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>$000</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>$000</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>$000</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17,333</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17,333</TD>
    <TD>&nbsp;</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">477</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">477</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>

<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17,333</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">477</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17,810</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Warrants Liability</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company issued warrants to purchase shares of common stock under the registered direct
financing completed in February&nbsp;2007. These warrants are being accounted for as a liability in
accordance with ASC 815, &#147;<I>Derivatives and Hedging&#148; </I>(&#147;ASC 815&#148;). At the date of the transaction,
the fair value of the warrants of $6.8&nbsp;million was determined utilizing the Black-Scholes option
pricing model utilizing the following assumptions: risk free interest rate &#151; 4.68%, expected
volatility &#151; 85%, expected dividend yield &#151; 0%, and a contractual life of 7&nbsp;years. The fair value
of the warrant is being re-measured each reporting period, with a derivative gain or loss
recognized in the consolidated statement of operations. Such gains or losses will continue to be
reported until the warrants are exercised or expired. The Company used the Black-Scholes
option-pricing model with the following assumptions to value the warrants:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>December 31,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
</TR>



<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exercise price</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">8.44</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">8.44</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Expected term</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="right">3.13 Yrs.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="right">2.63 Yrs.</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Risk free interest rate</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">1.02</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">0.68</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Expected volatility</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">121</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">118</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Expected dividend yield over expected term</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the three months ended June&nbsp;30, 2010 and 2011, the Company recognized the change
in the value of warrants of approximately $0.3&nbsp;million and $0.1&nbsp;million, respectively, as a gain on
the consolidated statement of operations. During the six months ended June&nbsp;30, 2010, the Company
recognized the $0.5&nbsp;million increase in the value of warrants as a loss on the consolidated
statement of operations. During the six months ended June&nbsp;30, 2011, the Company recognized the
$0.2&nbsp;million decrease in the value of warrants as a gain on the consolidated statement of
operations. The following table reconciles the beginning and ending balance of Level 3 inputs for
the six months ended June&nbsp;30, 2011:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="86%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Level 3</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>$000</B></TD>
    <TD>&nbsp;</TD>
</TR>


<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Balance as of December&nbsp;31, 2010</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">680</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Gain from change in valuation of warrants liability reported in earnings</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(203</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Balance as of June&nbsp;30, 2011</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">477</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>4. PREPAID EXPENSES AND OTHER CURRENT ASSETS</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Prepaid expenses and other current assets consist of the following:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>December 31,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>($000s)</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Research and development tax credit receivable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">660</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">998</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Prepayments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">317</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">476</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">405</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">214</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total prepaid expenses and other current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,382</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,688</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>5. ACCRUED LIABILITIES AND OTHER CURRENT LIABILITIES</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Accrued and other current liabilities consisted of the following:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>December 31,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>($000</B>s)</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Accrued research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,793</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,343</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,339</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,116</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,132</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,459</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>6. STOCK BASED COMPENSATION</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Stock based compensation has been reported within expense line items on the consolidated
statement of operations for the three months ended June&nbsp;30, 2010 and 2011 as shown in the following
table:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>For the three months</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>For the six months</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>ended June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>ended June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>($000s)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">93</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">41</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">165</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">90</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">General and administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">374</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">164</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">621</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">365</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Stock-based compensation costs before income taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">467</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">205</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">786</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">455</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Under the 2006 Plan, 5,200,000 shares of the Company&#146;s common stock have been reserved. The
awards granted under the 2006 Plan have a maximum maturity of 10&nbsp;years and generally vest over a
four-year period from the date of grant.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 8%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">A summary of activity for the options under the Company&#146;s 2006 Plan for the six months ended
June&nbsp;30, 2011 is as follows:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Weighted <BR>
Average</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Weighted</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Remaining</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Aggregate</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Average</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Contractual</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Intrinsic</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Options</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Exercise Price</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Term (years)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Value</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="10">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>(in $000s)</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Options outstanding at December&nbsp;31, 2010</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,489,932</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3.96</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7.22</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">938</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Granted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">199,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1.52</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exercised</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(6,638</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">0.41</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Expired</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cancelled / forfeited</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(139,265</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">6.32</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Options outstanding at June&nbsp;30, 2011</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,543,529</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3.74</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6.95</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">828</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Unvested at June&nbsp;30, 2011</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">968,024</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1.83</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8.75</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">153</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Vested and exercisable at June&nbsp;30, 2011</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,575,505</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4.45</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6.27</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">675</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">ASC 718 requires compensation expense associated with share-based awards to be recognized over
the requisite service period, which for the Company is the period between the grant date and the
date the award vests or becomes exercisable. Most of the awards granted by the Company (and still
outstanding), vest ratably over four years, with 1/4 of the award vesting one year from the date of
grant and 1/48 of the award vesting each month thereafter. However, certain awards made to
executive officers vest over three to five years, depending on the terms of their employment with
the Company. In addition, recent awards made to other employees vest ratably over four years, with
1/48 of the award vesting each month.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Effective January&nbsp;1, 2006, the Company elected to recognize all share-based awards issued
after the adoption of ASC 718 under the straight-line attribution method. ASC 718 requires
forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods
if actual forfeitures differ from those estimates. This analysis is evaluated quarterly and the
forfeiture rate adjusted as necessary. Ultimately, the actual expense recognized over the vesting
period is based on only those shares that vest.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The Company used the Black-Scholes option-pricing model with the following assumptions for
stock option grants to employees and directors for the six months ended June&nbsp;30, 2010 and 2011:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>For the six months</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>ended June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Expected term</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">5 &#150; 6Yrs</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">5 &#150; 6Yrs</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Risk free interest rate</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan=2>2.37 &#150; 2.96%</TD>
    <TD nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD nowrap align="center" colspan=2>1.47 &#150; 2.29%</TD>
    <TD nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Expected volatility</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan=2>90 &#150; 100%</TD>
    <TD nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan=2>93 &#150; 99%</TD>
    <TD nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Expected dividend yield over expected term</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan=2>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan=2>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Resulting weighted average grant fair
value</DIV></TD>
    <TD>&nbsp;</TD>

    <TD nowrap align="center" colspan=2>$1.80</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD nowrap align="center" colspan=2>$1.15</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">
<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">There were 199,500 options granted during the six months ended June&nbsp;30, 2011. For grants made
during the six months ended June&nbsp;30, 2010 and June&nbsp;30, 2011, the expected term assumption was
estimated using past history of early exercise behavior and estimated expectations of future
exercise behavior. Starting with the December&nbsp;2010 annual grants to the Company&#146;s employees, the
Company relied exclusively on its historical volatility as an input to the option pricing model as
the Company&#146;s management believes that this
rate will be representative of future volatility over the expected term of the options. Prior
to December&nbsp;2010, because the Company had been publicly traded for a limited period, the expected
volatility assumption was based on the historical volatility of peer companies over the expected
term of the option awards.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Estimates of pre-vesting option forfeitures are based on the Company&#146;s experience. For
outstanding options, the Company uses a forfeiture rate of 0 &#151; 50% depending on when and to whom
the options are granted. The Company adjusts its estimate of forfeitures over the requisite service
period based on the extent to which actual forfeitures differ, or are expected to differ, from such
estimates. Changes in estimated forfeitures are recognized through a cumulative adjustment in the
period of change and may impact the amount of compensation expense to be recognized in future
periods.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The weighted average risk-free interest rate represents interest rate for treasury constant
maturities published by the Federal Reserve Board. If the term of available treasury constant
maturity instruments is not equal to the expected term of an employee option, Cyclacel uses the
weighted average of the two Federal Reserve securities closest to the expected term of the employee
option.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the six months ended June&nbsp;30, 2011, 6,638 stock options were exercised resulting in
approximately $3,000 of cash proceeds to the Company. During the six months ended June&nbsp;30, 2010,
there were 124,277 stock options exercised for proceeds of approximately $0.1&nbsp;million. As the
Company presently has tax loss carry forwards from prior periods and expects to incur tax losses in
2011, the Company is not able to benefit from the deduction for exercised stock options in the
current reporting period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Restricted Stock</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In November&nbsp;2008, the Company issued restricted common stock to an employee subject to certain
forfeiture provisions. Specifically, one quarter of the award vested one year from the date of
grant and 1/48 of the award effectively vests each month thereafter. This restricted stock grant
is accounted for at fair value at the date of grant and an expense is recognized during the vesting
term. Summarized information for the restricted stock grant for the six months ended June&nbsp;30, 2011
is as follows:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Weighted Average Grant</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Restricted Stock</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Date Value Per Share</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Non-vested at December&nbsp;31, 2010</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23,954</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">0.44</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Vested</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(6,252</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">0.44</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Non-vested at June&nbsp;30, 2011</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17,702</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">0.44</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Restricted Stock Units</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Restricted stock units were issued to senior executives of the Company in November&nbsp;2008, which
entitle the holders to receive a specified number of shares of the Company&#146;s common stock over the
four year vesting term. A restricted stock unit grant is accounted for at fair value at the date
of grant which is equivalent to the market price of a share of the Company&#146;s common stock, and an
expense is recognized during the vesting term. There were no restricted stock unit grants prior to
November&nbsp;2008. Summarized information for restricted stock grants for the six months ended June&nbsp;30,
2011 is as follows:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Weighted Average Grant</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Restricted Stock Units</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Date Value Per Share</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>


<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Non-vested at December&nbsp;31, 2010</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">35,931</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">0.44</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Vested</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(9,378</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">0.44</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Non-vested at June&nbsp;30, 2011</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26,553</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">0.44</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>7. COMMITMENTS AND CONTINGENCIES</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Licensing Agreements</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The Company has entered into licensing agreements with academic and research organizations.
Under the terms of these agreements, the Company has received licenses to technology and patent
applications. The Company is required to pay royalties on future sales of product employing the
technology or falling under claims of patent applications.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Pursuant to the Daiichi Sankyo license under which the Company licenses certain patent rights
for sapacitabine, its lead drug candidate, the Company is under an obligation to use reasonable
endeavors to develop a product and obtain regulatory approval to sell a product and has agreed to
pay Daiichi Sankyo an up-front fee, reimbursement for Daiichi Sankyo&#146;s enumerated expenses,
milestone payments and royalties on a country-by-country basis. Under this agreement, aggregate
milestone payments totaling $11.7&nbsp;million could be payable subject to achievement of all the
specific contractual milestones and the Company&#146;s decision to continue with these projects. The
up-front fee and certain past reimbursements have been paid and, as a result of the SEAMLESS trial
entering Phase 3 during the first quarter of 2011, $1.6&nbsp;million was paid in July&nbsp;2011. Following
these milestone payments, a further $9.3&nbsp;million in aggregate milestone payments could be payable.
Royalties are payable in each country for the term of patent protection in the country or for ten
years following the first commercial sale of licensed products in the country, whichever is later.
Royalties are payable on net sales. Net sales are defined as the gross amount invoiced by the
Company or its affiliates or licensees, less discounts, credits, taxes, shipping and bad debt
losses. The agreement extends from its commencement date to the date on which no further amounts
are owed under it. If the Company wishes to appoint a third party to develop or commercialize a
sapacitabine-based product in Japan, within certain limitations, Daiichi Sankyo must be notified
and given a right of first refusal to develop and/or commercialize in Japan. In general, the
license may be terminated by the Company for technical, scientific, efficacy, safety, or commercial
reasons on six months notice, or twelve months, if after a launch of a sapacitabine-based product,
or by either party for material default. Effective July&nbsp;11, 2011, the license agreement was amended
to irrevocably waive a termination right Daiichi Sankyo possessed under a provision of the
agreement that required the Company to obtain regulatory approval to sell sapacitabine in at least
one country by September&nbsp;2011, and releases the Company from all claims and liability of any kind
arising under such provision. The amendment further provides that the royalty due from the Company
to Daiichi Sankyo on future net sales of sapacitabine be increased by a percentage between 1.25%
and 1.50% depending on the level of net sales of sapacitabine realized.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 8%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Guarantee</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">On July&nbsp;28, 2005 and as amended on March&nbsp;27, 2006, Cyclacel Group plc (&#147;Group&#148;) signed a
convertible Loan Note Instrument constituting convertible unsecured loan notes (the &#147;Loan&#148;) and
entered into a Facility Agreement (&#147;Agreement&#148;) with Scottish Enterprise (&#147;SE&#148;), as lender, whereby
SE subscribed for &#163;5&nbsp;million, or approximately $9&nbsp;million at the time, of the convertible loan
notes. The loan was subsequently converted into 1,231,527 preferred D shares of the Group in
satisfaction of all amounts owed by Group under the convertible loan notes. The number of preferred
D shares that SE received was calculated by dividing the principal amount outstanding under the
loan note by &#163;4.06. The preferred D shares were exchanged for shares in Xcyte Therapies, Inc. on
March&nbsp;27, 2006 as part of the transaction between Xcyte and Cyclacel Limited. However, Scottish
Enterprise retained the ability it had under the Agreement to receive a cash payment should the
research operations in Scotland be significantly reduced. The Company had guaranteed approximately
&#163;5&nbsp;million, the amount potentially due to SE, which will be calculated as a maximum of &#163;5&nbsp;million
less the market value of the shares held by SE at the time of any significant reduction in research
facilities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">On June&nbsp;22, 2009, the Company amended the Agreement with SE (the &#147;Amendment&#148;), in order to
allow the Company to implement a reduction of the Company&#146;s research operations located in Scotland
in exchange for the parties&#146; agreement to modify the payment terms of the Agreement in the
principal amount of &#163;5&nbsp;million (approximately $8.0&nbsp;million at December&nbsp;31, 2009), which SE had
previously entered into with the Company. The Agreement provided for repayment of &#163;5&nbsp;million in the
event the Company significantly reduced its Scottish research operations. Pursuant to the terms of
the Amendment, in association with Cyclacel&#146;s material reduction in staff at its Scottish research
facility, the parties agreed to a modified payment of &#163;1&nbsp;million (approximately $1.7&nbsp;million at
June&nbsp;22, 2009) payable in two equal tranches. On July&nbsp;1, 2009, the first installment of &#163;0.5
million (approximately $0.8&nbsp;million) was paid and the remaining amount of &#163;0.5&nbsp;million
(approximately $0.8&nbsp;million) was paid on January&nbsp;6, 2010. In addition, should a further reduction
below current minimum staff levels be effectuated before July&nbsp;2014 without SE&#146;s prior consent, the
Company will guarantee approximately &#163;4&nbsp;million, the amount potentially due to SE, which will be
calculated as a maximum of &#163;4&nbsp;million less the market value of the shares held by SE at the time of
any further reduction in research facilities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">This arrangement is accounted for as a liability and is measured at fair value. Changes in
fair value are recognized in earnings. Due to the nature of the associated contingency and the
likelihood of occurrence, the Company has concluded the fair value of this liability is immaterial
as of December&nbsp;31, 2010 and June&nbsp;30, 2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Legal proceedings</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On April&nbsp;27, 2010, the Company was served with a complaint filed by Celgene Corporation in the
United States District Court for the District of Delaware seeking a declaratory judgment that four
of its own patents, claiming the use of romidepsin injection in T-cell lymphomas, are invalid and
not infringed by Celgene&#146;s products, but directly involve the use and administration of Celgene&#146;s
ISTODAX<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> (romidepsin for injection) product. On June&nbsp;17, 2010, the Company filed its answer and
counterclaims to the declaratory judgment complaint. The Company filed counterclaims charging
Celgene with infringement of each of the Company&#146;s four patents and seeking damages for Celgene&#146;s
infringement as well as injunctive relief. The four patents directly involve the use and
administration of Celgene&#146;s ISTODAX<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> (romidepsin for injection) product.
</DIV>

<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>8. STOCKHOLDERS&#146; EQUITY</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Preferred Stock</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As of June&nbsp;30, 2011, there were 1,213,142 shares of Preferred Stock issued and outstanding at
an issue price of $10.00 per share. Dividends on the Preferred Stock are cumulative from the date
of original issuance at the annual rate of 6% of the liquidation preference of the Preferred Stock,
payable quarterly on
the first day of February, May, August and November, commencing February&nbsp;1, 2005. Any
dividends must be declared by the Company&#146;s Board of Directors and must come from funds that are
legally available for dividend payments. The Preferred Stock has a liquidation preference of $10
per share, plus accrued and unpaid dividends.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Preferred Stock is convertible at the option of the holder at any time into the Company&#146;s
shares of common stock at a conversion rate of approximately 0.42553 shares of common stock for
each share of Preferred Stock based on a price of $23.50. During 2010, 833,671 shares of Preferred
Stock were converted into 1,655,599 shares of the Company&#146;s common stock, which is described in
more detail below. Since inception through June&nbsp;30, 2011, holders have voluntarily converted
1,776,858 shares of Preferred Stock into common stock. The Company has reserved 516,228 shares of
common stock for issuance upon conversion of the remaining shares of Preferred Stock outstanding at
June&nbsp;30, 2011. The converted shares of Preferred Stock have been retired and canceled and shall
upon cancellation be restored to the status of authorized but unissued shares of preferred stock,
subject to reissuance by the Board of Directors as shares of Preferred Stock of one or more series.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company may automatically convert the Preferred Stock into common stock if the closing
price of the Company&#146;s common stock has exceeded $35.25, which is 150% of the conversion price of
the Preferred Stock, for at least 20 trading days during any 30-day trading period, ending within
five trading days prior to notice of automatic conversion.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Certificate of Designations governing the Preferred Stock provides that if the Company
fails to pay dividends on its Preferred Stock for six quarterly periods, holders of Preferred Stock
are entitled to nominate and elect two directors to the Company&#146;s Board of Directors. This right
accrued to the holders of Preferred Stock as of August&nbsp;2, 2010 and two directors were nominated and
elected at the annual meeting held on May&nbsp;24, 2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Preferred Stock has no maturity date and no voting rights prior to conversion into common
stock, except under limited circumstances.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">From November&nbsp;6, 2007, the Company may, at its option, redeem the Preferred Stock in whole or
in part, out of funds legally available at the redemption prices per share stated below, plus an
amount equal to accrued and unpaid dividends up to the date of redemption:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="86%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Year from November&nbsp;1, 2010 to October&nbsp;31, 2011</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">10.24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Year from November&nbsp;1, 2011 to October&nbsp;31, 2012</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">10.18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Year from November&nbsp;1, 2012 to October&nbsp;31, 2013</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">10.12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Year from November&nbsp;1, 2013 to October&nbsp;31, 2014</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">10.06</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">November&nbsp;1, 2014 and thereafter</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">10.00</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Preferred Stock is exchangeable, in whole but not in part, at the option of the Company on
any dividend payment date beginning on November&nbsp;1, 2005 (the &#147;Exchange Date&#148;) for the Company&#146;s 6%
Convertible Subordinated Debentures (&#147;Debentures&#148;) at the rate of $10 principal amount of
Debentures for each share of Preferred Stock. The Debentures, if issued, will mature 25&nbsp;years after
the Exchange Date and have terms substantially similar to those of the Preferred Stock.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Conversion of Convertible Preferred Stock</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">During the first and second quarters of 2010, Cyclacel entered into agreements to exchange
shares of the Company&#146;s Preferred Stock into shares of common stock. There were no such conversions
for the six months ended June&nbsp;30, 2011. The table below provides details of the aggregate
activities in 2010:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>For the three</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>For the six</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>months ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>months ended</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>June 30, 2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>June 30, 2010</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Preferred shares exchanged</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">710,271</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">833,671</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Common shares issued:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">At stated convertible option</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">302,242</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">354,752</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Incremental shares issued under an inducement offer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,113,961</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,300,847</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total common shares issued</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,416,203</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,655,599</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">ASC 260, EITF Topic D-42, &#147;<I>The Effect of the Calculation of Earnings per Share for the
Redemption or Induced Conversion of Preferred Stock&#148; </I>(&#147;ASC 260&#148;) requires that if convertible
preferred stock is converted to other securities pursuant to an inducement offer, the Company
should record the excess of (1)&nbsp;the fair value of all securities and other consideration
transferred to the holders of the convertible preferred stock and (2)&nbsp;the fair value of securities
issuable to the original conversion terms as an increase to net loss to arrive at a net loss
attributable to common shareholders. The stockholder received more shares of the Company&#146;s common
stock than would have been delivered pursuant to the original conversion terms of the Preferred
Stock, pursuant to a short term inducement offer. The excess of the fair value of the common stock
transferred to the stockholder over the carrying amount of the preferred stock in the Company&#146;s
balance sheet at the time of the transfer was considered to be an additional return to the holder
of the Preferred Stock. Specifically, the Company recorded deemed dividends related to the
additional shares issued under the exchange transactions of approximately $2.5&nbsp;million and $2.9
million for the three and six months ended June&nbsp;30, 2010,
respectively.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Common Stock</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>October&nbsp;2010 Private Placement</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On October&nbsp;7, 2010, the Company completed a private placement pursuant to which it sold
approximately $15.2&nbsp;million of its units to several institutional investors, for net proceeds of
approximately $14.0&nbsp;million. The units consist of one share of common stock and 0.5 of a warrant,
with each whole warrant representing the right to purchase one share of common stock at an exercise
price of $1.92 per share for a period of five years. As of June&nbsp;30, 2011, all options and warrants
issued to the investors are outstanding and have been classified as equity. The investors purchased
a total of 8,323,190 units at a price of $1.82625 per unit. The investors also have the right to
acquire up to 4,161,595 additional units at a price of $1.67 per unit (for $6.9&nbsp;million in gross
proceeds) at any time up to nine months after closing or by July&nbsp;6, 2011. As of June&nbsp;30, 2011, none
of the additional units had been exercised and, as of July&nbsp;6, 2011, the right to acquire the
additional units lapsed. The transaction date fair value of the warrants and additional optional
units was $5.1&nbsp;million and $2.8&nbsp;million, respectively. Net proceeds of approximately $14.0&nbsp;million
were allocated based on relative transaction date fair values in the following manner: $8.9&nbsp;million
($1.07 per share), $3.3&nbsp;million ($0.79 per warrant) and $1.8&nbsp;million ($0.43 per optional unit) to
common shares, warrants and the additional optional units, respectively.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In connection with the October&nbsp;2010 private placement, the Company granted to the investors
certain registration rights pursuant to a Registration Rights Agreement, dated October&nbsp;7, 2010, in
which the Company agreed, among other things, to register all of the shares of common stock
acquired from the Company (including upon exercise of the warrants and/or the options) within
thirty calendar days after the Company becomes eligible to use a registration statement on Form
S-3, and use commercially reasonable efforts to have the registration statement declared effective
as promptly as practicable thereafter. Upon the Company&#146;s failure to comply with the terms of the
Registration Rights Agreement and certain other conditions, the Company will be required to make
pro rata payments to each investor, as liquidated damages, in an amount equal to 1.5% of the
aggregate purchase price paid by such investor. The Company also agreed to other customary
obligations regarding registration, including indemnification and maintenance of the effectiveness
of the registration statement. The Company is currently in compliance with the applicable terms of
the Registration Rights Agreement, and the securities that were registrable under the terms of the
Registration Rights Agreement are currently subject to an effective registration statement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>January&nbsp;2010 Registered Direct Financings</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On January&nbsp;25, 2010, the Company completed the sale of 2,350,000 units in a &#147;registered
direct&#148; offering at a purchase price of $2.50 per unit to certain institutional investors of the
Company for gross proceeds of approximately $5.9&nbsp;million. Each unit consisted of one share of the
Company&#146;s common stock and one warrant to purchase 0.30 of one share of its common stock. The
warrants have a five-year term from the date of issuance, are exercisable beginning six months from
the date of issuance at an exercise price of $2.85 per share of common stock. As of June&nbsp;30, 2011,
warrants issued to the investors have been classified as equity. The transaction date fair value of
the warrants of $1.0&nbsp;million was determined utilizing the Black-Scholes option pricing model
utilizing the following assumptions: risk free interest rate &#151; 2.39%, expected volatility &#151; 90%,
expected dividend yield &#151; 0%, and a remaining contractual life of 5.00&nbsp;years. As of June&nbsp;30, 2011,
all the warrants are outstanding. Net proceeds of approximately $5.4&nbsp;million were allocated based
on relative transaction date fair values in the following manner: $4.5&nbsp;million ($1.93 per share) to
common shares and $0.9&nbsp;million ($1.29 per warrant) to the warrants.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On January&nbsp;13, 2010, the Company completed the sale of 2,850,000 units in a &#147;registered
direct&#148; offering to certain institutional investors. Each unit was sold at a purchase price of
$2.51 per unit and consists of one share of the Company&#146;s common stock and one warrant to purchase
0.25 of one share of its common stock for gross proceeds of approximately $7.2&nbsp;million. The
warrants have a five-year term from the date of issuance, are exercisable beginning six months from
the date of issuance at an exercise price of $3.26 per share of common stock. As of June&nbsp;30, 2011,
warrants issued to the investors have been classified as equity. The transaction date fair value of
the warrants of $1.3&nbsp;million was determined utilizing the Black-Scholes option pricing model
utilizing the following assumptions: risk free interest rate &#151; 2.55%, expected volatility &#151; 90%,
expected dividend yield &#151; 0%, and a remaining contractual life of 5.00&nbsp;years. As of June&nbsp;30, 2011,
all the warrants are outstanding. Net proceeds of approximately $6.5&nbsp;million were allocated based
on relative transaction date fair values in the following manner: $5.6&nbsp;million ($1.95 per share) to
common shares and $0.9&nbsp;million ($1.32 per warrant) to the warrants.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>July&nbsp;2009 Registered Direct Financing</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On July&nbsp;29, 2009, the Company sold its securities to select institutional investors consisting
of 4,000,000 units in a &#147;registered direct&#148; offering at a purchase price of $0.85 per unit. Each
unit consisted of (i)&nbsp;one share of the Company&#146;s common stock, (ii)&nbsp;one warrant to purchase 0.625
of one share of common stock (a &#147;Series&nbsp;I Warrant&#148;) and (iii)&nbsp;one warrant to purchase 0.1838805 of
one share of common stock (a &#147;Series&nbsp;II Warrant&#148;). The Series&nbsp;I Warrants had a seven-month term
from the date of issuance, were exercisable beginning six months from the date of issuance at an
exercise price of $1.00 per share of common stock. During the first quarter of 2010, all of the
Series&nbsp;I Warrants were exercised for $2.5&nbsp;million. The Series&nbsp;II Warrants have a five-year term
from the date of issuance, are exercisable beginning six months from the date of issuance at an
exercise price of $1.00 per share of common stock. During the first quarter of 2010,
43,266 common shares were issued upon exercise of Series&nbsp;II Warrants with proceeds of $43,266.
There were no exercises during the six months ended June&nbsp;30, 2011.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The net proceeds to the Company from the sale of the units, after deducting for the placement
agent&#146;s fees and offering expenses, were approximately $2.9&nbsp;million. As of June&nbsp;30, 2011, the
remaining Series&nbsp;II Warrants outstanding and exercisable into 692,256 of the Company&#146;s shares of
common stock have been classified as equity. The transaction date fair value of the Series&nbsp;II
Warrants of $0.6&nbsp;million was determined utilizing the Black-Scholes option pricing model utilizing
the following assumptions: risk free interest rate &#151; 2.69%, expected volatility &#151; 90%, expected
dividend yield &#151; 0%, and a remaining contractual life of 5.00&nbsp;years.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>December&nbsp;2007 Committed Equity Financing Facility</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On December&nbsp;10, 2007 and as amended on November&nbsp;24, 2009, Cyclacel entered into a Committed
Equity Financing Facility, or CEFF, with Kingsbridge, in which Kingsbridge committed to purchase
the lesser of 4,084,590 shares of common stock or $60&nbsp;million of common stock from Cyclacel over a
three-year period. The CEFF lapsed on December&nbsp;10, 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During March&nbsp;2010, the Company sold 1,563,208 shares of its common stock to Kingsbridge under
the CEFF, in consideration of aggregate proceeds of $3.1&nbsp;million. During December&nbsp;2009 and January
2010, the Company sold an aggregate of 1,583,626 shares of its common stock to Kingsbridge under
the terms of the CEFF in consideration of an aggregate of $1.3&nbsp;million, of which approximately $1.0
million was received in 2009, with the balance of $0.3&nbsp;million in respect of common shares
subscribed but unissued at December&nbsp;31, 2009, received by the Company in January&nbsp;2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Common Stock Warrants</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In connection with the Company&#146;s February&nbsp;16, 2007 &#147;registered direct&#148; offering the Company
issued to investors warrants to purchase 1,062,412 shares of common stock. The warrants issued to
the investors are being accounted for as a liability. At the date of the transaction, the fair
value of the warrants of $6.8&nbsp;million was determined utilizing the Black-Scholes option pricing
model utilizing the following assumptions: risk free interest rate &#151; 4.58%, expected volatility -
85%, expected dividend yield &#151; 0%, and a remaining contractual life of 6.88&nbsp;years. The value of the
warrant is being marked to market each reporting period as a derivative gain or loss on the
consolidated statement of operations until exercised or expiration. See &#147;Note 3 &#151; Fair Value&#148; for
further details.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->23<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The following table summarizes information about warrants outstanding at June&nbsp;30, 2011:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="58%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Weighted</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Average</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Expiration</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Common Shares</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Exercise</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Issued in Connection With</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Date</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Issuable</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Price</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">April&nbsp;2006 stock issuance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2013</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,571,429</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">7.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">February&nbsp;2007 stock issuance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2014</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,062,412</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">8.44</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">December&nbsp;2007 CEFF</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2013</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1.40</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">July&nbsp;2009 Series&nbsp;II stock issuance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2014</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">692,256</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">January&nbsp;2010 stock issuance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2015</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">712,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3.26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">January&nbsp;2010 stock issuance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2015</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">705,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2.85</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">October&nbsp;2010 stock issuance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2015</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,161,595</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1.92</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,005,192</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4.01</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Exercise of Stock Options</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the six months ended June&nbsp;30, 2011, there were 5,131 stock option exercises totaling
approximately $3,000. During the three months ended June&nbsp;30, 2010, there were 124,277 stock option
exercises totaling approximately $0.1&nbsp;million.
</DIV>

<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>9. SUBSEQUENT EVENTS</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Preferred Stock Dividend</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On July&nbsp;8, 2011, the Board of Directors decided not to declare the quarterly cash dividend on
the Preferred Stock with respect to the second quarter of 2011 that would have otherwise been
payable on August&nbsp;1, 2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Board also did not declare the quarterly cash dividend with respect to each of the four
quarters of fiscal year 2009 and the first, second and third quarters of 2010. To the extent that
any dividends payable on the Preferred Stock are not paid, such unpaid dividends are added to the
liquidity preference of the Preferred Stock. As the Company failed to pay in an aggregate amount
equal to at least six quarterly dividends (whether or not consecutive) on the Preferred Stock, the
size of the Company&#146;s Board was increased by two members and the holders of the Preferred Stock,
voting separately as a class, voted on May&nbsp;24, 2011 and elected two directors to fill the vacancies
created thereby, which directorships shall terminate when the Company pays all accrued but unpaid
dividends.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>License Agreement</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On July&nbsp;11, 2011, the Company entered into an amendment to its license agreement with Daiichi
Sankyo Company, Limited (&#147;Daiichi Sankyo&#148;), dated September&nbsp;10, 2003, relating to certain rights
which the Company has licensed from Daiichi Sankyo with regard to the Company&#146;s sapacitabine drug.
Effective July&nbsp;11, 2011, the license agreement was amended to irrevocably waive a termination right
Daiichi Sankyo possessed under a provision of the agreement that required the Company to obtain
regulatory approval to sell sapacitabine in at least one country by September&nbsp;2011, and releases
the Company from all claims and liability of any kind arising under such provision. The amendment
further provides that the royalty due from the Company to Daiichi Sankyo on future net sales of
sapacitabine be increased by a percentage between 1.25% and 1.50% depending on the level of net
sales of sapacitabine realized.
</DIV>

<!-- XBRL,ig -->

<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->24<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<!-- /XBRL,ig -->

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Financing</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On July&nbsp;7, 2011 the Company closed an underwritten offering for an aggregate of 7,617,646
units, at an offering price of $1.36 per unit, for gross proceeds of approximately $10.4&nbsp;million.
Each unit consists of (i)&nbsp;one share of common stock and (ii)&nbsp;a five-year warrant to purchase 0.5 of
a share of common stock at an exercise price of $1.36 per share, exercisable beginning six months
after the date of issuance. The shares of common stock and warrants were immediately separable and
were issued separately such that no units were issued. The net proceeds, after underwriting
discounts and commissions and other fees and expenses payable by the Company, were approximately
$9.3&nbsp;million.
</DIV>
<!-- /xbrl,ns -->

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->25<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">
<DIV align="left">
<A name="C17919103"></A>
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;2.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%"><I>This Quarterly Report on </I><I>Form 10-Q</I><I>, including, without limitation, Management&#146;s Discussion and
Analysis of Financial Condition and Results of Operations, contains &#147;forward-looking statements&#148;
within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Securities Exchange
Act of 1934, as amended (the &#147;Exchange Act&#148;). We intend that the forward-looking statements be
covered by the safe harbor for forward-looking statements in the Exchange Act. The forward-looking
information is based on various factors and was derived using numerous assumptions. All statements,
other than statements of historical fact, that address activities, events or developments that we
intend, expect, project, believe or anticipate will or may occur in the future are forward-looking
statements. Such statements are based upon certain assumptions and assessments made by our
management in light of their experience and their perception of historical trends, current
conditions, expected future developments and other factors they believe to be appropriate. These
forward-looking statements are usually accompanied by words such as &#147;believe,&#148; &#147;anticipate,&#148;
&#147;plan,&#148; &#147;seek,&#148; &#147;expect,&#148; &#147;intend&#148; and similar expressions.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%"><I>Forward-looking statements necessarily involve risks and uncertainties, and our actual results
could differ materially from those anticipated in the forward looking statements due to a number of
factors, including those set forth in Part&nbsp;I, Item&nbsp;1A, entitled &#147;Risk Factors,&#148; of our Annual
Report on </I><I>Form 10-K</I><I> for the year ended December&nbsp;31, 2010, as updated and supplemented by Part&nbsp;II,
Item&nbsp;1A, entitled &#147;Risk Factors,&#148; of our Quarterly Reports on </I><I>Form 10-Q</I><I> and other reports we
publicly file with the Securities and Exchange Commission, or the SEC. These factors as well as
other cautionary statements made in this Quarterly Report on </I><I>Form 10-Q</I><I>, should be read and
understood as being applicable to all related forward-looking statements wherever they appear
herein. The forward-looking statements contained in this Quarterly Report on </I><I>Form 10-Q</I><I> represent
our judgment as of the date hereof. We encourage you to read those descriptions carefully. We
caution you not to place undue reliance on the forward-looking statements contained in this report.
These statements, like all statements in this report, speak only as of the date of this report
(unless an earlier date is indicated) and we undertake no obligation to update or revise the
statements except as required by law. Such forward-looking statements are not guarantees of future
performance and actual results will likely differ, perhaps materially, from those suggested by such
forward-looking statements. In this report, &#147;Cyclacel,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our&#148; refer
to Cyclacel Pharmaceuticals, Inc.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Overview</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We are a biopharmaceutical company dedicated to the development and commercialization of
novel, mechanism-targeted drugs to treat human cancers and other serious diseases. Our strategy is
to build a diversified biopharmaceutical business focused in hematology and oncology based on a
portfolio of commercial products and a development pipeline of novel drug candidates.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our clinical development priorities are focused on sapacitabine in the following indications:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Acute myeloid leukemia, or AML, in the elderly;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Myelodysplastic syndromes, or MDS; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Non-small cell lung cancer, or NSCLC.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On January&nbsp;11, 2011, the Company opened enrollment of the SEAMLESS pivotal Phase 3 trial for
the Company&#146;s sapacitabine oral capsules as a front-line treatment of elderly patients aged 70
years or older with newly diagnosed AML who are not candidates for intensive induction
chemotherapy. SEAMLESS is a registration-directed clinical trial and is conducted under a Special
Protocol Assessment, or SPA, agreement with the U.S. Food and Drug Administration, or FDA. SEAMLESS
is a randomized study against an active control drug with the primary objective of demonstrating an
improvement in overall survival. SEAMLESS has two parts. The first part is a pilot study of a
single arm of the trial. The study&#146;s Data Safety Monitoring
Board, or DSMB, will review the data from the pilot study before we are allowed to enroll
patients in the second part in which patients will be randomized either to an active or control
treatment.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->26<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company has advanced two additional product candidates, seliciclib in Phase 2 for NSCLC
and nasopharyngeal cancer or NPC, and CYC116 in Phase 1 clinical development. The combination of
sapacitabine with seliciclib is also being evaluated in a Phase 1 clinical trial. The Company will
determine the feasibility of pursuing further development and/or partnering these assets depending
on the availability of funding and further clinical data. In addition, we market directly in the
United States Xclair<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Cream for radiation dermatitis and Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Liquid and Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Lozenges
for xerostomia.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Recent Developments</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On June&nbsp;6, 2011, we announced interim results from an ongoing, multicenter, Phase 1/2 clinical
trial examining the safety and effectiveness of oral sapacitabine, our lead product candidate,
administered sequentially with decitabine. Thirty-day mortality from all causes was 4.5%; 60-day
mortality from all causes was 9.5%. The overall response rate was 34.8%. An additional 26.1% of
patients stayed on study for more than 4 cycles with a decrease in bone marrow blast counts despite
not meeting criteria of response. Approximately 60.9% of patients received 4 or more cycles of the
regimen.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The data was reported during a poster session at the 2011 American Society of Clinical
Oncology, or ASCO, Annual Meeting in Chicago, Illinois. As reported at ASCO, no dose-limiting
toxicities were observed in 21 patients treated with the regimen who have had at least 60&nbsp;days of
follow-up. The median age in the group is 76&nbsp;years (range 72-88). Common adverse events regardless
of cause included anemia, anorexia, dehydration, diarrhea, dyspnea, edema, hypocalcemia, nausea,
febrile neutropenia, neutropenia, pneumonia, thrombocytopenia, and weakness, which were mostly
moderate in intensity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We believe, based on the interim results reported at ASCO that the sequential administration
of sapacitabine and decitabine appears safe and active in elderly patients with newly diagnosed
acute myeloid leukemia, or AML.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The treatment regimen under evaluation in this pilot study is being used as one of the arms in
SEAMLESS, the registration-directed, Phase 3 study of sapacitabine in elderly patients with newly
diagnosed AML who are not candidates for or have refused induction chemotherapy. SEAMLESS is being
conducted under a Special Protocol Assessment agreement that Cyclacel reached with the US Food and
Drug Administration.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Our pipeline and expertise in cell cycle biology</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our core area of expertise is in cell cycle biology and we focus primarily on the development
of orally-available anticancer agents that target the cell cycle with the aim of slowing the
progression or shrinking the size of tumors, and enhancing the quality of life and improving
survival rates of cancer patients. We are generating several families of anticancer drug candidates
that act on the cell cycle including nucleoside analogues, cyclin dependent kinase, or CDK
inhibitors and Aurora kinase/Vascular Endothelial Growth Factor Receptor 2, or AK/VEGFR2
inhibitors. Although a number of pharmaceutical and biotechnology companies are currently
attempting to develop nucleoside analogues, CDK inhibitor and AK inhibitor drugs, we believe that
our drug candidates are differentiated in that they are orally-available and interact with unique
target profiles and mechanisms. For example we believe that our sapacitabine is the only
orally-available nucleoside analogue to be tested in a Phase 3 trial for AML and in a Phase 2 trial
in MDS and seliciclib is the most advanced orally-available CDK inhibitor in Phase 2 trials.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Although our resources are primarily directed towards advancing our anticancer drug candidate
sapacitabine through in-house development activities we are also progressing, but with minimal
investment, our other novel drug series which are at earlier stages. As a consequence of our
progress in sapacitabine clinical development, research and development expenditures for the six
months ended June&nbsp;30, 2011
increased by $1.5&nbsp;million, or 42%, to $5.0&nbsp;million, compared to $3.5&nbsp;million for the six
months ended June&nbsp;30, 2010.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->27<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have retained rights to commercialize our clinical development candidates and our business
strategy is to enter into selective partnership arrangements with these programs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our corporate headquarters is located in Berkeley Heights, New Jersey, with a research
facility located in Dundee, Scotland.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">From our inception in 1996 through June&nbsp;30, 2011, we have devoted substantially all our
efforts and resources to our research and development activities. We have incurred significant net
losses since inception. As of June&nbsp;30, 2011, our accumulated deficit during the development stage
was approximately $250.0&nbsp;million. We expect to continue incurring substantial losses for the next
several years as we continue to develop our clinical and preclinical drug candidates. Our operating
expenses are comprised of research and development expenses and selling and general and
administrative expenses.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">To date, we have not generated significant product revenue but have financed our operations
and internal growth through, among other things, public and private equity offerings, licensing
revenue, interest on investments, government grants and research and development tax credits. Prior
to October&nbsp;2007, our revenue consisted of collaboration and grant revenue. Beginning in 2008, we
recognized revenue from sales of commercial products, for the first time, following the ALIGN
acquisition in October&nbsp;2007. We have recognized revenues from inception through June&nbsp;30, 2011
totaling approximately $9.4&nbsp;million, of which approximately $2.7&nbsp;million is derived from product
sales, approximately $3.1&nbsp;million from fees under collaborative agreements and approximately $3.6
million of grant revenue from various United Kingdom government grant awards.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->28<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Subsequent Events</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Preferred Stock Dividend</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On July&nbsp;8, 2011, our Board of Directors, or Board, decided not to declare the quarterly cash
dividend on our 6% Convertible Exchangeable Preferred Stock, or Preferred Stock, with respect to
the second quarter of 2011 that would have otherwise been payable on August&nbsp;1, 2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Board also did not declare the quarterly cash dividend with respect to each of the four
quarters of fiscal year 2009 and the first, second and third quarters of 2010. To the extent that
any dividends payable on the Preferred Stock are not paid, such unpaid dividends are added to the
liquidity preference of the Preferred Stock. As we failed to pay in an aggregate amount equal to at
least six quarterly dividends (whether or not consecutive) on the Preferred Stock, the size of the
our Board was increased by two members and the holders of the Preferred Stock, voting separately as
a class, voted on May&nbsp;24, 2011 and elected two directors to fill the vacancies created thereby,
which directorships shall terminate when we pay all accrued but unpaid dividends.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>License Agreement</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On July&nbsp;11, 2011, we entered into an amendment to our license agreement with Daiichi Sankyo
Company, Limited (&#147;Daiichi Sankyo&#148;), dated September&nbsp;10, 2003, relating to certain rights which we
have licensed from Daiichi Sankyo with regard to sapacitabine. Effective July&nbsp;11, 2011, the license
agreement was amended to irrevocably waive a termination right Daiichi Sankyo possessed under a
provision of the agreement that required us to obtain regulatory approval to sell sapacitabine in
at least one country by September&nbsp;2011, and releases us from all claims and liability of any kind
arising under such provision. The amendment further provides that the royalty due to Daiichi Sankyo
on future net sales of sapacitabine be increased by a percentage between 1.25% and 1.50% depending
on the level of net sales of sapacitabine realized.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Financing</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On July&nbsp;7, 2011, we closed an underwritten offering for an aggregate of 7,617,646 units, at an
offering price of $1.36 per unit, for gross proceeds of $10.4&nbsp;million. Each unit consists of (i)
one share of common stock and (ii)&nbsp;a five-year warrant to purchase 0.5 of a share of common stock
at an exercise price of $1.36 per share, exercisable beginning six months after the date of
issuance. The shares of common stock and warrants were immediately separable and were issued
separately such that no units were issued. The net proceeds, after underwriting discounts and
commissions and fees and expenses, were approximately $9.3&nbsp;million.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->29<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Results of Operations</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Three Months Ended June&nbsp;30, 2011 and 2010</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Revenues</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The following table summarizes the components of our revenues for the three months ended
June&nbsp;30, 2010 and 2011:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Increase (Decrease)</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>%</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>($000s)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Collaboration and
research and development
revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(100</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(100</TD>
    <TD nowrap>)%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Product revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">168</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">149</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">784</TD>
    <TD nowrap>%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">119</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">168</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">49</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">41</TD>
    <TD nowrap>%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We recognized $0.1&nbsp;million of collaboration and research and development revenue for the three
months ended June&nbsp;30, 2010, derived from an agreement with a pharmaceutical company under which we
provided one of our compounds for evaluation in the field of eye care. We had no collaboration and
research and development revenue for the three months ended June&nbsp;30, 2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Product revenue is derived from the sale of Xclair<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Cream, Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Liquid and Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>
Lozenges following the ALIGN asset acquisition on October&nbsp;5, 2007. During the three months ended
June&nbsp;30, 2010 and 2011, we recognized approximately $19,000 and $0.2&nbsp;million, respectively in
accordance with our revenue recognition policy. Product revenue was lower by $0.2&nbsp;million for the
three months ended June&nbsp;30, 2010 compared to the same period in 2011 as a result of recognizing
$0.2&nbsp;million in product returns during the three months ended June&nbsp;30, 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Grant revenue is recognized as we incur and pay for qualifying costs and services under the
applicable grant. Grant revenue is primarily derived from various United Kingdom government grant
awards. We have earned grant revenue in the past and will continue to pursue opportunities in the
future but did not recognize any grant revenue for the three months ended June&nbsp;30, 2010 or 2011 as
a result of finalization of a three-year European Union grant in the
first quarter of 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>The future</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We expect to continue to maintain the sales of ALIGN products in 2011 through the support of a
small sales and marketing infrastructure. We do not expect to earn any grant revenue during the
remainder of year, as no awards are expected during the year ended December&nbsp;31, 2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Cost of goods sold</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The following table summarizes cost of goods sold for the six months ended June&nbsp;30, 2010
and 2011:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Increase (Decrease)</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>%</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>($000s)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cost of goods sold</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">92</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">72</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(20</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(22</TD>
    <TD nowrap>)%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Total cost of sales represented 43% of product revenue for the three months ended June&nbsp;30,
2011. Total cost of sales was not a meaningful percentage of product revenue for the three months
ended June&nbsp;30, 2010 because of the low product revenue recognized during the period, as explained
above.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 8%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->30<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Research and development expenses</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">We expense all research and development costs as they are incurred. Research and development
expenses primarily include:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>clinical trial and regulatory-related costs;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>payroll and personnel-related expenses, including consultants and contract
research;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>preclinical studies and laboratory supplies and materials;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>technology license costs; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>rent and facility expenses for our laboratories.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The following table provides information with respect to our research and development
expenditure for the three months ended June&nbsp;30, 2010 and 2011:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Increase (Decrease)</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>%</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>($000s)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Sapacitabine</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,186</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,760</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">574</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">48</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Seliciclib</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">72</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(56</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(78</TD>
    <TD nowrap>)%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other research and development costs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">64</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">83</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">30</TD>
    <TD nowrap>%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total research and development costs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,322</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,859</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">537</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">41</TD>
    <TD nowrap>%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Total research and development expenses represented 29% and 47% of our operating expenses for
the three months ended June&nbsp;30, 2010 and 2011, respectively.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Research
and development expenditure increased by $0.5&nbsp;million to $1.9&nbsp;million for the three
month period ended June&nbsp;30, 2011 from $1.3&nbsp;million for the three month period ended June&nbsp;30, 2010.
The increase in costs of $0.5&nbsp;million is mostly due to a $0.6&nbsp;million increase in
sapacitabine-related expenses, primarily a $0.2&nbsp;million increase in capsule manufacture and testing
and a $0.2&nbsp;million increase in clinical trial expenses, as a result of the SEAMLESS trial entering
Phase 3. Seliciclib costs decreased $56,000, from $72,000 for the three months ended June&nbsp;30, 2010,
to $16,000 for the three months ended June&nbsp;30, 2011, primarily due to the completion of clinical
trials. Other research and development costs remained relatively flat, increasing $19,000 from
approximately $0.1&nbsp;million for the three months ended June&nbsp;30, 2010 to approximately $0.1&nbsp;million
for three months ended June&nbsp;30, 2011 as we have continued to concentrate financial resources on the
development of sapacitabine and selectively invest in other compounds.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>The future</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">We will continue to concentrate our resources on the development of sapacitabine. We
anticipate that overall research and development expenditures in 2011 will increase as we enroll
the SEAMLESS pivotal Phase 3 trial.
</DIV>

<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->31<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Selling, general and administrative expenses</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Selling, general and administrative expenses include costs for sales and marketing and
administrative personnel, legal and other professional expenses and general corporate expenses. The
following table summarizes the selling, general and administrative expenses for the three months
ended June&nbsp;30, 2010 and 2011:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Increase (Decrease)</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>%</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>($000s)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Selling, general and administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,091</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,034</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(1,057</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(34</TD>
    <TD nowrap>)%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Total selling, general and administrative expenses represented 69% and 51% of our operating
expenses for the three months ended June&nbsp;30, 2010 and 2011, respectively. Our selling, general and
administrative expenditure decreased by $1.1&nbsp;million from $3.1&nbsp;million for the three months ended
June&nbsp;30, 2010 to $2.0&nbsp;million for the three months ended June&nbsp;30, 2011. The decrease of $1.1
million in expenses was primarily attributable to a net decrease in professional and consultancy
costs of $0.8, million, a decrease in stock compensation of $0.4&nbsp;million, a decrease in rent
expense of $0.1&nbsp;million, a decrease in salaries of $0.1&nbsp;million, and an increase in patent costs of
$0.3&nbsp;million.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>The future</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We expect our selling, general and administrative expenditures in 2011 to remain at the same
level or to be less than our expenditures in 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Other income (expense)</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The following table summarizes other income (expense)&nbsp;for the three months ended June&nbsp;30, 2010
and 2011:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Increase (Decrease)</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>%</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="14"><B>($000s)</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other income (expense):</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Change in valuation of warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">273</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">125</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(148</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(54</TD>
    <TD nowrap>)%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Foreign exchange (losses)/gains</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(49</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(19</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(61</TD>
    <TD nowrap>)%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Interest income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">63</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Interest expense</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(9</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(100</TD>
    <TD nowrap>)%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total other income (expense)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">223</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">119</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(104</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(47</TD>
    <TD nowrap>)%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Total other income and expense, net, decreased by approximately $0.1&nbsp;million, from income of
$0.2&nbsp;million for the three months ended June&nbsp;30, 2010, to income of $0.1&nbsp;million for the three
months ended June&nbsp;30, 2011. The most significant impact is the change in the valuation of the
warrant liability described below.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The change in valuation of warrants relates to the issue of warrants to purchase shares of our
common stock under the registered direct financing completed in February&nbsp;2007. The warrants issued
to the investors meet the requirements of and are being accounted for as a liability in accordance
with ASC 480, &#147;<I>Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled
in, a Company&#146;s Own Stock.</I>&#148; The fair value of the warrants is re-measured each reporting period
with a derivative gain or loss recognized in the consolidated statement of operations. Such gains
or losses will continue to be reported until the warrants are exercised or expired. For the three
months ended June&nbsp;30, 2010 and 2011, the change in the value of warrants was a $0.3&nbsp;million
increase and a $0.1&nbsp;million decrease, respectively.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Foreign exchange gains (losses)&nbsp;decreased by $30,000 to a loss of $19,000 for the three months
ended June&nbsp;30, 2011 compared to a loss of $49,000 for the three months ended June&nbsp;30, 2010. Foreign
exchange gains/(losses) are reported in the consolidated statement of operations as a separate line
item within other income (expense).
</DIV>

<P align="center" style="font-size: 10pt; text-indent: 8%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->32<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Interest income increased by approximately $5,000 to $13,000 for the three months to June&nbsp;30,
2010 from $8,000 for the three months ended June&nbsp;30, 2010. This is mostly attributed to a higher
average daily balance of cash and cash equivalents during the three months ended June&nbsp;30, 2011
compared to the same period in 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Interest expense decreased by $9,000 from $9,000 for the three months ended June&nbsp;30, 2010 to
$0 for the three months ended June&nbsp;30, 2011. This reduction was primarily due to the elimination of
the accretion expense associated with the restructured Bothell lease, which expired in December
2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>The future</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The valuation of the warrant liability will continue to be re-measured at the end of each
reporting period. The valuation of the warrants is dependent upon many factors, including our stock
price, interest rates and the remaining term of the instrument and may fluctuate significantly,
which may have a significant impact on our statement of operations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Income tax benefit</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Credit is taken for research and development tax credits, which are claimed from the United
Kingdom&#146;s revenue and customs authority, or HMRC, in respect of qualifying research and development
costs incurred.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The following table summarizes research and development tax credits for the three months
ended June&nbsp;30, 2010 and 2011:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Increase (Decrease)</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>%</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>($000s)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Income tax benefit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">230</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">126</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(104</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(45</TD>
    <TD nowrap>)%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Research and development tax credits recoverable decreased by $0.1&nbsp;million to $0.1&nbsp;million for
the three months ended June&nbsp;30, 2011 from $0.2&nbsp;million for three months ended June&nbsp;30, 2010. The
level of tax credits recoverable is linked directly to qualifying research and development
expenditure incurred in any one year, but restricted to payroll taxes paid by us in the United
Kingdom in that same year. The $0.1&nbsp;million decrease between the three months ended June&nbsp;30, 2010
and 2011 is due to lower payroll taxes paid as a result of lower headcount in 2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>The future</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We expect to continue to be eligible to receive United Kingdom research and development tax
credits for the foreseeable future and will elect to do so.
</DIV>

<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->33<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Six Months Ended June&nbsp;30, 2010 and 2011</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Revenues</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The following table summarizes the components of our revenues for the six months ended
June&nbsp;30, 2010 and 2011:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Six Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Increase (Decrease)</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>%</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>($000s)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Collaboration and
research and development
revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(100</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(100</TD>
    <TD nowrap>)%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Product revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">273</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">360</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">87</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">32</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Grant revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(16</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(100</TD>
    <TD nowrap>)%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">389</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">360</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(29</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(7</TD>
    <TD nowrap>)%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We recognized $0.1&nbsp;million of collaboration and research and development revenue for the six
months ended June&nbsp;30, 2010 derived from an agreement with a pharmaceutical company under which we
provided one of our compounds for evaluation in the field of eye care. We had no collaboration and
research and development revenue for the six months ended June&nbsp;30, 2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Product revenue is derived from the sale of Xclair<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Cream, Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Liquid and Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>
Lozenges. During the six months ended June&nbsp;30, 2010 and 2011, we recognized product revenue of
approximately $0.3 and $0.4&nbsp;million, respectively, in accordance with our revenue recognition
policy. Product revenue was lower by $0.1&nbsp;million for the six months ended June&nbsp;30, 2010 compared
to the same period in 2011 due to $0.2&nbsp;million in product returns during six month ended June&nbsp;30,
2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Grant revenue is recognized as we incur and pay for qualifying costs and services under the
applicable grant. Grant revenue is primarily derived from various United Kingdom government grant
awards. We recognized $16,000 in grant revenue for the six months ended June&nbsp;30, 2010. We did not
recognize any grant revenue for the six months ended June&nbsp;30, 2011 as a result of finalization of a
three-year European Union grant in the first quarter of 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Cost of goods sold</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The following table summarizes cost of goods sold for the six months ended June&nbsp;30, 2010
and 2011:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Six Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Increase (Decrease)</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>%</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>($000s)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cost of goods sold</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">234</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">178</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(56</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(24</TD>
    <TD nowrap>)%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Total cost of sales represented 86% and 49% of product revenue for the six months ended June
30, 2010 and 2011, respectively. The high percentage for the six months ended June&nbsp;30, 2010 is the
result of lower product revenue driven by $0.2&nbsp;million of product returns during the period, as
described above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Research and development expenses</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">We expense all research and development costs as they are incurred. Research and development
expenses primarily include:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>clinical trial and regulatory-related costs;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>payroll and personnel-related expenses, including consultants and contract
research;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>preclinical studies and laboratory supplies and materials;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>technology license costs; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>rent and facility expenses for our laboratories.</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">
<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The following table provides information with respect to our research and development
expenditure for the six months ended June&nbsp;30, 2010 and 2011:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Six Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Increase (Decrease)</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>%</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>($000s)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Sapacitabine</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,803</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,731</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,928</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">69</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Seliciclib</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">133</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(108</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(81</TD>
    <TD nowrap>)%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other research and development costs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">561</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">183</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(378</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(67</TD>
    <TD nowrap>)%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total research and development expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,497</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,939</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,442</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">41</TD>
    <TD nowrap>%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Total research and development expenses represented 38% and 55% of our operating expenses for
the six months ended June&nbsp;30, 2010 and 2011, respectively.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Research and development expenditure increased by $1.4&nbsp;million to $4.9&nbsp;million for the six
month period ended June&nbsp;30, 2011 from $3.5 million for the six month period ended June&nbsp;30, 2010. The
increase in costs of $1.4&nbsp;million is primarily due to a $1.9&nbsp;million increase in sapacitabine
related costs and decreases of $0.1&nbsp;million and $0.4&nbsp;million in seliciclib and other research and
development costs, respectively, as we continue to focus on the development of sapacitabine. The
$1.9&nbsp;million increase in sapacitabine expenditures was primarily due to $1.6&nbsp;million of contractual
expenses, resulting from an achievement of a milestone triggered by the opening of enrollment in
our SEAMLESS trial, pursuant to the Daiichi Sankyo license under which we license certain patent
rights for sapacitabine, and a $0.4&nbsp;million increase in capsule manufacturing and testing.
Seliciclib costs decreased by $0.1&nbsp;million from $133,000 for the six months ended June&nbsp;30, 2010 to
$25,000 for six months ended June&nbsp;30, 2011 primarily due to the completion of clinical trials.
Other research and development costs decreased $0.4&nbsp;million to $0.2&nbsp;million for the six months
ended June&nbsp;30, 2011 from $0.6&nbsp;million for the six months ended June&nbsp;30, 2010, as we have
concentrated financial resources on the development of sapacitabine and reduced investment in other
compounds.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Selling, general and administrative expenses</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Selling, general and administrative expenses include costs for sales and marketing and
administrative personnel, legal and other professional expenses and general corporate expenses. The
following table summarizes the selling, general and administrative expenses for the six months
ended June&nbsp;30, 2010 and 2011:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Six Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Increase (Decrease)</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>%</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>($000s)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Selling, general and administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5,491</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,840</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(1,651</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(30</TD>
    <TD nowrap>)%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Total selling, general and administrative expenses represented 60% and 43% of our operating
expenses for the six months ended June&nbsp;30, 2010 and 2011, respectively. Our selling, general and
administrative expenditure decreased by $1.7&nbsp;million from $5.5&nbsp;million for the six months ended
June&nbsp;30, 2010 to $3.8&nbsp;million for the six months ended June&nbsp;30, 2011. The decrease of $1.7&nbsp;million
in expenses was primarily attributable to a net decrease in professional and consultancy costs of
$1.3&nbsp;million, a decrease in salaries of $0.4&nbsp;million, a decrease in rent of $0.2&nbsp;million as a
result of the expiration our lease on a facility in Bothell, Washington in December&nbsp;2010, and a
decrease in stock compensation of $0.3&nbsp;million. These amounts were partially offset by a $0.4
million increase in patent-related costs.
</DIV>

<P align="center" style="font-size: 10pt; text-indent: 8%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->35<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Other income (expense)</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The following table summarizes other income (expense)&nbsp;for the three months ended June&nbsp;30, 2010
and 2011:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Six Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Increase (Decrease)</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>%</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>($000s)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other income (expense):</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Change in valuation of warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(516</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">203</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">719</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">139</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Foreign exchange (losses)/gains</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(38</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(87</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(49</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(129</TD>
    <TD nowrap>)%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Interest income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">41</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Interest expense</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(33</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(100</TD>
    <TD nowrap>)%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total other income (expense)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(570</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">140</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">710</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(125</TD>
    <TD nowrap>)%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Total other income and expense, net, increased by approximately $0.7&nbsp;million, from an expense
of $0.6&nbsp;million for the six months ended June&nbsp;30, 2010, to income of $0.1&nbsp;million for the six
months ended June&nbsp;30, 2011. The most significant impact is the $0.7&nbsp;million increase in the change
in the valuation of the warrant liability, mostly due to the decrease in our common share price.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The change in valuation of warrants relates to the issue of warrants to purchase shares of our
common stock under the registered direct financing completed in February&nbsp;2007. The warrants issued
to the investors meet the requirements of and are being accounted for as a liability in accordance
with ASC 480, &#147;<I>Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled
in, a Company&#146;s Own Stock.</I>&#148; The fair value of the warrants is re-measured each reporting period
with a derivative gain or loss recognized in the consolidated statement of operations. Such gains
or losses will continue to be reported until the warrants are exercised or expired. For the six
months ended June&nbsp;30, 2010 and 2011, the change in the value of warrants was a $0.5&nbsp;million
increase and a $0.2&nbsp;million decrease, respectively.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Foreign exchange gains (losses)&nbsp;increased by $49,000 to a loss of $87,000 for the six months
ended June&nbsp;30, 2011 compared to a loss of $38,000 for the six months ended June&nbsp;30, 2010. Foreign
exchange gains/(losses) are reported in the consolidated statement of operations as a separate line
item within other income (expense).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Interest income increased by approximately $7,000 to $24,000 for the six months ended June&nbsp;30,
2010 from $17,000 for the six months ended June&nbsp;30, 2010. This is mostly attributed to a higher
average daily balance of cash and cash equivalents during the three months ended June&nbsp;30, 2011
compared to the same period in 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Interest expense decreased by $33,000 from $33,000 for the six months ended June&nbsp;30, 2010 to
$0 for the six months ended June&nbsp;30, 2011. This reduction was primarily due to the elimination of
the accretion expense associated with the restructured Bothell lease, which expired in December
2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>The future</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The valuation of the warrant liability will continue to be re-measured at the end of each
reporting period. The valuation of the warrants is dependent upon many factors, including our stock
price, interest rates and the remaining term of the instrument and may fluctuate significantly,
which may have a significant impact on our statement of operations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Income tax benefit</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Credit is taken for research and development tax credits, which are claimed from the United
Kingdom&#146;s revenue and customs authority, or HMRC, in respect of qualifying research and development
costs incurred.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 8%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->36<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The following table summarizes research and development tax credits for the six months
ended June&nbsp;30, 2010 and 2011:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Six Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Increase (Decrease)</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>$</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>%</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>($000s)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Income tax benefit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">363</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">317</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(46</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(13</TD>
    <TD nowrap>)%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Research and development tax credits recoverable decreased $46,000, from $0.4&nbsp;million for the
six months ended June&nbsp;30, 2010, to $0.3&nbsp;million for the six months ended June&nbsp;30, 2011. The level
of tax credits recoverable is linked directly to qualifying research and development expenditure
incurred in any one year, but restricted to payroll taxes paid by us in the United Kingdom in that
same year. The $46,000 decrease between the six months ended June&nbsp;30, 2010 and 2011 is due to lower
payroll taxes paid as a result of lower headcount in 2011.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 8%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->37<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Liquidity and Capital Resources</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The following is a summary of our key liquidity measures at December&nbsp;31, 2010 and June&nbsp;30, 2011:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>December 31,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>$ Difference</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>% Difference</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>($000s)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">29,495</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">20,614</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(8,881</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(30</TD>
    <TD nowrap>)%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Working capital:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">31,051</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">22,449</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(8,602</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(28</TD>
    <TD nowrap>)%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(6,535</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(6,040</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">495</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">8</TD>
    <TD nowrap>%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Working capital</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">24,516</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">16,409</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(8,107</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(33</TD>
    <TD nowrap>)%</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The objectives of our cash management policy are to safeguard and preserve funds, to maintain
liquidity sufficient to meet our cash flow requirements and to attain a market rate of return. At
June&nbsp;30, 2011, we had cash and cash equivalents of $20.6&nbsp;million as compared to $29.5&nbsp;million at
December&nbsp;31, 2010. The decrease in balance at June&nbsp;30, 2010 was primarily due to normal cash
outflows required to operate our business. Since our inception, we have not generated any
significant revenue and have relied primarily on the proceeds from sales of equity and preferred
securities to finance our operations and internal growth. Additional funding has come through
interest on investments, licensing revenue, government grants and research and development tax
credits. We have incurred significant losses since our inception. As of June&nbsp;30, 2011, we had an
accumulated deficit during the development stage of $250.0&nbsp;million. We believe that existing funds
together with cash generated from operations and recent financing activities are sufficient to
satisfy our planned working capital, capital expenditures, debt service and other financial
commitments for at least the next twelve months. Current business and capital market risks could
have a detrimental effect on the availability of sources of funding and our ability to access them
in the future which may delay or impede our progress of advancing our drugs currently in the clinic
to approval by the FDA for commercialization.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Cash provided by (used in) operating, investing and financing activities</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Cash provided by (used in) operating, investing and financing activities for the six months
ended June&nbsp;30, 2010 and 2011, is summarized as follows:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Six months ended June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>($000s)</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net cash used in operating activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(9,776</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(8,477</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net cash provided by investing activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net cash provided by (used in) financing activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17,855</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(441</TD>
    <TD nowrap>)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Operating activities</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Net cash used in operating activities decreased $1.3&nbsp;million, from $9.8&nbsp;million for the six
months ended June&nbsp;30, 2010 to $8.5&nbsp;million for the six months ended June&nbsp;30, 2011. The decrease in
cash outflow is primarily the result of better management of selling, general and administrative
expenses as the result of our continued focus on sapacitabine.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Investing activities</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Net cash provided by investing activities for the six months ended June&nbsp;30, 2010 was $27,000
as a result of the sale of laboratory equipment. There were no cash flows from investing activities
during the six months ended June&nbsp;30, 2011.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 8%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->38<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Financing activities</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Net cash used in financing activities for the six months ended June&nbsp;30, 2011 was $0.4&nbsp;million.
Net cash provided by financing activities was $17.9&nbsp;million for the six months ended June&nbsp;30, 2010.
During the six months ended June&nbsp;30, 2010, we completed two registered direct offerings in January
2010 for gross proceeds of approximately $13.0&nbsp;million, drew down the Kingsbridge CEFF totaling
approximately $2.8&nbsp;million and had investors exercising warrants totaling $2.7&nbsp;million. During the
six months ended June&nbsp;30, 2011, we paid a cash dividend to our holders of the Preferred Stock of
approximately $0.4&nbsp;million.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Operating Capital and Capital Expenditure Requirements</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We expect to continue to incur substantial operating losses in the future. While we have
generated modest product revenues from ALIGN product sales from October&nbsp;2007 through June&nbsp;30, 2011,
we cannot guarantee that we will generate any significant product revenues until a product
candidate has been approved by the FDA or similar regulatory agencies in other countries and
successfully commercialized.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We currently anticipate that our cash and cash equivalents, including net proceeds of $9.3
million from the underwritten offering closed in July&nbsp;2011, will be sufficient to fund our
operations for at least the next 12&nbsp;months. We cannot be certain that any of our programs will be
successful or that we will be able to raise sufficient funds to complete the development and
commercialize any of our product candidates currently in development, should they succeed.
Additionally, we plan to continue to evaluate in-licensing and acquisition opportunities to gain
access to new drugs or drug targets that would fit with our strategy. Any such transaction would
likely increase our funding needs in the future.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our future funding requirements will depend on many factors, including but not limited to:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the rate of progress and cost of our clinical trials, preclinical studies and
other discovery and research and development activities;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the costs associated with establishing manufacturing and commercialization
capabilities;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the costs of acquiring or investing in businesses, product candidates and
technologies;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the costs of filing, prosecuting, defending and enforcing any patent claims and
other intellectual property rights;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the costs and timing of seeking and obtaining FDA and other regulatory
approvals;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the effect of competing technological and market developments; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the economic and other terms and timing of any collaboration, licensing or
other arrangements into which we may enter.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Until we can generate a sufficient amount of product revenue to finance our cash requirements,
which we may never do, we expect to finance future cash needs primarily through public or private
equity offerings, debt financings or strategic collaborations. Although we are not reliant on
institutional credit finance and therefore not subject to debt covenant compliance requirements or
potential withdrawal of credit by banks, the current economic climate has also impacted the
availability of funds and activity in equity markets. We do not know whether additional funding
will be available on acceptable terms, or at all. If we are not able to secure additional funding
when needed, we may have to delay, reduce the scope of or eliminate one or more of our clinical
trials or research and development programs or make changes to our operating plan. In addition, we
may have to partner one or more of our product candidate programs at an earlier stage of
development, which would lower the economic value of those programs to us.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Off-Balance Sheet Arrangements</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">As of June&nbsp;30, 2011, we have no off-balance sheet arrangements.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 8%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->39<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Critical Accounting Policies</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Our discussion and analysis of our financial condition and results of operations is based on
our financial statements, which have been prepared in accordance with accounting principles
generally accepted in the United States. The preparation of these financial statements requires us
to make estimates and judgments that affect the reported amounts of assets, liabilities and
expenses and related disclosure of contingent assets and liabilities. We review our estimates on an
ongoing basis. We base our estimates on historical experience and on various other assumptions that
we believe to be reasonable under the circumstances. Actual results may differ from these estimates
under different assumptions or conditions. We believe the judgments and estimates required by the
following accounting policies to be critical in the preparation of our consolidated financial
statements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Revenue Recognition</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Product sales</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">We have adopted the following revenue recognition policy related to the sales of Xclair<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>
Cream, Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Liquid and Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Lozenges. We recognize revenue from these product sales when
persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered;
the selling price is fixed and determinable; and collectability is reasonably assured.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As we offer a general right of return on these product sales, we must consider the guidance in
ASC Topic 605. Under these guidelines, we account for all product sales using the &#147;sell-through&#148;
method. Under the sell-through method, revenue is not recognized upon shipment of product to
distributors. Instead, we record deferred revenue at gross invoice sales price and deferred cost of
sales at the cost at which those goods were held in inventory. We recognize revenue when such
inventory is sold through to pharmacies. To estimate products sold through to pharmacies, we rely
on third-party information, including information obtained from significant distributors with
respect to their inventory levels and sell-through to pharmacies. We estimate product returns based
on historical returns experience and other factors that affect the demand for our products as well
as the amount of product subject to return.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Stock-based Compensation</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The Company grants stock options, restricted stock units and restricted stock to officers,
employees, directors and consultants under the Company&#146;s 2006 Amended and Restated Equity Incentive
Plan, which was amended and restated as of April&nbsp;14, 2008. We also have outstanding options under
various stock-based compensation plans for employees and directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">ASC 718 requires measurement of compensation cost for all stock-based awards at fair value on
date of grant and recognition of compensation over the requisite service period for awards expected
to vest. The fair value of restricted stock and restricted stock units is determined based on the
number of shares granted and the quoted price of our common stock on the date of grant. The
determination of grant-date fair value for stock option awards is estimated using an option-pricing
model, which includes variables such as the expected volatility of our share price, the anticipated
exercise behavior of our employees, interest rates, and dividend yields. These variables are
projected based on our historical data, experience, and other factors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Such value is recognized as an expense over the requisite service period, net of estimated
forfeitures, using the straight-line attribution method. The estimation of stock awards that will
ultimately vest requires judgment, and to the extent actual results or updated estimates differ
from our current estimates, such amounts will be recorded as a cumulative adjustment in the period
estimates are revised. We consider many factors when estimating expected forfeitures, including
types of awards, employee class, and historical experience. If our actual forfeiture rate is
materially different from our estimate, the stock-based compensation expense could be significantly
different from what we have recorded in the current period.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->40<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Warrants Liability</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">With respect to warrants issued in February&nbsp;2007 as part of a financing and pursuant to ASC
815, since we are unable to control all the events or actions necessary to settle the warrants in
registered shares the warrants have been recorded as a current liability at fair value. The fair
value of the outstanding warrants is evaluated at each reporting period with any resulting change
in the fair value being reflected in the consolidated statements of operations. During the three
months ended June&nbsp;30, 2010 and 2011, the Company recognized gains from the change in the value of
warrants of approximately $0.3&nbsp;million and $0.1&nbsp;million, respectively. During the six months ended
June&nbsp;30, 2010, the Company recognized the change in the value of warrants as a loss of
approximately $0.5&nbsp;million. During the six months ended June&nbsp;30, 2011, the Company recognized the
change in the value of warrants as a gain of approximately $0.2&nbsp;million. Fair value
is estimated using an option-pricing model, which includes variables such as the expected
volatility of our share price, interest rates, and dividend yields. These variables are projected
based on our historical data, experience, and other factors. Changes in any of these variables
could result in material adjustments to the expense recognized for changes in the valuation of the
warrants liability.
</DIV>
<DIV align="left">
<A name="C17919104"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;3. Quantitative and Qualitative Disclosures About Market Risk.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">We are exposed to market risk related to fluctuations in foreign currency exchange rates.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Foreign Currency Risk</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We are exposed to foreign currency rate fluctuations related to the operation of our
subsidiary in the United Kingdom. At the end of each reporting period, income and expenses of the
subsidiary are re-measured into U.S. dollars using the average currency rate in effect for the
period and assets and liabilities are re-measured into U.S. dollars using either historical rates
or the exchange rate in effect at the end of the period. Intercompany loans with this subsidiary
are denominated in U.S. dollars and unrealized foreign exchange gains and losses arising on these
loans have been recorded in the consolidated statement of operations within the separate line item
foreign exchange gains/(losses) within other income (expense)&nbsp;up to September&nbsp;30, 2008.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We currently do not engage in foreign currency hedging. We enter into certain transactions
denominated in foreign currencies in respect of underlying operations and, therefore, we are
subject to currency exchange risks. We realized losses of $49,000 and gains of $2,000 for the
three months ended June&nbsp;30, 2010 and 2011, respectively. During the six months ended June&nbsp;30, 2010
and 2011, we realized losses of $38,000 and $66,000, respectively.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Common Stock Price Risk</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In February&nbsp;2007, we issued common stock and warrants. Pursuant to ASC 815, we recorded the
fair value of the warrants as a current liability. The fair value of the outstanding warrants is
evaluated at each reporting period with any resulting change in the fair value being reflected in
the condensed consolidated statements of operations. We recognized a loss of $0.3&nbsp;million and a
gain of $0.1&nbsp;million on the consolidated statement of operations for the three months ended June
30, 2010 and 2011, respectively, related to the change in the value of warrants. We recognized a
loss of $0.5&nbsp;million and a gain of $0.2&nbsp;million on the consolidated statement of operations for the
six months ended June&nbsp;30, 2010 and 2011, respectively, related to the change in the value of
warrants. Fair value of the derivative instruments will be affected by estimates of various factors
that may affect the respective instrument, including our stock price, the risk free rate of return
and expected volatility in the fair value of our stock price. As the fair value of this derivative
may fluctuate significantly from period to period, the resulting change in valuation may have a
significant impact on our results of operations.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->41<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">
<DIV align="left">
<A name="C17919105"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;4. Controls and Procedures</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Evaluation of Disclosure Controls and Procedures</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Under the supervision and with the participation of our management, including our principal
executive officer and principal financial and accounting officer, we conducted an evaluation of the
effectiveness, as of June&nbsp;30, 2011, of our disclosure controls and procedures, as defined in Rules
13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act.
The purpose of this evaluation was to determine whether as of the evaluation date our disclosure
controls and procedures were effective to provide reasonable assurance that the information we are
required to disclose in our filings with the SEC under the Exchange Act (i)&nbsp;is recorded, processed,
summarized and reported within the time periods specified in the SEC&#146;s rules and forms and (ii)
accumulated and communicated to our management, including our principal executive officer and
principal financial and accounting officer, as appropriate to allow timely decisions regarding
required disclosure. Based on that evaluation, management has concluded that as of June&nbsp;30, 2011,
our disclosure controls and procedures were not effective at the reasonable assurance level due to
the material weaknesses in our internal controls described in the amendment to our Annual Report on
Form 10-K for the year ended December&nbsp;31, 2010 in the section captioned &#147;Item&nbsp;9A &#151; Controls and
Procedures &#151; Management&#146;s Annual Report on Internal Control Over Financial Reporting&#148; that remain
present.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Changes in Internal Control Over Financial Reporting</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">There have been no changes in our internal control over financial reporting during the quarter
ended June&nbsp;30, 2011 that have materially affected, or are reasonably likely to materially affect,
our internal control over financial reporting other than those described below.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In response to the material weaknesses in our internal controls noted in our Annual Report on
Form 10-K for the year ended December&nbsp;31, 2010, filed on March&nbsp;31, 2011, management presented a
proposed remediation plan to our audit committee concerning our internal controls over financial
reporting, and the audit committee adopted management&#146;s remediation plan. We have implemented the
plan by hiring qualified finance professionals and retaining outside consultants. Remediation of
the material weaknesses will require management time and attention over the coming quarters and
will likely result in additional incremental expenses. Any failure on our part to remedy our
identified weaknesses or any additional errors or delays in our financial reporting would have a
material adverse effect on our business and results of operations and could have a substantial
adverse impact on the trading price of our common stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Subject to oversight by our board of directors, our chief executive officer will be
responsible for implementing management&#146;s internal control remediation plan, adopted by our audit
committee and approved by our board of directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Specifically, the remediation plan consists of strengthening the financial reporting function
through the hiring of qualified finance personnel, with experience in the interpretation and
application of accounting principles generally accepted in the United States, or GAAP, and
designing and placing into operation appropriate controls to prevent or detect on a timely basis
any potential material misstatements in the accounting, presentation and disclosure of cumulative
preferred dividends. It is anticipated that the remediation plan, once implemented, will
materially affect our internal control over financial reporting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We anticipate that the actions described above will remediate the material weakness described
in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2010.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->42<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Inherent Limitation on the Effectiveness of Internal Controls</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The effectiveness of any system of internal control over financial reporting, including ours,
is subject to inherent limitations, including the exercise of judgment in designing, implementing,
operating, and evaluating the controls and procedures, and the inability to eliminate misconduct
completely. Accordingly, any system of internal control over financial reporting, including ours,
no matter how well designed and operated, can only provide reasonable, not absolute assurances. In
addition, projections of any evaluation of effectiveness to future periods are subject to the risk
that controls may become inadequate because of changes in conditions, or that the degree of
compliance with the policies or procedures may deteriorate. We intend to continue to monitor and
upgrade our internal controls as necessary or appropriate for our business, but cannot assure you
that such improvements will be sufficient to provide us with effective internal control over
financial reporting.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->43<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="left">
<A name="C17919106"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>PART II. </B><B>OTHER INFORMATION</B>
</DIV>

<DIV align="left">
<A name="C17919107"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;1. Legal proceedings.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">From time to time, we may be involved in routine litigation incidental to the conduct of our
business. On April&nbsp;27, 2010, we were served with a complaint filed by Celgene Corporation in the
United States District Court for the District of Delaware seeking a declaratory judgment that four
of our own patents, claiming the use of romidepsin injection in T-cell lymphomas, are invalid and
not infringed by Celgene&#146;s products, but directly involve the use and administration of Celgene&#146;s
ISTODAX<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> (romidepsin for injection) product. On June&nbsp;17, 2010, we filed our answer and
counterclaims to the declaratory judgment complaint. We have filed counterclaims charging Celgene
with infringement of each of our four patents and seeking damages for Celgene&#146;s infringement as
well as injunctive relief. The four patents directly involve the use and administration of
Celgene&#146;s ISTODAX<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> (romidepsin for injection) product.
</DIV>
<DIV align="left">
<A name="C17919108"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;1A. Risk Factors.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><I>In analyzing our company, you should consider carefully the following risk factors, together
with all of the other information included in Part&nbsp;I, &#147;Item&nbsp;1A. Risk Factors&#148; in our Annual Report
on </I><I>Form 10-K</I><I> for the year ended December&nbsp;31, 2010. Factors that could cause or contribute to
differences in our actual results include those discussed in the following subsection, as well as
those discussed above in &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results
of Operations&#148; and elsewhere throughout this Quarterly Report on </I><I>Form 10-Q</I><I>. Each of the following
risk factors, either alone or taken together, could adversely affect our business, operating
results and financial condition, as well as adversely affect the value of an investment in our
common stock.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Risks Associated with Development and Commercialization of Our Drug Candidates</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Clinical trial designs that were discussed with the authorities prior to their commencement may
subsequently be considered insufficient for approval at the time of application for regulatory
approval. Thus, our SPA regarding our SEAMLESS trial does not guarantee marketing approval or
approval of our sapacitabine oral capsules for the treatment of acute myeloid leukemia.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On September&nbsp;13, 2010, we reached agreement with the FDA regarding an SPA on the design of a
pivotal Phase 3 trial for our sapacitabine oral capsules as a front-line treatment in elderly
patients aged 70&nbsp;years or older with newly diagnosed acute myeloid leukemia, or AML, who are not
candidates for intensive induction chemotherapy, or the SEAMLESS trial. An SPA provides trial
sponsors with an agreement from the FDA that the design and analysis of the trial adequately
address objectives in support of a submission for a marketing application if the trial is performed
according to the SPA. The SPA may only be changed through a written agreement between the sponsor
and the FDA or if the FDA becomes aware of a substantial scientific issue essential to product
efficacy or safety. On January&nbsp;11, 2011, we opened enrollment of the SEAMLESS trial.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">An SPA, however, neither guarantees approval nor provides any assurance that a marketing
application would be approved by the FDA. There are companies that have been granted SPAs but have
ultimately failed to obtain final approval to market their drugs. The FDA may revise previous
guidance or decide to ignore previous guidance at any time during the course of clinical activities
or after the completion of clinical trials. The FDA may raise issues relating to, among other
things, safety, study conduct, bias, deviation from the protocol, statistical power, patient
completion rates, changes in scientific or medical parameters or internal inconsistencies in the
data prior to making its final decision. The FDA may also seek the guidance of an outside advisory
committee prior to making its final decision. Even with successful clinical safety and efficacy
data, including such data from a clinical trial conducted pursuant to an SPA, we may be required to
conduct additional, expensive clinical trials to obtain regulatory approval.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->44<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>The development program for our lead drug candidate sapacitabine is based, in part, on intellectual
property rights we license from others and any termination of this license could seriously harm our
business.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Effective July&nbsp;11, 2011, the Daiichi Sankyo license under which we license certain patent rights for
sapacitabine, our lead drug candidate, was amended to
irrevocably waive a termination right Daiichi Sankyo possessed under a provision of the agreement
that required the Company to obtain regulatory approval to sell sapacitabine in at least one
country by September&nbsp;2011, and releases the Company from all claims and liability of any kind
arising under such provision. The amendment further provides that the royalty due from the Company
to Daiichi Sankyo on future net sales of sapacitabine be increased by a percentage between 1.25%
and 1.50% depending on the level of net sales of sapacitabine realized.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In general, the license may be terminated by us for technical, scientific, efficacy, safety,
or commercial reasons on six months notice, or twelve months if after a launch of a
sapacitabine-based product, or by either party for material default.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Although we are currently in compliance with all of our material obligations under this
license, if we were to breach any such obligations, our counterparty may be entitled to terminate
the license. This would restrict or delay or eliminate our ability to develop and commercialize
these drug candidates, which could adversely affect our business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>If we fail to enter into and maintain successful strategic alliances for our drug candidates, we
may have to reduce or delay our drug candidate development or increase our expenditures.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">An important element of our strategy for developing, manufacturing and commercializing our
drug candidates is entering into strategic alliances with pharmaceutical companies or other
industry participants to advance our programs and enable us to maintain our financial and
operational capacity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We face significant competition in seeking appropriate alliances. We may not be able to
negotiate alliances on acceptable terms, if at all. In addition, these alliances may be
unsuccessful. If we fail to create and maintain suitable alliances, we may have to limit the size
or scope of, or delay, one or more of our drug development or research programs. If we elect to
fund drug development or research programs on our own, we will have to increase our expenditures
and will need to obtain additional funding, which may be unavailable or available only on
unfavorable terms.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Clinical trials are expensive, time consuming, subject to delay and may be required to continue
beyond our available funding.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Clinical trials are expensive, complex, can take many years to conduct and may have uncertain
outcomes. We estimate that clinical trials of our most advanced drug candidates may be required to
continue beyond our available funding and may take several years more to complete. The designs used
in some of our trials have not been used widely by other pharmaceutical companies. Failure can
occur at any stage of the testing and we may experience numerous unforeseen events during, or as a
result of, the clinical trial process that could delay or prevent commercialization of our current
or future drug candidates, including but not limited to:
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->45<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>delays in securing clinical investigators or trial sites for our clinical
trials;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>delays in obtaining institutional review board, or IRB, and other regulatory
approvals to commence a clinical trial;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>slower than anticipated rates of patient recruitment and enrollment, or
reaching the targeted number of patients because of competition for patients from
other trials or other reasons;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>negative or inconclusive results from clinical trials;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>unforeseen safety issues;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>uncertain dosing issues may or may not be related to suboptimal pharmacokinetic
and pharmacodynamic behaviors;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>approval and introduction of new therapies or changes in standards of practice
or regulatory guidance that render our clinical trial endpoints or the targeting
of our proposed indications obsolete;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>inability to monitor patients adequately during or after treatment or problems
with investigator or patient compliance with the trial protocols;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>inability to replicate in large controlled studies safety and efficacy data
obtained from a limited number of patients in uncontrolled trials;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>inability or unwillingness of medical investigators to follow our clinical
protocols; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>unavailability of clinical trial supplies.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>If we suffer any significant delays, setbacks or negative results in, or termination of, our
clinical trials, we may be unable to continue development of our drug candidates or generate
revenue and our development costs could increase significantly. Adverse events have been observed
in our clinical trials and may force us to stop development of our product candidates or prevent
regulatory approval of our product candidates.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Adverse or inconclusive results from our clinical trials may substantially delay, or halt
entirely, any further development of our drug candidates. Many companies have failed to demonstrate
the safety or effectiveness of drug candidates in later stage clinical trials notwithstanding
favorable results in early stage clinical trials. Previously unforeseen and unacceptable side
effects could interrupt, delay or halt clinical trials of our drug candidates and could result in
the FDA or other regulatory authorities denying approval of our drug candidates. We will need to
demonstrate safety and efficacy for specific indications of use, and monitor safety and compliance
with clinical trial protocols throughout the development process. To date, long-term safety and
efficacy has not been demonstrated in clinical trials for any of our drug candidates. Toxicity and
&#147;serious adverse events&#148; as defined in trial protocols have been noted in preclinical and clinical
trials involving certain of our drug candidates. For example, neutropenia and gastro-intestinal
toxicity were observed in patients receiving sapacitabine and elevations of liver enzymes and
decrease in potassium levels have been observed in patients receiving seliciclib.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In addition, we may pursue clinical trials for sapacitabine and seliciclib in more than one
indication. There is a risk that severe toxicity observed in a trial for one indication could
result in the delay or suspension of all trials involving the same drug candidate. Even if we
believe the data collected from clinical trials of our drug candidates are promising with respect
to safety and efficacy, such data may not be deemed sufficient by regulatory authorities to warrant
product approval. Clinical data can be interpreted in different ways. Regulatory officials could
interpret such data in different ways than we do which could delay, limit or prevent regulatory
approval. The FDA, other regulatory authorities or we may suspend or terminate clinical trials at
any time. Any failure or significant delay in completing clinical trials for our drug
candidates, or in receiving regulatory approval for the commercialization of our drug
candidates, may severely harm our business and reputation.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->46<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>If our understanding of the role played by CDKs or AKs in regulating the cell cycle is incorrect,
this may hinder pursuit of our clinical and regulatory strategy.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our development of small molecule inhibitors of CDK and AK is based on our understanding of
the mechanisms of action of CDK and AK inhibitors and their interaction with other cellular
mechanisms. One of our drug candidates, seliciclib, is a CDK inhibitor, and CYC116 is an AK and
VEGFR2 inhibitor. Although a number of pharmaceutical and biotechnology companies are attempting to
develop CDK or AK inhibitor drugs for the treatment of cancer, no CDK or AK inhibitor has yet
reached the market. If our understanding of the role played by CDK or AK inhibitors in regulating
the cell cycle is incorrect, seliciclib and/or CYC116 may fail to produce therapeutically relevant
results hindering our ability to pursue our clinical and regulatory strategy.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>We are making use of biomarkers, which are not scientifically validated, and our reliance on
biomarker data may thus lead us to direct our resources inefficiently.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We are making use of biomarkers in an effort to facilitate our drug development and to
optimize our clinical trials. Biomarkers are proteins or other substances whose presence in the
blood can serve as an indicator of specific cell processes. We believe that these biological
markers serve a useful purpose in helping us to evaluate whether our drug candidates are having
their intended effects through their assumed mechanisms, and thus enable us to identify more
promising drug candidates at an early stage and to direct our resources efficiently. We also
believe that biomarkers may eventually allow us to improve patient selection in connection with
clinical trials and monitor patient compliance with trial protocols.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">For most purposes, however, biomarkers have not been scientifically validated. If our
understanding and use of biomarkers is inaccurate or flawed, or if our reliance on them is
otherwise misplaced, then we will not only fail to realize any benefits from using biomarkers, but
may also be led to invest time and financial resources inefficiently in attempting to develop
inappropriate drug candidates. Moreover, although the FDA has issued for comment a draft guidance
document on the potential use of biomarker data in clinical development, such data are not
currently accepted by the FDA or other regulatory agencies in the United States, the European Union
or elsewhere in applications for regulatory approval of drug candidates and there is no guarantee
that such data will ever be accepted by the relevant authorities in this connection. Our biomarker
data should not be interpreted as evidence of efficacy.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Due to our reliance on contract research organizations or other third parties to conduct clinical
trials, we may be unable to directly control the timing, conduct and expense of our clinical
trials.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We do not have the ability to independently conduct clinical trials required to obtain
regulatory approvals for our drug candidates. We must rely on third parties, such as contract
research organizations, data management companies, contract clinical research associates, medical
institutions, clinical investigators and contract laboratories to conduct our clinical trials. In
addition, we rely on third parties to assist with our preclinical development of drug candidates.
If these third parties do not successfully carry out their contractual duties or regulatory
obligations or meet expected deadlines, if the third parties need to be replaced or if the quality
or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical
protocols or regulatory requirements or for other reasons, our preclinical development activities
or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to
obtain regulatory approval for or successfully commercialize our drug candidates.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>To the extent we are able to enter into collaborative arrangements or strategic alliances, we will
be exposed to risks related to those collaborations and alliances.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Although we are not currently party to any collaboration arrangement or strategic alliance
that is material to our business, in the future we expect to be dependent upon collaborative
arrangements or strategic alliances to complete the development and commercialization of some of
our drug candidates
particularly after the Phase 2 stage of clinical testing. These arrangements may place the
development of our drug candidates outside our control, may require us to relinquish important
rights or may otherwise be on terms unfavorable to us.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->47<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We may be unable to locate and enter into favorable agreements with third parties, which could
delay or impair our ability to develop and commercialize our drug candidates and could increase our
costs of development and commercialization. Dependence on collaborative arrangements or strategic
alliances will subject us to a number of risks, including the risk that:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>we may not be able to control the amount and timing of resources that our
collaborators may devote to the drug candidates;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our collaborators may experience financial difficulties;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>we may be required to relinquish important rights such as marketing and
distribution rights;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>business combinations or significant changes in a collaborator&#146;s business
strategy may also adversely affect a collaborator&#146;s willingness or ability to
complete our obligations under any arrangement;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>a collaborator could independently move forward with a competing drug candidate
developed either independently or in collaboration with others, including our
competitors; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>collaborative arrangements are often terminated or allowed to expire, which
would delay the development and may increase the cost of developing our drug
candidates.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>We have no manufacturing capacity and will rely on third party manufacturers for the late stage
development and commercialization of any drugs or devices we may develop or sell.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We do not currently operate manufacturing facilities for clinical or commercial production of
our drug candidates under development or our currently marketed ALIGN products. We currently lack
the resources or the capacity to manufacture any of our products on a clinical or commercial scale.
We depend upon a third party, Sinclair, to manufacture the commercial products sold by our ALIGN
subsidiary and we cannot rely upon Sinclair to continue to supply the products. We anticipate
future reliance on a limited number of third party manufacturers until we are able, or decide to,
expand our operations to include manufacturing capacities. Any performance failure on the part of
manufacturers could delay late stage clinical development or regulatory approval of our drug, the
commercialization of our drugs or our ability to sell our commercial products, producing additional
losses and depriving us of potential product revenues.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">If the FDA or other regulatory agencies approve any of our drug candidates for commercial
sale, or if we significantly expand our clinical trials, we will need to manufacture them in larger
quantities and will be required to secure alternative third-party suppliers to our current
suppliers. To date, our drug candidates have been manufactured in small quantities for preclinical
testing and clinical trials and we may not be able to successfully increase the manufacturing
capacity, whether in collaboration with our current or future third-party manufacturers or on our
own, for any of our drug candidates in a timely or economic manner, or at all. Significant scale-up
of manufacturing may require additional validation studies, which the FDA and other regulatory
bodies must review and approve. If we are unable to successfully increase the manufacturing
capacity for a drug candidate whether for late stage clinical trials or for commercial sale or are
unable to secure alternative third-party suppliers to our current suppliers, the drug development,
regulatory approval or commercial launch of any related drugs may be delayed or blocked or there
may be a shortage in supply. Even if any third party manufacturer makes improvements in the
manufacturing process for our drug candidates, we may not own, or may have to share, the
intellectual property rights to such innovation.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->48<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>As we evolve from a company primarily involved in discovery and development to one also involved in
the commercialization of drugs and devices, we may encounter difficulties in managing our growth
and expanding our operations successfully.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In order to execute our business strategy, we will need to expand our development, control and
regulatory capabilities and develop financial, manufacturing, marketing and sales capabilities or
contract with third parties to provide these capabilities for us. If our operations expand, we
expect that we will need to manage additional relationships with various collaborative partners,
suppliers and other third parties. Our ability to manage our operations and any growth will require
us to make appropriate changes and upgrades, as necessary, to our operational, financial and
management controls, reporting systems and procedures wherever we may operate. Any inability to
manage growth could delay the execution of our business plan or disrupt our operations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>The failure to attract and retain skilled personnel and key relationships could impair our drug
development and commercialization efforts.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We are highly dependent on our senior management and key scientific, technical and sales and
marketing personnel. Competition for these types of personnel is intense. The loss of the services
of any member of our senior management, scientific, technical or sales or marketing staff may
significantly delay or prevent the achievement of drug development and other business objectives
and could have a material adverse effect on our business, operating results and financial
condition. We also rely on consultants and advisors to assist us in formulating our strategy. All
of our consultants and advisors are either self-employed or employed by other organizations, and
they may have conflicts of interest or other commitments, such as consulting or advisory contracts
with other organizations, that may affect their ability to contribute to us. The success of the
commercialization of the ALIGN products depends, in large part, on our continued ability to develop
and maintain important relationships with distributors and research and medical institutions.
Failure to do that could have a material adverse effect on our ability to commercialize the ALIGN
products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We intend to expand and develop new drug candidates. We will need to hire additional employees
in order to continue our clinical trials and market our drug candidates and medical devices. This
strategy will require us to recruit additional executive management and scientific and technical
personnel. There is currently intense competition for skilled executives and employees with
relevant scientific and technical expertise, and this competition is likely to continue. The
inability to attract and retain sufficient scientific, technical and managerial personnel could
limit or delay our product development efforts, which would adversely affect the development of our
drug candidates and commercialization of our potential drugs and growth of our business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Our drug candidates are subject to extensive regulation, which can be costly and time-consuming,
and we may not obtain approvals for the commercialization of any of our drug candidates.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The clinical development, manufacturing, selling and marketing of our drug candidates are
subject to extensive regulation by the FDA and other regulatory authorities in the United States,
the European Union and elsewhere. These regulations also vary in important, meaningful ways from
country to country. We are not permitted to market a potential drug in the United States until we
receive approval of an NDA from the FDA. We have not received an NDA approval from the FDA for any
of our drug candidates.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Obtaining an NDA approval is expensive and is a complex, lengthy and uncertain process. The
FDA approval process for a new drug involves completion of preclinical studies and the submission
of the results of these studies to the FDA, together with proposed clinical protocols,
manufacturing information, analytical data and other information in an Investigational New Drug, or
IND, which must become effective before human clinical trials may begin. Clinical development
typically involves three phases of study: Phase 1, 2 and 3. The most significant costs associated
with clinical development are the pivotal or suitable for registration late Phase 2 or Phase 3
clinical trials as they tend to be the longest and largest studies conducted during the drug
development process. After completion of clinical trials, an NDA may be submitted to the FDA.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->49<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In responding to an NDA, the FDA may refuse to file the application, or if accepted for
filing, the FDA may grant marketing approval, request additional information or deny the
application if it determines that the application does not provide an adequate basis for approval.
In addition, failure to comply with the FDA and other applicable foreign and U.S. regulatory
requirements may subject us to administrative or judicially imposed sanctions. These include
warning letters, civil and criminal penalties, injunctions, product seizure or detention, product
recalls, total or partial suspension of production and refusal to approve either pending NDAs, or
supplements to approved NDAs.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Despite the substantial time and expense invested in preparation and submission of an NDA or
equivalents in other jurisdictions, regulatory approval is never guaranteed. The FDA and other
regulatory authorities in the United States, the European Union and elsewhere exercise substantial
discretion in the drug approval process. The number, size and design of preclinical studies and
clinical trials that will be required for FDA or other regulatory approval will vary depending on
the drug candidate, the disease or condition for which the drug candidate is intended to be used
and the regulations and guidance documents applicable to any particular drug candidate. The FDA or
other regulators can delay, limit or deny approval of a drug candidate for many reasons, including,
but not limited to:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>those discussed in the risk factor which immediately follows;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the fact that the FDA or other regulatory officials may not approve our or our
third party manufacturer&#146;s processes or facilities; or</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the fact that new regulations may be enacted by the FDA or other regulators may
change their approval policies or adoption of new regulations requiring new or
different evidence of safety and efficacy for the intended use of a drug
candidate.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>With regard to the ALIGN products, and following regulatory approval of any of our drug candidates,
we are subject to ongoing regulatory obligations and restrictions, which may result in significant
expense and limit our ability to commercialize our potential products.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">With regard to our ALIGN products and our drug candidates, if any, approved by the FDA or by
another regulatory authority, we are held to extensive regulatory requirements over product
manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion and
record keeping. Regulatory approvals may also be subject to significant limitations on the
indicated uses or marketing of the drug candidates. Potentially costly follow-up or post-marketing
clinical studies may be required as a condition of approval to further substantiate safety or
efficacy, or to investigate specific issues of interest to the regulatory authority. Previously
unknown problems with the product or drug candidate, including adverse events of unanticipated
severity or frequency, may result in restrictions on the marketing of the drug or device, and could
include withdrawal of the drug or device from the market.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In addition, the law or regulatory policies governing pharmaceuticals may change. New
statutory requirements may be enacted or additional regulations may be enacted that could prevent
or delay regulatory approval of our drug candidates. We cannot predict the likelihood, nature or
extent of adverse government regulation that may arise from future legislation or administrative
action, either in the United States or elsewhere. If we are not able to maintain regulatory
compliance, we might not be permitted to market our drugs and our business could suffer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Our applications for regulatory approval could be delayed or denied due to problems with studies
conducted before we in-licensed the rights to some of our product candidates.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We currently license some of the compounds and drug candidates used in our research programs
from third parties. These include sapacitabine which was licensed from Daiichi Sankyo. Our present
research involving these compounds relies upon previous research conducted by third parties over
whom we had no control and before we in-licensed the drug candidates. In order to receive
regulatory approval of a drug candidate, we must present all relevant data and information obtained
during our research and development,
including research conducted prior to our licensure of the drug candidate. Although we are not
currently aware of any such problems, any problems that emerge with preclinical research and
testing conducted prior to our in-licensing may affect future results or our ability to document
prior research and to conduct clinical trials, which could delay, limit or prevent regulatory
approval for our drug candidates.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->50<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>We face intense competition and our competitors may develop drugs that are less expensive, safer,
or more effective than our drug candidates.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">A large number of drug candidates are in development for the treatment of leukemia, lung
cancer, lymphomas and nasopharyngeal cancer. Several pharmaceutical and biotechnology companies
have nucleoside analogs or other products on the market or in clinical trials which may be
competitive to sapacitabine in both hematological and oncology indications. These include Celgene,
Cephalon, Eisai, Johnson &#038; Johnson, Eli Lilly, Genzyme, GlaxoSmithKline, Hospira, Onconova,
Pfizer, Seattle Genetics and Sunesis. There are two other orally available CDK inhibitors in
Phase 2 clinical trials. PD-0332991 (Pfizer/Onyx) and PHA-848125 (Nerviano Medical Sciences) target
different subsets of kinase enzymes and have a different mechanism of action from seliciclib. We
believe that seliciclib is currently the most advanced orally available CDK-specific agent in Phase
2 clinical trials but that there are a number of companies, including AstraZeneca, Astex
Therapeutics, Bayer-Schering, Eisai, Merck, Nerviano Medical Sciences, Pfizer, Piramal Life
Sciences, and Roche that are developing CDK inhibitors in early stage clinical trials in cancer
patients. Although Aventis, a predecessor of Sanofi-Aventis, had previously announced that it has
ceased Phase 2 development of alvocidib or flavopiridol, a CDK inhibitor, we believe that the
National Cancer Institute&#146;s Cancer Therapy Evaluation Program, or CTEP, is continuing to enroll
patients in a CTEP sponsored trial in patients with chronic leukemia. A number of companies are
pursuing discovery and research activities in each of the other areas that are the subject of our
research and drug development programs. We believe that Amgen, Astex Therapeutics, AstraZeneca,
Entremed, Merck, jointly with Vertex, Nerviano Medical Sciences, Pfizer, Rigel, Sunesis and
Takeda-Millennium have commenced Phase 1, Phase 2, or Phase 3 clinical trials of Aurora kinase
inhibitors in patients with advanced cancers. Several companies have reported selection of Aurora
kinase inhibitor candidates for development and may have started or are expected to start clinical
trials within the next twelve months. We believe that Boehringer Ingelheim, GlaxoSmithKline, Merck,
Nerviano Medical Sciences, Takeda-Millennium and Tekmira Pharmaceuticals Corporation have commenced
Phase 1 or Phase 2 clinical trials with Plk inhibitor candidates for oncology indications. For our
ALIGN products, we believe that Beiersdorf, Daiichi Sankyo, Eisai, Johnson &#038; Johnson, MPM Medical
and other companies market products for radiation dermatitis and xerostomia.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our competitors, either alone or together with collaborators, may have substantially greater
financial resources and research and development staff. Our competitors may also have more
experience:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>developing drug candidates;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>conducting preclinical and clinical trials;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>obtaining regulatory approvals; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>commercializing product candidates.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our competitors may succeed in obtaining patent protection and regulatory approval and may
market drugs before we do. If our competitors market drugs that are less expensive, safer, more
effective or more convenient to administer than our potential drugs, or that reach the market
sooner than our potential drugs, we may not achieve commercial success. Scientific, clinical or
technical developments by our competitors may render our drug candidates obsolete or
noncompetitive. We anticipate that we will face increased competition in the future as new
companies enter the markets and as scientific developments progress. If our drug candidates obtain
regulatory approvals, but do not compete effectively in the marketplace, our business will suffer.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->51<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>The commercial success of the ALIGN products and our drug candidates depends upon their market
acceptance among physicians, patients, healthcare providers and payors and the medical community.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">It is necessary that our and our distribution partners&#146; products, including Xclair<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Cream,
Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Liquid and Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Lozenges achieve and maintain market acceptance. If our drug
candidates are approved by the FDA or by another regulatory authority, the resulting drugs, if any,
may not gain market acceptance among physicians, healthcare providers and payors, patients and the
medical community. The degree of market acceptance of any of our approved drugs or devices will
depend on a variety of factors, including:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>timing of market introduction, number and clinical profile of competitive
drugs;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our ability to provide acceptable evidence of safety and efficacy;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>relative convenience and ease of administration;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>cost-effectiveness;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>availability of coverage, reimbursement and adequate payment from health
maintenance organizations and other third party payors;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>prevalence and severity of adverse side effects; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>other potential advantages over alternative treatment methods.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">If our drugs fail to achieve market acceptance, we may not be able to generate significant
revenue and our business would suffer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>If we are unable to compete successfully in our market place, it will harm our business.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">There are existing products in the marketplace that compete with our products. Companies may
develop new products that compete with our products. Certain of these competitors and potential
competitors have longer operating histories, substantially greater product development capabilities
and financial, scientific, marketing and sales resources. Competitors and potential competitors may
also develop products that are safer, more effective or have other potential advantages compared to
our products. In addition, research, development and commercialization efforts by others could
render our products obsolete or non-competitive. Certain of our competitors and potential
competitors have broader product offerings and extensive customer bases allowing them to adopt
aggressive pricing policies that would enable them to gain market share. Competitive pressures
could result in price reductions, reduced margins and loss of market share. We could encounter
potential customers that, due to existing relationships with our competitors, are committed to
products offered by those competitors. As a result, those potential customers may not consider
purchasing our products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>There is uncertainty related to coverage, reimbursement and payment by healthcare providers and
payors for the ALIGN products and newly approved drugs, if any. The inability or failure to obtain
or maintain coverage could affect our ability to market the ALIGN products and our future drugs and
decrease our ability to generate revenue.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The availability and levels of coverage and reimbursement of newly approved drugs by
healthcare providers and payors is subject to significant uncertainty. The commercial success of
the ALIGN products and our drug candidates in both the United States and international markets is
substantially dependent on whether third party coverage and reimbursement is available. The United
States Centers for Medicare and Medicaid Services, health maintenance organizations and other third
party payors in the United States, the European Union and other jurisdictions are increasingly
attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of
new drugs and, as a result, they may not cover or provide adequate payment for our potential drugs.
The ALIGN products and our drug candidates may not be
considered cost-effective and reimbursement may not be available to consumers or may not be
sufficient to allow the ALIGN products or our drug candidates to be marketed on a competitive
basis.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->52<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In some countries, pricing of prescription drugs is subject to government control. In such
countries, pricing negotiations with governmental authorities can take three to 12&nbsp;months or longer
following application to the competent authorities. To obtain reimbursement or pricing approval in
such countries may require conducting an additional clinical trial comparing the cost-effectiveness
of the drug to other alternatives. In the United States, the Medicare Part&nbsp;D drug benefit
implemented in 2006 will limit drug coverage through formularies and other cost and utilization
management programs, while Medicare Part&nbsp;B limits drug payments to a certain percentage of average
price or through restrictive payment policies of &#147;least costly alternatives&#148; and &#147;inherent
reasonableness&#148; Our business could be materially harmed if coverage, reimbursement or pricing is
unavailable or set at unsatisfactory levels.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Intellectual property rights and distribution rights for our drug candidate seliciclib and ALIGN
products are licensed from others, and any termination of these licenses could harm our business.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have in-licensed certain patent rights in connection with the development program of our
drug candidate seliciclib. Pursuant to the CNRS and Institut Curie license under which we license
seliciclib, we are obligated to pay license fees, milestone payments and royalties and provide
regular progress reports. We are also obligated to use reasonable efforts to develop and
commercialize products based on the licensed patents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have in-licensed from Sinclair the distribution rights to the ALIGN products. This license
agreement imposes obligations on us and expires in 2015. Although we are currently in compliance
with all of our material obligations under this license, if we were to breach any such obligations,
Sinclair would be permitted to terminate the license. In addition, if we are unable to extend the
term of the license agreement, it would prevent us from distributing the ALIGN products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Although we are currently in compliance with all of our material obligations under these
licenses, if we were to breach any such obligations our counterparties may be entitled to terminate
the licenses. This would restrict or delay or eliminate our ability to develop and commercialize
the seliciclib or sell the ALIGN products, which could adversely affect our business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>We may be exposed to product liability claims that may damage our reputation and we may not be able
to obtain adequate insurance.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Because we conduct clinical trials in humans, we face the risk that the use of our drug
candidates will result in adverse effects. We believe that we have obtained reasonably adequate
product liability insurance coverage for our trials. We cannot predict, however, the possible harm
or side effects that may result from our clinical trials. Such claims may damage our reputation and
we may not have sufficient resources to pay for any liabilities resulting from a claim excluded
from, or beyond the limit of, our insurance coverage.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As we market commercialized products through our ALIGN subsidiary we are exposed to additional
risks of product liability claims. These risks exist even with respect to drugs and devices that
are approved for commercial sale by the FDA or other regulatory authorities in the United States,
the European Union or elsewhere and manufactured in facilities licensed and regulated by the FDA or
other such regulatory authorities. We have secured limited product liability insurance coverage,
but may not be able to maintain such insurance on acceptable terms with adequate coverage, or at a
reasonable cost. There is also a risk that third parties that we have agreed to indemnify could
incur liability. Even if we were ultimately successful in product liability litigation, the
litigation would consume substantial amounts of our financial and managerial resources and may
exceed insurance coverage creating adverse publicity, all of which would impair our ability to
generate sales of the litigated product as well as our other potential drugs.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->53<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>We may be required to defend lawsuits or pay damages in connection with the alleged or actual
violation of healthcare statutes such as fraud and abuse laws, and our corporate compliance
programs can never guarantee that we are in compliance with all relevant laws and regulations.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our commercialization efforts in the United States are subject to various federal and state
laws pertaining to promotion and healthcare fraud and abuse, including federal and state
anti-kickback, fraud and false claims laws. Anti-kickback laws make it illegal for a manufacturer
to offer or pay any remuneration in exchange for, or to induce, the referral of business, including
the purchase of a product. The federal government has published many regulations relating to the
anti-kickback statutes, including numerous safe harbors or exemptions for certain arrangements.
False claims laws prohibit anyone from knowingly and willingly presenting, or causing to be
presented for payment to third-party payers including Medicare and Medicaid, claims for reimbursed
products or services that are false or fraudulent, claims for items or services not provided as
claimed, or claims for medically unnecessary items or services.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our activities relating to the sale and marketing of our products will be subject to scrutiny
under these laws and regulations. It may be difficult to determine whether or not our activities,
comply with these complex legal requirements. Violations are punishable by significant criminal
and/or civil fines and other penalties, as well as the possibility of exclusion of the product from
coverage under governmental healthcare programs, including Medicare and Medicaid. If the government
were to investigate or make allegations against us or any of our employees, or sanction or convict
us or any of our employees, for violations of any of these legal requirements, this could have a
material adverse effect on our business, including our stock price. Our activities could be subject
to challenge for many reasons, including the broad scope and complexity of these laws and
regulations, the difficulties in interpreting and applying these legal requirements, and the high
degree of prosecutorial resources and attention being devoted to the biopharmaceutical industry and
health care fraud by law enforcement authorities. During the last few years, numerous
biopharmaceutical companies have paid multi-million dollar fines and entered into burdensome
settlement agreements for alleged violation of these requirements, and other companies are under
active investigation. Although we have developed and implemented corporate and field compliance
programs as part of our commercialization efforts, we cannot assure you that we or our employees,
directors or agents were, are or will be in compliance with all laws and regulations or that we
will not come under investigation, allegation or sanction.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In addition, we may be required to prepare and report product pricing-related information to
federal and state governmental authorities, such as the Department of Veterans Affairs and under
the Medicaid program. The calculations used to generate the pricing-related information are complex
and require the exercise of judgment. If we fail to accurately and timely report product
pricing-related information or to comply with any of these or any other laws or regulations,
various negative consequences could result, including criminal and/or civil prosecution,
substantial criminal and/or civil penalties, exclusion of the approved product from coverage under
governmental healthcare programs including Medicare and Medicaid, costly litigation and restatement
of our financial statements. In addition, our efforts to comply with this wide range of laws and
regulations are, and will continue to be, time-consuming and expensive.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>If our supplier upon whom we rely fails to produce on a timely basis the finished goods in the
volumes that we require or fails to meet quality standards and maintain necessary licensure from
regulatory authorities, we may be unable to meet demand for our products, potentially resulting in
lost revenues.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our licensor and supplier Sinclair contracts with third party manufacturers to supply the
finished goods to us to meet our needs. If any of Sinclair&#146;s third party manufacturers service
providers do not meet our or our licensor&#146;s requirements for quality, quantity or timeliness, or do
not achieve and maintain compliance with all applicable regulations, demand for our products or our
ability to continue supplying such products could substantially decline. As the third party
manufacturers are the sole supplier of the products any delays may impact our sales.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->54<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In all the countries where we sell or may sell our products, governmental regulations exist to
define standards for manufacturing, packaging, labeling and storing. All of our suppliers of raw
materials and
contract manufacturers must comply with these regulations. Failure to do so could result in
supply interruptions. In the United States, the FDA requires that all suppliers of pharmaceutical
bulk material and all manufacturers of pharmaceuticals for sale in or from the United States
achieve and maintain compliance with the FDA&#146;s Current Good Manufacturing Practice or cGMP
regulations and guidelines. Failure of our third-party manufacturers to comply with applicable
regulations could result in sanctions being imposed on them or us, including fines, injunctions,
civil penalties, disgorgement, suspension or withdrawal of approvals, license revocation, seizures
or recalls of products, operating restrictions and criminal prosecutions, any of which could
significantly and adversely affect supplies of our products. In addition, before any product batch
produced by our manufacturers can be shipped, it must conform to release specifications
pre-approved by regulators for the content of the pharmaceutical product. If the operations of one
or more of our manufacturers were to become unavailable for any reason, any required FDA review and
approval of the operations of an alternative supplier could cause a delay in the manufacture of our
products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Our customer base is highly concentrated.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our principal customers are a small number of wholesale drug distributors. These customers
comprise a significant part of the distribution network for pharmaceutical products in the United
States. Three large wholesale distributors, AmerisourceBergen Corporation, Cardinal Health, Inc.
and McKesson Corporation, control a significant share of the market in the United States. Our
ability to distribute any product, including Xclair<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Cream, Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Liquid and Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Lozenges
and to recognize revenues on a timely basis is substantially dependent on our ability to maintain
commercially reasonable agreements with each of these wholesale distributors and the extent to
which these distributors, over whom we have no control, comply with such agreements. Our agreements
with wholesaler distributors may contain terms that are not favorable, given our relative lack of
market leverage as a company with only three approved products or other factors, which could
adversely affect our commercialization of Xclair<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Cream, Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Liquid and Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Lozenges.
The loss of any of these customers could materially and adversely affect our ability to distribute
our products, resulting in a negative impact on our operations and financial condition.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>We may be unable to accurately estimate demand and monitor wholesaler inventory of Xclair<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Cream,
Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Liquid or Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Lozenges. Although we attempt to monitor wholesaler inventory of
Xclair<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Cream, Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Liquid or Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Lozenges, we also rely on third party information,
which is inherently uncertain and may not be accurate, to assist us in monitoring estimated
inventory levels and prescription trends. Inaccurate estimates of the demand and inventory levels
of the product may cause our revenues to fluctuate significantly from quarter to quarter and may
cause our operating results for a particular quarter to be below expectations.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Inventory levels of Xclair<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Cream, Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Liquid or Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Lozenges held by wholesalers
can also cause our operating results to fluctuate unexpectedly. For the three months ended June&nbsp;30,
2010 and 2011, approximately 91% and 90%, respectively, of our product sales in the United States
were to three wholesalers, Cardinal Health, Inc., McKesson Corporation and AmerisourceBergen.
Inventory levels held by those wholesalers can cause our operating results to fluctuate
unexpectedly if our sales to wholesalers do not match customer demand. We have entered into
inventory management agreements with these U.S. wholesalers under which they provide us with data
regarding inventory levels at these wholesalers. However, these wholesalers may not be completely
effective in matching inventory levels to customer demand, as they make estimates to determine
customer demand. In addition, inventory is held at retail pharmacies and other non-wholesaler
locations, for which we have no inventory management agreements and have no control in respect to
their buying patterns. Also, the non-retail sector in the United States, which includes government
institutions and large health maintenance organizations, tends to be less consistent in terms of
buying patterns, and often causes quarter-over-quarter fluctuations in inventory and ordering
patterns. We attempt to monitor inventory of Xclair<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>, Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Liquid or Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Lozenges in the
United States through the use of internal sales forecasts and the expiration dates of product
shipped, among other factors.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->55<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>The commercialization of our products is substantially dependent on our ability to develop
effective sales and marketing capabilities.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our successful commercialization of Xclair<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Cream, Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Liquid and Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Lozenges in
the United States will depend on our ability to establish and maintain effective sales and
marketing initiatives in the United States. Although we launched the ALIGN products with a small
specialty oncology sales force, we now sell and market our products via unique sales and marketing
strategies in order to reduce costs. We contracted, trained and deployed additional telemarketing
personnel to call on specialists who prescribe ALIGN products. We also utilize mailings, print
advertising, sampling, trade show attendance and other unique marketing programs to reach our
customer base. We may increase or decrease the size of our telemarketing sales force in the
future, depending on many factors, including the effectiveness of the sales force, the level of
market acceptance of Xclair<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Cream, Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Liquid and Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Lozenges and the results of our
clinical trials. Prior to our launches of these products, we had never sold or marketed any
products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">For our product candidates currently under development, our strategy is to develop compounds
through the Phase 2 stage of clinical testing and market or co-promote certain of our drugs on our
own. We have limited sales, marketing or distribution capabilities. We will depend primarily on
strategic alliances with third parties, which have established distribution systems and sales
forces, to commercialize our drugs. To the extent that we are unsuccessful in commercializing any
drugs or devices ourselves or through a strategic alliance, product revenues will suffer, we will
incur significant additional losses and our share price will be negatively affected.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Defending against claims relating to improper handling, storage or disposal of hazardous chemical,
radioactive or biological materials could be time consuming and expensive.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our research and development involves the controlled use of hazardous materials, including
chemicals, radioactive and biological materials such as chemical solvents, phosphorus and bacteria.
Our operations produce hazardous waste products. We cannot eliminate the risk of accidental
contamination or discharge and any resultant injury from those materials. Various laws and
regulations govern the use, manufacture, storage, handling and disposal of hazardous materials. We
may be sued for any injury or contamination that results from our use or the use by third parties
of these materials. Compliance with environmental laws and regulations may be expensive, and
current or future environmental regulations may impair our research, development and production
efforts.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Risks Related to Our Business and Financial Condition</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>The current economic conditions and financial market turmoil could adversely affect our business
and results of operations.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Economic conditions remain difficult with the continuing uncertainty in the global credit
markets, the financial services industry and the United States capital markets and with the United
States economy as a whole experiencing a period of substantial turmoil and uncertainty
characterized by unprecedented intervention by the United States federal government and the
failure, bankruptcy, or sale of various financial and other institutions. We believe the current
economic conditions and financial market turmoil could adversely affect our operations, business
and prospects, as well as our ability to obtain funds. If these circumstances persist or continue
to worsen, our future operating results could be adversely affected, particularly relative to our
current expectations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>We are at an early stage of development as a company and we do not have, and may never have, any
products that generate significant revenues.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We are at an early stage of development as a company and have a limited operating history on
which to evaluate our business and prospects. While we have earned modest product revenues from the
ALIGN business acquired in October&nbsp;2007, since beginning operations in 1996, we have not generated
any product revenues from our product candidates currently in development. We cannot guarantee that
any of our product candidates currently in development will ever become marketable products and we
do not anticipate material revenues from the ALIGN products in the foreseeable future.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->56<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">
We must demonstrate that
our drug candidates satisfy rigorous standards of safety and efficacy for their intended uses
before the FDA, and other regulatory authorities in the United States, the European Union and
elsewhere. Significant additional research, preclinical testing and clinical testing is required
before we can file applications with the FDA or other regulatory authorities for premarket approval
of our drug candidates. In addition, to compete effectively, our drugs must be easy to administer,
cost-effective and economical to manufacture on a commercial scale. We may not achieve any of these
objectives. Sapacitabine, our most advanced drug candidates for the treatment of cancer, is
currently in Phase 3 for AML and Phase 2 for MDS. Seliciclib is currently in Phase 2 clinical
trials. A combination trial of sapacitabine and seliciclib is currently in a Phase 1 clinical
trial. We cannot be certain that the clinical development of these or any other drug candidates in
preclinical testing or clinical development will be successful, that we will receive the regulatory
approvals required to commercialize them or that any of our other research and drug discovery
programs will yield a drug candidate suitable for investigation through clinical trials. Our
commercial revenues from our product candidates currently in development, if any, will be derived
from sales of drugs that will not become marketable for several years, if at all.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>We have a history of operating losses and we may never become profitable. Our stock is a highly
speculative investment.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have incurred operating losses in each year since beginning operations in 1996 due to costs
incurred in connection with our research and development activities and selling, general and
administrative costs associated with our operations, and we may never achieve profitability. As of
December&nbsp;31, 2010 and June&nbsp;30, 2011, our accumulated deficit was $241.8&nbsp;million and $250.0&nbsp;million,
respectively. Our net loss for the six months ended June&nbsp;30, 2010 and 2011 was $9.0&nbsp;million and
$8.1&nbsp;million, respectively. Our net loss applicable to common stockholders from inception through
June&nbsp;30, 2011 was $291.3&nbsp;million. Our drug candidates are in the mid-stages of clinical testing
and we must conduct significant additional clinical trials before we can seek the regulatory
approvals necessary to begin commercial sales of our drugs. We expect to incur continued losses for
several years, as we continue our research and development of our drug candidates, seek regulatory
approvals, commercialize any approved drugs and market and promote the ALIGN products: Xclair<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>
Cream, Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Liquid and Numoisyn<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Lozenges. If our drug candidates are unsuccessful in clinical
trials or we are unable to obtain regulatory approvals, or if our drugs are unsuccessful in the
market, we will not be profitable. If we fail to become and remain profitable, or if we are unable
to fund our continuing losses, particularly in light of the current economic conditions, you could
lose all or part of your investment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Capital markets are currently experiencing a period of disruption and instability, which has had
and could continue to have a negative impact on the availability and cost of capital.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The general disruption in the United States capital markets has impacted the broader worldwide
financial and credit markets and reduced the availability of debt and equity capital for the market
as a whole. These global conditions could persist for a prolonged period of time or worsen in the
future. Our ability to access the capital markets may be restricted at a time when we would like,
or need, to access those markets, which could have an impact on our flexibility to react to
changing economic and business conditions. The resulting lack of available credit, lack of
confidence in the financial sector, increased volatility in the financial markets could materially
and adversely affect the cost of debt financing and the proceeds of equity financing may be
materially adversely impacted by these market conditions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>If we fail to comply with the continued listing requirements of the NASDAQ Global Market our common
stock price may be delisted and the price of our common stock and our ability to access the capital
markets could be negatively impacted.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our common stock is currently listed for trading on the NASDAQ Global Market. We must satisfy
NASDAQ&#146;s continued listing requirements, including among other things, a minimum stockholders&#146;
equity of $10.0&nbsp;million and a minimum bid price for our common stock of $1.00 per share, or risk
delisting, which would have a material adverse effect on our business. A delisting of our common
stock from the NASDAQ Global Market could materially reduce the liquidity of our common stock and
result in a corresponding material reduction in the price of our common stock.

</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->57<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In addition, delisting could harm our
ability to raise capital through alternative financing sources on terms acceptable to us, or at
all, and may result in the potential loss of confidence by investors, suppliers, customers and
employees and fewer business development opportunities. During 2009, Cyclacel received notification
from the NASDAQ Stock Market that the Company was not in compliance with the minimum
$10&nbsp;million stockholders&#146; equity requirement for continued listing set forth in NASDAQ Marketplace
Rule&nbsp;5450(b)(1)(A). On January&nbsp;27, 2010, NASDAQ notified the Company that it regained compliance
with the minimum $50&nbsp;million market value of listed securities requirement and that it currently
complies with all other applicable standards for continued listing on The NASDAQ Global Market.
Accordingly, the Company&#146;s shares of common and preferred stock will continue to trade on The
NASDAQ Global Market.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Raising additional capital in the future may not be available to us on reasonable terms, if at all,
when or as we require additional funding. If we issue additional shares of our common stock or
other securities that may be convertible into, or exercisable or exchangeable for, our common
stock, our existing stockholders would experience further dilution. If we fail to obtain additional
funding, we may be unable to complete the development and commercialization of our lead drug
candidate, sapacitabine, or continue to fund our research and development programs.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have funded all of our operations and capital expenditures with proceeds from the issuance
of public equity securities, private placements of our securities, interest on investments,
licensing revenue, government grants, research and development tax credits and product revenue. In
order to conduct the lengthy and expensive research, preclinical testing and clinical trials
necessary to complete the development and marketing of our drug candidates, we will require
substantial additional funds. Based on our current operating plans of focusing on the advancement
of sapacitabine, we expect our existing resources to be sufficient to fund our planned operations
for at least the next twelve months. To meet our long-term financing requirements, we may raise
funds through public or private equity offerings, debt financings or strategic alliances. Raising
additional funds by issuing equity or convertible debt securities may cause our stockholders to
experience substantial dilution in their ownership interests and new investors may have rights
superior to the rights of our other stockholders. Raising additional funds through debt financing,
if available, may involve covenants that restrict our business activities and options. To the
extent that we raise additional funds through collaborations and licensing arrangements, we may
have to relinquish valuable rights to our drug discovery and other technologies, research programs
or drug candidates, or grant licenses on terms that may not be favorable to us. Additional funding
may not be available to us on favorable terms, or at all, particularly in light of the current
economic conditions. If we are unable to obtain additional funds, we may be forced to delay or
terminate our current clinical trials and the development and marketing of our drug candidates
including sapacitabine.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>To the extent we elect to fund the development of a drug candidate or the commercialization of a
drug at our expense, we will need substantial additional funding.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We plan to market drugs on our own, with or without a partner, that can be effectively
commercialized and sold in concentrated markets that do not require a large sales force to be
competitive. To achieve this goal, we will need to establish our own specialized sales force,
marketing organization and supporting distribution capabilities. The development and
commercialization of our drug candidates is very expensive, including our Phase 3 clinical trials
for sapacitabine. To the extent we elect to fund the full development of a drug candidate or the
commercialization of a drug at our expense, we will need to raise substantial additional funding
to:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>fund research and development and clinical trials connected with our research;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>fund clinical trials and seek regulatory approvals;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>build or access manufacturing and commercialization capabilities;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>implement additional internal control systems and infrastructure;</TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->58<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>commercialize and secure coverage, payment and reimbursement of our drug
candidates, if any such candidates receive regulatory approval;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>maintain, defend and expand the scope of our intellectual property; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>hire additional management, sales and scientific personnel.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our future funding requirements will depend on many factors, including:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the scope, rate of progress and cost of our clinical trials and other research and
development activities;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the costs and timing of seeking and obtaining regulatory approvals;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the costs of filing, prosecuting, defending and enforcing any patent claims and
other intellectual property rights;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the costs associated with establishing sales and marketing capabilities;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the costs of acquiring or investing in businesses, products and technologies;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the effect of competing technological and market developments; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the payment, other terms and timing of any strategic alliance, licensing or other
arrangements that we may establish.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">If we are not able to secure additional funding when needed, especially in light of the
current economic conditions and financial market turmoil, we may have to delay, reduce the scope of
or eliminate one or more of our clinical trials or research and development programs or future
commercialization efforts.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Any future workforce and expense reductions may have an adverse impact on our internal programs,
strategic plans, and our ability to hire and retain key personnel, and may also be distracting to
our management.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Further workforce and expense reductions in addition to those carried out in September&nbsp;2008
and June&nbsp;2009 could result in significant delays in implementing our strategic plans. In addition,
employees, whether or not directly affected by such reduction, may seek future employment with our
business partners or competitors. Although our employees are required to sign a confidentiality
agreement at the time of hire, the confidential nature of certain proprietary information may not
be maintained in the course of any such future employment. In addition, any additional workforce
reductions or restructurings would be expected to involve significant expense as a result of
contractual terms in certain of our existing agreements, including potential severance obligations
as well as any payments that may, under certain circumstances, be required under our agreement with
the Scottish Enterprise. Further, we believe that our future success will depend in large part upon
our ability to attract and retain highly skilled personnel. We may have difficulty retaining and
attracting such personnel as a result of a perceived risk of future workforce and expense
reductions. Finally, the implementation of expense reduction programs may result in the diversion
of the time and attention of our executive management team and other key employees, which could
adversely affect our business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Budget constraints resulting from our restructuring plan may negatively impact our research and
development, forcing us to delay our efforts to develop certain product candidates in favor of
developing others, which may prevent us from commercializing our product candidates as quickly as
possible.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Research and development is an expensive process. As part of our restructuring plan, we have
decided to focus our clinical development priorities on sapacitabine, while still possibly
continuing to progress additional programs pending the availability of clinical data and the
availability of funds, at which time we
will determine the feasibility of pursuing, if at all, further advanced development of
seliciclib, CYC116 or additional programs. Because we have had to prioritize our development
candidates as a result of budget constraints, we may not be able to fully realize the value of our
product candidates in a timely manner, if at all.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->59<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>We are exposed to risks related to foreign currency exchange rates.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Some of our costs and expenses are denominated in foreign currencies. Most of our foreign
expenses are associated with our research and development operations of our United Kingdom-based
wholly-owned subsidiary. When the United States dollar weakens against the British pound, the
United States dollar value of the foreign currency denominated expense increases, and when the
United States dollar strengthens against the British pound, the United States dollar value of the
foreign currency denominated expense decreases. Consequently, changes in exchange rates, and in
particular a weakening of the United States dollar, may adversely affect our results of operations
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Risks Related to our Intellectual Property</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>We may be subject to damages resulting from claims that our employees or we have wrongfully used or
disclosed alleged trade secrets of their former employers.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Many of our employees were previously employed at universities or other biotechnology or
pharmaceutical companies, including our competitors or potential competitors. Although no claims
against us are currently pending, we may be subject to claims that these employees or we have
inadvertently or otherwise used or disclosed trade secrets or other proprietary information of
their former employers. Litigation may be necessary to defend against these claims. If we fail in
defending such claims, in addition to paying monetary damages, we may lose valuable intellectual
property rights or personnel. A loss of key research personnel or their work product could hamper
or prevent our ability to commercialize certain potential drugs, which could severely harm our
business. Even if we are successful in defending against these claims, litigation could result in
substantial costs and be a distraction to management.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>If we fail to enforce adequately or defend our intellectual property rights our business may be
harmed.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our commercial success depends in large part on obtaining and maintaining patent and trade
secret protection for our drug candidates, the methods used to manufacture those drug candidates
and the methods for treating patients using those drug candidates.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Specifically, sapacitabine is covered in granted, composition of matter patents that expire in
2014 in the United States and 2012 outside the United States. Sapacitabine is further protected by
additional granted, composition of matter patents claiming certain, stable crystalline forms of
sapacitabine and their pharmaceutical compositions and therapeutic uses that expire in 2022 and
also patent applications claiming the combination of sapacitabine with decitabine which is being
tested as one of the arms of the SEAMLESS Phase 3 trial . In early development, amorphous
sapacitabine was used. We have used one of the stable, crystalline forms of sapacitabine in nearly
all our Phase 1 and in all of our Phase 2 clinical studies. We have also chosen this form for
commercialization. Additional patents claim certain medical uses and formulations of sapacitabine
which have emerged in our clinical trials. Seliciclib is protected by granted, composition of
matter patents that expire in 2016. Additional patents claim certain medical uses which have
emerged from our research programs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Failure to obtain, maintain or extend the patents could adversely affect our business. We will
only be able to protect our drug candidates and our technologies from unauthorized use by third
parties to the extent that valid and enforceable patents or trade secrets cover them.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->60<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our ability to obtain patents is uncertain because legal means afford only limited protections
and may not adequately protect our rights or permit it to gain or keep any competitive advantage.
Some legal principles remain unresolved and the breadth or interpretation of claims allowed in
patents in the United States, the European Union or elsewhere can still be difficult to ascertain
or predict. In addition, the specific
content of patents and patent applications that are necessary to support and interpret patent
claims is
highly
uncertain due to the complex nature of the relevant legal, scientific and factual
issues. Changes in either patent laws or in interpretations of patent laws in the United States,
the European Union or elsewhere may diminish the value of our intellectual property or narrow the
scope of our patent protection. Our existing patents and any future patents we obtain may not be
sufficiently broad to prevent others from practicing our technologies or from developing competing
products and technologies. In addition, we generally do not control the patent prosecution of
subject matter that we license from others and have not controlled the earlier stages of the patent
prosecution. Accordingly, we are unable to exercise the same degree of control over this
intellectual property as we would over our own.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Even if patents are issued regarding our drug candidates or methods of using them, those
patents can be challenged by our competitors who may argue such patents are invalid and/or
unenforceable. Patents also will not protect our drug candidates if competitors devise ways of
making or using these product candidates without legally infringing our patents. The U.S. Federal
Food, Drug and Cosmetic, or FD&#038;C, Act and FDA regulations and policies and equivalents in other
jurisdictions provide incentives to manufacturers to challenge patent validity or create modified,
noninfringing versions of a drug in order to facilitate the approval of abbreviated new drug
applications for generic substitutes. These same types of incentives encourage manufacturers to
submit new drug applications that rely on literature and clinical data not prepared for or by the
drug sponsor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Proprietary trade secrets and unpatented know-how are also very important to our business. We
rely on trade secrets to protect our technology, especially where we do not believe that patent
protection is appropriate or obtainable. However, trade secrets are difficult to protect. Our
employees, consultants, contractors, outside scientific collaborators and other advisors may
unintentionally or willfully disclose our confidential information to competitors, and
confidentiality agreements may not provide an adequate remedy in the event of unauthorized
disclosure of confidential information. Enforcing a claim that a third party obtained illegally and
is using trade secrets is expensive and time consuming, and the outcome is unpredictable. Moreover,
our competitors may independently develop equivalent knowledge, methods and know-how. Failure to
obtain or maintain trade secret protection could adversely affect our competitive business
position.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Intellectual property rights of third parties may increase our costs or delay or prevent us from
being able to commercialize our drug candidates and/or the ALIGN products.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">There is a risk that we are infringing or will infringe the proprietary rights of third
parties because patents and pending applications belonging to third parties exist in the United
States, the European Union and elsewhere in the world in the areas of our research and/or the ALIGN
products. Others might have been the first to make the inventions covered by each of our or our
licensors&#146; pending patent applications and issued patents and might have been the first to file
patent applications for these inventions. We are aware of several published patent applications,
and understand that others may exist, that could support claims that, if granted, could cover
various aspects of our developmental programs, including in some cases particular uses of our lead
drug candidate sapacitabine, seliciclib or other therapeutic candidates, or gene sequences and
techniques that we use in the course of our research and development. In addition, we understand
that other applications and patents exist relating to potential uses of sapacitabine and seliciclib
that are not part of our current clinical programs for these compounds. Numerous third-party United
States and foreign issued patents and pending applications exist in the area of kinases, including
CDK, AK and Plk for which we have research programs. For example, some pending patent applications
contain broad claims that could represent freedom to operate limitations for some of our kinase
programs should they be issued unchanged. Although we intend to continue to monitor these
applications, we cannot predict what claims will ultimately be allowed and if allowed what their
scope would be. In addition, because the patent application process can take several years to
complete, there may be currently pending applications, unknown to us, which may later result in
issued patents that cover the production, manufacture, commercialization or use of our drug
candidates. If we wish to use the technology or compound claimed in issued and unexpired patents
owned by others, we will need to obtain a license from the owner, enter into litigation to
challenge the validity of
the patents or incur the risk of litigation in the event that the owner asserts that we
infringe its patents. In one case we have opposed a European patent relating to human aurora kinase
and the patent has been finally revoked (no appeal was filed). We are also aware of a corresponding
U.S. patent containing method of treatment claims for specific cancers using aurora kinase
modulators which, if held valid, could potentially restrict the use of our aurora kinase inhibitors
once clinical trials are completed.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->61<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">There has been substantial litigation and other proceedings regarding patent and other
intellectual property rights in the pharmaceutical and biotechnology industries. Defending against
third party claims, including litigation in particular, would be costly and time consuming and
would divert management&#146;s attention from our business, which could lead to delays in our
development or commercialization efforts. If third parties are successful in their claims, we might
have to pay substantial damages or take other actions that are adverse to our business. As a result
of intellectual property infringement claims, or to avoid potential claims, we might:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>be prohibited from selling or licensing any product that we may develop unless
the patent holder licenses the patent to us, which it is not required to do;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>be required to pay substantial royalties or grant a cross license to our
patents to another patent holder;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>decide to move some of our screening work outside Europe;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>be required to pay substantial damages for past infringement, which we may have
to pay if a court determines that our product candidates or technologies infringe
a competitor&#146;s patent or other proprietary rights; or</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>be required to redesign the formulation of a drug candidate so it does not
infringe, which may not be possible or could require substantial funds and time.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Risks Related to Securities Regulations and Investment in Our Securities</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Failure to achieve and maintain internal controls is accordance with Sections&nbsp;302 and 404 of the
Sarbanes-Oxley Act of 2002 could have a material adverse effect on our business and stock price.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During March&nbsp;2011, we identified a deficiency in respect of our internal controls over
financial reporting, specifically our controls over the accounting for cumulative preferred stock
dividends, that constitutes a material weakness as described in the SEC&#146;s guidance regarding
Management&#146;s Report on Internal Control Over Financial Reporting as of December&nbsp;31, 2010. As a
result of this deficiency, the financial statements included in our Form 10-K for the year ended
December&nbsp;31, 2009, filed on March&nbsp;29, 2010, as amended by Amendment No.&nbsp;1 to our Annual Report on
Form 10-K/A for the year ended December&nbsp;31, 2009 filed on May&nbsp;17, 2010 and, as further amended by
Amendment No.&nbsp;2 to our Annual Report on Form 10-K/A for the year ended December&nbsp;31, 2009 filed on
May&nbsp;19, 2010, included errors related to the presentation and disclosure of undeclared cumulative
preferred stock dividends in the consolidated balance sheet and in the statement of stockholders&#146;
equity. Unaudited balance sheets for the each of the first three quarters of 2009 and 2010 also
contained errors. In addition, in May&nbsp;2010, we filed an amendment to our Annual Report on Form 10-K
for the year ended December&nbsp;31, 2009, to report a restatement of our financial statements and
report a material weakness in our internal control over financial reporting as of December&nbsp;31,
2009, specifically related to the operational failure of the controls in place to ensure the
correct computation of net loss per share and presentation of preferred stock dividends in the
consolidated statement of cash flows. In March&nbsp;2011, our auditors identified a further error in
respect of the accounting, presentation and disclosure of cumulative undeclared preferred stock
dividends, specifically the inclusion of undeclared cumulative preferred stock dividends as a
current liability in its consolidated financial statements, which resulted from the same material
weakness as described above. This has resulted in the restatement of our consolidated balance
sheets as of March&nbsp;31, 2009, June&nbsp;30, 2009, September&nbsp;30, 2009, December&nbsp;31, 2009, March&nbsp;31, 2010,
June&nbsp;30, 2010, and September&nbsp;30, 2010 and consolidated
statement of stockholders&#146; equity for the year ended December&nbsp;31, 2009 and selected financial
data as of and for the year ended December&nbsp;31, 2009.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->62<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">If we fail to maintain our internal controls or fail to implement required new or improved
controls, as such control standards are modified, supplemented or amended from time to time, we may
not be able to conclude on an ongoing basis that we have effective internal controls over financial
reporting. Effective internal controls are necessary for us to produce reliable financial reports
and are important in the prevention of financial fraud. If we cannot produce reliable financial
reports or prevent fraud, our business and operating results could be harmed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>We incur increased costs and management resources as a result of being a public company, and we
still may fail to comply with public company obligations.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As a public company, we face and will continue to face increased legal, accounting,
administrative and other costs and expenses as a public company that we would not incur as a
private company. Compliance with the Sarbanes Oxley Act of 2002, as well as other rules of the SEC,
the Public Company Accounting Oversight Board and the NASDAQ Global Market resulted in a
significant initial cost to us as well as an ongoing compliance costs. As a public company, we are
subject to Section&nbsp;404 of the Sarbanes Oxley Act relating to internal control over financial
reporting. We have completed a formal process to evaluate our internal controls for purposes of
Section&nbsp;404, and we concluded that as of December&nbsp;31, 2010, our internal control over financial
reporting was ineffective. As our business grows and changes, there can be no assurances that we
can maintain the effectiveness of our internal controls over financial reporting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Effective internal controls over financial reporting are necessary for us to provide reliable
financial reports and, together with adequate disclosure controls and procedures, are designed to
prevent fraud. If we cannot provide reliable financial reports or prevent fraud, our operating
results could be harmed. We have completed a formal process to evaluate our internal control over
financial reporting. However, guidance from regulatory authorities in the area of internal controls
continues to evolve and substantial uncertainty exists regarding our on-going ability to comply by
applicable deadlines. Any failure to implement required new or improved controls, or difficulties
encountered in their implementation, could harm our operating results or cause us to fail to meet
our reporting obligations. Ineffective internal controls could also cause investors to lose
confidence in our reported financial information, which could have a negative effect on the trading
price of our common stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Our common stock may have a volatile public trading price.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">An active public market for our common stock has not developed. Our stock can trade in small
volumes which may make the price of our stock highly volatile. The last reported price of our stock
may not represent the price at which you would be able to buy or sell the stock. The market prices
for securities of companies comparable to us have been highly volatile. Often, these stocks have
experienced significant price and volume fluctuations for reasons that are both related and
unrelated to the operating performance of the individual companies. In addition, the stock market
as a whole and biotechnology and other life science stocks in particular have experienced
significant recent volatility. Like our common stock, these stocks have experienced significant
price and volume fluctuations for reasons unrelated to the operating performance of the individual
companies. In addition, due to our existing stock price, we may not continue to qualify for
continued listing on the NASDAQ Global Market. To maintain listing, we are required to maintain a
minimum closing bid price of $1.00 per share and, among other requirements, to maintain a minimum
stockholders equity value of $10&nbsp;million. Factors giving rise to this volatility may include:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>disclosure of actual or potential clinical results with respect to product
candidates we are developing;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>regulatory developments in both the United States and abroad;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>developments concerning proprietary rights, including patents and litigation
matters;</TD>
</TR>


</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->63<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>public concern about the safety or efficacy of our product candidates or
technology, or related technology, or new technologies generally;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>concern about the safety or efficacy of our product candidates or technology,
or related technology, or new technologies generally;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>public announcements by our competitors or others; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>general market conditions and comments by securities analysts and investors.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Fluctuations in our operating losses could adversely affect the price of our common stock.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our operating losses may fluctuate significantly on a quarterly basis. Some of the factors
that may cause our operating losses to fluctuate on a period-to-period basis include the status of
our preclinical and clinical development programs, level of expenses incurred in connection with
our preclinical and clinical development programs, implementation or termination of collaboration,
licensing, manufacturing or other material agreements with third parties, non-recurring revenue or
expenses under any such agreement, and compliance with regulatory requirements. Period-to-period
comparisons of our historical and future financial results may not be meaningful, and investors
should not rely on them as an indication of future performance. Our fluctuating losses may fail to
meet the expectations of securities analysts or investors. Our failure to meet these expectations
may cause the price of our common stock to decline.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>If securities or industry analysts do not publish research or reports about us, if they change
their recommendations regarding our stock adversely or if our operating results do not meet their
expectations, our stock price and trading volume could decline.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The trading market for our common stock is influenced by the research and reports that
industry or securities analysts publish about us. If one or more of these analysts cease coverage
of us or fail to regularly publish reports on us, we could lose visibility in the financial
markets, which in turn could cause our stock price or trading volume to decline. Moreover, if one
or more of the analysts who cover us downgrade our stock or if our operating results do not meet
their expectations, our stock price could decline.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Anti-takeover provisions in our charter documents and provisions of Delaware law may make an
acquisition more difficult and could result in the entrenchment of management.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We are incorporated in Delaware. Anti-takeover provisions of Delaware law and our amended and
restated certificate of incorporation and amended and restated bylaws may make a change in control
or efforts to remove management more difficult. Also, under Delaware law, our Board of Directors
may adopt additional anti-takeover measures.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have the authority to issue up to 5&nbsp;million shares of preferred stock and to determine the
terms of those shares of stock without any further action by our stockholders. If the Board of
Directors exercises this power to issue preferred stock, it could be more difficult for a third
party to acquire a majority of our outstanding voting stock and vote the stock they acquire to
remove management or directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our amended and restated certificate of incorporation and amended and restated bylaws also
provides staggered terms for the members of our Board of Directors. Under Section&nbsp;141 of the
Delaware General Corporation Law, our directors may be removed by stockholders only for cause and
only by vote of the holders of a majority of voting shares then outstanding. These provisions may
prevent stockholders from replacing the entire board in a single proxy contest, making it more
difficult for a third party to acquire control of us without the consent of our Board of Directors.
These provisions could also delay the removal of management by the Board of Directors with or
without cause. In addition, our directors may only be removed for cause and amended and restated
bylaws limit the ability our stockholders to call special meetings of stockholders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Under Section&nbsp;203 of the Delaware General Corporation Law, a corporation may not engage in a
business combination with any holder of 15% or more of its capital stock until the holder has held
the stock for three years unless, among other possibilities, the Board of Directors approves the
transaction. Our Board of Directors could use this provision to prevent changes in management. The
existence of the foregoing provisions could limit the price that investors might be willing to pay
in the future for shares of our common stock.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->64<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>We have the authority to issue up to 5&nbsp;million shares of preferred stock and to determine the terms
of those shares of stock without any further action by our stockholders. If the Board of Directors
exercises this power to issue preferred stock, it could be more difficult for a third party to
acquire a majority of our outstanding voting stock and vote the stock they acquire to remove
management or directors.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our amended and restated certificate of incorporation and amended and restated bylaws also
provides staggered terms for the members of our Board of Directors. Under Section&nbsp;141 of the
Delaware General Corporation Law, our directors may be removed by stockholders only for cause and
only by vote of the holders of a majority of voting shares then outstanding. These provisions may
prevent stockholders from replacing the entire board in a single proxy contest, making it more
difficult for a third party to acquire control of us without the consent of our Board of Directors.
These provisions could also delay the removal of management by the Board of Directors with or
without cause. In addition, our directors may only be removed for cause and amended and restated
bylaws limit the ability our stockholders to call special meetings of stockholders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Under Section&nbsp;203 of the Delaware General Corporation Law, a corporation may not engage in a
business combination with any holder of 15% or more of its capital stock until the holder has held
the stock for three years unless, among other possibilities, the Board of Directors approves the
transaction. Our Board of Directors could use this provision to prevent changes in management. The
existence of the foregoing provisions could limit the price that investors might be willing to pay
in the future for shares of our common stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Certain severance-related agreements in our executive employment agreements may make an acquisition
more difficult and could result in the entrenchment of management.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In March&nbsp;2008 (as subsequently amended, most recently as of January&nbsp;1, 2011), we entered into
employment agreements with our President and Chief Executive Officer and our Executive Vice
President, Finance, Chief Financial Officer and Chief Operating Officer, which contain severance
arrangements in the event that such executive&#146;s employment is terminated without &#147;cause&#148; or as a
result of a &#147;change of control&#148; (as each such term is defined in each agreement). The financial
obligations triggered by these provisions may prevent a business combination or acquisition that
would be attractive to stockholders and could limit the price that investors would be willing to
pay in the future for our stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>In the event of an acquisition of our common stock, we cannot assure our common stockholders that
we will be able to negotiate terms that would provide for a price equivalent to, or more favorable
than, the price at which our shares of common stock may be trading at such time.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We may not effect a consolidation or merger with another entity without the vote or consent of
the holders of at least a majority of the shares of our preferred stock (in addition to the
approval of our common stockholders), unless the preferred stock that remains outstanding and its
rights, privileges and preferences are unaffected or are converted into or exchanged for preferred
stock of the surviving entity having rights, preferences and limitations substantially similar, but
no less favorable, to our convertible preferred stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In addition, in the event a third party seeks to acquire our company or acquire control of our
company by way of a merger, but the terms of such offer do not provide for our preferred stock to
remain outstanding or be converted into or exchanged for preferred stock of the surviving entity
having rights, preferences and limitations substantially similar, but no less favorable, to our
preferred stock, the terms of the Certificate of Designation of our preferred stock provide for an
adjustment to the conversion ratio of our preferred stock such that, depending on the terms of any
such transaction, preferred stockholders may be entitled, by their
terms, to receive up to $10.00 per share in common stock, causing our common stockholders not
to receive as favorable a price as the price at which such shares may be trading at the time of any
such transaction.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->65<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="left" style="font-size: 10pt; margin-top: 10pt">As of June&nbsp;30, 2011, there were 1,213,142 shares of our preferred stock issued
and outstanding. If the transaction were one in which proceeds were received by the Company for
distribution to stockholders, and the terms of the Certificate of Designation governing the
preferred stock were strictly complied with, approximately $13,344,563 would be paid to the
preferred holders before any distribution to the common stockholders, although the form of
transaction could affect how the holders of preferred stock are treated. In such an event, although
such a transaction would be subject to the approval of our holders of common stock, we cannot
assure our common stockholders that we will be able to negotiate terms that would provide for a
price equivalent to, or more favorable than, the price at which our shares of common stock may be
trading at such time. Thus, the terms of our preferred stock might hamper a third party&#146;s
acquisition of our company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Our certificate of incorporation and bylaws and certain provisions of Delaware law may delay or
prevent a change in our management and make it more difficult for a third party to acquire us.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our amended and restated certificate of incorporation and bylaws contain provisions that could
delay or prevent a change in our Board of Directors and management teams. Some of these provisions:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>authorize the issuance of preferred stock that can be created and issued by the
Board of Directors without prior stockholder approval, commonly referred to as
&#147;blank check&#148; preferred stock, with rights senior to those of our common stock;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>provide for the Board of Directors to be divided into three classes; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>require that stockholder actions must be effected at a duly called stockholder
meeting and prohibit stockholder action by written consent.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In addition, because we are incorporated in Delaware, we are governed by the provisions of
Section&nbsp;203 of the Delaware General Corporation Law, which limits the ability of large stockholders
to complete a business combination with, or acquisition of, us. These provisions may prevent a
business combination or acquisition that would be attractive to stockholders and could limit the
price that investors would be willing to pay in the future for our stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">These provisions also make it more difficult for our stockholders to replace members of our
Board of Directors. Because our Board of Directors is responsible for appointing the members of our
management team, these provisions could in turn affect any attempt to replace our current
management team. Additionally, these provisions may prevent an acquisition that would be attractive
to stockholders and could limit the price that investors would be willing to pay in the future for
our common stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>We may have limited ability to pay cash dividends on our preferred stock, and there is no assurance
that future quarterly dividends will be declared.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Delaware law may limit our ability to pay cash dividends on our preferred stock. Under
Delaware law, cash dividends on our preferred stock may only be paid from surplus or, if there is
no surplus, from the corporation&#146;s net profits for the current or preceding fiscal year. Delaware
law defines &#147;surplus&#148; as the amount by which the total assets of a corporation, after subtracting
its total liabilities, exceed the corporation&#146;s capital, as determined by its Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Since we are not profitable, our ability to pay cash dividends will require the availability
of adequate surplus. Even if adequate surplus is available to pay cash dividends on our preferred
stock, we may not have sufficient cash to pay dividends on the preferred stock or we may choose not
to declare the dividends.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On July&nbsp;8, 2011, the Board of Directors decided not to declare the quarterly cash dividend on
the preferred stock with respect to the second quarter of 2011 that would have otherwise been
payable on
August&nbsp;1, 2011. In addition, the Board of Directors also did not declare the quarterly cash
dividend with respect to each of the four quarters of fiscal year 2009 and the first, second and
third quarters of 2010.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->66<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>We have granted additional rights to our holders of preferred stock with respect to the management
of the Company as a result of having not declared quarterly dividends on our preferred stock for a
total of six quarterly dividend periods.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As a result of having not declared quarterly dividends on our preferred stock for a total of
six quarters, the size of the Company&#146;s Board was increased by two members and the holders of the
preferred stock, voting separately as a class, voted on May&nbsp;24, 2011 and elected two directors to
fill the vacancies created thereby. The directors elected by the holders of the preferred stock
will have the ability to participate in the management of the Company until all accrued but unpaid
dividends have been paid in full.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Our common and convertible preferred stock may experience extreme price and volume fluctuations,
which could lead to costly litigation for the Company and make an investment in the Company less
appealing.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The market price of our common and convertible preferred stock may fluctuate substantially due
to a variety of factors, including:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>additions to or departures of our key personnel;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>announcements of technological innovations or new products or services by us or
our competitors;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>announcements concerning our competitors or the biotechnology industry in
general;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>new regulatory pronouncements and changes in regulatory guidelines;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>general and industry-specific economic conditions;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>changes in financial estimates or recommendations by securities analysts;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>variations in our quarterly results;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>announcements about our collaborators or licensors; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>changes in accounting principles.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The market prices of the securities of biotechnology companies, particularly companies like us
without product revenues and earnings, have been highly volatile and are likely to remain highly
volatile in the future. This volatility has often been unrelated to the performance of particular
companies. In the past, companies that experience volatility in the market price of their
securities have often faced securities class action litigation. Moreover, market prices for stocks
of biotechnology-related and technology companies frequently reach levels that bear no relationship
to the performance of these companies. These market prices generally are not sustainable and are
highly volatile. Whether or not meritorious, litigation brought against us could result in
substantial costs, divert our management&#146;s attention and resources and harm our financial condition
and results of operations. In addition, due to our stock price from time to time, we may not
continue to qualify for continued listing on the NASDAQ Global Market. Please see Risk Factor: <I>Our
common stock may have a volatile public trading price.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>The future sale of our common and preferred stock and future issuances of our common stock upon
conversion of our preferred stock could negatively affect our stock price and cause dilution to
existing holders of our common stock.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">If our common or preferred stockholders sell substantial amounts of our stock in the public
market, or the market perceives that such sales may occur, the market price of our common and
preferred stock could fall. For example, we were approached by a preferred stockholder that elected
to convert 123,400 of its shares of preferred stock, which shares were converted into 239,396
shares of common stock in the first quarter of 2010. In addition, 710,271 shares of preferred stock
were converted to 1,416,203 shares of common stock during the second quarter of 2010. If
additional holders of preferred stock elect to convert their shares to shares of common stock at
renegotiated prices, such conversion as well as the sale of substantial amounts of our common or
preferred stock, could cause dilution to existing holders of our common stock, thereby also
negatively affecting the price of our common stock.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->67<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>If we exchange the convertible preferred stock for debentures, the exchange will be taxable but we
will not provide any cash to pay any tax liability that any convertible preferred stockholder may
incur.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">An exchange of convertible preferred stock for debentures, as well as any dividend make-whole
or interest make-whole payments paid in our common stock, will be taxable events for United States
federal income tax purposes, which may result in tax liability for the holder of convertible
preferred stock without any corresponding receipt of cash by the holder. In addition, the
debentures may be treated as having original issue discount, a portion of which would generally be
required to be included in the holder&#146;s gross income even though the cash to which such income is
attributable would not be received until maturity or redemption of the debenture. We will not
distribute any cash to the holders of the securities to pay these potential tax liabilities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>If we automatically convert the convertible preferred stock, there is a substantial risk of
fluctuation in the price of our common stock from the date we elect to automatically convert to the
conversion date.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We may automatically convert the convertible preferred stock into common stock if the closing
price of our common stock has exceeded $35.30. There is a risk of fluctuation in the price of our
common stock between the time when we may first elect to automatically convert the preferred and
the automatic conversion date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>We do not intend to pay cash dividends on our common stock in the foreseeable future.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We do not anticipate paying cash dividends on our common stock in the foreseeable future. Any
payment of cash dividends will depend on our financial condition, results of operations, capital
requirements, the outcome of the review of our strategic alternatives and other factors and will be
at the discretion of our Board of Directors. Accordingly, investors will have to rely on capital
appreciation, if any, to earn a return on their investment in our common stock. Furthermore, we may
in the future become subject to contractual restrictions on, or prohibitions against, the payment
of dividends.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>The number of shares of common stock which are registered, including the shares to be issued upon
exercise of our outstanding warrants, is significant in relation to our currently outstanding
common stock and could cause downward pressure on the market price for our common stock.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The number of shares of common stock registered for resale, including those shares which are
to be issued upon exercise of our outstanding warrants, is significant in relation to the number of
shares of common stock currently outstanding. If the security holder determines to sell a
substantial number of shares into the market at any given time, there may not be sufficient demand
in the market to purchase the shares without a decline in the market price for our common stock.
Moreover, continuous sales into the market of a number of shares in excess of the typical trading
volume for our common stock, or even the availability of such a large number of shares, could
depress the trading market for our common stock over an extended period of time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>If persons engage in short sales of our common stock, including sales of shares to be issued upon
exercise of our outstanding warrants, the price of our common stock may decline.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Selling short is a technique used by a stockholder to take advantage of an anticipated decline
in the price of a security. In addition, holders of options and warrants will sometimes sell short
knowing they can, in effect, cover through the exercise of an option or warrant, thus locking in a
profit. A significant number of short sales or a large volume of other sales within a relatively
short period of time can create downward pressure on the market price of a security. Further sales
of common stock issued upon exercise of our outstanding warrants could cause even greater declines
in the price of our common stock due to the number of additional shares available in the market
upon such exercise, which could encourage short sales that could further undermine the value of our
common stock. You could, therefore, experience a decline in the value of your investment as a
result of short sales of our common stock.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->68<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>We are exposed to risk related to the marketable securities we may purchase.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We may invest cash not required to meet short term obligations in short term marketable
securities. We may purchase securities in United States government, government-sponsored agencies
and highly rated corporate and asset-backed securities subject to an approved investment policy.
Historically, investment in these securities has been highly liquid and has experienced only very
limited defaults. However, recent volatility in the financial markets has created additional
uncertainty regarding the liquidity and safety of these investments. Although we believe our
marketable securities investments are safe and highly liquid, we cannot guarantee that our
investment portfolio will not be negatively impacted by recent or future market volatility or
credit restrictions.
</DIV>
<DIV align="left">
<A name="C17919109"></A>
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;2.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Unregistered Sales of Equity Securities and Use of Proceeds.</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">None.
</DIV>

<DIV align="left">
<A name="C17919110"></A>
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;3.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Defaults upon Senior Securities.</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">None.
</DIV>

<DIV align="left">
<A name="C17919111"></A>
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;4.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>(Removed and Reserved).</B></TD>
</TR>
</TABLE>
</DIV>
<DIV align="left">
<A name="C17919112"></A>
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;5.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Other Information.</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">None.
</DIV>

<DIV align="left">
<A name="C17919113"></A>
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;6.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Exhibits.</B></TD>
</TR>
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">1.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Underwriting Agreement, dated as of June&nbsp;30, 2011, by and among the
Company, Leerink Swann LLC and Lazard Capital Markets LLC, as
representative of the several underwriters named therein
(previously filed as Exhibit&nbsp;1.1 to the Registrant&#146;s Current Report
on Form&nbsp;8-K, originally filed with the SEC on July&nbsp;1, 2011 (File
No.&nbsp;000-50625), and incorporated herein by reference).</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Warrant to purchase shares of Cyclacel Pharmaceuticals,
Inc. Common Stock (previously filed as Exhibit&nbsp;4.1 to the
Registrant&#146;s Current Report on Form&nbsp;8-K, originally filed with the
SEC on July&nbsp;1, 2011 (File No.&nbsp;000-50625), and incorporated herein
by reference).</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.1*<B>&#134;</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">License Agreement between Sankyo Co., Ltd. and Cyclacel Limited,
dated September&nbsp;10, 2003, and letter amendments dated April&nbsp;1, 2004
and April&nbsp;28, 2004.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.2*<B>&#134;</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Amendment No.&nbsp;4 to License Agreement between Daiichi Sankyo
Company, Limited and Cyclacel Limited, dated July&nbsp;11, 2011.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">31.1*
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Certification of Principal Executive Officer Pursuant to Securities
Exchange Act Rule&nbsp;13a-14(a) As Adopted Pursuant to Section&nbsp;302 of
the Sarbanes-Oxley Act of 2002.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">31.2*
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Certification of Principal Financial Officer Pursuant to Securities
Exchange Act Rule&nbsp;13a-14(a) As Adopted Pursuant to Section&nbsp;302 of
the Sarbanes-Oxley Act of 2002.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">32.1**
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Certification of Principal Executive Officer pursuant to Section
906 of the Sarbanes-Oxley Act of 2002.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">32.2**
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Certification of Principal Financial Officer pursuant to Section
906 of the Sarbanes-Oxley Act of 2002.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">101***
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The following materials from Cyclacel Pharmaceuticals, Inc.&#146;s
Quarterly Report on Form&nbsp;10-Q for the quarter ended June&nbsp;30, 2011,
formatted in XBRL (Extensible Business Reporting Language): (i)&nbsp;the
Condensed Consolidated Statements of Income, (ii)&nbsp;the Condensed
Consolidated Balance Sheets, (iii)&nbsp;the Condensed Consolidated
Statements of Cash Flows, and (iv)&nbsp;Notes to Condensed Consolidated
Financial Statements.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->69<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV style="margin-top: 3pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">&#134;</TD>
    <TD>&nbsp;</TD>
    <TD>Certain portions of the exhibit have been omitted pursuant to a confidential treatment request
filed separately with the Securities and Exchange Commission.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">*</TD>
    <TD>&nbsp;</TD>
    <TD>Filed herein.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">**</TD>
    <TD>&nbsp;</TD>
    <TD>Furnished herewith.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">***</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part
of a registration statement or prospectus for purposes of Sections&nbsp;11 or 12 of the Securities Act
of 1933, as amended, is deemed not filed for purposes of Section&nbsp;18 of the Securities Exchange Act
of 1934, as amended, and otherwise is not subject to liability under these sections.</TD>
</TR>

</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->70<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C17919tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="left">
<A name="C17919114"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">
<BR>
<B>CYCLACEL PHARMACEUTICALS, INC.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Date: August 12, 2011&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Paul McBarron
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Paul McBarron&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Operating Officer, Chief Financial Officer
and
Executive Vice President, Finance&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->71<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>c17919exv10w1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 10.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><B>Exhibit&nbsp;10.1</B>
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 10pt">CONFIDENTIAL TREATMENT REQUESTED
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>SANKYO CO., LTD.</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>- and -</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>CYCLACEL LIMITED</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>CS-682 LICENCE AGREEMENT</B>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>TABLE OF CONTENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="86%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">Page</TD>
    <TD>&nbsp;</TD>
</TR>


<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">1. DEFINITIONS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2. LICENCES</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">3. PAYMENTS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">4. DEVELOPMENT AND COMMERCIALISATION</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">5. INTELLECTUAL PROPERTY &#151; OWNERSHIP</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">6. INTELLECTUAL PROPERTY &#151; PROSECUTION, MAINTENANCE AND ENFORCEMENT</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">7. WARRANTIES AND LIABILITY</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">8. CONFIDENTIALITY</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">9. TERM AND TERMINATION</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">10. EFFECTS OF TERMINATION</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">11. ASSIGNMENT/SUB-CONTRACTING</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">12. FORCE MAJEURE</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">13. GOVERNING LAW</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">14. JURISDICTION</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">15. WAIVER</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">16. SEVERANCE OF TERMS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">17. ENTIRE AGREEMENT/VARIATIONS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">18. NOTICES</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">19. COUNTERPARTS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">20. THIS AGREEMENT NOT TO CONSTITUTE A PARTNERSHIP</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">21. COSTS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">22. PUBLICITY</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SCHEDULE 1 DEVELOPMENT PLAN</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">35</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SCHEDULE 2 LICENSED MATERIALS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SCHEDULE 3 LICENSED PATENT RIGHTS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SCHEDULE 4 CNDAC PATENT RIGHTS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SCHEDULE 5 SUCCESSFUL COMPLETION CRITERIA</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SCHEDULE 6 RETAINED TECHNICAL DATA</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SCHEDULE 7 COMMITTED CLINICAL TRIALS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SCHEDULE 8 ADDRESSES FOR NOTICES</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">SCHEDULE 9 EXPERT&#146;S DECISION</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>THIS AGREEMENT is made on the Commencement Date</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>BETWEEN:</B>
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">SANKYO CO., LTD. a company incorporated in Japan whose principal place of business is at 5-1
Nihonbashi-honcho 3-chome Chuo-ku Tokyo 103-8426 Japan (&#147;Sankyo&#148;); and</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">CYCLACEL LIMITED a company incorporated in England whose principal place of business is at
Dundee Technopole, James Lindsay Place, Dundee DD1 5JJ, UK (&#147;Cyclacel&#148;).</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>WHEREAS:</B>
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(A)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Sankyo owns certain Patent Rights and Know How (as defined herein) relating to a nucleoside
analogue known as CS-682 and is the non-exclusive licensee of certain Patent Rights relating
to CNDAC.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(B)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Cyclacel is a biotechnology company specialising in the research and development of products
in the field of cancer.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(C)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Cyclacel wishes to have an exclusive licence and non-exclusive sub-licence (as appropriate)
to the Patent Rights and Know How described in (A)&nbsp;above for the purpose of developing,
marketing and selling a product based on CS-682 within the Territory and Sankyo is willing to
grant Cyclacel such a licence on the terms set out herein.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>1.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"><B>DEFINITIONS</B></DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">In this Agreement the following definitions shall apply unless the context
requires otherwise:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Affiliate&#148; &#151; any person, corporation, company, partnership,
joint venture, limited liability company and/or other entity which Controls, is
Controlled by, or is under common Control with a Party.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Agreement&#148; &#151; this document including any and all schedules,
appendices and other addenda to it as may be added and/or amended from time to
time in accordance with the provisions of this Agreement.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Blocking IP&#148; &#151; any and all intellectual property owned or
controlled by a Third Party (but not, subject to Clause 3.6, a Cyclacel
Licensee) which would be infringed by the development, manufacture, import,
marketing, distribution, sale or other disposal of Product.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Business Day&#148; &#151; 9.30 am to 5.30 pm local time on a day other
than a Saturday, Sunday, corporate holiday of a Party, or public holiday in the
UK or Japan.</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Candidate&#148; &#151; the compound known as CS-682 and other compounds
covered by Licensed Patent Rights.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;CNDAC&#148; &#151; the compound
1-(2-C-cyano-2-deoxy-&#946;-D-arabino-pentofurano-syl) cytosine, or known as CNDAC.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Clinical Trials&#148; &#151; means any or all of the Phase I Clinical
Trials, Phase II Clinical Trials or Phase III Clinical Trials.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;CNDAC Patent Rights&#148; &#151; any Patent Rights relating to
inventions comprised in the CNDAC Patent Rights listed in Schedule&nbsp;4.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Combination Product&#148; &#151; a product containing Product which
also:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">contains a therapeutically active
ingredient that is not Licensed IP or CNDAC Patent Rights; or</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">is administered through a therapeutically
active administration technology that is not Licensed IP or CNDAC
Patent Rights; or</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">is administered in accordance with a
diagnostic detection technology that is not Licensed IP or CNDAC
Patent Rights.</DIV></TD>
</TR>

</TABLE>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 12%">each of which shall be an &#147;Other Element&#148;.
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.10</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Commencement Date&#148; &#151; the date of execution of this Agreement by the Parties,
which is the latest date of signature below.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.11</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Competent Authority&#148; &#151; any national or local agency, authority, department,
inspectorate, minister, ministry official, parliament or public or statutory
person (whether autonomous or not) of any government of any country having
jurisdiction over either any of the activities contemplated by this Agreement
or over the Parties, including the European Commission, The Court of First
Instance and the European Court of Justice.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.12</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Confidential Information&#148; &#151; in the case of obligations on Cyclacel in
relation to Confidential Information, shall mean Know How and Material forming
part of Licensed IP and, in the case of each of Cyclacel and Sankyo, shall mean
the terms and conditions of this Agreement notwithstanding the provisions of
Clause 22 and any other commercially sensitive information of a Party marked
&#147;confidential&#148; supplied or otherwise made available to them, including but not
limited to those Know How or Material disclosed by Sankyo to Cyclacel under the
Confidential Disclosure Agreement dated February&nbsp;26, 2002 between the Parties
which relates to the subject matter
hereof, or coming into their possession in relation to the performance of
this Agreement.</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 2 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.13</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Control&#148; &#151; means the ownership either directly or indirectly of more than
50% of the issued share capital or any other comparable equity or ownership
interest with respect to a business entity or the legal power to direct or
cause the direction of the general management and policies of the Party in
question.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.14</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;CS-682&#148; &#151; the compound
1-(2-C-cyano-2-deoxy-&#946;-D-arabino-pentofurano-syl)-N(4)-palmitoylcytosine.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.15</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Cyclacel Licensee&#148; &#151; an entity or individual other than an Affiliate of
Cyclacel appointed by Cyclacel as a licensee pursuant to Clause 2.3.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.16</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Development Plan&#148; &#151; the plan for the development of Candidate and resultant
Product by or on behalf of Cyclacel, an outline of which is attached as
Schedule&nbsp;1, which plan may be updated or amended from time to time pursuant to
Clause 4.1.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.17</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Disclosing Party&#148; &#151; a Party which discloses Confidential Information to
another Party.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.18</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Documents&#148; &#151; reports, research notes, charts, graphs, comments,
computations, analyses, recordings, photographs, paper, notebooks, books,
files, ledgers, records, tapes, discs, diskettes, CD-ROM, computer information
storage means and any other media on which Know How can be permanently stored.</DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.19</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;EMEA&#148; &#151; European Medicines Evaluation Agency or any successor group thereto.</DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.20</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;European Union&#148; the countries of the European Union from time to time.</DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.21</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Exceptional Cause&#148;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">scientific or other technical cause
outside Cyclacel&#146;s or Cyclacel Licensee&#146;s reasonable control or
arising through the activities of Third Parties including any
significant, unexpected technical problems experienced with the
development of Candidate including but not limited to chemical
production of Candidate or polymorphic form of Candidate or Product
or significant, unexpected problems which relate to the safety,
efficacy or toxicology of Candidate, CNDAC or Product;</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 3 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">difficulty outside Cyclacel&#146;s or Cyclacel
Licensee&#146;s reasonable control in recruitment of patients into
trial(s); or</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">any significant, unexpected change in the
regulatory requirements in a country concerning the development of
Candidate or Product which comes into existence after the
Commencement Date, for example a new requirement for studies in
specific patient sub-groups.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.22</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Excluded Territories&#148; &#151; &#091;***&#093;</DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.23</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Expert&#146;s Decision&#148; &#151; the mechanism set out in Schedule&nbsp;9.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.24</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;FDA&#148; &#151; the U.S. Food and Drug Administration or any successor agency
thereto.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.25</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Force Majeure&#148; &#151; in relation to either Party, any event or circumstance
which is beyond the reasonable control of that Party which event or
circumstance that Party could not reasonably be expected to have taken into
account at the date of this Agreement and which results in or causes the
failure of that Party to perform any or all of its obligations under this
Agreement including acts of God, lightning, fire, storm, flood, earthquake,
requirement for quarantine due to infectious disease outbreak, accumulation of
snow or ice, lack of water arising from weather or environmental problems,
asteroid or meteor activity, strike, lockout or other industrial or student
disturbance, act of the public enemy, war declared or undeclared, threat of
war, terrorist act, blockade, revolution, riot, insurrection, civil commotion,
public demonstration, sabotage, act of vandalism, prevention from or hindrance
in obtaining in any way materials, energy or other supplies, explosion, fault
or failure of plant or machinery (which could not have been prevented by Good
Industry Practice) provided that lack of funds shall not be interpreted as a
cause beyond the reasonable control of that Party.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.26</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Good Industry Practice&#148; &#151; in relation to any undertaking and any
circumstance, the exercise of that degree of skill diligence, prudence and
foresight which would reasonably and ordinarily be expected from a skilled and
experienced person engaged in the same type of undertaking under the same or
similar circumstances.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.27</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Insolvency Event&#148; &#151; in relation to either Party or one of its Affiliates,
means any one of the following:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">a notice shall have been issued to
convene a meeting for the purpose of passing a resolution to wind up
that Party, or such a
resolution shall have been passed. For the avoidance of doubt a
resolution for the solvent reconstruction or reorganisation of
that Party or for the purpose of inclusion of any part of the
share capital of that Party in the Official List of the London
Stock Exchange or in the list of the American Stock Exchange or
quotation of the same on the National Association of Securities
Dealers Automated Quotation System or other such recognised
securities market shall not constitute an Insolvency Event; or</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 4 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">a resolution shall have been passed by
that Party&#146;s directors to seek a winding up, or an administration
order or a petition for a winding up or administration order shall
have been presented against that Party and appeal proceedings have
not been commenced by that Party within seven (7)&nbsp;days from the date
of such petition or such an order shall have been made; or</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">a receiver, administrative receiver,
receiver and manager, interim receiver, custodian, sequestrator or
similar officer is appointed in respect of that Party or over a
substantial part of its assets or any Third Party takes steps to
appoint such an officer in respect of that Party or an encumbrancer
takes steps to enforce or enforces its security; or</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">a proposal for a voluntary arrangement
shall have been made in relation to that Party under Part&nbsp;I
Insolvency Act 1986; or</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">a step or event shall have been taken or
arisen outside the United Kingdom which is similar or analogous to
any of the steps or events listed at (a)&nbsp;to (d)&nbsp;above which shall
include a Chapter&nbsp;XI filing in the USA; or</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(f)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">that Party takes any step outside the
ordinary course of business (including starting negotiations) with a
view to readjustment, rescheduling or deferral of any part of that
Party&#146;s indebtedness, or proposes or makes any general assignment,
composition or arrangement with or for the benefit of all or some of
that Party&#146;s creditors or makes or suspends or threatens to suspend
making payments to all or some of that Party&#146;s creditors or the
Party submits to any type of voluntary arrangement; or</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(g)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">where that Party is resident in the
United Kingdom it is deemed to be unable to pay its debts within the
meaning of Section&nbsp;123 Insolvency Act 1986.</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 5 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.28</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Know How&#148; &#151; technical and other information which is not in the public
domain, including information comprising or relating to concepts, discoveries,
data, designs, formulae, ideas, inventions, methods, models, assays, research
plans, procedures, designs for experiments and tests and results of
experimentation and testing (including results of research or development),
processes (including manufacturing processes, specifications and techniques),
laboratory records, chemical, pharmacological, toxicological, clinical,
analytical and quality control data, trial data, case report forms, data
analyses, reports, manufacturing data or summaries and information contained in
submissions to and information from ethical committees and regulatory
authorities. Know How includes Documents containing Know How and shall be
deemed to include any rights of action or intellectual property rights
protecting such Know How. The fact that an item is known to the public shall
not be taken to preclude the possibility that a compilation including the item,
and/or a development relating to the item, is not known to the public.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.29</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Legal Requirement&#148; &#151; any present or future law, regulation, directive,
instruction, direction or rule of any Competent Authority or Regulatory
Authority including any amendment, extension or replacement thereof which is
from time to time in force.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.30</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Licensed IP&#148; &#151; Licensed Patent Rights, Licensed Know How and Licensed
Materials.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.31</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Licensed Know How&#148; &#151; any and all Know How owned by Sankyo relating to the
Candidate.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.32</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Licensed Material&#148; &#151; any and all Material owned by Sankyo directly related
to the Candidate as set out in Schedule&nbsp;2 as of the Commencement Date unless
otherwise specified therein.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.33</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Licensed Patent Rights&#148; &#151; any Patent Rights owned by Sankyo relating to
inventions comprised in the Licensed Material or Licensed Know How, the Patent
Rights listed in Schedule&nbsp;3 and any subsequent Patent Rights owned by Sankyo
directly relating to the inventions of CS-682 comprised in the Patent Rights to
be added to Schedule&nbsp;3 in accordance with Clause 6.8. For avoidance of doubt,
Licensed Patent Rights exclude the CNDAC Patent Rights.</DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.34</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Material&#148; &#151; any chemical or biological substances including any: -</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">organic or inorganic element or compound;</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 6 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">nucleotide or nucleotide sequence
including DNA and RNA sequence;</DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">gene;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">vector or construct including plasmids,
phages or viruses;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">host organism including bacteria, fungi,
algae, protozoa and hybridomas;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(f)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">eukaryotic or prokaryotic cell line or
expression system or any development strain or product of that cell
line or expression system;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(g)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">protein including any peptide or amino
acid sequence, enzyme, antibody or protein conferring target
properties and any fragment of a protein or a peptide enzyme or
antibody;</DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(h)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">drug or pro-drug;</DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">assay or reagent; or</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(j)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">any other genetic or biologic material or
microorganism.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.35</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Marketing Authorisation&#148; &#151; any and all consents or other authorisations or
approvals required from a Regulatory Authority to market and sell a Product in
any country, but not any form of pricing or reimbursement approval.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.36</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Net Sales&#148; &#151; with respect to Product in relation to which Marketing
Authorisation and, if necessary in such country in the Territory, pricing
approval has been granted by the appropriate Regulatory Authority or other
Competent Authority for any jurisdiction for at least one indication, the gross
total amount originally invoiced by Cyclacel, its Affiliates or Cyclacel
Licensees to Third Parties for Products in the Territory less:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">quantity, trade and/or cash discounts
actually granted;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">amounts repaid or credited and allowances
including cash, credit or free goods allowances given by reason of
chargebacks, retroactive price reductions (provided that price
adjustments may be retrospectively made for up to two (2)
consecutive fiscal years) or billing errors and rebates (including
government-mandated rebates), actually allowed or paid;</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 7 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">amounts refunded or credited for Product
which was rejected, spoiled, damaged, outdated or returned;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">freight, shipment and insurance costs
incurred transporting Product to a Third Party purchaser;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">taxes, tariffs, customs duties and
surcharges and other governmental charges incurred in connection
with the sale, exportation or importation of Product.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(f)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">bad debt losses and costs for the
recovery of such bad debts.</DIV></TD>
</TR>

</TABLE>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 12%">The transfer of Product by Cyclacel or one of its Affiliates to another
Affiliate or Cyclacel Licensee shall not be considered a sale. In such cases
Net Sales shall be determined based on the invoiced sale price by the Affiliate
or Cyclacel Licensee to the first Third Party trade purchaser, less the
deductions allowed under this Clause.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 12%">Upon the sale or other disposal of Product other than in a bona fide arms length
transaction exclusively for money or upon any use of Product for the purposes
which do not result in a disposal of that Product in consideration of sales
revenue customary in the country of sale, such other sale, disposal or use shall
be deemed to constitute a sale at the relevant open market price in that country
in which the sale, other disposal or use occurs, or, if that price is not
ascertainable, a reasonable price assessed on an arm&#146;s length basis for the
goods or services provided in exchange for the supply. Disposal of Product for,
or use of Product in Clinical Trials for the purpose of obtaining a Marketing
Authorisation or pre-clinical trials or as free samples in quantities common in
the industry for this sort of Product shall not give rise to any deemed sale
under this Clause.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 12%">Such amounts shall be determined from the books and records of Cyclacel
maintained in accordance with GAAP (generally accepted accounting principles),
consistently applied.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 12%">For the avoidance of doubt it is declared and agreed that if the product can be
marketed and sold without pricing approval nothing in this definition requires
pricing approval for it to be classified as Product for the purposes of this
Agreement.
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.37</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Party or Parties&#148; &#151; Cyclacel or Sankyo or Cyclacel and Sankyo, as the case
may be.</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 8 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.38</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Patent Rights&#148; &#151; patent applications and patents, author certificates,
inventor certificates or certifications of invention, applications for
certificates of invention, utility certificates, improvement patents and
models and certificates of addition and all foreign counterparts of them,
including any divisions or divisional applications and patents,
refilings, renewals, continuations, continuations-in-part, patents of
addition, extensions (including patent term extensions), reissues,
substitutions, confirmations, registrations, revalidations, request for
continued examination, re-examinations or renewals thereof, pipeline and
administrative protections and additions, and any equivalents of the
foregoing in any and all countries of or to any of them including foreign
counterpart applications, as well as any supplementary protection
certificates and equivalent protection rights in respect of any of them.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.39</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Phase I Clinical Trial&#148; &#151; a human clinical trial normally conducted in
healthy volunteers or patients with the aim of establishing the
pharmacokinetic, pharmacodynamic and early safety profile of a product (alone
or in combination with another agent).</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.40</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Phase II Clinical Trial&#148; &#151; a human clinical trial where a product is tested
in a number of patients for the purpose of establishing preliminary data on the
efficacy and safety of a product.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.41</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Phase III Clinical Trial&#148; &#151; a human clinical trial conducted in a sufficient
number of patients to establish safety or efficacy for one or more
indication(s) tested and required for the filing of a submission to obtain
Marketing Authorisation.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.42</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Product&#148; &#151; a pharmaceutical product comprising the Candidate or otherwise
falling within a Valid Claim of the Licensed Patent Rights.</DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.43</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Professors&#148; &#151; &#091;***&#093;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.44</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Quarter&#148; &#151; each period of three months ending on 31 March, 30 June, 30
September or 31 December and &#147;Quarterly&#148; shall be construed accordingly.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.45</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Recipient Party&#148; &#151; the Party which receives Confidential Information from
the other Party.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.46</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Regulatory Authority&#148; &#151; shall mean any national, supranational, regional,
state or local regulatory agency, department, bureau, commission, council or
other governmental entity including the FDA and EMEA, in each country involved
in the granting of Marketing Authorisation for a Product.</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 9 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.47</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Results&#148; &#151; Know How, Patent Rights and Materials arising from any research,
development or commercialisation activity undertaken by or on behalf of
Cyclacel in connection with this Agreement.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.48</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Successful Completion&#148; &#151; shall mean that the Phase II Clinical Trial in
question has met the end points set out in Schedule&nbsp;5.</DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.49</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Territory&#148; &#151; the World excluding the Excluded Territories.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.50</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Third Party&#148; &#151; any entity or individual other than Cyclacel or Sankyo or
their respective Affiliates.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.51</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Valid Claim&#148; &#151; a claim of an issued and unexpired patent included within
Patent Rights, which has not been permanently revoked, held unenforceable or
invalid by a decision of a court or other governmental agency of competent
jurisdiction, un-appealable or un-appealed within the time allowed for appeal,
and which has not been admitted to be invalid or unenforceable through reissue
or disclaimer or otherwise.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1.52</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Year&#148; &#151; twelve (12)&nbsp;months commencing on 1 January and ending on 31
December.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">In this Agreement:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Unless the context otherwise requires all references to a
particular Clause, Schedule or paragraph shall be a reference to that Clause,
Schedule or paragraph, in or to this Agreement as it may be amended from time
to time pursuant to this Agreement;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">The table of contents and headings are inserted for
convenience only and shall be ignored in construing this Agreement;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Unless the contrary intention appears words importing the
masculine gender shall include the feminine and vice versa and words in the
singular include the plural and vice versa;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Unless the contrary intention appears words denoting persons
shall include any individual, partnership, company, corporation, joint venture,
trust, association (incorporated or not incorporated), organisation or other
entity, in each case whether or not having legal personality;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Reference to any statute, directive or regulation includes any
modification or re-enactment of that statute or regulation; and</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">References to the word &#147;include&#148; or &#147;including&#148; are to be
construed without limitation to the generality of the preceding words.</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 10 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>2.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"><B>LICENCES</B></DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Sankyo hereby grants to Cyclacel</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">an exclusive licence under the Licensed IP.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">a non-exclusive, royalty-free terminable sub-licence under the
CNDAC Patent Rights which are licensed with a right to sub-license by the
Professors to Sankyo.</DIV></TD>
</TR>

</TABLE>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">in each case to research, develop, make, have made, use, import, have imported, market, have
marketed, sell, offer for sale, have sold or otherwise dispose of Candidate (or any
constituent part of the same) and Product, for all indications in the Territory.
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">The Parties &#091;***&#093; which requires &#091;***&#093; with Product in the &#091;***&#093; and thus
&#091;***&#093;. Sankyo shall use its reasonable efforts &#091;***&#093;.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#091;***&#093; relation to the Candidate, Sankyo shall so notify
Cyclacel in writing &#091;***&#093; shall be &#091;***&#093; under the same commercial terms as set
out in this Agreement.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#091;***&#093; in relation to the Candidate, Sankyo shall so notify
&#091;***&#093; discuss in good faith issues relating to &#091;***&#093; including but not limited
to terms for the usage of data generated by Cyclacel &#091;***&#093;.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Sankyo shall not grant any rights or licences in the Licensed
IP or CNDAC Patent Rights to any Third Party &#091;***&#093;, or itself carry out any
activities utilising the Licensed IP or Sub-Licensed IP &#091;***&#093; which would or
would be reasonably expected to have an adverse impact upon the value or scope
of the rights granted to Cyclacel hereunder. &#091;***&#093;.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">The licences set out in Clause 2.1 shall include the right to grant
sub-licences. Save as otherwise provided in this Agreement, Cyclacel shall procure
that Cyclacel Licensees are bound by the same obligations, to the extent practicable,
as those hereunder, including, but not limited to the obligations of confidentiality
and non-use for unauthorised purpose. Cyclacel shall be responsible to Sankyo for the
acts and omissions, including breach of this Agreement, of any Cyclacel Licensee
provided that in the case of a Cyclacel Licensee committing a material breach that
would constitute a material breach of this Agreement, Cyclacel shall have sixty (60)
days to require such Cyclacel Licensee to remedy the breach or to terminate its
sub-licence before Cyclacel shall be considered to have committed a material breach
under Clause 9.3.1. Cyclacel shall give Sankyo prompt notification of the identity of
each Cyclacel Licensee with whom it concludes a sub-licence.</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 11 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">As soon as reasonably practicable following the Commencement Date and subject
to the provisions of Clause 3.2.2 Sankyo shall disclose, supply copies of, or otherwise
make available to Cyclacel the Licensed Materials and Documents containing the Licensed
Know How. In particular, and without limiting the foregoing, Sankyo shall supply
Cyclacel with quantities of the Candidate and CNDAC as listed in Schedule&nbsp;2 and all
synthesis data and methods relating to the Candidate. Cyclacel acknowledges that (i)
save as set out in Clause 7.2 Sankyo does not warrant the quality of any of the
Licensed Materials, and (ii)&nbsp;Sankyo has no further obligation to supply the Candidate
and CNDAC in addition to the quantities listed in Schedule&nbsp;2. Unless Cyclacel requests
transfer of any or all of those capsules in writing after the Commencement Date, the
Parties shall execute a separate entrustment agreement with respect to the maintenance
and analysis of capsules on stability in Schedule&nbsp;2, which sets forth that (i)&nbsp;Cyclacel
shall pay the expenses for entrustment to Sankyo and such expenses shall not be subject
to Clause 3.3.2, and that (ii)&nbsp;Sankyo shall perform the analysis after the expiration
dates for storage periods of such capsules on stability. Cyclacel acknowledges that
Sankyo would never be able to further extend expiration dates of such capsules
according to Sankyo&#146;s standards. Sankyo will transfer ownership of all formulated
Candidate as listed in Schedule&nbsp;2 and the current drug master file of the Candidate to
Cyclacel except for certain amount retained by Sankyo necessary for the technology
transfer or other purposes, including, but not limited to, to comply with regulatory
requirements. Ownership, title and risk of all Licensed Materials provided under this
Clause 2.4 shall be transferred from Sankyo to Cyclacel (i)&nbsp;at shipment if shipped by
Sankyo or its designee to Cyclacel, (ii)&nbsp;upon transfer of &#091;***&#093; in accordance with
Clause 7.4 or (iii)&nbsp;if Licensed Materials otherwise become available to Cyclacel.
Sankyo shall provide Cyclacel with all reasonable assistance requested by Cyclacel in
interpreting and understanding the Licensed IP and in the transfer, including updating
to the FDA, of &#091;***&#093; in accordance with Clause 7.4 at Cyclacel&#146;s cost. Such assistance
by Sankyo for the CMC technology transfer of synthesis and internal process checks
shall be deemed to be completed if either of the following events occurs:</DIV></TD>
</TR>

</TABLE>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 8%">&#091;***&#093;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">Sankyo shall maintain its copies of Documents containing the Licensed Know-How for the
lesser of eight (8)&nbsp;years or until requested by Cyclacel under Clause 2.7 or otherwise
agreed by the Parties. Should Sankyo intend to dispose of the Documents it shall so notify
Cyclacel and Cyclacel will be entitled to take ownership of such Documents at Cyclacel&#146;s
discretion and cost.
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Sankyo shall at Cyclacel&#146;s request execute or procure the execution of all such
deeds and documents as may be necessary or desirable to record any of the rights
granted to Cyclacel under this Agreement with any patent registry.</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 12 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Sankyo shall notify Cyclacel in the event that Sankyo generates any Patent
Rights or Know How relating to the Candidate or relating to CNDAC which also relates
to the Candidate and if Cyclacel so requests such Patent Rights or Know How shall
then automatically become part of the Licensed IP and shall be licensed to Cyclacel
on the same terms as set out herein.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Sankyo shall maintain those items of technical data listed in Schedule&nbsp;6 and
shall make the same available to Cyclacel for use in connection with the development or
commercialisation of Product (including, without limitation, for the purposes of
cross-referencing or inclusion in regulatory filings relating to Candidate or Product).
Sankyo shall exert its reasonable efforts to make such data available to Cyclacel
within thirty (30)&nbsp;Business Days of the Commencement Date or the date which such data
become available to Sankyo.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Sankyo shall promptly inform Cyclacel of any significant developments of which
it becomes aware concerning any part of the Licensed IP or CNDAC Patent Rights which
are licensed by Sankyo to Cyclacel.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>3.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"><B>PAYMENTS</B></DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">In consideration of the rights granted to Cyclacel under this Agreement
Cyclacel shall pay to Sankyo payments set out in this Clause 3.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Cyclacel shall pay to Sankyo a licence fee and costs comprised of the
following:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#091;***&#093; payable within thirty (30)&nbsp;days of the Commencement
Date;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Sankyo&#146;s reasonable costs incurred pursuant to Sankyo&#146;s
technology transfer obligations under Clause 2.4 within 30&nbsp;days of receipt of
Sankyo&#146;s Quarterly invoice and those costs incurred to Sankyo and reimbursed by
Cyclacel under Clause 6.1 provided that in the event such amounts exceed &#091;***&#093;
any amounts in excess of &#091;***&#093; shall be creditable against the milestone
payments set out in Clause 3.3.1 and provided further that such costs in excess
of &#091;***&#093; shall be subject to an overall maximum of &#091;***&#093;. The Parties
acknowledge that as of the end of June&nbsp;2003 Sankyo has incurred &#091;***&#093; in
transferring Licensed Know How and Licensed Materials to Cyclacel and that
Sankyo has invoiced Cyclacel for such amount. Notwithstanding the generality
of the foregoing, Cyclacel agrees to pay to Sankyo such &#091;***&#093; within thirty
(30)&nbsp;days of the Commencement Date.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Cyclacel shall pay to Sankyo the following non-refundable payments, provided,
the milestone payments set out in Clauses 3.3.1 to 3.3.5 shall be payable in relation
to the first Product only.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">subject to any set-off, if applied pursuant to Clause 3.2,
&#091;***&#093; within thirty (30)&nbsp;days of the Successful Completion of the first Phase
II Clinical Trial for Product;</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 13 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#091;***&#093; within thirty (30)&nbsp;days of the commencement of the first
Phase III Clinical Trial for Product, provided, however: (a)&nbsp;if Cyclacel
commenced the first Phase III Clinical Trial for Product without the Successful
Completion of the first Phase II Clinical Trial for Product, the payment under
Clause 3.3.1 above shall become also payable to Sankyo in addition to the
payment under this Clause 3.3.2 and; (b)&nbsp;in the event that Cyclacel is granted
Marketing Authorisation for Product in the USA, any country of the European
Union or Japan on the basis of any clinical trial results generated other than
pursuant to a formal Phase III Clinical Trial, the milestone payment under this
Clause 3.3.2 shall become due and payable by Cyclacel at the same time.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.3.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#091;***&#093; within thirty (30)&nbsp;days of the granting of the first
Marketing Authorisation and, if required in order to sell Product, pricing
approval for Product in the USA;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.3.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#091;***&#093; within thirty (30)&nbsp;days of the granting of the first
Marketing Authorisation and, if required in order to sell Product, pricing
approval for Product in any country of the European Union;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.3.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#091;***&#093; within thirty (30)&nbsp;days of the granting of the first
Marketing Authorisation and, if required in order to sell Product, pricing
approval for Product in Japan;</DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.3.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">royalties applicable on Net Sales as follows:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.3.6.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#091;***&#093; on annual Net Sales less than &#091;***&#093;</DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.3.6.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#091;***&#093; on annual Net Sales greater than or equal to &#091;***&#093; and less
than &#091;***&#093;</DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.3.6.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#091;***&#093; on annual Net Sales greater than or equal to &#091;***&#093;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">In the case of sales of Product by Cyclacel, its Affiliates or Cyclacel
Licensees in countries where such sale does not fall within a Valid Claim of a Licensed
Patent Right the royalty payable on Net Sales in such country shall be &#091;***&#093; regardless
of the volume of Net Sales in such country.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">In the event a Third Party launches a generic product which directly competes
with the Product and does not infringe Licensed IP and the volume of sales of Product
are less than or equal to &#091;***&#093; of the total volume of sales of Product plus all such
competing generic products in such country as evidenced by data compiled by IMS Health
of 1499 Post Road, Fairfield, CT 06430, USA or, in the event such data by IMS Health is
not available or the Parties agree it is not appropriate to use such data in such
country, a similar market research agency the
royalty payments set out in Clauses 3.3.6.1 to 3.3.6.3 shall no longer be payable to
Sankyo on Net Sales in such country.</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 14 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#091;***&#093;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">The royalties payable by Cyclacel hereunder shall be payable for the following
periods:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.7.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">In those countries where at the time of first commercial sale
in such county the sale of Product falls within a Valid Claim of Licensed
Patent Rights subsisting in that country, royalties shall be payable until the
latter of (i)&nbsp;the last to expire of such Licensed Patent Rights in that country
or (ii)&nbsp;the tenth (10th) anniversary of the date of first commercial sale in
that country;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.7.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">In those countries where at the time of first commercial sale
of Product in that country the sale of Product does not fall within a Valid
Claim of Licensed Patent Rights subsisting in that country, royalties shall be
payable until the tenth (10th) anniversary of the date of first commercial sale
in that country.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Disposal of reasonable quantities of Product for, or use of Product, in
Clinical Trials performed for the purpose of obtaining a Marketing Authorisation or
pre-clinical trials, or as free samples to be in quantities common in the industry for
this sort of Product shall not give rise to liability for payment of a royalty under
this Clause 3.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">In the event that Product is sold as a Combination Product containing a
therapeutically active ingredient that is not Licensed IP or CNDAC Patent Rights in a
country, the Net Sales of the Product shall be determined by multiplying &#091;***&#093;. In the
event Cyclacel wishes to develop a Combination Product which (1)&nbsp;is administered
through a therapeutically active administration technology that is not Licensed IP or
CNDAC Patent Rights, (2)&nbsp;is administered in accordance with a diagnostic detection
technology that is not Licensed IP or CNDAC Patent Rights or (3)&nbsp;otherwise depends for
a significant part of its value upon components which are not Licensed IP or CNDAC
Patent Rights, then the Parties shall separately discuss how to determine the Net Sales
applicable for such Combination Product. In the event the Parties fail to agree an
applicable Net Sales price for such combination product within sixty (60)&nbsp;days of
commencing such good faith discussions, such price shall be determined by a reputable
independent auditor appointed by agreement between the Parties or, failing which, the
President (or his or her nominee) for the time being of the Institute of Chartered
Accountants of England and Wales (or any successor body thereto).</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 15 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.10</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Cyclacel shall, and shall procure that its Affiliates and Cyclacel Licensees
shall, keep true and accurate records and books of account containing all data
necessary
for the calculation of the amounts payable by it to Sankyo pursuant to this
Agreement. Those records and books of account shall be kept for seven (7)&nbsp;years
following the end of Year to which they relate and shall, upon reasonable notice
having been given by Sankyo or its nominee, be open on Business Days for
examination, under the terms of confidentiality contained in this Agreement, by an
independent firm of accountants appointed by agreement between the Parties or
between Cyclacel and Sankyo&#146;s nominee (as appropriate) or, failing such agreement
within twenty-eight (28)&nbsp;days, by the President (or his or her nominee) for the time
being of the Institute of Chartered Accountants of England and Wales (or any
successor body thereto). Such examination shall take place not later than five (5)
years following the expiration of the period to which it relates and there shall be
no more than one such examination per year. Such independent accountant shall
provide a written report of his findings to each of Cyclacel and Sankyo in which he
certifies the moneys due to Sankyo in respect of the period under review. If such
examination demonstrates that Cyclacel has underpaid royalties due to Sankyo,
Cyclacel shall make a balancing payment within thirty (30)&nbsp;days. The cost of the
examination, review and certification shall be the responsibility of Cyclacel if
Cyclacel is shown to have underestimated the monies payable to Sankyo in any period
being reviewed by more than &#091;***&#093; and the responsibility of Sankyo otherwise.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.11</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Cyclacel shall make the royalty payments due to Sankyo under this Clause 3 at
Quarterly intervals. Within thirty (30)&nbsp;days of the end of each Quarter after first
commercial sale in any country, Cyclacel shall prepare a statement which shall show on
a Product by Product and a country by country basis for the previous Quarter all monies
due to Sankyo under Clause 3 and shall, if applicable, contain Cyclacel&#146;s reasonable
estimate of any amounts deductible pursuant to Clauses 3.4 and 3.5. That statement
shall include details of the particular Product description including to the extent it
requires use of Combination Product, sales of the Product and the royalty amount
payable for each country in the Territory. Cyclacel shall pay the royalty due under
Clause 3.3.6 within thirty (30)&nbsp;days of issuance of such statement. Within thirty (30)
days of the end of the final Quarter of each Year Cyclacel shall carry out a
reconciliation in relation to the royalty payments made and the royalty rate applied
during the previous Year and, if applicable, shall apply the formula set out in Clause
3.6. If such reconciliation demonstrates that Cyclacel has underpaid royalties due to
Sankyo it shall make a balancing payment within thirty (30)&nbsp;days and if it is
demonstrated that Cyclacel has overpaid royalties due to Sankyo, Sankyo shall make a
payment to Cyclacel of a balancing refund within thirty (30)&nbsp;days.</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 16 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.12</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">If Sankyo give notice to Cyclacel within ten (10)&nbsp;Business Days of the receipt
of any statement provided pursuant to Clause 3.11 that it does not accept it, that
statement shall be reviewed and certified by an independent accountant appointed by
agreement between the Parties or, in default of agreement within twenty eight (28)
days, by the President (or his or her nominee) for the time being of the
Institute of Chartered Accountants of England and Wales (or any successor body
thereto). Cyclacel shall make available all books and records required for the
purpose of that review and certification and the statements so certified shall be
final and binding between the Parties. The cost of the examination, review and
certification shall be the responsibility of Cyclacel if Cyclacel is shown to have
underestimated the monies payable to Sankyo in any period being reviewed by more
than &#091;***&#093; and the responsibility of Sankyo otherwise. Following any such
certification under Clause 3.10 or this Clause 3.12 the Parties shall forthwith make
any adjustments necessary in respect of the monies already paid to Sankyo in
relation to the period in question.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.13</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Where Product is sold in a currency other than US dollars the rate of exchange
to be used for converting such other currency into US dollars shall be the Telegraphic
Transfer Middle (T.T.M.) rate at which such other currency can be sold for US dollars
at the Bank of England in London at the close of business on the last working date for
the period for which payment is to be made.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.14</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">If any sums are unpaid by Cyclacel on the dates specified in this Clause then
Sankyo shall be entitled to charge Cyclacel interest on the amount unpaid at the rate
of &#091;***&#093; per annum above the prevailing Bank of England base lending rate from time to
time until payment in full is made.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.15</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Royalties or other payments payable under this Clause shall be payable
hereunder without any deduction or set-off save that if any law, regulation or treaty
requires a withholding of income taxes on any milestone, royalty payments or other
payments due to Sankyo, such taxes will be deducted for such payment and paid to the
appropriate taxing authorities. Certificates of such tax payments shall be delivered
to Sankyo along with the balance of the milestone, royalty payment or other payments.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.16</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">All payments made to Sankyo under the Agreement shall be made by telegraphic
transfer to the account of Sankyo Co. Ltd. at:</DIV></TD>
</TR>

</TABLE>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#091;***&#093;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">or any other bank account that may be notified by Sankyo to Cyclacel from time to time.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 17 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>4.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"><B>DEVELOPMENT AND COMMERCIALISATION</B></DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Cyclacel shall use commercially reasonable endeavours to pursue the development
and commercialisation of Product. For the purposes of this Clause 4 such reasonable
endeavours shall mean those efforts to develop and commercialise Product which are at
least the same as the efforts used by Cyclacel in relation to the development and
commercialisation of other Cyclacel pharmaceutical products under similar commercial
circumstances that have similar commercial value and development status to the Product.
Cyclacel shall
carry out such development in accordance with the key elements of the Development
Plan which plan may be updated and/or amended from time to time by Cyclacel and
Cyclacel shall provide Sankyo with a copy of any such updated or amended plan.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Without limiting the generality of the foregoing Cyclacel shall use its
reasonable endeavours &#091;***&#093;. If Cyclacel, its Affiliates or Cyclacel Licensees have
not &#091;***&#093; then provided such failure is not due to an Exceptional Cause Sankyo shall be
entitled to notify Cyclacel that it intends to terminate this Agreement, Cyclacel shall
have sixty (60)&nbsp;days to reply to Sankyo&#146;s notification and demonstrate that such
failure was due to an Exceptional Cause. In the event that the Parties agree that no
such Exceptional Cause has been demonstrated then Sankyo will have the right to
terminate this Agreement upon thirty (30)&nbsp;days written notice. &#091;***&#093;. The Parties
shall, no later the fifth (5th) anniversary of the Commencement Date discuss, in good
faith and review such time periods and, if appropriate, extend such period to &#091;***&#093;.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Cyclacel shall within thirty (30)&nbsp;days of each anniversary of the Commencement
Date provide Sankyo with a written summary of the progress which Cyclacel, its
Affiliates and/or Cyclacel Licensees has made against the Development Plan in the
previous twelve (12)&nbsp;month period. In addition, Cyclacel shall provide Sankyo within
seven (7)&nbsp;months of each annual written report with a brief update of such progress,
which update may be given in writing by facsimile or by e-mail.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">In the event that Cyclacel decides to appoint a Third Party, or if Cyclacel
receives an offer from a Third Party, in either case to develop and/or commercialise
Product solely in Japan or in Japan as part of a multi-territory sub-licence, it shall
so notify Sankyo which notification shall not be made prior to the first Successful
Completion of a &#091;***&#093; Clinical Trial or the decision by Cyclacel or a Cyclacel Licensee
to initiate &#091;***&#093; Clinical Trials and shall be accompanied by (i)&nbsp;details of the terms
upon which Cyclacel is prepared to offer for the appointment of a Third Party licensee
and (ii)&nbsp;the data and evidence on which Cyclacel or Cyclacel Licensee made such
decision. Sankyo shall notify Cyclacel within &#091;***&#093; of receipt of the Cyclacel
notification whether Sankyo wishes to develop and/or commercialise Product in Japan.
If Sankyo notifies Cyclacel that it does wish to develop and/or commercialise Product
in Japan the Parties shall meet and negotiate in good faith the terms of appointment of
Sankyo as Cyclacel Licensee in Japan. If Sankyo notifies Cyclacel that it does not
wish to develop and/or commercialise Product in Japan or, in the case where Sankyo has
notified Cyclacel that it does wish to develop and/or commercialise Product in Japan
but the Parties have failed to agree terms within &#091;***&#093; of commencing negotiations,
then Cyclacel shall be free to appoint a Third Party to develop and/or commercialise
Product in Japan provided that such appointment shall be on terms no more favourable
than those terms which Cyclacel was prepared to offer Sankyo. For the avoidance of
doubt if Cyclacel receives an offer at any time by a
Third Party to commercialise Product on a worldwide basis, Cyclacel shall notify
such Third Party that Sankyo has a first refusal right of Marketing in Japan and
Cyclacel shall propose to such Third Party to accept such condition. In such case,
the conditions imposed under this Clause will be accelerated and Cyclacel will serve
notification to Sankyo who will respond in accordance with the provisions herein.
&#091;***&#093;.</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 18 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>5.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"><B>INTELLECTUAL PROPERTY &#151; OWNERSHIP</B></DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Sankyo owns the Licensed IP and during the period of this Agreement shall not
assign, transfer, mortgage, charge or otherwise dispose of or encumber the same without
the prior written consent of Cyclacel.</DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Any and all Results shall vest in and be owned by Cyclacel.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>6.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"><B>INTELLECTUAL PROPERTY &#151; PROSECUTION, MAINTENANCE AND ENFORCEMENT</B></DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Sankyo shall at its own cost and expense file, prosecute and maintain Licensed
Patent Rights, including for the avoidance of doubt all annuity and renewal fees and
shall be responsible for the conduct of any claims or proceedings relating to the
Licensed Patent Rights, including any interference or opposition proceedings. Sankyo
shall keep Cyclacel and/or Cyclacel&#146;s nominated patent attorney fully and promptly
informed of such filing, prosecution and maintenance of the Licensed Patent Rights
including, without limitation, providing Cyclacel and/or Cyclacel&#146;s nominated patent
attorney with copies of all correspondence with any patent office and shall give
Cyclacel the right to comment thereon prior to any response being made to any such
patent office. Sankyo shall ensure that copies of all such patent office
correspondence provided to Cyclacel for comment shall be provided no less that sixty
(60)&nbsp;days prior to the expiry of any patent office deadline for response (if
applicable) and Cyclacel shall ensure that it provides Sankyo with its comments on such
correspondence not less than thirty (30)&nbsp;days prior to the expiry of any such patent
office deadline for response. Without limiting the generality of the foregoing
obligation to keep Cyclacel fully and promptly informed, Cyclacel may itself or through
its patent attorney make a written request to Sankyo or Sankyo&#146;s nominated patent
attorney not more than once per Quarter for a progress report on the filing,
prosecution and maintenance of the Licensed Patent Rights during the previous Quarter
and a summary of the anticipated activities for the next Quarter. Notwithstanding this
Clause 6.1, Cyclacel shall pay the costs and expenses of such filing, prosecution and
maintenance upon Sankyo&#146;s Quarterly invoice prior to its payment of the first
applicable milestone under Clauses 3.3.3, 3.3.4 or 3.3.5 and thereafter such costs
shall be borne by Sankyo, except that such costs borne by Cyclacel after its payment of
the Phase III entry milestone under 3.3.2, will be creditable against the first
applicable milestone under Clauses 3.3.3, 3.3.4 or 3.3.5.</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 19 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">If Sankyo fails to prosecute or maintain the Licensed Patent Rights or any part
thereof it must notify Cyclacel in writing at least thirty (30)&nbsp;days prior to the
expiry of any material deadline for the taking of any steps in such action, proceeding
or prosecution and thereafter Cyclacel may in its sole discretion prosecute or maintain
the Licensed Patent Rights or any part thereof. If Cyclacel decides to prosecute or
maintain the Licensed Patent Rights or any part thereof it shall do so at its own cost
and expense and Sankyo shall promptly arrange for its patent attorneys to transfer to
Cyclacel all relevant papers, files and other documents.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">If either Party learns of any infringement or threatened infringement by a
Third Party of Licensed IP then such Party shall promptly notify the other Party and
shall provide such other Party with available evidence of such infringement.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">In the event of an infringement of the Licensed IP Cyclacel shall have the
first right to bring any action or proceedings in accordance with the following:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Sankyo shall have the right to join as a co-plaintiff and be
separately represented by counsel of its own choice and at its own reasonable
cost and expense;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Sankyo shall otherwise at Cyclacel&#146;s reasonable request and
sole expense, provide Cyclacel with reasonable assistance in relation to such
action or proceedings;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">if Cyclacel succeeds in any proceedings whether at trial or by
way of settlement, Cyclacel shall be entitled to retain such award of costs and
damages made in such proceedings or settlement sum after having reimbursed
Sankyo for its costs and expenses incurred in assisting with the proceedings,
subject to Clause 6.4.1 where Cyclacel and Sankyo shall be equally entitled to
retain such award. If Cyclacel should lose such proceedings then Cyclacel
shall on demand reimburse Sankyo its costs and expenses incurred in assisting
with the proceedings;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">if Cyclacel fails to take any such proceedings Sankyo may give
Cyclacel notice requiring Cyclacel to take such proceedings jointly with Sankyo
within thirty (30)&nbsp;days of the date of the notice and if Cyclacel fails to do
so Sankyo shall be entitled to do so at its own cost and expense and Cyclacel
shall provide all necessary assistance to Sankyo in relation to such
proceedings including lending its name to such proceedings as a co-plaintiff.
If Cyclacel does not join with Sankyo in taking part in such proceedings
Cyclacel shall not be entitled to be separately represented in such
circumstances and Sankyo shall have sole conduct of such proceedings including
the right to settle them. If Sankyo succeeds in any such proceedings it shall
be entitled to retain the whole of any award of costs and damages made or
settlement sum
paid. If Cyclacel joins with Sankyo in taking part in such joint
proceedings Cyclacel shall be entitled to be separately represented in
such circumstances and Sankyo shall jointly conduct such proceedings with
Cyclacel including the right to settle them. If Sankyo and Cyclacel
succeed in any such proceedings they shall share equally any award of
costs and damages made or settlement sum paid.</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 20 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">If during the term of this Agreement either Party receives any notice, claim or
proceedings from any Third Party alleging infringement of that Third Party&#146;s
intellectual property or know how as a result of either Party&#146;s activities in relation
to this Agreement or use and exploitation of the Licensed IP the Party receiving that
notice shall:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.5.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">forthwith notify the other Party of such notice, claim or
proceedings;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.5.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">make no admission of liability without the prior consent of
the other Party;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.5.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">subject to Clause 6.6.1 below Cyclacel shall conduct the
defence of such claims or proceedings, including the right to settle them which
shall include taking a licence from such Third Party, and Sankyo shall at
Cyclacel&#146;s cost and expense co-operate with Cyclacel and its legal counsel and
be available at Cyclacel&#146;s reasonable request to assist in such proceedings.
Cyclacel shall keep Sankyo and its legal counsel fully and promptly informed at
all times as to the status of Cyclacel&#146;s defence.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Whilst Cyclacel conducts the defence of such claim or proceedings:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.6.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Cyclacel shall be responsible for and shall have conduct of
such claims or proceedings but shall fully consult with Sankyo in defending or
settling such claim or proceedings and Cyclacel shall not consent to any
settlement, order or judgment requiring Sankyo to pay costs, damages or provide
other relief without the written consent of Sankyo;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.6.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">if any such proceedings are settled by way of licence, then to
the extent any royalties payable to a Third Party under such licence relate to
Blocking IP they shall be deducted from the royalties payable by Cyclacel to
Sankyo to the same extent and in the same manner as set out in Clause 3.6.</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 21 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">At Cyclacel&#146;s request and expense Sankyo shall promptly take all necessary
steps to facilitate any application for a supplementary protection certificate
extension of term or its equivalent, for any of the Licensed Patent Rights.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Within sixty (60)&nbsp;days after each Year-end, Sankyo shall provide Cyclacel with
a report describing the status of the Licensed Patent Rights and Cyclacel shall
provide Sankyo with a report describing the status of the any Patent Rights owned by
Cyclacel under Clause 5.2. Such reports shall include, at a minimum, the patent
country, patent and application numbers, filing date, issue date, expiration date
and any other relevant information, and shall be used to update Schedule&nbsp;3.</DIV></TD>
</TR>

</TABLE>
</DIV>
<DIV align="right">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="96%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="65%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Sankyo&#146;s report shall be sent to:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Cyclacel Limited</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Dundee Technopole</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">James Lindsay Place</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Dundee DD1 5JJ</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">UK</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention: Chief Executive Officer</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Telephone: &#043;44 1382 206062</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Facsimile: &#043;44 1382 206067</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Cyclacel&#146;s report shall be sent to:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Sankyo Company, Limited</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;***&#093;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>7.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"><B>WARRANTIES AND LIABILITY</B></DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Each Party represents and warrants to the other Party that:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">it has the corporate power and authority and the legal right
to enter into this Agreement and that this Agreement is a legal and valid
obligation binding upon such Party and enforceable in accordance with its
terms. The execution, delivery and performance of the Agreement by such Party
does not conflict with any agreement, instrument or understanding, oral or
written, to which it is or by which it is bound, nor violate any law or
regulation of any court, governmental body or administrative or other agency
having jurisdiction over it;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">it has not, and during the term of the Agreement will not,
without the prior written consent of the other Party grant any rights to any
Third Party that would conflict with the rights granted to the other Party
hereunder;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">it has the right to grant the licenses granted or to be
granted herein;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">it is a corporation duly organised, validly existing and in
good standing under the laws of the jurisdiction in which it is incorporated;
and</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">the execution and delivery of this Agreement and the
performance of such Party&#146;s obligations do not constitute a default or require
any consent under any other contractual obligation of such Party.
</DIV></TD>
</TR>
</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 22 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>


<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Sankyo hereby warrants and undertakes that at the Commencement Date:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">it owns absolutely, co-owns or has the right to licence the
Licensed IP and the CNDAC Patent Rights sufficient to grant the licences
granted herein;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">it has obtained from each and every inventor of the Licensed
Patent Rights an assignment of all rights such inventors may have in the
Licensed Patent Rights and save as otherwise disclosed to Cyclacel in writing
it has not partially assigned, licensed, mortgaged, charged or otherwise
disposed of or encumbered its right, title or interest in the same;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">it has disclosed to Cyclacel all information relating to the
Licensed IP and CNDAC Patent Rights and any therapeutic use of the Candidate
which has been generated by Sankyo or Third Parties, provided that in the case
of Third Parties the disclosure of such information is not prohibited under any
confidentiality obligations; and</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">it has disclosed to Cyclacel the identity of the Third Parties
which have generated the information described in Clause 7.2.3; and</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">it has not granted to any other party any licence to research,
develop or commercialise the Candidate or CNDAC or any other compound falling
within a Valid Claim of the Licensed Patent Rights or the CNDAC Patent Rights.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.2.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">it has manufactured the &#147;samples of any capsules in storage&#148;,
which is identified in Schedule&nbsp;2, under GMP and it had obtained from &#091;***&#093; a
statement that &#091;***&#093; has stored the same under GMP.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Save as is expressly stated in Clause 7.1 or 7.2 NO REPRESENTATION, CONDITION
OR WARRANTY WHATSOEVER IS MADE OR GIVEN, EITHER EXPRESSED OR IMPLIED, BY OR ON BEHALF
OF CYCLACEL OR SANKYO. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY
OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE CANDIDATE WILL NOT INFRINGE
ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS. ALL CONDITIONS AND
WARRANTIES WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE ARE HEREBY EXPRESSLY
EXCLUDED INCLUDING ANY CONDITIONS AND WARRANTIES TO THE EFFECT THAT ANY OF THE LICENSED
IP IS VALID OR ENFORCEABLE.</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 23 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Cyclacel shall have the control of and be responsible for all Clinical Trials
conducted in relation to Product after execution of this Agreement including such
ongoing Clinical Trials described in Schedule&nbsp;7 and shall be the sponsor of such trials
and in such capacity, shall, notwithstanding its indemnity rights under Clause 7.5, be
responsible for the initial payment of any compensation due to any participants in such
trials who suffer death or bodily injury pursuant to any legal
rights or applicable industry guidelines. If it has not already done so prior to
the Commencement Date, Sankyo shall submit to the FDA an Annual Update, including
Information Amendment, to &#091;***&#093; detailing an extension to the shelf-life of Product
and shall transfer &#091;***&#093; for such ongoing Clinical Trial to Cyclacel. In the event
that the FDA does not accept an extension to the shelf life of Product for use in
such ongoing Clinical Trials Cyclacel&#146;s obligations hereunder in relation to such
ongoing Clinical Trials shall be suspended until such time as the FDA has accepted
the use of Product in such trials. Cyclacel (i)&nbsp;shall continue to conduct such
ongoing Clinical Trial after the Commencement Date in compliance with the Phase I
protocol provided by Sankyo, (ii)&nbsp;shall not amend or alter such protocol and (iii)
shall not terminate such ongoing Clinical Trial at least until the end of December
2003 for ethical reasons unless otherwise terminated in accordance with the
protocol.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Subject to the provisions of Clause 7.6 Sankyo shall be responsible for and
shall indemnify Cyclacel and its directors, officers, servants and agents (collectively
&#147;the Indemnified Party&#148;) against any and all liability, loss, damage, cost and expense
(including legal costs) incurred or suffered by the Indemnified Party as a result of a
breach of warranty by Sankyo under Clauses 7.1 or 7.2 or as a result of Sankyo&#146;s
activities in relation to the development of Candidate or Product prior to the
Commencement Date of this Agreement. An Indemnified Party that intends to claim
indemnification under this Clause 7.5 shall promptly notify Sankyo of any Third Party
claim in respect of which the Indemnified Party intends to claim that indemnification.
The Indemnified Party shall not compromise or settle the claim prior to any such
notice. Sankyo may assume and control the defence of any such Third Party claim,
provided however, that an Indemnified Party shall have the right to retain its own
counsel at its own cost and expense, if representation of that Indemnified Party by the
counsel retained by Sankyo would be inappropriate due to actual or potential differing
interests between the Indemnified Party and any other party represented by that counsel
in the proceedings. The Indemnified Party shall co-operate with Sankyo and its legal
representatives in the investigation of any matter covered by this indemnification.</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 24 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Cyclacel shall be responsible for and shall indemnify Sankyo and its
Affiliates, directors, officers, servants and agents (collectively &#147;the Indemnified
Party&#148;) against any and all liability, loss, damage, cost and expense (including legal
costs) incurred or suffered by the Indemnified Party as a result of any claim brought
against Sankyo or its Affiliates by a Third Party which arises</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.6.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">as a result of the activities by Cyclacel or its Affiliates,
Cyclacel Licensees, agents or distributors under this Agreement in relation to
the development or commercialisation of the Product being a claim that use of
any Product has caused death or bodily injury; or</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.6.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">as a result of a breach of warranty by Cyclacel under Clause
7.1.</DIV></TD>
</TR>

</TABLE>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">An Indemnified Party that intends to claim indemnification under this Clause 7.6 shall
promptly notify Cyclacel of any Third Party claim in respect of which the Indemnified Party
intends to claim the indemnification. The Indemnified Party shall not compromise or settle
the claim prior to any such notice. Cyclacel may assume and control the defence of any such
Third Party claim, provided however, that an Indemnified Party shall have the right to
retain its own counsel at its own cost and expense, if representation of that Indemnified
Party by the counsel retained by Cyclacel would be inappropriate due to actual or potential
differing interests between the Indemnified Party and any other party represented by that
counsel in the proceedings. The Indemnified Party shall co-operate with Cyclacel and its
legal representatives in the investigation of any matter covered by this indemnification.
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Subject to the indemnities in Clauses 7.5 and 7.6 neither Party shall be liable
to the other in contract, tort, negligence, breach of statutory duty or otherwise for
any loss, damage, costs or expenses of any nature whatsoever incurred or suffered by
the other or its Affiliates:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.7.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">of a direct nature where the same is a loss of turnover,
profits, business or goodwill; or</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.7.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">an indirect or consequential nature including any indirect or
consequential economic loss or other indirect or consequential loss of
turnover, profits, business or goodwill.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>8.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"><B>CONFIDENTIALITY</B></DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Subject to Clause 8.6, each of the Parties undertakes and agrees to:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">only use the Confidential Information for the purposes
envisaged under this Agreement and not to use the same for any other purpose
whatsoever;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">ensure that only those of their officers, consultants,
employees (including without limitation directors), sublicensees, Affiliates
and such third parties who are directly concerned with the carrying out of this
Agreement have access to the Confidential Information on a strictly applied
&#147;need to know&#148; basis and are informed of the secret and confidential nature of
it;</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 25 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">keep the Confidential Information secret and confidential and
not directly or indirectly to disclose or permit to be disclosed, make
available or permit to be made available the same to any Third Party for any
reason without the prior written consent of the Disclosing Party (except as set
out in the Development Plan and then under equivalent confidentiality
provisions);</DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">clearly identify the Confidential Information as confidential.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">The obligations of confidentiality referred to in Clause 8.1 shall not extend
to any Confidential Information which:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">is or becomes generally available to the public otherwise than
by reason of breach by a Recipient Party of the provisions of that Clause; or</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">is known to the Recipient Party and is at its free disposal
prior to its receipt from the Disclosing Party in circumstances where the
Recipient Party holds evidence that it has not been derived from access to the
Disclosing Party&#146;s Confidential Information; or</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">is mutually agreed in writing by the Parties to no longer be
confidential; or</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">is subsequently disclosed to the Recipient Party without
obligations of confidentiality by a Third Party owing no such obligations to
the Disclosing Party in respect of that Confidential Information; or</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">is required by a Legal Requirement to be disclosed and then
only (subject to Clause 8.3) when prompt written notice of this requirement has
been given to the Disclosing Party so that it may, if so advised, seek
appropriate relief to prevent such disclosure provided always that in such
circumstances such disclosure shall be only to the extent so required and shall
be subject to prior consultation with the Disclosing Party with a view to
agreeing timing and content of such disclosure.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">The requirement under Clause 8.2.5 to notify the Disclosing Party when
Confidential Information is required to be disclosed pursuant to Legal Requirement
shall not apply when such disclosure is required as part of any regulatory submission
or approval process.</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 26 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">All Confidential Information disclosed by the Disclosing Party to the Recipient
Party shall remain the property of the Disclosing Party subject to the use or disposal
of Materials pursuant to the Development Plan. In the event that a court or Competent
Authority assumes partial or complete control over the assets of a Recipient Party
based on the insolvency or bankruptcy of that Party, the Recipient Party shall:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">promptly notify such court or Competent Authority:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">that Confidential Information received
from the Disclosing Party under this Agreement remains the property
of the Disclosing Party; and</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">of the confidentiality obligations under
this Agreement; and</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">to the extent permitted by law, take all steps necessary or
desirable to maintain the confidentiality and security of the Disclosing
Party&#146;s Confidential Information and to ensure that the court or Competent
Authority maintains that Confidential Information in confidence in accordance
with this Agreement.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">The Parties agree that the obligations of confidentiality set out in this
Clause 8 shall continue to apply following the expiration or termination of this
Agreement for so long as there is Confidential Information which is not the subject of
Clause 8.2.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Sankyo acknowledges and agrees that Cyclacel shall be free to publish the
results arising pursuant to the exercise of its rights and licences under this
Agreement. Such publication may also include Licensed Know How comprising data related
to the Candidate and the development thereof provided that Cyclacel shall give Sankyo
prior written notice of any publication containing such Licensed Know How and Sankyo
shall have thirty (30)&nbsp;days to comment upon the same. Cyclacel shall consider any
comments from Sankyo in good faith. Cyclacel shall be free to publish the Licensed
Know How relating to the Candidate and/or its development following such thirty (30)
day period.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Results published under Clause 8.6, will be considered to be covered by Clause
8.2.3 in respect of future publications and Clause 8.6 will no longer apply.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>9.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"><B>TERM AND TERMINATION</B></DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">This Agreement shall commence on the Commencement Date and shall continue in
force until no payments are due hereunder or until termination under this Clause 9
whichever is the earlier.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Cyclacel may terminate this Agreement at any time upon six (6)&nbsp;months&#146; (upon
twelve (12)&nbsp;months&#146; if after Product launch) written notice to Sankyo for technical,
scientific, efficacy, safety or commercial reasons.</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 27 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Cyclacel on the one hand and Sankyo on the other hand (the &#147;Terminating Party&#148;)
shall have the right to terminate this Agreement upon giving thirty (30)&nbsp;days&#146; written
notice of termination to the other (the &#147;Defaulting Party&#148;) upon the occurrence of any
of the following events at any time during this Agreement:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">the Defaulting Party committing a material breach of this
Agreement which in the case of a breach capable of remedy shall not have been
remedied within thirty (30)&nbsp;days, or sixty (60)&nbsp;days in case of breach by
Cyclacel Licensee as permitted under Clause 2.3, of the receipt by it of a
notice identifying the breach and requiring its remedy. The Parties
acknowledge that non-payment of sums due by Cyclacel may amount to a material
breach having regard to the level of non-payment
and the reasons given by Cyclacel for such non-payment. The Parties
agree that any notification of material breach pursuant to this Clause
9.3 shall be sent to the chief executive officer of the Defaulting Party;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">if an Insolvency Event occurs in relation to the Defaulting
Party.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>10.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"><B>EFFECTS OF TERMINATION</B></DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Upon termination of this Agreement by Sankyo pursuant to Clause 4.2 or Clause
9.3 or by Cyclacel pursuant to Clause 9.2:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">the licences granted by Sankyo pursuant to Clause 2 under the Licensed IP,
and CNDAC Patent Rights shall terminate;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">if Sankyo so requests in writing, Cyclacel shall immediately deliver up to
Sankyo the Licensed IP, CNDAC Patent Rights and Documents containing or making
any reference to the Licensed IP or CNDAC Patent Rights as soon as reasonably
practicable. Within sixty (60)&nbsp;days of such termination, the Parties shall
negotiate and agree a separate Termination Agreement in regard to the transfer
of ownership and return to Sankyo of all regulatory submissions, and documents
filed with a Regulatory Authority for the Product in the Territory. The
Parties shall cooperate in order to provide the appropriate notice and
documentation to the Regulatory Authority for each submission as required by
applicable law; and</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">if Sankyo wishes to obtain an exclusive licence to the Cyclacel Results it
shall so notify Cyclacel and Cyclacel shall grant to Sankyo an exclusive,
worldwide, sub-licensable licence to the Cyclacel Results the commercial terms
of which shall be negotiated in good faith by the Parties, having regard to the
(i)&nbsp;length of time this Agreement has been in force, (ii)&nbsp;the development
efforts expended by Cyclacel, and (iii)&nbsp;the cause of termination. In the event
the Parties fail to agree the terms of such licence within sixty (60)&nbsp;days of
the date upon which Cyclacel receives written notice from Sankyo that it wishes
to obtain such a licence, the matter shall be referred to Expert&#146;s Decision for
resolution, whilst such exclusive license shall be temporarily granted to
Sankyo during such period.</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 28 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">In no event shall termination of this Agreement:</DIV></TD>
</TR>

</TABLE>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 8%">(i)&nbsp;relieve the Parties of any liability arising out of events occurring before the
effective date of such termination.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 8%">(ii)&nbsp;affect the continued operation or enforcement of any provision of this
Agreement which by its express terms is to survive termination.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 8%">(iii)&nbsp;release either Party from the obligation to pay any amounts that become due on
or before the effective date of termination.
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Upon termination of this Agreement by Sankyo pursuant to Clause 9.3 and at the
request of any Cyclacel Licensee Sankyo shall enter into a direct licensing arrangement
with such Cyclacel Licensee on terms substantially similar to those contained herein
save that any licence granted by Sankyo to such Cyclacel Licensee shall be consistent
with the terms of the licence granted by Cyclacel in relation to field, territory,
exclusivity/non-exclusivity, whether there is a right to sub-license, and payment
provisions and provided that: (i)&nbsp;such sub-licensee is in good standing under and in
compliance with all material terms and conditions of the sublicence agreement and this
Agreement; (ii)&nbsp;should Sankyo&#146;s ongoing direct costs related to such sublicense
including but not limited to IP costs under Clause 6.1, not be fully reimbursed by
revenue from such sublicensee on an annual basis then Sankyo can require that such
sublicensee reimburse Sankyo&#146;s costs, such reimbursement to be credited against future
revenue payable to Sankyo by such sublicensee; and (iii)&nbsp;Sankyo&#146;s obligations under
such sublicense agreement are no greater than those under this Agreement.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>11.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"><B>ASSIGNMENT/SUB-CONTRACTING</B></DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">11.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Neither this Agreement nor any interest hereunder shall be assignable by either
Cyclacel or by Sankyo without the written consent of the other, such consent not to be
unreasonably withheld, provided however that any Party may assign this Agreement to any
corporation with which it may merge or consolidate, or to which it may transfer all or
substantially all of its assets to which this Agreement relates, subject to obtaining a
direct deed of undertaking from such corporation addressed to the other Parties
agreeing to be bound by all the terms of this Agreement.</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 29 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>12.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"><B>FORCE MAJEURE</B></DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">12.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">If a Party (the &#147;Affected Party&#148;) is unable to carry out any of its obligations
under this Agreement due to Force Majeure this Agreement shall remain in effect but the
Affected Party&#146;s relevant obligations under this Agreement and the corresponding
obligations of the other Party (&#147;Non-Affected Party&#148;) under this Agreement, shall be
suspended for a period equal to the circumstance of Force Majeure provided that:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">12.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">the suspension of performance is of no greater scope than is required by the
Force Majeure;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">12.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">the Affected Party immediately gives the Non-Affected Party prompt written
notice describing the circumstance of Force Majeure, including the nature of
the occurrence and its expected duration, and continues to furnish regular
reports during the period of Force Majeure and notifies
the Non-Affected Party immediately of the cessation of the Force Majeure;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">12.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">the Affected Party uses all reasonable efforts to remedy its inability to
perform and to mitigate the effects of the circumstance of Force Majeure; and</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">12.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">a soon as practicable after the event which constitutes Force Majeure the
Parties discuss how best to continue their operations as far as possible in
accordance with this Agreement.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>13.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"><B>GOVERNING LAW</B></DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">13.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">The validity, construction and interpretation of this Agreement and any
determination of the performance which it requires shall be governed by the laws of
England.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>14.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"><B>JURISDICTION</B></DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">14.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">In the event of any material dispute concerning rights or obligations under
this Agreement then the Parties shall comply with the following procedure: the Chief
Executive Officer of Cyclacel and the President of Sankyo or its nominee shall be
notified in writing of the dispute by either Party. The Chief Executive Officer of
Cyclacel and the President of Sankyo or their nominees shall meet to resolve the
dispute in good faith. If such resolution is not reached within sixty (60)&nbsp;days of
such written notice, then the dispute shall be referred to the non-exclusive
jurisdiction of the courts of England and Wales.</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 30 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>15.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"><B>WAIVER</B></DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">15.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Save as expressly provided in this Agreement neither Party shall be deemed to
have waived any of its rights or remedies whatsoever unless the waiver is made in
writing, signed by a duly authorised representative of that Party and may be given
subject to any conditions thought fit by the grantor. Unless otherwise expressly
stated any waiver shall be effective only in the instance and for the purpose for which
it is given.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">15.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">No delay or failure of any Party in exercising or enforcing any of its rights
or remedies whatsoever shall operate as a waiver of those rights or remedies or so as
to preclude or impair the exercise or enforcement of those rights or remedies. No
single or partial exercise or enforcement of any right or remedy by any Party shall
preclude or impair any other or further exercise or enforcement of that right or remedy
by that Party.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>16.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"><B>SEVERANCE OF TERMS</B></DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">16.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">If the whole or any part of this Agreement is or becomes or is declared
illegal, invalid or unenforceable in any jurisdiction for any reason (including both by
reason of the provisions of any legislation and also by reason of any decision of any
court or Competent Authority which either has jurisdiction over this Agreement or has
jurisdiction over any of the Parties):</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">16.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">in the case of the illegality, invalidity or un-enforceability of the whole
of this Agreement it shall terminate in relation to the jurisdiction in
question; or</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">16.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">in the case of the illegality, invalidity or un-enforceability of part of
this Agreement that part shall be severed from this Agreement in the
jurisdiction in question and that illegality, invalidity or un-enforceability
shall not in any way whatsoever prejudice or affect the remaining parts of this
Agreement which shall continue in full force and effect provided that the said
remaining parts continue to satisfy the commercial intentions of the Parties
and provided that the remaining parts do constitute a substantial part of this
Agreement.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>17.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"><B>ENTIRE AGREEMENT/VARIATIONS</B></DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">17.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">This Agreement constitutes the entire agreement and understanding between the
Parties and supersedes all prior oral or written understandings, arrangements,
representations or agreements between them relating to the subject matter of this
Agreement. The Parties acknowledge that no claims shall arise in respect of any
understandings, arrangements, representations or agreements so superseded. No
director, employee or agent of any Party is authorised to make any representation or
warranty to another Party not contained in this Agreement, and each Party acknowledges
that it has not relied on any such oral or written representations or warranties.
Nothing in this Agreement removes or overrides any right of action by any Party in
respect of any fraudulent misrepresentation, fraudulent concealment or other fraudulent
action.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">17.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">No variation, amendments, modification or supplement to this Agreement shall be
valid unless agreed in writing in the English language and signed by a duly authorised
representative of each Party.
</DIV></TD>
</TR>
</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 31 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>


<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>18.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"><B>NOTICES</B></DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">18.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Any notice or other communication given pursuant to or made under or in
connection with the matters contemplated by this Agreement shall be in writing in the
English language and shall be delivered by hand or by courier or shall be sent by post
or recorded delivery to the address of the recipient set out in Schedule&nbsp;8 or as
specified by the recipient from time to time in accordance with Clause 18.3. Notices
sent by fax or E-Mail shall not be valid of themselves and must be confirmed in hard
copy form by hand or by recorded delivery.</DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">18.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Any notice given pursuant to this Clause shall be deemed to have been received:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">18.2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">if delivered by hand or by courier, at the time of delivery; or</DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">18.2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">if sent by recorded delivery, at the time of delivery.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">18.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">A Party may notify the other Parties to this Agreement of a change of its name,
relevant addressee, address or facsimile number for the purposes of</DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">18.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">8 provided that such notification shall only be effective on:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">18.4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">the date specified in the notification as the date on which the change is to
take place; or</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">18.4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">if no date is specified or the date specified is less than five (5)&nbsp;clear
Business Days after the date on which the notice is given, the date falling
five (5)&nbsp;clear Business Days after notice of any such change has been given.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">18.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">For the avoidance of doubt, the Parties agree that the provisions of this
Clause shall not apply in relation to the service of Service Documents (as defined in
Clause 18.5).</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">18.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#147;Service Document&#148; means a writ, summons, order, judgement or other document
related to or in connection with any Court proceeding, cause, matter or action arising
out of or connected in any way with this Agreement.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>19.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"><B>COUNTERPARTS</B></DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">19.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">This Agreement may be executed in any number of counterparts and by the Parties
on separate counterparts, each of which when so executed shall be an original of this
Agreement, and all of which shall together constitute one and the same instrument.
Complete sets of counterparts shall be lodged with each Party.</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 32 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>20.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"><B>THIS AGREEMENT NOT TO CONSTITUTE A PARTNERSHIP</B></DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">20.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Nothing in this Agreement and no action taken by the Parties pursuant to this
Agreement shall constitute or be deemed to constitute a partnership, association, joint
venture or other co-operative entity between the Parties and neither Party shall have
any authority to bind the other in any way except as provided in this Agreement.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>21.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"><B>COSTS</B></DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">21.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Each Party shall bear its own costs, legal fees and other expenses incurred in
the negotiation, preparation, execution and implementation of this Agreement and the
documents referred to herein unless otherwise set forth in this Agreement.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>22.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"><B>PUBLICITY</B></DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">22.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">No public announcements or other disclosure to third parties concerning the
financial or other terms of this Agreement shall be made, whether directly or
indirectly, by either Party to this Agreement, except as may be legally required or as
may be required for recording purposes, without first obtaining the approval of the
other Party and agreement upon the nature and text of such announcement or disclosure,
with the exception that:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">22.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">a Party may disclose the full terms of this Agreement to its investment
bankers, lawyers, accountants and other professional advisors or a Third Party
seeking to invest in, lend funds to acquire or merge with or be acquired by
such Party without the other Party&#146;s prior approval provided that such
disclosure is made under terms of confidentiality whether express or implied;
and</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">22.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">a Party may disclose the terms of this Agreement to any securities exchange
or regulatory authority or government body to which either Party is subject or
submits, wherever situated, including (without limitation) the US Securities
Exchange Commission, the London Stock Exchange or the Panel on Take-overs and
Mergers, if and to the extent required by the force of law provided that it
takes advantage of all provisions to keep confidential as many terms of this
Agreement as possible.</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 33 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">22.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">In respect of those public announcements and disclosures not permitted by
Clause 22.1 the Party desiring to make any such public announcement or other disclosure
shall inform the other Party of the proposed announcements or disclosure in reasonably
sufficient time prior to public release, and shall provide the other Party with a
written copy thereof, in order to allow such Party to comment upon such announcement or
disclosure, which comments shall be provided by such other Party within five (5)
Business Days. The Parties shall jointly develop press releases and information
materials that can be used by either Party for presentations to financial advisers, the
UK Stock Exchange, and similar recipients.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">IN WITNESS WHEREOF the Parties have executed this Agreement as of the Commencement Date.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="70%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">SIGNED by</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">for and on behalf of</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Takashi Shoda, President and Representative Director</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">SANKYO CO. LTD.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Date:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">SIGNED by</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">for and on behalf of</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Spiro Rombotis, Chief Executive Officer</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">CYCLACEL LIMITED</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Date:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 34 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>SCHEDULE 1<BR>
DEVELOPMENT PLAN</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">&#091;***&#093;
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 35 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>SCHEDULE 2<BR>
LICENSED MATERIALS</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">&#091;***&#093;
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 36 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>





<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>SCHEDULE 3<BR>
LICENSED PATENT RIGHTS</B>
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">Patent Rights owned by Sankyo
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">A. Licensed Patent Rights
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="65%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#091;*&#093; (Crystal of CS-682)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Publication No.&nbsp;WO 02/064609 A1 (22.08.2002)</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px">Crystal of pyrimidine nucleoside derivative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Country</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Appln. No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Appln. Date</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Patent No.</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Patent Date</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Expiry Date</B></TD>
    <TD>&nbsp;</TD>
</TR>


<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">PCT</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">06/02/2002</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Australia</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Brazil</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Canada</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">China</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Colombia</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Czech Republic</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">EPC</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD colspan="17" align="center">Austria, Belgium, Switzerland &#038; Liechtenstein, Cyprus, Germany, Denmark, Spain, Finland, France, Great Britain, Greece, Ireland, Italy, Luxembourg, Monaco, Netherlands, Portugal, Sweden, Turkey,<BR></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;*&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Hungary</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;*&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Israel</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">India</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Korea</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Mexico</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;*&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">New Zealand</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;*&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;*&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Russia</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;*&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;*&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">U. S. A.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;*&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;*&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Japan</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>




<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">B. Licensed Patent Rights
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>&#091;*&#093; (CS-682)</B>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Country</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Appln. No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Appln. Date</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Patent No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Patent Date</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Expiry Date</B></TD>
</TR>


<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Australia</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">30/09/1992</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">654212</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15/02/1995</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Brazil (pipeline)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">13/05/1997</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PI 1100621-8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">07/12/1999</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Canada</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">29/09/1992</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">China</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">30/09/1992</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">92113067.8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">03/08/1996</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Czech Republic</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">30/09/1992</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">289477</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">29/11/2001</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">EPC</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">92308904.9</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">30/09/1992</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">0536936</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">14/08/1996</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD colspan="11" align="center">Austria, Belgium, Switzerland &#038; Liechtenstein, Germany, Denmark, Spain, France, Great Britain, Greece, Ireland, Italy, Luxembourg, Monaco, Netherlands, Portugal, Sweden<BR></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Finland</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">105556</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15/09/2000</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Hong Kong</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2042/96</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">14/08/1996</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Hungary</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">30/09/1992</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Hungary (pipeline)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">211851</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">13/08/1996</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Indonesia</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ID0002812</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">22/06/1998</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Israel</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">103301</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">14/10/1997</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Korea</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">255491</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15/02/2000</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Mexico</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Norway</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">179675</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">27/11/1996</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">New Zealand</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">244574</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">14/06/1994</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;*&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Russian Fed.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2085557</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">27/07/1997</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Thailand</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9368</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Taiwan</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">29/09/2012</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">U. S. A.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">U. S. A.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5691319</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">25/11/1997</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">25/11/2014</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">South Africa</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Japan</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2569251</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">03/10/1996</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 2 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>





<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>SCHEDULE 4<BR>
CNDAC PATENT RIGHTS</B>
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">C. CNDAC Patent Rights
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><B>&#091;*&#093;</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">2002. 8.30</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><B>(CNDAC: Active form of CS-682)</B></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">Pyrimidine nucleoside derivatives</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Country</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Appln. No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Appln. Date</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Patent No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Patent Date</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Expiry Date</B></TD>
</TR>


<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;*&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;*&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;*&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;*&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;*&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;*&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;*&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">U. S. A.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5616567</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">01/04/1997</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">01/04/2014</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">U. S. A.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5654420</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">05/08/1997</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">05/08/2014</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&#091;*&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;*&#093;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>





<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>SCHEDULE 5<BR>
SUCCESSFUL COMPLETION CRITERIA</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">&#091;***&#093;
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>





<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>SCHEDULE 6<BR>
RETAINED TECHNICAL DATA</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">&#091;***&#093;
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>





<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>SCHEDULE 7<BR>
COMMITTED CLINICAL TRIALS</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">&#091;***&#093;
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>SCHEDULE 8<BR>
ADDRESSES FOR NOTICES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Cyclacel<BR>
Chief Executive Officer<BR>
Dundee Technopole<BR>
James Lindsay Place<BR>
Dundee DD1 5JJ<BR>
UK<BR>
Tel: &#043;44 1382 206062<BR>
Fax: &#043;44 1382 206067

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Sankyo Co., Ltd.<BR>
Director, Licensing Department<BR>
5-1 Nihonbashi-honcho 3-chome,<BR>
Chuo-ku, Tokyo 103-8426<BR>
JAPAN<BR>
Tel: &#091;***&#093;<BR>
Fax: &#091;***&#093;

</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 2 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>SCHEDULE 9<BR>
EXPERT&#146;S DECISION</B>
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">In the event the Parties fail to agree upon an appropriate level of consideration pursuant to
Clause 10.1.3, the matter shall be determined by an expert (&#147;Expert&#148;) which Expert shall be
suitably qualified to determine that particular matter and who shall be nominated jointly by
the Parties or, failing agreement between the Parties within twenty (20)&nbsp;business days of a
written request by either Party to the other seeking to initiate the Expert&#146;s decision
procedure, either Party may request the International Chamber of Commerce (Paris) to nominate
the Expert.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">The Parties shall within fourteen (14)&nbsp;days of the appointment of the Expert file written
submissions setting out their respective view on appropriate levels of consideration and
appropriate accompanying documents.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">In determining the matter referred pursuant to Clause 10.1.3 the Expert shall take into
account (i)&nbsp;the length of time this Agreement has been in force, (ii)&nbsp;the development efforts
expended by Cyclacel; and (iii)&nbsp;the cause of termination of the Agreement.</DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">In all cases the terms of appointment of the Expert by whomsoever appointed shall include:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">a commitment by the Parties to share equally the Expert&#146;s fee;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">a requirement on the Expert to act fairly as between the Parties and according
to the principles of natural justice;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">a requirement on the Expert to hold professional indemnity insurance both then
and for three years following the date of his determination;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">a commitment by the Parties to supply to the Expert all such assistance,
documents and information as he or she may require for the purpose of his or her
determination.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">a commitment by the Parties that all negotiations connected with the dispute
shall be conducted in confidence and without prejudice to the rights of the Parties in
any future proceedings.</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 3 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">The Expert&#146;s decision shall be final and binding on the Parties (save in the case of
negligence or manifest error).</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">The Parties expressly acknowledge and agree that they do not intend the reference to the
Expert to constitute an arbitration within the scope of any arbitration legislation, the
Expert&#146;s decision is not a quasi judicial procedure and the Parties shall have no right of
appeal against the Expert&#146;s decision provided always that this shall not be construed as
waiving any rights the Parties might have against the Expert for breaching his or her terms
of appointment or otherwise being negligent.</DIV></TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 4 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="94%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="middle"><DIV style="margin-left:0px; text-indent:-0px"><IMG src="c17919c1791901.gif" alt="(SANKYO LOGO)">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Licensing Department<BR>
SANKYO CO., LTD.<BR>
3-5-1, </B>Nihonbashi Honcho, <B>Chuo-ku, Tokyo, 103-8476, Japan<BR>
Phone: 81-3-5255-7084, Fax: 81-3-5255-7086</B></TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Spiro Rombotis<BR>
Chief Executive Officer<BR>
Cyclacel Limited<BR>
Dundee Technopole<BR>
James Lindsay Place<BR>
Dundee, DD1 5JJ<BR>
Scotland, United Kingdom

</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">

    <TD width="3%" nowrap align="left">Re:&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"> Amendment to CS-682 License Agreement<br>
Between Sankyo Co., Ltd. and Cyclacel Limited</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Dear Mr.&nbsp;Rombotis,
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As per your request, this letter is to confirm that we have agreed to amend the CS-682 License
Agreement as follows:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Clause 2.1.2 of CS-682 License Agreement is hereby amended by deleting the word
&#147;terminable&#148; from that Clause. As amended, the said Clause shall read as follows:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">a non-exclusive, royalty-free sub-license under the CNDAC Patent Rights
which are licensed with a right to sub-license by the Professors to Sankyo.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Cyclacel agrees to be responsible for and to indemnify Sankyo and its Affiliates,
directors, officers, servants and agents (collectively &#147;the Indemnified Party&#148;) against any
and all liability, loss, damage, cost and expense (including legal costs) incurred or suffered
by the Indemnified Party as a result of claim brought against Sankyo or its Affiliates by a
Third Party which arises as a result of the activities by Cyclacel or its Affiliates, Cyclacel
Licensees, agents or distributors under the CS-682 License Agreement in relation to the
deletion of &#147;terminable&#148; from Clause 2.1.2 thereof.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Sankyo agrees that in the event that Cyclacel&#146;s ability to exercise the said sub-license
is jeopardized or lost it will cooperate with Cyclacel, upon Cyclacel&#146;s request and at
Cyclacel&#146;s expenses, in taking any steps which Sankyo considers reasonably required to
preserve or restore the said sub-license and the rights granted under the CS-682 License
Agreement.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Notwithstanding with the items above, Cyclacel hereby acknowledges that Sankyo does not
amend its warranty as set forth in CS-682 License Agreement with respect to CNDAC Patent
Rights.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">This Amendment supersedes all prior oral or written understandings, arrangements,
representations or agreements, if any, between the parties relating to the subject matter of
this Amendment to the extent that they conflict with this Amendment.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">The validity, construction and interpretation of this Amendment to CS-682 License
Agreement and any determination of the performance which it requires shall be governed by the
laws of England.</DIV></TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">These agreements are made in consideration of the mutual covenants contained herein. Could you
please indicate your agreement by countersigning at the space indicated below and returning this
agreement to the undersigned.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Sincerely yours and agreed,<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Akira Morita
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Akira Morita&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"></TD>
    <TD colspan="3" align="left">Corporate Officer,<BR>
Director, Licensing Department<BR>
Date:&nbsp;April 28, 2004&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="55%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">AGREED:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Spiro Rombotis</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Spiro Rombotis
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Chief Executive Officer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date: 28 April&nbsp;2004</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->- 2 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="middle"><DIV style="margin-left:0px; text-indent:-0px"><IMG src="c17919c1791901.gif" alt="(SANKYO LOGO)">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Licensing Department<BR>
SANKYO CO., LTD.</B> <BR>
<B>3-5-1, </B>Nihonbashi Honcho, <B>Chuo-ku, Tokyo, 103-8476, Japan<BR>
Phone: 81-3-5255-7084, Fax: 81-3-5255-7086</B></TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 10pt">1st April, 2004
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="80%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dr. Spiro Rombotis</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Chief Executive Officer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Cylacel</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dundee Technopole</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">James Lindsay Place</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dundee DD1 5JJ
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>Tel: &#043;44 1382 206062</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">U K
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>Fax: &#043;44 1382 206067</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Re: Territory of the CS-682 Licensing Agreement
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Dear Dr.&nbsp;Rombotis;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">I am happy to inform you that, in accordance with Clause 2.2.1 of the CS-682 License Agreement
dated 10th September&nbsp;2003 (the &#147;Agreement&#148;) the license set out in Clause 2.1 of the Agreement is
hereby extended to the &#147;Excluded Territories&#148; under the same commercial terms as set out in the
Agreement.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">&#091;***&#093;
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">This letter agreement is to amend the Agreement in accordance with Clause 17.2 thereof.
Please sign two copies of this letter agreement and send one copy to us for our record.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Sincerely yours,<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Akira Morita
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Akira Morita&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Corporate Officer,<BR>
Director, Licensing Department&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="55%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Agreed and acknowledged this:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Spiro Rombotis</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Spiro Rombotis
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Chief Executive Officer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>c17919exv10w2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 10.2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><B>Exhibit&nbsp;10.2</B>
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 10pt">CONFIDENTIAL TREATMENT REQUESTED
</DIV>


<DIV align="CENTER" style="font-size: 10pt; margin-top: 10pt">Amendment No. 4
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">THIS AMENDMENT NO. 4 is made on 11&nbsp;day of July, 2011<BR>
BETWEEN:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">DAIICHI SANKYO COMPANY, LIMITED a company incorporated in Japan whose principal place of
business is at 5-1 Nihonbashi-honcho 3-chome Chuo-ku Tokyo 103-8426 Japan (&#147;Daiichi Sankyo&#148;);
and</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">CYCLACEL LIMITED a company incorporated in England whose principal place of business is at
Dundee Technopole, James Lindsay Place, Dundee DD1 5JJ, UK (&#147;Cyclacel&#148;).</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">WHEREAS:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(A)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Daiichi Sankyo (successor of SANKYO CO., LTD) and Cyclacel are Parties to the CS-682 LICENSE
AGREEMENT dated September&nbsp;10, 2003, as amended by letter amendments dated April&nbsp;1, 2004, April
28, 2004 and January&nbsp;13, 2005 (the &#147;License Agreement&#148;).</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(B)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Cyclacel asked Daiichi Sankyo to waive its termination right under the Clause 4.2 of the
License Agreement in consideration of the investment that Cyclacel has made in the Product (as
defined in the License Agreement).</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(C)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Cyclacel and Daiichi Sankyo wish to amend certain terms and conditions of the License
Agreement in consideration of Daiichi Sankyo&#146;s waiver of the Clause 4.2 termination right.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">NOW, therefore both Parties agree as follows:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Clause 3.3.6 of the License Agreement is hereby entirely deleted and replaced with:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.3.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">royalties applicable on Net Sales as follows:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.3.6.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#091;***&#093; on annual Net Sales less than &#091;***&#093;;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.3.6.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#091;***&#093; on annual Net Sales greater than or equal to &#091;***&#093; and less than
&#091;***&#093;;</DIV></TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.3.6.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">&#091;***&#093; on annual Net Sales greater than or equal to &#091;***&#093;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">




</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>



<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Clause 3.4 of the License Agreement is hereby entirely deleted and replaced with:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">In the case of sales of the Product by Cyclacel, its Affiliates
or Cyclacel Licensees in countries where such sale does not fall within a Valid
Claim of a Licensed Patent Right the royalty payable on Net Sales in such
country shall be &#091;***&#093; regardless of the volume of the Net Sales in such
country.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Clause 3.6 of the License Agreement is hereby entirely deleted and replaced with:
</DIV></TD>
</TR>

</TABLE>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">&#091;***&#093;</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Subject to the terms and conditions of this Amendment No.&nbsp;4, Daiichi Sankyo hereby
irrevocably waives its termination right under the Clause 4.2 of the License Agreement as
defined in (A)&nbsp;and releases Cyclacel and its officers, directors, employees and agents, and
their respective successors, heirs and assigns, from all claims and liability of any kind,
whether presently known or unknown, arising out of Cyclacel&#146;s performance or lack of
performance under Clause 4.2 of the License Agreement prior to the effective date of this
Amendment No.&nbsp;4. Clause 4.2 of the License Agreement is hereby entirely deleted as of the
effective Date of this Amendment No.&nbsp;4.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">The remainder of the License Agreement shall remain in full force and effect unless otherwise
modified by both Parties in writing.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">IN WITNESS WHEREOF the Parties have executed this Amendment No.&nbsp;4 as of the date first written
above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">SIGNED by<BR>
for and on behalf of<BR>
Daiichi Sankyo.<BR>
Date: July&nbsp;5, 2011

</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential
treatment under Rule&nbsp;24b-2 of the Securities Exchange Act of 1934.</B>
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="60%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Noriaki Ishida</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Noriaki Ishida, Corporate Officer, Vice President, Business Development &#038; Licensing
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">SIGNED by</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">for and on behalf of</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Cyclacel.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date: July&nbsp;11, 2011</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Paul McBarron</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Paul McBarron, Chief Operating Officer, Executive Vice President, Finance<BR>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>c17919exv31w1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 31.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><B>EXHIBIT 31.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Certification of Principal Executive Officer<BR>
Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002</B>
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>I, Spiro Rombotis, certify that:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>I have reviewed this Quarterly Report on Form 10-Q for the period ended June&nbsp;30, 2011 of
Cyclacel Pharmaceuticals, Inc.;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on my knowledge, this report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period
covered by this report;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on my knowledge, the financial statements, and other financial information included in
this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this
report;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The registrant&#146;s other certifying officer(s) and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>designed such disclosure controls and procedures, or caused such disclosure controls
and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us
by others within those entities, particularly during the period in which this report is
being prepared;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>designed such internal control over financial reporting, or caused such internal
control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with generally accepted
accounting principles;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures
and presented in this report our conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period covered by this report based on such
evaluation; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>disclosed in this report any change in the registrant&#146;s internal control over
financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the
registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant&#146;s internal control
over financial reporting: and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the
audit committee of the registrant&#146;s board of directors (or persons performing the equivalent
functions):</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to adversely affect
the registrant&#146;s ability to record, process, summarize and report financial information;
and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any fraud, whether or not material, that involves management or other employees who
have a significant role in the registrant&#146;s internal control over financial reporting.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date: August&nbsp;12, 2011</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Spiro Rombotis
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Spiro Rombotis
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">President &#038; Chief Executive Officer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><I>(Principal Executive Officer)</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>c17919exv31w2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 31.2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><B>EXHIBIT 31.2</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Certification of Principal Financial Officer<BR>
Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">I, Paul McBarron, certify that:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>I have reviewed this Quarterly Report on Form 10-Q for the period ended June&nbsp;30, 2011 of
Cyclacel Pharmaceuticals, Inc.;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on my knowledge, this report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period
covered by this report;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on my knowledge, the financial statements, and other financial information included in
this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this
report;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The registrant&#146;s other certifying officer(s) and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>designed such disclosure controls and procedures, or caused such disclosure controls
and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us
by others within those entities, particularly during the period in which this report is
being prepared;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>designed such internal control over financial reporting, or caused such internal
control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with generally accepted
accounting principles;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures
and presented in this report our conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period covered by this report based on such
evaluation; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>disclosed in this report any change in the registrant&#146;s internal control over
financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the
registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant&#146;s internal control
over financial reporting; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the
audit committee of the registrant&#146;s board of directors (or persons performing the equivalent
functions):</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to adversely affect
the registrant&#146;s ability to record, process, summarize and report financial information;
and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any fraud, whether or not material, that involves management or other employees who
have a significant role in the registrant&#146;s internal control over financial reporting.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date: August&nbsp;12, 2011</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Paul McBarron
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Paul McBarron
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Chief Operating Officer, Chief Financial Officer
and Executive Vice President, Finance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><I>(Principal Financial Officer)</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>c17919exv32w1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 32.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><B>EXHIBIT 32.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Certification of Principal Executive Officer<BR>
Pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Pursuant to 18 U.S.C. s 1350, as created by Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, the
undersigned officer of Cyclacel Pharmaceuticals, Inc. ( the &#147;Company&#148;) hereby certifies, to such
officer&#146;s knowledge, that:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Quarterly Report on Form 10-Q of the Company for the period ended June&nbsp;30, 2011
(the &#147;Report&#148;) fully complies with the requirements of Section 13(a) or Section&nbsp;15(d), as
applicable, of the Securities Exchange Act of 1934, as amended; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company.</TD>
</TR>

</TABLE>
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Date: August 12, 2011&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Spiro Rombotis
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Spiro Rombotis&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">President &#038; Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>c17919exv32w2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 32.2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><B>EXHIBIT 32.2</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Certification of Principal Financial Officer<BR>
Pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Pursuant to 18 U.S.C. s 1350, as created by Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, the
undersigned officer of Cyclacel Pharmaceuticals, Inc. ( the &#147;Company&#148;) hereby certifies, to such
officer&#146;s knowledge, that:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Quarterly Report on Form 10-Q of the Company for the period ended June&nbsp;30, 2011
(the &#147;Report&#148;) fully complies with the requirements of Section 13(a) or Section&nbsp;15(d), as
applicable, of the Securities Exchange Act of 1934, as amended; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company.</TD>
</TR>

</TABLE>
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Date: August 12, 2011&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Paul McBarron
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Paul McBarron&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Chief Operating Officer, Chief Financial Officer
and Executive Vice President, Finance&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>cycc-20110630.xml
<DESCRIPTION>EX-101 INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by RR Donnelley Tagger version 10.0.0.149; Copyright (C) RR Donnelley-->
<!--Based on XBRL 2.1-->
<!--Created on: 8/12/2011 3:26:18 AM-->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:cycc="http://cyclacel.com/2011-06-30" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31">
  <link:schemaRef xlink:type="simple" xlink:href="cycc-20110630.xsd" />
  <!--Context Section-->
  <context id="BalanceAsOf_31Dec2009">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Jun2010">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
    </entity>
    <period>
      <instant>2010-06-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Jun2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2010">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Jun2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
    </entity>
    <period>
      <startDate>2011-04-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="SixMonthsEnded_30Jun2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Jun2010">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
    </entity>
    <period>
      <startDate>2010-04-01</startDate>
      <endDate>2010-06-30</endDate>
    </period>
  </context>
  <context id="SixMonthsEnded_30Jun2010">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-06-30</endDate>
    </period>
  </context>
  <context id="OneHundredSeventyNineMonthsEnded_30Jun2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
    </entity>
    <period>
      <startDate>1996-08-13</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <!--Unit Section-->
  <unit id="USDEPS">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Shares">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="USD">
    <measure>iso4217:USD</measure>
  </unit>
  <!--Tuple Section-->
  <!--Element Section-->
  <!-- Begin Block Tagged Note -->
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="SixMonthsEnded_30Jun2011">
    &lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
    &lt;!-- Begin Block Tagged Note 1 - us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock--&gt;
    &lt;!-- xbrl,ns --&gt;
    &lt;!-- xbrl,nx --&gt;
    &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
    &lt;div align="center" style="font-size: 10pt; margin-top: 0pt"&gt;&lt;b&gt;
    &lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Nature of Operations&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Cyclacel Pharmaceuticals, Inc. (''Cyclacel&amp;#8217;&amp;#8217; or the ''Company&amp;#8217;&amp;#8217;) is a development-stage
    biopharmaceutical company dedicated to the development and commercialization of novel,
    mechanism-targeted drugs to treat human cancers and other serious diseases. Cyclacel&amp;#8217;s strategy is
    to build a diversified biopharmaceutical business focused in hematology and oncology based on a
    portfolio of commercial products and a development pipeline of novel drug candidates.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Cyclacel&amp;#8217;s clinical development priorities are focused on sapacitabine in the following
    indications:
    &lt;/div&gt;
    &lt;div style="margin-top: 10pt"&gt;
    &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"&gt;
    &lt;tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"&gt;
    &lt;td width="4%" style="background: transparent"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%" nowrap="nowrap" align="left"&gt;&lt;b&gt;&amp;#8226;&lt;/b&gt;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;Acute myeloid leukemia, or AML, in the elderly;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;/table&gt;
    &lt;/div&gt;
    &lt;div style="margin-top: 10pt"&gt;
    &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"&gt;
    &lt;tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"&gt;
    &lt;td width="4%" style="background: transparent"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%" nowrap="nowrap" align="left"&gt;&lt;b&gt;&amp;#8226;&lt;/b&gt;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;Myelodysplastic syndromes, or MDS; and&lt;/td&gt;
    &lt;/tr&gt;
    &lt;/table&gt;
    &lt;/div&gt;
    &lt;div style="margin-top: 10pt"&gt;
    &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"&gt;
    &lt;tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"&gt;
    &lt;td width="4%" style="background: transparent"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%" nowrap="nowrap" align="left"&gt;&lt;b&gt;&amp;#8226;&lt;/b&gt;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;Non-small cell lung cancer, or NSCLC.&lt;/td&gt;
    &lt;/tr&gt;
    &lt;/table&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;On January&amp;#160;11, 2011, the Company opened enrollment of the SEAMLESS pivotal Phase 3 trial for
    the Company&amp;#8217;s sapacitabine oral capsules as a front-line treatment of elderly patients aged 70
    years or older with newly diagnosed AML who are not candidates for intensive induction chemotherapy
    under a Special Protocol Assessment, or SPA, reached with the U.S. Food &amp;#038; Drug Administration, or
    FDA.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Company has advanced two additional product candidates, seliciclib in Phase 2 for NSCLC
    and nasopharyngeal cancer or NPC, and CYC116 in Phase 1 clinical development. The combination of
    sapacitabine with seliciclib is also being evaluated in a Phase 1 clinical trial. The Company will
    determine the feasibility of pursuing further development and/or partnering these assets depending
    on the availability of funding and further clinical data. In addition, the Company markets directly
    in the United States Xclair&lt;sup style="font-size: 85%; vertical-align: text-top"&gt;&amp;#174;&lt;/sup&gt; Cream for radiation dermatitis and Numoisyn&lt;sup style="font-size: 85%; vertical-align: text-top"&gt;&amp;#174;&lt;/sup&gt; Liquid and Numoisyn&lt;sup style="font-size: 85%; vertical-align: text-top"&gt;&amp;#174;&lt;/sup&gt;
    Lozenges for xerostomia.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;As a development stage enterprise, substantially all efforts of the Company to date have been
    devoted to performing research and development, conducting clinical trials, developing and
    acquiring intellectual property and raising capital.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The condensed consolidated balance sheet as of June&amp;#160;30, 2011, the condensed consolidated
    statements of operations for the three and six months ended June&amp;#160;30, 2011 and 2010 and the
    condensed consolidated statements of cash flows for the six months ended June&amp;#160;30, 2011 and 2010,
    and related disclosures contained in the accompanying notes are unaudited. The condensed
    consolidated balance sheet as of December&amp;#160;31, 2010 is derived from the audited consolidated
    financial statements included in the Annual Report on Form 10-K for the year ended December&amp;#160;31,
    2010 filed with the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;). The condensed consolidated
    financial statements are presented on the basis of accounting principles that are generally
    accepted in the United States (&amp;#8220;GAAP&amp;#8221;) for interim financial information and in accordance with the
    rules and regulations of the SEC; accordingly, they do not include all the information and
    footnotes required by accounting principles generally accepted in the United States for a complete
    set of financial statements. In the opinion of management, all adjustments, which include only
    normal recurring adjustments, necessary to present fairly the condensed consolidated balance sheet
    as of June&amp;#160;30, 2011, the results of operations for the three and six months ended June&amp;#160;30, 2011 and
    2010 and the consolidated statements of cash flows for the six months ended June&amp;#160;30, 2011 and 2010
    have been made. The interim results for the three and six months ended June&amp;#160;30, 2011 are not
    necessarily indicative of the results to be expected for the year ending December&amp;#160;31, 2011 or for
    any other year. The condensed consolidated financial statements should be read in conjunction with
    the audited consolidated financial statements and the
    accompanying notes included in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended
    December&amp;#160;31, 2010 filed with the SEC.
    &lt;/div&gt;
    &lt;!-- Folio --&gt;
    &lt;!-- /Folio --&gt;
    &lt;/div&gt;
    &lt;!-- PAGEBREAK --&gt;
    &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;Subsequent Developments&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Preferred Stock Dividend&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;On July&amp;#160;8, 2011, the Board of Directors (the &amp;#8220;Board&amp;#8221;) decided not to declare the quarterly
    cash dividend on the Company&amp;#8217;s 6% Convertible Exchangeable Preferred Stock (&amp;#8220;Preferred Stock&amp;#8221;) with
    respect to the second quarter of 2011 that would have otherwise been payable on August&amp;#160;1, 2011.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Board also did not declare the quarterly cash dividend with respect to each of the four
    quarters of fiscal year 2009 and the first, second and third quarters of 2010. To the extent that
    any dividends payable on the Preferred Stock are not paid, such unpaid dividends are added to the
    liquidity preference of the Preferred Stock. As the Company failed to pay in an aggregate amount
    equal to at least six quarterly dividends (whether or not consecutive) on the Preferred Stock, the
    size of the Company&amp;#8217;s Board was increased by two members and the holders of the Preferred Stock,
    voting separately as a class, voted on May&amp;#160;24, 2011 and elected two directors to fill the vacancies
    created thereby, which directorships shall terminate when the Company pays all accrued but unpaid
    dividends.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;License Agreement&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;On July&amp;#160;11, 2011, the Company entered into an amendment to its license agreement with Daiichi
    Sankyo Company, Limited (&amp;#8220;Daiichi Sankyo&amp;#8221;), dated September&amp;#160;10, 2003, relating to certain rights
    which the Company has licensed from Daiichi Sankyo with regard to the Company&amp;#8217;s sapacitabine drug.
    Effective July&amp;#160;11, 2011, the license agreement was amended to irrevocably waive a termination right
    Daiichi Sankyo possessed under a provision of the agreement that required the Company to obtain
    regulatory approval to sell sapacitabine in at least one country by September&amp;#160;2011, and releases
    the Company from all claims and liability of any kind arising under such provision. The amendment
    further provides that the royalty due from the Company to Daiichi Sankyo on future net sales of
    sapacitabine be increased by a percentage between 1.25% and 1.50% depending on the level of net
    sales of sapacitabine realized.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Financing&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;On July&amp;#160;7, 2011, the Company closed an underwritten offering for an aggregate of 7,617,646
    units, at an offering price of $1.36 per unit, for gross proceeds of approximately $10.4&amp;#160;million.
    Each unit consists of (i)&amp;#160;one share of common stock and (ii)&amp;#160;a five-year warrant to purchase 0.5 of
    a share of common stock at an exercise price of $1.36 per share, exercisable beginning six months
    after the date of issuance. The shares of common stock and warrants were immediately separable and
    were issued separately such that no units were issued. The net proceeds, after underwriting
    discounts and commissions and other fees and expenses payable by the Company, were approximately
    $9.3&amp;#160;million.
    &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="SixMonthsEnded_30Jun2011">
    &lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
    &lt;!-- Begin Block Tagged Note 2 - us-gaap:SignificantAccountingPoliciesTextBlock--&gt;
    &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Consolidation&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The accompanying condensed consolidated financial statements include the accounts of the
    Company and its wholly-owned subsidiaries for the indicated periods. All significant intercompany
    transactions and balances have been eliminated.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The preparation of financial statements in accordance with GAAP requires management to make
    estimates and assumptions that affect the reported amounts of assets, liabilities and related
    disclosures of contingent assets and liabilities at the date of the financial statements and the
    reported amounts of income and expenses during the reporting period. The Company reviews its
    estimates on an ongoing basis. The estimates are based on historical experience and on various
    other assumptions that the Company believes to be reasonable under the circumstances. Actual
    results may differ from these estimates.
    &lt;/div&gt;
    &lt;!-- Folio --&gt;
    &lt;!-- /Folio --&gt;
    &lt;/div&gt;
    &lt;!-- PAGEBREAK --&gt;
    &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Cash and cash equivalents are stated at cost, which is substantially the same as fair value.
    The Company considers all highly liquid investments with an original maturity of three months or
    less at the time of purchase to be cash equivalents. The Company&amp;#8217;s cash equivalents generally
    include investments in money market funds and corporate commercial paper.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Trade Accounts Receivable and Allowance for Doubtful Accounts&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;An allowance for doubtful accounts is provided, as necessary, on trade receivables based on
    their respective aging categories and historical collection experience, taking into consideration
    the type of payer, historical and projected collection outcomes, and current economic and business
    conditions that could affect the collectability of the Company&amp;#8217;s receivables. The allowance for
    doubtful accounts is reviewed, at a minimum, on a quarterly basis. Changes in the allowance for
    doubtful accounts are recorded as an adjustment to bad debt expense within general and
    administrative expenses. Material revisions to reserve estimates may result from adverse changes in
    collection experience. The Company writes off accounts against the allowance for doubtful accounts
    when reasonable collection efforts have been unsuccessful and it is likely the receivable will not
    be recovered. At December&amp;#160;31, 2010 and June&amp;#160;30, 2011, all receivables were deemed collectible.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;For the three months ended June&amp;#160;30, 2010 and 2011, approximately 87% and 92%, respectively, of
    the Company&amp;#8217;s product sales in the United States were to three wholesalers. For the six months
    ended June&amp;#160;30, 2010 and 2011, approximately 83% and 91%, respectively, of the Company&amp;#8217;s product
    sales in the United States were to three wholesalers.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Inventory&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Cyclacel values inventories at the lower of cost or market value. The Company determines cost
    using the first-in, first-out method. As of December&amp;#160;31, 2010 and June&amp;#160;30, 2011, all inventories
    were classified as finished goods. The Company analyzes its inventory levels at least quarterly to
    identify any items that may expire prior to sale, inventory that has a cost basis in excess of net
    realizable value, or inventory in excess of expected sales requirements. The determination of
    whether or not inventory costs will be realizable requires estimates by the Company&amp;#8217;s management.
    A critical input is future sales forecasts. The Company writes down the value of inventory to the
    extent that inventory is expected to expire before being sold or if the cost basis is in excess of net realizable value. If actual market conditions are less
    favorable than those projected by management, additional inventory write-downs may be required in
    future periods.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;i&gt;Product sales&lt;/i&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Company recognizes revenue from product sales when persuasive evidence of an arrangement
    exists; delivery has occurred or services have been rendered; the selling price is fixed or
    determinable; and collectability is reasonably assured.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%"&gt;The Company offers a general right of return on these product sales, and has considered the
    guidance in ASC 605-15, &amp;#8220;&lt;i&gt;Revenue Recognition -Products&lt;/i&gt;&amp;#8221; (&amp;#8220;ASC 605-15&amp;#8221;) and ASC 605 -10 &amp;#8220;&lt;i&gt;Revenue
    Recognition &amp;#8212; Overall&lt;/i&gt;&amp;#8221; (&amp;#8220;ASC 605-10&amp;#8221;). Under these guidelines, the Company accounts for all product
    sales using the &amp;#8220;sell-through&amp;#8221; method. Under the sell-through method, revenue is not recognized
    upon shipment of product to distributors. Instead, the Company records deferred revenue at gross
    invoice sales price and deferred cost of sales at the cost at which those goods were held in
    inventory. The Company recognizes revenue when such inventory is sold through to pharmacies. To
    estimate product sold through to pharmacies, the Company relies on third-party information,
    including information obtained from significant distributors with respect to their inventory levels
    and sell-through to pharmacies. The Company estimates product returns based on historical returns
    experience and other factors that affect demand for the Company&amp;#8217;s products as well as the amount of
    product subject to return.
    &lt;/div&gt;
    &lt;!-- Folio --&gt;
    &lt;!-- /Folio --&gt;
    &lt;/div&gt;
    &lt;!-- PAGEBREAK --&gt;
    &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%"&gt;Deferred revenue was $0.1&amp;#160;million at June&amp;#160;30, 2010 and 2011. Deferred cost of goods sold was
    approximately $58,000 and $11,000&amp;#160;million at June&amp;#160;30, 2010 and 2011, respectively.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;i&gt;Collaboration, research and development, and grant revenue&lt;/i&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Certain of the Company&amp;#8217;s revenues are earned from collaborative agreements. The Company
    recognizes revenue when persuasive evidence of an arrangement exists; delivery has occurred or
    services have been rendered; the fee is fixed or determinable; and collectability is reasonably
    assured. Determination of whether these criteria have been met is based on management&amp;#8217;s judgments
    regarding the nature of the research performed, the substance of the milestones met relative to
    those the Company must still perform, and the collectability of any related fees. Should changes in
    conditions cause management to determine these criteria are not met for certain future
    transactions, revenue recognized for any reporting period could be adversely affected.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Research and development revenues, which are earned under agreements with third parties for
    contract research and development activities, are recorded as the related services are performed.
    Milestone payments are non-refundable and recognized as revenue when earned, as evidenced by
    achievement of the specified milestones and the absence of ongoing performance obligations. Any
    amounts received in advance of performance are recorded as deferred revenue. None of the revenues
    recognized to date are refundable if the relevant research effort is not successful.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Grant revenues from government agencies and private research foundations are recognized as the
    related qualified research and development costs are incurred, up to the limit of the prior
    approval funding amounts. All grants received are not refundable.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Clinical Trial Accounting&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Data management and monitoring of all of the Company&amp;#8217;s clinical trials are performed by
    contract research organizations (''CROs&amp;#8217;&amp;#8217;) or clinical research associates (''CRAs&amp;#8217;&amp;#8217;) in accordance
    with the Company&amp;#8217;s standard operating procedures. Typically, CROs and some CRAs bill monthly for
    services performed, and others bill based upon milestones achieved. The Company accrues unbilled clinical trial expenses based on estimates of the level of services
    performed each period. Costs of setting up investigational sites for participation in the Company&amp;#8217;s
    clinical trials are expensed immediately as research and development expenses. Clinical trial site
    costs related to patient enrollment are accrued as patients are entered into the trial. Any initial
    payment made to the clinical trial site is recognized upon execution of the clinical trial
    agreements and expensed as research and development expenses.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Research and Development Expenditures&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Research and development expenses consist primarily of costs associated with the Company&amp;#8217;s
    product candidates, upfront fees, milestones, compensation and other expenses for research and
    development personnel, supplies and development materials, costs for consultants and related
    contract research, facility costs, amortization of purchased technology and depreciation.
    Expenditures relating to research and development are expensed as incurred.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Foreign currency and currency translation&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Transactions that are denominated in a foreign currency are re-measured into the functional
    currency at the current exchange rate on the date of the transaction. Any foreign
    currency-denominated monetary assets and liabilities are subsequently re-measured at current
    exchange rates, with gains or losses recognized as foreign exchange (losses)/gains in the statement
    of operations.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The assets and liabilities of the Company&amp;#8217;s international subsidiary are translated from its
    functional currency into United States dollars at exchange rates prevailing at the balance sheet
    date. Average rates of exchange during the period are used to translate the statement of
    operations, while historical rates of exchange are used to translate any equity transactions.
    &lt;/div&gt;
    &lt;!-- Folio --&gt;
    &lt;!-- /Folio --&gt;
    &lt;/div&gt;
    &lt;!-- PAGEBREAK --&gt;
    &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Translation adjustments arising on consolidation due to differences between average rates and
    balance sheet rates, as well as unrealized foreign exchange gains or losses arising from
    translation of intercompany loans that are of a long-term-investment nature, are recorded in other
    comprehensive income.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Derivative Instruments&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Derivative financial instruments are measured at fair value. Significant judgments and
    estimates are necessary in determining the fair value in the absence of quoted market values. These
    estimates are based on valuation methodologies and assumptions deemed appropriate in the
    circumstances. The use of different assumptions may have a material effect on the estimated fair
    value amount and the Company&amp;#8217;s results of operations.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Inputs used to determine fair value of financial and non-financial assets and liabilities are
    categorized using a fair value hierarchy that prioritizes observable and unobservable inputs into
    three broad levels, from Level 1, which is the most reliable, to Level 3, which is the least
    reliable (see &amp;#8220;Note 3 &amp;#8212; Fair Value Measurements&amp;#8221;). Management reviews the categorization of fair
    value inputs on a periodic basis and may determine that it is necessary to transfer an input from
    one level of the fair value hierarchy to another based on changes in events or circumstances, such
    as a change in the observability of an input. Any such transfer will be recognized at the end of
    the reporting period.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Company accounts for income taxes under the liability method. Under this method, deferred
    tax assets and liabilities are determined based on the difference between the financial statement
    and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the
    differences are expected to affect taxable income. Valuation allowances are established when
    necessary to reduce deferred tax assets to the amounts expected to be realized. The Company&amp;#8217;s
    management has established a full valuation allowance against its deferred tax assets based on the
    determination that it is not more likely than not that the Company will recognize the benefits of
    those assets.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Company adopted the guidance related to accounting for uncertainty in income taxes,
    primarily codified in ASC 740, &lt;i&gt;&amp;#8220;Income taxes&amp;#8221; &lt;/i&gt;(&amp;#8220;ASC 740&amp;#8221;). ASC 740 specifies the accounting for
    uncertainty in income taxes recognized in a company&amp;#8217;s financial statements by prescribing a minimum
    probability threshold a tax position is required to meet before being recognized in the financial
    statements.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Company records income tax benefits related to research and development tax credits, which
    will be claimed from H. M. Revenue &amp;#038; Customs, the United Kingdom&amp;#8217;s taxation and customs authority,
    with respect to qualifying research and development costs incurred in the same accounting period.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Company grants stock options, restricted stock units and restricted stock to officers,
    employees and directors under the 2006 Amended and Restated Equity Incentive Plan (&amp;#8220;2006 Plan&amp;#8221;),
    which was approved on March&amp;#160;16, 2006 and subsequently amended and restated on April&amp;#160;14, 2008. The
    Company also has outstanding options under various stock-based compensation plans for employees and
    directors. These plans are described more fully in &amp;#8220;Note 6 &amp;#8212; Stock-Based Compensation&amp;#8221;. The
    Company accounts for these plans under ASC 718, &amp;#8220;&lt;i&gt;Compensation &amp;#8212; Stock Compensation&lt;/i&gt;&amp;#8221; (&amp;#8220;ASC 718&amp;#8221;).
    &lt;/div&gt;
    &lt;!-- Folio --&gt;
    &lt;!-- /Folio --&gt;
    &lt;/div&gt;
    &lt;!-- PAGEBREAK --&gt;
    &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;ASC 718 requires measurement of compensation cost for all stock-based awards at fair value on
    date of grant and recognition of compensation over the requisite service period for awards expected
    to vest. The fair value of restricted stock and restricted stock units is determined based on the
    number of shares granted and the quoted price of the Company&amp;#8217;s common stock on the date of grant.
    The determination of grant-date fair value for stock option awards is estimated using the
    Black-Scholes model, which includes variables such as the expected volatility of our share price,
    the anticipated exercise behavior of our employees, interest rates, and dividend yields. These
    variables are projected based on our historical data, experience, and other
    factors. Changes in any of these variables could result in material adjustments to the expense
    recognized for share-based payments. Such value is recognized as expense over the requisite service
    period, net of estimated forfeitures, using the straight-line attribution method. The estimation of
    stock awards that will ultimately vest requires judgment, and to the extent actual results or
    updated estimates differ from current estimates, such amounts are recorded as a cumulative
    adjustment in the period estimates are revised. The Company considers many factors when estimating
    expected forfeitures, including type of awards granted employee class, and historical experience.
    Actual results and future estimates may differ substantially from current estimates.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Segments&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Company has determined its reportable segments in accordance with ASC 280, &amp;#8220;&lt;i&gt;Segment
    Reporting&lt;/i&gt;&amp;#8221; (&amp;#8220;ASC 280&amp;#8221;) and related disclosures about products, services, geographic areas and major
    customers. After considering its business activities and geographic reach, the Company has
    concluded that it operates in just one operating segment being the discovery, development and
    commercialization of novel, mechanism-targeted drugs to treat cancer and other serious disorders,
    with development operations in two geographic areas, namely the United States and the United
    Kingdom.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Net Loss per Common Share&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Company calculates net loss per common share in accordance with ASC 260, &amp;#8220;&lt;i&gt;Earnings Per
    Share&lt;/i&gt;&amp;#8221; (&amp;#8220;ASC 260&amp;#8221;). Basic and diluted net loss per common share were determined by dividing net loss
    applicable to common stockholders by the weighted average number of common shares outstanding
    during the period. The Company&amp;#8217;s potentially dilutive shares, which include outstanding common
    stock options, restricted stock, restricted stock units, convertible preferred stock, and common
    stock warrants, have not been included in the computation of diluted net loss per share for all
    periods as the result would be anti-dilutive.
    &lt;/div&gt;
    &lt;div align="center"&gt;
    &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
    &lt;!-- Begin Table Head --&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td width="72%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Head --&gt;
    &lt;!-- Begin Table Body --&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Stock options
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;3,187,291&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;3,543,529&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Restricted stock and restricted stock units
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;75,515&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;44,255&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Convertible preferred stock
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;516,228&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;516,228&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Options to purchase common stock and common
    stock warrants issued in connection with the
    October&amp;#160;2010 financing
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;6,242,398&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Common stock warrants
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;5,843,597&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;10,005,192&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 1px"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Total shares excluded from calculation
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;9,622,631&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;20,351,602&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 1px"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Body --&gt;
    &lt;/table&gt;
    &lt;/div&gt;
    &lt;!-- Folio --&gt;
    &lt;!-- /Folio --&gt;
    &lt;/div&gt;
    &lt;!-- PAGEBREAK --&gt;
    &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Comprehensive Income (Loss)&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;In accordance with ASC 220, &amp;#8220;&lt;i&gt;Comprehensive Income&lt;/i&gt;&amp;#8221; (&amp;#8220;ASC 220&amp;#8221;) all components of comprehensive
    income (loss), including net income (loss), are reported in the financial statements in the period
    in which they are recognized. ASC 220 defines comprehensive income (loss)&amp;#160;as the change in equity
    during a period from transactions and other events and circumstances from nonowner sources. Net
    income (loss)&amp;#160;and other comprehensive income (loss), including foreign currency translation
    adjustments, are reported, net of any related tax effect, to arrive at comprehensive income (loss).
    No taxes were recorded on items of other comprehensive income.
    &lt;/div&gt;
    &lt;div align="center"&gt;
    &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
    &lt;!-- Begin Table Head --&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td width="30%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Period from&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;August 13, 1996&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;(inception) to&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Head --&gt;
    &lt;!-- Begin Table Body --&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="center" colspan="18"&gt;$000&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Net loss
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;(3,933&lt;/td&gt;
    &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;(3,552&lt;/td&gt;
    &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;(9,040&lt;/td&gt;
    &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;(8,140&lt;/td&gt;
    &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;(246,446&lt;/td&gt;
    &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Translation adjustment
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;(19&lt;/td&gt;
    &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;139&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;4,001&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;(2,826&lt;/td&gt;
    &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;5,952&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Unrealized foreign
    exchange (loss)&amp;#160;gain
    on intercompany loans
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;9&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;(108&lt;/td&gt;
    &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;(3,979&lt;/td&gt;
    &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;2,834&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;(5,913&lt;/td&gt;
    &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 1px"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Comprehensive loss
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;(3,943&lt;/td&gt;
    &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;(3,521&lt;/td&gt;
    &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;(9,018&lt;/td&gt;
    &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;(8,132&lt;/td&gt;
    &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;(246,407&lt;/td&gt;
    &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 1px"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Body --&gt;
    &lt;/table&gt;
    &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:SignificantAccountingPoliciesTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:FairValueDisclosuresTextBlock contextRef="SixMonthsEnded_30Jun2011">
    &lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
    &lt;!-- Begin Block Tagged Note 3 - us-gaap:FairValueDisclosuresTextBlock--&gt;
    &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;3. FAIR VALUE MEASUREMENTS&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;As defined in ASC 820, fair value is based on the price that would be received to sell an
    asset or paid to transfer a liability in an orderly transaction between market participants at the
    measurement date. In order to increase consistency and comparability in fair value measurements,
    ASC 820 establishes a fair value hierarchy that prioritizes observable and unobservable inputs used
    to measure fair value into three broad levels, which are described below:
    &lt;/div&gt;
    &lt;div style="margin-top: 10pt"&gt;
    &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"&gt;
    &lt;tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"&gt;
    &lt;td width="4%" style="background: transparent"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%" nowrap="nowrap" align="left"&gt;&lt;b&gt;&amp;#8226;&lt;/b&gt;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;Level 1: Quoted prices (unadjusted)&amp;#160;in active markets that are accessible at the
    measurement date for assets or liabilities. The fair value hierarchy gives the highest
    priority to Level 1 inputs.&lt;/td&gt;
    &lt;/tr&gt;
    &lt;/table&gt;
    &lt;/div&gt;
    &lt;div style="margin-top: 10pt"&gt;
    &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"&gt;
    &lt;tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"&gt;
    &lt;td width="4%" style="background: transparent"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%" nowrap="nowrap" align="left"&gt;&lt;b&gt;&amp;#8226;&lt;/b&gt;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;Level 2: Inputs other than quoted prices within Level 1 that are observable for the
    asset or liability, either directly or indirectly.&lt;/td&gt;
    &lt;/tr&gt;
    &lt;/table&gt;
    &lt;/div&gt;
    &lt;div style="margin-top: 10pt"&gt;
    &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"&gt;
    &lt;tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"&gt;
    &lt;td width="4%" style="background: transparent"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%" nowrap="nowrap" align="left"&gt;&lt;b&gt;&amp;#8226;&lt;/b&gt;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;Level 3: Unobservable inputs that are used when little or no market data is available.
    The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/td&gt;
    &lt;/tr&gt;
    &lt;/table&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of
    observable inputs and minimize the use of unobservable inputs to the extent possible as well as
    considers counterparty credit risk in its assessment of fair value. Financial assets and
    liabilities carried at fair value on a recurring basis as of December&amp;#160;31, 2010 are classified in
    the table below in one of the three categories described above:
    &lt;/div&gt;
    &lt;div align="center"&gt;
    &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
    &lt;!-- Begin Table Head --&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td width="44%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;$000&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;$000&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;$000&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;$000&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Head --&gt;
    &lt;!-- Begin Table Body --&gt;
    &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Cash equivalents
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;29,066&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;29,066&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Warrants
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;680&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;680&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 1px"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Total
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;29,066&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;680&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;29,746&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 1px"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Body --&gt;
    &lt;/table&gt;
    &lt;/div&gt;
    &lt;!-- Folio --&gt;
    &lt;!-- /Folio --&gt;
    &lt;/div&gt;
    &lt;!-- PAGEBREAK --&gt;
    &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Financial assets and liabilities carried at fair value on a recurring basis as of June&amp;#160;30,
    2011 are classified in the table below in one of the three categories described above:
    &lt;/div&gt;
    &lt;div align="center"&gt;
    &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
    &lt;!-- Begin Table Head --&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td width="44%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;$000&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;$000&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;$000&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;$000&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Head --&gt;
    &lt;!-- Begin Table Body --&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Cash equivalents
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;17,333&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;17,333&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Warrants
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;477&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;477&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 1px"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Total
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;17,333&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;477&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;17,810&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 1px"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Body --&gt;
    &lt;/table&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Warrants Liability&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Company issued warrants to purchase shares of common stock under the registered direct
    financing completed in February&amp;#160;2007. These warrants are being accounted for as a liability in
    accordance with ASC 815, &amp;#8220;&lt;i&gt;Derivatives and Hedging&amp;#8221; &lt;/i&gt;(&amp;#8220;ASC 815&amp;#8221;). At the date of the transaction,
    the fair value of the warrants of $6.8&amp;#160;million was determined utilizing the Black-Scholes option
    pricing model utilizing the following assumptions: risk free interest rate &amp;#8212; 4.68%, expected
    volatility &amp;#8212; 85%, expected dividend yield &amp;#8212; 0%, and a contractual life of 7&amp;#160;years. The fair value
    of the warrant is being re-measured each reporting period, with a derivative gain or loss
    recognized in the consolidated statement of operations. Such gains or losses will continue to be
    reported until the warrants are exercised or expired. The Company used the Black-Scholes
    option-pricing model with the following assumptions to value the warrants:
    &lt;/div&gt;
    &lt;div align="center"&gt;
    &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
    &lt;!-- Begin Table Head --&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td width="72%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Head --&gt;
    &lt;!-- Begin Table Body --&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Exercise price
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="left"&gt;$&lt;/td&gt;
    &lt;td align="right"&gt;8.44&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="left"&gt;$&lt;/td&gt;
    &lt;td align="right"&gt;8.44&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Expected term
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td colspan="2" align="right"&gt;3.13 Yrs.&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td colspan="2" align="right"&gt;2.63 Yrs.&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Risk free interest rate
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;1.02&lt;/td&gt;
    &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;0.68&lt;/td&gt;
    &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Expected volatility
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;121&lt;/td&gt;
    &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;118&lt;/td&gt;
    &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Expected dividend yield over expected term
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Body --&gt;
    &lt;/table&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;During the three months ended June&amp;#160;30, 2010 and 2011, the Company recognized the change
    in the value of warrants of approximately $0.3&amp;#160;million and $0.1&amp;#160;million, respectively, as a gain on
    the consolidated statement of operations. During the six months ended June&amp;#160;30, 2010, the Company
    recognized the $0.5&amp;#160;million increase in the value of warrants as a loss on the consolidated
    statement of operations. During the six months ended June&amp;#160;30, 2011, the Company recognized the
    $0.2&amp;#160;million decrease in the value of warrants as a gain on the consolidated statement of
    operations. The following table reconciles the beginning and ending balance of Level 3 inputs for
    the six months ended June&amp;#160;30, 2011:
    &lt;/div&gt;
    &lt;div align="center"&gt;
    &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
    &lt;!-- Begin Table Head --&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td width="86%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;$000&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Head --&gt;
    &lt;!-- Begin Table Body --&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Balance as of December&amp;#160;31, 2010
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;680&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Gain from change in valuation of warrants liability reported in earnings
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;(203&lt;/td&gt;
    &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 1px"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Balance as of June&amp;#160;30, 2011
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;477&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 1px"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Body --&gt;
    &lt;/table&gt;
    &lt;/div&gt;
    &lt;!-- Folio --&gt;
    &lt;!-- /Folio --&gt;
    &lt;/div&gt;
    &lt;!-- PAGEBREAK --&gt;
    &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
    &lt;/div&gt;
  </us-gaap:FairValueDisclosuresTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <cycc:PrepaidExpensesAndOtherCurrentAssetsTextBlock contextRef="SixMonthsEnded_30Jun2011">
    &lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
    &lt;!-- Begin Block Tagged Note 4 - cycc:PrepaidExpensesAndOtherCurrentAssetsTextBlock--&gt;
    &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;4. PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Prepaid expenses and other current assets consist of the following:
    &lt;/div&gt;
    &lt;div align="center"&gt;
    &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
    &lt;!-- Begin Table Head --&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td width="72%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;($000s)&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Head --&gt;
    &lt;!-- Begin Table Body --&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Research and development tax credit receivable
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;660&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;998&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Prepayments
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;317&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;476&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Other current assets
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;405&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;214&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 1px"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Total prepaid expenses and other current assets
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;1,382&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;1,688&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 1px"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Body --&gt;
    &lt;/table&gt;
    &lt;/div&gt;
    &lt;/div&gt;
  </cycc:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="SixMonthsEnded_30Jun2011">
    &lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
    &lt;!-- Begin Block Tagged Note 5 - us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock--&gt;
    &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;5. ACCRUED LIABILITIES AND OTHER CURRENT LIABILITIES&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Accrued and other current liabilities consisted of the following:
    &lt;/div&gt;
    &lt;div align="center"&gt;
    &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
    &lt;!-- Begin Table Head --&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td width="72%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;($000&lt;/b&gt;s)&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Head --&gt;
    &lt;!-- Begin Table Body --&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Accrued research and development
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;2,793&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;3,343&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Other current liabilities
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;1,339&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;1,116&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 1px"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;4,132&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;4,459&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 1px"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Body --&gt;
    &lt;/table&gt;
    &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="SixMonthsEnded_30Jun2011">
    &lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
    &lt;!-- Begin Block Tagged Note 6 - us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock--&gt;
    &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;6. STOCK BASED COMPENSATION&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%"&gt;Stock based compensation has been reported within expense line items on the consolidated
    statement of operations for the three months ended June&amp;#160;30, 2010 and 2011 as shown in the following
    table:
    &lt;/div&gt;
    &lt;div align="center"&gt;
    &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
    &lt;!-- Begin Table Head --&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td width="44%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;For the three months&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;For the six months&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;ended June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;ended June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 0px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;($000s)&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 0px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Head --&gt;
    &lt;!-- Begin Table Body --&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Research and development
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;93&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;41&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;165&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;90&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;General and administrative
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;374&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;164&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;621&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;365&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 1px"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Stock-based compensation costs before income taxes
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;467&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;205&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;786&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;455&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 1px"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Body --&gt;
    &lt;/table&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%"&gt;Under the 2006 Plan, 5,200,000 shares of the Company&amp;#8217;s common stock have been reserved. The
    awards granted under the 2006 Plan have a maximum maturity of 10&amp;#160;years and generally vest over a
    four-year period from the date of grant.
    &lt;/div&gt;
    &lt;!-- Folio --&gt;
    &lt;!-- /Folio --&gt;
    &lt;/div&gt;
    &lt;!-- PAGEBREAK --&gt;
    &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%"&gt;A summary of activity for the options under the Company&amp;#8217;s 2006 Plan for the six months ended
    June&amp;#160;30, 2011 is as follows:
    &lt;/div&gt;
    &lt;div align="center"&gt;
    &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
    &lt;!-- Begin Table Head --&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td width="44%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Weighted &lt;br /&gt;
    Average&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Term (years)&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="10"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;(in $000s)&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Head --&gt;
    &lt;!-- Begin Table Body --&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Options outstanding at December&amp;#160;31, 2010
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;3,489,932&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="left"&gt;$&lt;/td&gt;
    &lt;td align="right"&gt;3.96&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;7.22&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;938&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Granted
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;199,500&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="left"&gt;$&lt;/td&gt;
    &lt;td align="right"&gt;1.52&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Exercised
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;(6,638&lt;/td&gt;
    &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="left"&gt;$&lt;/td&gt;
    &lt;td align="right"&gt;0.41&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Expired
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Cancelled / forfeited
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;(139,265&lt;/td&gt;
    &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="left"&gt;$&lt;/td&gt;
    &lt;td align="right"&gt;6.32&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 1px"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Options outstanding at June&amp;#160;30, 2011
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;3,543,529&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="left"&gt;$&lt;/td&gt;
    &lt;td align="right"&gt;3.74&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;6.95&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;828&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 1px"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Unvested at June&amp;#160;30, 2011
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;968,024&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="left"&gt;$&lt;/td&gt;
    &lt;td align="right"&gt;1.83&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;8.75&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;153&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 1px"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Vested and exercisable at June&amp;#160;30, 2011
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;2,575,505&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="left"&gt;$&lt;/td&gt;
    &lt;td align="right"&gt;4.45&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;6.27&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;675&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 1px"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Body --&gt;
    &lt;/table&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%"&gt;ASC 718 requires compensation expense associated with share-based awards to be recognized over
    the requisite service period, which for the Company is the period between the grant date and the
    date the award vests or becomes exercisable. Most of the awards granted by the Company (and still
    outstanding), vest ratably over four years, with 1/4 of the award vesting one year from the date of
    grant and 1/48 of the award vesting each month thereafter. However, certain awards made to
    executive officers vest over three to five years, depending on the terms of their employment with
    the Company. In addition, recent awards made to other employees vest ratably over four years, with
    1/48 of the award vesting each month.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%"&gt;Effective January&amp;#160;1, 2006, the Company elected to recognize all share-based awards issued
    after the adoption of ASC 718 under the straight-line attribution method. ASC 718 requires
    forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods
    if actual forfeitures differ from those estimates. This analysis is evaluated quarterly and the
    forfeiture rate adjusted as necessary. Ultimately, the actual expense recognized over the vesting
    period is based on only those shares that vest.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%"&gt;The Company used the Black-Scholes option-pricing model with the following assumptions for
    stock option grants to employees and directors for the six months ended June&amp;#160;30, 2010 and 2011:
    &lt;/div&gt;
    &lt;div align="center"&gt;
    &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
    &lt;!-- Begin Table Head --&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td width="72%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;For the six months&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;ended June 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Head --&gt;
    &lt;!-- Begin Table Body --&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Expected term
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td colspan="3" align="center"&gt;5 &amp;#8211; 6Yrs&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td colspan="3" align="center"&gt;5 &amp;#8211; 6Yrs&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Risk free interest rate
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;2.37 &amp;#8211; 2.96%&lt;/td&gt;
    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;1.47 &amp;#8211; 2.29%&lt;/td&gt;
    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Expected volatility
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;90 &amp;#8211; 100%&lt;/td&gt;
    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;93 &amp;#8211; 99%&lt;/td&gt;
    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Expected dividend yield over expected term
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&amp;#8212;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&amp;#8212;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Resulting weighted average grant fair
    value
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;$1.80&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;$1.15&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Body --&gt;
    &lt;/table&gt;
    &lt;/div&gt;
    &lt;!-- Folio --&gt;
    &lt;!-- /Folio --&gt;
    &lt;/div&gt;
    &lt;!-- PAGEBREAK --&gt;
    &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;There were 199,500 options granted during the six months ended June&amp;#160;30, 2011. For grants made
    during the six months ended June&amp;#160;30, 2010 and June&amp;#160;30, 2011, the expected term assumption was
    estimated using past history of early exercise behavior and estimated expectations of future
    exercise behavior. Starting with the December&amp;#160;2010 annual grants to the Company&amp;#8217;s employees, the
    Company relied exclusively on its historical volatility as an input to the option pricing model as
    the Company&amp;#8217;s management believes that this
    rate will be representative of future volatility over the expected term of the options. Prior
    to December&amp;#160;2010, because the Company had been publicly traded for a limited period, the expected
    volatility assumption was based on the historical volatility of peer companies over the expected
    term of the option awards.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Estimates of pre-vesting option forfeitures are based on the Company&amp;#8217;s experience. For
    outstanding options, the Company uses a forfeiture rate of 0 &amp;#8212; 50% depending on when and to whom
    the options are granted. The Company adjusts its estimate of forfeitures over the requisite service
    period based on the extent to which actual forfeitures differ, or are expected to differ, from such
    estimates. Changes in estimated forfeitures are recognized through a cumulative adjustment in the
    period of change and may impact the amount of compensation expense to be recognized in future
    periods.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The weighted average risk-free interest rate represents interest rate for treasury constant
    maturities published by the Federal Reserve Board. If the term of available treasury constant
    maturity instruments is not equal to the expected term of an employee option, Cyclacel uses the
    weighted average of the two Federal Reserve securities closest to the expected term of the employee
    option.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;During the six months ended June&amp;#160;30, 2011, 6,638 stock options were exercised resulting in
    approximately $3,000 of cash proceeds to the Company. During the six months ended June&amp;#160;30, 2010,
    there were 124,277 stock options exercised for proceeds of approximately $0.1&amp;#160;million. As the
    Company presently has tax loss carry forwards from prior periods and expects to incur tax losses in
    2011, the Company is not able to benefit from the deduction for exercised stock options in the
    current reporting period.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;i&gt;Restricted Stock&lt;/i&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;In November&amp;#160;2008, the Company issued restricted common stock to an employee subject to certain
    forfeiture provisions. Specifically, one quarter of the award vested one year from the date of
    grant and 1/48 of the award effectively vests each month thereafter. This restricted stock grant
    is accounted for at fair value at the date of grant and an expense is recognized during the vesting
    term. Summarized information for the restricted stock grant for the six months ended June&amp;#160;30, 2011
    is as follows:
    &lt;/div&gt;
    &lt;div align="center"&gt;
    &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
    &lt;!-- Begin Table Head --&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td width="72%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Weighted Average Grant&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Restricted Stock&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Date Value Per Share&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Head --&gt;
    &lt;!-- Begin Table Body --&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Non-vested at December&amp;#160;31, 2010
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;23,954&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="left"&gt;$&lt;/td&gt;
    &lt;td align="right"&gt;0.44&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Vested
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;(6,252&lt;/td&gt;
    &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="left"&gt;$&lt;/td&gt;
    &lt;td align="right"&gt;0.44&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Non-vested at June&amp;#160;30, 2011
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;17,702&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="left"&gt;$&lt;/td&gt;
    &lt;td align="right"&gt;0.44&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Body --&gt;
    &lt;/table&gt;
    &lt;/div&gt;
    &lt;!-- Folio --&gt;
    &lt;!-- /Folio --&gt;
    &lt;/div&gt;
    &lt;!-- PAGEBREAK --&gt;
    &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;i&gt;Restricted Stock Units&lt;/i&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Restricted stock units were issued to senior executives of the Company in November&amp;#160;2008, which
    entitle the holders to receive a specified number of shares of the Company&amp;#8217;s common stock over the
    four year vesting term. A restricted stock unit grant is accounted for at fair value at the date
    of grant which is equivalent to the market price of a share of the Company&amp;#8217;s common stock, and an
    expense is recognized during the vesting term. There were no restricted stock unit grants prior to
    November&amp;#160;2008. Summarized information for restricted stock grants for the six months ended June&amp;#160;30,
    2011 is as follows:
    &lt;/div&gt;
    &lt;div align="center"&gt;
    &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
    &lt;!-- Begin Table Head --&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td width="72%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Weighted Average Grant&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Restricted Stock Units&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Date Value Per Share&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Head --&gt;
    &lt;!-- Begin Table Body --&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Non-vested at December&amp;#160;31, 2010
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;35,931&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="left"&gt;$&lt;/td&gt;
    &lt;td align="right"&gt;0.44&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Vested
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;(9,378&lt;/td&gt;
    &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="left"&gt;$&lt;/td&gt;
    &lt;td align="right"&gt;0.44&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Non-vested at June&amp;#160;30, 2011
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;26,553&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="left"&gt;$&lt;/td&gt;
    &lt;td align="right"&gt;0.44&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Body --&gt;
    &lt;/table&gt;
    &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="SixMonthsEnded_30Jun2011">
    &lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
    &lt;!-- Begin Block Tagged Note 7 - us-gaap:CommitmentsAndContingenciesDisclosureTextBlock--&gt;
    &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;7. COMMITMENTS AND CONTINGENCIES&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Licensing Agreements&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%"&gt;The Company has entered into licensing agreements with academic and research organizations.
    Under the terms of these agreements, the Company has received licenses to technology and patent
    applications. The Company is required to pay royalties on future sales of product employing the
    technology or falling under claims of patent applications.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%"&gt;Pursuant to the Daiichi Sankyo license under which the Company licenses certain patent rights
    for sapacitabine, its lead drug candidate, the Company is under an obligation to use reasonable
    endeavors to develop a product and obtain regulatory approval to sell a product and has agreed to
    pay Daiichi Sankyo an up-front fee, reimbursement for Daiichi Sankyo&amp;#8217;s enumerated expenses,
    milestone payments and royalties on a country-by-country basis. Under this agreement, aggregate
    milestone payments totaling $11.7&amp;#160;million could be payable subject to achievement of all the
    specific contractual milestones and the Company&amp;#8217;s decision to continue with these projects. The
    up-front fee and certain past reimbursements have been paid and, as a result of the SEAMLESS trial
    entering Phase 3 during the first quarter of 2011, $1.6&amp;#160;million was paid in July&amp;#160;2011. Following
    these milestone payments, a further $9.3&amp;#160;million in aggregate milestone payments could be payable.
    Royalties are payable in each country for the term of patent protection in the country or for ten
    years following the first commercial sale of licensed products in the country, whichever is later.
    Royalties are payable on net sales. Net sales are defined as the gross amount invoiced by the
    Company or its affiliates or licensees, less discounts, credits, taxes, shipping and bad debt
    losses. The agreement extends from its commencement date to the date on which no further amounts
    are owed under it. If the Company wishes to appoint a third party to develop or commercialize a
    sapacitabine-based product in Japan, within certain limitations, Daiichi Sankyo must be notified
    and given a right of first refusal to develop and/or commercialize in Japan. In general, the
    license may be terminated by the Company for technical, scientific, efficacy, safety, or commercial
    reasons on six months notice, or twelve months, if after a launch of a sapacitabine-based product,
    or by either party for material default. Effective July&amp;#160;11, 2011, the license agreement was amended
    to irrevocably waive a termination right Daiichi Sankyo possessed under a provision of the
    agreement that required the Company to obtain regulatory approval to sell sapacitabine in at least
    one country by September&amp;#160;2011, and releases the Company from all claims and liability of any kind
    arising under such provision. The amendment further provides that the royalty due from the Company
    to Daiichi Sankyo on future net sales of sapacitabine be increased by a percentage between 1.25%
    and 1.50% depending on the level of net sales of sapacitabine realized.
    &lt;/div&gt;
    &lt;!-- Folio --&gt;
    &lt;!-- /Folio --&gt;
    &lt;/div&gt;
    &lt;!-- PAGEBREAK --&gt;
    &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Guarantee&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%"&gt;On July&amp;#160;28, 2005 and as amended on March&amp;#160;27, 2006, Cyclacel Group plc (&amp;#8220;Group&amp;#8221;) signed a
    convertible Loan Note Instrument constituting convertible unsecured loan notes (the &amp;#8220;Loan&amp;#8221;) and
    entered into a Facility Agreement (&amp;#8220;Agreement&amp;#8221;) with Scottish Enterprise (&amp;#8220;SE&amp;#8221;), as lender, whereby
    SE subscribed for &amp;#163;5&amp;#160;million, or approximately $9&amp;#160;million at the time, of the convertible loan
    notes. The loan was subsequently converted into 1,231,527 preferred D shares of the Group in
    satisfaction of all amounts owed by Group under the convertible loan notes. The number of preferred
    D shares that SE received was calculated by dividing the principal amount outstanding under the
    loan note by &amp;#163;4.06. The preferred D shares were exchanged for shares in Xcyte Therapies, Inc. on
    March&amp;#160;27, 2006 as part of the transaction between Xcyte and Cyclacel Limited. However, Scottish
    Enterprise retained the ability it had under the Agreement to receive a cash payment should the
    research operations in Scotland be significantly reduced. The Company had guaranteed approximately
    &amp;#163;5&amp;#160;million, the amount potentially due to SE, which will be calculated as a maximum of &amp;#163;5&amp;#160;million
    less the market value of the shares held by SE at the time of any significant reduction in research
    facilities.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%"&gt;On June&amp;#160;22, 2009, the Company amended the Agreement with SE (the &amp;#8220;Amendment&amp;#8221;), in order to
    allow the Company to implement a reduction of the Company&amp;#8217;s research operations located in Scotland
    in exchange for the parties&amp;#8217; agreement to modify the payment terms of the Agreement in the
    principal amount of &amp;#163;5&amp;#160;million (approximately $8.0&amp;#160;million at December&amp;#160;31, 2009), which SE had
    previously entered into with the Company. The Agreement provided for repayment of &amp;#163;5&amp;#160;million in the
    event the Company significantly reduced its Scottish research operations. Pursuant to the terms of
    the Amendment, in association with Cyclacel&amp;#8217;s material reduction in staff at its Scottish research
    facility, the parties agreed to a modified payment of &amp;#163;1&amp;#160;million (approximately $1.7&amp;#160;million at
    June&amp;#160;22, 2009) payable in two equal tranches. On July&amp;#160;1, 2009, the first installment of &amp;#163;0.5
    million (approximately $0.8&amp;#160;million) was paid and the remaining amount of &amp;#163;0.5&amp;#160;million
    (approximately $0.8&amp;#160;million) was paid on January&amp;#160;6, 2010. In addition, should a further reduction
    below current minimum staff levels be effectuated before July&amp;#160;2014 without SE&amp;#8217;s prior consent, the
    Company will guarantee approximately &amp;#163;4&amp;#160;million, the amount potentially due to SE, which will be
    calculated as a maximum of &amp;#163;4&amp;#160;million less the market value of the shares held by SE at the time of
    any further reduction in research facilities.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%"&gt;This arrangement is accounted for as a liability and is measured at fair value. Changes in
    fair value are recognized in earnings. Due to the nature of the associated contingency and the
    likelihood of occurrence, the Company has concluded the fair value of this liability is immaterial
    as of December&amp;#160;31, 2010 and June&amp;#160;30, 2011.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Legal proceedings&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;On April&amp;#160;27, 2010, the Company was served with a complaint filed by Celgene Corporation in the
    United States District Court for the District of Delaware seeking a declaratory judgment that four
    of its own patents, claiming the use of romidepsin injection in T-cell lymphomas, are invalid and
    not infringed by Celgene&amp;#8217;s products, but directly involve the use and administration of Celgene&amp;#8217;s
    ISTODAX&lt;sup style="font-size: 85%; vertical-align: text-top"&gt;&amp;#174;&lt;/sup&gt; (romidepsin for injection) product. On June&amp;#160;17, 2010, the Company filed its answer and
    counterclaims to the declaratory judgment complaint. The Company filed counterclaims charging
    Celgene with infringement of each of the Company&amp;#8217;s four patents and seeking damages for Celgene&amp;#8217;s
    infringement as well as injunctive relief. The four patents directly involve the use and
    administration of Celgene&amp;#8217;s ISTODAX&lt;sup style="font-size: 85%; vertical-align: text-top"&gt;&amp;#174;&lt;/sup&gt; (romidepsin for injection) product.
    &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="SixMonthsEnded_30Jun2011">
    &lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
    &lt;!-- Begin Block Tagged Note 8 - us-gaap:StockholdersEquityNoteDisclosureTextBlock--&gt;
    &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;8. STOCKHOLDERS&amp;#8217; EQUITY&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;As of June&amp;#160;30, 2011, there were 1,213,142 shares of Preferred Stock issued and outstanding at
    an issue price of $10.00 per share. Dividends on the Preferred Stock are cumulative from the date
    of original issuance at the annual rate of 6% of the liquidation preference of the Preferred Stock,
    payable quarterly on
    the first day of February, May, August and November, commencing February&amp;#160;1, 2005. Any
    dividends must be declared by the Company&amp;#8217;s Board of Directors and must come from funds that are
    legally available for dividend payments. The Preferred Stock has a liquidation preference of $10
    per share, plus accrued and unpaid dividends.
    &lt;/div&gt;
    &lt;!-- Folio --&gt;
    &lt;!-- /Folio --&gt;
    &lt;/div&gt;
    &lt;!-- PAGEBREAK --&gt;
    &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Preferred Stock is convertible at the option of the holder at any time into the Company&amp;#8217;s
    shares of common stock at a conversion rate of approximately 0.42553 shares of common stock for
    each share of Preferred Stock based on a price of $23.50. During 2010, 833,671 shares of Preferred
    Stock were converted into 1,655,599 shares of the Company&amp;#8217;s common stock, which is described in
    more detail below. Since inception through June&amp;#160;30, 2011, holders have voluntarily converted
    1,776,858 shares of Preferred Stock into common stock. The Company has reserved 516,228 shares of
    common stock for issuance upon conversion of the remaining shares of Preferred Stock outstanding at
    June&amp;#160;30, 2011. The converted shares of Preferred Stock have been retired and canceled and shall
    upon cancellation be restored to the status of authorized but unissued shares of preferred stock,
    subject to reissuance by the Board of Directors as shares of Preferred Stock of one or more series.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Company may automatically convert the Preferred Stock into common stock if the closing
    price of the Company&amp;#8217;s common stock has exceeded $35.25, which is 150% of the conversion price of
    the Preferred Stock, for at least 20 trading days during any 30-day trading period, ending within
    five trading days prior to notice of automatic conversion.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Certificate of Designations governing the Preferred Stock provides that if the Company
    fails to pay dividends on its Preferred Stock for six quarterly periods, holders of Preferred Stock
    are entitled to nominate and elect two directors to the Company&amp;#8217;s Board of Directors. This right
    accrued to the holders of Preferred Stock as of August&amp;#160;2, 2010 and two directors were nominated and
    elected at the annual meeting held on May&amp;#160;24, 2011.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Preferred Stock has no maturity date and no voting rights prior to conversion into common
    stock, except under limited circumstances.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;From November&amp;#160;6, 2007, the Company may, at its option, redeem the Preferred Stock in whole or
    in part, out of funds legally available at the redemption prices per share stated below, plus an
    amount equal to accrued and unpaid dividends up to the date of redemption:
    &lt;/div&gt;
    &lt;div align="center"&gt;
    &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
    &lt;!-- Begin Table Head --&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td width="86%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Head --&gt;
    &lt;!-- Begin Table Body --&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Year from November&amp;#160;1, 2010 to October&amp;#160;31, 2011
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="left"&gt;$&lt;/td&gt;
    &lt;td align="right"&gt;10.24&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Year from November&amp;#160;1, 2011 to October&amp;#160;31, 2012
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="left"&gt;$&lt;/td&gt;
    &lt;td align="right"&gt;10.18&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Year from November&amp;#160;1, 2012 to October&amp;#160;31, 2013
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="left"&gt;$&lt;/td&gt;
    &lt;td align="right"&gt;10.12&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Year from November&amp;#160;1, 2013 to October&amp;#160;31, 2014
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="left"&gt;$&lt;/td&gt;
    &lt;td align="right"&gt;10.06&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;November&amp;#160;1, 2014 and thereafter
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="left"&gt;$&lt;/td&gt;
    &lt;td align="right"&gt;10.00&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Body --&gt;
    &lt;/table&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Preferred Stock is exchangeable, in whole but not in part, at the option of the Company on
    any dividend payment date beginning on November&amp;#160;1, 2005 (the &amp;#8220;Exchange Date&amp;#8221;) for the Company&amp;#8217;s 6%
    Convertible Subordinated Debentures (&amp;#8220;Debentures&amp;#8221;) at the rate of $10 principal amount of
    Debentures for each share of Preferred Stock. The Debentures, if issued, will mature 25&amp;#160;years after
    the Exchange Date and have terms substantially similar to those of the Preferred Stock.
    &lt;/div&gt;
    &lt;!-- Folio --&gt;
    &lt;!-- /Folio --&gt;
    &lt;/div&gt;
    &lt;!-- PAGEBREAK --&gt;
    &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;i&gt;Conversion of Convertible Preferred Stock&lt;/i&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%"&gt;During the first and second quarters of 2010, Cyclacel entered into agreements to exchange
    shares of the Company&amp;#8217;s Preferred Stock into shares of common stock. There were no such conversions
    for the six months ended June&amp;#160;30, 2011. The table below provides details of the aggregate
    activities in 2010:
    &lt;/div&gt;
    &lt;div align="center"&gt;
    &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
    &lt;!-- Begin Table Head --&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td width="72%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;For the three&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;For the six&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;months ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;months ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;June 30, 2010&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;June 30, 2010&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Head --&gt;
    &lt;!-- Begin Table Body --&gt;
    &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Preferred shares exchanged
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;710,271&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;833,671&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 1px"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Common shares issued:
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;At stated convertible option
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;302,242&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;354,752&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Incremental shares issued under an inducement offer
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;1,113,961&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;1,300,847&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 1px"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Total common shares issued
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;1,416,203&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;1,655,599&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 1px"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Body --&gt;
    &lt;/table&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%"&gt;ASC 260, EITF Topic D-42, &amp;#8220;&lt;i&gt;The Effect of the Calculation of Earnings per Share for the
    Redemption or Induced Conversion of Preferred Stock&amp;#8221; &lt;/i&gt;(&amp;#8220;ASC 260&amp;#8221;) requires that if convertible
    preferred stock is converted to other securities pursuant to an inducement offer, the Company
    should record the excess of (1)&amp;#160;the fair value of all securities and other consideration
    transferred to the holders of the convertible preferred stock and (2)&amp;#160;the fair value of securities
    issuable to the original conversion terms as an increase to net loss to arrive at a net loss
    attributable to common shareholders. The stockholder received more shares of the Company&amp;#8217;s common
    stock than would have been delivered pursuant to the original conversion terms of the Preferred
    Stock, pursuant to a short term inducement offer. The excess of the fair value of the common stock
    transferred to the stockholder over the carrying amount of the preferred stock in the Company&amp;#8217;s
    balance sheet at the time of the transfer was considered to be an additional return to the holder
    of the Preferred Stock. Specifically, the Company recorded deemed dividends related to the
    additional shares issued under the exchange transactions of approximately $2.5&amp;#160;million and $2.9
    million for the three and six months ended June&amp;#160;30, 2010, respectively.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;i&gt;October&amp;#160;2010 Private Placement&lt;/i&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;On October&amp;#160;7, 2010, the Company completed a private placement pursuant to which it sold
    approximately $15.2&amp;#160;million of its units to several institutional investors, for net proceeds of
    approximately $14.0&amp;#160;million. The units consist of one share of common stock and 0.5 of a warrant,
    with each whole warrant representing the right to purchase one share of common stock at an exercise
    price of $1.92 per share for a period of five years. As of June&amp;#160;30, 2011, all options and warrants
    issued to the investors are outstanding and have been classified as equity. The investors purchased
    a total of 8,323,190 units at a price of $1.82625 per unit. The investors also have the right to
    acquire up to 4,161,595 additional units at a price of $1.67 per unit (for $6.9&amp;#160;million in gross
    proceeds) at any time up to nine months after closing or by July&amp;#160;6, 2011. As of June&amp;#160;30, 2011, none
    of the additional units had been exercised and, as of July&amp;#160;6, 2011, the right to acquire the
    additional units lapsed. The transaction date fair value of the warrants and additional optional
    units was $5.1&amp;#160;million and $2.8&amp;#160;million, respectively. Net proceeds of approximately $14.0&amp;#160;million
    were allocated based on relative transaction date fair values in the following manner: $8.9&amp;#160;million
    ($1.07 per share), $3.3&amp;#160;million ($0.79 per warrant) and $1.8&amp;#160;million ($0.43 per optional unit) to
    common shares, warrants and the additional optional units, respectively.
    &lt;/div&gt;
    &lt;!-- Folio --&gt;
    &lt;!-- /Folio --&gt;
    &lt;/div&gt;
    &lt;!-- PAGEBREAK --&gt;
    &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;In connection with the October&amp;#160;2010 private placement, the Company granted to the investors
    certain registration rights pursuant to a Registration Rights Agreement, dated October&amp;#160;7, 2010, in
    which the Company agreed, among other things, to register all of the shares of common stock
    acquired from the Company (including upon exercise of the warrants and/or the options) within
    thirty calendar days after the Company becomes eligible to use a registration statement on Form
    S-3, and use commercially reasonable efforts to have the registration statement declared effective
    as promptly as practicable thereafter. Upon the Company&amp;#8217;s failure to comply with the terms of the
    Registration Rights Agreement and certain other conditions, the Company will be required to make
    pro rata payments to each investor, as liquidated damages, in an amount equal to 1.5% of the
    aggregate purchase price paid by such investor. The Company also agreed to other customary
    obligations regarding registration, including indemnification and maintenance of the effectiveness
    of the registration statement. The Company is currently in compliance with the applicable terms of
    the Registration Rights Agreement, and the securities that were registrable under the terms of the
    Registration Rights Agreement are currently subject to an effective registration statement.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;i&gt;January&amp;#160;2010 Registered Direct Financings&lt;/i&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;On January&amp;#160;25, 2010, the Company completed the sale of 2,350,000 units in a &amp;#8220;registered
    direct&amp;#8221; offering at a purchase price of $2.50 per unit to certain institutional investors of the
    Company for gross proceeds of approximately $5.9&amp;#160;million. Each unit consisted of one share of the
    Company&amp;#8217;s common stock and one warrant to purchase 0.30 of one share of its common stock. The
    warrants have a five-year term from the date of issuance, are exercisable beginning six months from
    the date of issuance at an exercise price of $2.85 per share of common stock. As of June&amp;#160;30, 2011,
    warrants issued to the investors have been classified as equity. The transaction date fair value of
    the warrants of $1.0&amp;#160;million was determined utilizing the Black-Scholes option pricing model
    utilizing the following assumptions: risk free interest rate &amp;#8212; 2.39%, expected volatility &amp;#8212; 90%,
    expected dividend yield &amp;#8212; 0%, and a remaining contractual life of 5.00&amp;#160;years. As of June&amp;#160;30, 2011,
    all the warrants are outstanding. Net proceeds of approximately $5.4&amp;#160;million were allocated based
    on relative transaction date fair values in the following manner: $4.5&amp;#160;million ($1.93 per share) to
    common shares and $0.9&amp;#160;million ($1.29 per warrant) to the warrants.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;On January&amp;#160;13, 2010, the Company completed the sale of 2,850,000 units in a &amp;#8220;registered
    direct&amp;#8221; offering to certain institutional investors. Each unit was sold at a purchase price of
    $2.51 per unit and consists of one share of the Company&amp;#8217;s common stock and one warrant to purchase
    0.25 of one share of its common stock for gross proceeds of approximately $7.2&amp;#160;million. The
    warrants have a five-year term from the date of issuance, are exercisable beginning six months from
    the date of issuance at an exercise price of $3.26 per share of common stock. As of June&amp;#160;30, 2011,
    warrants issued to the investors have been classified as equity. The transaction date fair value of
    the warrants of $1.3&amp;#160;million was determined utilizing the Black-Scholes option pricing model
    utilizing the following assumptions: risk free interest rate &amp;#8212; 2.55%, expected volatility &amp;#8212; 90%,
    expected dividend yield &amp;#8212; 0%, and a remaining contractual life of 5.00&amp;#160;years. As of June&amp;#160;30, 2011,
    all the warrants are outstanding. Net proceeds of approximately $6.5&amp;#160;million were allocated based
    on relative transaction date fair values in the following manner: $5.6&amp;#160;million ($1.95 per share) to
    common shares and $0.9&amp;#160;million ($1.32 per warrant) to the warrants.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;i&gt;July&amp;#160;2009 Registered Direct Financing&lt;/i&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;On July&amp;#160;29, 2009, the Company sold its securities to select institutional investors consisting
    of 4,000,000 units in a &amp;#8220;registered direct&amp;#8221; offering at a purchase price of $0.85 per unit. Each
    unit consisted of (i)&amp;#160;one share of the Company&amp;#8217;s common stock, (ii)&amp;#160;one warrant to purchase 0.625
    of one share of common stock (a &amp;#8220;Series&amp;#160;I Warrant&amp;#8221;) and (iii)&amp;#160;one warrant to purchase 0.1838805 of
    one share of common stock (a &amp;#8220;Series&amp;#160;II Warrant&amp;#8221;). The Series&amp;#160;I Warrants had a seven-month term
    from the date of issuance, were exercisable beginning six months from the date of issuance at an
    exercise price of $1.00 per share of common stock. During the first quarter of 2010, all of the
    Series&amp;#160;I Warrants were exercised for $2.5&amp;#160;million. The Series&amp;#160;II Warrants have a five-year term
    from the date of issuance, are exercisable beginning six months from the date of issuance at an
    exercise price of $1.00 per share of common stock. During the first quarter of 2010,
    43,266 common shares were issued upon exercise of Series&amp;#160;II Warrants with proceeds of $43,266.
    There were no exercises during the six months ended June&amp;#160;30, 2011.
    &lt;/div&gt;
    &lt;!-- Folio --&gt;
    &lt;!-- /Folio --&gt;
    &lt;/div&gt;
    &lt;!-- PAGEBREAK --&gt;
    &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The net proceeds to the Company from the sale of the units, after deducting for the placement
    agent&amp;#8217;s fees and offering expenses, were approximately $2.9&amp;#160;million. As of June&amp;#160;30, 2011, the
    remaining Series&amp;#160;II Warrants outstanding and exercisable into 692,256 of the Company&amp;#8217;s shares of
    common stock have been classified as equity. The transaction date fair value of the Series&amp;#160;II
    Warrants of $0.6&amp;#160;million was determined utilizing the Black-Scholes option pricing model utilizing
    the following assumptions: risk free interest rate &amp;#8212; 2.69%, expected volatility &amp;#8212; 90%, expected
    dividend yield &amp;#8212; 0%, and a remaining contractual life of 5.00&amp;#160;years.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;i&gt;December&amp;#160;2007 Committed Equity Financing Facility&lt;/i&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;On December&amp;#160;10, 2007 and as amended on November&amp;#160;24, 2009, Cyclacel entered into a Committed
    Equity Financing Facility, or CEFF, with Kingsbridge, in which Kingsbridge committed to purchase
    the lesser of 4,084,590 shares of common stock or $60&amp;#160;million of common stock from Cyclacel over a
    three-year period. The CEFF lapsed on December&amp;#160;10, 2010.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;During March&amp;#160;2010, the Company sold 1,563,208 shares of its common stock to Kingsbridge under
    the CEFF, in consideration of aggregate proceeds of $3.1&amp;#160;million. During December&amp;#160;2009 and January
    2010, the Company sold an aggregate of 1,583,626 shares of its common stock to Kingsbridge under
    the terms of the CEFF in consideration of an aggregate of $1.3&amp;#160;million, of which approximately $1.0
    million was received in 2009, with the balance of $0.3&amp;#160;million in respect of common shares
    subscribed but unissued at December&amp;#160;31, 2009, received by the Company in January&amp;#160;2010.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;i&gt;Common Stock Warrants&lt;/i&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;In connection with the Company&amp;#8217;s February&amp;#160;16, 2007 &amp;#8220;registered direct&amp;#8221; offering the Company
    issued to investors warrants to purchase 1,062,412 shares of common stock. The warrants issued to
    the investors are being accounted for as a liability. At the date of the transaction, the fair
    value of the warrants of $6.8&amp;#160;million was determined utilizing the Black-Scholes option pricing
    model utilizing the following assumptions: risk free interest rate &amp;#8212; 4.58%, expected volatility -
    85%, expected dividend yield &amp;#8212; 0%, and a remaining contractual life of 6.88&amp;#160;years. The value of the
    warrant is being marked to market each reporting period as a derivative gain or loss on the
    consolidated statement of operations until exercised or expiration. See &amp;#8220;Note 3 &amp;#8212; Fair Value&amp;#8221; for
    further details.
    &lt;/div&gt;
    &lt;!-- Folio --&gt;
    &lt;!-- /Folio --&gt;
    &lt;/div&gt;
    &lt;!-- PAGEBREAK --&gt;
    &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The following table summarizes information about warrants outstanding at June&amp;#160;30, 2011:
    &lt;/div&gt;
    &lt;div align="center"&gt;
    &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
    &lt;!-- Begin Table Head --&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td width="58%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
    &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Expiration&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Common Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 10pt" valign="bottom"&gt;
    &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Issued in Connection With&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Date&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Issuable&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Head --&gt;
    &lt;!-- Begin Table Body --&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;April&amp;#160;2006 stock issuance
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;2013&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;2,571,429&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="left"&gt;$&lt;/td&gt;
    &lt;td align="right"&gt;7.00&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;February&amp;#160;2007 stock issuance
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;2014&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;1,062,412&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="left"&gt;$&lt;/td&gt;
    &lt;td align="right"&gt;8.44&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;December&amp;#160;2007 CEFF
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;2013&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;100,000&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="left"&gt;$&lt;/td&gt;
    &lt;td align="right"&gt;1.40&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;July&amp;#160;2009 Series&amp;#160;II stock issuance
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;2014&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;692,256&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="left"&gt;$&lt;/td&gt;
    &lt;td align="right"&gt;1.00&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;January&amp;#160;2010 stock issuance
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;2015&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;712,500&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="left"&gt;$&lt;/td&gt;
    &lt;td align="right"&gt;3.26&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;January&amp;#160;2010 stock issuance
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;2015&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;705,000&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="left"&gt;$&lt;/td&gt;
    &lt;td align="right"&gt;2.85&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom" style="background: #cceeff"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;October&amp;#160;2010 stock issuance
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;2015&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;4,161,595&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="left"&gt;$&lt;/td&gt;
    &lt;td align="right"&gt;1.92&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 1px"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr valign="bottom"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;Total
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="right"&gt;10,005,192&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td align="left"&gt;$&lt;/td&gt;
    &lt;td align="right"&gt;4.01&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr style="font-size: 1px"&gt;
    &lt;td&gt;
    &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
    &lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;td&gt;&amp;#160;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;!-- End Table Body --&gt;
    &lt;/table&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Exercise of Stock Options&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;During the six months ended June&amp;#160;30, 2011, there were 5,131 stock option exercises totaling
    approximately $3,000. During the three months ended June&amp;#160;30, 2010, there were 124,277 stock option
    exercises totaling approximately $0.1&amp;#160;million.
    &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:SubsequentEventsTextBlock contextRef="SixMonthsEnded_30Jun2011">
    &lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
    &lt;!-- Begin Block Tagged Note 9 - us-gaap:SubsequentEventsTextBlock--&gt;
    &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;9. SUBSEQUENT EVENTS&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Preferred Stock Dividend&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;On July&amp;#160;8, 2011, the Board of Directors decided not to declare the quarterly cash dividend on
    the Preferred Stock with respect to the second quarter of 2011 that would have otherwise been
    payable on August&amp;#160;1, 2011.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Board also did not declare the quarterly cash dividend with respect to each of the four
    quarters of fiscal year 2009 and the first, second and third quarters of 2010. To the extent that
    any dividends payable on the Preferred Stock are not paid, such unpaid dividends are added to the
    liquidity preference of the Preferred Stock. As the Company failed to pay in an aggregate amount
    equal to at least six quarterly dividends (whether or not consecutive) on the Preferred Stock, the
    size of the Company&amp;#8217;s Board was increased by two members and the holders of the Preferred Stock,
    voting separately as a class, voted on May&amp;#160;24, 2011 and elected two directors to fill the vacancies
    created thereby, which directorships shall terminate when the Company pays all accrued but unpaid
    dividends.
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;License Agreement&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;On July&amp;#160;11, 2011, the Company entered into an amendment to its license agreement with Daiichi
    Sankyo Company, Limited (&amp;#8220;Daiichi Sankyo&amp;#8221;), dated September&amp;#160;10, 2003, relating to certain rights
    which the Company has licensed from Daiichi Sankyo with regard to the Company&amp;#8217;s sapacitabine drug.
    Effective July&amp;#160;11, 2011, the license agreement was amended to irrevocably waive a termination right
    Daiichi Sankyo possessed under a provision of the agreement that required the Company to obtain
    regulatory approval to sell sapacitabine in at least one country by September&amp;#160;2011, and releases
    the Company from all claims and liability of any kind arising under such provision. The amendment
    further provides that the royalty due from the Company to Daiichi Sankyo on future net sales of
    sapacitabine be increased by a percentage between 1.25% and 1.50% depending on the level of net
    sales of sapacitabine realized.
    &lt;/div&gt;
    &lt;!-- Folio --&gt;
    &lt;!-- /Folio --&gt;
    &lt;/div&gt;
    &lt;!-- PAGEBREAK --&gt;
    &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Financing&lt;/i&gt;&lt;/b&gt;
    &lt;/div&gt;
    &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;On July&amp;#160;7, 2011 the Company closed an underwritten offering for an aggregate of 7,617,646
    units, at an offering price of $1.36 per unit, for gross proceeds of approximately $10.4&amp;#160;million.
    Each unit consists of (i)&amp;#160;one share of common stock and (ii)&amp;#160;a five-year warrant to purchase 0.5 of
    a share of common stock at an exercise price of $1.36 per share, exercisable beginning six months
    after the date of issuance. The shares of common stock and warrants were immediately separable and
    were issued separately such that no units were issued. The net proceeds, after underwriting
    discounts and commissions and other fees and expenses payable by the Company, were approximately
    $9.3&amp;#160;million.
    &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:SubsequentEventsTextBlock>
  <!-- End Block Tagged Note -->
  <cycc:AcquisitionsOfEquipmentPurchasedThroughCapitalLeases contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">3470000</cycc:AcquisitionsOfEquipmentPurchasedThroughCapitalLeases>
  <cycc:ChangeInValuationOfWarrants contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-6273000</cycc:ChangeInValuationOfWarrants>
  <cycc:ChangeInValuationOfWarrants contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">516000</cycc:ChangeInValuationOfWarrants>
  <cycc:ChangeInValuationOfWarrants contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-273000</cycc:ChangeInValuationOfWarrants>
  <cycc:ChangeInValuationOfWarrants contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-203000</cycc:ChangeInValuationOfWarrants>
  <cycc:ChangeInValuationOfWarrants contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-125000</cycc:ChangeInValuationOfWarrants>
  <cycc:ChangeInValuationOfWarrantsAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-6273000</cycc:ChangeInValuationOfWarrantsAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities>
  <cycc:ChangeInValuationOfWarrantsAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">516000</cycc:ChangeInValuationOfWarrantsAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities>
  <cycc:ChangeInValuationOfWarrantsAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-203000</cycc:ChangeInValuationOfWarrantsAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities>
  <cycc:DividendsOnPreferredOrdinaryShares contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">38123000</cycc:DividendsOnPreferredOrdinaryShares>
  <cycc:DividendsPreferredStocks contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">3293000</cycc:DividendsPreferredStocks>
  <cycc:DividendsPreferredStocks contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">403000</cycc:DividendsPreferredStocks>
  <cycc:DividendsPreferredStocks contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">114000</cycc:DividendsPreferredStocks>
  <cycc:DividendsPreferredStocks contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">364000</cycc:DividendsPreferredStocks>
  <cycc:DividendsPreferredStocks contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">182000</cycc:DividendsPreferredStocks>
  <cycc:GainLossOnPriceRisksDerivativesNet contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-44000</cycc:GainLossOnPriceRisksDerivativesNet>
  <cycc:GoodwillImpairmentLosses contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">7934000</cycc:GoodwillImpairmentLosses>
  <cycc:IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">592000</cycc:IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements>
  <cycc:IssuanceOfOrdinarySharesInLieuOfCashBonus contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">164000</cycc:IssuanceOfOrdinarySharesInLieuOfCashBonus>
  <cycc:IssuanceOfOrdinarySharesOnConversionOfBridgingLoan contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">1638000</cycc:IssuanceOfOrdinarySharesOnConversionOfBridgingLoan>
  <cycc:IssuanceOfOtherLongTermPayableOnAlignAcquisition contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">1122000</cycc:IssuanceOfOtherLongTermPayableOnAlignAcquisition>
  <cycc:IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">8893000</cycc:IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest>
  <cycc:IssuanceOfStocksAndWarrantsForServicesOrClaims contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">446000</cycc:IssuanceOfStocksAndWarrantsForServicesOrClaims>
  <cycc:PaymentForLoans contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">455000</cycc:PaymentForLoans>
  <cycc:PaymentUnderGuarantee contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">1652000</cycc:PaymentUnderGuarantee>
  <cycc:PreferredStockLiquidationPreferenceValue contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">13344562000</cycc:PreferredStockLiquidationPreferenceValue>
  <cycc:PreferredStockLiquidationPreferenceValue contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">13344562000</cycc:PreferredStockLiquidationPreferenceValue>
  <cycc:ProceedsOfCommittableLoanNotesIssuedFromShareholders contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">8883000</cycc:ProceedsOfCommittableLoanNotesIssuedFromShareholders>
  <cycc:RedeemablePreferredStocksDividends contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">3515000</cycc:RedeemablePreferredStocksDividends>
  <cycc:RedeemablePreferredStocksDividends contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">2915000</cycc:RedeemablePreferredStocksDividends>
  <cycc:RedeemablePreferredStocksDividends contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">2496000</cycc:RedeemablePreferredStocksDividends>
  <cycc:StockOptionPlanExpenses contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">1215000</cycc:StockOptionPlanExpenses>
  <dei:AmendmentFlag contextRef="SixMonthsEnded_30Jun2011">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="SixMonthsEnded_30Jun2011">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="SixMonthsEnded_30Jun2011">Q2</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="SixMonthsEnded_30Jun2011">2011</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="SixMonthsEnded_30Jun2011">2011-06-30</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="SixMonthsEnded_30Jun2011">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="SixMonthsEnded_30Jun2011">0001130166</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="BalanceAsOf_30Jun2011" unitRef="Shares" decimals="INF">54224093</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="SixMonthsEnded_30Jun2011">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="SixMonthsEnded_30Jun2011">Smaller Reporting Company</dei:EntityFilerCategory>
  <dei:EntityPublicFloat contextRef="BalanceAsOf_30Jun2010" unitRef="USD" decimals="0">63554944</dei:EntityPublicFloat>
  <dei:EntityRegistrantName contextRef="SixMonthsEnded_30Jun2011">Cyclacel Pharmaceuticals, Inc.</dei:EntityRegistrantName>
  <dei:EntityVoluntaryFilers contextRef="SixMonthsEnded_30Jun2011">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="SixMonthsEnded_30Jun2011">No</dei:EntityWellKnownSeasonedIssuer>
  <us-gaap:AccountsPayableCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">1723000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">1104000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccretionExpense contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">100000</us-gaap:AccretionExpense>
  <us-gaap:AccretionExpense contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">2000</us-gaap:AccretionExpense>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">4132000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">4459000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">31000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">39000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AdditionalPaidInCapital contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">266666000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">266529000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">2517000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">886000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:Assets contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">31459000</us-gaap:Assets>
  <us-gaap:Assets contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">22695000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">31051000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">22449000</us-gaap:AssetsCurrent>
  <us-gaap:CashAcquiredFromAcquisition contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">17915000</us-gaap:CashAcquiredFromAcquisition>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Dec2009" unitRef="USD" decimals="-3">11493000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_30Jun2010" unitRef="USD" decimals="-3">19543000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">29495000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">20614000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">20614000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">8050000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-8881000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="BalanceAsOf_31Dec2010" unitRef="USDEPS" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="BalanceAsOf_30Jun2011" unitRef="USDEPS" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="BalanceAsOf_30Jun2011" unitRef="Shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" decimals="INF">46564914</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="BalanceAsOf_30Jun2011" unitRef="Shares" decimals="INF">46587182</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" decimals="INF">46564914</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="BalanceAsOf_30Jun2011" unitRef="Shares" decimals="INF">46587182</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">47000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">47000</us-gaap:CommonStockValue>
  <us-gaap:CostOfGoodsSold contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">1570000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">234000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">92000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">178000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">72000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostsAndExpenses contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">279476000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">9222000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">4505000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">8957000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">3965000</us-gaap:CostsAndExpenses>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">12486000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">240000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">172000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:EarningsPerShareBasic contextRef="SixMonthsEnded_30Jun2010" unitRef="USDEPS" decimals="2">-0.36</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USDEPS" decimals="2">-0.18</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="SixMonthsEnded_30Jun2011" unitRef="USDEPS" decimals="2">-0.18</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USDEPS" decimals="2">-0.08</us-gaap:EarningsPerShareBasic>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">464000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-56000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">16000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-4342000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-38000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-49000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-87000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-19000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-7768000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-21000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-308000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-99000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">9000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GoodwillImpairmentLoss contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">7934000</us-gaap:GoodwillImpairmentLoss>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">221000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-264642000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-9403000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-4163000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-8457000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-3678000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-18196000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-363000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-230000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-317000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-126000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-6372000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-2183000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-482000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">511000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">88000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">279000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:InterestExpense contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">4677000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">33000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">9000</us-gaap:InterestExpense>
  <us-gaap:InterestPaidNet contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-1914000</us-gaap:InterestPaidNet>
  <us-gaap:InterestPaidNet contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-187000</us-gaap:InterestPaidNet>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">174000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">147000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InvestmentIncomeAmortizationOfPremium contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-2297000</us-gaap:InvestmentIncomeAmortizationOfPremium>
  <us-gaap:InvestmentIncomeInterest contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">13704000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">17000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">8000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">24000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">13000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:Liabilities contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">6535000</us-gaap:Liabilities>
  <us-gaap:Liabilities contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">6040000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">31459000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">22695000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">6535000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">6040000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LicenseAndServicesRevenue contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">3100000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">100000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">100000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LoansAndLeasesReceivableRelatedPartiesCollections contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-1645000</us-gaap:LoansAndLeasesReceivableRelatedPartiesCollections>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">234112000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">17855000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-441000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-6364000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">27000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-207598000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-9776000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-8456000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-246446000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-9040000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-3933000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-8140000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-3552000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-291377000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-12358000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-6543000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-8504000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-3734000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NonoperatingIncomeExpense contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">5404000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-570000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">223000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">140000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">119000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OperatingIncomeLoss contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-270046000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-8833000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">-4386000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-8597000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-3797000</us-gaap:OperatingIncomeLoss>
  <us-gaap:PaymentsForRepurchaseOfEquity contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">1951000</us-gaap:PaymentsForRepurchaseOfEquity>
  <us-gaap:PaymentsForRestructuring contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-1779000</us-gaap:PaymentsForRestructuring>
  <us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">1898000</us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock>
  <us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">364000</us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock>
  <us-gaap:PaymentsOfFinancingCosts contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-3550000</us-gaap:PaymentsOfFinancingCosts>
  <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">3763000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">8831000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">8000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">156657000</us-gaap:PaymentsToAcquireShortTermInvestments>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="BalanceAsOf_31Dec2010" unitRef="USDEPS" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="BalanceAsOf_30Jun2011" unitRef="USDEPS" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="BalanceAsOf_30Jun2011" unitRef="Shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" decimals="INF">1213142</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="BalanceAsOf_30Jun2011" unitRef="Shares" decimals="INF">1213142</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" decimals="INF">1213142</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="BalanceAsOf_30Jun2011" unitRef="Shares" decimals="INF">1213142</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockValue contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">1000</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">1000</us-gaap:PreferredStockValue>
  <us-gaap:PrepaidExpenseAndOtherAssets contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">1382000</us-gaap:PrepaidExpenseAndOtherAssets>
  <us-gaap:PrepaidExpenseAndOtherAssets contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">1688000</us-gaap:PrepaidExpenseAndOtherAssets>
  <us-gaap:ProceedsFromIncomeTaxRefunds contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">17522000</us-gaap:ProceedsFromIncomeTaxRefunds>
  <us-gaap:ProceedsFromIncomeTaxRefunds contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">110000</us-gaap:ProceedsFromIncomeTaxRefunds>
  <us-gaap:ProceedsFromInterestReceived contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">11726000</us-gaap:ProceedsFromInterestReceived>
  <us-gaap:ProceedsFromInterestReceived contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">11000</us-gaap:ProceedsFromInterestReceived>
  <us-gaap:ProceedsFromInterestReceived contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">11000</us-gaap:ProceedsFromInterestReceived>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">82324000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">15155000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-80000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">121678000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <us-gaap:ProceedsFromLoans contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">9103000</us-gaap:ProceedsFromLoans>
  <us-gaap:ProceedsFromNotesPayable contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">414000</us-gaap:ProceedsFromNotesPayable>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">158000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">35000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:ProceedsFromSaleOfShortTermInvestments contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">162729000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">173000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">2700000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">3000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">408000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">246000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RecognitionOfDeferredRevenue contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">98000</us-gaap:RecognitionOfDeferredRevenue>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">3719000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">181532000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">3497000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">1322000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">4939000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">1859000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:RestructuringCharges contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">2634000</us-gaap:RestructuringCharges>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">-241821000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">-249961000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RevenueFromGrants contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">3648000</us-gaap:RevenueFromGrants>
  <us-gaap:RevenueFromGrants contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">16000</us-gaap:RevenueFromGrants>
  <us-gaap:SalesRevenueGoodsNet contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">2682000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">273000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">19000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">360000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">168000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueNet contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">9430000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">389000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">119000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">360000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">168000</us-gaap:SalesRevenueNet>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">85806000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">5491000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="ThreeMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">3091000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">3840000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="ThreeMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">2034000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ShareBasedCompensation contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">18596000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="SixMonthsEnded_30Jun2010" unitRef="USD" decimals="-3">786000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="SixMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">455000</us-gaap:ShareBasedCompensation>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">24924000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">16655000</us-gaap:StockholdersEquity>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="OneHundredSeventyNineMonthsEnded_30Jun2011" unitRef="USD" decimals="-3">-308000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">680000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="BalanceAsOf_30Jun2011" unitRef="USD" decimals="-3">477000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="SixMonthsEnded_30Jun2010" unitRef="Shares" decimals="0">34157279</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="ThreeMonthsEnded_30Jun2010" unitRef="Shares" decimals="0">36565972</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="SixMonthsEnded_30Jun2011" unitRef="Shares" decimals="0">46577577</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="ThreeMonthsEnded_30Jun2011" unitRef="Shares" decimals="0">46582915</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <!--Footnote Section-->
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>cycc-20110630.xsd
<DESCRIPTION>EX-101 SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by Bowne Inc. -->
<!-- Based on XBRL 2.1 -->
<!--Updated on 6/1/2011 02:15:41 AM by RRD XChanger (TM) version 2.0.10.0-->
<!--Modified on: 8/12/2011 3:26:30 AM-->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" targetNamespace="http://cyclacel.com/2011-06-30" xmlns:cycc="http://cyclacel.com/2011-06-30" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" elementFormDefault="qualified" attributeFormDefault="unqualified" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://cyclacel.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>00 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/BalanceSheets" id="BalanceSheets">
        <link:definition>0110 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
        <link:definition>0111 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/StatementsOfOperations" id="StatementsOfOperations">
        <link:definition>0120 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
        <link:definition>0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/NatureOfOperationsAndBasisOfPresentation" id="NatureOfOperationsAndBasisOfPresentation">
        <link:definition>0201 - Disclosure - Nature of Operations and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>0202 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>0203 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssets" id="PrepaidExpensesAndOtherCurrentAssets">
        <link:definition>0204 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/AccruedLiabilitiesAndOtherCurrentLiabilities" id="AccruedLiabilitiesAndOtherCurrentLiabilities">
        <link:definition>0205 - Disclosure - Accrued Liabilities and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/StockBasedCompensation" id="StockBasedCompensation">
        <link:definition>0206 - Disclosure - Stock Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>0207 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>0208 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>0209 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cycc-20110630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cycc-20110630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cycc-20110630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links, all" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2011-01-31" schemaLocation="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd" />
  <import namespace="http://fasb.org/us-gaap/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd" />
  <element name="DocumentAndEntityInformationAbstract" id="cycc_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="true" nillable="true" />
  <!-- elements -->
  <element id="cycc_PaymentUnderGuarantee" name="PaymentUnderGuarantee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="ChangeInValuationOfWarrants" id="cycc_ChangeInValuationOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="cycc_ProceedsOfCommittableLoanNotesIssuedFromShareholders" name="ProceedsOfCommittableLoanNotesIssuedFromShareholders" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="cycc_CashReceivedDuringPeriodForAbstract" name="CashReceivedDuringPeriodForAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cycc_ScheduleOfNonCashTransactionsAbstract" name="ScheduleOfNonCashTransactionsAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cycc_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" name="AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="cycc_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" name="IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="cycc_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" name="IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="cycc_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" name="IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="cycc_IssuanceOfOrdinarySharesInLieuOfCashBonus" name="IssuanceOfOrdinarySharesInLieuOfCashBonus" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="cycc_IssuanceOfOtherLongTermPayableOnAlignAcquisition" name="IssuanceOfOtherLongTermPayableOnAlignAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" id="cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="cycc_PreferredStockLiquidationPreferenceValue" name="PreferredStockLiquidationPreferenceValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="cycc_ChangeInValuationOfWarrantsAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities" name="ChangeInValuationOfWarrantsAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="cycc_GainLossOnPriceRisksDerivativesNet" name="GainLossOnPriceRisksDerivativesNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="cycc_GoodwillImpairmentLosses" name="GoodwillImpairmentLosses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="cycc_StockOptionPlanExpenses" name="StockOptionPlanExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="cycc_IssuanceOfStocksAndWarrantsForServicesOrClaims" name="IssuanceOfStocksAndWarrantsForServicesOrClaims" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="cycc_PaymentForLoans" name="PaymentForLoans" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="cycc_RedeemablePreferredStocksDividends" name="RedeemablePreferredStocksDividends" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="cycc_DividendsPreferredStocks" name="DividendsPreferredStocks" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="cycc_DividendsOnPreferredOrdinaryShares" name="DividendsOnPreferredOrdinaryShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract" name="PrepaidExpensesAndOtherCurrentAssetsAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>cycc-20110630_cal.xml
<DESCRIPTION>EX-101 CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by Bowne Inc. -->
<!-- Based on XBRL 2.1 -->
<!--Updated on 6/1/2011 02:15:41 AM by RRD XChanger (TM) version 2.0.10.0-->
<!--Modified on: 8/12/2011 3:26:30 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="cycc-20110630.xsd#DocumentAndEntityInformation" roleURI="http://cyclacel.com/role/DocumentAndEntityInformation" />
  <calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/DocumentAndEntityInformation" xlink:title="00 - Document - Document and Entity Information" />
  <roleRef roleURI="http://cyclacel.com/role/BalanceSheets" xlink:href="cycc-20110630.xsd#BalanceSheets" xlink:type="simple" />
  <roleRef roleURI="http://cyclacel.com/role/BalanceSheetsParenthetical" xlink:href="cycc-20110630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://cyclacel.com/role/StatementsOfOperations" xlink:href="cycc-20110630.xsd#StatementsOfOperations" xlink:type="simple" />
  <roleRef roleURI="http://cyclacel.com/role/StatementsOfCashFlows" xlink:href="cycc-20110630.xsd#StatementsOfCashFlows" xlink:type="simple" />
  <calculationLink xlink:role="http://cyclacel.com/role/BalanceSheets" xlink:title="0110 - Statement - Condensed Consolidated Balance Sheets" xlink:type="extended">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_AssetsCurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_InventoryFinishedGoodsNetOfReserves" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_InventoryFinishedGoodsNetOfReserves" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_Assets" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_AssetsCurrent" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_PropertyPlantAndEquipmentNet" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_PropertyPlantAndEquipmentNet" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_LiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_AccountsPayableCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_AccountsPayableCurrent" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_WarrantsAndRightsOutstanding" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_WarrantsAndRightsOutstanding" order="60" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_Liabilities" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Liabilities" xlink:to="loc_LiabilitiesCurrent" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_LiabilitiesAndStockholdersEquity" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesAndStockholdersEquity" xlink:to="loc_Liabilities" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_StockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_PreferredStockValue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_PreferredStockValue" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_CommonStockValue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_CommonStockValue" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_AdditionalPaidInCapital" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_AdditionalPaidInCapital" order="60" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="80" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_RetainedEarningsAccumulatedDeficit" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_RetainedEarningsAccumulatedDeficit" order="100" use="optional" weight="1" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesAndStockholdersEquity" xlink:to="loc_StockholdersEquity" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_AccruedLiabilitiesCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_AccruedLiabilitiesCurrent" order="30" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_PrepaidExpenseAndOtherAssets" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_PrepaidExpenseAndOtherAssets" order="45" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://cyclacel.com/role/StatementsOfOperations" xlink:title="0120 - Statement - Condensed Consolidated Statements of Operations (Unaudited)" xlink:type="extended">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_RedeemablePreferredStocksDividends" xlink:label="cycc_RedeemablePreferredStocksDividends" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="cycc_RedeemablePreferredStocksDividends" order="10" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_NetIncomeLoss" order="40" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetIncomeLoss" xlink:to="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_OperatingIncomeLoss" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_OperatingIncomeLoss" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_SalesRevenueNet" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OperatingIncomeLoss" xlink:to="loc_SalesRevenueNet" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_LicenseAndServicesRevenue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_SalesRevenueNet" xlink:to="loc_LicenseAndServicesRevenue" order="30" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_SalesRevenueGoodsNet" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_SalesRevenueNet" xlink:to="loc_SalesRevenueGoodsNet" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_RevenueFromGrants" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_SalesRevenueNet" xlink:to="loc_RevenueFromGrants" order="60" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_CostsAndExpenses" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OperatingIncomeLoss" xlink:to="loc_CostsAndExpenses" order="40" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_CostOfGoodsSold" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CostsAndExpenses" xlink:to="loc_CostOfGoodsSold" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_ResearchAndDevelopmentExpense" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CostsAndExpenses" xlink:to="loc_ResearchAndDevelopmentExpense" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_SellingGeneralAndAdministrativeExpense" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CostsAndExpenses" xlink:to="loc_SellingGeneralAndAdministrativeExpense" order="60" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_GoodwillImpairmentLoss" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CostsAndExpenses" xlink:to="loc_GoodwillImpairmentLoss" order="90" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_RestructuringCharges" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CostsAndExpenses" xlink:to="loc_RestructuringCharges" order="100" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_NonoperatingIncomeExpense" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_NonoperatingIncomeExpense" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_PaymentsOfFinancingCosts" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NonoperatingIncomeExpense" xlink:to="loc_PaymentsOfFinancingCosts" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_PaymentUnderGuarantee" xlink:label="cycc_PaymentUnderGuarantee" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NonoperatingIncomeExpense" xlink:to="cycc_PaymentUnderGuarantee" order="40" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_GainLossOnDerivativeInstrumentsNetPretax" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NonoperatingIncomeExpense" xlink:to="loc_GainLossOnDerivativeInstrumentsNetPretax" order="60" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_ChangeInValuationOfWarrants" xlink:label="cycc_ChangeInValuationOfWarrants" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NonoperatingIncomeExpense" xlink:to="cycc_ChangeInValuationOfWarrants" order="80" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_ForeignCurrencyTransactionGainLossBeforeTax" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NonoperatingIncomeExpense" xlink:to="loc_ForeignCurrencyTransactionGainLossBeforeTax" order="100" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_InvestmentIncomeInterest" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NonoperatingIncomeExpense" xlink:to="loc_InvestmentIncomeInterest" order="120" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_InterestExpense" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NonoperatingIncomeExpense" xlink:to="loc_InterestExpense" order="140" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_IncomeTaxExpenseBenefit" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetIncomeLoss" xlink:to="loc_IncomeTaxExpenseBenefit" order="40" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_DividendsPreferredStocks" xlink:label="cycc_DividendsPreferredStocks" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="cycc_DividendsPreferredStocks" order="15" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_GainLossOnPriceRisksDerivativesNet" xlink:label="cycc_GainLossOnPriceRisksDerivativesNet" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NonoperatingIncomeExpense" xlink:to="cycc_GainLossOnPriceRisksDerivativesNet" order="5" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_DividendsOnPreferredOrdinaryShares" xlink:label="cycc_DividendsOnPreferredOrdinaryShares" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="cycc_DividendsOnPreferredOrdinaryShares" order="5" use="optional" weight="-1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://cyclacel.com/role/StatementsOfCashFlows" xlink:title="0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" xlink:type="extended">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_NetCashProvidedByUsedInInvestingActivities" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_PaymentsToAcquireBusinessesNetOfCashAcquired" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_PaymentsToAcquireBusinessesNetOfCashAcquired" order="20" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment" order="40" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_ProceedsFromSaleOfPropertyPlantAndEquipment" order="60" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_PaymentsToAcquireShortTermInvestments" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_PaymentsToAcquireShortTermInvestments" order="80" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="loc_ProceedsFromSaleOfShortTermInvestments" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_ProceedsFromSaleOfShortTermInvestments" order="100" use="optional" weight="1" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_NetCashProvidedByUsedInFinancingActivities" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_RepaymentsOfLongTermCapitalLeaseObligations" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_RepaymentsOfLongTermCapitalLeaseObligations" order="20" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="loc_PaymentsOfDividendsPreferredStockAndPreferenceStock" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_PaymentsOfDividendsPreferredStockAndPreferenceStock" order="100" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_ProceedsOfCommittableLoanNotesIssuedFromShareholders" xlink:label="cycc_ProceedsOfCommittableLoanNotesIssuedFromShareholders" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="cycc_ProceedsOfCommittableLoanNotesIssuedFromShareholders" order="180" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="loc_PaymentsForRepurchaseOfEquity" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_PaymentsForRepurchaseOfEquity" order="240" use="optional" weight="-1" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities" order="60" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_EffectOfExchangeRateOnCashAndCashEquivalents" order="80" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="50" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_ProceedsFromIssuanceOfCommonStock" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ProceedsFromIssuanceOfCommonStock" order="55" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_NetCashProvidedByUsedInOperatingActivities" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NetIncomeLoss" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccretionExpense" xlink:label="loc_AccretionExpense" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_AccretionExpense" order="50" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:label="loc_InvestmentIncomeAmortizationOfPremium" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_InvestmentIncomeAmortizationOfPremium" order="60" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_UnrealizedGainLossOnDerivatives" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_UnrealizedGainLossOnDerivatives" order="80" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_DepreciationDepletionAndAmortization" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_DepreciationDepletionAndAmortization" order="140" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_AmortizationOfIntangibleAssets" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_AmortizationOfIntangibleAssets" order="160" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_ImpairmentOfLongLivedAssetsHeldForUse" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ImpairmentOfLongLivedAssetsHeldForUse" order="180" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_ForeignCurrencyTransactionGainLossUnrealized" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ForeignCurrencyTransactionGainLossUnrealized" order="220" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="loc_RecognitionOfDeferredRevenue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RecognitionOfDeferredRevenue" order="240" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_GainLossOnSaleOfPropertyPlantEquipment" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GainLossOnSaleOfPropertyPlantEquipment" order="300" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_ShareBasedCompensation" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ShareBasedCompensation" order="320" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_AmortizationOfFinancingCostsAndDiscounts" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_AmortizationOfFinancingCostsAndDiscounts" order="370" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="380" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_IncreaseDecreaseInAccountsPayable" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInAccountsPayable" order="390" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_CashAcquiredFromAcquisition" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CashAcquiredFromAcquisition" order="210" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_PaymentsForRestructuring" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PaymentsForRestructuring" order="327.5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_ProceedsFromStockOptionsExercised" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ProceedsFromStockOptionsExercised" order="52.5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_ProceedsFromNotesPayable" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ProceedsFromNotesPayable" order="130" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LoansAndLeasesReceivableRelatedPartiesCollections" xlink:label="loc_LoansAndLeasesReceivableRelatedPartiesCollections" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_LoansAndLeasesReceivableRelatedPartiesCollections" order="190" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromLoans" xlink:label="loc_ProceedsFromLoans" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ProceedsFromLoans" order="15" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_ChangeInValuationOfWarrantsAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities" xlink:label="cycc_ChangeInValuationOfWarrantsAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="cycc_ChangeInValuationOfWarrantsAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities" order="70" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_GainLossOnPriceRisksDerivativesNet" xlink:label="cycc_GainLossOnPriceRisksDerivativesNet" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="cycc_GainLossOnPriceRisksDerivativesNet" order="95" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_GoodwillImpairmentLosses" xlink:label="cycc_GoodwillImpairmentLosses" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="cycc_GoodwillImpairmentLosses" order="185" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_StockOptionPlanExpenses" xlink:label="cycc_StockOptionPlanExpenses" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="cycc_StockOptionPlanExpenses" order="245" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_IssuanceOfStocksAndWarrantsForServicesOrClaims" xlink:label="cycc_IssuanceOfStocksAndWarrantsForServicesOrClaims" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="cycc_IssuanceOfStocksAndWarrantsForServicesOrClaims" order="10" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_PaymentForLoans" xlink:label="cycc_PaymentForLoans" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="cycc_PaymentForLoans" order="115" use="optional" weight="-1" priority="1" />
  </calculationLink>
  <roleRef xlink:type="simple" xlink:href="cycc-20110630.xsd#NatureOfOperationsAndBasisOfPresentation" roleURI="http://cyclacel.com/role/NatureOfOperationsAndBasisOfPresentation" />
  <calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/NatureOfOperationsAndBasisOfPresentation" xlink:title="0201 - Disclosure - Nature of Operations and Basis of Presentation" />
  <roleRef xlink:type="simple" xlink:href="cycc-20110630.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://cyclacel.com/role/SummaryOfSignificantAccountingPolicies" />
  <calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="0202 - Disclosure - Summary of Significant Accounting Policies" />
  <roleRef xlink:type="simple" xlink:href="cycc-20110630.xsd#FairValueMeasurements" roleURI="http://cyclacel.com/role/FairValueMeasurements" />
  <calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/FairValueMeasurements" xlink:title="0203 - Disclosure - Fair Value Measurements" />
  <roleRef xlink:type="simple" xlink:href="cycc-20110630.xsd#PrepaidExpensesAndOtherCurrentAssets" roleURI="http://cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssets" />
  <calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="0204 - Disclosure - Prepaid Expenses and Other Current Assets" />
  <roleRef xlink:type="simple" xlink:href="cycc-20110630.xsd#AccruedLiabilitiesAndOtherCurrentLiabilities" roleURI="http://cyclacel.com/role/AccruedLiabilitiesAndOtherCurrentLiabilities" />
  <calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:title="0205 - Disclosure - Accrued Liabilities and Other Current Liabilities" />
  <roleRef xlink:type="simple" xlink:href="cycc-20110630.xsd#StockBasedCompensation" roleURI="http://cyclacel.com/role/StockBasedCompensation" />
  <calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StockBasedCompensation" xlink:title="0206 - Disclosure - Stock Based Compensation" />
  <roleRef xlink:type="simple" xlink:href="cycc-20110630.xsd#CommitmentsAndContingencies" roleURI="http://cyclacel.com/role/CommitmentsAndContingencies" />
  <calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/CommitmentsAndContingencies" xlink:title="0207 - Disclosure - Commitments and Contingencies" />
  <roleRef xlink:type="simple" xlink:href="cycc-20110630.xsd#StockholdersEquity" roleURI="http://cyclacel.com/role/StockholdersEquity" />
  <calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StockholdersEquity" xlink:title="0208 - Disclosure - Stockholders' Equity" />
  <roleRef xlink:type="simple" xlink:href="cycc-20110630.xsd#SubsequentEvents" roleURI="http://cyclacel.com/role/SubsequentEvents" />
  <calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/SubsequentEvents" xlink:title="0209 - Disclosure - Subsequent Events" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>cycc-20110630_lab.xml
<DESCRIPTION>EX-101 LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by Bowne Inc. -->
<!-- Based on XBRL 2.1 -->
<!--Updated on 6/1/2011 02:15:42 AM by RRD XChanger (TM) version 2.0.10.0-->
<!--Modified on: 8/12/2011 3:26:30 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase&#xD;&#xA;    http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="cycc_DocumentAndEntityInformationAbstract" xlink:href="cycc-20110630.xsd#cycc_DocumentAndEntityInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cycc_DocumentAndEntityInformationAbstract" xlink:to="cycc_DocumentAndEntityInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:label="cycc_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plant and equipment (net)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrant liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants and Rights Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value; 5,000,000 shares authorized at December 31, 2010 and June 30, 2011; 1,213,142 shares issued and outstanding at December 31, 2010 and June 30, 2011. Aggregate preference in liquidation (including undeclared cumulative dividends) of $13,344,562 at December 31, 2010 and June 30, 2011</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional Paid in Capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="us-gaap_SalesRevenueNetAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetAbstract" xlink:to="us-gaap_SalesRevenueNetAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SalesRevenueNetAbstract_lbl" xml:lang="en-US">Revenues:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetAbstract_lbl" xml:lang="en-US">Sales Revenue, Net [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNet" xlink:to="us-gaap_SalesRevenueGoodsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xml:lang="en-US">Product revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xml:lang="en-US">Sales Revenue, Goods, Net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="us-gaap_RevenueFromGrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromGrants" xlink:to="us-gaap_RevenueFromGrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromGrants_lbl" xml:lang="en-US">Grant revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromGrants_lbl" xml:lang="en-US">Revenue from Grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_RevenueFromGrants_lbl" xml:lang="en-US">Grant revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US">Total revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US">Sales Revenue, Net, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US">Total revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">Costs and Expenses [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostOfGoodsSold_lbl" xml:lang="en-US">Cost of goods sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsSold_lbl" xml:lang="en-US">Cost of Goods Sold</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Costs and Expenses, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_PaymentUnderGuarantee" xlink:label="cycc_PaymentUnderGuarantee" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cycc_PaymentUnderGuarantee" xlink:to="cycc_PaymentUnderGuarantee_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cycc_PaymentUnderGuarantee_lbl" xml:lang="en-US">Payment under guarantee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cycc_PaymentUnderGuarantee_lbl" xml:lang="en-US">The cash outflow form a repayment of an unsecured loan facility agreement with the Scottish Enterprise having terms of repayment due if the Company significantly reduced its Scottish research operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cycc_PaymentUnderGuarantee_lbl" xml:lang="en-US">Payment under guarantee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cycc_PaymentUnderGuarantee_lbl" xml:lang="en-US">Payment under guarantee</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" xml:lang="en-US">Change in valuation of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" xml:lang="en-US">Change in valuation of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" xml:lang="en-US">Change in valuation of derivative</label>
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_ChangeInValuationOfWarrants" xlink:label="cycc_ChangeInValuationOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cycc_ChangeInValuationOfWarrants" xlink:to="cycc_ChangeInValuationOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cycc_ChangeInValuationOfWarrants_lbl" xml:lang="en-US">Change In Valuation Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cycc_ChangeInValuationOfWarrants_lbl" xml:lang="en-US">Change in valuation of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cycc_ChangeInValuationOfWarrants_lbl" xml:lang="en-US">Change in valuation of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cycc_ChangeInValuationOfWarrants_lbl" xml:lang="en-US">Change in valuation of warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Investment Income, Interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense), Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss applicable to common shareholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss applicable to common shareholders</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:label="us-gaap_InvestmentIncomeAmortizationOfPremium" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:to="us-gaap_InvestmentIncomeAmortizationOfPremium_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentIncomeAmortizationOfPremium_lbl" xml:lang="en-US">Amortization of investment premiums, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeAmortizationOfPremium_lbl" xml:lang="en-US">Investment Income, Amortization of Premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InvestmentIncomeAmortizationOfPremium_lbl" xml:lang="en-US">Amortization of investment premiums, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xml:lang="en-US">Change in valuation of derivative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xml:lang="en-US">Change in valuation of derivative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US">Fixed asset impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US">Impairment of Long-Lived Assets Held-for-use</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US">Fixed asset impairment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Unrealized foreign exchange loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Unrealized foreign exchange loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="us-gaap_RecognitionOfDeferredRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecognitionOfDeferredRevenue" xlink:to="us-gaap_RecognitionOfDeferredRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecognitionOfDeferredRevenue_lbl" xml:lang="en-US">Recognition of Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RecognitionOfDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RecognitionOfDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">(Gain) loss on disposal of property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain (Loss) on Sale of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">(Gain) loss on disposal of property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Investing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xml:lang="en-US">Purchase of ALIGN</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xml:lang="en-US">Purchase of ALIGN</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US">Purchase of short-term investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US">Payments to Acquire Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US">Purchase of short-term investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xml:lang="en-US">Payment of capital lease obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xml:lang="en-US">Repayments of Long-term Capital Lease Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xml:lang="en-US">Payment of capital lease obligations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:to="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Payment of preferred stock dividend</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Payments of Dividends, Preferred Stock and Preference Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Payment of preferred stock dividend</label>
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_ProceedsOfCommittableLoanNotesIssuedFromShareholders" xlink:label="cycc_ProceedsOfCommittableLoanNotesIssuedFromShareholders" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cycc_ProceedsOfCommittableLoanNotesIssuedFromShareholders" xlink:to="cycc_ProceedsOfCommittableLoanNotesIssuedFromShareholders_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cycc_ProceedsOfCommittableLoanNotesIssuedFromShareholders_lbl" xml:lang="en-US">Proceeds Of Committable Loan Notes Issued From Shareholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cycc_ProceedsOfCommittableLoanNotesIssuedFromShareholders_lbl" xml:lang="en-US">Proceeds of committable loan notes issued from shareholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cycc_ProceedsOfCommittableLoanNotesIssuedFromShareholders_lbl" xml:lang="en-US">Cash received from a loan issued by shareholders.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="us-gaap_PaymentsForRepurchaseOfEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfEquity" xlink:to="us-gaap_PaymentsForRepurchaseOfEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfEquity_lbl" xml:lang="en-US">Costs associated with stock purchase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfEquity_lbl" xml:lang="en-US">Payments for Repurchase of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfEquity_lbl" xml:lang="en-US">Costs associated with stock purchase</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents at end of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flows information:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_CashReceivedDuringPeriodForAbstract" xlink:label="cycc_CashReceivedDuringPeriodForAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cycc_CashReceivedDuringPeriodForAbstract" xlink:to="cycc_CashReceivedDuringPeriodForAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cycc_CashReceivedDuringPeriodForAbstract_lbl" xml:lang="en-US">Cash Received During Period For [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cycc_CashReceivedDuringPeriodForAbstract_lbl" xml:lang="en-US">Cash received during the period for:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cycc_CashReceivedDuringPeriodForAbstract_lbl" xml:lang="en-US">Supplemental cash received information.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="us-gaap_ProceedsFromInterestReceived" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromInterestReceived" xlink:to="us-gaap_ProceedsFromInterestReceived_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromInterestReceived_lbl" xml:lang="en-US">Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromInterestReceived_lbl" xml:lang="en-US">Proceeds from Interest Received</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds_lbl" xml:lang="en-US">Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds_lbl" xml:lang="en-US">Proceeds from Income Tax Refunds</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForOperatingActivitiesAbstract" xlink:label="us-gaap_PaymentsForOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForOperatingActivitiesAbstract" xlink:to="us-gaap_PaymentsForOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsForOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash paid during the period for:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForOperatingActivitiesAbstract_lbl" xml:lang="en-US">Payments for Operating Activities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid, Net</label>
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_ScheduleOfNonCashTransactionsAbstract" xlink:label="cycc_ScheduleOfNonCashTransactionsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cycc_ScheduleOfNonCashTransactionsAbstract" xlink:to="cycc_ScheduleOfNonCashTransactionsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cycc_ScheduleOfNonCashTransactionsAbstract_lbl" xml:lang="en-US">Schedule Of Non Cash Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cycc_ScheduleOfNonCashTransactionsAbstract_lbl" xml:lang="en-US">Schedule of non-cash transactions:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cycc_ScheduleOfNonCashTransactionsAbstract_lbl" xml:lang="en-US">Designated to encapsulate the entire footnote disclosure that gives information on the supplemental cash flow activities for noncash (or part noncash) transactions for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period.</label>
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" xlink:label="cycc_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cycc_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" xlink:to="cycc_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cycc_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases_lbl" xml:lang="en-US">Acquisitions of equipment purchased through capital leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cycc_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases_lbl" xml:lang="en-US">Assets acquired under capital leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cycc_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases_lbl" xml:lang="en-US">Acquisitions of equipment purchased through capital leases</label>
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" xlink:label="cycc_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cycc_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" xlink:to="cycc_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cycc_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements_lbl" xml:lang="en-US">Issuance of Ordinary shares in connection with license agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cycc_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements_lbl" xml:lang="en-US">Issuance of common shares in connection with license agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cycc_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements_lbl" xml:lang="en-US">Issuance of ordinary shares through issuance of license agreements.</label>
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" xlink:label="cycc_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cycc_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" xlink:to="cycc_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cycc_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan_lbl" xml:lang="en-US">Issuance of Ordinary shares on conversion of bridging loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cycc_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan_lbl" xml:lang="en-US">Issuance of ordinary shares through conversion of bridge loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cycc_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan_lbl" xml:lang="en-US">Issuance of Ordinary shares on conversion of bridging loan</label>
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" xlink:label="cycc_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cycc_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" xlink:to="cycc_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cycc_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest_lbl" xml:lang="en-US">Issuance Of Preferred Ordinary Class C Shares On Conversion Of Secured Convertible Loan Notes And Accrued Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cycc_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest_lbl" xml:lang="en-US">Issuance of Preferred Ordinary "C" shares on conversion of secured convertible loan notes and accrued interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cycc_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest_lbl" xml:lang="en-US">Issuance of Preferred shares on conversion of secured convertible loan notes and accrued interest.</label>
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_IssuanceOfOrdinarySharesInLieuOfCashBonus" xlink:label="cycc_IssuanceOfOrdinarySharesInLieuOfCashBonus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cycc_IssuanceOfOrdinarySharesInLieuOfCashBonus" xlink:to="cycc_IssuanceOfOrdinarySharesInLieuOfCashBonus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cycc_IssuanceOfOrdinarySharesInLieuOfCashBonus_lbl" xml:lang="en-US">Issuance of Ordinary shares in lieu of cash bonus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cycc_IssuanceOfOrdinarySharesInLieuOfCashBonus_lbl" xml:lang="en-US">Issuance of ordinary shares in lieu of cash bonuses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cycc_IssuanceOfOrdinarySharesInLieuOfCashBonus_lbl" xml:lang="en-US">Issuance of Ordinary shares in lieu of cash bonus</label>
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_IssuanceOfOtherLongTermPayableOnAlignAcquisition" xlink:label="cycc_IssuanceOfOtherLongTermPayableOnAlignAcquisition" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cycc_IssuanceOfOtherLongTermPayableOnAlignAcquisition" xlink:to="cycc_IssuanceOfOtherLongTermPayableOnAlignAcquisition_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cycc_IssuanceOfOtherLongTermPayableOnAlignAcquisition_lbl" xml:lang="en-US">Issuance of other long term payable on ALIGN acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cycc_IssuanceOfOtherLongTermPayableOnAlignAcquisition_lbl" xml:lang="en-US">Issuance of other long term payable as result of acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cycc_IssuanceOfOtherLongTermPayableOnAlignAcquisition_lbl" xml:lang="en-US">Issuance of other long term payable on ALIGN acquisition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">NATURE OF OPERATIONS AND BASIS OF PRESENTATION</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">Prepaid Expenses And Other Current Assets [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK BASED COMPENSATION</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</label>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</label>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</label>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</label>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Condensed Consolidated Balance Sheets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements of Operations [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements of Cash Flows [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_PrepaidExpenseAndOtherAssets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_PaymentsOfFinancingCosts" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_PaymentsOfFinancingCosts" xml:lang="en-US">Payments of Financing Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_PaymentsOfFinancingCosts" xml:lang="en-US">Costs associated with aborted 2004 IPO</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_PaymentsOfFinancingCosts" xml:lang="en-US">Payments of Financing Costs, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_PaymentsOfFinancingCosts" xml:lang="en-US">Costs associated with aborted 2004 IPO</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServicesRevenue" xlink:to="lab_LicenseAndServicesRevenue" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LicenseAndServicesRevenue" xml:lang="en-US">License and Services Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LicenseAndServicesRevenue" xml:lang="en-US">Collaboration and research and development revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="lab_EarningsPerShareBasic" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_WeightedAverageNumberOfSharesOutstandingBasic" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average common shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_AmortizationOfFinancingCostsAndDiscounts" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_IncreaseDecreaseInAccountsPayable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_ProceedsFromIssuanceOfCommonStock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_AccruedLiabilitiesCurrent" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued liabilities and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued liabilities and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionExpense" xlink:to="lab_AccretionExpense" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_AccretionExpense" xml:lang="en-US">Accretion Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_AccretionExpense" xml:lang="en-US">Accretion of interest on notes payable, net of amortization of debt premium</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="lab_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Proceeds from issuance of ordinary and preferred ordinary shares, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_CashAcquiredFromAcquisition" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_CashAcquiredFromAcquisition" xml:lang="en-US">Cash Acquired from Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_CashAcquiredFromAcquisition" xml:lang="en-US">Cash and cash equivalents assumed on stock purchase</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="lab_GoodwillImpairmentLoss" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_GoodwillImpairmentLoss" xml:lang="en-US">Goodwill, Impairment Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_GoodwillImpairmentLoss" xml:lang="en-US">Goodwill and intangibles impairment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRestructuring" xlink:to="lab_PaymentsForRestructuring" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_PaymentsForRestructuring" xml:lang="en-US">Payments for Restructuring</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_PaymentsForRestructuring" xml:lang="en-US">Provision for restructuring</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_ProceedsFromStockOptionsExercised" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ProceedsFromStockOptionsExercised" xml:lang="en-US">Net proceeds from stock options and warrants exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="lab_ProceedsFromNotesPayable" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ProceedsFromNotesPayable" xml:lang="en-US">Proceeds from Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ProceedsFromNotesPayable" xml:lang="en-US">Government loan received</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LoansAndLeasesReceivableRelatedPartiesCollections" xlink:label="us-gaap_LoansAndLeasesReceivableRelatedPartiesCollections" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansAndLeasesReceivableRelatedPartiesCollections" xlink:to="lab_LoansAndLeasesReceivableRelatedPartiesCollections" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LoansAndLeasesReceivableRelatedPartiesCollections" xml:lang="en-US">Loans and Leases Receivable, Related Parties, Collections</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_LoansAndLeasesReceivableRelatedPartiesCollections" xml:lang="en-US">Loans received from shareholders</label>
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_PreferredStockLiquidationPreferenceValue" xlink:label="cycc_PreferredStockLiquidationPreferenceValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cycc_PreferredStockLiquidationPreferenceValue" xlink:to="cycc_PreferredStockLiquidationPreferenceValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cycc_PreferredStockLiquidationPreferenceValue_lbl" xml:lang="en-US">Preferred stock, liquidation preference value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cycc_PreferredStockLiquidationPreferenceValue_lbl" xml:lang="en-US">The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cycc_PreferredStockLiquidationPreferenceValue_lbl" xml:lang="en-US">Preferred stock, liquidation preference value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromLoans" xlink:label="us-gaap_ProceedsFromLoans" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoans" xlink:to="lab_ProceedsFromLoans" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ProceedsFromLoans" xml:lang="en-US">Proceeds from Loans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ProceedsFromLoans" xml:lang="en-US">Loan received from Cyclacel Group Plc</label>
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_ChangeInValuationOfWarrantsAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities" xlink:label="cycc_ChangeInValuationOfWarrantsAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cycc_ChangeInValuationOfWarrantsAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities" xlink:to="cycc_ChangeInValuationOfWarrantsAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cycc_ChangeInValuationOfWarrantsAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities_lbl" xml:lang="en-US">Change In Valuation Of Warrants Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cycc_ChangeInValuationOfWarrantsAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities_lbl" xml:lang="en-US">Change in valuation of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cycc_ChangeInValuationOfWarrantsAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities_lbl" xml:lang="en-US">Amount recognized during the period for the change in valuation of warrants.</label>
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_GainLossOnPriceRisksDerivativesNet" xlink:label="cycc_GainLossOnPriceRisksDerivativesNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cycc_GainLossOnPriceRisksDerivativesNet" xlink:to="cycc_GainLossOnPriceRisksDerivativesNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cycc_GainLossOnPriceRisksDerivativesNet_lbl" xml:lang="en-US">Gain Loss On Price Risks Derivatives Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cycc_GainLossOnPriceRisksDerivativesNet_lbl" xml:lang="en-US">Warrant re-pricing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cycc_GainLossOnPriceRisksDerivativesNet_lbl" xml:lang="en-US">Warrant re-pricing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cycc_GainLossOnPriceRisksDerivativesNet_lbl" xml:lang="en-US">Amount recognized during the period as a result in changes to the pricing terms of the warrants.</label>
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_GoodwillImpairmentLosses" xlink:label="cycc_GoodwillImpairmentLosses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cycc_GoodwillImpairmentLosses" xlink:to="cycc_GoodwillImpairmentLosses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cycc_GoodwillImpairmentLosses_lbl" xml:lang="en-US">Goodwill Impairment Losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cycc_GoodwillImpairmentLosses_lbl" xml:lang="en-US">Goodwill and intangibles impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cycc_GoodwillImpairmentLosses_lbl" xml:lang="en-US">The aggregate amount of write-downs for goodwill and other intangible assets recognized during the period.</label>
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_StockOptionPlanExpenses" xlink:label="cycc_StockOptionPlanExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cycc_StockOptionPlanExpenses" xlink:to="cycc_StockOptionPlanExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cycc_StockOptionPlanExpenses_lbl" xml:lang="en-US">Stock Option Plan Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cycc_StockOptionPlanExpenses_lbl" xml:lang="en-US">Compensation for warrants issued to non employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cycc_StockOptionPlanExpenses_lbl" xml:lang="en-US">The aggregate amount of noncash, equity-based issued to non-employees for services rendered. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</label>
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_IssuanceOfStocksAndWarrantsForServicesOrClaims" xlink:label="cycc_IssuanceOfStocksAndWarrantsForServicesOrClaims" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cycc_IssuanceOfStocksAndWarrantsForServicesOrClaims" xlink:to="cycc_IssuanceOfStocksAndWarrantsForServicesOrClaims_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cycc_IssuanceOfStocksAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Issuance Of Stocks And Warrants For Services Or Claims</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cycc_IssuanceOfStocksAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Shares issued for IP rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cycc_IssuanceOfStocksAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">The aggregate amount of noncash, equity-based issued intellectual property rights.  As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</label>
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_PaymentForLoans" xlink:label="cycc_PaymentForLoans" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cycc_PaymentForLoans" xlink:to="cycc_PaymentForLoans_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cycc_PaymentForLoans_lbl" xml:lang="en-US">Payment For Loans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cycc_PaymentForLoans_lbl" xml:lang="en-US">Repayment of government loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cycc_PaymentForLoans_lbl" xml:lang="en-US">The outflow of cash to repay a government loan.</label>
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_RedeemablePreferredStocksDividends" xlink:label="cycc_RedeemablePreferredStocksDividends" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cycc_RedeemablePreferredStocksDividends" xlink:to="cycc_RedeemablePreferredStocksDividends_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cycc_RedeemablePreferredStocksDividends_lbl" xml:lang="en-US">Redeemable Preferred Stocks Dividends</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cycc_RedeemablePreferredStocksDividends_lbl" xml:lang="en-US">Deemed dividend on convertible exchangeable preferred shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cycc_RedeemablePreferredStocksDividends_lbl" xml:lang="en-US">The amount of dividends deemed declared in the period to preferred shareholders as a result of the preferred shares being converted into common stock.</label>
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_DividendsPreferredStocks" xlink:label="cycc_DividendsPreferredStocks" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cycc_DividendsPreferredStocks" xlink:to="cycc_DividendsPreferredStocks_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cycc_DividendsPreferredStocks_lbl" xml:lang="en-US">Dividends Preferred Stocks</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cycc_DividendsPreferredStocks_lbl" xml:lang="en-US">Dividend on convertible exchangeable preferred shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="cycc_DividendsPreferredStocks_lbl" xml:lang="en-US">Dividend on convertible exchangeable preferred shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cycc_DividendsPreferredStocks_lbl" xml:lang="en-US">The amount of dividends declared in the period to preferred shareholders even if not paid.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="lab_SubsequentEventsAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Nature of Operations and Basis of Presentation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Nature of Operations and Basis of Presentation [Abstract]</label>
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_DividendsOnPreferredOrdinaryShares" xlink:label="cycc_DividendsOnPreferredOrdinaryShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cycc_DividendsOnPreferredOrdinaryShares" xlink:to="cycc_DividendsOnPreferredOrdinaryShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cycc_DividendsOnPreferredOrdinaryShares_lbl" xml:lang="en-US">Dividends on preferred ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cycc_DividendsOnPreferredOrdinaryShares_lbl" xml:lang="en-US">Dividends on preferred ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cycc_DividendsOnPreferredOrdinaryShares_lbl" xml:lang="en-US">Dividends on preferred ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cycc_DividendsOnPreferredOrdinaryShares_lbl" xml:lang="en-US">Dividends on preferred ordinary shares.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_FairValueDisclosuresAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign exchange (losses)/gains</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="lab_EquityAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Cumulative Effects of Changes in Accounting Principles, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Loss before taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Loss before taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xml:lang="en-US">Proceeds from Sale of Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xml:lang="en-US">Redemptions of short-term investments, net of maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xml:lang="en-US">Redemptions of short-term investments, net of maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US">Restructuring Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US">Provision for restructuring</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US">Restructuring costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US">Restructuring costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Amortization of Financing Costs and Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Amortization of issuance costs of Preferred Ordinary "C" shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Amortization of issuance costs of Preferred Ordinary "C" shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_PrepaidExpenseAndOtherAssets" xml:lang="en-US">Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_PrepaidExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_PrepaidExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_EarningsPerShareBasic" xml:lang="en-US">Net loss per share- Basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_EarningsPerShareBasic" xml:lang="en-US">Net loss per share- Basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Deficit accumulated during the development stage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Deficit accumulated during the development stage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_EquityAbstract" xml:lang="en-US">Stockholders' Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lab_AccountingPoliciesAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_AccountingPoliciesAbstract" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Stock Based Compensation [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="lab_SubsequentEventsTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_SubsequentEventsTextBlock" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_PayablesAndAccrualsAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_PayablesAndAccrualsAbstract" xml:lang="en-US">Accrued Liabilities and Other Current Liabilities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xml:lang="en-US">ACCRUED LIABILITIES AND OTHER CURRENT LIABILITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Measurements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Prepaid expenses and other current assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 100,000,000 shares authorized at December 31, 2010 and June 30, 2011; 46,564,914 and 46,587,182 shares issued and outstanding at December 31, 2010 and June 30, 2011 respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid, Deferred Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses, inventory and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable, accrued liabilities and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by financing activities</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>cycc-20110630_pre.xml
<DESCRIPTION>EX-101 PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by Bowne Inc. -->
<!-- Based on XBRL 2.1 -->
<!--Updated on 6/1/2011 02:15:42 AM by RRD XChanger (TM) version 2.0.10.0-->
<!--Modified on: 8/12/2011 3:26:30 AM-->
<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef roleURI="http://cyclacel.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="cycc-20110630.xsd#DocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="cycc-20110630.xsd#NatureOfOperationsAndBasisOfPresentation" roleURI="http://cyclacel.com/role/NatureOfOperationsAndBasisOfPresentation" />
  <roleRef xlink:type="simple" xlink:href="cycc-20110630.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://cyclacel.com/role/SummaryOfSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="cycc-20110630.xsd#FairValueMeasurements" roleURI="http://cyclacel.com/role/FairValueMeasurements" />
  <roleRef xlink:type="simple" xlink:href="cycc-20110630.xsd#PrepaidExpensesAndOtherCurrentAssets" roleURI="http://cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssets" />
  <roleRef xlink:type="simple" xlink:href="cycc-20110630.xsd#AccruedLiabilitiesAndOtherCurrentLiabilities" roleURI="http://cyclacel.com/role/AccruedLiabilitiesAndOtherCurrentLiabilities" />
  <roleRef xlink:type="simple" xlink:href="cycc-20110630.xsd#StockBasedCompensation" roleURI="http://cyclacel.com/role/StockBasedCompensation" />
  <roleRef xlink:type="simple" xlink:href="cycc-20110630.xsd#CommitmentsAndContingencies" roleURI="http://cyclacel.com/role/CommitmentsAndContingencies" />
  <roleRef xlink:type="simple" xlink:href="cycc-20110630.xsd#StockholdersEquity" roleURI="http://cyclacel.com/role/StockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="cycc-20110630.xsd#SubsequentEvents" roleURI="http://cyclacel.com/role/SubsequentEvents" />
  <presentationLink xlink:role="http://cyclacel.com/role/DocumentAndEntityInformation" xlink:title="00 - Document - Document and Entity Information" xlink:type="extended">
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_DocumentAndEntityInformationAbstract" xlink:label="cycc_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cycc_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="60" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cycc_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="120" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cycc_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="100" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cycc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cycc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="40" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cycc_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="180" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cycc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="200" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cycc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers" order="220" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cycc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="240" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cycc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="260" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cycc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="300" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cycc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat" order="280" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cycc_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="160" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cycc_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="140" use="optional" />
  </presentationLink>
  <roleRef xlink:type="simple" xlink:href="cycc-20110630.xsd#BalanceSheets" roleURI="http://cyclacel.com/role/BalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="cycc-20110630.xsd#BalanceSheetsParenthetical" roleURI="http://cyclacel.com/role/BalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="cycc-20110630.xsd#StatementsOfOperations" roleURI="http://cyclacel.com/role/StatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="cycc-20110630.xsd#StatementsOfCashFlows" roleURI="http://cyclacel.com/role/StatementsOfCashFlows" />
  <presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/BalanceSheets" xlink:title="0110 - Statement - Condensed Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_AssetsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_AssetsAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_AssetsCurrentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_AssetsCurrentAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue" order="20" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_InventoryFinishedGoodsNetOfReserves" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_InventoryFinishedGoodsNetOfReserves" order="40" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_AssetsCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_AssetsCurrent" order="80" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_PropertyPlantAndEquipmentNet" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_PropertyPlantAndEquipmentNet" order="40" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_Assets" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_Assets" order="80" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_LiabilitiesAndStockholdersEquityAbstract" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_LiabilitiesCurrentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_LiabilitiesCurrentAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_AccountsPayableCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_AccountsPayableCurrent" order="20" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_WarrantsAndRightsOutstanding" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_WarrantsAndRightsOutstanding" order="60" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_LiabilitiesCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_LiabilitiesCurrent" order="100" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_Liabilities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_Liabilities" order="40" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_StockholdersEquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_StockholdersEquityAbstract" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_PreferredStockValue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_PreferredStockValue" order="20" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_CommonStockValue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_CommonStockValue" order="40" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_AdditionalPaidInCapital" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_AdditionalPaidInCapital" order="60" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="80" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_RetainedEarningsAccumulatedDeficit" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_RetainedEarningsAccumulatedDeficit" order="100" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_StockholdersEquity" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_StockholdersEquity" order="120" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_LiabilitiesAndStockholdersEquity" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_LiabilitiesAndStockholdersEquity" order="100" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_AccruedLiabilitiesCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_AccruedLiabilitiesCurrent" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_PrepaidExpenseAndOtherAssets" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_PrepaidExpenseAndOtherAssets" order="45" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/BalanceSheetsParenthetical" xlink:title="0111 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_LiabilitiesAndStockholdersEquityAbstract" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_StockholdersEquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_StockholdersEquityAbstract" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_PreferredStockParOrStatedValuePerShare" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_PreferredStockParOrStatedValuePerShare" order="20" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_PreferredStockSharesAuthorized" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_PreferredStockSharesAuthorized" order="40" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_PreferredStockSharesIssued" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_PreferredStockSharesIssued" order="60" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_PreferredStockSharesOutstanding" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_PreferredStockSharesOutstanding" order="80" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_CommonStockParOrStatedValuePerShare" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_CommonStockParOrStatedValuePerShare" order="120" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_CommonStockSharesAuthorized" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_CommonStockSharesAuthorized" order="140" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_CommonStockSharesIssued" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_CommonStockSharesIssued" order="160" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_CommonStockSharesOutstanding" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_CommonStockSharesOutstanding" order="180" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_PreferredStockLiquidationPreferenceValue" xlink:label="cycc_PreferredStockLiquidationPreferenceValue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="cycc_PreferredStockLiquidationPreferenceValue" order="115" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StatementsOfOperations" xlink:title="0120 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="loc_SalesRevenueNetAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_SalesRevenueNetAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_SalesRevenueGoodsNet" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SalesRevenueNetAbstract" xlink:to="loc_SalesRevenueGoodsNet" order="40" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_RevenueFromGrants" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SalesRevenueNetAbstract" xlink:to="loc_RevenueFromGrants" order="60" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_SalesRevenueNet" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SalesRevenueNetAbstract" xlink:to="loc_SalesRevenueNet" order="80" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_CostsAndExpensesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_CostsAndExpensesAbstract" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_CostOfGoodsSold" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CostsAndExpensesAbstract" xlink:to="loc_CostOfGoodsSold" order="20" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_ResearchAndDevelopmentExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CostsAndExpensesAbstract" xlink:to="loc_ResearchAndDevelopmentExpense" order="40" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_SellingGeneralAndAdministrativeExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CostsAndExpensesAbstract" xlink:to="loc_SellingGeneralAndAdministrativeExpense" order="60" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_RestructuringCharges" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CostsAndExpensesAbstract" xlink:to="loc_RestructuringCharges" order="100" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_CostsAndExpenses" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CostsAndExpensesAbstract" xlink:to="loc_CostsAndExpenses" order="120" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_OperatingIncomeLoss" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_OperatingIncomeLoss" order="60" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_NonoperatingIncomeExpenseAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_NonoperatingIncomeExpenseAbstract" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_PaymentUnderGuarantee" xlink:label="cycc_PaymentUnderGuarantee" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NonoperatingIncomeExpenseAbstract" xlink:to="cycc_PaymentUnderGuarantee" order="40" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_ChangeInValuationOfWarrants" xlink:label="cycc_ChangeInValuationOfWarrants" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NonoperatingIncomeExpenseAbstract" xlink:to="cycc_ChangeInValuationOfWarrants" order="80" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_ForeignCurrencyTransactionGainLossBeforeTax" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NonoperatingIncomeExpenseAbstract" xlink:to="loc_ForeignCurrencyTransactionGainLossBeforeTax" order="100" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_InvestmentIncomeInterest" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NonoperatingIncomeExpenseAbstract" xlink:to="loc_InvestmentIncomeInterest" order="120" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_InterestExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NonoperatingIncomeExpenseAbstract" xlink:to="loc_InterestExpense" order="140" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_NonoperatingIncomeExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_NonoperatingIncomeExpense" order="100" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="120" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_IncomeTaxExpenseBenefit" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_IncomeTaxExpenseBenefit" order="140" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_NetIncomeLoss" order="160" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_PaymentsOfFinancingCosts" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NonoperatingIncomeExpenseAbstract" xlink:to="loc_PaymentsOfFinancingCosts" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_LicenseAndServicesRevenue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SalesRevenueNetAbstract" xlink:to="loc_LicenseAndServicesRevenue" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_EarningsPerShareBasic" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_EarningsPerShareBasic" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_WeightedAverageNumberOfSharesOutstandingBasic" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_WeightedAverageNumberOfSharesOutstandingBasic" order="295" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_GoodwillImpairmentLoss" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CostsAndExpensesAbstract" xlink:to="loc_GoodwillImpairmentLoss" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_GainLossOnDerivativeInstrumentsNetPretax" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NonoperatingIncomeExpenseAbstract" xlink:to="loc_GainLossOnDerivativeInstrumentsNetPretax" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_NetIncomeLossAvailableToCommonStockholdersBasic" order="265" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_RedeemablePreferredStocksDividends" xlink:label="cycc_RedeemablePreferredStocksDividends" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="cycc_RedeemablePreferredStocksDividends" order="246.25" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_DividendsPreferredStocks" xlink:label="cycc_DividendsPreferredStocks" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="cycc_DividendsPreferredStocks" order="258.75" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_GainLossOnPriceRisksDerivativesNet" xlink:label="cycc_GainLossOnPriceRisksDerivativesNet" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NonoperatingIncomeExpenseAbstract" xlink:to="cycc_GainLossOnPriceRisksDerivativesNet" order="95" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_DividendsOnPreferredOrdinaryShares" xlink:label="cycc_DividendsOnPreferredOrdinaryShares" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="cycc_DividendsOnPreferredOrdinaryShares" order="205" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StatementsOfCashFlows" xlink:title="0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NetIncomeLoss" order="20" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:label="loc_InvestmentIncomeAmortizationOfPremium" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_InvestmentIncomeAmortizationOfPremium" order="40" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_UnrealizedGainLossOnDerivatives" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_UnrealizedGainLossOnDerivatives" order="60" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_DepreciationDepletionAndAmortization" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_DepreciationDepletionAndAmortization" order="120" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_AmortizationOfIntangibleAssets" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_AmortizationOfIntangibleAssets" order="140" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_ImpairmentOfLongLivedAssetsHeldForUse" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ImpairmentOfLongLivedAssetsHeldForUse" order="160" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_ForeignCurrencyTransactionGainLossUnrealized" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ForeignCurrencyTransactionGainLossUnrealized" order="200" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="loc_RecognitionOfDeferredRevenue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_RecognitionOfDeferredRevenue" order="220" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_GainLossOnSaleOfPropertyPlantEquipment" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_GainLossOnSaleOfPropertyPlantEquipment" order="280" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_ShareBasedCompensation" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ShareBasedCompensation" order="300" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_IncreaseDecreaseInOperatingCapitalAbstract" order="360" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="20" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_NetCashProvidedByUsedInOperatingActivities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities" order="60" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_PaymentsToAcquireBusinessesNetOfCashAcquired" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_PaymentsToAcquireBusinessesNetOfCashAcquired" order="20" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment" order="40" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_ProceedsFromSaleOfPropertyPlantAndEquipment" order="60" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_PaymentsToAcquireShortTermInvestments" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_PaymentsToAcquireShortTermInvestments" order="80" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="loc_ProceedsFromSaleOfShortTermInvestments" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_ProceedsFromSaleOfShortTermInvestments" order="100" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_NetCashProvidedByUsedInInvestingActivities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities" order="120" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_RepaymentsOfLongTermCapitalLeaseObligations" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_RepaymentsOfLongTermCapitalLeaseObligations" order="20" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="loc_PaymentsOfDividendsPreferredStockAndPreferenceStock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_PaymentsOfDividendsPreferredStockAndPreferenceStock" order="100" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_ProceedsOfCommittableLoanNotesIssuedFromShareholders" xlink:label="cycc_ProceedsOfCommittableLoanNotesIssuedFromShareholders" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="cycc_ProceedsOfCommittableLoanNotesIssuedFromShareholders" order="180" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="loc_PaymentsForRepurchaseOfEquity" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_PaymentsForRepurchaseOfEquity" order="240" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_NetCashProvidedByUsedInFinancingActivities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities" order="260" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_EffectOfExchangeRateOnCashAndCashEquivalents" order="80" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" order="100" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue" order="120" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue_1" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue_1" order="140" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_SupplementalCashFlowInformationAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_SupplementalCashFlowInformationAbstract" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_CashReceivedDuringPeriodForAbstract" xlink:label="cycc_CashReceivedDuringPeriodForAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SupplementalCashFlowInformationAbstract" xlink:to="cycc_CashReceivedDuringPeriodForAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="loc_ProceedsFromInterestReceived" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cycc_CashReceivedDuringPeriodForAbstract" xlink:to="loc_ProceedsFromInterestReceived" order="20" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="loc_ProceedsFromIncomeTaxRefunds" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cycc_CashReceivedDuringPeriodForAbstract" xlink:to="loc_ProceedsFromIncomeTaxRefunds" order="40" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForOperatingActivitiesAbstract" xlink:label="loc_PaymentsForOperatingActivitiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SupplementalCashFlowInformationAbstract" xlink:to="loc_PaymentsForOperatingActivitiesAbstract" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_InterestPaidNet" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PaymentsForOperatingActivitiesAbstract" xlink:to="loc_InterestPaidNet" order="20" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_ScheduleOfNonCashTransactionsAbstract" xlink:label="cycc_ScheduleOfNonCashTransactionsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PaymentsForOperatingActivitiesAbstract" xlink:to="cycc_ScheduleOfNonCashTransactionsAbstract" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" xlink:label="cycc_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cycc_ScheduleOfNonCashTransactionsAbstract" xlink:to="cycc_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" order="20" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" xlink:label="cycc_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cycc_ScheduleOfNonCashTransactionsAbstract" xlink:to="cycc_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" order="40" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" xlink:label="cycc_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cycc_ScheduleOfNonCashTransactionsAbstract" xlink:to="cycc_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" order="60" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" xlink:label="cycc_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cycc_ScheduleOfNonCashTransactionsAbstract" xlink:to="cycc_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" order="80" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_IssuanceOfOrdinarySharesInLieuOfCashBonus" xlink:label="cycc_IssuanceOfOrdinarySharesInLieuOfCashBonus" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cycc_ScheduleOfNonCashTransactionsAbstract" xlink:to="cycc_IssuanceOfOrdinarySharesInLieuOfCashBonus" order="100" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_IssuanceOfOtherLongTermPayableOnAlignAcquisition" xlink:label="cycc_IssuanceOfOtherLongTermPayableOnAlignAcquisition" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cycc_ScheduleOfNonCashTransactionsAbstract" xlink:to="cycc_IssuanceOfOtherLongTermPayableOnAlignAcquisition" order="120" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccretionExpense" xlink:label="loc_AccretionExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_AccretionExpense" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_AmortizationOfFinancingCostsAndDiscounts" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_AmortizationOfFinancingCostsAndDiscounts" order="350" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_IncreaseDecreaseInAccountsPayable" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInAccountsPayable" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_ProceedsFromIssuanceOfCommonStock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ProceedsFromIssuanceOfCommonStock" order="55" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_CashAcquiredFromAcquisition" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_CashAcquiredFromAcquisition" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_PaymentsForRestructuring" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_PaymentsForRestructuring" order="307.5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_ProceedsFromStockOptionsExercised" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ProceedsFromStockOptionsExercised" order="67.8125" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_ProceedsFromNotesPayable" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ProceedsFromNotesPayable" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LoansAndLeasesReceivableRelatedPartiesCollections" xlink:label="loc_LoansAndLeasesReceivableRelatedPartiesCollections" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_LoansAndLeasesReceivableRelatedPartiesCollections" order="190" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromLoans" xlink:label="loc_ProceedsFromLoans" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ProceedsFromLoans" order="175" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_ChangeInValuationOfWarrantsAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities" xlink:label="cycc_ChangeInValuationOfWarrantsAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="cycc_ChangeInValuationOfWarrantsAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities" order="71.25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_GainLossOnPriceRisksDerivativesNet" xlink:label="cycc_GainLossOnPriceRisksDerivativesNet" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="cycc_GainLossOnPriceRisksDerivativesNet" order="105" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_GoodwillImpairmentLosses" xlink:label="cycc_GoodwillImpairmentLosses" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="cycc_GoodwillImpairmentLosses" order="165" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_StockOptionPlanExpenses" xlink:label="cycc_StockOptionPlanExpenses" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="cycc_StockOptionPlanExpenses" order="237.5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_IssuanceOfStocksAndWarrantsForServicesOrClaims" xlink:label="cycc_IssuanceOfStocksAndWarrantsForServicesOrClaims" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="cycc_IssuanceOfStocksAndWarrantsForServicesOrClaims" order="262.5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_PaymentForLoans" xlink:label="cycc_PaymentForLoans" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="cycc_PaymentForLoans" order="128.75" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/NatureOfOperationsAndBasisOfPresentation" xlink:title="0201 - Disclosure - Nature of Operations and Basis of Presentation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="0202 - Disclosure - Summary of Significant Accounting Policies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_SignificantAccountingPoliciesTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AccountingPoliciesAbstract" xlink:to="loc_SignificantAccountingPoliciesTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/FairValueMeasurements" xlink:title="0203 - Disclosure - Fair Value Measurements">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_FairValueDisclosuresTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_FairValueDisclosuresAbstract" xlink:to="loc_FairValueDisclosuresTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="0204 - Disclosure - Prepaid Expenses and Other Current Assets">
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="cycc-20110630.xsd#cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:title="0205 - Disclosure - Accrued Liabilities and Other Current Liabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PayablesAndAccrualsAbstract" xlink:to="loc_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StockBasedCompensation" xlink:title="0206 - Disclosure - Stock Based Compensation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/CommitmentsAndContingencies" xlink:title="0207 - Disclosure - Commitments and Contingencies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_CommitmentsAndContingenciesDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_CommitmentsAndContingenciesDisclosureTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StockholdersEquity" xlink:title="0208 - Disclosure - Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_StockholdersEquityNoteDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EquityAbstract" xlink:to="loc_StockholdersEquityNoteDisclosureTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/SubsequentEvents" xlink:title="0209 - Disclosure - Subsequent Events">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_SubsequentEventsTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SubsequentEventsAbstract" xlink:to="loc_SubsequentEventsTextBlock" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>c17919c1791901.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c17919c1791901.gif
M1TE&.#EA*0`K`.8``,CE*OW^^,7!NU9.3:FCG=+(S/G\[<7E1^KVL?S\_,3D
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MEL&TPN[XN<GG-\#B(IZ*K]SAO<GG/OKZ^/GX^OW]_?[^_O___R'Y!```````
M+``````I`"L```?_@'^"@X2"?GY_AX6+?WV'B(R1C0E^?0E_"15]CH:(EGU_
M4A5?H)*+E5^4C1</("<A(2<D+Q<50D)]0I20IH177Y-]7@(V10,\/`,H#`TD
M0AE?E9R]OJ2.$`P#,`[<W6112F`9?J34C%<7%R\3<=WN[E$:+2]"O.:)FPD8
M*._N,#Q1`+IXD<H>-3\)^GQ9,:`?-QXR"`AP(0.%A`NJ[N'[\@5,PW[Q'CQZ
MH(1`"XV#*I&3P*4?&1DDKFQ*\T>"#0PH"WTY(8/,NS8,7CAZ!($`!IHYI;5@
ML`U>@TLI$P@P8="<I3]A)'SL-D`$P@0R';7`D1/?ICX0IOQP-V"%)5(5_RB!
MG79/FA!-&("LY084PI\K"$O]*:<1X1=<?2Z<T-O-(K"$B'0I*KPI;J4+8!@[
MX&'C!:9-@?MD`$57DA_`-"C(6)'@`H@Q46!\F_`@6A\:#(8,D0'F@J--T2)5
M2N`%"`P&."X(&<:`2Y0!-DZ\J(##.!DR#/PJM%35D",21<AP$:$0;@LP#*90
MP%";03L'+G!4J-"=D,(K/?C!*'+"-X07?F30`@DF0%#!`RCXY``!HES2!V#"
M64)"3P[`,,`4$CP@A264X-""`)HY$!1@Z$S&B$(FR.#/#`Q0(`$.?ES0PP0S
M-,5-?&!=44\O?J3X#AEQ/#<#%UP<HV`W%&0@!?\PP24"3!IR)7*%%U/$$<</
M5F()0QL\Q,%#&S_\`P,,5PIP01J(C&.($)T<PM$%-/2``0AT]F`G!B=@8*>=
M),A)YW1^L-G'AHE0,DH"R8U&2FN'SC=<.JK<HLEIO_V!T2$*A1;&!1G$)<0>
MMG`4!J@9I'/7?!=\4<&F0H0AA&<9D6/("V!,,($(+]!P`@2ZBI!!!B>`(4$#
M8`@@0`,3M"#!!#V8(``%$X3QPA6%Y"*!#`,(0,,%%LP@0`46H.#"!2M8P-(4
M`I`@P1#/6B``%RZ0``0%87#B1P6#I(9M`T*\ZP($(@`Q0`,B$#L`%P+@``$0
M*%#P@`LS]/`'`RB8`,K_O0\F\$4&)H`Q1A$-,%#1$V!80,``4=@`Q@P#:'""
M'!@,8,$7#0P`AA?IC8-I'QP$L(<)2XQ!@0T3K'<$'G18X,,2:.10P!$:')&#
M#R$,\<06<C1-AP9!F#%4`EN,T#,$'M`12QYYN+&&!T%T3845/OBP0A`%%-!$
M$Q98P003=<]]A0];[,R!$49PP$<3&1C100>%;[%%``&4(;D3D9=1Q0UE4"YY
M&0&X@;D;912:P`@C&&!$&FG48$`'4)B^"0=.("$[$@%0[D3/E`>`1,^UT^X$
M8%IH48/J(P1?0Q:+=U%\#80;X+P!I$-/>!:DET[]"--?$4`'*;#``@((>/_]
MK09S+'"&]V>`C\`"YI_!/@+N@V_^^NK'P`$4&\"AAQT``&"''3IX`P#NT+\D
M)$&``$#@&Q"80`8FL'\#5$,7C!"!.6`!"PI0P`$V>(`/Z$`'']A@!A6@APQ^
MX`,F)"$*]8#"#)80"UW8'AM*4((=J(`(1"@!$7;`PQL2005`#*(0ATA$%93`
I`&4P0!?J4`<QB.$,9XA!#"+@Q`A,,0)8S*(6M\A%*W*@+&`D1"```#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EAFAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) (USD $)<br>In Thousands, except Share data</strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="nump">5,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="nump">1,213,142<span></span></td>
        <td class="nump">1,213,142<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="nump">1,213,142<span></span></td>
        <td class="nump">1,213,142<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_PreferredStockLiquidationPreferenceValue', window );">Preferred stock, liquidation preference value</a></td>
        <td class="nump">$ 13,344,562<span></span></td>
        <td class="nump">$ 13,344,562<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">100,000,000<span></span></td>
        <td class="nump">100,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">46,587,182<span></span></td>
        <td class="nump">46,564,914<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">46,587,182<span></span></td>
        <td class="nump">46,564,914<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_PreferredStockLiquidationPreferenceValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_PreferredStockLiquidationPreferenceValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 129<br> -Paragraph 4<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 02<br> -Paragraph 29<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 129<br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 02<br> -Paragraph 29<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 129<br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 02<br> -Paragraph 29<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 02<br> -Paragraph 29<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EBJAI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) (USD $)<br>In Thousands, except Share data</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
        <th class="th" colspan="1">181 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2010</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2010</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNetAbstract', window );"><strong>Revenues:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Collaboration and research and development revenue</a></td>
        <td class="text"> <span></span></td>
        <td class="nump">$ 100<span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">$ 100<span></span></td>
        <td class="nump">$ 3,100<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product revenue</a></td>
        <td class="nump">168<span></span></td>
        <td class="nump">19<span></span></td>
        <td class="nump">360<span></span></td>
        <td class="nump">273<span></span></td>
        <td class="nump">2,682<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Grant revenue</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">16<span></span></td>
        <td class="nump">3,648<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total revenue</a></td>
        <td class="nump">168<span></span></td>
        <td class="nump">119<span></span></td>
        <td class="nump">360<span></span></td>
        <td class="nump">389<span></span></td>
        <td class="nump">9,430<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of goods sold</a></td>
        <td class="nump">72<span></span></td>
        <td class="nump">92<span></span></td>
        <td class="nump">178<span></span></td>
        <td class="nump">234<span></span></td>
        <td class="nump">1,570<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">1,859<span></span></td>
        <td class="nump">1,322<span></span></td>
        <td class="nump">4,939<span></span></td>
        <td class="nump">3,497<span></span></td>
        <td class="nump">181,532<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
        <td class="nump">2,034<span></span></td>
        <td class="nump">3,091<span></span></td>
        <td class="nump">3,840<span></span></td>
        <td class="nump">5,491<span></span></td>
        <td class="nump">85,806<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill and intangibles impairment</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">7,934<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">2,634<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
        <td class="nump">3,965<span></span></td>
        <td class="nump">4,505<span></span></td>
        <td class="nump">8,957<span></span></td>
        <td class="nump">9,222<span></span></td>
        <td class="nump">279,476<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
        <td class="num">(3,797)<span></span></td>
        <td class="num">(4,386)<span></span></td>
        <td class="num">(8,597)<span></span></td>
        <td class="num">(8,833)<span></span></td>
        <td class="num">(270,046)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Costs associated with aborted 2004 IPO</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="num">(3,550)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_PaymentUnderGuarantee', window );">Payment under guarantee</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="num">(1,652)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in valuation of derivative</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="num">(308)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_ChangeInValuationOfWarrants', window );">Change in valuation of warrants</a></td>
        <td class="nump">125<span></span></td>
        <td class="nump">273<span></span></td>
        <td class="nump">203<span></span></td>
        <td class="num">(516)<span></span></td>
        <td class="nump">6,273<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_GainLossOnPriceRisksDerivativesNet', window );">Warrant re-pricing</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="num">(44)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange (losses)/gains</a></td>
        <td class="num">(19)<span></span></td>
        <td class="num">(49)<span></span></td>
        <td class="num">(87)<span></span></td>
        <td class="num">(38)<span></span></td>
        <td class="num">(4,342)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
        <td class="nump">13<span></span></td>
        <td class="nump">8<span></span></td>
        <td class="nump">24<span></span></td>
        <td class="nump">17<span></span></td>
        <td class="nump">13,704<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="text"> <span></span></td>
        <td class="num">(9)<span></span></td>
        <td class="text"> <span></span></td>
        <td class="num">(33)<span></span></td>
        <td class="num">(4,677)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
        <td class="nump">119<span></span></td>
        <td class="nump">223<span></span></td>
        <td class="nump">140<span></span></td>
        <td class="num">(570)<span></span></td>
        <td class="nump">5,404<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before taxes</a></td>
        <td class="num">(3,678)<span></span></td>
        <td class="num">(4,163)<span></span></td>
        <td class="num">(8,457)<span></span></td>
        <td class="num">(9,403)<span></span></td>
        <td class="num">(264,642)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
        <td class="nump">126<span></span></td>
        <td class="nump">230<span></span></td>
        <td class="nump">317<span></span></td>
        <td class="nump">363<span></span></td>
        <td class="nump">18,196<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(3,552)<span></span></td>
        <td class="num">(3,933)<span></span></td>
        <td class="num">(8,140)<span></span></td>
        <td class="num">(9,040)<span></span></td>
        <td class="num">(246,446)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_DividendsOnPreferredOrdinaryShares', window );">Dividends on preferred ordinary shares</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="num">(38,123)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_RedeemablePreferredStocksDividends', window );">Deemed dividend on convertible exchangeable preferred shares</a></td>
        <td class="text"> <span></span></td>
        <td class="num">(2,496)<span></span></td>
        <td class="text"> <span></span></td>
        <td class="num">(2,915)<span></span></td>
        <td class="num">(3,515)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_DividendsPreferredStocks', window );">Dividend on convertible exchangeable preferred shares</a></td>
        <td class="num">(182)<span></span></td>
        <td class="num">(114)<span></span></td>
        <td class="num">(364)<span></span></td>
        <td class="num">(403)<span></span></td>
        <td class="num">(3,293)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss applicable to common shareholders</a></td>
        <td class="num">$ (3,734)<span></span></td>
        <td class="num">$ (6,543)<span></span></td>
        <td class="num">$ (8,504)<span></span></td>
        <td class="num">$ (12,358)<span></span></td>
        <td class="num">$ (291,377)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share- Basic and diluted</a></td>
        <td class="num">$ (0.08)<span></span></td>
        <td class="num">$ (0.18)<span></span></td>
        <td class="num">$ (0.18)<span></span></td>
        <td class="num">$ (0.36)<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding</a></td>
        <td class="nump">46,582,915<span></span></td>
        <td class="nump">36,565,972<span></span></td>
        <td class="nump">46,577,577<span></span></td>
        <td class="nump">34,157,279<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_ChangeInValuationOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Change in valuation of warrants</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_ChangeInValuationOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_DividendsOnPreferredOrdinaryShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Dividends on preferred ordinary shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_DividendsOnPreferredOrdinaryShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_DividendsPreferredStocks">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of dividends declared in the period to preferred shareholders even if not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_DividendsPreferredStocks</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_GainLossOnPriceRisksDerivativesNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount recognized during the period as a result in changes to the pricing terms of the warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_GainLossOnPriceRisksDerivativesNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_PaymentUnderGuarantee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow form a repayment of an unsecured loan facility agreement with the Scottish Enterprise having terms of repayment due if the Company significantly reduced its Scottish research operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_PaymentUnderGuarantee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_RedeemablePreferredStocksDividends">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of dividends deemed declared in the period to preferred shareholders as a result of the preferred shares being converted into common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_RedeemablePreferredStocksDividends</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs related to goods produced and sold during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfGoodsSold</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs of sales and operating expenses for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostsAndExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostsAndExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=6945512&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number 07-4<br> -Paragraph 4<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 20<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 7<br> -Paragraph 18<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 128<br> -Paragraph 36, 37, 38<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 21<br> -Article 9<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1252-109256<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate foreign currency transaction gain (loss) (both realized and unrealized) included in determining net income for the reporting period. Excludes foreign currency transactions designated as hedges of net investment in a foreign entity and intercompany foreign currency transactions that are of a long-term nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements. For certain enterprises, primarily banks, that are dealers in foreign exchange, foreign currency transaction gains (losses) may be disclosed as dealer gains (losses).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 52<br> -Paragraph 30<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6935481&amp;loc=SL5618551-113959<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDerivativeInstrumentsNetPretax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Loss recognized during the period that results from the write-down of goodwill after comparing the implied fair value of reporting unit goodwill with the carrying amount of that goodwill. Goodwill is assessed at least annually for impairment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13777-109266<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 142<br> -Paragraph 20<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 142<br> -Paragraph 45<br> -Subparagraph e<br> -Clause 5<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 141R<br> -Paragraph 72<br> -Subparagraph d<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 142<br> -Paragraph 47<br> -Subparagraph b<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6905597&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 142<br> -Paragraph 43<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6905597&amp;loc=d3e13854-109267<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillImpairmentLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 4<br> -Section 08<br> -Paragraph h<br> -Subparagraph 1(i)<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph h<br> -Article 4<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 109<br> -Paragraph 45<br> -Subparagraph a, b<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cost of borrowed funds accounted for as interest that was charged against earnings during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 34<br> -Paragraph 21<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 9<br> -Article 9<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher OTS<br> -Name Federal Regulation (FR)<br> -Number Title 12<br> -Chapter V<br> -Section 563c.102<br> -Paragraph 9<br> -Subsection II<br> -LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy.  It will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 7<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 115<br> -Paragraph 14<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentIncomeInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndServicesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LicenseAndServicesRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph A7<br> -Appendix A<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 130<br> -Paragraph 10, 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph d<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number 87-21<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 19<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28, 29, 30<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 128<br> -Paragraph 9<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1377-109256<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 7<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for loan and debt issuance costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 18, 19, 20<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsOfFinancingCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 141<br> -Paragraph 51<br> -Subparagraph g<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 2<br> -Paragraph 12, 13<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 86<br> -Paragraph 11, 12<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding asset retirement obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6394695&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section P<br> -Subsection 3, 4<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394695&amp;loc=d3e140864-122747<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestructuringCharges</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueFromGrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueGoodsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNetAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueNetAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 43<br> -Chapter 4<br> -Paragraph 5A<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 4<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6386349&amp;loc=d3e3636-108311<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SellingGeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 128<br> -Paragraph 171<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 128<br> -Paragraph 40<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 128<br> -Paragraph 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number 07-4<br> -Paragraph 4<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E4MAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">Cyclacel Pharmaceuticals, Inc.<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001130166<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Jun. 30,
         2011<span></span></td>
        <td class="text"><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2011<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q2<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
        <td class="text"> <span></span></td>
        <td class="nump">$ 63,554,944<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="nump">54,224,093<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, and Other.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityPublicFloat</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityVoluntaryFilers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
        <td class="text">
    <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
    <!-- Begin Block Tagged Note 7 - us-gaap:CommitmentsAndContingenciesDisclosureTextBlock-->
    <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>7. COMMITMENTS AND CONTINGENCIES</b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Licensing Agreements</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The Company has entered into licensing agreements with academic and research organizations.
    Under the terms of these agreements, the Company has received licenses to technology and patent
    applications. The Company is required to pay royalties on future sales of product employing the
    technology or falling under claims of patent applications.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Pursuant to the Daiichi Sankyo license under which the Company licenses certain patent rights
    for sapacitabine, its lead drug candidate, the Company is under an obligation to use reasonable
    endeavors to develop a product and obtain regulatory approval to sell a product and has agreed to
    pay Daiichi Sankyo an up-front fee, reimbursement for Daiichi Sankyo&#8217;s enumerated expenses,
    milestone payments and royalties on a country-by-country basis. Under this agreement, aggregate
    milestone payments totaling $11.7&#160;million could be payable subject to achievement of all the
    specific contractual milestones and the Company&#8217;s decision to continue with these projects. The
    up-front fee and certain past reimbursements have been paid and, as a result of the SEAMLESS trial
    entering Phase 3 during the first quarter of 2011, $1.6&#160;million was paid in July&#160;2011. Following
    these milestone payments, a further $9.3&#160;million in aggregate milestone payments could be payable.
    Royalties are payable in each country for the term of patent protection in the country or for ten
    years following the first commercial sale of licensed products in the country, whichever is later.
    Royalties are payable on net sales. Net sales are defined as the gross amount invoiced by the
    Company or its affiliates or licensees, less discounts, credits, taxes, shipping and bad debt
    losses. The agreement extends from its commencement date to the date on which no further amounts
    are owed under it. If the Company wishes to appoint a third party to develop or commercialize a
    sapacitabine-based product in Japan, within certain limitations, Daiichi Sankyo must be notified
    and given a right of first refusal to develop and/or commercialize in Japan. In general, the
    license may be terminated by the Company for technical, scientific, efficacy, safety, or commercial
    reasons on six months notice, or twelve months, if after a launch of a sapacitabine-based product,
    or by either party for material default. Effective July&#160;11, 2011, the license agreement was amended
    to irrevocably waive a termination right Daiichi Sankyo possessed under a provision of the
    agreement that required the Company to obtain regulatory approval to sell sapacitabine in at least
    one country by September&#160;2011, and releases the Company from all claims and liability of any kind
    arising under such provision. The amendment further provides that the royalty due from the Company
    to Daiichi Sankyo on future net sales of sapacitabine be increased by a percentage between 1.25%
    and 1.50% depending on the level of net sales of sapacitabine realized.
    </div>
    <!-- Folio -->
    <!-- /Folio -->
    </div>
    <!-- PAGEBREAK -->
    <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Guarantee</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">On July&#160;28, 2005 and as amended on March&#160;27, 2006, Cyclacel Group plc (&#8220;Group&#8221;) signed a
    convertible Loan Note Instrument constituting convertible unsecured loan notes (the &#8220;Loan&#8221;) and
    entered into a Facility Agreement (&#8220;Agreement&#8221;) with Scottish Enterprise (&#8220;SE&#8221;), as lender, whereby
    SE subscribed for &#163;5&#160;million, or approximately $9&#160;million at the time, of the convertible loan
    notes. The loan was subsequently converted into 1,231,527 preferred D shares of the Group in
    satisfaction of all amounts owed by Group under the convertible loan notes. The number of preferred
    D shares that SE received was calculated by dividing the principal amount outstanding under the
    loan note by &#163;4.06. The preferred D shares were exchanged for shares in Xcyte Therapies, Inc. on
    March&#160;27, 2006 as part of the transaction between Xcyte and Cyclacel Limited. However, Scottish
    Enterprise retained the ability it had under the Agreement to receive a cash payment should the
    research operations in Scotland be significantly reduced. The Company had guaranteed approximately
    &#163;5&#160;million, the amount potentially due to SE, which will be calculated as a maximum of &#163;5&#160;million
    less the market value of the shares held by SE at the time of any significant reduction in research
    facilities.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">On June&#160;22, 2009, the Company amended the Agreement with SE (the &#8220;Amendment&#8221;), in order to
    allow the Company to implement a reduction of the Company&#8217;s research operations located in Scotland
    in exchange for the parties&#8217; agreement to modify the payment terms of the Agreement in the
    principal amount of &#163;5&#160;million (approximately $8.0&#160;million at December&#160;31, 2009), which SE had
    previously entered into with the Company. The Agreement provided for repayment of &#163;5&#160;million in the
    event the Company significantly reduced its Scottish research operations. Pursuant to the terms of
    the Amendment, in association with Cyclacel&#8217;s material reduction in staff at its Scottish research
    facility, the parties agreed to a modified payment of &#163;1&#160;million (approximately $1.7&#160;million at
    June&#160;22, 2009) payable in two equal tranches. On July&#160;1, 2009, the first installment of &#163;0.5
    million (approximately $0.8&#160;million) was paid and the remaining amount of &#163;0.5&#160;million
    (approximately $0.8&#160;million) was paid on January&#160;6, 2010. In addition, should a further reduction
    below current minimum staff levels be effectuated before July&#160;2014 without SE&#8217;s prior consent, the
    Company will guarantee approximately &#163;4&#160;million, the amount potentially due to SE, which will be
    calculated as a maximum of &#163;4&#160;million less the market value of the shares held by SE at the time of
    any further reduction in research facilities.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">This arrangement is accounted for as a liability and is measured at fair value. Changes in
    fair value are recognized in earnings. Due to the nature of the associated contingency and the
    likelihood of occurrence, the Company has concluded the fair value of this liability is immaterial
    as of December&#160;31, 2010 and June&#160;30, 2011.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Legal proceedings</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On April&#160;27, 2010, the Company was served with a complaint filed by Celgene Corporation in the
    United States District Court for the District of Delaware seeking a declaratory judgment that four
    of its own patents, claiming the use of romidepsin injection in T-cell lymphomas, are invalid and
    not infringed by Celgene&#8217;s products, but directly involve the use and administration of Celgene&#8217;s
    ISTODAX<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> (romidepsin for injection) product. On June&#160;17, 2010, the Company filed its answer and
    counterclaims to the declaratory judgment complaint. The Company filed counterclaims charging
    Celgene with infringement of each of the Company&#8217;s four patents and seeking damages for Celgene&#8217;s
    infringement as well as injunctive relief. The four patents directly involve the use and
    administration of Celgene&#8217;s ISTODAX<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> (romidepsin for injection) product.
    </div>
    </div>
  <span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name FASB Interpretation (FIN)<br> -Number 14<br> -Paragraph 3<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 5<br> -Paragraph 9, 10, 11, 12<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
        <td class="text">
    <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
    <!-- Begin Block Tagged Note 3 - us-gaap:FairValueDisclosuresTextBlock-->
    <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>3. FAIR VALUE MEASUREMENTS</b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As defined in ASC 820, fair value is based on the price that would be received to sell an
    asset or paid to transfer a liability in an orderly transaction between market participants at the
    measurement date. In order to increase consistency and comparability in fair value measurements,
    ASC 820 establishes a fair value hierarchy that prioritizes observable and unobservable inputs used
    to measure fair value into three broad levels, which are described below:
    </div>
    <div style="margin-top: 10pt">
    <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left">
    <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <td width="4%" style="background: transparent">&#160;</td>
    <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td>
    <td width="1%">&#160;</td>
    <td>Level 1: Quoted prices (unadjusted)&#160;in active markets that are accessible at the
    measurement date for assets or liabilities. The fair value hierarchy gives the highest
    priority to Level 1 inputs.</td>
    </tr>
    </table>
    </div>
    <div style="margin-top: 10pt">
    <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left">
    <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <td width="4%" style="background: transparent">&#160;</td>
    <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td>
    <td width="1%">&#160;</td>
    <td>Level 2: Inputs other than quoted prices within Level 1 that are observable for the
    asset or liability, either directly or indirectly.</td>
    </tr>
    </table>
    </div>
    <div style="margin-top: 10pt">
    <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left">
    <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <td width="4%" style="background: transparent">&#160;</td>
    <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td>
    <td width="1%">&#160;</td>
    <td>Level 3: Unobservable inputs that are used when little or no market data is available.
    The fair value hierarchy gives the lowest priority to Level 3 inputs.</td>
    </tr>
    </table>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In determining fair value, the Company utilizes valuation techniques that maximize the use of
    observable inputs and minimize the use of unobservable inputs to the extent possible as well as
    considers counterparty credit risk in its assessment of fair value. Financial assets and
    liabilities carried at fair value on a recurring basis as of December&#160;31, 2010 are classified in
    the table below in one of the three categories described above:
    </div>
    <div align="center">
    <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
    <!-- Begin Table Head -->
    <tr valign="bottom">
    <td width="44%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>Level 1</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>Level 2</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>Level 3</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>Total</b></td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>$000</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>$000</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>$000</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>$000</b></td>
    <td>&#160;</td>
    </tr>
    <!-- End Table Head -->
    <!-- Begin Table Body -->
    <tr valign="bottom"><!-- Blank Space -->
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Cash equivalents
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">29,066</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">29,066</td>
    <td>&#160;</td>
    </tr>
    <tr>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Warrants
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">680</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">680</td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 1px">
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom"><!-- Blank Space -->
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Total
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">29,066</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">680</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">29,746</td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 1px">
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    </tr>
    <!-- End Table Body -->
    </table>
    </div>
    <!-- Folio -->
    <!-- /Folio -->
    </div>
    <!-- PAGEBREAK -->
    <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Financial assets and liabilities carried at fair value on a recurring basis as of June&#160;30,
    2011 are classified in the table below in one of the three categories described above:
    </div>
    <div align="center">
    <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
    <!-- Begin Table Head -->
    <tr valign="bottom">
    <td width="44%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>Level 1</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>Level 2</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>Level 3</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>Total</b></td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>$000</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>$000</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>$000</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>$000</b></td>
    <td>&#160;</td>
    </tr>
    <tr>
    <td>&#160;</td>
    </tr>
    <!-- End Table Head -->
    <!-- Begin Table Body -->
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Cash equivalents
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">17,333</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">17,333</td>
    <td>&#160;</td>
    </tr>
    <tr>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Warrants
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">477</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">477</td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 1px">
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
    <td>&#160;</td>
    </tr>
    <tr>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Total
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">17,333</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">477</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">17,810</td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 1px">
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    </tr>
    <!-- End Table Body -->
    </table>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Warrants Liability</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company issued warrants to purchase shares of common stock under the registered direct
    financing completed in February&#160;2007. These warrants are being accounted for as a liability in
    accordance with ASC 815, &#8220;<i>Derivatives and Hedging&#8221; </i>(&#8220;ASC 815&#8221;). At the date of the transaction,
    the fair value of the warrants of $6.8&#160;million was determined utilizing the Black-Scholes option
    pricing model utilizing the following assumptions: risk free interest rate &#8212; 4.68%, expected
    volatility &#8212; 85%, expected dividend yield &#8212; 0%, and a contractual life of 7&#160;years. The fair value
    of the warrant is being re-measured each reporting period, with a derivative gain or loss
    recognized in the consolidated statement of operations. Such gains or losses will continue to be
    reported until the warrants are exercised or expired. The Company used the Black-Scholes
    option-pricing model with the following assumptions to value the warrants:
    </div>
    <div align="center">
    <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
    <!-- Begin Table Head -->
    <tr valign="bottom">
    <td width="72%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>December 31,</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>June 30,</b></td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
    <td>&#160;</td>
    </tr>
    <!-- End Table Head -->
    <!-- Begin Table Body -->
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Exercise price
    </div></td>
    <td>&#160;</td>
    <td align="left">$</td>
    <td align="right">8.44</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="left">$</td>
    <td align="right">8.44</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Expected term
    </div></td>
    <td>&#160;</td>
    <td colspan="2" align="right">3.13 Yrs.</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" align="right">2.63 Yrs.</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Risk free interest rate
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="left">&#160;</td>
    <td align="right">1.02</td>
    <td nowrap="nowrap">%</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="left">&#160;</td>
    <td align="right">0.68</td>
    <td nowrap="nowrap">%</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Expected volatility
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="left">&#160;</td>
    <td align="right">121</td>
    <td nowrap="nowrap">%</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="left">&#160;</td>
    <td align="right">118</td>
    <td nowrap="nowrap">%</td>
    </tr>
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Expected dividend yield over expected term
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">&#8212;</td>
    <td>&#160;</td>
    </tr>
    <!-- End Table Body -->
    </table>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the three months ended June&#160;30, 2010 and 2011, the Company recognized the change
    in the value of warrants of approximately $0.3&#160;million and $0.1&#160;million, respectively, as a gain on
    the consolidated statement of operations. During the six months ended June&#160;30, 2010, the Company
    recognized the $0.5&#160;million increase in the value of warrants as a loss on the consolidated
    statement of operations. During the six months ended June&#160;30, 2011, the Company recognized the
    $0.2&#160;million decrease in the value of warrants as a gain on the consolidated statement of
    operations. The following table reconciles the beginning and ending balance of Level 3 inputs for
    the six months ended June&#160;30, 2011:
    </div>
    <div align="center">
    <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
    <!-- Begin Table Head -->
    <tr valign="bottom">
    <td width="86%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Level 3</b></td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>$000</b></td>
    <td>&#160;</td>
    </tr>
    <!-- End Table Head -->
    <!-- Begin Table Body -->
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Balance as of December&#160;31, 2010
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">680</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Gain from change in valuation of warrants liability reported in earnings
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="left">&#160;</td>
    <td align="right">(203</td>
    <td nowrap="nowrap">)</td>
    </tr>
    <tr style="font-size: 1px">
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Balance as of June&#160;30, 2011
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">477</td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 1px">
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    </tr>
    <!-- End Table Body -->
    </table>
    </div>
    <!-- Folio -->
    <!-- /Folio -->
    </div>
    <!-- PAGEBREAK -->
    <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
    </div>
  <span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19296-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 159<br> -Paragraph 17-22, 27, 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 107<br> -Paragraph 15C, 15D<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13504-108611<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 107<br> -Paragraph 15A<br> -Subparagraph a-d<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13537-108611<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 133<br> -Paragraph 44A, 44B<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19207-110258<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 107<br> -Paragraph 3, 10, 14, 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 107<br> -Paragraph 15B<br> -Subparagraph a, b<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 157<br> -Paragraph 32, 33, 34<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
        <td class="text">
    <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
    <!-- Begin Block Tagged Note 9 - us-gaap:SubsequentEventsTextBlock-->
    <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>9. SUBSEQUENT EVENTS</b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Preferred Stock Dividend</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On July&#160;8, 2011, the Board of Directors decided not to declare the quarterly cash dividend on
    the Preferred Stock with respect to the second quarter of 2011 that would have otherwise been
    payable on August&#160;1, 2011.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Board also did not declare the quarterly cash dividend with respect to each of the four
    quarters of fiscal year 2009 and the first, second and third quarters of 2010. To the extent that
    any dividends payable on the Preferred Stock are not paid, such unpaid dividends are added to the
    liquidity preference of the Preferred Stock. As the Company failed to pay in an aggregate amount
    equal to at least six quarterly dividends (whether or not consecutive) on the Preferred Stock, the
    size of the Company&#8217;s Board was increased by two members and the holders of the Preferred Stock,
    voting separately as a class, voted on May&#160;24, 2011 and elected two directors to fill the vacancies
    created thereby, which directorships shall terminate when the Company pays all accrued but unpaid
    dividends.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>License Agreement</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On July&#160;11, 2011, the Company entered into an amendment to its license agreement with Daiichi
    Sankyo Company, Limited (&#8220;Daiichi Sankyo&#8221;), dated September&#160;10, 2003, relating to certain rights
    which the Company has licensed from Daiichi Sankyo with regard to the Company&#8217;s sapacitabine drug.
    Effective July&#160;11, 2011, the license agreement was amended to irrevocably waive a termination right
    Daiichi Sankyo possessed under a provision of the agreement that required the Company to obtain
    regulatory approval to sell sapacitabine in at least one country by September&#160;2011, and releases
    the Company from all claims and liability of any kind arising under such provision. The amendment
    further provides that the royalty due from the Company to Daiichi Sankyo on future net sales of
    sapacitabine be increased by a percentage between 1.25% and 1.50% depending on the level of net
    sales of sapacitabine realized.
    </div>
    <!-- Folio -->
    <!-- /Folio -->
    </div>
    <!-- PAGEBREAK -->
    <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Financing</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On July&#160;7, 2011 the Company closed an underwritten offering for an aggregate of 7,617,646
    units, at an offering price of $1.36 per unit, for gross proceeds of approximately $10.4&#160;million.
    Each unit consists of (i)&#160;one share of common stock and (ii)&#160;a five-year warrant to purchase 0.5 of
    a share of common stock at an exercise price of $1.36 per share, exercisable beginning six months
    after the date of issuance. The shares of common stock and warrants were immediately separable and
    were issued separately such that no units were issued. The net proceeds, after underwriting
    discounts and commissions and other fees and expenses payable by the Company, were approximately
    $9.3&#160;million.
    </div>
    </div>
  <span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
        <td class="text">
    <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
    <!-- Begin Block Tagged Note 8 - us-gaap:StockholdersEquityNoteDisclosureTextBlock-->
    <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>8. STOCKHOLDERS&#8217; EQUITY</b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Preferred Stock</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As of June&#160;30, 2011, there were 1,213,142 shares of Preferred Stock issued and outstanding at
    an issue price of $10.00 per share. Dividends on the Preferred Stock are cumulative from the date
    of original issuance at the annual rate of 6% of the liquidation preference of the Preferred Stock,
    payable quarterly on
    the first day of February, May, August and November, commencing February&#160;1, 2005. Any
    dividends must be declared by the Company&#8217;s Board of Directors and must come from funds that are
    legally available for dividend payments. The Preferred Stock has a liquidation preference of $10
    per share, plus accrued and unpaid dividends.
    </div>
    <!-- Folio -->
    <!-- /Folio -->
    </div>
    <!-- PAGEBREAK -->
    <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Preferred Stock is convertible at the option of the holder at any time into the Company&#8217;s
    shares of common stock at a conversion rate of approximately 0.42553 shares of common stock for
    each share of Preferred Stock based on a price of $23.50. During 2010, 833,671 shares of Preferred
    Stock were converted into 1,655,599 shares of the Company&#8217;s common stock, which is described in
    more detail below. Since inception through June&#160;30, 2011, holders have voluntarily converted
    1,776,858 shares of Preferred Stock into common stock. The Company has reserved 516,228 shares of
    common stock for issuance upon conversion of the remaining shares of Preferred Stock outstanding at
    June&#160;30, 2011. The converted shares of Preferred Stock have been retired and canceled and shall
    upon cancellation be restored to the status of authorized but unissued shares of preferred stock,
    subject to reissuance by the Board of Directors as shares of Preferred Stock of one or more series.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company may automatically convert the Preferred Stock into common stock if the closing
    price of the Company&#8217;s common stock has exceeded $35.25, which is 150% of the conversion price of
    the Preferred Stock, for at least 20 trading days during any 30-day trading period, ending within
    five trading days prior to notice of automatic conversion.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Certificate of Designations governing the Preferred Stock provides that if the Company
    fails to pay dividends on its Preferred Stock for six quarterly periods, holders of Preferred Stock
    are entitled to nominate and elect two directors to the Company&#8217;s Board of Directors. This right
    accrued to the holders of Preferred Stock as of August&#160;2, 2010 and two directors were nominated and
    elected at the annual meeting held on May&#160;24, 2011.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Preferred Stock has no maturity date and no voting rights prior to conversion into common
    stock, except under limited circumstances.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">From November&#160;6, 2007, the Company may, at its option, redeem the Preferred Stock in whole or
    in part, out of funds legally available at the redemption prices per share stated below, plus an
    amount equal to accrued and unpaid dividends up to the date of redemption:
    </div>
    <div align="center">
    <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
    <!-- Begin Table Head -->
    <tr valign="bottom">
    <td width="86%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    </tr>
    <!-- End Table Head -->
    <!-- Begin Table Body -->
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Year from November&#160;1, 2010 to October&#160;31, 2011
    </div></td>
    <td>&#160;</td>
    <td align="left">$</td>
    <td align="right">10.24</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Year from November&#160;1, 2011 to October&#160;31, 2012
    </div></td>
    <td>&#160;</td>
    <td align="left">$</td>
    <td align="right">10.18</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Year from November&#160;1, 2012 to October&#160;31, 2013
    </div></td>
    <td>&#160;</td>
    <td align="left">$</td>
    <td align="right">10.12</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Year from November&#160;1, 2013 to October&#160;31, 2014
    </div></td>
    <td>&#160;</td>
    <td align="left">$</td>
    <td align="right">10.06</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">November&#160;1, 2014 and thereafter
    </div></td>
    <td>&#160;</td>
    <td align="left">$</td>
    <td align="right">10.00</td>
    <td>&#160;</td>
    </tr>
    <!-- End Table Body -->
    </table>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Preferred Stock is exchangeable, in whole but not in part, at the option of the Company on
    any dividend payment date beginning on November&#160;1, 2005 (the &#8220;Exchange Date&#8221;) for the Company&#8217;s 6%
    Convertible Subordinated Debentures (&#8220;Debentures&#8221;) at the rate of $10 principal amount of
    Debentures for each share of Preferred Stock. The Debentures, if issued, will mature 25&#160;years after
    the Exchange Date and have terms substantially similar to those of the Preferred Stock.
    </div>
    <!-- Folio -->
    <!-- /Folio -->
    </div>
    <!-- PAGEBREAK -->
    <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><i>Conversion of Convertible Preferred Stock</i>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">During the first and second quarters of 2010, Cyclacel entered into agreements to exchange
    shares of the Company&#8217;s Preferred Stock into shares of common stock. There were no such conversions
    for the six months ended June&#160;30, 2011. The table below provides details of the aggregate
    activities in 2010:
    </div>
    <div align="center">
    <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
    <!-- Begin Table Head -->
    <tr valign="bottom">
    <td width="72%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>For the three</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>For the six</b></td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>months ended</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>months ended</b></td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>June 30, 2010</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>June 30, 2010</b></td>
    <td>&#160;</td>
    </tr>
    <!-- End Table Head -->
    <!-- Begin Table Body -->
    <tr valign="bottom"><!-- Blank Space -->
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Preferred shares exchanged
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">710,271</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">833,671</td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 1px">
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom"><!-- Blank Space -->
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Common shares issued:
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom"><!-- Blank Space -->
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">At stated convertible option
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">302,242</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">354,752</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom"><!-- Blank Space -->
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Incremental shares issued under an inducement offer
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">1,113,961</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">1,300,847</td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 1px">
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom"><!-- Blank Space -->
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Total common shares issued
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">1,416,203</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">1,655,599</td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 1px">
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    </tr>
    <!-- End Table Body -->
    </table>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">ASC 260, EITF Topic D-42, &#8220;<i>The Effect of the Calculation of Earnings per Share for the
    Redemption or Induced Conversion of Preferred Stock&#8221; </i>(&#8220;ASC 260&#8221;) requires that if convertible
    preferred stock is converted to other securities pursuant to an inducement offer, the Company
    should record the excess of (1)&#160;the fair value of all securities and other consideration
    transferred to the holders of the convertible preferred stock and (2)&#160;the fair value of securities
    issuable to the original conversion terms as an increase to net loss to arrive at a net loss
    attributable to common shareholders. The stockholder received more shares of the Company&#8217;s common
    stock than would have been delivered pursuant to the original conversion terms of the Preferred
    Stock, pursuant to a short term inducement offer. The excess of the fair value of the common stock
    transferred to the stockholder over the carrying amount of the preferred stock in the Company&#8217;s
    balance sheet at the time of the transfer was considered to be an additional return to the holder
    of the Preferred Stock. Specifically, the Company recorded deemed dividends related to the
    additional shares issued under the exchange transactions of approximately $2.5&#160;million and $2.9
    million for the three and six months ended June&#160;30, 2010, respectively.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Common Stock</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><i>October&#160;2010 Private Placement</i>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On October&#160;7, 2010, the Company completed a private placement pursuant to which it sold
    approximately $15.2&#160;million of its units to several institutional investors, for net proceeds of
    approximately $14.0&#160;million. The units consist of one share of common stock and 0.5 of a warrant,
    with each whole warrant representing the right to purchase one share of common stock at an exercise
    price of $1.92 per share for a period of five years. As of June&#160;30, 2011, all options and warrants
    issued to the investors are outstanding and have been classified as equity. The investors purchased
    a total of 8,323,190 units at a price of $1.82625 per unit. The investors also have the right to
    acquire up to 4,161,595 additional units at a price of $1.67 per unit (for $6.9&#160;million in gross
    proceeds) at any time up to nine months after closing or by July&#160;6, 2011. As of June&#160;30, 2011, none
    of the additional units had been exercised and, as of July&#160;6, 2011, the right to acquire the
    additional units lapsed. The transaction date fair value of the warrants and additional optional
    units was $5.1&#160;million and $2.8&#160;million, respectively. Net proceeds of approximately $14.0&#160;million
    were allocated based on relative transaction date fair values in the following manner: $8.9&#160;million
    ($1.07 per share), $3.3&#160;million ($0.79 per warrant) and $1.8&#160;million ($0.43 per optional unit) to
    common shares, warrants and the additional optional units, respectively.
    </div>
    <!-- Folio -->
    <!-- /Folio -->
    </div>
    <!-- PAGEBREAK -->
    <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In connection with the October&#160;2010 private placement, the Company granted to the investors
    certain registration rights pursuant to a Registration Rights Agreement, dated October&#160;7, 2010, in
    which the Company agreed, among other things, to register all of the shares of common stock
    acquired from the Company (including upon exercise of the warrants and/or the options) within
    thirty calendar days after the Company becomes eligible to use a registration statement on Form
    S-3, and use commercially reasonable efforts to have the registration statement declared effective
    as promptly as practicable thereafter. Upon the Company&#8217;s failure to comply with the terms of the
    Registration Rights Agreement and certain other conditions, the Company will be required to make
    pro rata payments to each investor, as liquidated damages, in an amount equal to 1.5% of the
    aggregate purchase price paid by such investor. The Company also agreed to other customary
    obligations regarding registration, including indemnification and maintenance of the effectiveness
    of the registration statement. The Company is currently in compliance with the applicable terms of
    the Registration Rights Agreement, and the securities that were registrable under the terms of the
    Registration Rights Agreement are currently subject to an effective registration statement.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><i>January&#160;2010 Registered Direct Financings</i>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On January&#160;25, 2010, the Company completed the sale of 2,350,000 units in a &#8220;registered
    direct&#8221; offering at a purchase price of $2.50 per unit to certain institutional investors of the
    Company for gross proceeds of approximately $5.9&#160;million. Each unit consisted of one share of the
    Company&#8217;s common stock and one warrant to purchase 0.30 of one share of its common stock. The
    warrants have a five-year term from the date of issuance, are exercisable beginning six months from
    the date of issuance at an exercise price of $2.85 per share of common stock. As of June&#160;30, 2011,
    warrants issued to the investors have been classified as equity. The transaction date fair value of
    the warrants of $1.0&#160;million was determined utilizing the Black-Scholes option pricing model
    utilizing the following assumptions: risk free interest rate &#8212; 2.39%, expected volatility &#8212; 90%,
    expected dividend yield &#8212; 0%, and a remaining contractual life of 5.00&#160;years. As of June&#160;30, 2011,
    all the warrants are outstanding. Net proceeds of approximately $5.4&#160;million were allocated based
    on relative transaction date fair values in the following manner: $4.5&#160;million ($1.93 per share) to
    common shares and $0.9&#160;million ($1.29 per warrant) to the warrants.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On January&#160;13, 2010, the Company completed the sale of 2,850,000 units in a &#8220;registered
    direct&#8221; offering to certain institutional investors. Each unit was sold at a purchase price of
    $2.51 per unit and consists of one share of the Company&#8217;s common stock and one warrant to purchase
    0.25 of one share of its common stock for gross proceeds of approximately $7.2&#160;million. The
    warrants have a five-year term from the date of issuance, are exercisable beginning six months from
    the date of issuance at an exercise price of $3.26 per share of common stock. As of June&#160;30, 2011,
    warrants issued to the investors have been classified as equity. The transaction date fair value of
    the warrants of $1.3&#160;million was determined utilizing the Black-Scholes option pricing model
    utilizing the following assumptions: risk free interest rate &#8212; 2.55%, expected volatility &#8212; 90%,
    expected dividend yield &#8212; 0%, and a remaining contractual life of 5.00&#160;years. As of June&#160;30, 2011,
    all the warrants are outstanding. Net proceeds of approximately $6.5&#160;million were allocated based
    on relative transaction date fair values in the following manner: $5.6&#160;million ($1.95 per share) to
    common shares and $0.9&#160;million ($1.32 per warrant) to the warrants.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><i>July&#160;2009 Registered Direct Financing</i>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On July&#160;29, 2009, the Company sold its securities to select institutional investors consisting
    of 4,000,000 units in a &#8220;registered direct&#8221; offering at a purchase price of $0.85 per unit. Each
    unit consisted of (i)&#160;one share of the Company&#8217;s common stock, (ii)&#160;one warrant to purchase 0.625
    of one share of common stock (a &#8220;Series&#160;I Warrant&#8221;) and (iii)&#160;one warrant to purchase 0.1838805 of
    one share of common stock (a &#8220;Series&#160;II Warrant&#8221;). The Series&#160;I Warrants had a seven-month term
    from the date of issuance, were exercisable beginning six months from the date of issuance at an
    exercise price of $1.00 per share of common stock. During the first quarter of 2010, all of the
    Series&#160;I Warrants were exercised for $2.5&#160;million. The Series&#160;II Warrants have a five-year term
    from the date of issuance, are exercisable beginning six months from the date of issuance at an
    exercise price of $1.00 per share of common stock. During the first quarter of 2010,
    43,266 common shares were issued upon exercise of Series&#160;II Warrants with proceeds of $43,266.
    There were no exercises during the six months ended June&#160;30, 2011.
    </div>
    <!-- Folio -->
    <!-- /Folio -->
    </div>
    <!-- PAGEBREAK -->
    <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The net proceeds to the Company from the sale of the units, after deducting for the placement
    agent&#8217;s fees and offering expenses, were approximately $2.9&#160;million. As of June&#160;30, 2011, the
    remaining Series&#160;II Warrants outstanding and exercisable into 692,256 of the Company&#8217;s shares of
    common stock have been classified as equity. The transaction date fair value of the Series&#160;II
    Warrants of $0.6&#160;million was determined utilizing the Black-Scholes option pricing model utilizing
    the following assumptions: risk free interest rate &#8212; 2.69%, expected volatility &#8212; 90%, expected
    dividend yield &#8212; 0%, and a remaining contractual life of 5.00&#160;years.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><i>December&#160;2007 Committed Equity Financing Facility</i>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On December&#160;10, 2007 and as amended on November&#160;24, 2009, Cyclacel entered into a Committed
    Equity Financing Facility, or CEFF, with Kingsbridge, in which Kingsbridge committed to purchase
    the lesser of 4,084,590 shares of common stock or $60&#160;million of common stock from Cyclacel over a
    three-year period. The CEFF lapsed on December&#160;10, 2010.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During March&#160;2010, the Company sold 1,563,208 shares of its common stock to Kingsbridge under
    the CEFF, in consideration of aggregate proceeds of $3.1&#160;million. During December&#160;2009 and January
    2010, the Company sold an aggregate of 1,583,626 shares of its common stock to Kingsbridge under
    the terms of the CEFF in consideration of an aggregate of $1.3&#160;million, of which approximately $1.0
    million was received in 2009, with the balance of $0.3&#160;million in respect of common shares
    subscribed but unissued at December&#160;31, 2009, received by the Company in January&#160;2010.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><i>Common Stock Warrants</i>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In connection with the Company&#8217;s February&#160;16, 2007 &#8220;registered direct&#8221; offering the Company
    issued to investors warrants to purchase 1,062,412 shares of common stock. The warrants issued to
    the investors are being accounted for as a liability. At the date of the transaction, the fair
    value of the warrants of $6.8&#160;million was determined utilizing the Black-Scholes option pricing
    model utilizing the following assumptions: risk free interest rate &#8212; 4.58%, expected volatility -
    85%, expected dividend yield &#8212; 0%, and a remaining contractual life of 6.88&#160;years. The value of the
    warrant is being marked to market each reporting period as a derivative gain or loss on the
    consolidated statement of operations until exercised or expiration. See &#8220;Note 3 &#8212; Fair Value&#8221; for
    further details.
    </div>
    <!-- Folio -->
    <!-- /Folio -->
    </div>
    <!-- PAGEBREAK -->
    <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The following table summarizes information about warrants outstanding at June&#160;30, 2011:
    </div>
    <div align="center">
    <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
    <!-- Begin Table Head -->
    <tr valign="bottom">
    <td width="58%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>Weighted</b></td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>Average</b></td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>Expiration</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>Common Shares</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>Exercise</b></td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"><b>Issued in Connection With</b></td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Date</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Issuable</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Price</b></td>
    <td>&#160;</td>
    </tr>
    <!-- End Table Head -->
    <!-- Begin Table Body -->
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">April&#160;2006 stock issuance
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">2013</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">2,571,429</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="left">$</td>
    <td align="right">7.00</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">February&#160;2007 stock issuance
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">2014</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">1,062,412</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="left">$</td>
    <td align="right">8.44</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">December&#160;2007 CEFF
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">2013</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">100,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="left">$</td>
    <td align="right">1.40</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">July&#160;2009 Series&#160;II stock issuance
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">2014</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">692,256</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="left">$</td>
    <td align="right">1.00</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">January&#160;2010 stock issuance
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">2015</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">712,500</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="left">$</td>
    <td align="right">3.26</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">January&#160;2010 stock issuance
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">2015</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">705,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="left">$</td>
    <td align="right">2.85</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">October&#160;2010 stock issuance
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">2015</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">4,161,595</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="left">$</td>
    <td align="right">1.92</td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 1px">
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom"><!-- Blank Space -->
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Total
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">10,005,192</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="left">$</td>
    <td align="right">4.01</td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 1px">
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    </tr>
    <!-- End Table Body -->
    </table>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Exercise of Stock Options</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the six months ended June&#160;30, 2011, there were 5,131 stock option exercises totaling
    approximately $3,000. During the three months ended June&#160;30, 2010, there were 124,277 stock option
    exercises totaling approximately $0.1&#160;million.
    </div>
    </div>
  <span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 129<br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 5<br> -Paragraph 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Article 4<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section C<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 4<br> -Section 08<br> -Paragraph d<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 43<br> -Chapter 1<br> -Section B<br> -Paragraph 7, 11A<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 22: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 23: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Nature of Operations and Basis of Presentation<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Operations and Basis of Presentation [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">NATURE OF OPERATIONS AND BASIS OF PRESENTATION</a></td>
        <td class="text">
    <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
    <!-- Begin Block Tagged Note 1 - us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-->
    <!-- xbrl,ns -->
    <!-- xbrl,nx -->
    <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
    <div align="center" style="font-size: 10pt; margin-top: 0pt"><b>
    </b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION</b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Nature of Operations</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Cyclacel Pharmaceuticals, Inc. (''Cyclacel&#8217;&#8217; or the ''Company&#8217;&#8217;) is a development-stage
    biopharmaceutical company dedicated to the development and commercialization of novel,
    mechanism-targeted drugs to treat human cancers and other serious diseases. Cyclacel&#8217;s strategy is
    to build a diversified biopharmaceutical business focused in hematology and oncology based on a
    portfolio of commercial products and a development pipeline of novel drug candidates.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Cyclacel&#8217;s clinical development priorities are focused on sapacitabine in the following
    indications:
    </div>
    <div style="margin-top: 10pt">
    <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left">
    <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <td width="4%" style="background: transparent">&#160;</td>
    <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td>
    <td width="1%">&#160;</td>
    <td>Acute myeloid leukemia, or AML, in the elderly;</td>
    </tr>
    </table>
    </div>
    <div style="margin-top: 10pt">
    <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left">
    <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <td width="4%" style="background: transparent">&#160;</td>
    <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td>
    <td width="1%">&#160;</td>
    <td>Myelodysplastic syndromes, or MDS; and</td>
    </tr>
    </table>
    </div>
    <div style="margin-top: 10pt">
    <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left">
    <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <td width="4%" style="background: transparent">&#160;</td>
    <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td>
    <td width="1%">&#160;</td>
    <td>Non-small cell lung cancer, or NSCLC.</td>
    </tr>
    </table>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On January&#160;11, 2011, the Company opened enrollment of the SEAMLESS pivotal Phase 3 trial for
    the Company&#8217;s sapacitabine oral capsules as a front-line treatment of elderly patients aged 70
    years or older with newly diagnosed AML who are not candidates for intensive induction chemotherapy
    under a Special Protocol Assessment, or SPA, reached with the U.S. Food &#038; Drug Administration, or
    FDA.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company has advanced two additional product candidates, seliciclib in Phase 2 for NSCLC
    and nasopharyngeal cancer or NPC, and CYC116 in Phase 1 clinical development. The combination of
    sapacitabine with seliciclib is also being evaluated in a Phase 1 clinical trial. The Company will
    determine the feasibility of pursuing further development and/or partnering these assets depending
    on the availability of funding and further clinical data. In addition, the Company markets directly
    in the United States Xclair<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> Cream for radiation dermatitis and Numoisyn<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> Liquid and Numoisyn<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup>
    Lozenges for xerostomia.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As a development stage enterprise, substantially all efforts of the Company to date have been
    devoted to performing research and development, conducting clinical trials, developing and
    acquiring intellectual property and raising capital.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Basis of Presentation</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The condensed consolidated balance sheet as of June&#160;30, 2011, the condensed consolidated
    statements of operations for the three and six months ended June&#160;30, 2011 and 2010 and the
    condensed consolidated statements of cash flows for the six months ended June&#160;30, 2011 and 2010,
    and related disclosures contained in the accompanying notes are unaudited. The condensed
    consolidated balance sheet as of December&#160;31, 2010 is derived from the audited consolidated
    financial statements included in the Annual Report on Form 10-K for the year ended December&#160;31,
    2010 filed with the Securities and Exchange Commission (&#8220;SEC&#8221;). The condensed consolidated
    financial statements are presented on the basis of accounting principles that are generally
    accepted in the United States (&#8220;GAAP&#8221;) for interim financial information and in accordance with the
    rules and regulations of the SEC; accordingly, they do not include all the information and
    footnotes required by accounting principles generally accepted in the United States for a complete
    set of financial statements. In the opinion of management, all adjustments, which include only
    normal recurring adjustments, necessary to present fairly the condensed consolidated balance sheet
    as of June&#160;30, 2011, the results of operations for the three and six months ended June&#160;30, 2011 and
    2010 and the consolidated statements of cash flows for the six months ended June&#160;30, 2011 and 2010
    have been made. The interim results for the three and six months ended June&#160;30, 2011 are not
    necessarily indicative of the results to be expected for the year ending December&#160;31, 2011 or for
    any other year. The condensed consolidated financial statements should be read in conjunction with
    the audited consolidated financial statements and the
    accompanying notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended
    December&#160;31, 2010 filed with the SEC.
    </div>
    <!-- Folio -->
    <!-- /Folio -->
    </div>
    <!-- PAGEBREAK -->
    <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>Subsequent Developments</b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Preferred Stock Dividend</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On July&#160;8, 2011, the Board of Directors (the &#8220;Board&#8221;) decided not to declare the quarterly
    cash dividend on the Company&#8217;s 6% Convertible Exchangeable Preferred Stock (&#8220;Preferred Stock&#8221;) with
    respect to the second quarter of 2011 that would have otherwise been payable on August&#160;1, 2011.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Board also did not declare the quarterly cash dividend with respect to each of the four
    quarters of fiscal year 2009 and the first, second and third quarters of 2010. To the extent that
    any dividends payable on the Preferred Stock are not paid, such unpaid dividends are added to the
    liquidity preference of the Preferred Stock. As the Company failed to pay in an aggregate amount
    equal to at least six quarterly dividends (whether or not consecutive) on the Preferred Stock, the
    size of the Company&#8217;s Board was increased by two members and the holders of the Preferred Stock,
    voting separately as a class, voted on May&#160;24, 2011 and elected two directors to fill the vacancies
    created thereby, which directorships shall terminate when the Company pays all accrued but unpaid
    dividends.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>License Agreement</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On July&#160;11, 2011, the Company entered into an amendment to its license agreement with Daiichi
    Sankyo Company, Limited (&#8220;Daiichi Sankyo&#8221;), dated September&#160;10, 2003, relating to certain rights
    which the Company has licensed from Daiichi Sankyo with regard to the Company&#8217;s sapacitabine drug.
    Effective July&#160;11, 2011, the license agreement was amended to irrevocably waive a termination right
    Daiichi Sankyo possessed under a provision of the agreement that required the Company to obtain
    regulatory approval to sell sapacitabine in at least one country by September&#160;2011, and releases
    the Company from all claims and liability of any kind arising under such provision. The amendment
    further provides that the royalty due from the Company to Daiichi Sankyo on future net sales of
    sapacitabine be increased by a percentage between 1.25% and 1.50% depending on the level of net
    sales of sapacitabine realized.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Financing</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On July&#160;7, 2011, the Company closed an underwritten offering for an aggregate of 7,617,646
    units, at an offering price of $1.36 per unit, for gross proceeds of approximately $10.4&#160;million.
    Each unit consists of (i)&#160;one share of common stock and (ii)&#160;a five-year warrant to purchase 0.5 of
    a share of common stock at an exercise price of $1.36 per share, exercisable beginning six months
    after the date of issuance. The shares of common stock and warrants were immediately separable and
    were issued separately such that no units were issued. The net proceeds, after underwriting
    discounts and commissions and other fees and expenses payable by the Company, were approximately
    $9.3&#160;million.
    </div>
    </div>
  <span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122524<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6921930&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6970148&amp;loc=SL6228881-111685<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Name Statement of Position (SOP)<br> -Publisher AICPA<br> -Number 94-6<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name FASB Staff Position (FSP)<br> -Number FAS140-4/FIN46(R)-8<br> -Paragraph 8, C1, C7<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Name FASB Interpretation (FIN)<br> -Publisher FASB<br> -Number 46R<br> -Paragraph 4, 14, 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209116<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -URI http://asc.fasb.org/subtopic&amp;trid=2134480<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 2-6<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 915<br> -SubTopic 235<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122150<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6359553&amp;loc=d3e288-107754<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid Expenses and Other Current Assets [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
        <td class="text">
    <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
    <!-- Begin Block Tagged Note 4 - cycc:PrepaidExpensesAndOtherCurrentAssetsTextBlock-->
    <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>4. PREPAID EXPENSES AND OTHER CURRENT ASSETS</b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Prepaid expenses and other current assets consist of the following:
    </div>
    <div align="center">
    <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
    <!-- Begin Table Head -->
    <tr valign="bottom">
    <td width="72%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>December 31,</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>June 30,</b></td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="6"><b>($000s)</b></td>
    <td>&#160;</td>
    </tr>
    <!-- End Table Head -->
    <!-- Begin Table Body -->
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Research and development tax credit receivable
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">660</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">998</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Prepayments
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">317</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">476</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Other current assets
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">405</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">214</td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 1px">
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Total prepaid expenses and other current assets
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">1,382</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">1,688</td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 1px">
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    </tr>
    <!-- End Table Body -->
    </table>
    </div>
    </div>
  <span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Prepaid expenses and other current assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>PREPAID EXPENSES AND OTHER CURRENT ASSETS</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accrued Liabilities and Other Current Liabilities<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Liabilities and Other Current Liabilities [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED LIABILITIES AND OTHER CURRENT LIABILITIES</a></td>
        <td class="text">
    <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
    <!-- Begin Block Tagged Note 5 - us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-->
    <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>5. ACCRUED LIABILITIES AND OTHER CURRENT LIABILITIES</b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Accrued and other current liabilities consisted of the following:
    </div>
    <div align="center">
    <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
    <!-- Begin Table Head -->
    <tr valign="bottom">
    <td width="72%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>December 31,</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>June 30,</b></td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="6"><b>($000</b>s)</td>
    <td>&#160;</td>
    </tr>
    <!-- End Table Head -->
    <!-- Begin Table Body -->
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Accrued research and development
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">2,793</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">3,343</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Other current liabilities
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">1,339</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">1,116</td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 1px">
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">4,132</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">4,459</td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 1px">
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    </tr>
    <!-- End Table Body -->
    </table>
    </div>
    </div>
  <span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PayablesAndAccrualsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>26
<FILENAME>0000950123-11-076776-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950123-11-076776-xbrl.zip
M4$L#!!0````(`"M[##]"5`-BIW4``.Z\`P`1`!P`8WEC8RTR,#$Q,#8S,"YX
M;6Q55`D``R%^14XA?D5.=7@+``$$)0X```0Y`0``[%SK<]LVMO]^9^[_@/4V
M;3JCIYTXB>UT1[&=KMO$]EC.W/;3'8B$)#0DP25(R>I??\\#($%9LI/;QL[N
M=+N[M240..?@/'[G01_]XR9-Q$(55IOL]<ZP-]@1*HM,K+/9ZYW*=J6-M-[Y
MQP___5]'?^MV?WES]4[$)JI2E94B*I0L52PF*W%U)4Y,EJDD42MQ+6<S5?A=
MQ7#0PW^&SUX=BF.3KPH]FY?BZ?'WK:>Z77?&&VEA3WB.#MOM#>MOCMUY)CL0
M+_O#W?[N8#@4>P>[^P?#EV+TGA?>3(I$`%>9?;TS+\O\H-]?+I<]_+AGBAD\
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M*+SHCL]^WOEA,`"B]@;#_?VC?O.8W[C?VODH5X4V<7`.B;'\`8GI#G=!.D=]
M_YG?(7CFJ.]8NH>_P4]5!K(:?$7\#0>LP'\F?\.OB;_AG\@?Z^?7=G]_2#^O
MP8S5>_A@;D^S6,5?T24".T5Y`O'"7>,S\%-'_>;3>J'*XF`9W[;_[/.D,=8W
M_QZR&'YY66S5C,=7_Y8T!I^F&8,OHAE?GRP^13/^H"PN,O7/*HL+%8_5`JA;
MG>OLJ_<A@.OVNX.7W>'>%[`;P#H?,GT+Z%3X&4KLP_CD]')<2R/6"^"D.1S7
MG0,B+V1IBOIC^")5TE:%^L&!Q@/8YZCO/ZP?[V]^GK8]49E)=;9M8\*3!W8N
M"V6W[7Q[BZ-^P`$O6F-X3#O6#-]_W,9=@-U;6VP51;@#W,=U!5AU_4+@\]-$
M4>IS^QOQ1LUT)MXD)OK(&5`LSDVI1'V=C)D/+HJ9S/3O$I\'B&M-HF/Z993%
ME\`9;$^_7DS?@MBR2,MD#)_0N?9$VR@Q2/4UJ`\?YG3I"@'U?2'HVZ0\!&)/
M+HZO?[T\%?,2LK_+#V_>G1V+G6Z__S][Q_W^R?6)^.6?U^_?"4@'Q74A,ZN1
M()GT^Z?G.V)#VG-]U;_!O8;XL/NQ6P9/]N(2L'VW^^VL/&Q1LE5L0]$57TID
MF^A`Y>ID=B.-_-W-K>]`CX4M5PGXGRE(O3N5J4Y6!^*[:YTJ*\[54ER95&;?
M=>B#C@47,#T4J2R`YVZBIN6!&.CL4.S<WE<F>@89>00LJ&*G=8S5OZL#2*OS
MLMZK-#ELE9>T$6XQ:>_87_\=CMAZ)A+V:2<.;QTY[(GST?6'JU-Q\59<7)Y>
MC:[/+L['8G1^(MZ,QF=C_/SRZG1\>GY-7STH=?B#QA_.90D*(<Q47.3H^$!Y
M+)VL_;(O2-.A0'OMZ@SCT8%X]H2(/':U`7$)#BZ%GZI21S*Q'7&613WQ]+OO
M_(IO99H?_OTE^+'#X$=A"E'.E8!U)LUEMMJ\['NAK9`BAMB;F!PMI`L!;::8
MKXDV>>MX\"ZT&3P0P^]8?BD-G1/L(&06XT*((6A[SE)1NIF!11W>.U71',S8
MIET(H#.%6\5%-;.T(99VQ+P"8Q$1IDR%I4T-G`1!'D-G946L+;AL97MB@R@L
MR!]N4LU6P"&?"!M/*IW$R*^F<A0$_W@#DY/*`@BQ5DQ-5&'Y"5P2UC!*DQC8
MCRC)(OYEXNM3D@_)35%.P2,9Y+<1@L@+$U=1R7RT!"YRG:L$#JPE1()`QF-T
M;,#@(^A=2Y01D$>2:9$-MU"`0P?7!B&XEA6(PLI<1KJ4$V0*9(?Z`3))S%)G
M,Z8<3D7]04,[N(\[Q]!&6VY6PG$0HY<Z+N>O=X:#P9,=,3%%K(K7.X,=`1PE
MN8RYD.E^MTBE^WV;T$A$)-X#0>)=.[00"R=\H&O[-J@LQ8'X^X#^<PA:$WV<
M%0:`[X&@P)B#"+-;N\>>'[@<O_==C_*E#?<'[+/*>-M^>[!?9I8%5O/XWSLM
M)6J[2:<*N_N!*[SG@.&33R,(?Q]%%43X=`6:I6.0<O51I5IVT(.-WK_K>`U2
M"5QFLMJ\4[\LUC]`??@4I_V7>OUGJ]=[5*QX9?-$6O#OPJX@W30(P%##WI^,
M#]$G_Z55?VG5YVC5.:1[-I5)0K<BDBJ;.:A":G4^/GYWW/NSE>I/C/,7F?A)
M9I4L5@V[PV%'8'K8(7_K<*,PN<H@KJNL@!!.D1]P"BX8GX)[/AV/`<`L3"D)
MJEHE]N"&$?%,3>%P5[-9&Z"%,,$4B"YE;JL$`06"TFF!K!$R(D#HSW:!0.2`
M'S"E$Q+3Q!<#/FVE)*!%N`*#R^!JR[G(U!+6QUK.,H,8!>@6R[DAW)*9,H!:
M2#4$G%)!KKI`\(*@#=$K%I8(?LI\Q0>!,L/^4HQS10COLC"E`9L1(PN@U"*U
MI`KCRU%'`/VP0\SDH$`^],8]\=:86+!,!GLO#\4)XKY1G`+:(O0*!^,6?-[;
MD]%#`L'K0`7F>!_Q`M4;`/\2!`=.B5-Y#VP#&78`H2<ZTH`:)QB\62UV2;1D
M%TPS`N%,6@+?JVRFZ/[1@,A^+H\[M.+XU^/A<+_99K@1C/8$D@MP>X*U)<XV
M^)26DI'T0^*`K<1"6J#`I0H%7K&BG`9.D[?/([7FD[Q@ECI)^)P8,I@B)5U%
MM`N)B9[H1)<KU-B\*FR%1TRK@E*8M6RI#QR#1RPSR&Q@%2R!DR6H$2AWK,#^
MXAHX&P9#<B%U(IL3IA6M(9'Y0QI!R5+V(&^LKZUMX*`/'^DD7:BH3%8>H;.>
M9AHE0@44*WZ!Y$`7J&VVRC<HV,OG3PZQTT]YE`]!I%T8:0+G^N(9.U?8!C\5
MV,Q/24,*"79*5PCF!3D7$,Q)TWF5&@W!^PN<_D[_JP+H^65/8;&^,[\K4'9V
M-#>J,+8T@'8?TK)':QF_H(Q?4&D)DCJKP("K"34`0>'!<6*44U,@&)3$^7ZO
M.Y!3H\V#AP!O.5$J\]8`$8&+`[DJX,D4E1-K<[*(YB3H@(`.%BW)T6(0;9D;
M.!.WT&FW\QT17!C9"OKJ)`&]K=@7P7$EI^B%U)8VE#G8?_)E)+REH/0&S)]D
M%=8C'[FBQ!X2/\,0&-6%4RR!<&-:V+E2)09?H/RG*E,---@;A-!@\S;.X=:E
M5MS%U/4T4GA\N,1>(-V0U3<BI?HT*%\,NVT^D]9BIXE^@"WXH"V\M,^/I)V+
M:6*6S?F?>VJG"5>%2NB,N"XB6ZJW2YUQU"#7'+DB&2H?H`M7'ZDR6<7H2WVL
M<M37S-Q]'2<J4NE$%0&AC-8&&,7`50)<B1$RI4P$G[7A?J:^)AY*2F=14L4-
M#Z,L0WNZ4EC.PICS%DP8=*O[<RU&Q%E.@!MIX].(P*E.0N@S5E'E"T<@U-,;
M+`3.R*>DVM*0V-,:O@\.QZ?']6_#P^_7Q/>I'.(5Y&R,7*1"2B;>3/'.JHS\
M#WA`>#A'%%K.94D/S@`!%^@*O?>)5%XVTFK'R)#V'T>CRY#X&EX6.@WHU!FZ
M2(YZ*!+$'T!1$9,:>,'QX04#9-+&694XXZHA^?&A>Q1X259DKH!\#<%<=\OD
MSW'UVK%.>L:4K+6%0B?+$WV;!53+Y1Z1(->2:L<)P"3G)Q2!^4V715@%=T&O
M[TK'J<P@2'&T0/IE_%ME*26`$+&<:X@JGCV3^8O*D+T$&`&%HVC1>BH#M;46
MP">%*=8-,05\`_QL]W)MZW0*<:_'A-VKY,]UB8&!.;_XA1TA'UA'>KB26+$U
M>HWV7/X!OC@C<]?G+DC#A?B"\4)Y7?>'85D?T,L-I&'(]KI_PFO?ZCR'F&O4
MB2IENP2=\>&[',UF'V/GIDIBI`;0+)D"//-;E7$&B6;<),2;'/06SQ4&O0W!
M9=UW;TJU/\N?\TEW!)QU?WYZ?">XPI[I6VJ);.JF]C=_M7F;R]&/IV^N3D<_
M/T;S]8\@PS$`:G"GZ&%.&N!K'Z?=":!TJHJ"_#,VVD]H`,/50!\/H&))JDJ"
M>M3+T(.^,;*("0E1FFH*B+3X>1!M:4DKW,8JTF@:&/TP55&0OQ:<HO^K@H0;
MZT@.@*%_C)T@/#[89$K[3^#CC/(_K-UZ]$*%W'7!AE!@[;L6F8UK`*>&?LQW
M5:U"_^-I1>[):1$P69*S(7=,3FL)F1L[YERNB!S@8E3-(.`%)3X6Z4,7DOCR
MJ-82:[Z.C7>Q=@WD8@*18!'-N_^IJ9S;=D];AA,6<T=R9CAP78?&J2YLV?$"
MY4]U$;<>1N<&7I]%#YR@M:*HF^C@*;.AC''U^LW[RF(N=8SI--!=9?A+L`6N
MD7%<]]#YF(1J$5C6R6E/A5C#\;QV2D^,;"L;!_"2N*Q;K@A%PG]G,P"*F*/+
M%"$<GP*^"%-L(T"1$B5M21&ZN8>&RJ?+N:*8"'&":J40L`!/823^?@OWG88;
M5)>UFD'+FE@QEI+"6*&HF0YP$VN,*86?.OZ).15T[199N'QC80BC6I5+[/XC
M,L5J!ZB:!<3'10D@^KT,W,SNLP#HJ(1A!%(0UYX&!`5!CU'S0F*9$K(7YSC<
M:R@H(S59>3!:/SO7.2(#PMQ4(<2K`)FV/`S>EV5<&T5%A4*H2J<QKJ+B+^1!
MZQCO=(3@1XQ`APB.?&TA8G/+@DI9A(A0P\$&@/282EWPNP9,E3B^I.>+7<V)
MU'!WFLD?R^SCRO@].^*=3@FQA4[=/>#6ACZ](QC2C3$M:N.H(8'=P5Z'ZPE4
M\34B@H@BP63I?2BG6ZQ*(6=8B7?$NVR_38)WF3,T*Q=$[NV]X+B)4ZO3Z11G
M&2&FW"7G#>)#,TL9VJ.,P3`7)@(/N8*O<#M9:S]B86+2X<PV_;FA[@ELX_LK
M>6$6VKHTD*!S?2K%P3I-7:M+F@G*TX=52I4-Y'HRQPW9^5ELW:U/J]0>T60(
M_\%EPE/@DS;<)$O$589H%NE6QXLOB?J$B=0IN[-$!Z5[7/118U`JN&#)C%/,
MJ'GG9*368Y>JNT(_K8I]P8)R([.2"6P?5ZJI"06R61,ZR'9:T0A<!EFYE9C;
M;VR@3%3;3TLL[^)0(A:0)ZI<(OP8]G:?/R$^A[WG@R=-!\.'BP01,$T[^03:
M']D^#<Y)P$7$#^KRW,QH-OO:7-V+39X.RY`*\0QKS;+0)<`6D.246TE4>0E!
M`,CX16=_"/][MN_[F!JK(5CJ"A[,"\VXXYMA;V\?KYD6=FC'60%6BFH7*15S
M`0VMZD:G''._`1SUK*$<,K$$==BY&$E@2#.4T);K$T_U]\T#:'DTV.V'Z'"H
MC'$5:-53':Z5$)D7JDN(;RF+0K*7SZLBH@;>H/>\UF6Y;5?B7=W@K)Y5FWBG
MYSI^"2&_"8XJ9X0VZN*&.V:*8)VF(IW(M;45%HW8C'EF?2-OC@,KEA#`A$Y3
MA=TPE"E#&CRXKOWP&M@:JST-XB'/0:X@,WR[X4HF`>W<WU_'$5QK4-ULQ#HW
M.D!;CW1R?3:<QIPJ5X[$"@P$A08:3U:AJG:8B):B\"G?O.KM;5.6S:86?G+4
M_U)SX<TP_RFPMWV4_W/&_<?@'_14`X(L1W5)]=)@1UK9__0A_MU@B/_3!/%O
M5N79[8GQA_?O1U>_XES[^.S'\[.W9\>C\VLQ.CZ^^'!^?7;^H[B\@*LY.QT_
M3NVG91A?04>R5=#\G&*KK_;[EEN5U=UI)MB'2&JHH`^$!#)9=<T2>W78X(8L
M&R"7:LK5KL8,7_/;6182;`2(C:IRI=M1[+`>FH2,RMHMNOZ`#2KE*M&<^#TL
ME/E@*?B<VI+\[6._TH#7G1<<IQR<WW*SM[I?V$?S0-\&O2",]*G\Z&Y<>49Y
MR!["79KSO7`GCW(;USO`0C@"I[16')ZWZ=3@7-=MMJ3I+8:=7XK?Y+=HC(?'
M=4)X3SN4+2#`I:C[JOR;R`-]-ZEJ1]JX\O-"[A%";J2[[3DER,:T6EJT@W51
M4>\/_G]F\&'JB/*S@30+U;SG,`?$9@J:T$`ZP(#PEOB="+&0]&J&&U4B?'#K
M&D+X.@'+@&3`-W$PL8#0@N"!DR!J:NDBJE+^4Q1HD33J45=+J0642JQ8(72M
MLQT;,/!7=^*3HP.67VGL#G\X!7N#3+EN5#SBVU">+JH/JX8NTDTRHQA-+3)8
MY'7M8+LVQD0%=8DV9*G-BU/0E7+*$5H+Y254:\2\?:YG<WB:Z[)@AJ"NW$%F
MUX3&4VC@`0PBQ??(7%K/O4_7\_0=Q@3?*G(V`,JIW'`@9RIL`^L<M@RY_5;.
MNBS6QA1\A`Q)!M\*)"D_]$=S@Q[=%^!!T$V%;RU)L/`'C5F`38'DD0_H5RI2
MP)]+>S`<FR6%!8S9)Z::E-,JJ9<_LI:.,E28@,#8$U@#%&U]M2;NH![6,P@=
M*HX0\T7-LZW=;EU7`K5U#1&JJLUXPJU4,U/X@!5XZ,C0;!Q&V\99=T0I/[K9
M.5,K.\7DIGR%?Z6'M%.N<*0]V!./`!Y^XSIY<(*IRHC?JR!]J@H<\1?8<#&I
MCA@;N3?KF@DN'42&B#I:09AVFP?%LFWUS$!FKE067H2+W9MN@R,CW0;$<(&C
MUVF5TFW(H!_BXN(Q]?IL/>KU*8>@AP+R\+6.F+H163"&0D8O<1IR4OJX3GX%
M3G#F'$P]!I/A"U7#@)YX+W'^@B9=N%Q(`153WF(1!G*,DQPS75DRQM<@0<XU
M6_YB-JC-VN0S^#G"0-.`TYG$/QQS6S2WI>+KVP".@Z`?GNOF31L0766VBM!:
M:!\"]7B!B?ZHG'-OE(`&LYM!D@G?P`*;`H`@RKN&&W#G;9,\&`Y"ZZ2*1HS%
MZ,80X(N'[*Z^;8W:W#]B,_#C/,A.JVCW\@47;5_M/ND$/@:'R'S];)OU^7<`
MN(R[<02,1$4-":03<S&%JPN+;T&LSR,YC/K_XF+/<3'<P,5]#(3%Z,_DXB%C
MY%F&?RG%%*O'1F7^'74"4I:`!M(5Y#W@!'AN`9$9MI`=[F#HU?(H]1L4EA:[
MXK3U"0XU\(&"COL)HHU(53G'5&=TWXCL?48=4!Z45JEKS"^)(V1$WXOO\,P,
ME09"VB$A35:_*TJPZLU6W.BP34>IB2>E<1B-_PC-BKI`H&FI"X7HJ<'U:II:
MU6@@AO2R$^Q."^?<WT;I\C2K1I^-;K+58.%6"KE&$CV]F=1LU7JH'J5C0W!I
M=]J`47]3[3=MUN8$FLV1.,L>>:)"2NJ$OHE0[9IQRT:;K-\9VTA$6*R.:(`V
MKR@:N#864PX11`%(7L/0/G3%9IFYACX(A%/L6K3!0$8P"!)*S#9RPLD4OJN)
MPC/=^T36`)I!,4\=F&GNZ/8UW;JAGCC#T$KO-3BC"?`2@HJD!E)3N3#<&P`J
MD2E#70R/T2:K]OAL\_)6PP\)I8LR89@P44UCU<,")UQ?''M(EW>%?QP*;@GR
M`3/+](,6+W=:E%R&L:ZAX8'K:$UAA^3Q.]DIBXB073LB$\Z":[.5I-<:%<V2
M<(\+X2CVG%@[O,IC6^X0##W!/Y3!8P<F(DA/*HW`4K=KG`6&:_CZT`VN)4G3
M1D3#U#?TJ$/)WH.`SAZZ]+,%]0F9.URXHAI2\:6*IVM"?GE;R-0413?K$3G_
MS5H07J'`(C+7UV:;:\3.>1"*SN=8*JCQS2K-!4[P!*/QL=@?/.\.GW?"><:[
MM%]TG2*&26\S?]*:4FFV;TT=4D+-7XDN!,D[3F:2P^-KU[Q[*"X65';X#$(&
M[3<Z/OAB'X@0Y4)_#L6V.]UUED$M[239A-D:M!`<BJK8!<!FJMD\),R#A_IP
M$:YT7W=JLP*-Q+!6&YS+R:H<^[=SG?NWD[T*X+@IYFIZ4N$8&+[38$LEXS97
MG!CB"SQNF,T?!\&&NNR^E+,P:$C,)AL5OT3G'F-X-74+9-E$')P4=6-$&!4(
MO#"\F:ND\>UU)%@O'-_R+^1,J,?<BH84[?ZOO7=O;AM'UH>_"M_\,E5)%2V+
MNFMF=ZH<VYGQV23VVL[.SE^G:`FV.:%(#4G9\?GT+[H;``%>)%D292K6ULY,
M8I-$H]%H-/KRM&0>!.`)4\?#"WEH>IW3?5+Z4I9-OD>^:LS:/(!BV2>]?L76
M75[DVTAK6R@32"9,Z>$<?85RV:;D;<E:<S(9=&R*2W;&>C::LF[DM$EMQ(5.
M=?$[J8A-#SM%W%V1E*@%-<9L@J6_XBHUYXZ#Q?6/D/CD4O(HQ1B4&:>69G;S
MEV`$D;3WHB]Y=)QD]S(DQ[UM-IQ<D@-LS@7WVX9UDMWCM(5QZ_`O"WDT\V^Z
M`[O9I(^\Y7<<_N=5QC8OT!7;>R(Z[?ON32BA#\H+AN$'=YCK(YC\(I;8L<C9
MG.N81/+(8N>346IHE$[U0<MI-'6'O+P5*^&E++J%QIPX0!=9=+?,L..>:<()
M*15V')=I\P:I+H]D`\"]#AR:>K$9P_N=TICIA<9@]U^S\1VR4>5]NE@*B5,(
M%,R?J!\CX1(5ZDP<S2)HE&;=\PW#57@(CHD)7M1\6C-YAZ>#53^N)C-(J$_@
MQBL^;FLU>EF?MCC@*-6!P>EQ185D>;>LNO^-W!D?TPR$&Q`4.A=E,0)0#R>$
M3#6F^UP^C2$U>E)K1V02/N4"S<)K?\.D-QGL=3R4MF2PB[UX6:(KU`Z4<4%M
M(XH48[7W9$T;%(:`B2&20Q3W.9/P]"X9"=CW@&%_.^?U)XFC159[S:7;-$F?
M8-9G*6T0>DEKEX,P.(@8A.M4,$Q;'#>C&6A^&&&2F@'<`&(7CNXAZ*Y#^8"6
M)T>7)NQ28MV;6*H6F28@B*9=<L,7D0I:&]:1U%DR<X'<Y0)3A2!DT$K6/I!E
M5=86;EA?PD#;MK2<&=4X5E`4]#G%*4^^QLTW.B_$ZE&$0=KU:6QAFT+[FWZ$
MQ70PW$&<(B"!XA?.D0SK<:O_`>:G)G`+>%INZ@\RY4%+)B&I@XH?6N-2`29/
M'7R+&])X/MC\@B/K""")24D,>B4UVP,RZA4(#:T]94_=43ZKD@.IC-(EVJHC
MZ5C"BUQCP"S-/7QA7_J)F[BZ/H>EF83\LAUBB@\<$[X_S]#(X*:8ND7M_;P2
M"[6LV1AQ92_/XS*PV%!#%4JE*([#D4?8!_#Z4>GK1F:7\!K+*N+"*A5^#H^Q
M[)-JYM&A%')=!OE7W%!ZF@(E$-L!HNE2!DE20(-U`\<OQI/XB72;LW.T4U]=
MK<1+9&3@S5Y7AZ0V,YE55*\5\Z,$7@4KW5B'-%=+62Y:ZM6M60XA:1,7,;5X
M6/8HT[J.0Y$Q'[,$.<(W*&5X""T,>66>1%W`4VSD3<G0*J\0%])1($-B`F,C
M&1W/FQ(EDH:ECTU6`%52"F-4";Y$$!90;CK('%9'BF(X-];`WB)FUG=A]).@
MN8X@B`(.*ID@)HY0A"J0:FR4IXIL5:4]<>79=ZQR3,N.S/>$ZDM-!RTQ;[P<
M?[;K/]>HT2K0K=/O6)P#AN!+I\^46G!J#XF"$3A\)@0+(2*+<:J$QG-5BNGC
MT#'K9E/$&T0+W-;VO8VX)7S\%)Z%W#"**D0MTVB7+FX-*IFK%NQL!J7`TZDO
MCW3]F8G(X<`!8^'GA`G/_,25`F;DHN9TN0VN(;I6X"=L.(GY_D\!N&6N&=]T
M;'0?I'C68S:-`,8PT>IT-,DP*A7+[5]=75!)+QH1VZW?"B/&OR;RCT9/6C(2
M_PM><_Q:)+_K>>,*:6@L^V,(BQECF.9TT-([$-TJ-!UX*X!&I&Y*WQ#>8)F0
M)?&6,-E/E.3I^<G:59!4JJ#!_.R!3BKD%":`I%.6!1W1O9H@,/PG8P:0^46T
M2:>G1B!<VV`_8VH1V!\^%HAFC%W))?7J.WKL_2&])PX^E6\M$I1U,)YM0R*4
M<&J.A8>U!X$ZXV4%`XF$%&SI7E*9WJE8I!*!,F-FMHS!'15AZ,#D/Z3L`]@D
M&O8D204(2"`_7%@@$*1>Q%0"\2DM4UVX#1`3+1;@!Y)X<Y643SI=);S$\UN=
M[C#/#5;\:73%_ST#[:@[._9N[><H+%^<@BF.EBI;#@.M:@?Q.V>,HF"W`L8B
M5B7"KB$HZLPT@>_$]M?"%;-`E@3G=WQ604BR8#=H+BY?G85Z*0]_R=75,%RW
M^,^"NP-PJ1VD&=3"AYCQ[X`+&&P">2Y/^)ZY5Q#"D!2[U2/PA*&K`$:'H&,T
M2[&&7O""FQ*E`]\I\I"C^IF@I>A;6K5@ZN)-Y<8L54EQW;Q`.455&IGZJDKB
M3=U;?\\0($3/42-_?)RO,-)K8@@X&.2*HL9@5TD;3Z]_$:FBZ##A-BQH)2)"
M"(Y9Z0*GQ(Q*N.0>2HS/09X.>LA=93V"5PNB=N)8E_2.<=XT"DU>1/VDCZ\X
M=%&`6;==6PX6ZS]([V>2C#I(\ADDF\7JA$G=[IIL&;5MB'0=!@?:3TK-)"$)
M(J,?;Z.HQES]Z_<>7PYN@8L<0-F)!0)$X0UX$92/>!9H/_"(<#C]9>0"TEAO
MHM`=B^BV3=;#)W1).%HI#09"(``)H7CXF@USI^?:F><PV5$Y'_%IZUW,C*P,
M+`AN&VDD9:MMI(I\3EUDLJ@-C5O)L+2T,"/P8O*8UT\FB#<2Z7CH:W.?C``*
M)/N1<UA'B<0C!,K,W$#D'*;'"_BHE2LGHVJT!0-`&KI`*O61QGDL[(&(QYBA
M#`A"2@;1(.&3#CVAPN0::R$E(H_L=P($D*2GB9BI!4UV'2*?::G>N9K"[28Y
M8[WCM?O]Q1T3&7]?FH8D:C(3H%&K6$SA7;(Y1EZL\HIDE$.PV_T^[^ZD)'.<
M2@U>VY1MI4RKD@K3-&T%AH*/:$6ON3%)Y[#`I?Q6_@99:EX@#Q@#-I+_6$$5
MB?N`9O1)MX#,E94%/NYWH9700,*=+ZQ+63LBWHVA00;E7D-TBT8P]B7GXVS$
MTLB1QDYQ.Y;Q*)V0&PUBIJS*C@;3'/,0/=<IXHIYYON:"9!6OLAZ&"^)"TG3
MES*3%XE?TK40A&\AM5B5N_`MCJB&V9):W-YJ;]-]C07LUDMB;7.'JL'`2_64
M<,?A5."FI;F0FDM80QP&69L%(FJ->5_&SK.E4T\Z!4=<MV.@2Z16]CM-VU**
M13N$SK2OZ*F!J;[)9B_R3YGGD?BABJ"*G"J#>)$I6#X#71>CUV=48(X5EHW?
M($Q@/(J\&[(21`&;\G/>2%4$9WT,&'H`Q<5E<!H2D`?YOB6$%L#N<=/7R&,W
MB3/TBXBII,C-+Y@&#6F4*5-3H==DJM1S"2^,.`,\A28MHU-T5B)VEW2M_,ZM
MD(8E<W*U]BW',VCF(%(7A7OE7YR#XW!BK"1H/N5,'M%+ECOCNQ**AVTM,*9E
M(U+X]FE>'P7A.)9N5^7UPIIG#<![^X<Y0C0>D+X[UMSI-3K819R:H)C"J4J$
M@011JH;!WQ">$OGB,[\"S+E;?DEED51);#+UPR<)D)3"2::F0JO9[%E'`C@/
M'KIDHIK]E%Q57$5!A1"_Y%WXK@F,C^_"3PW<02$]>!PC*A]&YR7L)9<:#=2O
M9Q,!&#C5W;.N1E$D*0(X6:YD?>T#B)S9'.#I20,K]0Y8KYAIQJUN"..BBTA<
M7&G^`BR"N">$PXBU3'U7@*0;C)06AN"FN*"+I\E:0H6(?FGH3#GS$4`\=_WH
M&=</DM$/>1E-N5LT3]T>3#1":(YX/#B#XK1^?90\*64;94YN/1_).)WVKLTE
M"_>)=QK"3'K_%#!MZ4)A&JXL0M!EUWUTX0PR7%>J=%\&6"AI54O?DO=58PQ(
M`1)7,$X1AJA%<H!TGR,!-*`T:85M%UK@K"2#UO1(Y#16H1HC#8=-10HO'<+\
MGD&I)>8A$)H=3HR-E4=)^-(4EEYIWHH.@9>)1N$W-8".;.$A/7"`CVM3!=[H
M>EPRRHLUAYBJ%:'/?_!=OI!7(RSIY7IC#,%:HZ]$C`J+"K_Q1BVR^M2-XB$$
MY[*\@H<S@1I(++#3:S4`DF!*!J1V2,S!&W;O/D"AIWA5:3R;'-4L3AWB08HB
M;3UYS!^;3LJ43!I=E0'*183O:P$4:`]F&_@0*L@M0DBN4+0:_`'510F-EXY(
MR:`"8P#`1J1?4H\8)*%B7!"K+#4CTQ0Y)_:5S(-L6%?`=N'.R88`)7A"^=91
M:34>W+\#ZC^B>4C#Z)91N-O6*HD`;@'*O:@1H9M0O4CJZS7`DHS.<[3%2/0(
ML1VL2<X8F:;_@(LJ=8[T:XM480.%7-2!*H^LO%),"2`M=4OK*$@JX"M_*X#(
MY54X!TS!WYC,*+E9N`M2G`IA2PKM8_K!$74BFQB5@NA,")J<3!]*3Q7<DCB3
M>O..=`W28AX)1B*8*56-W",2WCL#?J)!5]`P1R87J5<>IH2;$!F"B29Z4#%+
MMVM%L[LZ^+_U5;YWC7."[EO@-4373BP(+H)T@S.W-6@66T9BIC2%2^F&7,X(
MXA_-E3D6->YR;P!"0%9%V2K[SK;N6,A%;'H/H#50PB`<Q'^I3'"\LB%VQ1$B
MITI9Q\(SN)7+!O)I1CA5K*0?QH:@9I';O9OBXHB6+M(#1/$7TKRP)='9G"9%
M"CZ+^SHY!F/$.WFRK4RO216C%!A/FLL<F\_;7*^!=]F+)P<)EP>&?(MF=Z2W
M`>U>]NE,<Z'`;@-3G@^+[8MC_1*K$Z`U/P*-\ACFF,TU,[]]"$07,T=!FA;T
M4QI!W*^WN@^_\*/C$R(@\ZD?D_UR!0=6C38F5X`CT.4LQI/.E^1*<^N>LKR+
MMV6O9%N>NA$$4F/K0IH&V6G/VY>]C.L,FB2.A#7CSV"=RRD52#NI02I:5&`;
M)/&6.+,@OVY$8`BA85W*!A("8^*1P;$.1Y](1DA-6GUHXP8K;/EL,DLY1MLT
MA/.;3A"<)=SDZ;NYMF7:19D(T.V(4H]$F8\"FVJJ-C53U2U#O"0!G<U1)/RT
M37%E<#!C]56VQQ1<5F:)4AR%ZT<+)RY*NNT5I_4P:"8^J@(BSJD#R:5E=_0(
MDX$+^ZHOW1\]UUE]3A-VO5E[_BI,T,?7./SOT`0L>R/6FJ_?A`D_1DK;I_=;
M2[8CU_JC/^OY9=N=R^>'%7]_-^G/M7-/HA+!>[-HY9>B;KDI!.$C/U3_^8;^
M^R:S6:`(D8L[_T'+/.*@(-AJ-^WT^%J'BITA==?74!)+:NN`2.,$3[];F(]G
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M@UI\C]CB.M>4_)<XF:[#!%(:R=7*O@L_(T7;A`];-29X86TQM'NMEMUKU_:Z
MTFK:[:YC]YI[;;&Y[=;FVPWZ%W!K>2?5187T+_"4%#I!#M$WG_G9/CMM?L\^
MO:!4)*V_@PCD>YSV2Y;"%0<06R4!Q**9:%.8%SUL9:+ZT%&9?RT,F&B09I3=
MTHQ%.CB"`;S7$TH@4)7Y)26RB+YKV3SW3'NZ-/(GQTGK7YXR6%P-R1$H`1'=
M#?+UP8*,=+^)$%E:YT6EZS2>"$"Z*AD0FYYE&Q$*F)('!4]CE)312T$80$-$
MKN)#?BV$JM,OLJ2_C##UY3GST'F=0[#0ZK!I)"TWS%P'E:6E0R1"KCX5(6$)
M(K].((!F,H\>$4S\$HIZ"PPGJ]PG*(+`U@N0>U<ZM5<?D&PW7T5`;T__GO[7
M3'\M@Z'[A_8/57JE6C+KX"(UN%*#N_++]GZO[1_:W8=6W6M'LSM(=7;:MN4,
MA[T?=K\MS9^>R9]K1&_Y3"T?3Z%><Q,LJICH*^][[4G.R.$[?O]C&#]]SR^<
M>S'LK9B?5>?DPA]Q3JOFT>TS*_>9E=5D5M9H/OOU>07SV6(F;Q%UA9&F%P^&
MEBV6,\!QWT*SL(WJ^Y=,/?IBU(9MC(<E&P!]]\]:A31V_ZYM#]OM)0>$W[^O
MX0RZW;+,@]V8P=!N=LJD?S=F,+"='9]!J].S.YW>VG-XD62F0HSL'5`^3EF%
MP\9E9D4*G?8:-1C5DM:QF\WJ4\*JV6OVH+7^3JN6O5U[6'JJ[*!%\C6'84^?
M,UM7:`D7`")*CV`'IRQH_6:5RXIK5/W>K$;K-<NR['?CJ.0F8[_NBINKF'9G
M-\6#:QYG?8M\GU"[3[_?D[\G_P>LW3#3>7?'S]+9>3]+J^S"L1LS&-I-9[=-
MKX'MM'?;UX5^EF99Y>/>OJECP<V>_CW]KYG^Z@K.])_\XW`6']RY[O1GK>]<
MVBG^@MMO(X_%UUPG??##T;=?\25)"OZ($W1WQ\86XLP?'*1/4&BQ_!DY,C3#
MPEY8)REDJ1H06__ROURRVW^^N?*^4T(5YE/];[OY/[,``JAO?C78=')^?/WG
MQ:EUGTQ\Z^+KAT]GQ]:;@\/#/]K'AX<GUR?6?W^__OS)<AI-"[W8'C4-/3P\
M_?+&>G.?)-.?#P\?'Q\;C^U&&-T=7E\>?H=O.?"R^.-!HKW9&"?C-W/"JWD>
MM*T#:ZGY[U@A7[MA?3PZN[3^<_3IZZGU^?3HZNOEZ>?3+]=7*'DWBV1STVCW
ML2A%4PUR!E"OIW=&-'L3"1!WPK"68(T1&S'O@?JJQ-B?4U9S05LA"WO/>V.S
M:9K6&0LAQ"W4&K[1D%4ULA)=&%4'>ZQB2U*\$1VCG]K/GHD/PJ!>,`(T629[
MAJ>MH,%Y&FED://6/BD1;`5[M)9/\29[\4$301H(6^_@\&:/2@0"S[?IHWI#
ML]O%#?/#QY\729)I8YDBJZECI%*O+9M7@Y8M5UNZT*WTRLKI*O\,/X["Z&=Y
MNOQBZ8Y[%"6^PGP-<P:GG`_?"$4^_^RKB\_)M-!GL8DNM0%]==!J]7Y)M_^"
M`9:M#(*_B]Z-/UO_UCHPQ-:[64`123;6@@N(`(R@M+3=M!ZX[@@:K"%*U+QM
M1PBOU-`,NN^F7>1R+2C2K7+'1Z0"UWMN1C#9+5)LGJ>TM:0C-DIC.7-@N;-^
MOPM>RRYH_6R);JU4UXMM\_XV]@44K?-=(,4M;0&=ZFK1VB=SO*FSS+:8AU^G
MED3\.,/6D/)O>]'=B^X*HMO^V?I:8#`H^<3VP]A-@\M@PA_@0A>$TFJ"GBY@
MQKD/KN?#^UH7G04:F=L0T)<DKXO;5>GBS0)2Z!V_TZF:K19FT*?G_["ECVS;
MF;#1?>#]/6."QQ/WNS>1'32I#3=1G5\3;`\!?1?-QPL-/K.ORS24)ZQJ<D^#
MI-U3\-;)(C"#GT2/0BORXF_80Q(&AV[WL>Q4I3=-_UC0;IJ^KK=Z'0&`0K;C
M.K5)YOIK%B'2A.B3C`@))]SPGQA`?VT'VL`Y391+[,4BVV\*T_8>6C+"--%"
M!<JQ?P4UA2+K5C9PAAXVRJ!U;\('MM"@_=%Q%SJ=5U%WOJ=_3_\ZW]_U4B/#
MQA#FZ$+[HBZ4MG:&TO8.4(J8B)N@<]?WQ&KE0ZJ$I7:KO)_/?CZU*5=3K_MN
M\,VZXE8OR[]9WR#]_J']0RL?@B\*A^[&]PCGR(E@=4%";PWM9J^L%&3+:[J3
MN/T[0.*Z:URPD:K9CAO?<G_4J>G`#DC*#I#8&ZQ1IEYCTO;IE/N,_SWY]2=_
MR6,,?K._9.T?^M$?JMLE"UVHM3#W]C>K']?2XVO;+X4JV1M[M:H=V-._IW^C
M)]R^V9'\[@83N(J2EM;+5P(XTW1IVTV1V`\E,OF$I7VNTCY7:4__GOY]KM(^
M5^GE*=WG*NW0GMCGPNSG\WKF4U$LN+J,IWV*A].WVZ4(TYL;>$7J=L`1N0,D
MKKO&^Q2/UR(I.T!BIU^&3K7;I.V]_OLD@SWY]2=_:X?A*XV,[PW2'_>`Y&L[
M</9ID)M3<_O([)[^FM)?761\0P!\\`</_B`OB=8G"=Z#XWIJ:]]41E%QN/M:
M`R7QXG@&F"Z2QB2TIK-H=`\H=O&]&S$,9X_"R20,^+"`GL@M!40U`CB^.T"Y
MB_@'"'B(2+ZE<'IPA[AW/DLHROV1W40S-WI*%[;5;/81L(L/IBB`\/@-@[==
M0K^DIB406#>Q_&@P>"@:\_$8HBH1=I[3M2UYE+::Z5*<L,A[<!.$G8$8_^]L
MS/EUIQYU?K'2M7FG?4%\57OP?<,Z0H0R`B23L?H44U"$_!,3_$8\IV;+__ZV
MUQBD/)EXO@_0,(]NK%!E.`<(/`:X`J]_\+G1=G`UN@]]6"#L$TS#`<`4/#4)
MQ\S/O'4;^G[XB)SEJS[!M^*?"=CE%G(,L-$+X/!$,"7-%K$ZC=[@)]MBWZ=\
ME25ZX$,(7:=P-?1G!UWM22X8#QZ7OK'UY#%_;#S8Y,_!*K@(+1IQMLU<GR_Q
M+;*IG_+DB;E1#MF-:##YB2"2*#L1.Q"@<6.+N:-[_H-I&`&2JC7E0A".;1(7
MES-9RH0%76\094N!RG.A#N\";)PC\C0`)`<,?Q<F%R?\/Q(&)^0?1E@?3NK5
MC`\)GXOE]Q#UR_=QJE[`)8'OM!LF1P':8)7Y[WQ30&`[L.\L&GF(C1D!9_E>
M&Q,[%+80_#(G&8)%N-`'IF3@Y$N%`H@C>=5I>?6))OW6JT@4V'7Z7V=05T)D
M66UGWQE\+QD:!_>=IU]7(/A4F`N$-KIA?T(6H?+MTMZ90:.SA9YL+T7?2X0?
M3Z61#=>$#:]SZ3T?GFPWG+;U9U2"RKG1]9Q+1ZO16Y>.NGG*+XMO8Q5[!3?0
MV\=I-)_3F^BGNM'?Y%?<M>E_42V0WL=W0%J>U4RL=L+B/*N3V,JRLF6SH=AE
M$SZP*/7G;/ZH67$)=B!4MA$2:^CH+G8KG\PBZ6FDDJ4)=@BR&+0(RE=$"?1F
M/A&PYTVH;,WMACXW;%)-A`LWG/*FZIY4=SJ-PN_>A)^7_I/UMMEHY_VJ,"#_
MC9/[C<U'C4'(O0?^MDW^9O((:I#2R[G_-%;$WO=E&&',/^=[A-]QHKOYZ:B6
M,Z5\(;]Y&,>RL8X^!1II<_.8NXXT&)]'*S^/,5MJ'F(]YB^%='NF\[@V')WD
MB@3:@I'G"P3Z&[C4(7X[2`B?(I7T^1A9X'28</00D4B%8DG>O'K_Z:"W]S_^
ML%ZF#58/[3H##;[L(%#K5LW.#T+'+FKT4`NC<^,H:U5?#G^#`_,V"B?"B(+S
M->T_HI^O:6A=A2/YL\R-X%#<A1[;K>;Z';;W&6!UPC)[03U4;,'50@?MRP`V
M*>`[F:*VT^`MQ5V/Y_;>W62SX]'3:/3S!3_C7&\,+J\@9O%1,#Z';GK'LPCZ
MN!TA"LR/WOFX8QU8SV=&[2%^3.N[T[`N+D\OCLY.K-/_7IQ^N3J]LHZ^G%CG
MU[^?7EK'7R\O3[]<6T=75Z<OU!A9,!\=K,!]=#]0X\@1+8`$)1)-A67*F_)G
MO'JWPCXM:R?H_Z%N]?7/MC+(W2=1[9.HMI1$M5/2T#.9\@Z<=?'[2OCR@[CK
M+EG,H'LOVBEC\/F&4XR[).YWU2J6*T</.]#6XL+<Z]46RW<X+,LC6''K5>U/
M1'/U:5(;?)FV4]MJU$Y_PR#-+[GMSPMN)+40@$ZS6U<!:#D;SB=]U8ZZ/6)$
MC8X!Q'.PILOZ+FJA*1R[/2C+4'UQ7>'8O<&&38%7K2WVE?,O$)8P/?O/]RUO
MTLTOXPI'5$0>7[A/,`7^UVC&QI]2<'=)DO:C-`0AZ/S10P%=Z\"JAF$[%B[H
M-JRCX^/+KZ<GUJ>SHP]GG\ZNSPHC!MIO4?*W'380RU)PXAI]"RAD`(7C^Z"!
M4,O[H,$NT;_;[L5]T.!'6<=]T$#,9Q\T*`P:I%R)BS,+7W700%HK44GPH!;^
M@9;=']86&+)MMSN;A=BNW$=T7F:6UF*U';O='M9UM1W;<?8='G?!^;KCY-<M
MS%25^*RX#SNVTZZMR[AC=[IK:+"]DMB[C#=DEV[,95R-#[(*MW(ZVODM5#NS
M(,:2JDOF0SWR<1@G\17@IWYP8S:^$"D3/[H?N:?YD=?DT(XYCGL-Z^KZ_/A?
MUH>CJ],3Z_C\,R2;'UV?G7])KX;;\`\/R*UVA5"]-\!:1.&5W+?N78!(94%:
MY0=0H%#I1R$:;J@'S/(2-GD^8`#B]*Z&_P!E5_%]^!A(``#EJ:8149F\>J?U
MOM/MGOX]_:_+O?BQ0*>F1\KV;=)GDIUBHVR"Z%U?V=7<[ND)NJEPS(\[L]V6
MD'V@:;.!IAK-9[\^KV>W-FOG;]Y^`=0/P.P?-1Q;5L-5"Y][?6.PG3+(VA>G
MS.G5M@AFN&N`62Q@D>M38Z+QQ`N\.(FP/5`M=D>[7SV&_LI"6%O2>J5HTR].
M6GN=K;N/X>T#_7ORZT]^W=(L,#IT4!`=&D%4SKIAMV$$4)'\=PP*^VN2L]7I
MU;;8NU7?,N3^8(U4LHH7M+L__#:GO_8)+'OZ:TI__9M8B+R)KZJY<:O9[%D7
MOAO85M?F?[$Y/[26R%J;`YK[H.7T?XG-5LGW[@.3V18QBQY$VU:BWGUTHW%L
MW0'\,O9^S8U,[[N<]._>9#;A_TUF$2`T\_&=9LIR[(^+-]8[NKWZ3]8#=(["
MUBTN#7<;SJ(#>%(TP"54:+V!,5+2F,?LG<8=W;"D'%GQ;,(?Q=6`EL\/L#(R
M`R84C73352T2EG2E;W/A4LJ;(?*+T8BAV[$;BTR9?7?>?7+,GOX]_;L9<ML_
MM**!MV0I[Q\,K#YN9>!/(NLP_?`1MQ'<.X8#UB[D5YG]N1?Z:@2LQF(D2;UD
M$]>#IB8[0.O1W5W$[KA]O@E:]YN@ZM6JO2J5E![S]8[XI67F^CM`[1DGU@MB
M;_3#[H+*$[;.Z3Y:S\5>;4JJS?T%M+G_D69VS:*)]0Z].KN5BK5@7MC?9;^'
MG9?W"R^I>-]Y@;6'1%\(="%\?>$LB1.7.L>Z2=U;&;;MSF!H#[=0WY[K[O=V
M>2(;P]H&+_N-5FVQ`8;M'<.5_XVB(+78&<YP:'>;U?<,6&-?.(UN363O1WZH
M;FD[TN+=\#:II!MKS^Z5ZJ#E^[%6OY.:C;JD=?_(#[W$D7+Z?>I%-3E25-2W
M58OEV#]4PPVPU:/D&'H=^SX;6X>0>W#+O(U;7Y4<*TY[:+=*4^;K=+#T&G6!
M#ON1']HG@=8M!W__4`T?>A'\UV*W6'$N6RVLM+;=[?!_6M7CPJ[E$JMO"6"O
M,:QM&<2@M>^OM+ECYN5SW?</U?"ANEUSO@:0!P]]<FI]\`Q[`[O9JEZMK^5Q
M'M06F&'0Z-?VV'&Z&X;MWQ\[^V-G_]"SCYV-;Y#_B(,E@/ZG&)?!!(5Z'S0M
MN]OOVMTM%"NO<=1T&IW:JO->HU7;&O3>.J?@_JC9'S7[AU;8)W6M9#ZZ.K;Z
MSL"*V-\S+\)FH!K0AT1[=^,X''FNQ(&G`F>!#"(*E)/0NF'\,Z/P+N!4C+&J
MF,B&BE7\?NPES((*9V_$1'VQ;3W>>Z-[5=DJZE^A:!7^*HJ0;UCR"/71\".L
M/Z9J9#A5$UDHC3^!!Y`@K&R.+?[5&P;X)+%^_#:LSV&<R/KL3(7US9-!R#L8
M)$X\WZ=A-#_E>YOJIR,75NZ)ZJBA@-K"I%R;>.4<=HR1\!WP<H8!PP=S)=8T
M$,T31N=?&!1_@KF<=5@(#+^,F'N;L*AA_1X^,DZ+;8U8E+A>(*<X<<><12%]
MG_-C-`/$,O[I6[X@4:Q5@Q.,-%_36WA`3&?,N#2,B70"FV;11):Y>Y'%)E,_
MQ`8-./-T\04O&]89)V4\QL81-L@*]GXW:!-M:NE3C,5+<)C&689)<ZO6-[RQ
M3F]OV0C9^S]N,'.CIU1C8'YGLV<;<L9\_C@7/\X"M8DX/7[17O/B>";CL+CD
M-.LQE9,#%^2V3@O+`9\.3K$#[-S@)DGDW<SP\0E+[L-QP\JJ`OJ^"/O.0#?0
M'@>V3ESA+D$Q\"8I,@!*;,0>(`')MKQ;*^#+',><`38T;8AG-S'_/BP\[6TQ
MC(?5\3/7-P8<>YR+:H.$<3IX#!`)4-D>N/Y3[`%/+,:-^1D2]C=G.&<+EQA#
M1:2?!HD"COTU(_,\3LEL6%]]&L-_HB42A$EEF-%Q^(B0-1I&*"U.$:T:+$G@
M/XD9"'"(Y)YS#U[;IE!>:P(W`]*`]@^^._IV<#6Z#WT`K4`9.IA&'I3M\WTS
M9CXI,J/?!AP)L\E4-?0@D@G/0H@AB@,*3;J;$4J4"]<H":.X%,Y@41N05P]B
ML&]+O1/T[W8!RKY5P[ZAP9;XN`?,KQ@P_P>IH3KE)AA9R?SFL6$WD%J\=G9=
MX=&N15\8M!SG%ZOW9Q2__&`OX<^^].)OW!YG@/O)R167LPVC7C^S$+'5:/<-
MCK4:P]Y/2W[[1;0#O.HT.EFJ6\,-4EVW(+O:NP^A[R;0CO/I1:5FV#2X#T9[
MW45FV#9('FY97*H3"?ZNQW\WMIX\YHMK-:M0UZ\"+;2=LHR7(*UNFN*2Q3,?
M77>/$I#*)<P4X6*Z=3WA<`"/S\L>/F^=QF`+1:#/)LK99)1O8]&+/30H_W9'
M.>,BQD6<_TO4$BL\4!F+&,\BV`;+^\B<A@7W=.%Z`Y^Z"(X\]T/D;"L>@[RB
MAG[6W('6HRM\NJFC>!;#Z%.76XOW7IR$!(?*7/#0,@G0<L/NW0>/4X_)$NI=
M&D>T#N9OW<[`@:MB&.:[#>LJ<2/2'=)GF4=8$/,+P*N;>BG+X%>5]])./<G2
MB1HQWT,:1SZ?XP.#&$5@>?R#-$]OQ(=(#1YP-+O0O'@Z2^20PEMJ.EPE"\MH
MXM++U2&&6FZ`A`?I44[XN/0J>K@?/=^GN-P4L(6#Q!41'\%&G3;ES#975L14
MA&@V`$='NGOY#(J9:T/4S9W%S`AQW+MC@CF>SFY\;P0>\<@%"00_L&OYW@3*
MRU1@4"=%:'N=D;J\I8YV>*F8]7P>4\9G.$)J/'!U9R<L9I6;M8B[;,53+Y3#
MJ8QS(-T1.U!10Z)(CY*X?!T-!A1*\7?@*PM&#%5$+I@I%]B,2O$EY-_/!4XX
M39KUW/K%ZC9_,L.#C_=\G3'X$O(_AY-4G*6.`ZJ%GD.X:S4F165BW$52#:#$
M:E-62Y>+*QLA&(,KG,NP7Y`@"#F7QIML"!L#>>E&"-6O,!85ST;WIH[C&^/X
MW@WN^$>@2[K27MEUTH)'R3TWI.XX'=9H-IGYM#-I\KBQJ<6Y,1_.A1&.@JR=
MN$^6QWDVHC"<.^%V&4:U"V/XN0`]_[ZN2T4X;IM"#JN>,_$B+_YVD/<PI"HL
MSOP"HT@1<^,9/U:@"SV7:-&D3D"APV9'G1/?IP'^CVR,+;PN"7.=6S5\CS>L
MLUL5VD;([@?7\]'JF3\$7PG^TV@V(0)C;K`E%I=-/H#0\SFMR@\">;2(36%;
MQT\CWQWQ`P`WGEK^').$>DH>P]P\8C:2<Q[Y80QL*J,`?RA($`H!Z=BF#)P\
MV\2Q+42-,(*-,=E1TAZ`"+2\0W@!T>Y.IU'X701VK;=M1.J'S>+&]US#AOPR
M,\[:`0WKV>0U;:7JE'77ZMBM?C]#<$HK"+`B``3#I+39<-)1N"7KPPI91W'>
M&A$;Q(>C-H:./!87`"X&;A0AYCQE#Z`&F\(I+O>\2$\%Z4`.>`$7(?4^JC0:
M*+7^M#P=D'3:(:!A`G;K)5I*"QO/1O+$TN9L\D)7=7SH"-0?W^\A67)$935"
MJ?SOGKAY)MQP@#V"S8]P,&_1;63#.^(LL+[P\RUK534'6<Y#$@@(NB39:"K!
M%T-7,/'LYB\V0E4@DH*(?NUDYT+WP(]2-/*NN"QXMV!"01($9"J)E(I\B@T>
ML"MG,C&9)B.:4<1E.4V8[:%-EF:)GZ91(!ED-((C4%J4Y"@@'X',53&Z6%#[
MQO2(Q!'4^:C=F8ST#M">G$/8UD$<I'RXB:NDG.R2(DJ?F?'@I#/;-W#8YS[L
M%/VU#$C7\:&UP?H%GK2%X'@XR#Z78(78>^'9_X/D%9S`J8>XNM8%/\.O(`6Q
M(DG9O+MY9[,5OH3!05I87'.@UU;;'G9K75O<;'36H._EBO^V$YY:$X:Q58H4
M6B>TK,I%X`7U0XWK09V^W6_6&@%ZPX*QCW?*[U;@5+&^!EY"&6W;=JU<9F_E
M,R"%O'3"GY*$5LP"CYQ55""5[>0)[JHR#PV&%D1H($B\Q*<0V'WHCZ'"BJI[
M&'KZK9B<+'S08`;?@F&>V3I4QD&D,T=41JG:)_)5'.7=$3!QX9-8WG$B?,32
M>T)A%"B\^7OF\8=%=`6>YLOQC248U$1WBTL36W9>MO#,"$8NZ9X1L]7BZD$X
M;^:Q\(+*BKCB-9WKZBEV\SRGLB5UK.[]//[>S[-S]-?265#'A_9^GDVS:3-^
M'LT<V7M[]MZ>U^'M:7?M8;OZC@;UN='MO3VIMV=HM_L[TG1C[^W9OFYH]>SN
M.G"$.R<8&_/VZ#_YQ^$L/KASW>G/)UX,B5BSB)W?'FN9>9?,AQ3!XS!.8CRC
M/T"VXH6+""KQ-1>B#SZW3W[%KTD:\4><TKL[+D=?0G[0'QRD3]`96?Z,)(F3
M,?$PRS`^"L;0YI5?[U@P\EB<4JLH@(PWD.E+=OO/-U?>]\]XH3V%^^S_MIM<
MDD%TW_QJ,/3D_/CZSXM3ZSZ9^-;%UP^?SHZM-P>'AW^TCP\/3ZY/K/_^?OWY
MD^4TFM8UMV=CQ(1Q_</#TR]OK#?W23+]^?#P\?&Q\=ANA-'=X?7EX7?XE@,O
MBS\>)-J;C7$R?C/'<,@SI6\=6*LQ9'<<<&CQ]1O6\?GGSV?7GT^_7%]91U].
M^-^_7)]]^>WTR_'9Z55J&U;BBC.)@3^@V^^3QPU>K`LXNHL8YK)K3L&*:5H,
MCP(9=&B0H]<G"2U?T>LJ>JG(P!VY8S;Q1@+Z)F9N-+JWN-2Z@?=_5+@@DM>^
M*C@>'3H)`+;4)\TD+Z!".`S'@@+"X4G8Z#X(_?".(&ZF+N0VTR#N=,J?%.,:
MF=7H0$-P'_1S3MTG*PJ?7!^314.9#FS%KB_SSD/(WA-99,+;1H-HXX>1=>OZ
M/OR:X(9&ONO1Y(@LDZ(MKN?%+(IG;NJ5/'$];W3O65=N\.U)KB@35),W4V>^
MXK>$T1+3P8,HA4?B_`+7&3\AO(#9F+;NPR5F',WNK!%DUX/O-)<V2:.Z@17>
M\!F32Y'3.4.$(3?F.HV?.-*3/&;N0TC^XS%[8'XXM5RU/"``X0U2&+$[R"2'
M`AO,(GV@_..8^7[F!9`LE+JQ\G^"/&18Q,F;30]NHQ!RUQ@#T"YO<L/92K4G
M,'OS#;/F()A-6*2J>("7PM_)]2,WA2!O<"K..]H\NC2Z%CJEHZ>#FZ<#\4?(
MZ/>X5,N-Y,7IUK'Y'_F?[Y2CNF"0)$Q<E-2WCM/HY])J840?BE3@#?*AIGF3
M+I\EYSU.'%S:G*5J.PA7_@B/2M$R/1T_EC!4A8[O,7\U%JL_PI-GQE3U4HQY
MF4`"[64:3E\3_'8JH9`5KZ]1S%?Z@8FZ&]=#*%H;ZY!$CK3TR5^='GW^='IU
M9261Y_HJA,'0RW[!Q859;=WI?NM%?"PM+922@]\ZC5Z>KU"C@Z-S&O]GYFM@
M:+)H3>!*">V"$\^OGPVU*+,((>+>#AOM_$``=B>EH$@`L@LLU-&E$CR(4LC%
MATH.R$:5PB>]^C)_7N@#OD`)HR1G2F16+X!JA'>8B&0@:IT&HI7R$:(?D!O-
MQ0;4+WQ=J)^QW+9QYNLBV`1(?Z!/P)B,YDZ'TQ>PA-1[@ULEXH_XS)C=<NV%
M2&@$L@B)XZ*BQ`L>0DZ+K)R@(:0FX],#C>?>WGJ^1P5+D20=2N;X`%!7$R/1
M_.\C?OAX>,RYW^'W\;TWG>*I&D"]#E>;[$8<9)1\3D>8VN54QB/3V+V$`D=0
MUX2_)13(4,OU#81F#T(E.C0OH<$Q+/4(18JH4[Q$U8#(*3Y"W0CJ7JY30P\.
M-%`]$1R[4?*D*^4PTE82$?R$?M"."('E)Y4Q[`C^VX#`#/G?Y%[&>CA7%&5E
M]/)D%D/E'^3>8P113(6S\(Z;"J`[\9#"LBF4KXC=SF(Z#-0!$HP/<_1*:A"K
MD5O`4%JBU3W*(Q-*CVYH(WB!6P";26+/;03((>>KS"WI`$@=V9#RS7\XXO(;
MN[<L>;)-KM%`=`3B.:#%T&"Z(X8O)(_,YWJ-?H%`@X2$Z/*-,`O`_L*H8RG?
MQ4$$`*%/%O-0+F@Y@72HO0`U"/O"Y4JR86EXCH;^<AR]*%;R)Q57T'SN!(-_
M0K>%EA=%["$<(:3EHTO!8,E*T"*T=IDEG^)NB)6@NFG"OE#A0@C4T%@0FAI\
MVNH`SN9B@T%G'BK6!`R;6.Q.4*OJ5'ZRKM@TR5>".K8PBN%%JFA*100V,)RB
MPEZ$![D*N5'EFO#0-V[2R7WJQ:F-"15X*0.$C@`VDUTB-CH^,$YK8YFP,)[X
M0<;2:@5!D5J?#.=3RUBI3PS5Z^RY`0Z-0&II+[A0M0(>?8C82/A:I]'J_I1N
M5:>1*YM$&8+]"0.4C\;'@=TZOR;FE>>>F+?-W[B=`K6F[(6OF.<Y^V>`:+!=
MRGA0N@*$X3/<([4G^Q(W5E4)_A:%LZDU]4?6.VE2MIJ_X$_5WYU?WG,5>H>'
M.TV+&YG<9D@\L`D^A6Y`[I`S5;](%8Y>,L.D"OWI68#5A7`7A?>X.N9K_`Z$
M5AL>/FF,[LHM;-RG7>LC%VC<Z\H!8$Q#_=3X&!K&5Z,P2?BI;)W"%Z<10`#H
MKUZ=ZN^@N>L#6R.PF3@)-V*O7YTB(.TH\FY$[HMD=_N7;LZXI+I@LSAOF#=!
M-51<6QK7.A.!=30\\H]T%_(3SHH4(-=_DJ])ECEVJ^W8W58?*OUN602\/,FD
M#)%(R/(N\#3&M^Y(X@*#NA76#QD]7%71&RE2<)96G<PT44E10`.=&+BVG*_*
M:P&3XC;`:.9+.P'1?J3YRQ<O&'E3UU?URUI-NB)*&H2"&OA*NE*=1K-'Y!6P
M1=2%4MDTK;'X#3_1_CMZXA^#A"%WZH$U>A:,&GSKT7`E^\_"NTRD+D[HA10L
MEIJ>/@Q;6NW53P1OH*%S2RFFT311CAB<S>+,E@>BER"`0KI.Z:XQLLJHGI7N
M.WRJ>-]1'$R]4U.XF,OB2Z#$1P.<H:[`TC^4P`CJ-[,5^D#'G52H8W-+",TY
M=QMIU>K3$*Y0'M09XIG,IW)U*D'A)7J%)CYX<9VX?+097L'F#22$!BX@6DX:
M9;6)M1.B<`^H4V#$G&8QK6&Z&D>('_*J)[DI7$&DSK@<;=/'A0>*'DMJM5!,
MAZ;#21XKIN"0,CW-J?`C:4F9:I1/&1,1E,?(A8MLUK+T)E.?/N]J[)J3^5<D
ME#XWCTGO*>&D(>%.+G:SNH_#;N1LUSZJ6\$A8*IXMT_B4=H8NO]58XB!N9#3
M3//%S7J7.1L&C6;AZ5"6&]`<OI>2S]>$;S))!WOPPED,6#GZ`:H`;E2Q^K4Q
M%V'\CD6BHISYHEGH+.!Z*DB,]2W4#G@-5V=RP7(VK*PK5O)?^7LL)7,H9[+C
M!#J/8*)2CQJ2HZYIQK;DQ\?M+3"ZD"QCLPJ$=R%`J4,4E`P(#23G%C(N7Y*?
M6_Y"!Z,K;D_%>_:][GH"<`>!(,$U[>@>SN"<^>CHFYVN^@!$P3=FGN9FHZL<
MHX44-QN#',7O4]^==&)&;,*/)_39%&P,/DJ))G[F<&&0;YW0HQR:3"<)<<JE
MOD$E#C3P#0,U)8$%^#4;3P\2$[QMQ=C7`&_XU$#@AO%-D[WJ\Y$[*(S<1+%2
M$Q,ED3*)P7!&"<ZYR?`H4V=FQHK43)GU3TMAXR]S9.9'6^^TE%?;I_Q"Z,?E
M"YV4U"\BBN#H(&6?2WR/$89*6EP@[_R9">*^4-I&FA>OX_U(E9+FS$=9I!T^
M<=@Q,2"**`=EX*)700(BI$UV1BH`G>E@X7O?F._=AX0%%(Y(ID<L'S7DGQCY
M,WGD:[3A:.`O5O.$[AD3J4K%&N+96)[$-@<=KF*<CDP0F=UQ_2C`4X"_+W6]
M[RAK[(BK`C][:P!(-,.E##<]@.L1#95<Q&SR77`NWWH^W9..F0\>6/Y2-`WI
M)#5.9TA<Q2Q6=+N?>)37RA_GFT_91NK'N)X^H&X`1A#[AOH;@D\^5TKH`/QK
M-KY+'8=03"(\?;=XDH:/,@(*;GSPV<D[',0L^4-1..'VQC3V@,R_THC(]0$4
M$5C^TV1Z'TY<B.)`O4T`V5CCU#L`.#)><`L!)F/^&3U+L1#;NN%*F%J)^$\8
MH@!WL*0&G2ECT/30]T8:H`4?I*'/KJ[/3X[^"P(1\[MP7@8&W9]^L?!6S!6K
MK)U``>`"H2?B]3LD>/PS\%/KG<846!+%F/=R*N)0U[>24R@S)!<8;`GB1XP=
MCZ5#!W18)/RH,OI1M+)*RLP+'7W:_`RWL4'B141.RB)*JUPE:6)@D&R.@8]U
M24)T<&FD_(W=B0LJ%#A3NCC&:"[<Z,&)`7KWKUE`+GF$8;RE.1F#S1,0H>F6
MD9*7%9#GIYP]+YVIB@PS3*T756^G?\_X,0./O9[DLH&67+8T+W;,N0ZE<=?G
MQ__Z_?S3R>GEE7[]/OWWU[/K/U\FL>Q".0$S&%XO8A$<H24U!TA7H<39+:=M
M.YV6YM#-3$76J&+"C^8FE9=*@):%)]*ZR[?\KM1L0BR*OLK-3P&U'LMP4W8,
M.)LU0$H#TDO9`V'D\;ESTPO&XY=3528J4'4E2FCO)WDN^!Z7_+$KL&YA2+!;
MY6\S1-@J(0DOPVD[-WFC2V^[8Q=CA1_9333#)G.?7?ZOH]D=1,B!4;*JTY:)
M`L`Q^7CV(MUM6$<R$#A6G)+1=CI2<\%NXZ1`&$DTME2;,\3JG%&2AV#H[0R^
MBW:6*P$X?;!EH66=@IR$\T!!X\L4%CKELJMV+^XN94Q^*PM/E"C8UM2?X0TH
MDC(U"_#BK2:^#R\^`\@TOU>-2(K8'VF+QK0L''Z'OE.X1:-KKT2X1$Q'J0>C
M%!P^(D;$G`"Y!4U70[/1:76[[;*/J$Y^:-*IFNWLW!2NKJNIFE:[T6TJQ$RR
M7P?MMMWK.T4J343@\'NH`'/!KEZW:W>'PV?6Q-MI7?J8R=">O*-/0LQU2O@.
M(Z\0/\(\V"+P+UH:"<M;IK)E*3^FU7&CDMO,+K_Q:<$Z&LJQ^_V>/>@.YNGS
M`'/^4N*S<19RCN,]L>OT[%9+^YJT_<WE2S7R;(H)C4H@!/]2[UTY746'2QG>
M_/6]OG3EWTS3$".68$8*)BX"J;[X"W]9MMDEXO&7OBM":UAM'XKD9?1'\9OO
MC"!39\E]2"7Z<"^<!>*D3,E)0X.Q=L)HZ9T14YP3ZKU(E<?SN':+23&0/A3B
M)3O:EH>KD\]?APPMSI40P`H0QE,N4N&AGQ-$2*C"8#`W4=/&IG*O+[,/*8/^
M.SAF^#!OV]U&JZOM30=R7XSH>"QA\%-78I%I("$J,!6)RR""R--E\BF6":K`
M@7;S`(P#^6L)*R^2;2C93GCNP-`Q/B.!(43&F1`Q8J9&[M87%TX3B+Z0:C]A
M$(X1$;,[P`()I$LFN\!F)I1G+*%R7_JQ+`L8ZU8BN!RRW\,XNO==,\T$EG"J
M(/,[)$VX%-@H8V(QY1`2"K&/V_$QU-K$SNG-D-^B$BD64NC$>,+"$9\I)T]X
M/<EVU#QXFLO3)$Q@C,@4R#3/1?1R-FWB"6.84(/N<TSOT6,+G2J]I\M;+;!I
M@S!%-5=]UOD/'T*DG\H?TBVB[5Y-C0C]2EL6U,`T$;D+LL_#R(OX/0/.F=%V
MU>1'L,#S8"\86VKV3:?;!&X3(I0H0=HYMQB;E.A1Z'8`N=:1"E=#<-&&(Y7:
M;L"FRIOZ,CV1?WJ2-@0!W'IIK^-IAZ$I;K9(XUUBFU-X2.'-SS/J^=%J)DC?
M:J.^>M290>]UHK;\("`,?RH4\OS^EJ$K+OSG7'\7Q;4V7("]1HFSTVRT=@S_
M8#'OG7F\;]6)]TX9/L)F>%^S/=&:MR[M6JW+&BB4]=P3[7F\[]2)]\W>C[,G
MRE:C(],M1-^)6O%_C3:3U6%>;,>3*E,^@2([M;+!UT-I`\+*+O2RJE)%:2T'
M3SFW.MG"-V#>!*(6IT1&FMU<NNRI3$@%Y"VC6D%F813=77NB%.A8\Q)?S<`(
M%O?)$W;#*</687IQ0_ICL\I"W""$3?^66SH%&:PTI/9E;,LSS]E+'K[T#:RU
M(_>:33EG$TIC:FEY?U3HJFTA(,U@DRA"?Y"IH%#W`%VU*+DMYG=$WXWHHA+&
M97&B?8!B`?;NL>'^U26M-$JZC<T^R/7^HF`>Y8:,0OX?X5B*165Y4ZMZ,LN(
M4C`._C>I)[*1DK(]6.@'+8Z-9(%EL0(Q]7UH>!#)4L"OFON<+LZ4I:H<=12E
M4-1GL`V@WN2!NKQQY0<,>O57]SU@[$[0O^NHHU*_8B+)1XD(<1^QC6!L;HE>
MKIXV0>T/M9:ZNMZ!I=PTN;N^EJMAY<*Q;,G6G?5<]9I,;(LN8TDHONZ[P3?K
MBML:+/_F^HZ`=-*;O>J_^H?JYO%)+7UAWJN:\!=8^+Q_I\]O.*U^]8C,*Y(G
M\K@J/UW$8NW$%L^I<%UG&QS,:'"\%;>Y^AZ',]"*AO[>XBK7E?XE'?7[$V*W
M'WJ)>,RQ<.@(!!#T8A8X3NK`GIU]:+]]7\5#=3/PCA*9(:6GW5,DJ!8F7KO9
MLEN=ZMLHKDI>MV/W2[N`[O?]_J&7.[;/`%H1@CP`CZN?W2F*-G]G-I(5R;>;
MCMRON*<<VW':]K!7VWN=8[>;37O0Z6]6'E[US:[$,;<K%[OJR-\?$*_BH;H9
MAM>`^:]"^?KI49,SH@.5?<WJ.RZM3*`HQ-R?$;O@/=MU^NN?JBBREXZNCJU6
MKVE;IV?7'ZWK<.J-K).#3LO64P-A7$RK@CP?PI!7^4@"HDTD9YT*A#"L^,%^
M8#*9B&9PF98&\1^?!82\:"9X99.ZTOQ`8@E28F`LTQRT!]]+Q/BT5%"[3Q,I
MF5I:K=2=RNQ"Q'Y#J&A*49IJZ(\%MKJ=KT84D'X`HA81A!G4D,68#O7.>9_*
M4![=##".M;$1+`,)`G0^;RPP*6D8!'D1<\G7!V;1D+/SAD^_:\TE)B6$!L0:
M8_B6&$T!:6A5=)00"8`.@0*5QT))EF!/#.1B%"'<+Q3]RY_3"&Z21-[-+)&C
MZ`>?F!MEG<4I+$V*UDR5RTL6W(NE0EYP80FL1URTM-)[S'S^56#8-(/_63[O
M;*8G#2)J?PU!`B&)",HU)U(TQ51FBD#PF)'?5RH0.I^@QI;>Y`OP9$)@)O=Y
M"1$=6TJQ'&Y<'RO.XWO&%S&#/:S`I6^A/15A^J$`$VTWD$.K4#`1!#6918$I
MQS1,2?8L-ZZI;1'DW)IUC[3Q&+1CX5S5RP<C:ELHAA$REQ)1=#T7VY>2?S6X
M[#B/3_&V50`?BAN-_V9(H\F?WNK)5Y0[NE3691-*.*%C$P#<^$];!2P4`8CM
M(A.9.<&Y8A.LBKO@^@32LB\@QQ:AGQ5UVSA34_S$''F%8'@(9,>PR!K2W)'T
MJ23=4!,"<2"!2ZW$?,L`]78;K;S,"=3#&70'IY8HT'_=1WA=[(V`XNX%#PA*
M$1,N`:AB@4:90G1DA^L4X$*3OJ+!<)O'B<234(GY)MP+%_=FHTMM;AX1UE3V
MM$&,/LSIIRH)\5O`@`8T$02#HUH![#,#)?^S:(0=ON:,!]G9?!=#DYXX1<B6
MZ$*-84LK54:(!H$(0#V(^(F`-0$-:SX@%AS>Y+.GDUO0KIV>J6)6O*<>3CIF
M2:"?0B/?C6/"<@9("D1@(WZG7Y`<D!)"G>*`TH'=;K5M9]@4JX-'KC[S0:O7
MZN+DX8'LAUT_#D6=@\9Q,<H(+2U1D=VQG9[#[UE=79V6C-GKJP&M=\#MM[U&
M02L*?OQ@)R^Y7"28[PW`(1H\@+8R0G52(R6!_"$Z))E(R#V9O3Y_,0,N3L8!
ME)L8=!+`-9*"E?:GP^\6#&J;HBMY6'06T1B^.XUE!P.]5P-6_.1M`BEQ`D-4
M?8RD4@+DTJ?A4'[;;12`@8L3*P]PG3E[L`V;IC&64A9BFT,A`B#P$U*^PF3"
M`UH@FI1-5O622WO13=P@8-'/`%N?ER0:\1V7O&8_W>?O;>MMNZ@+W[NWS49_
MB`\*=KXGCC@%',&G.VU\6C(9^?M>;13#>6.;2Y21*^,+\3-.^M=9+E1\#)\A
M<%0@('Q5HX%BRR%W_)HG]1U"GN>5MEA9T>PN8G<I"*M$&#&,_4O]B4MZXBCM
M_3G&35!N/$BLGWR;5P+]M\&2!W6'5T7`!KJ#)H6AH`R"3+Z?`4+/G)&&4A_G
MVHM9[SR$Y,;&-@!O)75>D>8Y%+:M.`O?&WA%T'PP>0*,=V[ENA%!%I'6UL>[
M80`XR$\\+AB>N`TB]JW);8R:T\TIX#L@FH@;UT&;FK?!*VE[/NSZ(-O3`F8^
MOX*A?92><<4?5^")3';2$_Q"4.?)%%!Z\<^@L49T>U5UN`WKZS0LO4LA=A&4
M(-)U=PIM]:3,ZI=*Z4B9(TA&-U7E-B#MDNG-++O3Z"V5)^XW91N%4(OIZKUG
MR2B3.X#:4@G$1KAB$1@RM;\(<I@N3J/[DS&/M,^I,M_(1$"\%WYF8X6:',U$
MED.K).UV(28ZBP'B*A(NF+0O,5SZ[MP()5=?72!52C1HD`FU!DGD`0A`<PD+
M7`WH4RU^P*19HG#IBL0FU\!:='%`2&=:;`^_KQ9<-)M&^<DU&5F@1.1YHKF/
MT`F&1ZTDD!JA%37R7DJ^$%Y5SD%O+QRDS"ECQA9NA[F6&ZCC+X42A*IDA+^R
M/GJPKB;D_G8OBGE*N_-OBKBRHKENRVYWFW:S*:UZV'.ZWS92$Z8I$.B7[E!%
M-Q,!)()Q;FY!Q,-L=)NIE0ZJ2:B5DAND(41Z'U5JQCO'2.P66&P-ZQ24#8XM
M+I1LG+M29L<K</)I]TUX55XF]5MCL]%NYCXM6_,:];/B#)8''9X9+EX/#^!Z
M2+X\`W(8/R6`&:EQ@#@V1<VL+-C77#_P?KKELQ_)W&2-!1MTM4MLKOYW[F4G
M,[.RF^HRM]+YEY1T9FHPNA,6-)N"^\F846M9\,8EGN_]G[S]?^#VVK>#JQ'X
M""2X&7(#;P/AF,FKCO%6>F'@Y,\H(!'_S$VV^!MG/$,`6P9`G81$H`2J]8O5
M:K2'/]G8"A[A\1Y"N*A@"Q+]L6'S)\%-]:1":WCR`#Q/?YH_3#<U#=A4;\+N
M>[>XE%W`SU`,6L87(4Y9:O.N&6>FKV'A#:[;*&BS4W1W$Z?A^A>X3I$+%>YN
MP[9V=RN^7-$UK5GD3(`OM#*7.B'?DCG;1/$K.@&<]G-.@,&F3H#%NEW7QMC[
M)?3')0<'C0:GAY.>'FB5DA:/BY3X6OJ;1FPV6MV%2GRY\ZA?X$^MO_IO-UJ]
M'5;_!6Z8NJG_;O?UJ?]>D3*N5/UW&[T2]=]=5_VW6R^@_C/WDTQ+ON9PWN7D
MQ>XF)I7#HI:L>`:`@M5OFQ!G0@CDLDN".`44)C>7N`Z<8DN=9*M<8YK2*J;H
M!IQCJ0O<O%J\\[1<B&<?439_/_N!XMM&K]55DR^/6+TSF'"%:.SIU\^L/^C;
M1NX+9G1X2Y+A#-J#0;.KE/+*I!320H=!*=D4.W$Q+!D<X-&'QR>1,N<,%0VQ
MESA$YYR?4D'G#E'':#>3/T1SD$\"YRF%>4K=K,(/6<X!?2JBA6-A_D`)*PU>
M%E@B"UFYM#GR(IRD+W?:=JO7RVAY9)Q,T<BZHN?Q";UL^FGWEKXO-+^)D"4_
MJE#YGP.,M0_5+`^8:&0=F&CYJ?C)>T\B\PQL$3(84X]6OCZJG[:,Y$A'L]8)
MG/SM3";6R=,#;+4@QN`<VC;9I)XB!]7"UE@T?&K8S9/,;/A?WY>(ZM8;MNQ6
MMS?O-)K76F5]RQV'S4^!QOI#-^:;11;<FL9\^D)Z@UC+F.\MZ\M1#\E[="7&
M_!9,SWP[7.@78%&S16`"-?=+K4_KH^@R_E)F:)YBITE=#HC/?!-/2`L7XIU2
M4PJP6TNP%].YTRQ*&6!#&LGQZ<>/-ATA_X+`P4WDC>\DG"M$9;6?XN8CKN8\
M%2"ZT*>:SCIN_0XZ=G?8+.MIA=DQ!<[1['.H*=5$,=/3E0/RS4!V`>4TB:@4
MGX_(+@'^E3';:6[3+2;,@L_0:-L,XA3</AR[V^/G=U/O495S^7#^ZPN#H:]T
M(6A1,1:G95?C13B-3^H&0[L@7499,X5;;$C=ILG91R.7S`?"IFI4/AB?WZ!M
M]UJ]U>=G)"7CBA?.-3-PH3_&AM^0I&>S?!I-,[7U$3M_B9QL!/B$7:ABG#)M
MF`Z+`L\/=5N?BFH#P_@32=NS&]D;S6B8Q6W2LJ[?0(&BR>R`".,5!@ZWH9;U
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M(\O;683)+0).>7^O?,:],A5]@0\]F_"7^:?`Q\@Y/!&I/C?0W.JQ\":6E-SO
M7CU:=7?P*M">]_2_+/VU1/7=/[1BC?:2T-!_,,@Z_(%AH?</52M`1U#J=K<1
M0/M:RL^J?#E5ENDF6%,QL?)>C#>[':#W5-P!:B9U9=,QC.SG8;.?T3V:FY+'
MJ;O@#R^YW\PJ58XMCVVN:BE0JZ\'`HC\0'.Z@$!R)5OI!VD5>S2-/-_P,_<4
MG`D%Z/-7U.K%(H>^!"TB:V),Y&FSNWW'[K360(9ZYM@K=$[L;[9QXA;0+O.^
M8?0+UU,XUVA27"UMRK==9^$<-#K5=GG>JDHM"Y"??OQ8%W&MK2YU*(6SSL+J
M-#H[IDD+DH4+<HCVBO59M(E$JGI+:L5G_E;5:G%);CVEMEM7J>T[W%JMMWZ%
M`J0=TZ][R=R`9#:[=3_YH3+ZQ]&GQ3`V>ZE]%FT*K:S.<@NP=)N5VQU'K:[C
M0W5M5U#'A_8M%/8/U5OT-BI@V+IA+UMEIQMXC+JVL\X95_T9W&DT]WUCZ_Y0
M;;M!U/&A&G:H*$$;/]7+>O%^<T[YZSC\-J#'YQ8I/:,>V"8P2*HNY3JO[<CJ
M+DKC3VN-$;A99?1G"FW:<-,V:J<)/'XIT'B-`J?5L5O]OD$##9@G)$M#LZ@`
M:A[S]9_\XW`6']RY[O3GJ[0M04QU=Y`<?^+%`-P\B]@UY_L'GS_S*[XG911_
MQ"7U[H[/%-/I#P[2)RAH7_Z,&GQV$[._9WQ-3Q\`W%(-AD4)_"^7[/:?;ZZ\
M[Y^1L:?`U_]M-SEG83'?_&KLG9/SX^L_+TZM^V3B6Q=?/WPZ.[;>'!P>_M$^
M/CP\N3ZQ_OO[]>=/EM-H6M=0*2*@?@\/3[^\L=[<)\GTY\/#Q\?'QF.[$49W
MA]>7A]_A6PZ\+/YXD&AO-L;)^,V<I(7\_(?6@;5P[K7/]#>UQ+!A77W]<'7Z
M[Z^G7ZZMT__P?U]5K`U*U%2F+X5U(NI@7EA+Y7!<!CH"^8?0C1#UA#!GH`1J
MS$8>*)`@1*@0@7B+3PMP!A]0>^/[M-)'-:+)M^>@`C)9QB>;D3"`H\U@/3@"
MI33MOH*`KH^@^:%DG8:8ND]X/G%M>32[F\5).C%G"="%"NI+B(6(13OVB&W+
M\"S+%RQ3DCU>PIDH_!%OQ]1_(!ZY/G8@L%1!J4+.L"57Z:=>-#9>QCI&ZSH4
M;4P2J&$"?HL#)GC2FJ-H/"Y:41>!,1)$Z+4)GW<6(%QO^@EXQAV/,QU6""<8
M*L>HQ0S3,'5S;5V.8A,"PO5\44?M/DET856M2CC#XO"28,-<FGSFQ@D>S^DZ
MI%2^>[QG6%<%32]"P@%BHQD4A+TOF;T&Z0#B,@^(@00#BOED_R.J.'T,K0EF
M&*30[YEV3=DQ:;R'$`O88C9U(SJ%L8@-D1QL^"U5<']V]5!&AS8%H4GX5*$'
M%(S5?N>,NO4$0-B#.X*:=UE?"U0+Q,&(W3S9HNY7O7OO31%O`M[&:D58"LY3
M`^,:UBM&0!QW-(IFJE87)(:&40NRU28VG[P1@'VDJ,9U4]2.HVMJR4T3NR`@
M[`,L281*6>@4(>;E*K1F5#4GKL?7SB/RK]S@VU,HOVE;G[R)!PNM=U43+XAG
MU2^<7]Y+G/HK-DV*D1G:M@"`,W$E"1*?2,A#V-^[BGB!.V^2(%4F@'AG`&*,
M?1>[4"7'KRK0#60<S>Z$6)TJ8.IY?"Y@GX8P`3SF&_,A!&SN)_XK[%^FI%_A
M_M.(&?JG81P#XH-J^`R8`@^>['N'N-]J5#P,4U1VC4\`=7X#_*1!.$.@`5\8
M/9&-_D#*+V;004YG!>A,J1$!Y0OKF_E;7"<5K*3H9!-`^SIX1^J$'"P/[&RN
M@[P)J3-5)$V(`D_6-P\.I<C#/BPT<3PSU-RIM%?),0TC*U[QJ;&$,$>(]?#)
M]?GGQS.6[T[`)YYA.K38FB6`JP\`0X`?E&+C&.RY8::>QM8_D,GLWL$ODT>`
MS7$:K>Y/.$^GT6W^Q$_Z*:,B47%<^.R!(?07'TT.0D.:H_%Q?*XBQOM2WF7U
M=0$<8CWT=-^6YJN&ULNOK]@&B"3^,0(4F"!%.T!,@0S<1M_N.?R?3H](E_!6
MB/2J7M2AU=H]!6EH+X=IRVW`/(ZS5(]9I/5X/AIB#IC7!#[4<>B*D0=3S$%W
MJ79=17/']^R%^'5B&-5<)(MB)WI)%D/OZ!V\!.C<9,+&'O&4S#$8F#\GCC8-
MF$ZSUE#KH1H+0MEZ*7V22-!!T"2TF9(@Y0\:\YL`*.]80"I/)OP;JML8]<%0
MZ&82U$R9]2;J21'6&8WR=E@`RK**CZ?,U;"L3V?T-!K]?`0=:<CW$9_?@J]H
M"J?%A6QY=GT?A;.[^V-WRE6L_PE/+,./<QZPWSDK^6EZ!6B3R=,7KH>+/3NX
M.OC2UZN3-W@CGO`+WC_?'+3?_-KN],$Y_(_#E<G29G6,[23/`H!^0//A_%:!
MJ%5!_$&OU6^GU,\9?@4B2SQES?DD=;ET5430-;A%5R#I8/M,6K1NK69E%)5R
M:1%-3JN[09J.QG_-X@2[#%V'E^#+&/$;_Q>6?.*'VG7(_W#LQO=?^9XZ"\X)
M>B6X.P*#GE"'7W:[K$G]]EE4[6;]4=BQJ6VY.7Y(MW)\'B@WT3ETM7*C)ZJ2
MKN;4&S@M;:J+J2@B63V*;JV*"&T-B^C,#/U<ZE;;+9UF!:2L>J@Y3F=K?%FT
M1KT*2%GU&',&K6<1\YOK!;!K0?+Y?>32B[_%)PI(+(9."I4<11V-9XMIT`D.
MPS&T^3OC]KX7@0[ZA(ZH2LCL#]LZG25#:]2=B2O8^:VI/\Z"%%8`4`6$NU9Y
M:ZLAOSO4A&%ETI::WB>/S<YO0>U_"(-9-=-Q](VV-"E+D'\.+'A@48RGW`<`
M'>4'UJ?0#2J:1WNP>"+E1!7/".[)G\+@[II%DPNZ')\'1^`ITFYUU<S':17+
MV5(D%<XF=PP?0USHN(@S5]"J@XWI1PDT504>P94[/@K&1Q2E.9.`D%7,?S#0
M#^GJ)U'(,=+L_&%II'T,HRL6/?#=')]'Q^32KF+VG4ZO:/++T*--Y():LO*'
M8.(54=K5;GB9`?.D?`5'U6\S%WLELXH40;>5H\@<5Z?+.,0_B2ZU7'PN5/@9
M,3<-4C\0+/%1?'[[OVWGA(V6,*W:[4ZGV],I6W+DC1*[)`LW0RSY*/FI01#G
MKKX!"1KH8Q1.<.?*Z'8UFF30UF?R?+*T65VR,3_!X9V,^:?,PFJN+%U'VV:+
MB5B=XM6N,:WAMNA;]6[3Z@Q[*U*(OZ&$T@N^ETZEM[P2[=72&5DR,M$V9M[/
M1S(D^M%W[Y;,2;SE@[%_'.9>3[]Z3'V;/V(VT9_,C?@W``MKR0$.#IS60=NA
M(<J^E8YV$HYF$_7(!8(O?^0_6_(:^>N_6S12Z7?*A@)JGC,0_+MH*/6=_$!$
MQ?/8!_\^:/8.VDUS,.-;^:&NGZ;+CN`T#_YM?AM>3C]Y&B1>\G3,`';;/^-O
M?_\7>UKRVUQX':?=='H]&J'P6[FA,)B&TBX,.0U;^3F'&;VM;ZJS+Q_YG:W3
M:G6:P[9!TIPQ<_21$%]*B/"KQ$V6%IL_66R,6_BM[(@?/9]%QWRA[R!K8[F!
MKOB,^5N6^K0,X.G#&Q_.CGHQN_&]T4<_=).%;)^C;YMO?NVUN]W.L-/1A]:^
MGAU8]I(/DB_N9%DQ5CU,+OCZ3?B?9HG'MV-L6V?!J*&/;'X^._A_0G\6)/PJ
M@;Q9=EF_A/H(F6]DA_B#^?Z_@O`QN&)N'`;\V@&&1K324"7?,A/7CZ@W02QN
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MO3YH=ILUI7Q1QL%@,'`V17KJC[EPH_,(_")LC*+&7T<7S7/WY.G%5<X5U&PT
MFXY&[^)1-TAF,5<K)I.\6T>SY#Z$GF;C9W&QQ*%&=UQSY<M'W`!IR_OZ-DJ:
MZ&"Q`8YU>MU>9^ATYE!%@ZU)T?*,XA0-^LZ@M2Y%2_EJ-\JHG*=V/=HVRK)E
M:-N(@='IE\EXT?&\].!+.E.>-WC,K_B0Z!5?0??B2DSL;C^[YXU!EZ=H19];
MN[.9X5>-;PY;E4Y_X0UG4/'T%R45/G/ZX)BH-)#;Z@\[_5Z.*'W<9U"UFE`.
M6ZT\6U:D8%6Y['2;W8JYL,CK,^QFM=7FN;#0-=I[#A=.V#3B[Z-CBO_91_\]
MY*QI#JN*T@\Z&1_9,J2L2?R*&K?3K`FA"W5C:TU"3]T(JE5C:>I_<&-OM`(+
M,Q>-%K_`-1OM7DI:X4#/I65935%(C3/8,#7+K=EV:%E6>Q12TWPF-0AE<7Y[
M^GV$-4>7_,)X'A1?SZM)#.V9%M%S"-K05%93+`?=7DT)7YCYNB&Z/X81\^X"
M\IV/GA",SL5:!EE5\H'=\F>R,</-%;*T.Z;.?`9%FYG*BJ+3'KPLV2N7,V>"
M)W7A]T+_8[^F_%Y8&+TU?G\-))!,-7NUW^\]5^A3DC8TF55+<YT-$9X6VZ4E
M=F=!G$287`DI#A<12ZK2ENVFN0#+4E,VARM^)D"A33AE4?($B<>)0JVH9@;#
M8<D$YI&R-ODK7JK7)[6PY+':6LOY8YOTI;\[OX5*LT]<?L843O^=^6.^3;Y6
M%<3+[,BE*,D0KQ*+(*Y^S&GP@AFWE47)?!@(34K/<7W*XL]>$$9>\B1+P;AY
M9'Z%8(<_L^0>@E@/3)3I5[,76CUN.9O6SQ;G5`]FKFA]#64U_:MEW.KVG]-[
MY:Q;U0+M9+R+KXYQ*]O`[5XF:O#"K.,?%.[8#RQ@MUY%QHXS<(:]@GGGAG\^
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M$[^0EOGD5PIQY+3[S;Q(%`V_`I&K;9J<F;LQ>E95:]F3M6H&+3H=*UNPE<$)
ML^?.,A1I1:_KJK5>MVVF-FG?7F'0Y2;=:V:R?Y89E%LH^69RFZ_H6S3BINA;
MM0IP9?HV5"0X3V`*R_4V7PL^3WQ*2!@)&U?"K5V"ZI]58\JVLQ`"I<.O0N6*
M)T.5)*T,6+LB40!.QQ\BK/U+-F+>`UR6+QE6JU^X$0I"Z/N$X%E1I,?I=3(;
MX;ETF=,2$-$7U`]G_.&)P*)507;%2.BM=L=Q3/?$\A1M9":KVCR#;K>&9"]&
M^W6JI)H,B6T`Z+<SF8++$[21B:R8?MRODN:M=2]H-?O=X6"9J91BSJ\YE55C
MO?U,=44]R%XB7+@QLM-`5T6RT>E)'-K"49<E:-45SAII*PV^<@BJ/<QX]#8Y
M]X5BXE0Z]X7AKFXW=Y`O-?S1@^OY8+)<AUI-H+A>Y!/B-R>J0Z?=SVGDY]"U
MN4FMZJYLM;LY1?PR,UAYS_2RZ!QU6X2%^Z[;S-DB-5N#A7NWW][D%,(@E$<1
M?:7*&$ZWDV5_V?"K4+EJ.4BFLGBC-*T,9YP!8MP&HQ;&#EZ"3PMA(H>K$'5N
M/E.AC<6%*V-C%8S]/.)6E//!(&/PK$W(ZMF([<%V>++X/,C$E*KCR6*]_EQ2
M1.\#:!)QR6175>I`F?$K;RRB-<S`O\TE80ZU4*PP2F91%K=C<[ZW?B;-H6SX
M8B+/;TO:0!T%X[0E`OZD&D8/,I?V%0C;[,S6:_-5P31,',J**F^Z&>2NLN&+
MB;P.!0;@AUG,*8"V5QA:U]$!JPDP]#,9G\^A:,%<C`H80#BHM'2('UK%&F<Q
M/1N9QZJ(;Y60?'4?1@GTA:JZ2,7I]GJ9M/>EB,G0;^SL+8*^+3?P9HE=&?IM
M?6*K`(#K9C'6Y@^Y&?*6!^K:.'F;`X)S6D[;Z;3FDU8$O+8*6<^`S=LD61N&
MA%N*ME+@M94)W##SEB1P,^W&Y@A_`4+;LRA8O@O"\RB`G.+%2<TK]5[+9,W/
M&VP39"T+UY%)&W\.6=3$#`J<5.$''V=65?\QI]]M97E83L**Q*X8OG>RFGXU
MPBA-CI(N*C*[':>?J=J91\**Q*[!Q9>@:W&;EPW0I1IH:C[O:JXCK78F0W0A
M'>N0O>):=YU,PLM+$+G0]39G6Z]*XLOX:EI.MM!U->K*9UA=>]>ADRFISPU;
M3A5VU*RRL+#CE.\U??!R$@M`.RIW63C=<F%80,]F)K)B?5.YREB3ZNVY+7JM
M?J;=SG+4S)E!VJ$S/OW.HI$75V4\],LW8B$5ZQ"]1D[<2].XR/6Y)H'%(IXM
M65L%S[N94PNE8VV"JF7K77(&ZY)4<;,LO`L\*K:2M:)59LUG(B+SQL]2.E5N
M>T`9@LTOVFYA)O;YC>_=N=4E@K?[F2#U,PC*SB1F;C0"@,<33I(?XM)4VNQP
MX'0SC?[F$K$JO2N>69U,S+02VE:N7FBW7HYSBTRK83LKD]ODW$*IZZY#71K=
M/;YWH[NJZB%ZF42LHI&SM"4N'VPL\7VU%HI<@WDC;^U3YJ#5<089E+7%HVZ.
MRJ53CX?#WKI4HJJ'D_TWZ/Q;D>[N=;+'3F;8YU"UXGV^]QP*P,J595&RFKLB
M^<^X78M&?B9MJ]JE[4T3LK+.'VZ))0OEMKDUEBSV@Z]!2E72.^RTRSGT+(I6
M-%T&Y9+RK.%7EM0YHKJ)^:\AH)N9_QIBF2>`^3X_E'YC`8M<'YHYC">`F)%$
MB+Y;I04^Z`Z:Y@&P'#%K3V`UN>YVALY+4+OJ-F@W7X;>%7?-().$_=+<7=BU
M,V,CKT2O:('!QL?A!'Y?87\<?O'(;+;"P9]-X&J;J3_8)C&+KHR9H-)2Q&P<
MCX/?'#(1N$4(%YO'W'!ZO2PO%M"0`LL7@;=7E;V:\3@N(,*D^`\WPLL%WZ*7
MWMU]LG+.3Q$\1R;V-V^L35"UI'QG"@R?016#W[/QT0-7:G?LRVQRPR*(-&32
M@E:J)<RG)#7!\>5T^ZW^4*/V.31LBORE#MWB"?2ZO>ZPWWKA"2RA"0O)[_2Z
M_3[_?UWYO\P$!JVATUUK`O_?P<'',$R",&'6%4&6'!SP7_WC\/M-Y/,__/]0
M2P,$%`````@`*WL,/S^&NO7O#0``ZZ0``!4`'`!C>6-C+3(P,3$P-C,P7V-A
M;"YX;6Q55`D``R%^14XA?D5.=7@+``$$)0X```0Y`0``[5W=<^.V$7_O3/\'
MUGEH\B!+LB^7G.>N&7^<KYJQ(X]LMWGKP"0DH4<!"D#*5O[Z+D!"$BF`!.4/
M@=<\699V@=W]+18++`A^_.5I%@<+S`5A]--!_[!W$&`:LHC0R:>#5'20"`DY
M^.4??_W+Q[]U.L%O9Z.KX`NFF*,$1\$C2:;JNVO$OP;G;+[D9#)-@N_/?P@>
MEL$9>Z0X&-#P,.AT=!-G2``GHUE;1X?]]6_W\T@U"S^^[_:[1[U^/^@=G?1_
M/'G7#TZO99.CT47PV_D4T0GFP?=WUS]HX:&EWF&_=]A;M78-6HR):NXD^+G;
M/\H:/#XY>G]RW(/V,LJ8T*\/(%,`EJ#BT\$T2>8GW>[CX^/ATP./#QF?`&/O
MN*L)#S+*DR=!"M2/QYJVW_WM^NHVG.(9ZA`J$D3#-9=LQL37__#A0U?]"J2"
MG`C%?\5"E"AL:N4*K!3ROXXFZ\BO.OVCSG'_\$E$!V"#(/C(68Q'>!PH`4Z2
MY1Q_.A!D-H^EX.J[*<?C3P?A,@P[THZ]]\<]R?_=!0O3&:;)*8T^TX0DRP$=
M,SY34A\$LMW[T6`E/O#'*,3Q8<AF7?ECMYJ_FXD7HCA,8_7=%0A3$!,_)9A&
M.-*"RE9W[B]OF"2RC5XOZ`2:?O,CHE&0,0<F:;4QZY4_0[%TCMLIQHFHL[21
MN`C5\P2X01RTF^*$@+T;26/D?*9HMPD$`VEN,1P/YS+B@(UKC53-]8(BG2,Q
MO8S98R.)MIB,`IF]O<:OS=Z1.S*(`_Z[D@0^GS,8,U2&8O@D6$RRT)NW$IB<
M;#70E)0@9\S"`D$L@Q7C18/D`JN(-$;B084EF%DF",U51.[B.!'Z&V6Z3J^?
M1Z?O\J__<RH$R'.><NEGNH,8/>!8=5O^O;L'$26V$%3DG\^_IV2!8HGY:7*.
M.%_"?/HO%*?8(+HCWTJE#>\XY47M$`]U!_"QX##;LT).T17I+(M?'0+>H?G'
MG,V,ILW[8XV$9SS"_-/!$:07J0"AV%QV*$/%(Y89`Z0>^P%M0!<@,./+2T*)
MF.+H"V.1^!4GP_$("\P76!@@<^+R$S`GT7.XWGD'5Z::=?SOW>AE:Y>@\'88
MW'`&<V6RO('HKS(C&,MS.5.`8QBL74WN&0;5PGKKZE<$/9"8)`173'LFHKV,
MRS!D*95YX!(]Q+ABGK80[LUG[&9>C6&+R-X.YG_#W(OD+$RCD11$#--$+D+E
MHMX`236YQ\!4"Y[#\]X[>#84JQ[1?AB_;'43+MX.A0UAP4MN$Q9^G;(8A!5R
M%DB6U0!86'Q`I5(;`U0>8^2$2B4.;YHHX3$&K\^L;UO2&:GVYC;UCF*4UUN'
M.6>S&:.5`&R3>&S];6&]34I/HXADHMP@$@WH.9J39+WCMYGHV2@]!L(JL[>Y
M!.2FZ4P:$4?#9(HYN-*<XRFF@BSP@(9LAJ^8R);W=^C)G)`W:\%G_)KJDN/Z
MLW>XCG""",719\0I9+-B0[,+/"8A,:VM7)@\1L]%_!RP?L\-,=\3-!.%O[$_
M#'F*(Z=]B0I:'\"QK_1M4N>H''N'"J1N<YBL/C_-934'O$Y%/NL^:36YGUO6
MU3+K\?)C/3(?NZ7*VC/*;35U1EUW.W*LNZV;"]@X6#<8?']/40II"8Y^\*<:
M!S/H>CH]72`2RYVQ.[:1R>91[0P)$AK\L'$+S<;6=A56?@-33(3Q3/947/&(
M"[(@`$M4'C+.7'L;.3M"(<>6LW*K6=<ZQ#HPQN:<,`Y3V-Y"8<$4=3[73L@,
M:CCE"WO'9BWQ)=@!0E]":`I9WCK2G>$QXWF6#LDY%M>$*ID'-,$<"UFZ*;:2
M94S7.)FR2)8U1:("J+%>^X:]^^%7VW7?-S2!MUM'N;9T4ADHC%1[@W4/0T<[
MC=$0WH)[BV(L1GB!:8K-=>LMBKV!6N&(J\5A65AO#7]%PCPSO\5\`?]HL8WE
M%2OM_O8FS(ZS+J-81?9V6;BIDC[A4S,@UF2^`F&6UML-DUQ2&6^_J$*U<<]N
MB\97ZQM$]79?_)P)=2X@WS,P67Z;Q.?)8%O:>K?O[-'XP[$:H+>PCK'8OD"Q
M-]/;'&73[@5)O9V$Y>E-T%J>QKV`D1HS=<8MU\L8>2KIO46D1FYO9X-;'$.;
MD^SAJ1BD/XUF\@AN(H?^`MN!<F7T%C%7!;R=3>3P?R1Q/)C-$>'2W2P+1QNA
MM]#8!,ZA^.`=%##Z$YZ&2<K!H\ZGB$^,D[N9S%L8S.(V+':^Y4XKHZR8L]C#
M5P7M_^.62H4YO)VZ;M`RKW1=$HIH*)U4>K2IOF@EW=^V:)VSKNJ,5ME?(>FS
M5*AR&>XI=/@E17*=A<NCJHK0;RM72>[O>N8+(E2.\B&]P)PL5-(RH#)B*W>!
MI?(-QXGQ=)4[J]_`-=/%*9%[1DG*,G:R:P$&5!ZB5!H/Q_H1`=,(JB3W&XYZ
M^>M/MNUK-%W"O$HF-#OK$2[O0&"!0BF==K!L[C4?5VS$[3>(C=7Q-Q]<YSN9
MMCI),I9B;:3^HV6774/CW[:0EM&>H&]1M`&(DLC:_AYF#ZLU1"[L&:9X;#R_
M:Z7T^42!0=S7R.0L4_[JD%+I\))IOK?3^F'?'0YOV572`\)^*O*91[8L@*R3
MQ!M.0CPBXJM8IXN&*J0SE]]1R5F-')C*TZHO#\O*4:1HN:L,>03+7+Z\G2*^
MM8GFS-7^L5.A7"U8ED'T6@>-MZ\/TN>,CW<Z9RS;"U2#?IXS-M\N<P-#2NZQ
MA1PC@2]P]M=49FS$OJ<CJU*Z&\ZD,T9GRWM`;$"S1!/BS2FL!1:V1\6;,.]S
MV_".G89@?H[/4D$H%@)GCV`I>+)?3$7B9NS[C$,-(2SO-[HI6+\'N:\,=TL/
MZXTK+BA7,'\+&%>HY^\.*`@=8ARI.H<\)30<-X*X"7<;,6ZBG[=%[BU/O9TR
MGMQA/JL^6^_(UT9<W33S=ZMUVS%=,75D;".HCJIY_J3Q+IGQQ@-$SL;SMB9M
M46)5N=TE<S8R[^>4RWQ5B[YB="*],[^,XDHB.GR(R:3XQ&GA\$L#;M^&<`6`
MZ],R#?3S/VT>CBW;>#"^LR^PO-=7?E-YX*)!*RT$?2<]'8+XBVU%ZXD%UFUL
M-B-)(K>CKABBO[($BX$0*8[4I"/WEO*=*>/!CIW::1FBS]!48^K?I2W:12\9
MAQ"5\G`J@]'8>J=9#7W+('702,=BUQ7N-Y!4&8WF[1KP\WB,PP0`>PK5X9(1
M2O"0FLUB<.AF[*V$N9F*WMXOM;D*DH%6WODOMRV:IQ\[-M3&X+:CJKJ(U!(G
MV*B?.>-=X/EFH"UHI5%TN&;(BX7PZIG"71;"1N96QNLF"M9?<_/GQ3:[#,`*
M5ZR^T\:_TW3RAC@L9;$?I]LF:2$>VTIX.XN5#V6>SAA/R!_YB6B8C6<DG1EP
M<N1K(7B.FGF["KFG$,IC\@>.3(\<F`)@+4<+4:S5R=^ZTP6><QP291?X'*M(
M(I_[W7!$`XIN;"V$TDTQAS/,^YKU"@%D0!-8^9*'&-O?QE3#T$(,ZU32Z/D7
M3M?/=F?EDBL('U$F]C]Q'%TR?F]^+L"-KX58.FKF[TYS_6-#Z]G#@&PS]A8"
MW$Q!O=KPL$8XPB&;4)(%G8M\I\E^N5HU>0N!K%:H:3WA#8%;YVR&$V%5A^5<
M&5L(IJMJJTOU_(-5E2+5&\SENR5@96S+96V$+83-IHJ&R<-=FD*N5KS,05X;
M143V1K_:S+6*M85(NBNGL?W).VS+&[X#FK\>0,\.KF]"V+6A%N*^JZK:"SS<
M8MA6J?2:3B?$MWB^"7"WM-(X^G>=U^8C+K+XICX+8IE4*ZE]@\ZA[%BICTYN
M_2M'%4[Y;%Q<5G?$J4#J&UP.(\VNS"H5^NFP^EG1?9?Y53%[J$03GY\P#XDP
M/WM7S^,;@`W+_!:M=)GKJ`)(#W!4)R3M,YV=M.6H%971&W3^7;\N3['*E%J=
M1Q<C'&*RD#*/L'J?W0WBZNUB+(YQ:#O&OT,;+41W!RTU[!7IC`^Q5FE6,SAS
MFA;B9M"B_LZ1-[CI[33Z;YH_Q'7'Y/8AZ!'+Z^SESM,=RQ5V/2/UZKWYAGQ-
M&O3J]LA]J'K?X<]K:UX7X`;WV'QX\PN&C#=6FP>NG;:5J%BU614JW_A6H8T<
M6N[A6UZV44W:1B2LRJP*4F\,Q/K,<G;_%^13.B+#8E6_M6C(SV-$9D9\FK;0
M1MB:ZNAT'OCEP<RW&4`D4P9I)O$-#J?'_\I*:'LWO[3.<M^6U&"$QP4K"#*;
MK]?,-B!^14G*\>:;?<%9Y#UB0AV@%"!W7@63?=R/!A47>+FWU:VZ)JQT&U?^
M;<WE8>Y]YYWD]XF!,8).(`M",1/0`OR3-55Z.S&B4:":D]\;E=D=@UOI>GP)
MHY5,*!F34-ZEDFUM@V/=L)B$RJWJ$7!MZ>7M[]ISV?I'9>OG#4DS;S05K-L*
MMM38W?*7D%_(Y!Y?PZ(<^L^OQ*@WM(7QY>UJZ:ALQN.R&25?H!@#HXB[VZSX
MDG*A2VGY*\UU1:W>A&[MO+Q%W?HM&_A=V<!Y,X%N1T4(U5*0-Q64=-C=Y/(A
MA11'5P0]D%C-,26I-WYQ,7VS]EX>@F;]EZ'XL0Q%WERPP65`PZ33,V*V3*P,
M9T4<8K2%\Q5BLJ6GLD'?;\5@R1@HSL`HY.YVRRY`4+%(/NFF7D@SP=1U@JMD
M?WD+5G97-N-/93-N<"M_-(O[3!_,KXO0-P\X^E^)ZY5\K]1+V6`_&_TN9_I[
M4!+N.?G5@\"_I_+E>0O7"7Z;YS5RIG(?90M]V,Z.-$NP*=?'KF1\@`$+__P/
M4$L#!!0````(`"M[##^[95Q[^BX``!4X`@`5`!P`8WEC8RTR,#$Q,#8S,%]L
M86(N>&UL550)``,A?D5.(7Y%3G5X"P`!!"4.```$.0$``.5];7/C.([P]ZNZ
M_\"G=^N9[BJG.^F>G=OIV=DKQW%Z?)N.O;8SLUM75UN*1-NZD26?)*>3^?5'
MD-2;)4J4]0+UWE7M32<A((`$0!`$@3_]^_/>(4_4#VS/_?'5U=O+5X2ZIF?9
M[O;'5\?@P@A,VW[U[W_^UW_YT_^[N"!_NU[>D4_4I;X14HM\L<,=_]UGP_^5
M3+S#BV]O=R%Y/7E#'E_(M??%I63FFF_)Q46$XMH(&*3G"ESOWUXE?WLX6!PM
M^^-W[Z[>O;^\NB*7[S]>_>'CM^_)^#.@7"YOR-\F.\/=4I^\7G]^$Q'/,%V^
MO;I\>QEC^\RXV-@<W4?RQW=7[P7"#Q_??_?QPR7#)T8ZMOOK(Z.)L)EP@Q]?
M[<+P\/'=NR]?OKQ]?O2=MYZ_98"7']Y%`U^)D1^?`SLS^LN':.S5N[]]OEN9
M.[HW+FPW"`W73*``31'<U????_^._Y4-#>R/`8>_\TPCY&M32=?__]WSS0_L
M_XU_(.S_E,/AIXL(Y@)^=7'U_N+#U=OGP'K%)H20/_F>0Y=T0S@U'\.7`_WQ
M56#O#PYPP7^W\^FFF"3']]\!_#N7;F$QX0O?PQ>NOH,O_$[^>NV%AG-G/%+G
M%8'A#\N9DL7O,PC3D.]ZH_<L4K-4.O#3':,F0R=]#JEK42NB%.!+%INCYT+"
MD0):S\P@=$!B/#_"Q[_ZXROSQ33_<>.9QSUUP[%K3=W0#E]F[L;S]US`QH]!
MZ!MFF)TQ`+L`M;G\[L,EGX\:B-[%)`(-8S]+I^&;T;?8/RO8EB/>F1Y3I4-X
MX8B9%>`;W]N?P6'HU0#ZA_/HG'*48<>G@7?T37KNO(L/,!O!(,'V4O?B855+
M*/B4_#GZ%C%<BXBOD=3GR']&'_RO/PD033G*:!#__,8('CD-;)O8&L:!F]=W
MU`F#Z#=<<BXNKZ1U^9W\]3_&04##X'0]Y(RI!O4K3>6D@N@4CZ@M)SI+R[:X
M1R^@=VDR2V>K6)C^/%ZMINO5Z;JW0J+3F#8^:$#B.3GZ/NBLCI3FQF(*JX+P
MO,R>#,05W4)B<E(B1Q&#PWQ$$F4]6L78$8EH'H)H3XQ@QW8A^,_T?X[VD^$P
MRH)Q.#%\_X7Y_#\;SO%T"ZL)BR/ZM1A+JX(6()9JU"`NKRH,B#L!)OR#)N"]
M*TTK7/!_I,!'Q`A)A(%P%'AJ-7.?&$V>_W)KNW:PH]8GS[.">QK.-TL:4/^)
M!HJYT8+$4:D:3*452@,,2YVT2<N)80S9N_*T0/.(1+"$`X\(`R?>AD0(!N)J
MZ>RY@W"M*EVJ4P'O;T(7OG>@?OBR8*+`SYO,8A[@/,B67#&_Y2`XTZW#1GKV
MR\9C69MJFG(J&X&,R`&`^,9'(S#RVJ7AF]X-4",V%C$;,1BW/M@6I]34X-H8
MM7'!/:`IUIJ'8^5Y#.DX5G'^XA1V0EJ8"D6W.W/]Z<.=;3S:CAW:-&#*O0H]
M\]>=YUC4#T!CPY>*^(<^.(Y.U64OK76ZL%AZ68^^G/S=S<;7L[O9>C9=D?']
M#5FMYY.__#2_NYDN5]^0Z5\?9NN_]Z[137E*P/FNDT;P#1$H!A&(21&J%V@L
M`T!7+8V0HWKT`-2G7O#120#[CT#6ICH%,*Q8Y-@TO:,;!@OCQ7AT:,4A4#$8
MR5,K)3WCN16.1//D2JC)^T]R,#F(T?U[=V=1*T?'LHXGX+\8OF]`I-.UEI`6
M$\R/(22#0'*-@N5R$!QAUV$C+?)EX[$$OYJFG$!)D-C:]Q_Z.Y]HX?P(()*"
M&I*_H[V_#<>_T?-K\()_*5JJ9W<`TUHQGP-P#$N/[BD_$-,-U/'[$&,@+<QF
M?QI4._XQO(A'O1C'\*(:M<_\V3,^Y2#]G\L:DBU#$^,P].W'8P@>+`D]YLP.
MYKBV8+@HV^!$4*8L4:1P)-8]DI+H[/51;AC>K9&"E();%CF2!#!T1'Y_^?;R
M\HH=UWSR!'`_D#^,+B\OX7\DV#%)8F[A,=QYOOT;`S)"<D--NG^D/OEP-2)L
MV2^YV_@?1Y>2#Y?\-U<_D*O1^ZL/HZMOWT<X["`X`CP;ZB6NI2:^MV2\W?H\
M/9H<.`.4+2*Q76;_F0I8(DGUM>V:SI&C/;H6-1T#V#2/^Z/#!CQ18ME/MD5=
M*W@#]]B_9P1^^/;;T1^^>Z])QE#4B.GWW%^%D"S.EWI!_17,LI9PJ(&'H&Q5
MK*GU3P4Y#)4LIZY:2V/U1+C)[84/+%WBU`?CV,)IS4(>:`BZHV)%K3.G$,/0
ME6*JJF4KMULAZTIG?.#JRHSOY#5F(`(8CHYD6:C2#S%Z2+J1IDA;GH0'-@B=
M:)%^7%VHCLU70@U'*RHB]!4@0]*/ZI"W2L@\==@;15,ZX:3'ER/>?N^YE6?_
M_#"D]R`*<C-//T[&X`7N4Y34/!%J0:(O09VSH`88VG,<7=+RJ2,<$O\(V#D'
M*#JC>?(KA4#7$9TS7\GP`>B$YBDI*TGX1[W..4#4B=(3GG+T0'1!?;93#!V,
M#I2>B@JE!^E(UQGEB#)??9(K!QF(]%><X<K&#T8/JL\\A2*%>73K@8<>4VPM
MRX8+-<-9&+8U<R?&P0X-9;ZE:C12DFTY\9DLV^*A:&FV9>3D,U?CT<RMMJT+
MVR6F`.@_X_9<PF$X7.).B@GO-:E<W!)3:Q[NJ,]T\^#3'74#^XG.7-/;TSLO
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M-)_8/J]R`U[M8/I\H&Y`JSH$J(=C7>&6DY^]OBT>BW=U6T9/3F#F!^@`!._S
MJ`3H_R!2DV0^7)2BE`"#.(D`6?,-]Q]7GJ-.U3D9A2?A!<2>"G9J"*8\Y\@H
ME`EX0+J%<21@`U&D6)]0/HZL"@CM\YP14"8S4-+]ANT8CL?+NDJE4GIYI3!8
MYP\-1K)GD1(`O'-))5$%WK^`X>;02J`0CBL-B4]!178=\7!`'89S*_KC.8RG
ML;6'RNNASU^MEZN(+C#24:(6:YD3AA8DVL&C!G5Y7U\`C\A6@'.)-#((^C^E
MM,+0IQ1#603X6L;T/_2/9GCT&:F3G>%OE>6NBH>B[39*LD\VF=PXS)=)62=;
MTQ<?RA%,Y^@UE"-7Z=G<RQVXT,];VN<LU`!(R[/<G^;%1^PD"T_!8N%('/TK
M(3JM@@7#\$S<O>=Z67JDK%2$GS3@<!9!FZ'TDE0"89E)3<+R(2I(9R4VAR"O
MI3Z_Z3],=2[]:3@RDVQ(T#<-0U>*MKX+XP4.4@^N1?U/1P-N7&AA0UO%0(2&
MOZ4DQQU^"T=U(M!%DE!%0OX>7(SEM<]\LHU&=R*ZENP7S`NO-25\O:.BW:!W
M##>.]X5`WV%B$)\>)$O>AKD&C+&`FD>H=.!X[,>-8?(*R\38^I3R<;RS/--@
MLC*],+2A]Q_[KG_P[8"2G?$$2L%^W@>`,4%O'2FQ-QP0,MD-]X4$]M:U-[;)
MZ'9>V%#K:++OVLQ'B5'[441!*ISG!F_;G>S"ON!?CY"4F.FNZ.YO__]DV"YX
M('/WAOKV$S_ESEPXA`&=D`.R\&FH?"NB#X[C#=1E+^T4Z,+V9DK/(RR?3,#`
MR6M`\(9X+DEPD!02>7DK$/5M#EIB=+)C/_'RFE"M01379`;SBRP3W\V1C/KE
M'MW7R%/5,;-W@>SR4*WAE7>SAE:,JT6O5GQKYOX<?6F^B=HD%.UEI<,1/%P-
M\F,_MV1LO]YN)2$JB9BY)(8A\PWYI4NMKG)KSN:B5]M4Z<$/G`U-W[AS+OKS
M.&\]G[)3B>@78KZL&3D!.\HS^B*S>DW9R8FJ'RC7PH#C=Y[!9-KUK`&.%SJ$
M%MM!",HG`C0S.*.RWRA633T<K\-[&?FG;=V+QF+V<E?34]`,7?Q9!@11VKC7
M(C<:+D-_(Q)!X)FMB(+R/(;<*"S9+B0V*]*9(0.\@:@;4A[<C4.MFX;>HP@5
ME-0+R7=R(-,/%-3E15YX%EZ2=,G#NNHD/5Q&=&,!@^>@R:U;"SSTN6-%U\OP
MOFCBN8R=(^-H'L?YA1,IQC%7D@:?;=?S[?`EVAS&KI7%(MYW?Z;ASK.2;5IU
M-]\K!5@[;>^3G-W%>_L\YD%#$B^U\)JZ=*,L>:0<C2D@2N+SBYD;BNB:T;`R
M_^9D#)(+5D1HQNU*#QC(A(Z?#-N!NCYK+U5W45;"N#8"V]29<ATL`U@4?6:5
MRU:-`BU+YQPR\PXV#8G#$!#C<'!L,ZKX9,H"FU!94V+I/XVG-0:C@X.X[8E1
M`:.RDF@:VXAP?$B>+/*J]FJ6)D:P6_@>-!:TKE\>`LJV_CA1<6R&]I,H]U.1
M%7@&(C3C=";+)_:I)A9$$W46I?E[!<AP@O2F0)1/2&("1HP"(<^P+?9`73F+
M$2KR^$)>`S9VLGM#DJ>_"<9!O*0=6_]]E([ZVEM2T`#;H1D3QBQ7*TK>S:>P
MRBQW-VW9&LWM?P>OP'-7O!0468X_!9NF'WV,N-&NRGX+_^9YET>AI0,Q27C3
M%'^,Y#TN\+.^0O-V>H,TWGM^:/\FK\(7/MW;Q[WF[9,"=ABWD*6,E5U)%@(.
MY7ZRA+B\,*?&0L:"G=P&'@0@.Q:X^5ICO=]BUF&JX$KSE$^)`.L*!6/)^K,?
M#ZY/#0?Z$Q7E[JEB6Y50.#9#DYFTM:@`P;(36F0USY_LW#2<QT<"190IL+VG
MF_6\-/V9@!O*;)%I<YK8OQT*_X`2`2GCI9@+/5`<8U"'K;1%T('#,@OZM.4$
M,`TJ*E*D8'JW"RTQ,B(QL"A*4<)3CR&'C(<P<T-&OOWHT'$04.65<!404AA`
MBY7,@;X4`NUHKD&5AO<6@1&#P_5_=&Z#C02,C`O9Z/'TNC\8M@_^\'QSY[G;
M.[816H*HGZACW7K^@SJC4`\6Z?1:A[',Z54'$.WTJD]<3@IO[6?FSG&](7:,
MI_^S:@,6$EA0(X"^X.!2C0@@N-AX_L4Q7PBIM]-JYTLTI`<1B2^NF(YZ*(;Z
M)"+/9KTW$0D\EN6H3V/9H7`CL!'Z;(IC%42\>S<E+?`D49`(!TDA21]]1R1!
MA659$):PS^IQIK=U;>%7W=`-94Q:LD"V8C[*0;"JR56SD:TJIQ[?>]Y]-3$%
M13]C$-B2(Z"HT#J6JIS!24QZEW7LM>K&MDXZ1LT.*'`/P7FX\0Q?%HS>$+)W
M>458!>>ZP-CU.G18*Z[640:)Y1C4H2XG>:\!^HVX[V86P+*#@Q?`@X,-.4@\
M(W(`3#PZ1"-TO;L*C;@\"8$#!G$M)G`0CH1,NV'NG)HDB"O98U5G2%"\-@)J
M04DIRGRADCBY:C!2U>92TC-5F@M'HE5E+J&FN&DL>831D%,:#^^_]'(MJF'P
MA:!Z4D)UKV],F-,>T!LJ_IM*PY%MW2NRXNH@0'N)4I/%D\<IFM!X22?U*%1<
M7@8G*60BZ`7F.-6YM/]TLL;<10C(ZPC%&^`T2?F2:`:2[W7*[0+J'-I6Y(5'
M941=BY<Z+;US.A?94-2T#NOE*JN#"?5UE&8^I&*AZR`8^K.#H@75AQ[^,X.2
M_/O*9-X!/R]H[UD!VJ,GA`5$MS$B^[&%ITZEB`9E<S18UK`])5@&9H,J*54D
M[6*_(VB-G0H;E'`[L-Q_63,Y6'MC\W^.-CME'@/;I<Q9@4J;\PWP)/^BNA^M
MAP)'3<]A,ZV@=>"Q5+,^C?D*VHRL'1QCO`T9W\T^W?>ND&TP(5'`<QPYE"18
M>*E;X(]K:X0**^#9QYHA&I-,_!9:Y53<G]1!,!!#4LEBJ1E10@_&B%106"J.
MP[I`:<Y:@6%9Q"QR+"/1G@K['@5O%7LT-KYG4FKQJDH%MT4ZUJ8.!B1S4Y_)
MC+W1!T<S.'5)S,NJQ"!*)@3R:G-@MJ=E+D\O</7,#Z(GL-IY?KBF_KZZL)TF
M[$#V_S+&2K?^(L#![/IJXDJWB@#`+J![4NJ9:O\1Q4;L%&SRJX2M65=L-=C<
M.UTLS`V]CM'0!![*-JYM-K0@!W>M5!!`:QR!&WZ(MUEH=_@AW:I;B4,Z]GF,
M8I]V0:1WP('>]@*\@[IDZG4YT>W/K>T:KMG"E5,IHD'9(PV6->Q2"9:!V:=*
M2@O>IDF((5XYU6>GPB(EW`[LRFD9]50-Q/-"\&5D>M0=9-+,'QU[*^IK*Z:P
M%@:L5S2UF<P^JM$&QU++VB0J^[6RLX@IT^,<GD3G):"]JV=SMA(,\1-??LB*
M4@`Y&C+OBL<Z3XPP5K#_(-1\<V.#@72M8.'+[#R>VCUV+?$+RO29_Z;BR%T+
M$VZ`Z@RFB\)5-=!@!Z]JDUHFSH<(`PGX(P!+HD:+9;7&';=*,2[>]%5R*IX[
M0`0Y02A^B1WJ0EG:!HUAHZC-?`/US.TPA,KD=Y[AWGLA#69!<*06C^BD*I2?
M3$$#/`BM9)LP'/>8/0=)O\UGSZ=0?9\SWY`4,@+8"$='!#YRRR]\NNY04-6Q
MM@O6P6U(L>X`ZRYGW1:LBQN]KEFO;'/;(N_\P.93D_*B+YP_0S`N669GN#3#
M;_'=IUO/9YZBO#B8;T0'HPJ#K8#!=8E*&2ER?@H!L-V<$J+RTN8%\+PJ"#PH
M=L>DZXL=[N2V%Z%`\VCJ,!+[+AO/)PD46!`!A^VA=+TJ0XRH-@YP#3^"VBQR
MBG<M-]ULJ!DR.92E<99,SN8NSR9U+?@/".B3X93<J-9#@;.0Y["97LHZ\'B+
M64S/@OHV]!#,/D-4+&8]%#B+>0Z;Z<6L`]_))G[@GUJ%AA^6;1G%=(Z94?']
M%V8_?C8<99T<[C[""9U?T-$$G!@A>:1;VW4AX@^G7$X,SA7D5\^A0#UU2[?^
MSKBD[/=*_GJL3G(\'!S*#T8.T'OK>%]F+G/`]OR@5'&?J@V-5+^D'G.9@B9Z
MH&@53NJ0ER\>DH*&$CJFXP5'GXH(?]R<S$[P]7^!VB*#7`T!GJ00-+PD580$
MX5-+>>Z_.?K,/HB=B1T<%)JD#X80\*O!3AS?TX#I-YRG35"Q_8Y`B8`E`I@P
MZ!(1ZB58UY"Q.#YE"<;"'96[$9R_N]'XRB#<^3QE5-[,,)@R9)B1ME229]0Y
M/&)5%7<H!<'/<E6QH<IM/1T_A.<HQ305O&07PU`?E6C2FGU%$@'%EFPH*B!;
MM2_IYNA:.BG?>9`AJ$`Q&VH5R(X?A@H4T903*S8`(:?W#$)/Y9]W;V101((-
MXK:E?M=876#T^Y>:G5WU(`=P(W-FJV>H%]:GDZ5Y+5.?F\S]S(`;G8K];L&F
M_9ZJBTV>C,(J55=(;+8&768(7FW(`C*&XR;5(X_`,%XDI,7#_\K<4>L(K[?N
M/7Z]D.I\H++M=0`1`@"U6(I#`%I0_08!:I"4/UE*6$CB8=`BGI2&QPX$M,*<
MMR&NYU[PDW.8@D<*!#3AZ88&]M;EE^ZA1ZAK&H?@Z+"?^?;+O@K/?3>>%T(:
M4CK^&>Z,D&RA.6<Z9@!UQ@$PR$48($Z:>F;"]T4VB?QOK]F_#X8?1K]XDYE5
M/C1Q!MZ"8'$P.R`6W=@N[Z^4H<)X](XA,1PG_3C+97Y$P8,76$W#!5:I?_#M
M@$;^AQ%Y'YQ5@]^,\J;P6Y=W6Y&U>AEQJ5*]Y)%]F`-8'J1N,0`VGR&4)DP"
M+0<!)MZ418Z"[::9;-'6\D?1`>\^$8A$#%X+(7KY;*UWOG?<[M*)[H6YE^?A
M0;#$31B.#?,Y2/JUT^=3F.]FF$(%^A#7!8G3;T`+.+KLNP:D_,,V69<5MV5-
M,<(.O=0_83*GC;UL58-<WP9V"-)"F?5EV]3<MY@A]E]X>F@P<R>>ZU)N['^Q
MP]V=;?(ZT5N?TJ(*!TV1(5BDQJS'9NEL3/W:IH9DY@\C$A\(;X11I`7SC=.,
MD8K404>@)4:,%T6#NYP%R!-G[*+/0:6M[G(2O!-1B&R8G1J3GX<VG2L5=W/@
MCLE'P'M^7?NVM64^):3(UYFC,BP#,F/5S%;:+S6*81BN*OIJ62R/:ZO$!@,>
M)3[^\&%8:MJ(<95^%G`O7KO@>%H#7/163%+\-#"B9>*P0^NDB+D5-=FIWA*_
M"NWT<YZQ:XU-TS]"3K<("9;/87=?135Y74]F@8GLZI-8)K5;?M3:.-^D'O7&
M>LD_3B;B)6%`YBY)"``020))T9!^C,C(()(.TFDH7]]Z8<VO5SB_KR:OE+8O
MD'-KIN8V]=H18G6&G%N[R[FML2T.8G);G,\^O."9>V?3HZC:?NVYQYI'^1SP
M@'Q>)6L:1_43R&%XN`JRZA[%'88D3HY^!#S8BMN<S5,WMI!-K#`A^GJV8S>@
M)5Q4<V=AO,"#\KD[=NRMFPI>5O"OB0/7BM1BM,B8:"%`LRDUJ"O7.4#$]C!(
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M$*`4;#R#Q52EQAK0?9=HK$U:P2LQCH-$2/CE!T=#)!XB\^C*!+"7PVDK["ZG
MB_'LADS_MIC>KZ;"0YZO?YHNR>1AN9S"+KM:33LR%1K5%Q%9[&^'3>P:+S,)
MS/(I65+(3[=XT3@>ZKR&_,6X"53%'MP8*\XNW=)DI/?QABBQ=OI6R,X[G>OY
MY"]P"I[>D,G\,R@%SA&X&_9N,H5KTGB)1$PXYI&X#;]XY"G!\2/&8;C<HM8L
MIPC*3'G\7$!=.!3H!]?J(D$J_786JYGB;[4P8"GS.53F7P[//W^>K;GOSK>Q
MR9P??Z?W*&??=EA*D/"(5`;-`$-/4*I5%F@6E5XAV4%?*6O`(P6@ZC*8B4'I
M`J.%H>H16+QY_C2_NYDN5]^0Z5\?9NN_]Q]S:LI$"OX;6429IWJUHVZ26HO:
M_Q@SO;9`MV\=8ZM6QX":;[?>TSL&(C21_>-4`0O0]:L@2GY``7)_K"W@JEDK
M7L/:DO3G&"D!K&>OJ#QZW3)!,9R_4\.?NM8-\ZJ:+ZX:<__K7,5EM.2J<4U6
MOQQG<T&(PACB`P2^0-@G"'SC;+&XD2?Y150]M1V94*#M7R!*^8NDH7!0$U$H
M0=A<#B+D4>W"UF1@S<:UM_0"&]Z*I[DY76CX6QOKF^!I<5D!Z=EK.65.>/@R
M87A\PYFY%GW^"WUIOJ@*M/VO;BE_T3(7#FJRWB4(FR^\0$XD=L+1$X:_J0SP
MUY?<990)X,<P"-E)C1W26A.(TF^@28<&YR>B4@+1@MQ48F]/B,236_ZM4?QL
M)/E<4YD2+LB2'CP?#ON0:Y*DE3>6)@5V-#DJY?9$@@K'MB`[)7C;DQKI6<9?
M(>(S#:7EUG:H/V&>R=;S6]N#3I!BR48A;UF1R`QI+@D%Z%H3`(Z;1,@;+ON2
M;FTHZ.2&]\:^!8>R&"O6PA=SEUWY[)CF2U^$K[6U3Y`3P-YP\7_VG*,;&KX0
MU]:VAAQ:K.57\)==_Y-!S06@$&%K$A!C%W:@J=G_A3K.7USOB[NB1N"YU.+-
M%DN"^O5$08D>2R0J^,V*AF)P<Q$I1=R:J,!7+GZ%SY#H.Z+EJ=]0:!;'1\<V
M;QW/"-L2E`Q*+.$HX"LK$*D!S84@AZRUA1>8"4?=.-`D(IA1*PBSC1-$"6J\
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M`BB'X_824I$?3[PFW9WH=3D!ZN8YR=MK=RL2U-M-*_Q>D.S2+1B+N^:4\]]#
M9P"/>5M@?W@I7N/1\^$']L5OR6PQ[[<)=7N3/R)K^$C?[[IZ68/^#$Y4Z-BU
M5M1_8C\$2_I$W:.J57W)>!R34\E`9'.T*>_,Z)21>BHW=U&A:)>Y#7(TD<,Q
M1+X.[1//<4#"DQH64,*"K:EHJFXQ0,<3%?_]8H[ZD_^IX4/'^F!!_>@ADVTJ
M9%\Q%D?N2PF/9+Z2XOXF^A=J;W?,YHV9H!E;>G_</U)_OLFER90M0$T<.`MS
M%J/1@C7BL#/#59>E4X,0P1.)@`@,L*GG$Y=&A*/IWRW!X!+1B6F-74.RFVT"
MX9V;BM:FT1GO(<OIMVR9)NFLL:T,WM)`11?5\4H?',?4U&4OLC+G\-5K%-6'
M=C\W5/QWYLK".X$LZJ>.!E;!H456]1B*UJ<6)TA=P..RBZF<5V68J!)N`/W`
MRQA*`D8U.>DN@*%!>D5[[53%RW0R,<J!NC$WZ28[T48$@/S$\<7P(>LM&!&7
M\JJE\6BS*(S3X_XDRJ#?)2T;98*N:D-2CT?:@:H8B+<<7<H[TY@R4O,MZD1Y
M^M3@490[W;]C>@[EZ2Z@H`*BIJTIT[]3?\50]UX9ZE>;*?A4\D*A1(FSP_!T
MMXC<M,J6T=FIIIX05B05?$A4!0Q+C+7IA%TG:F+N1:TP9&7I>%\R4HXY_&S1
MQY`<?+JWCWO,F\&BW3GN`\(W:%$3E_V"LC_6=P:KD0W)0]1EO=QMK,MSS[ZD
M!I/Z#F;2-&85>V4)OJ$YGHU93WNC<;\.X/D0S\-)&X_!N::0G3"6?8AA=M2-
M+[0@D"I753,1Z6@-ZCM3Q')R<]<LD#\2#1=R-^ZX#46%-IU!/R@%[^8"7:"?
M#(=?]AI,!_:@(]$A+FH,C:<.GSS/^F([SFQ_,&P?[J[NO$`5-U0-QE&"<M(C
M^=>CN3/15Q)Y*C71P!%)AA(8BR'PM:GF\L[\0/8W:(L6$#N&1/3O9#K#K><O
MF7OJ'\WPZ*=>T)]Z<,KAN$E'*O)/DXZJZ.[.SU(3JLQ[V7@^R0S&S#G2(=SW
MGFS>"!`H]\LHQSG`<`=N?N`IOM-GZIMV0"V-LXH"#O]84LI0T0E$BY->#ALJ
MTLN=:W&"D&`DAL,^/N@R<T_A2)]F2/@XGF0H';`F5,4=CO+PKJ'EMW#JX?BJ
M4D1^D8:4T=V+8IP06JX/H@.P'(VM!164?_(8+I?[;+PCK$]-:C]ABC<TPX5+
M[SNX:`V6G!X@7E:B7A@^CT][CD--KJ`*N3\##U+"Y+D,QXF433GM3(7.82V7
M>`DXN!$66$B"9A27)Y>8H%U7C`O#,6N/X4@1Y8X$,2E9?K;=SBVIN-J=S8[\
MHM%9$E_C761..*T)B].OI19CZ58M6H"]=VFI0551@Y:H0[BH3N8D&&0$E$=]
MGP`'6M>2)ARN=U3%E!V0D/W5LC?1;QYI^(52E_\Z/=#-H`"+PT<8/F$GIR#D
MAH9/$7_]`'_C:HG39A53)'!\76X7-9Q<.0[?N\T07.36%E+:BS\;D5;NR/)1
MV`ZLBM2[M+LJZ)V\F(YA,O(^^=[Q0!9.+FFYP5XYV;&OTYD+6B43-7^1I\*Q
M]=_'0/1C6'MLTV=B8CN4G2LA^+CVV#\@M/[`3HTS5[YG=K=CY@`\\02)(O7N
M\FL(^W'WDQ?OX-U]JM\]OVL^\M<__(-DYI+XDV2^(=%'2>JK9.V1^+L$`BCP
M9?@M_)O?(\'7`5?\?9(0@+)A8LTG<RN>XOED?D,42L+QLWJ?A?$>\J3!4'M;
MU_Z-"87%@\_"MQ+EBR`R#3^:Y3.6<[0:6/-/ANT"7W/F+]DF7=K!K\$-H^:)
M??6)!HS9HMG3@4*PKOK,Q%:R&J1?:Z=+3SZ`Q0"%]9F[A,,2#DQ2T&"5^HX&
M-.-*ZB13FXL#@VS]FDG39@Z=_DIS=S8#.F;+"(@!-VI')P2;):P7.VUZ\F3)
M^28A]??Q@;$34U9XYUWL5JK'8IBM"L(38Z48V+.)*J5"G6%PDA:!Y/Z<2[U^
M?D1/&EV/#P@,&=NMSPTUI/."5H-/X=LAO;"\+ZZXTM^F^16I[`G7D/\$)<W*
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MJL1Y__.-R-4)",.3!'88IJ2DS=PG`AF*86N%7UG<0>H\J/AL07PHCH!DV5KA
MZBR#!R^<^%WST7`@R8D9HO!%SL5;\L]CYV1"))O-HENBXB$8U]+%9":WS]F_
M]WS)7/1Q52(L-QH=W`]I!E;T:%W2@Z26Z<DVF^F$=,VM13>HNG<,-X[WA3^?
M!T5CK@L4QWPAQBDG;>K1DEJ4[B%C)7N_'-PP=;:8?U2H6CI0"-JFSTRL@-4@
M_>JD+CT%HA\!GC[U@P;Q$A9%=<]FZ8:!P<E;#H/'2$P"F"J$_(Q.GT4`CO.<
M/.L3K_EPM/UL5OE>'^_P$<<!L>044-,Q?+Z]I^.1S$2<\"TSQC*12AF)/)TA
M\DAAGY8S*EP'+U.YHTT[$T_`R<04S:)Z+()-J2(\MB2J@?W:CW(J\BH62]JI
MT4`Q%6=2CV@9LHRM545$OE+N=.U>3<[4UJZFF8/:I<2&(U%(H([X61:KI3X!
MQ\>`'<C8+$V?X$:]JD>`<CA2?X`*\J-L-EVZ.[%PY03DPP+Q4"+&#J+*_]S?
M&JZL,)+T)H`F++S*01#I6:I-2]*UH$*J6L*-(X*M3DPDKYW,2&?"W=84Y%Z\
M&>'1IR?=5>#B"TJ+!K(\2(R]1$VZC@E^%9/0AAL\=^.M<B[KD(@H9NGV6@*%
MZ1I7,I-WDI4@2.YR!3TECG.</E]04P;7B?X:>-*\)O@:>=+WFKMA"M$9OC5L
MGS]&@4+&CA<PNUOENI2#X'@D.FQ$CD8=^CNQ9S'1GD_MK2OJ.9HO:]]P`X._
M/8QRXZ[IAHU9&\\*\9(82(2"I'`0GG[Y&M"\&9%'CHDP5'U;A?:YC8[5Y+7#
M\XO>O-LR#-V8AK+U&YO,;!SYZU'>#`N2.=B)E[J!_41%OSU@ZYZ&\XV:JQ06
MPM&0#!XB$,4+>2]*GR$N9/MLR_JD&;:=@C)%/;8ZX1>V%8;P=!!2<Y-"4N.N
M)J4T=JL>/#-/5JM520$?$]<+[K+%@[)L<!UZ.7EQ)5V1>XBFAT.BMTP0F"5(
MS(*"4#!K&4M'QF'HVX_'D`=/0P_J"/1>4;HN!T5&JR]Q0*>Q3`02RN#=Z,1S
M0]L]VNXV.=^+S5^,8[L&#3[;KN<SVS63E8#'KI7%(DS;9YZP,G.?J'P@I<JT
MR@B7>),:DY&.,TA/26`G`CU)X1]%<LJI')'I,S.ML4,_"^F>VS.^M\%&-MUL
MJ"F[F,IG",PODTTJX-L+WW9-^^``LGMF[QE5;#X=^%/$.X[4XR\:?SPD%R0$
M_%C*]7]E*LIT.'Y86&EFDH>E&:W#D>)SR,:TXX.BMTP>\BT)5*);T!D"U=/3
MICSK/B%V@A@XY65BDJG[9SB0:;OS_'!-_7VUU3NI9LC`18LXAN`"7N^E-V8<
M66K$'F0A[64M0\97D/!EIQT.6>Y\#]<BJ.+WS\-LF<0*CVV^F<HXT]((Z=SE
M!;M="_XS3>IO*W@5*("/"`D!+!`%CDMY\W^D4.'(;ZO,QI$YR#N/7]U"5HRJ
M?CF6)/\SLETFTYE:Q.P<XF^5=Q:9H42.[?M^[`RZ:Y13[D>USI[SPG86?6G&
M`*DNCRR(XY5\DZ@\_<MV0IVT0-(7YYK4TNZI529"#HGD.@?UP5!;)+5.K8ZR
M1:4O,CVO8F#"H?E6$\,C--]KC[-L:Y]L6Z3HYIV\FKQ"2G7X)^16):X+>-MD
M6U*A&&/\TD]</A3NPGQX9&BY2(IKS7%WMP^E4GDF`](T%'50Q+GW^>IXJ;X0
M6!O/DI5KZM*-K8IF)!'W6*Y>2XB6HXIUMO(S.`@9!X]B(&XH>V!TJXS/U/!=
M9E.#!?5YGA4D@)I%9S$YCK"!A(\<\6317)71[LV-+LG171R\G1!V_4*0S)74
MLIUCB-.H8_@,E!]T0\-VJ15QD<HSN6'B:RHE/0(DL2R]3N>H2&"D2XRSN9)_
M)4:*E52!)(L^4<<[\`?+06ALT?SVKYM!I?DZS<TI+%XDWTA]$]TY#^'M"_23
MMT5(%@)B_,)S2YF#2X,D;;(B/ZHF#J2VE^<P&C?"/)?#7AMMRT2#A>?80%G%
MJI4!H#7?KF`AU89;D_;N3O=EQ.;?O>WW<+2#.RU[Z]K,E$%ISG1RB$0R"*.0
MR/1\DZY<)ENH\),O=QEXH9NH$UZ%O#5%BB.3[4Q%)+?MSD%GLMV8Z>+:?=>\
M+%*F%-X0I/WT_>J:/H?7CKI;>\GX8;P4SC&@>BJLI+SKHT<9Q3G9>;A>3?_Z
M,+U?D^G/[/^O>O7L:E&:?]T,PPD?CRC@LO4<N"YLQ_&/AE-EJTLAT#K:5C&1
M:FJK2WUWT=12<@L>2?A0*RZ5]I,*J,H,H,Q?AV`XI?L2M3:43*2HC.*6J5\E
M6XODJLK:MOT15->VY:DZ<8<[FJ/.[U?:GIN<=DTFRX?I#;F;C:]G=[/U;+HB
MX_L;,E__-%V2R<-R"9M+ZJ_]7A-VSK[\0-0.=40*S,TH96_2=B;Y4IS26;JK
M=3I5%:\_<^\(V7#>2(>2S]2`T?N*FB.=4E\W`E%00SJ"%WEE:0S=%$?(7D/%
MDB@%05Q'*5R),^!QFE369C#=J%(;N/=FE34IJ[K?+?)'!)ZNU4FG;V5;S%;>
MGW;3:++LGF/"R__Q`W19,TDQ3%2*&PFC-R(S7H$8*]1?CW+9`_/WEV\O+Z]X
MQT_>]_('<G5Y.;H4_XOJ)!K'<.?YO`F$$9(;:M+](UNJ#U<CPFS8)5^]_SBZ
ME'RXY+^Y^H%\^]WH#]]]._K^ZEO^5_CQC_\VNOKC^PBGK-;,%_X8!B'[!Z^B
MK(4?LA`/T$[XB3HO&'?L/C0[9H3R_\Y<*<\W,K>D,(U`?1',D9#7$;HW\(Y-
M8AR1"&=/B1^U[NG;FX53@S#BN>LNVS=?!I,GT@OC^)DDX#KE63SQFO4%^=0;
M[C]QX!QF8JH/8DC!LB"^6FJ+JQ'<[O*3B7,2".F7U=+]N/#IP(+7Q3R=`]6.
MIWH9,B("#RF079Q\A!:XA?01.^;'2NOBX%Z+M,1NADO)>>_LE@EQMBBL7I/R
MWES+,L)E!U3^!,2BUO6+Z(4:)^56]D*-F^-&**!IQFO>*==VWZ02K3MNE:M3
MBJ(YIUS0#FE.CQ&GFYA3`ZTI</N\)OREN:[B5?[[CI'&?F8_L7_`U2;[X7\!
M4$L#!!0````(`"M[##\P<ORG_A4```1'`0`5`!P`8WEC8RTR,#$Q,#8S,%]P
M<F4N>&UL550)``,A?D5.(7Y%3G5X"P`!!"4.```$.0$``.T]V7+C.)+O&S'_
MP/4\;/>##]G==4753MBR7>,85TEA5TWW/'7`)"1AFP+4(.ECOGX!D*!X`""H
MPR0Q_50N"0GEA40BD9GX^+?G9>@]0AHA@C\=C(Y.#CR(?1(@//]TD$2'(/(1
M.OC;__[EOS[^]^&A]^O%W:WW&6)(00P#[PG%"_'9%T!_]\9D]4+1?!%[/XQ_
M]!Y>O`ORA*%W@_TC[_!03G$!(@9)<#K7Z=%H_=WW52"F95^^.1X=GYZ,1M[)
MZ8?1SQ]^.O7.O_`I[^XNO5_'"X#GD'H_?/ORHT2>S71R-#HY.LEG^\*HF"$Q
MW0?OW?'H-)WP[,/IFP]G)VR^=&2(\.\/#">/<0)''YXC].E@$<>K#\?'3T]/
M1T]G1X3.&>C)Z/C7+[?W_@(NP2'"40RP#P\\-OY#)#Z\)3Z(!1L+X,\/-)03
MG!WGOZ4=P?]W*(<=\H\.1Z>'9Z.CYR@X2%&TF/]`$L,_4)$S>O_^_;'X]H#Q
MP/,^4A+".SCS^+_?[VYR&/_%#X$/PR.?+(_YE\>7Q$^6$,?G.+C",8I?;O",
MT*4@G?TNG_-#_+*"GPXBM%R%4'ZVH'#VZ8#-YQ]R.9R\.3OA1/W5/-]Q&;WV
MTW\%<4+A9#99<9UE<T;LAY@.HF@RFU(8L5_.?JJ9=/NYMD;[/EDN`7V9S.[1
M'#,U]@'CD.^3A+$(SZ<D1#Z"D0W2MC-MC?(U0/2?($S@%P@BQB<N5"L,-8!;
M(\1$L@(HN'I>01Q!+JM)O(!TG%#*]2V*H!U^=O-LC2X3"DU@<(O``PI1C&J_
M5/C&!NUV\VVOL3'Q?Q?&?4R6G%/6RTH'N35*;+HEBH4Z,=+'1&@\V]XL&6@$
MWPV_%B0,V/YU]4?"#)\UKRI0.S`V#Q'\(V&$7CW:+MHZ3(;&JF`(;]FO9K_-
M@;;=55#,YS@Y\0X].;[X)\"!EP)[VCT)/L<0!S!(MSV&;DC\TH"0[^*$-K&,
M?_*;">GSARBFP(_E1"%X@&$ZDR7<<2L4,\X*?R""_M&</!X'$`F?A_\AT#\\
M&66^Q%_91SD>W]BT%3SK7^?H%`5\3LNH`>K+B=B?)9G7O95LQ/$*<&MTZ"]0
M&$CH&27+5MS*L"`JU`EER^73P1OFW"81PXBL."P(7X/'YPR-@*-R'8*Y@LF5
M[P?%Y0KN&9M'IUWP6>(_A1011D)PR8X2!J6NC!L4WS4T2/Z?=,'_%/D[.$<<
M9QQ_!4L5^]7#!L5]-0D9\SO1_12C,:.#@O"&;6_/_X`O6N;7Q@V0^S4:,O;_
MU`7[,W?Z&D4^"/\%`=5;'_W000E!3X:T0>^Z6P>_P##\!R9/^)X=)PF&P4T4
M)9!JUX-V_*!$TD!+;IZZD\L_29@P)M*7:Q2RTXM6'K5Q`Y1#C0;)_R[WAW31
MWL$5H?PD>\\8F>C%H!L^0&GH2)%"Z6372%$3^C%FIG-.J'[+KHP:H`@J%$C.
M=W(DRY2"+)<$BWC*_8*1'4V2F`?U^=6'?E$8@08H%S-!F9C..MPUILE#B/SK
MD(!J*$4S9H!"*.$OET8G'I2D(?7LTO/E-?M,M4T8Q@Y*!@8ZI#?;B9DJX\6]
M;#M)%$8.6`X%*J04M-OTQ^-JT'G;B/@%"/GU[OT"6MX150"V#LF7YIL*9B]@
MC'Q.=$ML*M`[N+A@V[BX%2G>A-I=7J@A=XK2&$0+9DJ?6F-4`#1?951N$NPN
M."H*4K[18*1XAUZ.#/M[3-C<F&=*L+\B$J(T,R*;Q<NFV=@&S4#T(!9U$AW.
M`5BEA@B&<20_J5JD[./?<B0GLVN$&3*(V4P2(<.=!\/&$FQSH[HY0>G]K0'U
MZH`NC*H]"]<V586[/DK)B)E!=DP*;E/*M<@*3!\A?2`1%&,Y+"*4&7EFH[N4
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M),W`'LBXR6'28.[H^>87=HH#:0[Y':^.,EPT<NZ8A_=?NF;\]:FX@Y9QG3U6
MEGD(\E1A;<@T=</Q,DNO%V+;="/=TUFF:^&U\I/[Z!EO*EH+?UAY/AJPCS25
MR`O:=9%AY:CNSCVV\E2B[:AK5,@^TL;W:T/Z+\(ZSJZ&CX(`I81,`0IN\!BL
M4,RIJI]6="/[+TTMZH[ZLNQXEBR3D.<;I-7"9,E(6$`<H4=X@WVRA+<D2B\J
MOH%G]=&TW0P#4(*V).TE--F]<MS!&"`,@RM`,3O0106^7,(9\I'*W;(!ZK\*
MV%"QGX-1]V)7E9U;>-5#$*L*:T,EZX"/2$TGC`TN%(9W7&JFR,W@1KT;B#&T
MK!O;`W$W1Y=UR.?E#,X=APO]:623%^W5KGEXKU,MS*C+0];/^Q:O+M]\;_G"
ME13N;-H\>7BT2?*P]T-IUA__3";^\^[^S[O[/^/2KQB7=DW6Y=`M,Z\3*M9,
M(**`4TA%B65CJ%H/V/_3E"TEC@:TR^2G%;7G2;Q@%/U[O?5K)5\'&)K$ZQ0X
M&OI6D2V:;=A*60X>IH0E]H[&P%4DF]-V&B&&*6=5\HYK,>W"=5V+/=L*JO]"
MMR)C/_'07DG>8J\VCAZ4I+6[M*K&WBT):_=H[<@!2K:R.ZOZ5[@E5?/>W+^N
M/5O*5[4KJUKN=21D3;ODLG]QBQC-@6!V^@7$/E1E`;6$[;<X6Q(C93MR(J:M
MZ_]1B6>?6C;#6$_GD9FWGM#[X3L&28#8F$ZBVFDZ2(Z=(=ZG'=E)I!*$,+J#
MCQ`G\"LTH:T=V=7::^!X'I+4X>UH+5&17EE<WB#.];#.[*A9#56R7"/M:+`I
MH_.:,>FS**Y1)EG5QO1<A`J,'0TG51C2;%)[+[L:ODZ68H]))`K9\J=_]'NB
M?FC/-T4]XH[>TG&")S.Q9]R34!T*J(SH2H1-^E>480EA1Z_7>%\<QCG>+.F2
MV9Z0B`8=&7>4>Z)Q?-_%VH"^H\[./0S9G//TE<F0T7X>+'F'I)@?[QZA7MJV
M@'T7NRT=CCI+3.MCFOAQ0AD3Q@M`Y\IZ7/6POLM6C;6K90-5KECX3?T781UC
M-\L%LH`:GJ_+FQ3R4X[JN<NKQ'DOUK1K&7XEF)2)E;G3^I.,!4S/Y6M!0>\J
MXW5W)N"%4_H=,W0_)X"'2:#Z@D0]L"M)62O>^E)$3<!NG=SWJ=0PG/,;A%U>
M;J5ODM]@?G$CF#R9R4XX*G$9AP]':$8R=AL2VH'H=F-3KPF%:([34A7_Y1NC
M-F*\8:1]!@CSS>0"SM@8=6UT*^A!*$)KJESU=GE#WTB\%YWR[(99,"8W]<6?
M;NA@1*XGP=5L,4FA/@)1&S$@:58PWW%"6&^LMY8S;3SAX7K`KI8WKT]R_#IQ
M3#"C/&'$K[-"T@TH'<>V(1A]05A0*U6?'>G+LZ19/%]@O"#!VMJIF]&_XJ_W
M7/5>E1=N1EYRUF2+]@)B.%-V5M&.'(22*/!V=MN!L3&,5OF^Y^*K8+N?-..N
M5V$6D(CR:F<\%Z%?A?3T0P?C`.I)<#0Y[A;Y61.)>T@?V7]D.HM"OH:Q/<_3
M,6#N:#<4V9Y+5B]=@`CY"IEJQO7<\FJPEFOT_6Z%V4F[=,B[AL/@G*$"YO!K
MLGR`=#*K%3[HY-H2ON?R;DE-K@>[K1?H0@]X-M,3"L.;Y0H@RGFD<9UT`_M^
MCZS#.Y/ACI=RYW99!H(G^!)2]"A266XPSX80?@?;PZ84QLJ8N3WH8-PM>Y(R
M=7CKF#J4CA#GCP"%_"V0;Z10ZY854^D,?>L9>F[J6],CC?V;;8U]\:2U^ROL
M.QA`N.2TE.O>HDOTB`*(`^4%J0U4CP5J38,4XD]OCDXWEJ,RS+%[2>9H5\A1
MR4\_MN]2TV,N9?7SNZ.W?9?5>H.94G;LNT,14[M\JU%4@EE##6*/M:9&>EM[
M+[#=U=J;X%PO)Y2Y_H"^I*<!XRHT0`UF/1IHR&-4>U^6KUTGS1^%O@[)4[U,
M^FRC,FD^GR<F[+I,NM!.,B?2KNFG8GA'+BS'9$H)5]#@XN4[X_T-SK-+SWUF
M9M+&B89LRPTFZ4$#4*W$"MYL:[H<C30/Y.YG<W4V7PNYE@9T'OQ?DEU`?R-W
MT"?81R$LT<X.;5L;AOW\S'"5:S_\<+3&M9J<=[XD-$;_SE)TF1NU1,G2(B]1
M`]=9D_@]+CU=7J.&!8X67W['%(*0]X1312A5NU<CA,O*TDC\;JN*>I/.<@D9
MQCX2HF1_AU#(%`?%Q:+0%3LPEQ7&C@.N9E"7;>D-$RV>HX<0:M\J:0)P656:
M:'>U9>?Z/G0RNR5X?LLL:9`2_7<8!M>$?E<GW]O!N:PREBQPM2UH<Q72>K]6
M*%`[<)?UJ!TG\G.^8TX.9^X<H]3^7F:XZY,$S<-=5A<SY5(]=N3,]$8]UAX_
MS\7D1T-^/16_3$.`8UZQ(+KU&--9S(`NJXPM#Z3RN%9$+),W8<!?$H;,O&J.
M3+J!+BN'CN8\8]DQOX6QCNVF$;R$Z;\%9F6/C9M["%L#NZPT;?@@%4GI``\Z
M[%OEP31],5-NRK9OA&XZ48>Y!"U7D%YM["C=[>56;_8E^WN:K>ZRAWP1U89*
M-YM*J1F07IQLF?=@G&3`>0]&NAR]A)0EA=_(N<\\>N;2)1'"D!E0GGJ7\C+[
M1OEH7BOPGMD3B\50K;RTH]/1?:?&A-*!D%?3&`[4;8`=TA,#E;WKFK8C+:'$
MAS`0/2$4<8,F-6D#/6`]:4.FHSV$:VOE?D%H_`W2I;F1BR7<@)7#CD!'6_?5
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M._`A:$4[BMQLL*[FP3FSH)2^,&/)7X"QUX8:W'#5H$;*?D)?*Z%M#%T:NZH%
MOXT<T@-.S'XJM%)-N,*=IB\GJU4H^`5"R:\;/"-TF0K,T,;%%G((FF!-C+'B
MJD]MIC@5=]"'O'#L4CQ2FFYS[/2D$:H]6&<2;:>LZ\?-;(ARM&=-\3I0/LLA
M>=%P/UH?WH7@VVJSZAZT3HFC+6W*1&=/<]S!65)OSEGG477X<*5=I<31'A^%
MB%B[ED2V@`,R]&W(<C1-5UJY*4!!O2UH6B-1&=&5@-MI;O5MNQS]WEEQC3-V
M[R]@D/!<G*]$!*$*A=BZ==H&<#AB;$-5[Y:I1KHB`2\25=-1>A\A<C*GV15%
M\&U!23)?%*_$E1=]F\W3V2[=2JESV6]&Y%`6.K^<!-AG/"DWMKW!8X(Q%+SY
M!<4+^9K/G$*H2E7<=K*!*<46E/;.M6NI&1-.(ON]2/1<N*`HF#,CRF^[VZB$
M:19'=,%$8N^2WQN5H-8`>QR"*!JK2+V'?D)Y!3W_*$;%7`C>;\SW:<)O.Y5/
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M4T`YO\8D#--[1%7,8H,YAJLB&Q`K=>?]QKK3_\U#L*7!2F1CABM[!3%2MIL_
MA/U:&>VBD.\&\ZJ,+*[V"Z`4\)(-G7.5NE49WVP[X.[]UUSU0??.N$Q7WXZ.
M^N.V_,<\V_XJVM/BI??1_M\(WU8'"`F>4!BN7W/BI*GMC7ZLV_+6DIU76O5]
MI1<.6;PO9W8UJ!2R=JC3,M92+0-59UM$)5Y)R.L8JZ"&^\]R5[LF]![21V:M
MH@D=AP`M&S)E[&9P6B7:,B/OVG':>TW)@G",#-6)0CUDF`<*-2UY,LR[H\V/
M%+8;],?C(L=N&6;IQ]5/2XR$SS'$P3HR6&(E(RH$/@R/F+*G2'P%<4)Y-E"J
MWT0<GB]`A")Q(9?_3LX:%//Y3IAJ>(<>O^D/2<1F8/])I_+(S%M/Y@$<>&(Z
M_GEIP@Y.Q!,Z!SC+6Q@S[$B(@E0;Q65CCEN>TP#"O,[:5'&VHWF["!)LA?I:
M_-^8VEV$ZJO*W?]$5Q9EI_HCHQ:[9\^K%7N_AH&Z3Y9+0%_87HKF&,V0SYO#
MIRDFO'26<<LO!#G6YNFT:IZRB;@=*DSEK>?R\LFZR4:LD&2P-Z;!G?39,(G&
M9!IL`3MS%QNEDO?8L*3$J;5YS4ZUHHW,%PCX*BL5>ZV7XEEU*7(X3P!Z)<@N
M'F.6)*P1-*T\\_!.7I-68&1:<@WCNUII-G+(WWTVD^#4$INFS_S)L()\WR]]
M\SHNOXRX7G$_55=<-HTGYQ%^N9C)RZ;RLKEVTQRX&6E387@[^!WU,V[^2=VR
MVF2"SLI&-I%-H7EQ*R*=6HE9"=PM`@\H3,,&9?(+W]17Y,_5%9E-YQ6@%(NR
M.&<W26G\\CRO``1A0^,5_>B.2GR*J>AZ"18^6@LIDX%I,]WU#W38ZJ))SH4J
MH9V2[)2-$/%>[7OI:VOPIG8XY8">@/1*H!VLFC5B(N<ZQR5+H1%5/J):](&C
M*],R#79AVPF[,!W6.%\4<3;9BJUG[,HX[$8?I/W8F@U.&8ST#8B489@7W_.P
M`<3JD-;;JM4H0`O?H0S?1?F"GIPUX@9+T1*^DPH-&Q1-=J#M!%TM^XUDF9=P
MM"32J44M-O/LZ9;R2R;KM?Q.Z0%D0/_C96!=/+8@?MFP1JL#.@DXUSC,T\'M
MUE\+V*Z6GEH&>:C9G@"WEE7R$,$_$C;=U:,ZT/R^?N<C0;P,II,NY&6\C6W'
M=4.[:9]>QL:XJO1CN^NS:N;[NCVZ%O57:]*H7#\?CSF>W*MF__E_4$L#!!0`
M```(`"M[##^C`1\O^@<``"0V```1`!P`8WEC8RTR,#$Q,#8S,"YX<V155`D`
M`R%^14XA?D5.=7@+``$$)0X```0Y`0``[5IM;^,V$OY^0/\#SU]N%SA;5MS-
M-4;2(G$V"P-.'.3ENM\*6J)M7B122U))_.\[0TJ6++_)V:9U<?YB2.3,PYEY
M-.20].DOKW%$GIG27(JSAM]J-P@3@0RYF)PU4MVD.N"\\<O//_SC])_-)OEZ
M<3<@7YA@BAH6DA=NIK;MFJHGTI/)3/')U)`/O8]D-",7\D4PTA=!BS2;.<0%
MU:`IA<,Z:OE%WV,26ECH//9\[ZCM^Z1]U/4_=7_TR?DU0M[=79*OO2D5$Z;(
MAX?KC[GQ@-1N^>U6>XYV#5Z,N87KDI\\_\@!=KI'Q]U.&_"<I`ZF+*8$XB#T
M66-J3-+UO)>7E]9+IR75!)3:OO?U>G!OY1I.L/LZ4A%?$,>67*'C<:$-%0'+
MY2,NGC:(8_<(`C.'7Y+/K/%/3DX\V]L@AJH),S<T9CJA`9N+![,@@O>H%<C8
M^MQL'S<[[1P;NH.ZLD(*D<:K#0^-\LPL81X(-4&**1[`UQ.QF`ES)55\R<8T
MC<Q9XUM*(TM%@U!C%!^EABT(I*(D4@0X-/.1R^'ZY+G.!M!'R"D50AIJX!NP
M[]B2)%R,9?8*#1BOKI(1>P!["3X\WO57QP`[O4L9I.C%N0@_"\/-K`]P*K:#
M-`@/SQH;)>8#YT.';,P%MR:VVZ1)<NWR(Q4A<5"DA'7J50&JV"FDTU#\;)\3
MQ31@6<T!-&3:F<@FS6*`W?0"&@5IM&7`K#4GX.V\7-`(D^I^RIC1CHC%IHV1
M]WV,_3V$AV7![TD1,H'S$3QI&7$W_V28Q($>*%A+P2U5X.N4&0Y&K.!CL7\+
M.?Y;R"$?%L;X>""K3-8\G'HX'B:X:,.X6>*LZ=M,TE'-#"K`B1R3`IY\>!0T
M#3G('*A:2U6/ZNE5)%]6,%5T;2:J\R:B$)U8^`-1ZXBZH295K)PS4`-`4<N!
MG=N2[XZ[VM(;Z83"#$L%KH-(:L"#%P=<R2ZL(2PXMI?A#Q0NY%H:QU3-AN-[
M/A%0=084"KD@D"F47V)R"\D1<)8G7SW9+?0=5>G+8)&G$C`ID$D.?:"N3-T5
MY>J_-$K9-:,82CMU.:96=VTAIE,E!E&(A2%EG`,+919@:DDH#S^_)KBDX)0V
MA`I,]5*%M=BYUO/RO);D%HY^K'*4@9(<U<Y[%I=DP,0A'U@KLP:3BTI9..!T
MQ".P=HF.4H]C;R>-+2Q^JK*8@9,2Q@HB2[T'-A<+1AD\V<.TGHPQ#TI5QYJ^
M+0P=+RU2"),=V)6!#D24B8#(Q-S850*R`ZIK7+Z9*$J(30);*/E/E9(2EDV6
M!;0#+TL),I51R)3^_"WE9E9*CL7V+2S\M#(Q,HA_$0=R"/YBB3W2[%L*+GY^
M+DJTI=8M@3]9+IMS`.(0_@^BCC]X-W#'QL2>_'?QU/VLH7F<1'AC8-NFBHW/
M&GBVW\1C_/9QI_T;#-YZC:-<!/$WW$%8WBKV9N/F"%0%2R!+%Q->HB1L27'%
M+M]K.,NY0?5>,0K!8?2_"8W`3N\/<QV8WM7UZL?Q3KZ7M^7OY'Q$1[LZ#RHL
M>D>O!XB_TMU3KWQ=`V^+USFGX*U4AHBE:ZX:EU'N;F\@`XNW7?/&*4(DVR=-
M_ZCI'[=>=9C;6M.4ROU?'1NL"KXU<STTH8,F=/RWFE`PL9L)N=[.)E@LS8+6
M1#Y[(>/9?:(/`&MM6*F##\U"N=[H8ZI'UI-4-R>4)K5'7ZGHL<CHO&6=+=E=
MIS5F\Y7@^4@;10/CED',UM_JB;N4M[?-76B#4J]O6(RK!#@%BR$HIJCQ1<DT
MR04YB$#^V6?(2R[#!PL3IBK;)-!L@+.&@3U8@P@>P0R`B>K>,P?QOCYS4KMK
M^I+7<T]NZ0P;'@640U]2JJ@P##%M5-9TEOV*I6"&JEEMSZK6;O+4]8W<I1%T
ML!$W:PAT?ROH"SS]L=K#\:]4H<6ZQ-M&J?URJV!(R8"Q$.\/[/[!X#`#2<6-
M-$SWM89]^)62\?V4*I;5M7,"WZ2[IX'`"XX[%C#^S,++%-/IUJ)>257D7/8U
MU!&MYM%WI.LN3J]S#_^C$J81&XYOI$`''N"[U&"?O7BH.%A3>,]</`]@MZ5M
M)0Z?)&Z]$A2X354PQ8.*ARF,.YGV:,(-C08,VN:?\MMT]_13QLQ#P>%XJ$(N
MP"B;@;HO>E((9FG\E9OI@`=X2'H^42P_+7?1^`Z`ORHD@6+A6V(R1)>R/XH-
MQQ>*AQ/X;G$2VQ:,39K['P78:XR9`O'<J5Y$M>ZM<NV>!;#%#EV3X>4Y'BJ4
M[*RV#XLW:)KEJ+W?2/L?Y6KZ##A+W4W]A11IC7Q;4O@;^(R']`,I)@],Q5#C
MX8!#<1[QB2C-LBM<KZFW9Q'(2Z'MEUD/[-5<1#)X:I3+KYWTG._NKY==D[?_
MJ:OL/)WM2>>``S.A57$=#&)E[TB+(K&N_#L3Z_;/9N<O>T-5?Q[^+]7NR/U!
M0D4H1<`C=L/,0&IH@0?,W$>-DU;V7PPQ.8?E\SF[2=NZN_CN$?:T1/E"N4`7
MAO`90!%QQ_63O@3<9T![9AK\RH-31W+/IH3"2RG#%X#OQY#D"OO0DX+X]?U[
M2IO-X6%BTQ<T\FEKOF]8U[VG[A2+C[4<I]\\\6`O=\_4,WQQ>JB@8N'QBM6Z
MGM:>.I\=OX#)6&05F_IJ\[XFUQT+8=>!X(M+C+Z$R2]D(IR[5$=R3TF:6UBQ
M/'=M??^^.S042QL#5_0NN;9!<D^=K%/55<]<=M/Y"X]>3CUW9`Z/OP-02P$"
M'@,4````"``K>PP_0E0#8J=U``#NO`,`$0`8```````!````I($`````8WEC
M8RTR,#$Q,#8S,"YX;6Q55`4``R%^14YU>`L``00E#@``!#D!``!02P$"'@,4
M````"``K>PP_/X:Z]>\-``#KI```%0`8```````!````I('R=0``8WEC8RTR
M,#$Q,#8S,%]C86PN>&UL550%``,A?D5.=7@+``$$)0X```0Y`0``4$L!`AX#
M%`````@`*WL,/[ME7'OZ+@``%3@"`!4`&````````0```*2!,(0``&-Y8V,M
M,C`Q,3`V,S!?;&%B+GAM;%54!0`#(7Y%3G5X"P`!!"4.```$.0$``%!+`0(>
M`Q0````(`"M[##\P<ORG_A4```1'`0`5`!@```````$```"D@7FS``!C>6-C
M+3(P,3$P-C,P7W!R92YX;6Q55`4``R%^14YU>`L``00E#@``!#D!``!02P$"
M'@,4````"``K>PP_HP$?+_H'```D-@``$0`8```````!````I('&R0``8WEC
M8RTR,#$Q,#8S,"YX<V155`4``R%^14YU>`L``00E#@``!#D!``!02P4&````
/``4`!0"_`0``"](`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Based Compensation<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock Based Compensation [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK BASED COMPENSATION</a></td>
        <td class="text">
    <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
    <!-- Begin Block Tagged Note 6 - us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-->
    <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>6. STOCK BASED COMPENSATION</b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Stock based compensation has been reported within expense line items on the consolidated
    statement of operations for the three months ended June&#160;30, 2010 and 2011 as shown in the following
    table:
    </div>
    <div align="center">
    <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
    <!-- Begin Table Head -->
    <tr valign="bottom">
    <td width="44%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="6"><b>For the three months</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="6"><b>For the six months</b></td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>ended June 30,</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>ended June 30,</b></td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 0px solid #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="6"><b>($000s)</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 0px solid #000000">&#160;</td>
    <td>&#160;</td>
    </tr>
    <!-- End Table Head -->
    <!-- Begin Table Body -->
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Research and development
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">93</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">41</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">165</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">90</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">General and administrative
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">374</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">164</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">621</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">365</td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 1px">
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Stock-based compensation costs before income taxes
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">467</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">205</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">786</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">455</td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 1px">
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    </tr>
    <!-- End Table Body -->
    </table>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Under the 2006 Plan, 5,200,000 shares of the Company&#8217;s common stock have been reserved. The
    awards granted under the 2006 Plan have a maximum maturity of 10&#160;years and generally vest over a
    four-year period from the date of grant.
    </div>
    <!-- Folio -->
    <!-- /Folio -->
    </div>
    <!-- PAGEBREAK -->
    <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">A summary of activity for the options under the Company&#8217;s 2006 Plan for the six months ended
    June&#160;30, 2011 is as follows:
    </div>
    <div align="center">
    <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
    <!-- Begin Table Head -->
    <tr valign="bottom">
    <td width="44%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>Weighted <br />
    Average</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2">&#160;</td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>Weighted</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>Remaining</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>Aggregate</b></td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>Average</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>Contractual</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>Intrinsic</b></td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Options</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Exercise Price</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Term (years)</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Value</b></td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="10">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>(in $000s)</b></td>
    <td>&#160;</td>
    </tr>
    <!-- End Table Head -->
    <!-- Begin Table Body -->
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Options outstanding at December&#160;31, 2010
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">3,489,932</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="left">$</td>
    <td align="right">3.96</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">7.22</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">938</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Granted
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">199,500</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="left">$</td>
    <td align="right">1.52</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Exercised
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="left">&#160;</td>
    <td align="right">(6,638</td>
    <td nowrap="nowrap">)</td>
    <td>&#160;</td>
    <td align="left">$</td>
    <td align="right">0.41</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Expired
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Cancelled / forfeited
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="left">&#160;</td>
    <td align="right">(139,265</td>
    <td nowrap="nowrap">)</td>
    <td>&#160;</td>
    <td align="left">$</td>
    <td align="right">6.32</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 1px">
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Options outstanding at June&#160;30, 2011
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">3,543,529</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="left">$</td>
    <td align="right">3.74</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">6.95</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">828</td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 1px">
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Unvested at June&#160;30, 2011
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">968,024</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="left">$</td>
    <td align="right">1.83</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">8.75</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">153</td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 1px">
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Vested and exercisable at June&#160;30, 2011
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">2,575,505</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="left">$</td>
    <td align="right">4.45</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">6.27</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">675</td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 1px">
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    </tr>
    <!-- End Table Body -->
    </table>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">ASC 718 requires compensation expense associated with share-based awards to be recognized over
    the requisite service period, which for the Company is the period between the grant date and the
    date the award vests or becomes exercisable. Most of the awards granted by the Company (and still
    outstanding), vest ratably over four years, with 1/4 of the award vesting one year from the date of
    grant and 1/48 of the award vesting each month thereafter. However, certain awards made to
    executive officers vest over three to five years, depending on the terms of their employment with
    the Company. In addition, recent awards made to other employees vest ratably over four years, with
    1/48 of the award vesting each month.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Effective January&#160;1, 2006, the Company elected to recognize all share-based awards issued
    after the adoption of ASC 718 under the straight-line attribution method. ASC 718 requires
    forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods
    if actual forfeitures differ from those estimates. This analysis is evaluated quarterly and the
    forfeiture rate adjusted as necessary. Ultimately, the actual expense recognized over the vesting
    period is based on only those shares that vest.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The Company used the Black-Scholes option-pricing model with the following assumptions for
    stock option grants to employees and directors for the six months ended June&#160;30, 2010 and 2011:
    </div>
    <div align="center">
    <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
    <!-- Begin Table Head -->
    <tr valign="bottom">
    <td width="72%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="6"><b>For the six months</b></td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>ended June 30,</b></td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
    <td>&#160;</td>
    </tr>
    <!-- End Table Head -->
    <!-- Begin Table Body -->
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Expected term
    </div></td>
    <td>&#160;</td>
    <td colspan="3" align="center">5 &#8211; 6Yrs</td>
    <td>&#160;</td>
    <td colspan="3" align="center">5 &#8211; 6Yrs</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Risk free interest rate
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2">2.37 &#8211; 2.96%</td>
    <td nowrap="nowrap">&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2">1.47 &#8211; 2.29%</td>
    <td nowrap="nowrap">&#160;</td>
    </tr>
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Expected volatility
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2">90 &#8211; 100%</td>
    <td nowrap="nowrap">&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2">93 &#8211; 99%</td>
    <td nowrap="nowrap">&#160;</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Expected dividend yield over expected term
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2">&#8212;</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Resulting weighted average grant fair
    value
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2">$1.80</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2">$1.15</td>
    <td>&#160;</td>
    </tr>
    <!-- End Table Body -->
    </table>
    </div>
    <!-- Folio -->
    <!-- /Folio -->
    </div>
    <!-- PAGEBREAK -->
    <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">There were 199,500 options granted during the six months ended June&#160;30, 2011. For grants made
    during the six months ended June&#160;30, 2010 and June&#160;30, 2011, the expected term assumption was
    estimated using past history of early exercise behavior and estimated expectations of future
    exercise behavior. Starting with the December&#160;2010 annual grants to the Company&#8217;s employees, the
    Company relied exclusively on its historical volatility as an input to the option pricing model as
    the Company&#8217;s management believes that this
    rate will be representative of future volatility over the expected term of the options. Prior
    to December&#160;2010, because the Company had been publicly traded for a limited period, the expected
    volatility assumption was based on the historical volatility of peer companies over the expected
    term of the option awards.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Estimates of pre-vesting option forfeitures are based on the Company&#8217;s experience. For
    outstanding options, the Company uses a forfeiture rate of 0 &#8212; 50% depending on when and to whom
    the options are granted. The Company adjusts its estimate of forfeitures over the requisite service
    period based on the extent to which actual forfeitures differ, or are expected to differ, from such
    estimates. Changes in estimated forfeitures are recognized through a cumulative adjustment in the
    period of change and may impact the amount of compensation expense to be recognized in future
    periods.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The weighted average risk-free interest rate represents interest rate for treasury constant
    maturities published by the Federal Reserve Board. If the term of available treasury constant
    maturity instruments is not equal to the expected term of an employee option, Cyclacel uses the
    weighted average of the two Federal Reserve securities closest to the expected term of the employee
    option.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the six months ended June&#160;30, 2011, 6,638 stock options were exercised resulting in
    approximately $3,000 of cash proceeds to the Company. During the six months ended June&#160;30, 2010,
    there were 124,277 stock options exercised for proceeds of approximately $0.1&#160;million. As the
    Company presently has tax loss carry forwards from prior periods and expects to incur tax losses in
    2011, the Company is not able to benefit from the deduction for exercised stock options in the
    current reporting period.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><i>Restricted Stock</i>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In November&#160;2008, the Company issued restricted common stock to an employee subject to certain
    forfeiture provisions. Specifically, one quarter of the award vested one year from the date of
    grant and 1/48 of the award effectively vests each month thereafter. This restricted stock grant
    is accounted for at fair value at the date of grant and an expense is recognized during the vesting
    term. Summarized information for the restricted stock grant for the six months ended June&#160;30, 2011
    is as follows:
    </div>
    <div align="center">
    <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
    <!-- Begin Table Head -->
    <tr valign="bottom">
    <td width="72%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>Weighted Average Grant</b></td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Restricted Stock</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Date Value Per Share</b></td>
    <td>&#160;</td>
    </tr>
    <tr>
    <td>&#160;</td>
    </tr>
    <!-- End Table Head -->
    <!-- Begin Table Body -->
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Non-vested at December&#160;31, 2010
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">23,954</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="left">$</td>
    <td align="right">0.44</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Vested
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="left">&#160;</td>
    <td align="right">(6,252</td>
    <td nowrap="nowrap">)</td>
    <td>&#160;</td>
    <td align="left">$</td>
    <td align="right">0.44</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Non-vested at June&#160;30, 2011
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">17,702</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="left">$</td>
    <td align="right">0.44</td>
    <td>&#160;</td>
    </tr>
    <!-- End Table Body -->
    </table>
    </div>
    <!-- Folio -->
    <!-- /Folio -->
    </div>
    <!-- PAGEBREAK -->
    <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><i>Restricted Stock Units</i>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Restricted stock units were issued to senior executives of the Company in November&#160;2008, which
    entitle the holders to receive a specified number of shares of the Company&#8217;s common stock over the
    four year vesting term. A restricted stock unit grant is accounted for at fair value at the date
    of grant which is equivalent to the market price of a share of the Company&#8217;s common stock, and an
    expense is recognized during the vesting term. There were no restricted stock unit grants prior to
    November&#160;2008. Summarized information for restricted stock grants for the six months ended June&#160;30,
    2011 is as follows:
    </div>
    <div align="center">
    <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
    <!-- Begin Table Head -->
    <tr valign="bottom">
    <td width="72%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>Weighted Average Grant</b></td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Restricted Stock Units</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Date Value Per Share</b></td>
    <td>&#160;</td>
    </tr>
    <tr>
    <td>&#160;</td>
    </tr>
    <!-- End Table Head -->
    <!-- Begin Table Body -->
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Non-vested at December&#160;31, 2010
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">35,931</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="left">$</td>
    <td align="right">0.44</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Vested
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="left">&#160;</td>
    <td align="right">(9,378</td>
    <td nowrap="nowrap">)</td>
    <td>&#160;</td>
    <td align="left">$</td>
    <td align="right">0.44</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Non-vested at June&#160;30, 2011
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">26,553</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="left">$</td>
    <td align="right">0.44</td>
    <td>&#160;</td>
    </tr>
    <!-- End Table Body -->
    </table>
    </div>
    </div>
  <span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Statement of Position (SOP)<br> -Number 93-6<br> -Paragraph 53<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 123R<br> -Paragraph 64, 65, A240<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E6LBI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)<br>In Thousands</strong></div>
        </th>
        <th class="th" colspan="2">6 Months Ended</th>
        <th class="th" colspan="1">181 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2010</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (8,140)<span></span></td>
        <td class="num">$ (9,040)<span></span></td>
        <td class="num">$ (246,446)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Accretion of interest on notes payable, net of amortization of debt premium</a></td>
        <td class="text"> <span></span></td>
        <td class="nump">2<span></span></td>
        <td class="nump">100<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeAmortizationOfPremium', window );">Amortization of investment premiums, net</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="num">(2,297)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in valuation of derivative</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">308<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_ChangeInValuationOfWarrantsAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities', window );">Change in valuation of warrants</a></td>
        <td class="num">(203)<span></span></td>
        <td class="nump">516<span></span></td>
        <td class="num">(6,273)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_GainLossOnPriceRisksDerivativesNet', window );">Warrant re-pricing</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">44<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">172<span></span></td>
        <td class="nump">240<span></span></td>
        <td class="nump">12,486<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">886<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Fixed asset impairment</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">221<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_GoodwillImpairmentLosses', window );">Goodwill and intangibles impairment</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">7,934<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign exchange loss</a></td>
        <td class="nump">21<span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">7,768<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecognitionOfDeferredRevenue', window );">Deferred revenue</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="num">(98)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_StockOptionPlanExpenses', window );">Compensation for warrants issued to non employees</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">1,215<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_IssuanceOfStocksAndWarrantsForServicesOrClaims', window );">Shares issued for IP rights</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">446<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">(Gain) loss on disposal of property, plant and equipment</a></td>
        <td class="text"> <span></span></td>
        <td class="num">(9)<span></span></td>
        <td class="nump">99<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
        <td class="nump">455<span></span></td>
        <td class="nump">786<span></span></td>
        <td class="nump">18,596<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Provision for restructuring</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">1,779<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of issuance costs of Preferred Ordinary "C" shares</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">2,517<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, inventory and other current assets</a></td>
        <td class="num">(279)<span></span></td>
        <td class="num">(88)<span></span></td>
        <td class="num">(511)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable, accrued liabilities and other current liabilities</a></td>
        <td class="num">(482)<span></span></td>
        <td class="num">(2,183)<span></span></td>
        <td class="num">(6,372)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(8,456)<span></span></td>
        <td class="num">(9,776)<span></span></td>
        <td class="num">(207,598)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Purchase of ALIGN</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="num">(3,763)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, plant and equipment</a></td>
        <td class="text"> <span></span></td>
        <td class="num">(8)<span></span></td>
        <td class="num">(8,831)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property, plant and equipment</a></td>
        <td class="text"> <span></span></td>
        <td class="nump">35<span></span></td>
        <td class="nump">158<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchase of short-term investments</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="num">(156,657)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Redemptions of short-term investments, net of maturities</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">162,729<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
        <td class="text"> <span></span></td>
        <td class="nump">27<span></span></td>
        <td class="num">(6,364)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Payment of capital lease obligations</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="num">(3,719)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of ordinary and preferred ordinary shares, net of issuance costs</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">121,678<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and warrants, net of issuance costs</a></td>
        <td class="num">(80)<span></span></td>
        <td class="nump">15,155<span></span></td>
        <td class="nump">82,324<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from stock options and warrants exercised</a></td>
        <td class="nump">3<span></span></td>
        <td class="nump">2,700<span></span></td>
        <td class="nump">173<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock', window );">Payment of preferred stock dividend</a></td>
        <td class="num">(364)<span></span></td>
        <td class="text"> <span></span></td>
        <td class="num">(1,898)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_PaymentForLoans', window );">Repayment of government loan</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="num">(455)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Government loan received</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">414<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLoans', window );">Loan received from Cyclacel Group Plc</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">9,103<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_ProceedsOfCommittableLoanNotesIssuedFromShareholders', window );">Proceeds of committable loan notes issued from shareholders</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">8,883<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansAndLeasesReceivableRelatedPartiesCollections', window );">Loans received from shareholders</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">1,645<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash and cash equivalents assumed on stock purchase</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">17,915<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfEquity', window );">Costs associated with stock purchase</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="num">(1,951)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
        <td class="num">(441)<span></span></td>
        <td class="nump">17,855<span></span></td>
        <td class="nump">234,112<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
        <td class="nump">16<span></span></td>
        <td class="num">(56)<span></span></td>
        <td class="nump">464<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
        <td class="num">(8,881)<span></span></td>
        <td class="nump">8,050<span></span></td>
        <td class="nump">20,614<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
        <td class="nump">29,495<span></span></td>
        <td class="nump">11,493<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
        <td class="nump">20,614<span></span></td>
        <td class="nump">19,543<span></span></td>
        <td class="nump">20,614<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_CashReceivedDuringPeriodForAbstract', window );"><strong>Cash received during the period for:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestReceived', window );">Interest</a></td>
        <td class="nump">11<span></span></td>
        <td class="nump">11<span></span></td>
        <td class="nump">11,726<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIncomeTaxRefunds', window );">Taxes</a></td>
        <td class="text"> <span></span></td>
        <td class="nump">110<span></span></td>
        <td class="nump">17,522<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForOperatingActivitiesAbstract', window );"><strong>Cash paid during the period for:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
        <td class="text"> <span></span></td>
        <td class="num">(187)<span></span></td>
        <td class="num">(1,914)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_ScheduleOfNonCashTransactionsAbstract', window );"><strong>Schedule of non-cash transactions:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases', window );">Acquisitions of equipment purchased through capital leases</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">3,470<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements', window );">Issuance of common shares in connection with license agreements</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">592<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan', window );">Issuance of Ordinary shares on conversion of bridging loan</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">1,638<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest', window );">Issuance of Preferred Ordinary "C" shares on conversion of secured convertible loan notes and accrued interest</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">8,893<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_IssuanceOfOrdinarySharesInLieuOfCashBonus', window );">Issuance of Ordinary shares in lieu of cash bonus</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">164<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_IssuanceOfOtherLongTermPayableOnAlignAcquisition', window );">Issuance of other long term payable on ALIGN acquisition</a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">$ 1,122<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Assets acquired under capital leases.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_CashReceivedDuringPeriodForAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Supplemental cash received information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_CashReceivedDuringPeriodForAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_ChangeInValuationOfWarrantsAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount recognized during the period for the change in valuation of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_ChangeInValuationOfWarrantsAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_GainLossOnPriceRisksDerivativesNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount recognized during the period as a result in changes to the pricing terms of the warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_GainLossOnPriceRisksDerivativesNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_GoodwillImpairmentLosses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of write-downs for goodwill and other intangible assets recognized during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_GoodwillImpairmentLosses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of ordinary shares through issuance of license agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_IssuanceOfOrdinarySharesInLieuOfCashBonus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of ordinary shares in lieu of cash bonuses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_IssuanceOfOrdinarySharesInLieuOfCashBonus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of ordinary shares through conversion of bridge loan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_IssuanceOfOtherLongTermPayableOnAlignAcquisition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of other long term payable as result of acquisition.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_IssuanceOfOtherLongTermPayableOnAlignAcquisition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of Preferred shares on conversion of secured convertible loan notes and accrued interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_IssuanceOfStocksAndWarrantsForServicesOrClaims">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based issued intellectual property rights.  As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_IssuanceOfStocksAndWarrantsForServicesOrClaims</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_PaymentForLoans">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The outflow of cash to repay a government loan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_PaymentForLoans</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_ProceedsOfCommittableLoanNotesIssuedFromShareholders">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash received from a loan issued by shareholders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_ProceedsOfCommittableLoanNotesIssuedFromShareholders</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_ScheduleOfNonCashTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Designated to encapsulate the entire footnote disclosure that gives information on the supplemental cash flow activities for noncash (or part noncash) transactions for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_ScheduleOfNonCashTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_StockOptionPlanExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based issued to non-employees for services rendered. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_StockOptionPlanExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6394232&amp;loc=d3e17558-110866<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 143<br> -Paragraph 14<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 146<br> -Paragraph 6<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6392676&amp;loc=d3e7480-110848<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccretionExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The component of interest expense representing the noncash expenses charged against earnings in the period to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include Noncash Interest Expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfFinancingCostsAndDiscounts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 142<br> -Paragraph 45<br> -Subparagraph a(2)<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 15, 16, 17<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAcquiredFromAcquisition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 7<br> -Footnote 1<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 8, 9<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 7, 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The effect of exchange rate changes on cash balances held in foreign currencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 25<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate unrealized foreign currency transaction gain (loss) (pretax) included in determining net income for the reporting period. Represents the aggregate of gains (losses) on transactions that are unsettled as of the balance sheet date, which is therefore an adjustment to reconcile income (loss) from continuing operations to net cash provided by or used in continuing operations. Excludes foreign currency transactions designated as hedges of net investment in a foreign entity and intercompany foreign currency transactions that are of a long-term nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting entity's financial statements. For certain entities, primarily banks, that are dealers in foreign exchange, foreign currency transaction gains (losses) may be disclosed as dealer gains (losses).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 52<br> -Paragraph 30<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ForeignCurrencyTransactionGainLossUnrealized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfPropertyPlantEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6390789&amp;loc=d3e2420-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 144<br> -Paragraph 26<br> -Subparagraph b<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 225<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6743430&amp;loc=d3e92212-112881<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 144<br> -Paragraph 7, 25<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Impairment<br> -URI http://asc.fasb.org/extlink&amp;oid=6515133<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets,or  income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period net of cash paid for interest that is capitalized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 29<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 27<br> -Subparagraph e<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaidNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeAmortizationOfPremium">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the amount of amortization of purchase premium related to an investment in debt securities. The purchase premium is amortized to expense over the life (holding period) of the security to arrive at an amount of periodic interest income which results in a constant effective yield on the investment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 115<br> -Paragraph 14<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 91<br> -Paragraph 18<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentIncomeAmortizationOfPremium</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansAndLeasesReceivableRelatedPartiesCollections">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reflects the amount of collections received from related parties to reduce the carrying amounts of loans and leases receivable due from them.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.7(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 57<br> -Paragraph 2<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher OTS<br> -Name Federal Regulation (FR)<br> -Number Title 12<br> -Chapter V<br> -Section 563c.102<br> -Subsection I<br> -Paragraph 8<br> -Subparagraph j<br> -LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy.  It will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 9<br> -Section 03<br> -Paragraph 7<br> -Subparagraph e<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LoansAndLeasesReceivableRelatedPartiesCollections</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph A7<br> -Appendix A<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 130<br> -Paragraph 10, 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph d<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number 87-21<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 19<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28, 29, 30<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow to reacquire common and preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 18<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 20<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForRepurchaseOfEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid during the reporting period for charges associated with the consolidation and relocation of operations, disposition or abandonment of operations or productive assets (that is, for reorganizing and restructuring charges and other related expenses). These charges may be incurred in connection with a business combination, change in strategic plan, a managerial response to declines in demand, increasing costs or other environmental factors.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForRestructuring</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for the return on capital for preferred shareholders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 18<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 20<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 15, 17<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 17<br> -Subparagraph c<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 15, 17<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 159<br> -Section Appendix C<br> -Paragraph 5<br> -Subparagraph c<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireShortTermInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIncomeTaxRefunds">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash received during the period as refunds for the overpayment of taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 29<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIncomeTaxRefunds</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestReceived">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Interest received on loans and other debt instruments during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 27<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromInterestReceived</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 18<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 19<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 18<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 19<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLoans">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash received from principal payments made on loans related to operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 27<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromLoans</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 18<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 19<br> -Subparagraph b<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 16<br> -Subparagraph c<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 15, 16<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 159<br> -Section Appendix C<br> -Paragraph 5<br> -Subparagraph c<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfShortTermInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 123R<br> -Paragraph A240<br> -Subparagraph i<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 18<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 19<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecognitionOfDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br> -Subsection 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RecognitionOfDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 26, 31<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrealizedGainLossOnDerivatives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
        <td class="text">
    <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
    <!-- Begin Block Tagged Note 2 - us-gaap:SignificantAccountingPoliciesTextBlock-->
    <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Consolidation</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The accompanying condensed consolidated financial statements include the accounts of the
    Company and its wholly-owned subsidiaries for the indicated periods. All significant intercompany
    transactions and balances have been eliminated.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Use of Estimates</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The preparation of financial statements in accordance with GAAP requires management to make
    estimates and assumptions that affect the reported amounts of assets, liabilities and related
    disclosures of contingent assets and liabilities at the date of the financial statements and the
    reported amounts of income and expenses during the reporting period. The Company reviews its
    estimates on an ongoing basis. The estimates are based on historical experience and on various
    other assumptions that the Company believes to be reasonable under the circumstances. Actual
    results may differ from these estimates.
    </div>
    <!-- Folio -->
    <!-- /Folio -->
    </div>
    <!-- PAGEBREAK -->
    <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Cash and Cash Equivalents</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Cash and cash equivalents are stated at cost, which is substantially the same as fair value.
    The Company considers all highly liquid investments with an original maturity of three months or
    less at the time of purchase to be cash equivalents. The Company&#8217;s cash equivalents generally
    include investments in money market funds and corporate commercial paper.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Trade Accounts Receivable and Allowance for Doubtful Accounts</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">An allowance for doubtful accounts is provided, as necessary, on trade receivables based on
    their respective aging categories and historical collection experience, taking into consideration
    the type of payer, historical and projected collection outcomes, and current economic and business
    conditions that could affect the collectability of the Company&#8217;s receivables. The allowance for
    doubtful accounts is reviewed, at a minimum, on a quarterly basis. Changes in the allowance for
    doubtful accounts are recorded as an adjustment to bad debt expense within general and
    administrative expenses. Material revisions to reserve estimates may result from adverse changes in
    collection experience. The Company writes off accounts against the allowance for doubtful accounts
    when reasonable collection efforts have been unsuccessful and it is likely the receivable will not
    be recovered. At December&#160;31, 2010 and June&#160;30, 2011, all receivables were deemed collectible.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">For the three months ended June&#160;30, 2010 and 2011, approximately 87% and 92%, respectively, of
    the Company&#8217;s product sales in the United States were to three wholesalers. For the six months
    ended June&#160;30, 2010 and 2011, approximately 83% and 91%, respectively, of the Company&#8217;s product
    sales in the United States were to three wholesalers.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Inventory</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Cyclacel values inventories at the lower of cost or market value. The Company determines cost
    using the first-in, first-out method. As of December&#160;31, 2010 and June&#160;30, 2011, all inventories
    were classified as finished goods. The Company analyzes its inventory levels at least quarterly to
    identify any items that may expire prior to sale, inventory that has a cost basis in excess of net
    realizable value, or inventory in excess of expected sales requirements. The determination of
    whether or not inventory costs will be realizable requires estimates by the Company&#8217;s management.
    A critical input is future sales forecasts. The Company writes down the value of inventory to the
    extent that inventory is expected to expire before being sold or if the cost basis is in excess of net realizable value. If actual market conditions are less
    favorable than those projected by management, additional inventory write-downs may be required in
    future periods.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Revenue Recognition</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><i>Product sales</i>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company recognizes revenue from product sales when persuasive evidence of an arrangement
    exists; delivery has occurred or services have been rendered; the selling price is fixed or
    determinable; and collectability is reasonably assured.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The Company offers a general right of return on these product sales, and has considered the
    guidance in ASC 605-15, &#8220;<i>Revenue Recognition -Products</i>&#8221; (&#8220;ASC 605-15&#8221;) and ASC 605 -10 &#8220;<i>Revenue
    Recognition &#8212; Overall</i>&#8221; (&#8220;ASC 605-10&#8221;). Under these guidelines, the Company accounts for all product
    sales using the &#8220;sell-through&#8221; method. Under the sell-through method, revenue is not recognized
    upon shipment of product to distributors. Instead, the Company records deferred revenue at gross
    invoice sales price and deferred cost of sales at the cost at which those goods were held in
    inventory. The Company recognizes revenue when such inventory is sold through to pharmacies. To
    estimate product sold through to pharmacies, the Company relies on third-party information,
    including information obtained from significant distributors with respect to their inventory levels
    and sell-through to pharmacies. The Company estimates product returns based on historical returns
    experience and other factors that affect demand for the Company&#8217;s products as well as the amount of
    product subject to return.
    </div>
    <!-- Folio -->
    <!-- /Folio -->
    </div>
    <!-- PAGEBREAK -->
    <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Deferred revenue was $0.1&#160;million at June&#160;30, 2010 and 2011. Deferred cost of goods sold was
    approximately $58,000 and $11,000&#160;million at June&#160;30, 2010 and 2011, respectively.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><i>Collaboration, research and development, and grant revenue</i>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Certain of the Company&#8217;s revenues are earned from collaborative agreements. The Company
    recognizes revenue when persuasive evidence of an arrangement exists; delivery has occurred or
    services have been rendered; the fee is fixed or determinable; and collectability is reasonably
    assured. Determination of whether these criteria have been met is based on management&#8217;s judgments
    regarding the nature of the research performed, the substance of the milestones met relative to
    those the Company must still perform, and the collectability of any related fees. Should changes in
    conditions cause management to determine these criteria are not met for certain future
    transactions, revenue recognized for any reporting period could be adversely affected.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Research and development revenues, which are earned under agreements with third parties for
    contract research and development activities, are recorded as the related services are performed.
    Milestone payments are non-refundable and recognized as revenue when earned, as evidenced by
    achievement of the specified milestones and the absence of ongoing performance obligations. Any
    amounts received in advance of performance are recorded as deferred revenue. None of the revenues
    recognized to date are refundable if the relevant research effort is not successful.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Grant revenues from government agencies and private research foundations are recognized as the
    related qualified research and development costs are incurred, up to the limit of the prior
    approval funding amounts. All grants received are not refundable.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Clinical Trial Accounting</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Data management and monitoring of all of the Company&#8217;s clinical trials are performed by
    contract research organizations (''CROs&#8217;&#8217;) or clinical research associates (''CRAs&#8217;&#8217;) in accordance
    with the Company&#8217;s standard operating procedures. Typically, CROs and some CRAs bill monthly for
    services performed, and others bill based upon milestones achieved. The Company accrues unbilled clinical trial expenses based on estimates of the level of services
    performed each period. Costs of setting up investigational sites for participation in the Company&#8217;s
    clinical trials are expensed immediately as research and development expenses. Clinical trial site
    costs related to patient enrollment are accrued as patients are entered into the trial. Any initial
    payment made to the clinical trial site is recognized upon execution of the clinical trial
    agreements and expensed as research and development expenses.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Research and Development Expenditures</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Research and development expenses consist primarily of costs associated with the Company&#8217;s
    product candidates, upfront fees, milestones, compensation and other expenses for research and
    development personnel, supplies and development materials, costs for consultants and related
    contract research, facility costs, amortization of purchased technology and depreciation.
    Expenditures relating to research and development are expensed as incurred.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Foreign currency and currency translation</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Transactions that are denominated in a foreign currency are re-measured into the functional
    currency at the current exchange rate on the date of the transaction. Any foreign
    currency-denominated monetary assets and liabilities are subsequently re-measured at current
    exchange rates, with gains or losses recognized as foreign exchange (losses)/gains in the statement
    of operations.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The assets and liabilities of the Company&#8217;s international subsidiary are translated from its
    functional currency into United States dollars at exchange rates prevailing at the balance sheet
    date. Average rates of exchange during the period are used to translate the statement of
    operations, while historical rates of exchange are used to translate any equity transactions.
    </div>
    <!-- Folio -->
    <!-- /Folio -->
    </div>
    <!-- PAGEBREAK -->
    <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Translation adjustments arising on consolidation due to differences between average rates and
    balance sheet rates, as well as unrealized foreign exchange gains or losses arising from
    translation of intercompany loans that are of a long-term-investment nature, are recorded in other
    comprehensive income.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Derivative Instruments</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Derivative financial instruments are measured at fair value. Significant judgments and
    estimates are necessary in determining the fair value in the absence of quoted market values. These
    estimates are based on valuation methodologies and assumptions deemed appropriate in the
    circumstances. The use of different assumptions may have a material effect on the estimated fair
    value amount and the Company&#8217;s results of operations.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Fair Value Measurements</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Inputs used to determine fair value of financial and non-financial assets and liabilities are
    categorized using a fair value hierarchy that prioritizes observable and unobservable inputs into
    three broad levels, from Level 1, which is the most reliable, to Level 3, which is the least
    reliable (see &#8220;Note 3 &#8212; Fair Value Measurements&#8221;). Management reviews the categorization of fair
    value inputs on a periodic basis and may determine that it is necessary to transfer an input from
    one level of the fair value hierarchy to another based on changes in events or circumstances, such
    as a change in the observability of an input. Any such transfer will be recognized at the end of
    the reporting period.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Income Taxes</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company accounts for income taxes under the liability method. Under this method, deferred
    tax assets and liabilities are determined based on the difference between the financial statement
    and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the
    differences are expected to affect taxable income. Valuation allowances are established when
    necessary to reduce deferred tax assets to the amounts expected to be realized. The Company&#8217;s
    management has established a full valuation allowance against its deferred tax assets based on the
    determination that it is not more likely than not that the Company will recognize the benefits of
    those assets.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company adopted the guidance related to accounting for uncertainty in income taxes,
    primarily codified in ASC 740, <i>&#8220;Income taxes&#8221; </i>(&#8220;ASC 740&#8221;). ASC 740 specifies the accounting for
    uncertainty in income taxes recognized in a company&#8217;s financial statements by prescribing a minimum
    probability threshold a tax position is required to meet before being recognized in the financial
    statements.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company records income tax benefits related to research and development tax credits, which
    will be claimed from H. M. Revenue &#038; Customs, the United Kingdom&#8217;s taxation and customs authority,
    with respect to qualifying research and development costs incurred in the same accounting period.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Stock-based Compensation</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company grants stock options, restricted stock units and restricted stock to officers,
    employees and directors under the 2006 Amended and Restated Equity Incentive Plan (&#8220;2006 Plan&#8221;),
    which was approved on March&#160;16, 2006 and subsequently amended and restated on April&#160;14, 2008. The
    Company also has outstanding options under various stock-based compensation plans for employees and
    directors. These plans are described more fully in &#8220;Note 6 &#8212; Stock-Based Compensation&#8221;. The
    Company accounts for these plans under ASC 718, &#8220;<i>Compensation &#8212; Stock Compensation</i>&#8221; (&#8220;ASC 718&#8221;).
    </div>
    <!-- Folio -->
    <!-- /Folio -->
    </div>
    <!-- PAGEBREAK -->
    <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">ASC 718 requires measurement of compensation cost for all stock-based awards at fair value on
    date of grant and recognition of compensation over the requisite service period for awards expected
    to vest. The fair value of restricted stock and restricted stock units is determined based on the
    number of shares granted and the quoted price of the Company&#8217;s common stock on the date of grant.
    The determination of grant-date fair value for stock option awards is estimated using the
    Black-Scholes model, which includes variables such as the expected volatility of our share price,
    the anticipated exercise behavior of our employees, interest rates, and dividend yields. These
    variables are projected based on our historical data, experience, and other
    factors. Changes in any of these variables could result in material adjustments to the expense
    recognized for share-based payments. Such value is recognized as expense over the requisite service
    period, net of estimated forfeitures, using the straight-line attribution method. The estimation of
    stock awards that will ultimately vest requires judgment, and to the extent actual results or
    updated estimates differ from current estimates, such amounts are recorded as a cumulative
    adjustment in the period estimates are revised. The Company considers many factors when estimating
    expected forfeitures, including type of awards granted employee class, and historical experience.
    Actual results and future estimates may differ substantially from current estimates.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Segments</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company has determined its reportable segments in accordance with ASC 280, &#8220;<i>Segment
    Reporting</i>&#8221; (&#8220;ASC 280&#8221;) and related disclosures about products, services, geographic areas and major
    customers. After considering its business activities and geographic reach, the Company has
    concluded that it operates in just one operating segment being the discovery, development and
    commercialization of novel, mechanism-targeted drugs to treat cancer and other serious disorders,
    with development operations in two geographic areas, namely the United States and the United
    Kingdom.
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Net Loss per Common Share</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company calculates net loss per common share in accordance with ASC 260, &#8220;<i>Earnings Per
    Share</i>&#8221; (&#8220;ASC 260&#8221;). Basic and diluted net loss per common share were determined by dividing net loss
    applicable to common stockholders by the weighted average number of common shares outstanding
    during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common
    stock options, restricted stock, restricted stock units, convertible preferred stock, and common
    stock warrants, have not been included in the computation of diluted net loss per share for all
    periods as the result would be anti-dilutive.
    </div>
    <div align="center">
    <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
    <!-- Begin Table Head -->
    <tr valign="bottom">
    <td width="72%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>June 30,</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>June 30,</b></td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
    <td>&#160;</td>
    </tr>
    <!-- End Table Head -->
    <!-- Begin Table Body -->
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Stock options
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">3,187,291</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">3,543,529</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Restricted stock and restricted stock units
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">75,515</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">44,255</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Convertible preferred stock
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">516,228</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">516,228</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Options to purchase common stock and common
    stock warrants issued in connection with the
    October&#160;2010 financing
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">6,242,398</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Common stock warrants
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">5,843,597</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">10,005,192</td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 1px">
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Total shares excluded from calculation
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">9,622,631</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">20,351,602</td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 1px">
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    </tr>
    <!-- End Table Body -->
    </table>
    </div>
    <!-- Folio -->
    <!-- /Folio -->
    </div>
    <!-- PAGEBREAK -->
    <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
    <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Comprehensive Income (Loss)</i></b>
    </div>
    <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In accordance with ASC 220, &#8220;<i>Comprehensive Income</i>&#8221; (&#8220;ASC 220&#8221;) all components of comprehensive
    income (loss), including net income (loss), are reported in the financial statements in the period
    in which they are recognized. ASC 220 defines comprehensive income (loss)&#160;as the change in equity
    during a period from transactions and other events and circumstances from nonowner sources. Net
    income (loss)&#160;and other comprehensive income (loss), including foreign currency translation
    adjustments, are reported, net of any related tax effect, to arrive at comprehensive income (loss).
    No taxes were recorded on items of other comprehensive income.
    </div>
    <div align="center">
    <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
    <!-- Begin Table Head -->
    <tr valign="bottom">
    <td width="30%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="3%">&#160;</td>
    <td width="1%">&#160;</td>
    <td width="9%">&#160;</td>
    <td width="1%">&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>Period from</b></td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>August 13, 1996</b></td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="6"><b>Three Months Ended</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="6"><b>Six Months Ended</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2"><b>(inception) to</b></td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>June 30,</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>June 30,</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>June 30,</b></td>
    <td>&#160;</td>
    </tr>
    <tr style="font-size: 10pt" valign="bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
    <td>&#160;</td>
    </tr>
    <!-- End Table Head -->
    <!-- Begin Table Body -->
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td align="center" colspan="18">$000</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Net loss
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="left">&#160;</td>
    <td align="right">(3,933</td>
    <td nowrap="nowrap">)</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="left">&#160;</td>
    <td align="right">(3,552</td>
    <td nowrap="nowrap">)</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="left">&#160;</td>
    <td align="right">(9,040</td>
    <td nowrap="nowrap">)</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="left">&#160;</td>
    <td align="right">(8,140</td>
    <td nowrap="nowrap">)</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="left">&#160;</td>
    <td align="right">(246,446</td>
    <td nowrap="nowrap">)</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Translation adjustment
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="left">&#160;</td>
    <td align="right">(19</td>
    <td nowrap="nowrap">)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">139</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">4,001</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="left">&#160;</td>
    <td align="right">(2,826</td>
    <td nowrap="nowrap">)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">5,952</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom" style="background: #cceeff">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Unrealized foreign
    exchange (loss)&#160;gain
    on intercompany loans
    </div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">9</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="left">&#160;</td>
    <td align="right">(108</td>
    <td nowrap="nowrap">)</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="left">&#160;</td>
    <td align="right">(3,979</td>
    <td nowrap="nowrap">)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td align="right">2,834</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="left">&#160;</td>
    <td align="right">(5,913</td>
    <td nowrap="nowrap">)</td>
    </tr>
    <tr style="font-size: 1px">
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
    <td>&#160;</td>
    </tr>
    <tr valign="bottom">
    <td>
    <div style="margin-left:15px; text-indent:-15px">Comprehensive loss
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="left">&#160;</td>
    <td align="right">(3,943</td>
    <td nowrap="nowrap">)</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="left">&#160;</td>
    <td align="right">(3,521</td>
    <td nowrap="nowrap">)</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="left">&#160;</td>
    <td align="right">(9,018</td>
    <td nowrap="nowrap">)</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="left">&#160;</td>
    <td align="right">(8,132</td>
    <td nowrap="nowrap">)</td>
    <td>&#160;</td>
    <td nowrap="nowrap" align="left">&#160;</td>
    <td align="right">(246,407</td>
    <td nowrap="nowrap">)</td>
    </tr>
    <tr style="font-size: 1px">
    <td>
    <div style="margin-left:15px; text-indent:-15px">&#160;
    </div></td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
    <td>&#160;</td>
    </tr>
    <!-- End Table Body -->
    </table>
    </div>
    </div>
  <span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 22<br> -Paragraph 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E51AE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (USD $)<br>In Thousands</strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 20,614<span></span></td>
        <td class="nump">$ 29,495<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Inventory</a></td>
        <td class="nump">147<span></span></td>
        <td class="nump">174<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">1,688<span></span></td>
        <td class="nump">1,382<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">22,449<span></span></td>
        <td class="nump">31,051<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment (net)</a></td>
        <td class="nump">246<span></span></td>
        <td class="nump">408<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">22,695<span></span></td>
        <td class="nump">31,459<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">1,104<span></span></td>
        <td class="nump">1,723<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities and other current liabilities</a></td>
        <td class="nump">4,459<span></span></td>
        <td class="nump">4,132<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
        <td class="nump">477<span></span></td>
        <td class="nump">680<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">6,040<span></span></td>
        <td class="nump">6,535<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">6,040<span></span></td>
        <td class="nump">6,535<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 shares authorized at December 31, 2010 and June 30, 2011; 1,213,142 shares issued and outstanding at December 31, 2010 and June 30, 2011. Aggregate preference in liquidation (including undeclared cumulative dividends) of $13,344,562 at December 31, 2010 and June 30, 2011</a></td>
        <td class="nump">1<span></span></td>
        <td class="nump">1<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 100,000,000 shares authorized at December 31, 2010 and June 30, 2011; 46,564,914 and 46,587,182 shares issued and outstanding at December 31, 2010 and June 30, 2011 respectively</a></td>
        <td class="nump">47<span></span></td>
        <td class="nump">47<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">266,529<span></span></td>
        <td class="nump">266,666<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
        <td class="nump">39<span></span></td>
        <td class="nump">31<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Deficit accumulated during the development stage</a></td>
        <td class="num">(249,961)<span></span></td>
        <td class="num">(241,821)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
        <td class="nump">16,655<span></span></td>
        <td class="nump">24,924<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
        <td class="nump">$ 22,695<span></span></td>
        <td class="nump">$ 31,459<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 19<br> -Subparagraph a<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 20<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e653-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 130<br> -Paragraph 14, 17, 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name FASB Staff Position (FSP)<br> -Number FAS115-1/124-1<br> -Paragraph 15D<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e637-108580<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e681-108580<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 7<br> -Section 03<br> -Paragraph 12<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Topic 210<br> -SubTopic 10<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br> -Section S99<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -Paragraph 1<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Concepts (CON)<br> -Number 6<br> -Paragraph 25<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 18<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Section 45<br> -SubTopic 10<br> -Topic 210<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Paragraph 1<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 9<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 7<br> -Footnote 1<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 8, 9<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 7, 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 6<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section BB<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=6386940&amp;loc=d3e100047-122729<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryFinishedGoodsNetOfReserves</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 32<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.32)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 7<br> -Section 03<br> -Paragraph 25<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 21<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 129<br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 02<br> -Paragraph 29<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amount for an unclassified balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs and the carrying amount as of the balance sheet date of assets not otherwise specified in the taxonomy. Also includes assets not individually reported in the financial statements, or not separately disclosed in notes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 7<br> -Section 03<br> -Paragraph 8<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 12<br> -Paragraph 5<br> -Subparagraph b, c<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph A3<br> -Appendix A<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of warrants and rights outstanding. "Equity warrants and rights outstanding" represents derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 4<br> -Section 08<br> -Paragraph i<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number 00-27<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number 98-5<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WarrantsAndRightsOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.3.0.11</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ReportType />
  <ContextCount>9</ContextCount>
  <ElementCount>128</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>true</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0110 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0111 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0120 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0201 - Disclosure - Nature of Operations and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/NatureOfOperationsAndBasisOfPresentation</Role>
      <ShortName>Nature of Operations and Basis of Presentation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0202 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0203 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0204 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0205 - Disclosure - Accrued Liabilities and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/AccruedLiabilitiesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Liabilities and Other Current Liabilities</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0206 - Disclosure - Stock Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/StockBasedCompensation</Role>
      <ShortName>Stock Based Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0207 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0208 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0209 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 0110 - Statement - Condensed Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Jun. 30, 2010'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2009'</Log>
    <Log type="Info">Process Flow-Through: 0111 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 0120 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</Log>
    <Log type="Info">Process Flow-Through: 0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</Log>
  </Logs>
  <InputFiles>
    <File>cycc-20110630.xml</File>
    <File>cycc-20110630.xsd</File>
    <File>cycc-20110630_cal.xml</File>
    <File>cycc-20110630_lab.xml</File>
    <File>cycc-20110630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>32
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%\R.38Q,#0Q.5]E93<Q7S0X.3A?8CDQ85\W.&1A
M-F9C-C4P93@B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%\R.38Q,#0Q.5]E93<Q7S0X.3A?8CDQ85\W
M.&1A-F9C-C4P93@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,CDV
M,3`T,3E?964W,5\T.#DX7V(Y,6%?-SAD839F8S8U,&4X+U=O<FMB;V]K+FAT
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O
M;G-O;&ED871E9%]"86QA;F-E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O;G-O;&ED871E9%]"86QA;F-E,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E
M9%]#;VYS;VQI9&%T961?4W1A=&5M93PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M
M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y.871U
M<F5?;V9?3W!E<F%T:6]N<U]A;F1?0F%S:7,\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#8N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y3=6UM87)Y7V]F7U-I9VYI9FEC86YT7T%C
M8V]U;G0\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,#<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y&
M86ER7U9A;'5E7TUE87-U<F5M96YT<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P."YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/E!R97!A:61?17AP96YS97-?86YD7T]T:&5R7T-U
M<CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970P.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D%C8W)U
M961?3&EA8FEL:71I97-?86YD7T]T:&5R7SPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,"YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K7T)A<V5D7T-O;7!E;G-A=&EO;CPO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970Q,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;6UI=&UE
M;G1S7V%N9%]#;VYT:6YG96YC:65S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$R+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^4W1O8VMH;VQD97)S7T5Q=6ET>3PO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970Q,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U8G-E<75E;G1?179E;G1S
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#$T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@/"]X.D5X8V5L5V]R:W-H965T<SX-"B`@/'@Z4W1Y;&5S:&5E="!(
M4F5F/3-$(E=O<FMS:&5E=',O<F5P;W)T+F-S<R(O/@T*("`\>#I!8W1I=F53
M:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0<F]T96-T4W1R=6-T=7)E
M/D9A;'-E/"]X.E!R;W1E8W13=')U8W1U<F4^#0H@(#QX.E!R;W1E8W17:6YD
M;W=S/D9A;'-E/"]X.E!R;W1E8W17:6YD;W=S/@T*(#PO>#I%>&-E;%=O<FMB
M;V]K/@T*/"]X;6P^/"%;96YD:69=+2T^#0H\+VAE860^#0H@(#QB;V1Y/@T*
M("`@/'`^5&AI<R!P86=E('-H;W5L9"!B92!O<&5N960@=VET:"!-:6-R;W-O
M9G0@17AC96P@6%`@;W(@;F5W97(N/"]P/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?,CDV,3`T,3E?964W,5\T.#DX7V(Y,6%?
M-SAD839F8S8U,&4X#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S(Y
M-C$P-#$Y7V5E-S%?-#@Y.%]B.3%A7S<X9&$V9F,V-3!E."]7;W)K<VAE971S
M+U-H965T,#$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$4T34%%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/D1O8W5M96YT(&%N9"!%;G1I='D@26YF;W)M871I;VX@*%531"`F
M;F)S<#LD*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P
M+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@
M,S`L(#(P,3`\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^1&]C=6UE;G0@86YD($5N=&ET>2!);F9O<FUA=&EO;B!;06)S
M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5N=&ET>2!296=I<W1R86YT($YA;64\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/D-Y8VQA8V5L(%!H87)M86-E=71I8V%L<RP@26YC+CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M16YT:71Y($-E;G1R86P@26YD97@@2V5Y/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XP,#`Q,3,P,38V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!4>7!E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ,"U1/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!097)I;V0@
M16YD($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DIU;B`S
M,"P-"@D),C`Q,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06UE;F1M96YT($9L86<\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/F9A;'-E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@665A<B!&;V-U
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,C`Q,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE
M;G0@1FES8V%L(%!E<FEO9"!&;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^43(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-U<G)E;G0@1FES8V%L(%EE87(@16YD($1A=&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/BTM,3(M,S$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!7
M96QL+6MN;W=N(%-E87-O;F5D($ES<W5E<CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^3F\\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!6;VQU;G1A<GD@1FEL97)S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y.;SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($-U<G)E;G0@
M4F5P;W)T:6YG(%-T871U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^665S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%;G1I='D@1FEL97(@0V%T96=O<GD\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/E-M86QL97(@4F5P;W)T:6YG($-O;7!A;GD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N
M=&ET>2!0=6)L:6,@1FQO870\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B9N8G-P.R0@-C,L-34T+#DT-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($-O;6UO;B!3=&]C:RP@
M4VAA<F5S($]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU-"PR,C0L,#DS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\R.38Q,#0Q.5]E93<Q7S0X.3A?8CDQ85\W.&1A-F9C-C4P
M93@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,CDV,3`T,3E?964W
M,5\T.#DX7V(Y,6%?-SAD839F8S8U,&4X+U=O<FMS:&5E=',O4VAE970P,BYH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P134Q044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0V]N
M9&5N<V5D($-O;G-O;&ED871E9"!"86QA;F-E(%-H965T<R`H55-$("9N8G-P
M.R0I/&)R/DEN(%1H;W5S86YD<SPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,#QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#=7)R96YT(&%S<V5T<SH\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S
M:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)FYB<W`[)"`R,"PV,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#(Y+#0Y-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV96YT
M;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-S0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M97!A:60@97AP96YS97,@86YD(&]T:&5R(&-U<G)E;G0@87-S971S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8X.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S@R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@
M8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(R+#0T.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,Q+#`U,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')O<&5R='DL('!L86YT(&%N9"!E<75I<&UE;G0@
M*&YE="D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(T-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1O=&%L(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C(L-CDU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S$L-#4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-U<G)E;G0@;&EA8FEL:71I97,Z/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U
M;G1S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M,3`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PW,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%C8W)U960@;&EA8FEL:71I97,@86YD(&]T:&5R(&-U<G)E
M;G0@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0L-#4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-"PQ,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E=A<G)A;G0@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C=7)R96YT(&QI86)I
M;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#`T,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L
M-3,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&]T86P@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8L,#0P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-BPU,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1O8VMH;VQD97)S)R!E
M<75I='DZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R969E<G)E9"!S=&]C:RP@)FYB<W`[)#`N,#`Q('!A<B!V86QU93L@
M-2PP,#`L,#`P('-H87)E<R!A=71H;W)I>F5D(&%T($1E8V5M8F5R(#,Q+"`R
M,#$P(&%N9"!*=6YE(#,P+"`R,#$Q.R`Q+#(Q,RPQ-#(@<VAA<F5S(&ES<W5E
M9"!A;F0@;W5T<W1A;F1I;F<@870@1&5C96UB97(@,S$L(#(P,3`@86YD($IU
M;F4@,S`L(#(P,3$N($%G9W)E9V%T92!P<F5F97)E;F-E(&EN(&QI<75I9&%T
M:6]N("AI;F-L=61I;F<@=6YD96-L87)E9"!C=6UU;&%T:79E(&1I=FED96YD
M<RD@;V8@)FYB<W`[)#$S+#,T-"PU-C(@870@1&5C96UB97(@,S$L(#(P,3`@
M86YD($IU;F4@,S`L(#(P,3$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VUM;VX@<W1O8VLL("9N8G-P.R0P+C`P,2!P87(@=F%L=64[
M(#$P,"PP,#`L,#`P('-H87)E<R!A=71H;W)I>F5D(&%T($1E8V5M8F5R(#,Q
M+"`R,#$P(&%N9"!*=6YE(#,P+"`R,#$Q.R`T-BPU-C0L.3$T(&%N9"`T-BPU
M.#<L,3@R('-H87)E<R!I<W-U960@86YD(&]U='-T86YD:6YG(&%T($1E8V5M
M8F5R(#,Q+"`R,#$P(&%N9"!*=6YE(#,P+"`R,#$Q(')E<W!E8W1I=F5L>3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA
M;"!P86ED+6EN(&-A<&ET86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(V-BPU,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR-C8L-C8V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-U;75L871E9"!O=&AE<B!C;VUP<F5H
M96YS:79E(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1E9FEC:70@86-C=6UU;&%T960@9'5R:6YG('1H92!D979E;&]P;65N
M="!S=&%G93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C0Y+#DV
M,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@R-#$L.#(Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L('-T;V-K:&]L9&5R<R<@97%U:71Y/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-BPV-34\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-"PY,C0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A
M;"!L:6%B:6QI=&EE<R!A;F0@<W1O8VMH;VQD97)S)R!E<75I='D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@,C(L-CDU/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[
M)"`S,2PT-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7S(Y-C$P-#$Y7V5E-S%?-#@Y.%]B.3%A7S<X9&$V9F,V-3!E.`T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\R.38Q,#0Q.5]E93<Q7S0X.3A?
M8CDQ85\W.&1A-F9C-C4P93@O5V]R:W-H965T<R]3:&5E=#`S+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%049!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#;VYD96YS960@
M0V]N<V]L:61A=&5D($)A;&%N8V4@4VAE971S("A087)E;G1H971I8V%L*2`H
M55-$("9N8G-P.R0I/&)R/DEN(%1H;W5S86YD<RP@97AC97!T(%-H87)E(&1A
M=&$\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN
M(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3`\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4W1O8VMH;VQD97)S)R!E<75I='DZ/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C
M:RP@<&%R('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF
M;F)S<#LD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)FYB<W`[)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!S
M:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL('-H87)E
M<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C$S
M+#$T,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L,C$S+#$T,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!S:&%R97,@;W5T<W1A
M;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C$S+#$T
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L,C$S+#$T,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!L:7%U:61A=&EO;B!P<F5F
M97)E;F-E('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF
M;F)S<#LD(#$S+#,T-"PU-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#$S+#,T-"PU-C(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S
M=&]C:RP@<&%R('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XF;F)S<#LD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S
M:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3`P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,#`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R
M97,@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-BPU
M.#<L,3@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-#8L-38T+#DQ-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@;W5T<W1A
M;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0V+#4X-RPQ
M.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT-BPU-C0L.3$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%\R.38Q,#0Q.5]E93<Q7S0X.3A?8CDQ85\W.&1A-F9C-C4P93@-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,CDV,3`T,3E?964W,5\T
M.#DX7V(Y,6%?-SAD839F8S8U,&4X+U=O<FMS:&5E=',O4VAE970P-"YH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14)*04D^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]N9&5N
M<V5D($-O;G-O;&ED871E9"!3=&%T96UE;G1S(&]F($]P97)A=&EO;G,@*%5N
M875D:71E9"D@*%531"`F;F)S<#LD*3QB<CY);B!4:&]U<V%N9',L(&5X8V5P
M="!3:&%R92!D871A/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXV($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$X,2!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,3QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$P/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,#QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$Q/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E
M=F5N=65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VQL86)O<F%T:6]N(&%N9"!R97-E87)C:"!A;F0@9&5V96QO<&UE
M;G0@<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB
M<W`[)"`Q,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XF;F)S<#LD(#$P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@,RPQ,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V1U8W0@<F5V
M96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M-S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#8X,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1W)A;G0@<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS+#8T.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(')E=F5N=64\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$V.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,V,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,X.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL-#,P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D]P97)A=&EN9R!E>'!E;G-E<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]S="!O9B!G;V]D<R!S;VQD/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDR/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU-S`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A
M<F-H(&%N9"!D979E;&]P;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PX-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#,R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0L.3,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPT.3<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#$L-3,R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y396QL:6YG+"!G
M96YE<F%L(&%N9"!A9&UI;FES=')A=&EV93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,BPP,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS+#`Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,L.#0P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PT.3$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-2PX,#8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=O;V1W
M:6QL(&%N9"!I;G1A;F=I8FQE<R!I;7!A:7)M96YT/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XW+#DS-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S=')U8W1U<FEN9R!C;W-T<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPV,S0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!O
M<&5R871I;F<@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L.38U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-"PU,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XX+#DU-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/CDL,C(R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<Y+#0W-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P97)A=&EN9R!L
M;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#<Y-RD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T+#,X
M-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@X+#4Y-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@X+#@S,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@R-S`L,#0V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/=&AE<B!I;F-O;64@
M*&5X<&5N<V4I.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;W-T<R!A<W-O8VEA=&5D('=I=&@@86)O<G1E9"`R,#`T($E0
M3SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPU-3`I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y087EM
M96YT('5N9&5R(&=U87)A;G1E93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,2PV-3(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#:&%N9V4@:6X@=F%L=6%T:6]N(&]F(&1E<FEV871I
M=F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,P."D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H86YG
M92!I;B!V86QU871I;VX@;V8@=V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(W,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(P,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#4Q-BD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#(W,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N="!R92UP
M<FEC:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T-"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9O
M<F5I9VX@97AC:&%N9V4@*&QO<W-E<RDO9V%I;G,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#$Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#0Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#@W*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,X*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0L,S0R*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E<W0@
M:6YC;VUE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3,L-S`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y);G1E<F5S="!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#,S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#0L-C<W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&]T:&5R(&EN8V]M92`H
M97AP96YS92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(R
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$T,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#4W,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU+#0P-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DQO<W,@8F5F;W)E('1A>&5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@S+#8W."D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T+#$V,RD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X+#0U-RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Y+#0P,RD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R
M-C0L-C0R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^26YC;VUE('1A>"!B96YE9FET/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-C,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."PQ.38\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPU-3(I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPY,S,I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH."PQ
M-#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH.2PP-#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,C0V+#0T-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1I=FED96YD<R!O;B!P<F5F97)R960@;W)D
M:6YA<GD@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S
M."PQ,C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$965M960@9&EV:61E;F0@;VX@8V]N=F5R=&EB;&4@97AC:&%N
M9V5A8FQE('!R969E<G)E9"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#(L-#DV*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#(L.3$U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#,L-3$U*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&EV:61E;F0@;VX@8V]N
M=F5R=&EB;&4@97AC:&%N9V5A8FQE('!R969E<G)E9"!S:&%R97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$X,BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,30I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S8T*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0P,RD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#(Y
M,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@;&]S<R!A<'!L:6-A8FQE('1O(&-O;6UO;B!S:&%R96AO;&1E
M<G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)FYB<W`[)"`H,RPW
M,S0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XF;F)S<#LD("@V+#4T,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B9N8G-P.R0@*#@L-3`T*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)FYB<W`[)"`H,3(L,S4X
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)FYB<W`[)"`H,CDQ+#,W-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S('!E<B!S:&%R92T@0F%S:6,@
M86YD(&1I;'5T960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)FYB
M<W`[)"`H,"XP."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B9N8G-P.R0@*#`N,3@I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XF;F)S<#LD("@P+C$X*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)FYB<W`[)"`H
M,"XS-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E=E:6=H=&5D(&%V97)A9V4@8V]M;6]N('-H87)E<R!O=71S=&%N
M9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#8L-3@R+#DQ
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,V+#4V-2PY-S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT-BPU-S<L-3<W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S0L,34W+#(W.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,CDV,3`T,3E?964W,5\T.#DX
M7V(Y,6%?-SAD839F8S8U,&4X#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S(Y-C$P-#$Y7V5E-S%?-#@Y.%]B.3%A7S<X9&$V9F,V-3!E."]7;W)K
M<VAE971S+U-H965T,#4N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4V3$))/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/D-O;F1E;G-E9"!#;VYS;VQI9&%T960@4W1A=&5M96YT
M<R!O9B!#87-H($9L;W=S("A5;F%U9&ET960I("A54T0@)FYB<W`[)"D\8G(^
M26X@5&AO=7-A;F1S/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#(^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ.#$@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-A<V@@9FQO=W,@9G)O;2!O
M<&5R871I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^)FYB<W`[)"`H."PQ-#`I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XF;F)S<#LD("@Y+#`T,"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B9N8G-P
M.R0@*#(T-BPT-#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%D:G5S=&UE;G1S('1O(')E8V]N8VEL
M92!N970@;&]S<R!T;R!N970@8V%S:"!U<V5D(&EN(&]P97)A=&EN9R!A8W1I
M=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!8V-R971I;VX@;V8@:6YT97)E<W0@;VX@;F]T97,@<&%Y86)L92P@
M;F5T(&]F(&%M;W)T:7IA=&EO;B!O9B!D96)T('!R96UI=6T\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T:7IA=&EO;B!O9B!I
M;G9E<W1M96YT('!R96UI=6US+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#(L,CDW*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0VAA;F=E(&EN('9A;'5A=&EO;B!O9B!D97)I
M=F%T:79E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,#@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H
M86YG92!I;B!V86QU871I;VX@;V8@=V%R<F%N=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#(P,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@V+#(W,RD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@<F4M<')I
M8VEN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<')E
M8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR-#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,BPT.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T:7IA=&EO;B!O9B!I;G1A
M;F=I8FQE(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.#@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y&:7AE9"!A<W-E="!I;7!A:7)M96YT/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D=O;V1W:6QL(&%N9"!I;G1A;F=I8FQE<R!I
M;7!A:7)M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#DS
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^56YR96%L:7IE9"!F;W)E:6=N(&5X8VAA;F=E(&QO<W,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPW-C@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E=F5N
M=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DX*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M<&5N
M<V%T:6]N(&9O<B!W87)R86YT<R!I<W-U960@=&\@;F]N(&5M<&QO>65E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR,34\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!I
M<W-U960@9F]R($E0(')I9VAT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-#0V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#XH1V%I;BD@;&]S<R!O;B!D:7-P;W-A;"!O9B!P<F]P97)T
M>2P@<&QA;G0@86YD(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XY.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4W1O8VL@8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-34\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW.#8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."PU.38\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W9I
M<VEO;B!F;W(@<F5S=')U8W1U<FEN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PW-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%M;W)T:7IA=&EO;B!O9B!I<W-U86YC92!C;W-T
M<R!O9B!0<F5F97)R960@3W)D:6YA<GD@(D,B('-H87)E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,BPU,3<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0VAA;F=E<R!I
M;B!O<&5R871I;F<@87-S971S(&%N9"!L:6%B:6QI=&EE<SH\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E<&%I9"!E>'!E
M;G-E<RP@:6YV96YT;W)Y(&%N9"!O=&AE<B!C=7)R96YT(&%S<V5T<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C<Y*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@X*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4Q,2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U
M;G1S('!A>6%B;&4L(&%C8W)U960@;&EA8FEL:71I97,@86YD(&]T:&5R(&-U
M<G)E;G0@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#0X,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@R+#$X,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@V+#,W,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S:"!U<V5D(&EN(&]P97)A
M=&EN9R!A8W1I=FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@X+#0U-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@Y+#<W-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@R,#<L-3DX*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);G9E<W1I;F<@86-T
M:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4'5R8VAA<V4@;V8@04Q)1TX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#,L-S8S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4'5R8VAA<V4@;V8@<')O<&5R='DL('!L86YT
M(&%N9"!E<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH."PX,S$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M('-A;&4@;V8@<')O<&5R='DL('!L
M86YT(&%N9"!E<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,34X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0=7)C:&%S92!O9B!S:&]R="UT97)M(&EN=F5S=&UE;G1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-38L-C4W*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5D
M96UP=&EO;G,@;V8@<VAO<G0M=&5R;2!I;G9E<W1M96YT<RP@;F5T(&]F(&UA
M='5R:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V,BPW
M,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@8V%S:"!P<F]V:61E9"!B>2`H=7-E9"!I;BD@:6YV97-T:6YG
M(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-BPS-C0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D9I;F%N8VEN9R!A8W1I=FET:65S.CPO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y087EM96YT(&]F
M(&-A<&ET86P@;&5A<V4@;V)L:6=A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#,L-S$Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!I<W-U86YC92!O
M9B!O<F1I;F%R>2!A;F0@<')E9F5R<F5D(&]R9&EN87)Y('-H87)E<RP@;F5T
M(&]F(&ES<W5A;F-E(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,C$L-C<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(&ES<W5A;F-E(&]F(&-O;6UO
M;B!S=&]C:R!A;F0@=V%R<F%N=',L(&YE="!O9B!I<W-U86YC92!C;W-T<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.#`I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34L,34U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#(L,S(T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.970@<')O8V5E9',@9G)O;2!S=&]C:R!O<'1I;VYS(&%N9"!W87)R86YT
M<R!E>&5R8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M+#<P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$W,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4&%Y;65N="!O9B!P<F5F97)R960@<W1O8VL@9&EV:61E;F0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,V-"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#@Y."D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E
M<&%Y;65N="!O9B!G;W9E<FYM96YT(&QO86X\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#0U-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D=O=F5R;FUE;G0@;&]A;B!R96-E:79E9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#$T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;V%N(')E8V5I
M=F5D(&9R;VT@0WEC;&%C96P@1W)O=7`@4&QC/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XY+#$P,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@;V8@8V]M;6ET=&%B;&4@
M;&]A;B!N;W1E<R!I<W-U960@9G)O;2!S:&%R96AO;&1E<G,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C@L.#@S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;V%N<R!R96-E:79E9"!F
M<F]M('-H87)E:&]L9&5R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PV-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',@87-S=6UE9"!O
M;B!S=&]C:R!P=7)C:&%S93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3<L.3$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;W-T<R!A<W-O8VEA=&5D('=I=&@@<W1O8VL@<'5R8VAA
M<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L.34Q*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE
M="!C87-H('!R;W9I9&5D(&)Y("AU<V5D(&EN*2!F:6YA;F-I;F<@86-T:79I
M=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#0Q*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+#@U
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(S-"PQ,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5F9F5C="!O9B!E>&-H86YG92!R871E(&-H86YG97,@;VX@
M8V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@U-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT-C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@:6YC<F5A<V4@*&1E8W)E87-E
M*2!I;B!C87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@X+#@X,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#`U,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#8Q-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@
M8V%S:"!E<75I=F%L96YT<R!A="!B96=I;FYI;F<@;V8@<&5R:6]D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.2PT.34\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PT.3,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@
M86YD(&-A<V@@97%U:79A;&5N=',@870@96YD(&]F('!E<FEO9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`L-C$T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL-30S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`L-C$T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D-A<V@@<F5C96EV960@9'5R:6YG('1H92!P97)I;V0@9F]R.CPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E
M<F5S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q+#<R
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5&%X97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W
M+#4R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY#87-H('!A:60@9'5R:6YG('1H92!P97)I;V0@9F]R
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)
M;G1E<F5S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3@W*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L
M.3$T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY38VAE9'5L92!O9B!N;VXM8V%S:"!T<F%N<V%C=&EO
M;G,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%C<75I<VET:6]N<R!O9B!E<75I<&UE;G0@<'5R8VAA<V5D('1H<F]U9V@@
M8V%P:71A;"!L96%S97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,L-#<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<VAA<F5S(&EN(&-O;FYE8W1I
M;VX@=VET:"!L:6-E;G-E(&%G<F5E;65N=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@3W)D:6YA<GD@<VAA<F5S
M(&]N(&-O;G9E<G-I;VX@;V8@8G)I9&=I;F<@;&]A;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PV,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(%!R969E<G)E
M9"!/<F1I;F%R>2`B0R(@<VAA<F5S(&]N(&-O;G9E<G-I;VX@;V8@<V5C=7)E
M9"!C;VYV97)T:6)L92!L;V%N(&YO=&5S(&%N9"!A8V-R=65D(&EN=&5R97-T
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#@Y,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N
M8V4@;V8@3W)D:6YA<GD@<VAA<F5S(&EN(&QI974@;V8@8V%S:"!B;VYU<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O
M9B!O=&AE<B!L;VYG('1E<FT@<&%Y86)L92!O;B!!3$E'3B!A8W%U:7-I=&EO
M;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`Q+#$R
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,CDV
M,3`T,3E?964W,5\T.#DX7V(Y,6%?-SAD839F8S8U,&4X#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+S(Y-C$P-#$Y7V5E-S%?-#@Y.%]B.3%A7S<X
M9&$V9F,V-3!E."]7;W)K<VAE971S+U-H965T,#8N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4R
M2#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.871U<F4@;V8@3W!E<F%T:6]N
M<R!A;F0@0F%S:7,@;V8@4')E<V5N=&%T:6]N/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3F%T=7)E(&]F($]P97)A
M=&EO;G,@86YD($)A<VES(&]F(%!R97-E;G1A=&EO;B!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DY!5%52
M12!/1B!/4$52051)3TY3($%.1"!"05-)4R!/1B!04D5314Y4051)3TX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/@T*("`@(#PA+2U$3T-465!%
M(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO
M;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT
M;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@(#PA+2T@0F5G:6X@0FQO
M8VL@5&%G9V5D($YO=&4@,2`M('5S+6=A87`Z3W)G86YI>F%T:6]N0V]N<V]L
M:61A=&EO;D%N9%!R97-E;G1A=&EO;D]F1FEN86YC:6%L4W1A=&5M96YT<T1I
M<V-L;W-U<F5497AT0FQO8VLM+3X-"B`@("`\(2TM('AB<FPL;G,@+2T^#0H@
M("`@/"$M+2!X8G)L+&YX("TM/@T*("`@(#QD:78@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+%1I;65S+'-E<FEF.R!M87)G:6XM
M;&5F=#H@,&EN.R`G/@T*("`@(#QD:78@86QI9VX],T1C96YT97(@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`P<'0G/CQB/@T*("`@
M(#PO8CX-"B`@("`\+V1I=CX-"B`@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/CQB/C$N
M($Y!5%5212!/1B!/4$52051)3TY3($%.1"!"05-)4R!/1B!04D5314Y4051)
M3TX\+V(^#0H@("`@/"]D:78^#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SX\8CX\
M:3Y.871U<F4@;V8@3W!E<F%T:6]N<SPO:3X\+V(^#0H@("`@/"]D:78^#0H@
M("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@-"4G/D-Y8VQA8V5L
M(%!H87)M86-E=71I8V%L<RP@26YC+B`H)R=#>6-L86-E;"8C.#(Q-SLF(S@R
M,3<[(&]R('1H92`G)T-O;7!A;GDF(S@R,3<[)B,X,C$W.RD@:7,@82!D979E
M;&]P;65N="US=&%G90T*("`@(&)I;W!H87)M86-E=71I8V%L(&-O;7!A;GD@
M9&5D:6-A=&5D('1O('1H92!D979E;&]P;65N="!A;F0@8V]M;65R8VEA;&EZ
M871I;VX@;V8@;F]V96PL#0H@("`@;65C:&%N:7-M+71A<F=E=&5D(&1R=6=S
M('1O('1R96%T(&AU;6%N(&-A;F-E<G,@86YD(&]T:&5R('-E<FEO=7,@9&ES
M96%S97,N($-Y8VQA8V5L)B,X,C$W.W,@<W1R871E9WD@:7,-"B`@("!T;R!B
M=6EL9"!A(&1I=F5R<VEF:65D(&)I;W!H87)M86-E=71I8V%L(&)U<VEN97-S
M(&9O8W5S960@:6X@:&5M871O;&]G>2!A;F0@;VYC;VQO9WD@8F%S960@;VX@
M80T*("`@('!O<G1F;VQI;R!O9B!C;VUM97)C:6%L('!R;V1U8W1S(&%N9"!A
M(&1E=F5L;W!M96YT('!I<&5L:6YE(&]F(&YO=F5L(&1R=6<@8V%N9&ED871E
M<RX-"B`@("`\+V1I=CX-"B`@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD
M96YT.B`T)2<^0WEC;&%C96PF(S@R,3<[<R!C;&EN:6-A;"!D979E;&]P;65N
M="!P<FEO<FET:65S(&%R92!F;V-U<V5D(&]N('-A<&%C:71A8FEN92!I;B!T
M:&4@9F]L;&]W:6YG#0H@("`@:6YD:6-A=&EO;G,Z#0H@("`@/"]D:78^#0H@
M("`@/&1I=B!S='EL93TS1"=M87)G:6XM=&]P.B`Q,'!T)SX-"B`@("`\=&%B
M;&4@=VED=&@],T0Q,#`E(&)O<F1E<CTS1#`@8V5L;'!A9&1I;F<],T0P(&-E
M;&QS<&%C:6YG/3-$,"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/@T*("`@(#QT<B!V86QI9VX],T1T;W`@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!C;VQO<CH@(S`P,#`P,#L@8F%C:V=R;W5N9#H@
M=')A;G-P87)E;G0G/@T*("`@(#QT9"!W:61T:#TS1#0E('-T>6QE/3-$)V)A
M8VMG<F]U;F0Z('1R86YS<&%R96YT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!W
M:61T:#TS1#,E(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&QE9G0^/&(^)B,X
M,C(V.SPO8CX\+W1D/@T*("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^
M#0H@("`@/'1D/D%C=71E(&UY96QO:60@;&5U:V5M:6$L(&]R($%-3"P@:6X@
M=&AE(&5L9&5R;'D[/"]T9#X-"B`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M("`@/"]D:78^#0H@("`@/&1I=B!S='EL93TS1"=M87)G:6XM=&]P.B`Q,'!T
M)SX-"B`@("`\=&%B;&4@=VED=&@],T0Q,#`E(&)O<F1E<CTS1#`@8V5L;'!A
M9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*("`@(#QT<B!V86QI9VX],T1T
M;W`@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!C;VQO<CH@(S`P,#`P,#L@
M8F%C:V=R;W5N9#H@=')A;G-P87)E;G0G/@T*("`@(#QT9"!W:61T:#TS1#0E
M('-T>6QE/3-$)V)A8VMG<F]U;F0Z('1R86YS<&%R96YT)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!W:61T:#TS1#,E(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1&QE9G0^/&(^)B,X,C(V.SPO8CX\+W1D/@T*("`@(#QT9"!W:61T:#TS1#$E
M/B8C,38P.SPO=&0^#0H@("`@/'1D/DUY96QO9'ES<&QA<W1I8R!S>6YD<F]M
M97,L(&]R($U$4SL@86YD/"]T9#X-"B`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@("`@/"]D:78^#0H@("`@/&1I=B!S='EL93TS1"=M87)G:6XM=&]P.B`Q
M,'!T)SX-"B`@("`\=&%B;&4@=VED=&@],T0Q,#`E(&)O<F1E<CTS1#`@8V5L
M;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*("`@(#QT<B!V86QI9VX]
M,T1T;W`@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!C;VQO<CH@(S`P,#`P
M,#L@8F%C:V=R;W5N9#H@=')A;G-P87)E;G0G/@T*("`@(#QT9"!W:61T:#TS
M1#0E('-T>6QE/3-$)V)A8VMG<F]U;F0Z('1R86YS<&%R96YT)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!W:61T:#TS1#,E(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1&QE9G0^/&(^)B,X,C(V.SPO8CX\+W1D/@T*("`@(#QT9"!W:61T:#TS
M1#$E/B8C,38P.SPO=&0^#0H@("`@/'1D/DYO;BUS;6%L;"!C96QL(&QU;F<@
M8V%N8V5R+"!O<B!.4T-,0RX\+W1D/@T*("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@("`\+V1I=CX-"B`@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD
M96YT.B`T)2<^3VX@2F%N=6%R>28C,38P.S$Q+"`R,#$Q+"!T:&4@0V]M<&%N
M>2!O<&5N960@96YR;VQL;65N="!O9B!T:&4@4T5!34Q%4U,@<&EV;W1A;"!0
M:&%S92`S('1R:6%L(&9O<@T*("`@('1H92!#;VUP86YY)B,X,C$W.W,@<V%P
M86-I=&%B:6YE(&]R86P@8V%P<W5L97,@87,@82!F<F]N="UL:6YE('1R96%T
M;65N="!O9B!E;&1E<FQY('!A=&EE;G1S(&%G960@-S`-"B`@("!Y96%R<R!O
M<B!O;&1E<B!W:71H(&YE=VQY(&1I86=N;W-E9"!!34P@=VAO(&%R92!N;W0@
M8V%N9&ED871E<R!F;W(@:6YT96YS:79E(&EN9'5C=&EO;B!C:&5M;W1H97)A
M<'D-"B`@("!U;F1E<B!A(%-P96-I86P@4')O=&]C;VP@07-S97-S;65N="P@
M;W(@4U!!+"!R96%C:&5D('=I=&@@=&AE(%4N4RX@1F]O9"`F(S`S.#L@1')U
M9R!!9&UI;FES=')A=&EO;BP@;W(-"B`@("!&1$$N#0H@("`@/"]D:78^#0H@
M("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@-"4G/E1H92!#;VUP
M86YY(&AA<R!A9'9A;F-E9"!T=V\@861D:71I;VYA;"!P<F]D=6-T(&-A;F1I
M9&%T97,L('-E;&EC:6-L:6(@:6X@4&AA<V4@,B!F;W(@3E-#3$,-"B`@("!A
M;F0@;F%S;W!H87)Y;F=E86P@8V%N8V5R(&]R($Y00RP@86YD($-90S$Q-B!I
M;B!0:&%S92`Q(&-L:6YI8V%L(&1E=F5L;W!M96YT+B!4:&4@8V]M8FEN871I
M;VX@;V8-"B`@("!S87!A8VET86)I;F4@=VET:"!S96QI8VEC;&EB(&ES(&%L
M<V\@8F5I;F<@979A;'5A=&5D(&EN(&$@4&AA<V4@,2!C;&EN:6-A;"!T<FEA
M;"X@5&AE($-O;7!A;GD@=VEL;`T*("`@(&1E=&5R;6EN92!T:&4@9F5A<VEB
M:6QI='D@;V8@<'5R<W5I;F<@9G5R=&AE<B!D979E;&]P;65N="!A;F0O;W(@
M<&%R=&YE<FEN9R!T:&5S92!A<W-E=',@9&5P96YD:6YG#0H@("`@;VX@=&AE
M(&%V86EL86)I;&ET>2!O9B!F=6YD:6YG(&%N9"!F=7)T:&5R(&-L:6YI8V%L
M(&1A=&$N($EN(&%D9&ET:6]N+"!T:&4@0V]M<&%N>2!M87)K971S(&1I<F5C
M=&QY#0H@("`@:6X@=&AE(%5N:71E9"!3=&%T97,@6&-L86ER/'-U<"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#@U)3L@=F5R=&EC86PM86QI9VXZ('1E>'0M=&]P
M)SXF(S$W-#L\+W-U<#X@0W)E86T@9F]R(')A9&EA=&EO;B!D97)M871I=&ES
M(&%N9"!.=6UO:7-Y;CQS=7`@<W1Y;&4],T0G9F]N="US:7IE.B`X-24[('9E
M<G1I8V%L+6%L:6=N.B!T97AT+71O<"<^)B,Q-S0[/"]S=7`^($QI<75I9"!A
M;F0@3G5M;VES>6X\<W5P('-T>6QE/3-$)V9O;G0M<VEZ93H@.#4E.R!V97)T
M:6-A;"UA;&EG;CH@=&5X="UT;W`G/B8C,3<T.SPO<W5P/@T*("`@($QO>F5N
M9V5S(&9O<B!X97)O<W1O;6EA+@T*("`@(#PO9&EV/@T*("`@(#QD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O
M<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY!<R!A(&1E=F5L;W!M96YT('-T
M86=E(&5N=&5R<')I<V4L('-U8G-T86YT:6%L;'D@86QL(&5F9F]R=',@;V8@
M=&AE($-O;7!A;GD@=&\@9&%T92!H879E(&)E96X-"B`@("!D979O=&5D('1O
M('!E<F9O<FUI;F<@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT+"!C;VYD=6-T
M:6YG(&-L:6YI8V%L('1R:6%L<RP@9&5V96QO<&EN9R!A;F0-"B`@("!A8W%U
M:7)I;F<@:6YT96QL96-T=6%L('!R;W!E<G1Y(&%N9"!R86ES:6YG(&-A<&ET
M86PN#0H@("`@/"]D:78^#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SX\8CX\:3Y"
M87-I<R!O9B!0<F5S96YT871I;VX\+VD^/"]B/@T*("`@(#PO9&EV/@T*("`@
M(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M;6%R9VEN+71O<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY4:&4@8V]N9&5N
M<V5D(&-O;G-O;&ED871E9"!B86QA;F-E('-H965T(&%S(&]F($IU;F4F(S$V
M,#LS,"P@,C`Q,2P@=&AE(&-O;F1E;G-E9"!C;VYS;VQI9&%T960-"B`@("!S
M=&%T96UE;G1S(&]F(&]P97)A=&EO;G,@9F]R('1H92!T:')E92!A;F0@<VEX
M(&UO;G1H<R!E;F1E9"!*=6YE)B,Q-C`[,S`L(#(P,3$@86YD(#(P,3`@86YD
M('1H90T*("`@(&-O;F1E;G-E9"!C;VYS;VQI9&%T960@<W1A=&5M96YT<R!O
M9B!C87-H(&9L;W=S(&9O<B!T:&4@<VEX(&UO;G1H<R!E;F1E9"!*=6YE)B,Q
M-C`[,S`L(#(P,3$@86YD(#(P,3`L#0H@("`@86YD(')E;&%T960@9&ES8VQO
M<W5R97,@8V]N=&%I;F5D(&EN('1H92!A8V-O;7!A;GEI;F<@;F]T97,@87)E
M('5N875D:71E9"X@5&AE(&-O;F1E;G-E9`T*("`@(&-O;G-O;&ED871E9"!B
M86QA;F-E('-H965T(&%S(&]F($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3`@:7,@
M9&5R:79E9"!F<F]M('1H92!A=61I=&5D(&-O;G-O;&ED871E9`T*("`@(&9I
M;F%N8VEA;"!S=&%T96UE;G1S(&EN8VQU9&5D(&EN('1H92!!;FYU86P@4F5P
M;W)T(&]N($9O<FT@,3`M2R!F;W(@=&AE('EE87(@96YD960@1&5C96UB97(F
M(S$V,#LS,2P-"B`@("`R,#$P(&9I;&5D('=I=&@@=&AE(%-E8W5R:71I97,@
M86YD($5X8VAA;F=E($-O;6UI<W-I;VX@*"8C.#(R,#M314,F(S@R,C$[*2X@
M5&AE(&-O;F1E;G-E9"!C;VYS;VQI9&%T960-"B`@("!F:6YA;F-I86P@<W1A
M=&5M96YT<R!A<F4@<')E<V5N=&5D(&]N('1H92!B87-I<R!O9B!A8V-O=6YT
M:6YG('!R:6YC:7!L97,@=&AA="!A<F4@9V5N97)A;&QY#0H@("`@86-C97!T
M960@:6X@=&AE(%5N:71E9"!3=&%T97,@*"8C.#(R,#M'04%0)B,X,C(Q.RD@
M9F]R(&EN=&5R:6T@9FEN86YC:6%L(&EN9F]R;6%T:6]N(&%N9"!I;B!A8V-O
M<F1A;F-E('=I=&@@=&AE#0H@("`@<G5L97,@86YD(')E9W5L871I;VYS(&]F
M('1H92!314,[(&%C8V]R9&EN9VQY+"!T:&5Y(&1O(&YO="!I;F-L=61E(&%L
M;"!T:&4@:6YF;W)M871I;VX@86YD#0H@("`@9F]O=&YO=&5S(')E<75I<F5D
M(&)Y(&%C8V]U;G1I;F<@<')I;F-I<&QE<R!G96YE<F%L;'D@86-C97!T960@
M:6X@=&AE(%5N:71E9"!3=&%T97,@9F]R(&$@8V]M<&QE=&4-"B`@("!S970@
M;V8@9FEN86YC:6%L('-T871E;65N=',N($EN('1H92!O<&EN:6]N(&]F(&UA
M;F%G96UE;G0L(&%L;"!A9&IU<W1M96YT<RP@=VAI8V@@:6YC;'5D92!O;FQY
M#0H@("`@;F]R;6%L(')E8W5R<FEN9R!A9&IU<W1M96YT<RP@;F5C97-S87)Y
M('1O('!R97-E;G0@9F%I<FQY('1H92!C;VYD96YS960@8V]N<V]L:61A=&5D
M(&)A;&%N8V4@<VAE970-"B`@("!A<R!O9B!*=6YE)B,Q-C`[,S`L(#(P,3$L
M('1H92!R97-U;'1S(&]F(&]P97)A=&EO;G,@9F]R('1H92!T:')E92!A;F0@
M<VEX(&UO;G1H<R!E;F1E9"!*=6YE)B,Q-C`[,S`L(#(P,3$@86YD#0H@("`@
M,C`Q,"!A;F0@=&AE(&-O;G-O;&ED871E9"!S=&%T96UE;G1S(&]F(&-A<V@@
M9FQO=W,@9F]R('1H92!S:7@@;6]N=&AS(&5N9&5D($IU;F4F(S$V,#LS,"P@
M,C`Q,2!A;F0@,C`Q,`T*("`@(&AA=F4@8F5E;B!M861E+B!4:&4@:6YT97)I
M;2!R97-U;'1S(&9O<B!T:&4@=&AR964@86YD('-I>"!M;VYT:',@96YD960@
M2G5N928C,38P.S,P+"`R,#$Q(&%R92!N;W0-"B`@("!N96-E<W-A<FEL>2!I
M;F1I8V%T:79E(&]F('1H92!R97-U;'1S('1O(&)E(&5X<&5C=&5D(&9O<B!T
M:&4@>65A<B!E;F1I;F<@1&5C96UB97(F(S$V,#LS,2P@,C`Q,2!O<B!F;W(-
M"B`@("!A;GD@;W1H97(@>65A<BX@5&AE(&-O;F1E;G-E9"!C;VYS;VQI9&%T
M960@9FEN86YC:6%L('-T871E;65N=',@<VAO=6QD(&)E(')E860@:6X@8V]N
M:G5N8W1I;VX@=VET:`T*("`@('1H92!A=61I=&5D(&-O;G-O;&ED871E9"!F
M:6YA;F-I86P@<W1A=&5M96YT<R!A;F0@=&AE#0H@("`@86-C;VUP86YY:6YG
M(&YO=&5S(&EN8VQU9&5D(&EN('1H92!#;VUP86YY)B,X,C$W.W,@06YN=6%L
M(%)E<&]R="!O;B!&;W)M(#$P+4L@9F]R('1H92!Y96%R(&5N9&5D#0H@("`@
M1&5C96UB97(F(S$V,#LS,2P@,C`Q,"!F:6QE9"!W:71H('1H92!314,N#0H@
M("`@/"]D:78^#0H@("`@/"$M+2!&;VQI;R`M+3X-"B`@("`\(2TM("]&;VQI
M;R`M+3X-"B`@("`\+V1I=CX-"B`@("`\(2TM(%!!1T5"4D5!2R`M+3X-"B`@
M("`\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N
M)RQ4:6UE<RQS97)I9CL@;6%R9VEN+6QE9G0Z(#!I;CL@)SX-"B`@("`\9&EV
M(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I
M;BUT;W`Z(#$P<'0G/CQB/E-U8G-E<75E;G0@1&5V96QO<&UE;G1S/"]B/@T*
M("`@(#PO9&EV/@T*("`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^/&(^/&D^4')E9F5R
M<F5D(%-T;V-K($1I=FED96YD/"]I/CPO8CX-"B`@("`\+V1I=CX-"B`@("`\
M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA
M<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD96YT.B`T)2<^3VX@2G5L>28C,38P
M.S@L(#(P,3$L('1H92!";V%R9"!O9B!$:7)E8W1O<G,@*'1H92`F(S@R,C`[
M0F]A<F0F(S@R,C$[*2!D96-I9&5D(&YO="!T;R!D96-L87)E('1H92!Q=6%R
M=&5R;'D-"B`@("!C87-H(&1I=FED96YD(&]N('1H92!#;VUP86YY)B,X,C$W
M.W,@-B4@0V]N=F5R=&EB;&4@17AC:&%N9V5A8FQE(%!R969E<G)E9"!3=&]C
M:R`H)B,X,C(P.U!R969E<G)E9"!3=&]C:R8C.#(R,3LI('=I=&@-"B`@("!R
M97-P96-T('1O('1H92!S96-O;F0@<75A<G1E<B!O9B`R,#$Q('1H870@=V]U
M;&0@:&%V92!O=&AE<G=I<V4@8F5E;B!P87EA8FQE(&]N($%U9W5S="8C,38P
M.S$L(#(P,3$N#0H@("`@/"]D:78^#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T
M97AT+6EN9&5N=#H@-"4G/E1H92!";V%R9"!A;'-O(&1I9"!N;W0@9&5C;&%R
M92!T:&4@<75A<G1E<FQY(&-A<V@@9&EV:61E;F0@=VET:"!R97-P96-T('1O
M(&5A8V@@;V8@=&AE(&9O=7(-"B`@("!Q=6%R=&5R<R!O9B!F:7-C86P@>65A
M<B`R,#`Y(&%N9"!T:&4@9FER<W0L('-E8V]N9"!A;F0@=&AI<F0@<75A<G1E
M<G,@;V8@,C`Q,"X@5&\@=&AE(&5X=&5N="!T:&%T#0H@("`@86YY(&1I=FED
M96YD<R!P87EA8FQE(&]N('1H92!0<F5F97)R960@4W1O8VL@87)E(&YO="!P
M86ED+"!S=6-H('5N<&%I9"!D:79I9&5N9',@87)E(&%D9&5D('1O('1H90T*
M("`@(&QI<75I9&ET>2!P<F5F97)E;F-E(&]F('1H92!0<F5F97)R960@4W1O
M8VLN($%S('1H92!#;VUP86YY(&9A:6QE9"!T;R!P87D@:6X@86X@86=G<F5G
M871E(&%M;W5N=`T*("`@(&5Q=6%L('1O(&%T(&QE87-T('-I>"!Q=6%R=&5R
M;'D@9&EV:61E;F1S("AW:&5T:&5R(&]R(&YO="!C;VYS96-U=&EV92D@;VX@
M=&AE(%!R969E<G)E9"!3=&]C:RP@=&AE#0H@("`@<VEZ92!O9B!T:&4@0V]M
M<&%N>28C.#(Q-SMS($)O87)D('=A<R!I;F-R96%S960@8GD@='=O(&UE;6)E
M<G,@86YD('1H92!H;VQD97)S(&]F('1H92!0<F5F97)R960@4W1O8VLL#0H@
M("`@=F]T:6YG('-E<&%R871E;'D@87,@82!C;&%S<RP@=F]T960@;VX@36%Y
M)B,Q-C`[,C0L(#(P,3$@86YD(&5L96-T960@='=O(&1I<F5C=&]R<R!T;R!F
M:6QL('1H92!V86-A;F-I97,-"B`@("!C<F5A=&5D('1H97)E8GDL('=H:6-H
M(&1I<F5C=&]R<VAI<',@<VAA;&P@=&5R;6EN871E('=H96X@=&AE($-O;7!A
M;GD@<&%Y<R!A;&P@86-C<G5E9"!B=70@=6YP86ED#0H@("`@9&EV:61E;F1S
M+@T*("`@(#PO9&EV/@T*("`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^/&(^/&D^3&EC
M96YS92!!9W)E96UE;G0\+VD^/"]B/@T*("`@(#PO9&EV/@T*("`@(#QD:78@
M86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN
M+71O<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY/;B!*=6QY)B,Q-C`[,3$L
M(#(P,3$L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A;B!A;65N9&UE;G0@
M=&\@:71S(&QI8V5N<V4@86=R965M96YT('=I=&@@1&%I:6-H:0T*("`@(%-A
M;FMY;R!#;VUP86YY+"!,:6UI=&5D("@F(S@R,C`[1&%I:6-H:2!386YK>6\F
M(S@R,C$[*2P@9&%T960@4V5P=&5M8F5R)B,Q-C`[,3`L(#(P,#,L(')E;&%T
M:6YG('1O(&-E<G1A:6X@<FEG:'1S#0H@("`@=VAI8V@@=&AE($-O;7!A;GD@
M:&%S(&QI8V5N<V5D(&9R;VT@1&%I:6-H:2!386YK>6\@=VET:"!R96=A<F0@
M=&\@=&AE($-O;7!A;GDF(S@R,3<[<R!S87!A8VET86)I;F4@9')U9RX-"B`@
M("!%9F9E8W1I=F4@2G5L>28C,38P.S$Q+"`R,#$Q+"!T:&4@;&EC96YS92!A
M9W)E96UE;G0@=V%S(&%M96YD960@=&\@:7)R979O8V%B;'D@=V%I=F4@82!T
M97)M:6YA=&EO;B!R:6=H=`T*("`@($1A:6EC:&D@4V%N:WEO('!O<W-E<W-E
M9"!U;F1E<B!A('!R;W9I<VEO;B!O9B!T:&4@86=R965M96YT('1H870@<F5Q
M=6ER960@=&AE($-O;7!A;GD@=&\@;V)T86EN#0H@("`@<F5G=6QA=&]R>2!A
M<'!R;W9A;"!T;R!S96QL('-A<&%C:71A8FEN92!I;B!A="!L96%S="!O;F4@
M8V]U;G1R>2!B>2!397!T96UB97(F(S$V,#LR,#$Q+"!A;F0@<F5L96%S97,-
M"B`@("!T:&4@0V]M<&%N>2!F<F]M(&%L;"!C;&%I;7,@86YD(&QI86)I;&ET
M>2!O9B!A;GD@:VEN9"!A<FES:6YG('5N9&5R('-U8V@@<')O=FES:6]N+B!4
M:&4@86UE;F1M96YT#0H@("`@9G5R=&AE<B!P<F]V:61E<R!T:&%T('1H92!R
M;WEA;'1Y(&1U92!F<F]M('1H92!#;VUP86YY('1O($1A:6EC:&D@4V%N:WEO
M(&]N(&9U='5R92!N970@<V%L97,@;V8-"B`@("!S87!A8VET86)I;F4@8F4@
M:6YC<F5A<V5D(&)Y(&$@<&5R8V5N=&%G92!B971W965N(#$N,C4E(&%N9"`Q
M+C4P)2!D97!E;F1I;F<@;VX@=&AE(&QE=F5L(&]F(&YE=`T*("`@('-A;&5S
M(&]F('-A<&%C:71A8FEN92!R96%L:7IE9"X-"B`@("`\+V1I=CX-"B`@("`\
M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA
M<F=I;BUT;W`Z(#$P<'0G/CQB/CQI/D9I;F%N8VEN9SPO:3X\+V(^#0H@("`@
M/"]D:78^#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@-"4G
M/D]N($IU;'DF(S$V,#LW+"`R,#$Q+"!T:&4@0V]M<&%N>2!C;&]S960@86X@
M=6YD97)W<FET=&5N(&]F9F5R:6YG(&9O<B!A;B!A9V=R96=A=&4@;V8@-RPV
M,3<L-C0V#0H@("`@=6YI=',L(&%T(&%N(&]F9F5R:6YG('!R:6-E(&]F("9N
M8G-P.R0Q+C,V('!E<B!U;FET+"!F;W(@9W)O<W,@<')O8V5E9',@;V8@87!P
M<F]X:6UA=&5L>2`F;F)S<#LD,3`N-"8C,38P.VUI;&QI;VXN#0H@("`@16%C
M:"!U;FET(&-O;G-I<W1S(&]F("AI*28C,38P.V]N92!S:&%R92!O9B!C;VUM
M;VX@<W1O8VL@86YD("AI:2DF(S$V,#MA(&9I=F4M>65A<B!W87)R86YT('1O
M('!U<F-H87-E(#`N-2!O9@T*("`@(&$@<VAA<F4@;V8@8V]M;6]N('-T;V-K
M(&%T(&%N(&5X97)C:7-E('!R:6-E(&]F("9N8G-P.R0Q+C,V('!E<B!S:&%R
M92P@97AE<F-I<V%B;&4@8F5G:6YN:6YG('-I>"!M;VYT:',-"B`@("!A9G1E
M<B!T:&4@9&%T92!O9B!I<W-U86YC92X@5&AE('-H87)E<R!O9B!C;VUM;VX@
M<W1O8VL@86YD('=A<G)A;G1S('=E<F4@:6UM961I871E;'D@<V5P87)A8FQE
M(&%N9`T*("`@('=E<F4@:7-S=65D('-E<&%R871E;'D@<W5C:"!T:&%T(&YO
M('5N:71S('=E<F4@:7-S=65D+B!4:&4@;F5T('!R;V-E961S+"!A9G1E<B!U
M;F1E<G=R:71I;F<-"B`@("!D:7-C;W5N=',@86YD(&-O;6UI<W-I;VYS(&%N
M9"!O=&AE<B!F965S(&%N9"!E>'!E;G-E<R!P87EA8FQE(&)Y('1H92!#;VUP
M86YY+"!W97)E(&%P<')O>&EM871E;'D-"B`@("`F;F)S<#LD.2XS)B,Q-C`[
M;6EL;&EO;BX-"B`@("`\+V1I=CX-"B`@("`\+V1I=CX-"B`@/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R.38Q,#0Q.5]E93<Q
M7S0X.3A?8CDQ85\W.&1A-F9C-C4P93@-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO,CDV,3`T,3E?964W,5\T.#DX7V(Y,6%?-SAD839F8S8U,&4X
M+U=O<FMS:&5E=',O4VAE970P-RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13)(/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/E-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N
M=&EN9R!0;VQI8VEE<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y*=6XN(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N
M=&EN9R!0;VQI8VEE<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-534U!4ED@3T8@4TE'3DE&24-!3E0@
M04-#3U5.5$E.1R!03TQ)0TE%4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^#0H@("`@/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O
M1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW
M,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@
M+2T^#0H@("`@/"$M+2!"96=I;B!";&]C:R!486=G960@3F]T92`R("T@=7,M
M9V%A<#I3:6=N:69I8V%N=$%C8V]U;G1I;F=0;VQI8VEE<U1E>'1";&]C:RTM
M/@T*("`@(#QD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@
M4F]M86XG+%1I;65S+'-E<FEF.R!M87)G:6XM;&5F=#H@,&EN.R`G/@T*("`@
M(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M;6%R9VEN+71O<#H@,3!P="<^/&(^,BX@4U5-34%262!/1B!324=.249)0T%.
M5"!!0T-/54Y424Y'(%!/3$E#2453/"]B/@T*("`@(#PO9&EV/@T*("`@(#QD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R
M9VEN+71O<#H@,3!P="<^/&(^/&D^0V]N<V]L:61A=&EO;CPO:3X\+V(^#0H@
M("`@/"]D:78^#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@
M-"4G/E1H92!A8V-O;7!A;GEI;F<@8V]N9&5N<V5D(&-O;G-O;&ED871E9"!F
M:6YA;F-I86P@<W1A=&5M96YT<R!I;F-L=61E('1H92!A8V-O=6YT<R!O9B!T
M:&4-"B`@("!#;VUP86YY(&%N9"!I=',@=VAO;&QY+6]W;F5D('-U8G-I9&EA
M<FEE<R!F;W(@=&AE(&EN9&EC871E9"!P97)I;V1S+B!!;&P@<VEG;FEF:6-A
M;G0@:6YT97)C;VUP86YY#0H@("`@=')A;G-A8W1I;VYS(&%N9"!B86QA;F-E
M<R!H879E(&)E96X@96QI;6EN871E9"X-"B`@("`\+V1I=CX-"B`@("`\9&EV
M(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I
M;BUT;W`Z(#$P<'0G/CQB/CQI/E5S92!O9B!%<W1I;6%T97,\+VD^/"]B/@T*
M("`@(#PO9&EV/@T*("`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P=#L@=&5X="UI;F1E;G0Z
M(#0E)SY4:&4@<')E<&%R871I;VX@;V8@9FEN86YC:6%L('-T871E;65N=',@
M:6X@86-C;W)D86YC92!W:71H($=!05`@<F5Q=6ER97,@;6%N86=E;65N="!T
M;R!M86ME#0H@("`@97-T:6UA=&5S(&%N9"!A<W-U;7!T:6]N<R!T:&%T(&%F
M9F5C="!T:&4@<F5P;W)T960@86UO=6YT<R!O9B!A<W-E=',L(&QI86)I;&ET
M:65S(&%N9"!R96QA=&5D#0H@("`@9&ES8VQO<W5R97,@;V8@8V]N=&EN9V5N
M="!A<W-E=',@86YD(&QI86)I;&ET:65S(&%T('1H92!D871E(&]F('1H92!F
M:6YA;F-I86P@<W1A=&5M96YT<R!A;F0@=&AE#0H@("`@<F5P;W)T960@86UO
M=6YT<R!O9B!I;F-O;64@86YD(&5X<&5N<V5S(&1U<FEN9R!T:&4@<F5P;W)T
M:6YG('!E<FEO9"X@5&AE($-O;7!A;GD@<F5V:65W<R!I=',-"B`@("!E<W1I
M;6%T97,@;VX@86X@;VYG;VEN9R!B87-I<RX@5&AE(&5S=&EM871E<R!A<F4@
M8F%S960@;VX@:&ES=&]R:6-A;"!E>'!E<FEE;F-E(&%N9"!O;B!V87)I;W5S
M#0H@("`@;W1H97(@87-S=6UP=&EO;G,@=&AA="!T:&4@0V]M<&%N>2!B96QI
M979E<R!T;R!B92!R96%S;VYA8FQE('5N9&5R('1H92!C:7)C=6US=&%N8V5S
M+B!!8W1U86P-"B`@("!R97-U;'1S(&UA>2!D:69F97(@9G)O;2!T:&5S92!E
M<W1I;6%T97,N#0H@("`@/"]D:78^#0H@("`@/"$M+2!&;VQI;R`M+3X-"B`@
M("`\(2TM("]&;VQI;R`M+3X-"B`@("`\+V1I=CX-"B`@("`\(2TM(%!!1T5"
M4D5!2R`M+3X-"B`@("`\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM
M97,@3F5W(%)O;6%N)RQ4:6UE<RQS97)I9CL@;6%R9VEN+6QE9G0Z(#!I;CL@
M)SX-"B`@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/CQB/CQI/D-A<V@@86YD($-A<V@@
M17%U:79A;&5N=',\+VD^/"]B/@T*("`@(#PO9&EV/@T*("`@(#QD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O
M<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY#87-H(&%N9"!C87-H(&5Q=6EV
M86QE;G1S(&%R92!S=&%T960@870@8V]S="P@=VAI8V@@:7,@<W5B<W1A;G1I
M86QL>2!T:&4@<V%M92!A<R!F86ER('9A;'5E+@T*("`@(%1H92!#;VUP86YY
M(&-O;G-I9&5R<R!A;&P@:&EG:&QY(&QI<75I9"!I;G9E<W1M96YT<R!W:71H
M(&%N(&]R:6=I;F%L(&UA='5R:71Y(&]F('1H<F5E(&UO;G1H<R!O<@T*("`@
M(&QE<W,@870@=&AE('1I;64@;V8@<'5R8VAA<V4@=&\@8F4@8V%S:"!E<75I
M=F%L96YT<RX@5&AE($-O;7!A;GDF(S@R,3<[<R!C87-H(&5Q=6EV86QE;G1S
M(&=E;F5R86QL>0T*("`@(&EN8VQU9&4@:6YV97-T;65N=',@:6X@;6]N97D@
M;6%R:V5T(&9U;F1S(&%N9"!C;W)P;W)A=&4@8V]M;65R8VEA;"!P87!E<BX-
M"B`@("`\+V1I=CX-"B`@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/CQB/CQI/E1R861E
M($%C8V]U;G1S(%)E8V5I=F%B;&4@86YD($%L;&]W86YC92!F;W(@1&]U8G1F
M=6P@06-C;W5N=',\+VD^/"]B/@T*("`@(#PO9&EV/@T*("`@(#QD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O
M<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY!;B!A;&QO=V%N8V4@9F]R(&1O
M=6)T9G5L(&%C8V]U;G1S(&ES('!R;W9I9&5D+"!A<R!N96-E<W-A<GDL(&]N
M('1R861E(')E8V5I=F%B;&5S(&)A<V5D(&]N#0H@("`@=&AE:7(@<F5S<&5C
M=&EV92!A9VEN9R!C871E9V]R:65S(&%N9"!H:7-T;W)I8V%L(&-O;&QE8W1I
M;VX@97AP97)I96YC92P@=&%K:6YG(&EN=&\@8V]N<VED97)A=&EO;@T*("`@
M('1H92!T>7!E(&]F('!A>65R+"!H:7-T;W)I8V%L(&%N9"!P<F]J96-T960@
M8V]L;&5C=&EO;B!O=71C;VUE<RP@86YD(&-U<G)E;G0@96-O;F]M:6,@86YD
M(&)U<VEN97-S#0H@("`@8V]N9&ET:6]N<R!T:&%T(&-O=6QD(&%F9F5C="!T
M:&4@8V]L;&5C=&%B:6QI='D@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!R96-E
M:79A8FQE<RX@5&AE(&%L;&]W86YC92!F;W(-"B`@("!D;W5B=&9U;"!A8V-O
M=6YT<R!I<R!R979I97=E9"P@870@82!M:6YI;75M+"!O;B!A('%U87)T97)L
M>2!B87-I<RX@0VAA;F=E<R!I;B!T:&4@86QL;W=A;F-E(&9O<@T*("`@(&1O
M=6)T9G5L(&%C8V]U;G1S(&%R92!R96-O<F1E9"!A<R!A;B!A9&IU<W1M96YT
M('1O(&)A9"!D96)T(&5X<&5N<V4@=VET:&EN(&=E;F5R86P@86YD#0H@("`@
M861M:6YI<W1R871I=F4@97AP96YS97,N($UA=&5R:6%L(')E=FES:6]N<R!T
M;R!R97-E<G9E(&5S=&EM871E<R!M87D@<F5S=6QT(&9R;VT@861V97)S92!C
M:&%N9V5S(&EN#0H@("`@8V]L;&5C=&EO;B!E>'!E<FEE;F-E+B!4:&4@0V]M
M<&%N>2!W<FET97,@;V9F(&%C8V]U;G1S(&%G86EN<W0@=&AE(&%L;&]W86YC
M92!F;W(@9&]U8G1F=6P@86-C;W5N=',-"B`@("!W:&5N(')E87-O;F%B;&4@
M8V]L;&5C=&EO;B!E9F9O<G1S(&AA=F4@8F5E;B!U;G-U8V-E<W-F=6P@86YD
M(&ET(&ES(&QI:V5L>2!T:&4@<F5C96EV86)L92!W:6QL(&YO=`T*("`@(&)E
M(')E8V]V97)E9"X@070@1&5C96UB97(F(S$V,#LS,2P@,C`Q,"!A;F0@2G5N
M928C,38P.S,P+"`R,#$Q+"!A;&P@<F5C96EV86)L97,@=V5R92!D965M960@
M8V]L;&5C=&EB;&4N#0H@("`@/"]D:78^#0H@("`@/&1I=B!A;&EG;CTS1&QE
M9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T
M.R!T97AT+6EN9&5N=#H@-"4G/D9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D
M($IU;F4F(S$V,#LS,"P@,C`Q,"!A;F0@,C`Q,2P@87!P<F]X:6UA=&5L>2`X
M-R4@86YD(#DR)2P@<F5S<&5C=&EV96QY+"!O9@T*("`@('1H92!#;VUP86YY
M)B,X,C$W.W,@<')O9'5C="!S86QE<R!I;B!T:&4@56YI=&5D(%-T871E<R!W
M97)E('1O('1H<F5E('=H;VQE<V%L97)S+B!&;W(@=&AE('-I>"!M;VYT:',-
M"B`@("!E;F1E9"!*=6YE)B,Q-C`[,S`L(#(P,3`@86YD(#(P,3$L(&%P<')O
M>&EM871E;'D@.#,E(&%N9"`Y,24L(')E<W!E8W1I=F5L>2P@;V8@=&AE($-O
M;7!A;GDF(S@R,3<[<R!P<F]D=6-T#0H@("`@<V%L97,@:6X@=&AE(%5N:71E
M9"!3=&%T97,@=V5R92!T;R!T:')E92!W:&]L97-A;&5R<RX-"B`@("`\+V1I
M=CX-"B`@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/CQB/CQI/DEN=F5N=&]R>3PO:3X\
M+V(^#0H@("`@/"]D:78^#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN
M9&5N=#H@-"4G/D-Y8VQA8V5L('9A;'5E<R!I;G9E;G1O<FEE<R!A="!T:&4@
M;&]W97(@;V8@8V]S="!O<B!M87)K970@=F%L=64N(%1H92!#;VUP86YY(&1E
M=&5R;6EN97,@8V]S=`T*("`@('5S:6YG('1H92!F:7)S="UI;BP@9FER<W0M
M;W5T(&UE=&AO9"X@07,@;V8@1&5C96UB97(F(S$V,#LS,2P@,C`Q,"!A;F0@
M2G5N928C,38P.S,P+"`R,#$Q+"!A;&P@:6YV96YT;W)I97,-"B`@("!W97)E
M(&-L87-S:69I960@87,@9FEN:7-H960@9V]O9',N(%1H92!#;VUP86YY(&%N
M86QY>F5S(&ET<R!I;G9E;G1O<GD@;&5V96QS(&%T(&QE87-T('%U87)T97)L
M>2!T;PT*("`@(&ED96YT:69Y(&%N>2!I=&5M<R!T:&%T(&UA>2!E>'!I<F4@
M<')I;W(@=&\@<V%L92P@:6YV96YT;W)Y('1H870@:&%S(&$@8V]S="!B87-I
M<R!I;B!E>&-E<W,@;V8@;F5T#0H@("`@<F5A;&EZ86)L92!V86QU92P@;W(@
M:6YV96YT;W)Y(&EN(&5X8V5S<R!O9B!E>'!E8W1E9"!S86QE<R!R97%U:7)E
M;65N=',N(%1H92!D971E<FUI;F%T:6]N(&]F#0H@("`@=VAE=&AE<B!O<B!N
M;W0@:6YV96YT;W)Y(&-O<W1S('=I;&P@8F4@<F5A;&EZ86)L92!R97%U:7)E
M<R!E<W1I;6%T97,@8GD@=&AE($-O;7!A;GDF(S@R,3<[<R!M86YA9V5M96YT
M+@T*("`@($$@8W)I=&EC86P@:6YP=70@:7,@9G5T=7)E('-A;&5S(&9O<F5C
M87-T<RX@5&AE($-O;7!A;GD@=W)I=&5S(&1O=VX@=&AE('9A;'5E(&]F(&EN
M=F5N=&]R>2!T;R!T:&4-"B`@("!E>'1E;G0@=&AA="!I;G9E;G1O<GD@:7,@
M97AP96-T960@=&\@97AP:7)E(&)E9F]R92!B96EN9R!S;VQD(&]R(&EF('1H
M92!C;W-T(&)A<VES(&ES(&EN(&5X8V5S<R!O9B!N970@<F5A;&EZ86)L92!V
M86QU92X@268@86-T=6%L(&UA<FME="!C;VYD:71I;VYS(&%R92!L97-S#0H@
M("`@9F%V;W)A8FQE('1H86X@=&AO<V4@<')O:F5C=&5D(&)Y(&UA;F%G96UE
M;G0L(&%D9&ET:6]N86P@:6YV96YT;W)Y('=R:71E+61O=VYS(&UA>2!B92!R
M97%U:7)E9"!I;@T*("`@(&9U='5R92!P97)I;V1S+@T*("`@(#PO9&EV/@T*
M("`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@;6%R9VEN+71O<#H@,3!P="<^/&(^/&D^4F5V96YU92!296-O9VYI=&EO
M;CPO:3X\+V(^#0H@("`@/"]D:78^#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SX\
M:3Y0<F]D=6-T('-A;&5S/"]I/@T*("`@(#PO9&EV/@T*("`@(#QD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O
M<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY4:&4@0V]M<&%N>2!R96-O9VYI
M>F5S(')E=F5N=64@9G)O;2!P<F]D=6-T('-A;&5S('=H96X@<&5R<W5A<VEV
M92!E=FED96YC92!O9B!A;B!A<G)A;F=E;65N=`T*("`@(&5X:7-T<SL@9&5L
M:79E<GD@:&%S(&]C8W5R<F5D(&]R('-E<G9I8V5S(&AA=F4@8F5E;B!R96YD
M97)E9#L@=&AE('-E;&QI;F<@<')I8V4@:7,@9FEX960@;W(-"B`@("!D971E
M<FUI;F%B;&4[(&%N9"!C;VQL96-T86)I;&ET>2!I<R!R96%S;VYA8FQY(&%S
M<W5R960N#0H@("`@/"]D:78^#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT
M+6EN9&5N=#H@."4G/E1H92!#;VUP86YY(&]F9F5R<R!A(&=E;F5R86P@<FEG
M:'0@;V8@<F5T=7)N(&]N('1H97-E('!R;V1U8W0@<V%L97,L(&%N9"!H87,@
M8V]N<VED97)E9"!T:&4-"B`@("!G=6ED86YC92!I;B!!4T,@-C`U+3$U+"`F
M(S@R,C`[/&D^4F5V96YU92!296-O9VYI=&EO;B`M4')O9'5C=',\+VD^)B,X
M,C(Q.R`H)B,X,C(P.T%30R`V,#4M,34F(S@R,C$[*2!A;F0@05-#(#8P-2`M
M,3`@)B,X,C(P.SQI/E)E=F5N=64-"B`@("!296-O9VYI=&EO;B`F(S@R,3([
M($]V97)A;&P\+VD^)B,X,C(Q.R`H)B,X,C(P.T%30R`V,#4M,3`F(S@R,C$[
M*2X@56YD97(@=&AE<V4@9W5I9&5L:6YE<RP@=&AE($-O;7!A;GD@86-C;W5N
M=',@9F]R(&%L;"!P<F]D=6-T#0H@("`@<V%L97,@=7-I;F<@=&AE("8C.#(R
M,#MS96QL+71H<F]U9V@F(S@R,C$[(&UE=&AO9"X@56YD97(@=&AE('-E;&PM
M=&AR;W5G:"!M971H;V0L(')E=F5N=64@:7,@;F]T(')E8V]G;FEZ960-"B`@
M("!U<&]N('-H:7!M96YT(&]F('!R;V1U8W0@=&\@9&ES=')I8G5T;W)S+B!)
M;G-T96%D+"!T:&4@0V]M<&%N>2!R96-O<F1S(&1E9F5R<F5D(')E=F5N=64@
M870@9W)O<W,-"B`@("!I;G9O:6-E('-A;&5S('!R:6-E(&%N9"!D969E<G)E
M9"!C;W-T(&]F('-A;&5S(&%T('1H92!C;W-T(&%T('=H:6-H('1H;W-E(&=O
M;V1S('=E<F4@:&5L9"!I;@T*("`@(&EN=F5N=&]R>2X@5&AE($-O;7!A;GD@
M<F5C;V=N:7IE<R!R979E;G5E('=H96X@<W5C:"!I;G9E;G1O<GD@:7,@<V]L
M9"!T:')O=6=H('1O('!H87)M86-I97,N(%1O#0H@("`@97-T:6UA=&4@<')O
M9'5C="!S;VQD('1H<F]U9V@@=&\@<&AA<FUA8VEE<RP@=&AE($-O;7!A;GD@
M<F5L:65S(&]N('1H:7)D+7!A<G1Y(&EN9F]R;6%T:6]N+`T*("`@(&EN8VQU
M9&EN9R!I;F9O<FUA=&EO;B!O8G1A:6YE9"!F<F]M('-I9VYI9FEC86YT(&1I
M<W1R:6)U=&]R<R!W:71H(')E<W!E8W0@=&\@=&AE:7(@:6YV96YT;W)Y(&QE
M=F5L<PT*("`@(&%N9"!S96QL+71H<F]U9V@@=&\@<&AA<FUA8VEE<RX@5&AE
M($-O;7!A;GD@97-T:6UA=&5S('!R;V1U8W0@<F5T=7)N<R!B87-E9"!O;B!H
M:7-T;W)I8V%L(')E='5R;G,-"B`@("!E>'!E<FEE;F-E(&%N9"!O=&AE<B!F
M86-T;W)S('1H870@869F96-T(&1E;6%N9"!F;W(@=&AE($-O;7!A;GDF(S@R
M,3<[<R!P<F]D=6-T<R!A<R!W96QL(&%S('1H92!A;6]U;G0@;V8-"B`@("!P
M<F]D=6-T('-U8FIE8W0@=&\@<F5T=7)N+@T*("`@(#PO9&EV/@T*("`@(#PA
M+2T@1F]L:6\@+2T^#0H@("`@/"$M+2`O1F]L:6\@+2T^#0H@("`@/"]D:78^
M#0H@("`@/"$M+2!004=%0E)%04L@+2T^#0H@("`@/&1I=B!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L5&EM97,L<V5R:68[(&UA
M<F=I;BUL969T.B`P:6X[("<^#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT
M+6EN9&5N=#H@."4G/D1E9F5R<F5D(')E=F5N=64@=V%S("9N8G-P.R0P+C$F
M(S$V,#MM:6QL:6]N(&%T($IU;F4F(S$V,#LS,"P@,C`Q,"!A;F0@,C`Q,2X@
M1&5F97)R960@8V]S="!O9B!G;V]D<R!S;VQD('=A<PT*("`@(&%P<')O>&EM
M871E;'D@)FYB<W`[)#4X+#`P,"!A;F0@)FYB<W`[)#$Q+#`P,"8C,38P.VUI
M;&QI;VX@870@2G5N928C,38P.S,P+"`R,#$P(&%N9"`R,#$Q+"!R97-P96-T
M:79E;'DN#0H@("`@/"]D:78^#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SX\:3Y#
M;VQL86)O<F%T:6]N+"!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0L(&%N9"!G
M<F%N="!R979E;G5E/"]I/@T*("`@(#PO9&EV/@T*("`@(#QD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@
M,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY#97)T86EN(&]F('1H92!#;VUP86YY
M)B,X,C$W.W,@<F5V96YU97,@87)E(&5A<FYE9"!F<F]M(&-O;&QA8F]R871I
M=F4@86=R965M96YT<RX@5&AE($-O;7!A;GD-"B`@("!R96-O9VYI>F5S(')E
M=F5N=64@=VAE;B!P97)S=6%S:79E(&5V:61E;F-E(&]F(&%N(&%R<F%N9V5M
M96YT(&5X:7-T<SL@9&5L:79E<GD@:&%S(&]C8W5R<F5D(&]R#0H@("`@<V5R
M=FEC97,@:&%V92!B965N(')E;F1E<F5D.R!T:&4@9F5E(&ES(&9I>&5D(&]R
M(&1E=&5R;6EN86)L93L@86YD(&-O;&QE8W1A8FEL:71Y(&ES(')E87-O;F%B
M;'D-"B`@("!A<W-U<F5D+B!$971E<FUI;F%T:6]N(&]F('=H971H97(@=&AE
M<V4@8W)I=&5R:6$@:&%V92!B965N(&UE="!I<R!B87-E9"!O;B!M86YA9V5M
M96YT)B,X,C$W.W,@:G5D9VUE;G1S#0H@("`@<F5G87)D:6YG('1H92!N871U
M<F4@;V8@=&AE(')E<V5A<F-H('!E<F9O<FUE9"P@=&AE('-U8G-T86YC92!O
M9B!T:&4@;6EL97-T;VYE<R!M970@<F5L871I=F4@=&\-"B`@("!T:&]S92!T
M:&4@0V]M<&%N>2!M=7-T('-T:6QL('!E<F9O<FTL(&%N9"!T:&4@8V]L;&5C
M=&%B:6QI='D@;V8@86YY(')E;&%T960@9F5E<RX@4VAO=6QD(&-H86YG97,@
M:6X-"B`@("!C;VYD:71I;VYS(&-A=7-E(&UA;F%G96UE;G0@=&\@9&5T97)M
M:6YE('1H97-E(&-R:71E<FEA(&%R92!N;W0@;65T(&9O<B!C97)T86EN(&9U
M='5R90T*("`@('1R86YS86-T:6]N<RP@<F5V96YU92!R96-O9VYI>F5D(&9O
M<B!A;GD@<F5P;W)T:6YG('!E<FEO9"!C;W5L9"!B92!A9'9E<G-E;'D@869F
M96-T960N#0H@("`@/"]D:78^#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT
M+6EN9&5N=#H@-"4G/E)E<V5A<F-H(&%N9"!D979E;&]P;65N="!R979E;G5E
M<RP@=VAI8V@@87)E(&5A<FYE9"!U;F1E<B!A9W)E96UE;G1S('=I=&@@=&AI
M<F0@<&%R=&EE<R!F;W(-"B`@("!C;VYT<F%C="!R97-E87)C:"!A;F0@9&5V
M96QO<&UE;G0@86-T:79I=&EE<RP@87)E(')E8V]R9&5D(&%S('1H92!R96QA
M=&5D('-E<G9I8V5S(&%R92!P97)F;W)M960N#0H@("`@36EL97-T;VYE('!A
M>6UE;G1S(&%R92!N;VXM<F5F=6YD86)L92!A;F0@<F5C;V=N:7IE9"!A<R!R
M979E;G5E('=H96X@96%R;F5D+"!A<R!E=FED96YC960@8GD-"B`@("!A8VAI
M979E;65N="!O9B!T:&4@<W!E8VEF:65D(&UI;&5S=&]N97,@86YD('1H92!A
M8G-E;F-E(&]F(&]N9V]I;F<@<&5R9F]R;6%N8V4@;V)L:6=A=&EO;G,N($%N
M>0T*("`@(&%M;W5N=',@<F5C96EV960@:6X@861V86YC92!O9B!P97)F;W)M
M86YC92!A<F4@<F5C;W)D960@87,@9&5F97)R960@<F5V96YU92X@3F]N92!O
M9B!T:&4@<F5V96YU97,-"B`@("!R96-O9VYI>F5D('1O(&1A=&4@87)E(')E
M9G5N9&%B;&4@:68@=&AE(')E;&5V86YT(')E<V5A<F-H(&5F9F]R="!I<R!N
M;W0@<W5C8V5S<V9U;"X-"B`@("`\+V1I=CX-"B`@("`\9&EV(&%L:6=N/3-$
M;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P
M<'0[('1E>'0M:6YD96YT.B`T)2<^1W)A;G0@<F5V96YU97,@9G)O;2!G;W9E
M<FYM96YT(&%G96YC:65S(&%N9"!P<FEV871E(')E<V5A<F-H(&9O=6YD871I
M;VYS(&%R92!R96-O9VYI>F5D(&%S('1H90T*("`@(')E;&%T960@<75A;&EF
M:65D(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!C;W-T<R!A<F4@:6YC=7)R
M960L('5P('1O('1H92!L:6UI="!O9B!T:&4@<')I;W(-"B`@("!A<'!R;W9A
M;"!F=6YD:6YG(&%M;W5N=',N($%L;"!G<F%N=',@<F5C96EV960@87)E(&YO
M="!R969U;F1A8FQE+@T*("`@(#PO9&EV/@T*("`@(#QD:78@86QI9VX],T1L
M969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P
M="<^/&(^/&D^0VQI;FEC86P@5')I86P@06-C;W5N=&EN9SPO:3X\+V(^#0H@
M("`@/"]D:78^#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@
M-"4G/D1A=&$@;6%N86=E;65N="!A;F0@;6]N:71O<FEN9R!O9B!A;&P@;V8@
M=&AE($-O;7!A;GDF(S@R,3<[<R!C;&EN:6-A;"!T<FEA;',@87)E('!E<F9O
M<FUE9"!B>0T*("`@(&-O;G1R86-T(')E<V5A<F-H(&]R9V%N:7IA=&EO;G,@
M*"<G0U)/<R8C.#(Q-SLF(S@R,3<[*2!O<B!C;&EN:6-A;"!R97-E87)C:"!A
M<W-O8VEA=&5S("@G)T-207,F(S@R,3<[)B,X,C$W.RD@:6X@86-C;W)D86YC
M90T*("`@('=I=&@@=&AE($-O;7!A;GDF(S@R,3<[<R!S=&%N9&%R9"!O<&5R
M871I;F<@<')O8V5D=7)E<RX@5'EP:6-A;&QY+"!#4D]S(&%N9"!S;VUE($-2
M07,@8FEL;"!M;VYT:&QY(&9O<@T*("`@('-E<G9I8V5S('!E<F9O<FUE9"P@
M86YD(&]T:&5R<R!B:6QL(&)A<V5D('5P;VX@;6EL97-T;VYE<R!A8VAI979E
M9"X@5&AE($-O;7!A;GD@86-C<G5E<R!U;F)I;&QE9"!C;&EN:6-A;"!T<FEA
M;"!E>'!E;G-E<R!B87-E9"!O;B!E<W1I;6%T97,@;V8@=&AE(&QE=F5L(&]F
M('-E<G9I8V5S#0H@("`@<&5R9F]R;65D(&5A8V@@<&5R:6]D+B!#;W-T<R!O
M9B!S971T:6YG('5P(&EN=F5S=&EG871I;VYA;"!S:71E<R!F;W(@<&%R=&EC
M:7!A=&EO;B!I;B!T:&4@0V]M<&%N>28C.#(Q-SMS#0H@("`@8VQI;FEC86P@
M=')I86QS(&%R92!E>'!E;G-E9"!I;6UE9&EA=&5L>2!A<R!R97-E87)C:"!A
M;F0@9&5V96QO<&UE;G0@97AP96YS97,N($-L:6YI8V%L('1R:6%L('-I=&4-
M"B`@("!C;W-T<R!R96QA=&5D('1O('!A=&EE;G0@96YR;VQL;65N="!A<F4@
M86-C<G5E9"!A<R!P871I96YT<R!A<F4@96YT97)E9"!I;G1O('1H92!T<FEA
M;"X@06YY(&EN:71I86P-"B`@("!P87EM96YT(&UA9&4@=&\@=&AE(&-L:6YI
M8V%L('1R:6%L('-I=&4@:7,@<F5C;V=N:7IE9"!U<&]N(&5X96-U=&EO;B!O
M9B!T:&4@8VQI;FEC86P@=')I86P-"B`@("!A9W)E96UE;G1S(&%N9"!E>'!E
M;G-E9"!A<R!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@97AP96YS97,N#0H@
M("`@/"]D:78^#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SX\8CX\:3Y297-E87)C
M:"!A;F0@1&5V96QO<&UE;G0@17AP96YD:71U<F5S/"]I/CPO8CX-"B`@("`\
M+V1I=CX-"B`@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD96YT.B`T)2<^
M4F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&5X<&5N<V5S(&-O;G-I<W0@<')I
M;6%R:6QY(&]F(&-O<W1S(&%S<V]C:6%T960@=VET:"!T:&4@0V]M<&%N>28C
M.#(Q-SMS#0H@("`@<')O9'5C="!C86YD:61A=&5S+"!U<&9R;VYT(&9E97,L
M(&UI;&5S=&]N97,L(&-O;7!E;G-A=&EO;B!A;F0@;W1H97(@97AP96YS97,@
M9F]R(')E<V5A<F-H(&%N9`T*("`@(&1E=F5L;W!M96YT('!E<G-O;FYE;"P@
M<W5P<&QI97,@86YD(&1E=F5L;W!M96YT(&UA=&5R:6%L<RP@8V]S=',@9F]R
M(&-O;G-U;'1A;G1S(&%N9"!R96QA=&5D#0H@("`@8V]N=')A8W0@<F5S96%R
M8V@L(&9A8VEL:71Y(&-O<W1S+"!A;6]R=&EZ871I;VX@;V8@<'5R8VAA<V5D
M('1E8VAN;VQO9WD@86YD(&1E<')E8VEA=&EO;BX-"B`@("!%>'!E;F1I='5R
M97,@<F5L871I;F<@=&\@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&%R92!E
M>'!E;G-E9"!A<R!I;F-U<G)E9"X-"B`@("`\+V1I=CX-"B`@("`\9&EV(&%L
M:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT
M;W`Z(#$P<'0G/CQB/CQI/D9O<F5I9VX@8W5R<F5N8WD@86YD(&-U<G)E;F-Y
M('1R86YS;&%T:6]N/"]I/CPO8CX-"B`@("`\+V1I=CX-"B`@("`\9&EV(&%L
M:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT
M;W`Z(#$P<'0[('1E>'0M:6YD96YT.B`T)2<^5')A;G-A8W1I;VYS('1H870@
M87)E(&1E;F]M:6YA=&5D(&EN(&$@9F]R96EG;B!C=7)R96YC>2!A<F4@<F4M
M;65A<W5R960@:6YT;R!T:&4@9G5N8W1I;VYA;`T*("`@(&-U<G)E;F-Y(&%T
M('1H92!C=7)R96YT(&5X8VAA;F=E(')A=&4@;VX@=&AE(&1A=&4@;V8@=&AE
M('1R86YS86-T:6]N+B!!;GD@9F]R96EG;@T*("`@(&-U<G)E;F-Y+61E;F]M
M:6YA=&5D(&UO;F5T87)Y(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@87)E('-U
M8G-E<75E;G1L>2!R92UM96%S=7)E9"!A="!C=7)R96YT#0H@("`@97AC:&%N
M9V4@<F%T97,L('=I=&@@9V%I;G,@;W(@;&]S<V5S(')E8V]G;FEZ960@87,@
M9F]R96EG;B!E>&-H86YG92`H;&]S<V5S*2]G86EN<R!I;B!T:&4@<W1A=&5M
M96YT#0H@("`@;V8@;W!E<F%T:6]N<RX-"B`@("`\+V1I=CX-"B`@("`\9&EV
M(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I
M;BUT;W`Z(#$P<'0[('1E>'0M:6YD96YT.B`T)2<^5&AE(&%S<V5T<R!A;F0@
M;&EA8FEL:71I97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!I;G1E<FYA=&EO
M;F%L('-U8G-I9&EA<GD@87)E('1R86YS;&%T960@9G)O;2!I=',-"B`@("!F
M=6YC=&EO;F%L(&-U<G)E;F-Y(&EN=&\@56YI=&5D(%-T871E<R!D;VQL87)S
M(&%T(&5X8VAA;F=E(')A=&5S('!R979A:6QI;F<@870@=&AE(&)A;&%N8V4@
M<VAE970-"B`@("!D871E+B!!=F5R86=E(')A=&5S(&]F(&5X8VAA;F=E(&1U
M<FEN9R!T:&4@<&5R:6]D(&%R92!U<V5D('1O('1R86YS;&%T92!T:&4@<W1A
M=&5M96YT(&]F#0H@("`@;W!E<F%T:6]N<RP@=VAI;&4@:&ES=&]R:6-A;"!R
M871E<R!O9B!E>&-H86YG92!A<F4@=7-E9"!T;R!T<F%N<VQA=&4@86YY(&5Q
M=6ET>2!T<F%N<V%C=&EO;G,N#0H@("`@/"]D:78^#0H@("`@/"$M+2!&;VQI
M;R`M+3X-"B`@("`\(2TM("]&;VQI;R`M+3X-"B`@("`\+V1I=CX-"B`@("`\
M(2TM(%!!1T5"4D5!2R`M+3X-"B`@("`\9&EV('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RQ4:6UE<RQS97)I9CL@;6%R9VEN+6QE
M9G0Z(#!I;CL@)SX-"B`@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD96YT
M.B`T)2<^5')A;G-L871I;VX@861J=7-T;65N=',@87)I<VEN9R!O;B!C;VYS
M;VQI9&%T:6]N(&1U92!T;R!D:69F97)E;F-E<R!B971W965N(&%V97)A9V4@
M<F%T97,@86YD#0H@("`@8F%L86YC92!S:&5E="!R871E<RP@87,@=V5L;"!A
M<R!U;G)E86QI>F5D(&9O<F5I9VX@97AC:&%N9V4@9V%I;G,@;W(@;&]S<V5S
M(&%R:7-I;F<@9G)O;0T*("`@('1R86YS;&%T:6]N(&]F(&EN=&5R8V]M<&%N
M>2!L;V%N<R!T:&%T(&%R92!O9B!A(&QO;F<M=&5R;2UI;G9E<W1M96YT(&YA
M='5R92P@87)E(')E8V]R9&5D(&EN(&]T:&5R#0H@("`@8V]M<')E:&5N<VEV
M92!I;F-O;64N#0H@("`@/"]D:78^#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SX\
M8CX\:3Y$97)I=F%T:79E($EN<W1R=6UE;G1S/"]I/CPO8CX-"B`@("`\+V1I
M=CX-"B`@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD96YT.B`T)2<^1&5R
M:79A=&EV92!F:6YA;F-I86P@:6YS=')U;65N=',@87)E(&UE87-U<F5D(&%T
M(&9A:7(@=F%L=64N(%-I9VYI9FEC86YT(&IU9&=M96YT<R!A;F0-"B`@("!E
M<W1I;6%T97,@87)E(&YE8V5S<V%R>2!I;B!D971E<FUI;FEN9R!T:&4@9F%I
M<B!V86QU92!I;B!T:&4@86)S96YC92!O9B!Q=6]T960@;6%R:V5T('9A;'5E
M<RX@5&AE<V4-"B`@("!E<W1I;6%T97,@87)E(&)A<V5D(&]N('9A;'5A=&EO
M;B!M971H;V1O;&]G:65S(&%N9"!A<W-U;7!T:6]N<R!D965M960@87!P<F]P
M<FEA=&4@:6X@=&AE#0H@("`@8VER8W5M<W1A;F-E<RX@5&AE('5S92!O9B!D
M:69F97)E;G0@87-S=6UP=&EO;G,@;6%Y(&AA=F4@82!M871E<FEA;"!E9F9E
M8W0@;VX@=&AE(&5S=&EM871E9"!F86ER#0H@("`@=F%L=64@86UO=6YT(&%N
M9"!T:&4@0V]M<&%N>28C.#(Q-SMS(')E<W5L=',@;V8@;W!E<F%T:6]N<RX-
M"B`@("`\+V1I=CX-"B`@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/CQB/CQI/D9A:7(@
M5F%L=64@365A<W5R96UE;G1S/"]I/CPO8CX-"B`@("`\+V1I=CX-"B`@("`\
M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA
M<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD96YT.B`T)2<^26YP=71S('5S960@
M=&\@9&5T97)M:6YE(&9A:7(@=F%L=64@;V8@9FEN86YC:6%L(&%N9"!N;VXM
M9FEN86YC:6%L(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@87)E#0H@("`@8V%T
M96=O<FEZ960@=7-I;F<@82!F86ER('9A;'5E(&AI97)A<F-H>2!T:&%T('!R
M:6]R:71I>F5S(&]B<V5R=F%B;&4@86YD('5N;V)S97)V86)L92!I;G!U=',@
M:6YT;PT*("`@('1H<F5E(&)R;V%D(&QE=F5L<RP@9G)O;2!,979E;"`Q+"!W
M:&EC:"!I<R!T:&4@;6]S="!R96QI86)L92P@=&\@3&5V96P@,RP@=VAI8V@@
M:7,@=&AE(&QE87-T#0H@("`@<F5L:6%B;&4@*'-E92`F(S@R,C`[3F]T92`S
M("8C.#(Q,CL@1F%I<B!686QU92!-96%S=7)E;65N=',F(S@R,C$[*2X@36%N
M86=E;65N="!R979I97=S('1H92!C871E9V]R:7IA=&EO;B!O9B!F86ER#0H@
M("`@=F%L=64@:6YP=71S(&]N(&$@<&5R:6]D:6,@8F%S:7,@86YD(&UA>2!D
M971E<FUI;F4@=&AA="!I="!I<R!N96-E<W-A<GD@=&\@=')A;G-F97(@86X@
M:6YP=70@9G)O;0T*("`@(&]N92!L979E;"!O9B!T:&4@9F%I<B!V86QU92!H
M:65R87)C:'D@=&\@86YO=&AE<B!B87-E9"!O;B!C:&%N9V5S(&EN(&5V96YT
M<R!O<B!C:7)C=6US=&%N8V5S+"!S=6-H#0H@("`@87,@82!C:&%N9V4@:6X@
M=&AE(&]B<V5R=F%B:6QI='D@;V8@86X@:6YP=70N($%N>2!S=6-H('1R86YS
M9F5R('=I;&P@8F4@<F5C;V=N:7IE9"!A="!T:&4@96YD(&]F#0H@("`@=&AE
M(')E<&]R=&EN9R!P97)I;V0N#0H@("`@/"]D:78^#0H@("`@/&1I=B!A;&EG
M;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P
M.B`Q,'!T)SX\8CX\:3Y);F-O;64@5&%X97,\+VD^/"]B/@T*("`@(#PO9&EV
M/@T*("`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+71O<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY4:&4@
M0V]M<&%N>2!A8V-O=6YT<R!F;W(@:6YC;VUE('1A>&5S('5N9&5R('1H92!L
M:6%B:6QI='D@;65T:&]D+B!5;F1E<B!T:&ES(&UE=&AO9"P@9&5F97)R960-
M"B`@("!T87@@87-S971S(&%N9"!L:6%B:6QI=&EE<R!A<F4@9&5T97)M:6YE
M9"!B87-E9"!O;B!T:&4@9&EF9F5R96YC92!B971W965N('1H92!F:6YA;F-I
M86P@<W1A=&5M96YT#0H@("`@86YD('1A>"!B87-E<R!O9B!A<W-E=',@86YD
M(&QI86)I;&ET:65S('5S:6YG(&5N86-T960@=&%X(')A=&5S(&EN(&5F9F5C
M="!F;W(@=&AE('EE87(@:6X@=VAI8V@@=&AE#0H@("`@9&EF9F5R96YC97,@
M87)E(&5X<&5C=&5D('1O(&%F9F5C="!T87AA8FQE(&EN8V]M92X@5F%L=6%T
M:6]N(&%L;&]W86YC97,@87)E(&5S=&%B;&ES:&5D('=H96X-"B`@("!N96-E
M<W-A<GD@=&\@<F5D=6-E(&1E9F5R<F5D('1A>"!A<W-E=',@=&\@=&AE(&%M
M;W5N=',@97AP96-T960@=&\@8F4@<F5A;&EZ960N(%1H92!#;VUP86YY)B,X
M,C$W.W,-"B`@("!M86YA9V5M96YT(&AA<R!E<W1A8FQI<VAE9"!A(&9U;&P@
M=F%L=6%T:6]N(&%L;&]W86YC92!A9V%I;G-T(&ET<R!D969E<G)E9"!T87@@
M87-S971S(&)A<V5D(&]N('1H90T*("`@(&1E=&5R;6EN871I;VX@=&AA="!I
M="!I<R!N;W0@;6]R92!L:6ME;'D@=&AA;B!N;W0@=&AA="!T:&4@0V]M<&%N
M>2!W:6QL(')E8V]G;FEZ92!T:&4@8F5N969I=',@;V8-"B`@("!T:&]S92!A
M<W-E=',N#0H@("`@/"]D:78^#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT
M+6EN9&5N=#H@-"4G/E1H92!#;VUP86YY(&%D;W!T960@=&AE(&=U:61A;F-E
M(')E;&%T960@=&\@86-C;W5N=&EN9R!F;W(@=6YC97)T86EN='D@:6X@:6YC
M;VUE('1A>&5S+`T*("`@('!R:6UA<FEL>2!C;V1I9FEE9"!I;B!!4T,@-S0P
M+"`\:3XF(S@R,C`[26YC;VUE('1A>&5S)B,X,C(Q.R`\+VD^*"8C.#(R,#M!
M4T,@-S0P)B,X,C(Q.RDN($%30R`W-#`@<W!E8VEF:65S('1H92!A8V-O=6YT
M:6YG(&9O<@T*("`@('5N8V5R=&%I;G1Y(&EN(&EN8V]M92!T87AE<R!R96-O
M9VYI>F5D(&EN(&$@8V]M<&%N>28C.#(Q-SMS(&9I;F%N8VEA;"!S=&%T96UE
M;G1S(&)Y('!R97-C<FEB:6YG(&$@;6EN:6UU;0T*("`@('!R;V)A8FEL:71Y
M('1H<F5S:&]L9"!A('1A>"!P;W-I=&EO;B!I<R!R97%U:7)E9"!T;R!M965T
M(&)E9F]R92!B96EN9R!R96-O9VYI>F5D(&EN('1H92!F:6YA;F-I86P-"B`@
M("!S=&%T96UE;G1S+@T*("`@(#PO9&EV/@T*("`@(#QD:78@86QI9VX],T1L
M969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P
M=#L@=&5X="UI;F1E;G0Z(#0E)SY4:&4@0V]M<&%N>2!R96-O<F1S(&EN8V]M
M92!T87@@8F5N969I=',@<F5L871E9"!T;R!R97-E87)C:"!A;F0@9&5V96QO
M<&UE;G0@=&%X(&-R961I=',L('=H:6-H#0H@("`@=VEL;"!B92!C;&%I;65D
M(&9R;VT@2"X@32X@4F5V96YU92`F(S`S.#L@0W5S=&]M<RP@=&AE(%5N:71E
M9"!+:6YG9&]M)B,X,C$W.W,@=&%X871I;VX@86YD(&-U<W1O;7,@875T:&]R
M:71Y+`T*("`@('=I=&@@<F5S<&5C="!T;R!Q=6%L:69Y:6YG(')E<V5A<F-H
M(&%N9"!D979E;&]P;65N="!C;W-T<R!I;F-U<G)E9"!I;B!T:&4@<V%M92!A
M8V-O=6YT:6YG('!E<FEO9"X-"B`@("`\+V1I=CX-"B`@("`\9&EV(&%L:6=N
M/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z
M(#$P<'0G/CQB/CQI/E-T;V-K+6)A<V5D($-O;7!E;G-A=&EO;CPO:3X\+V(^
M#0H@("`@/"]D:78^#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN9&5N
M=#H@-"4G/E1H92!#;VUP86YY(&=R86YT<R!S=&]C:R!O<'1I;VYS+"!R97-T
M<FEC=&5D('-T;V-K('5N:71S(&%N9"!R97-T<FEC=&5D('-T;V-K('1O(&]F
M9FEC97)S+`T*("`@(&5M<&QO>65E<R!A;F0@9&ER96-T;W)S('5N9&5R('1H
M92`R,#`V($%M96YD960@86YD(%)E<W1A=&5D($5Q=6ET>2!);F-E;G1I=F4@
M4&QA;B`H)B,X,C(P.S(P,#8@4&QA;B8C.#(R,3LI+`T*("`@('=H:6-H('=A
M<R!A<'!R;W9E9"!O;B!-87)C:"8C,38P.S$V+"`R,#`V(&%N9"!S=6)S97%U
M96YT;'D@86UE;F1E9"!A;F0@<F5S=&%T960@;VX@07!R:6PF(S$V,#LQ-"P@
M,C`P."X@5&AE#0H@("`@0V]M<&%N>2!A;'-O(&AA<R!O=71S=&%N9&EN9R!O
M<'1I;VYS('5N9&5R('9A<FEO=7,@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N
M('!L86YS(&9O<B!E;7!L;WEE97,@86YD#0H@("`@9&ER96-T;W)S+B!4:&5S
M92!P;&%N<R!A<F4@9&5S8W)I8F5D(&UO<F4@9G5L;'D@:6X@)B,X,C(P.TYO
M=&4@-B`F(S@R,3([(%-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;B8C.#(R,3LN
M(%1H90T*("`@($-O;7!A;GD@86-C;W5N=',@9F]R('1H97-E('!L86YS('5N
M9&5R($%30R`W,3@L("8C.#(R,#L\:3Y#;VUP96YS871I;VX@)B,X,C$R.R!3
M=&]C:R!#;VUP96YS871I;VX\+VD^)B,X,C(Q.R`H)B,X,C(P.T%30R`W,3@F
M(S@R,C$[*2X-"B`@("`\+V1I=CX-"B`@("`\(2TM($9O;&EO("TM/@T*("`@
M(#PA+2T@+T9O;&EO("TM/@T*("`@(#PO9&EV/@T*("`@(#PA+2T@4$%'14)2
M14%+("TM/@T*("`@(#QD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE
M<R!.97<@4F]M86XG+%1I;65S+'-E<FEF.R!M87)G:6XM;&5F=#H@,&EN.R`G
M/@T*("`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+71O<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY!4T,@
M-S$X(')E<75I<F5S(&UE87-U<F5M96YT(&]F(&-O;7!E;G-A=&EO;B!C;W-T
M(&9O<B!A;&P@<W1O8VLM8F%S960@87=A<F1S(&%T(&9A:7(@=F%L=64@;VX-
M"B`@("!D871E(&]F(&=R86YT(&%N9"!R96-O9VYI=&EO;B!O9B!C;VUP96YS
M871I;VX@;W9E<B!T:&4@<F5Q=6ES:71E('-E<G9I8V4@<&5R:6]D(&9O<B!A
M=V%R9',@97AP96-T960-"B`@("!T;R!V97-T+B!4:&4@9F%I<B!V86QU92!O
M9B!R97-T<FEC=&5D('-T;V-K(&%N9"!R97-T<FEC=&5D('-T;V-K('5N:71S
M(&ES(&1E=&5R;6EN960@8F%S960@;VX@=&AE#0H@("`@;G5M8F5R(&]F('-H
M87)E<R!G<F%N=&5D(&%N9"!T:&4@<75O=&5D('!R:6-E(&]F('1H92!#;VUP
M86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K(&]N('1H92!D871E(&]F(&=R86YT
M+@T*("`@(%1H92!D971E<FUI;F%T:6]N(&]F(&=R86YT+61A=&4@9F%I<B!V
M86QU92!F;W(@<W1O8VL@;W!T:6]N(&%W87)D<R!I<R!E<W1I;6%T960@=7-I
M;F<@=&AE#0H@("`@0FQA8VLM4V-H;VQE<R!M;V1E;"P@=VAI8V@@:6YC;'5D
M97,@=F%R:6%B;&5S('-U8V@@87,@=&AE(&5X<&5C=&5D('9O;&%T:6QI='D@
M;V8@;W5R('-H87)E('!R:6-E+`T*("`@('1H92!A;G1I8VEP871E9"!E>&5R
M8VES92!B96AA=FEO<B!O9B!O=7(@96UP;&]Y965S+"!I;G1E<F5S="!R871E
M<RP@86YD(&1I=FED96YD('EI96QD<RX@5&AE<V4-"B`@("!V87)I86)L97,@
M87)E('!R;VIE8W1E9"!B87-E9"!O;B!O=7(@:&ES=&]R:6-A;"!D871A+"!E
M>'!E<FEE;F-E+"!A;F0@;W1H97(-"B`@("!F86-T;W)S+B!#:&%N9V5S(&EN
M(&%N>2!O9B!T:&5S92!V87)I86)L97,@8V]U;&0@<F5S=6QT(&EN(&UA=&5R
M:6%L(&%D:G5S=&UE;G1S('1O('1H92!E>'!E;G-E#0H@("`@<F5C;V=N:7IE
M9"!F;W(@<VAA<F4M8F%S960@<&%Y;65N=',N(%-U8V@@=F%L=64@:7,@<F5C
M;V=N:7IE9"!A<R!E>'!E;G-E(&]V97(@=&AE(')E<75I<VET92!S97)V:6-E
M#0H@("`@<&5R:6]D+"!N970@;V8@97-T:6UA=&5D(&9O<F9E:71U<F5S+"!U
M<VEN9R!T:&4@<W1R86EG:'0M;&EN92!A='1R:6)U=&EO;B!M971H;V0N(%1H
M92!E<W1I;6%T:6]N(&]F#0H@("`@<W1O8VL@87=A<F1S('1H870@=VEL;"!U
M;'1I;6%T96QY('9E<W0@<F5Q=6ER97,@:G5D9VUE;G0L(&%N9"!T;R!T:&4@
M97AT96YT(&%C='5A;"!R97-U;'1S(&]R#0H@("`@=7!D871E9"!E<W1I;6%T
M97,@9&EF9F5R(&9R;VT@8W5R<F5N="!E<W1I;6%T97,L('-U8V@@86UO=6YT
M<R!A<F4@<F5C;W)D960@87,@82!C=6UU;&%T:79E#0H@("`@861J=7-T;65N
M="!I;B!T:&4@<&5R:6]D(&5S=&EM871E<R!A<F4@<F5V:7-E9"X@5&AE($-O
M;7!A;GD@8V]N<VED97)S(&UA;GD@9F%C=&]R<R!W:&5N(&5S=&EM871I;F<-
M"B`@("!E>'!E8W1E9"!F;W)F96ET=7)E<RP@:6YC;'5D:6YG('1Y<&4@;V8@
M87=A<F1S(&=R86YT960@96UP;&]Y964@8VQA<W,L(&%N9"!H:7-T;W)I8V%L
M(&5X<&5R:65N8V4N#0H@("`@06-T=6%L(')E<W5L=',@86YD(&9U='5R92!E
M<W1I;6%T97,@;6%Y(&1I9F9E<B!S=6)S=&%N=&EA;&QY(&9R;VT@8W5R<F5N
M="!E<W1I;6%T97,N#0H@("`@/"]D:78^#0H@("`@/&1I=B!A;&EG;CTS1&QE
M9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T
M)SX\8CX\:3Y396=M96YT<SPO:3X\+V(^#0H@("`@/"]D:78^#0H@("`@/&1I
M=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G
M:6XM=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@-"4G/E1H92!#;VUP86YY(&AA
M<R!D971E<FUI;F5D(&ET<R!R97!O<G1A8FQE('-E9VUE;G1S(&EN(&%C8V]R
M9&%N8V4@=VET:"!!4T,@,C@P+"`F(S@R,C`[/&D^4V5G;65N=`T*("`@(%)E
M<&]R=&EN9SPO:3XF(S@R,C$[("@F(S@R,C`[05-#(#(X,"8C.#(R,3LI(&%N
M9"!R96QA=&5D(&1I<V-L;W-U<F5S(&%B;W5T('!R;V1U8W1S+"!S97)V:6-E
M<RP@9V5O9W)A<&AI8R!A<F5A<R!A;F0@;6%J;W(-"B`@("!C=7-T;VUE<G,N
M($%F=&5R(&-O;G-I9&5R:6YG(&ET<R!B=7-I;F5S<R!A8W1I=FET:65S(&%N
M9"!G96]G<F%P:&EC(')E86-H+"!T:&4@0V]M<&%N>2!H87,-"B`@("!C;VYC
M;'5D960@=&AA="!I="!O<&5R871E<R!I;B!J=7-T(&]N92!O<&5R871I;F<@
M<V5G;65N="!B96EN9R!T:&4@9&ES8V]V97)Y+"!D979E;&]P;65N="!A;F0-
M"B`@("!C;VUM97)C:6%L:7IA=&EO;B!O9B!N;W9E;"P@;65C:&%N:7-M+71A
M<F=E=&5D(&1R=6=S('1O('1R96%T(&-A;F-E<B!A;F0@;W1H97(@<V5R:6]U
M<R!D:7-O<F1E<G,L#0H@("`@=VET:"!D979E;&]P;65N="!O<&5R871I;VYS
M(&EN('1W;R!G96]G<F%P:&EC(&%R96%S+"!N86UE;'D@=&AE(%5N:71E9"!3
M=&%T97,@86YD('1H92!5;FET960-"B`@("!+:6YG9&]M+@T*("`@(#PO9&EV
M/@T*("`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^/&(^/&D^3F5T($QO<W,@<&5R($-O
M;6UO;B!3:&%R93PO:3X\+V(^#0H@("`@/"]D:78^#0H@("`@/&1I=B!A;&EG
M;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P
M.B`Q,'!T.R!T97AT+6EN9&5N=#H@-"4G/E1H92!#;VUP86YY(&-A;&-U;&%T
M97,@;F5T(&QO<W,@<&5R(&-O;6UO;B!S:&%R92!I;B!A8V-O<F1A;F-E('=I
M=&@@05-#(#(V,"P@)B,X,C(P.SQI/D5A<FYI;F=S(%!E<@T*("`@(%-H87)E
M/"]I/B8C.#(R,3L@*"8C.#(R,#M!4T,@,C8P)B,X,C(Q.RDN($)A<VEC(&%N
M9"!D:6QU=&5D(&YE="!L;W-S('!E<B!C;VUM;VX@<VAA<F4@=V5R92!D971E
M<FUI;F5D(&)Y(&1I=FED:6YG(&YE="!L;W-S#0H@("`@87!P;&EC86)L92!T
M;R!C;VUM;VX@<W1O8VMH;VQD97)S(&)Y('1H92!W96EG:'1E9"!A=F5R86=E
M(&YU;6)E<B!O9B!C;VUM;VX@<VAA<F5S(&]U='-T86YD:6YG#0H@("`@9'5R
M:6YG('1H92!P97)I;V0N(%1H92!#;VUP86YY)B,X,C$W.W,@<&]T96YT:6%L
M;'D@9&EL=71I=F4@<VAA<F5S+"!W:&EC:"!I;F-L=61E(&]U='-T86YD:6YG
M(&-O;6UO;@T*("`@('-T;V-K(&]P=&EO;G,L(')E<W1R:6-T960@<W1O8VLL
M(')E<W1R:6-T960@<W1O8VL@=6YI=',L(&-O;G9E<G1I8FQE('!R969E<G)E
M9"!S=&]C:RP@86YD(&-O;6UO;@T*("`@('-T;V-K('=A<G)A;G1S+"!H879E
M(&YO="!B965N(&EN8VQU9&5D(&EN('1H92!C;VUP=71A=&EO;B!O9B!D:6QU
M=&5D(&YE="!L;W-S('!E<B!S:&%R92!F;W(@86QL#0H@("`@<&5R:6]D<R!A
M<R!T:&4@<F5S=6QT('=O=6QD(&)E(&%N=&DM9&EL=71I=F4N#0H@("`@/"]D
M:78^#0H@("`@/&1I=B!A;&EG;CTS1&-E;G1E<CX-"B`@("`\=&%B;&4@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)R!C96QL
M<W!A8VEN9STS1#`@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@]
M,T0Q,#`E/@T*("`@(#PA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`@("`\
M='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@(#QT9"!W:61T:#TS1#<R)3XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS1#,E/B8C,38P.SPO=&0^#0H@("`@
M/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`\=&0@=VED=&@],T0Y
M)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^
M#0H@("`@/'1D('=I9'1H/3-$,R4^)B,Q-C`[/"]T9#X-"B`@("`\=&0@=VED
M=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS1#DE/B8C,38P
M.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`\
M+W1R/@T*("`@(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G('9A;&EG
M;CTS1&)O='1O;3X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N
M=&5R(&-O;'-P86X],T0R/CQB/DIU;F4@,S`L/"]B/CPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\8CY*
M=6YE(#,P+#PO8CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#PO
M='(^#0H@("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT
M97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O
M;&ED(",P,#`P,#`G/CQB/C(P,3`\+V(^/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\8CXR,#$Q/"]B/CPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/"]T<CX-"B`@("`\(2TM
M($5N9"!486)L92!(96%D("TM/@T*("`@(#PA+2T@0F5G:6X@5&%B;&4@0F]D
M>2`M+3X-"B`@("`\='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG
M<F]U;F0Z("-C8V5E9F8G/@T*("`@(#QT9#X-"B`@("`\9&EV('-T>6QE/3-$
M)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY3=&]C:R!O
M<'1I;VYS#0H@("`@/"]D:78^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI9VX],T1R:6=H=#XS
M+#$X-RPR.3$\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG
M;CTS1')I9VAT/C,L-30S+#4R.3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/"]T<CX-"B`@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@(#QT
M9#X-"B`@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M
M:6YD96YT.BTQ-7!X)SY297-T<FEC=&5D('-T;V-K(&%N9"!R97-T<FEC=&5D
M('-T;V-K('5N:71S#0H@("`@/"]D:78^/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI9VX],T1R
M:6=H=#XW-2PU,34\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!A
M;&EG;CTS1')I9VAT/C0T+#(U-3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/"]T<CX-"B`@("`\='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)V)A8VMG<F]U;F0Z("-C8V5E9F8G/@T*("`@(#QT9#X-"B`@("`\9&EV('-T
M>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY#
M;VYV97)T:6)L92!P<F5F97)R960@<W1O8VL-"B`@("`\+V1I=CX\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!A;&EG;CTS1')I9VAT/C4Q-BPR,C@\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!A;&EG;CTS1')I9VAT/C4Q-BPR,C@\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#PO='(^#0H@("`@/'1R('9A;&EG;CTS
M1&)O='1O;3X-"B`@("`\=&0^#0H@("`@/&1I=B!S='EL93TS1"=M87)G:6XM
M;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^3W!T:6]N<R!T;R!P=7)C
M:&%S92!C;VUM;VX@<W1O8VL@86YD(&-O;6UO;@T*("`@('-T;V-K('=A<G)A
M;G1S(&ES<W5E9"!I;B!C;VYN96-T:6]N('=I=&@@=&AE#0H@("`@3V-T;V)E
M<B8C,38P.S(P,3`@9FEN86YC:6YG#0H@("`@/"]D:78^/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M86QI9VX],T1R:6=H=#XF(S@R,3([/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@86QI9VX],T1R:6=H=#XV+#(T,BPS.3@\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#PO='(^#0H@("`@/'1R('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=B86-K9W)O=6YD.B`C8V-E969F)SX-"B`@("`\=&0^
M#0H@("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN
M9&5N=#HM,35P>"<^0V]M;6]N('-T;V-K('=A<G)A;G1S#0H@("`@/"]D:78^
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@86QI9VX],T1R:6=H=#XU+#@T,RPU.3<\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG;CTS1')I9VAT/C$P+#`P-2PQ
M.3(\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#PO='(^#0H@("`@
M/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,7!X)SX-"B`@("`\=&0^#0H@("`@
M/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM
M,35P>"<^)B,Q-C`[#0H@("`@/"]D:78^/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L
M:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,7!X('-O;&ED(",P
M,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS
M<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#%P
M>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#PO='(^#0H@("`@/'1R('9A;&EG;CTS1&)O='1O;3X-"B`@
M("`\=&0^#0H@("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T
M97AT+6EN9&5N=#HM,35P>"<^5&]T86P@<VAA<F5S(&5X8VQU9&5D(&9R;VT@
M8V%L8W5L871I;VX-"B`@("`\+V1I=CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG;CTS1')I
M9VAT/CDL-C(R+#8S,3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M(&%L:6=N/3-$<FEG:'0^,C`L,S4Q+#8P,CPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/"]T<CX-"B`@("`\='(@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q<'@G/@T*("`@(#QT9#X-"B`@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL
M969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SXF(S$V,#L-"B`@("`\+V1I
M=CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B
M;W)D97(M=&]P.B`S<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@
M(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^#0H@("`@/"]T86)L93X-"B`@("`\
M+V1I=CX-"B`@("`\(2TM($9O;&EO("TM/@T*("`@(#PA+2T@+T9O;&EO("TM
M/@T*("`@(#PO9&EV/@T*("`@(#PA+2T@4$%'14)214%+("TM/@T*("`@(#QD
M:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+%1I
M;65S+'-E<FEF.R!M87)G:6XM;&5F=#H@,&EN.R`G/@T*("`@(#QD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O
M<#H@,3!P="<^/&(^/&D^0V]M<')E:&5N<VEV92!);F-O;64@*$QO<W,I/"]I
M/CPO8CX-"B`@("`\+V1I=CX-"B`@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E>'0M
M:6YD96YT.B`T)2<^26X@86-C;W)D86YC92!W:71H($%30R`R,C`L("8C.#(R
M,#L\:3Y#;VUP<F5H96YS:79E($EN8V]M93PO:3XF(S@R,C$[("@F(S@R,C`[
M05-#(#(R,"8C.#(R,3LI(&%L;"!C;VUP;VYE;G1S(&]F(&-O;7!R96AE;G-I
M=F4-"B`@("!I;F-O;64@*&QO<W,I+"!I;F-L=61I;F<@;F5T(&EN8V]M92`H
M;&]S<RDL(&%R92!R97!O<G1E9"!I;B!T:&4@9FEN86YC:6%L('-T871E;65N
M=',@:6X@=&AE('!E<FEO9`T*("`@(&EN('=H:6-H('1H97D@87)E(')E8V]G
M;FEZ960N($%30R`R,C`@9&5F:6YE<R!C;VUP<F5H96YS:79E(&EN8V]M92`H
M;&]S<RDF(S$V,#MA<R!T:&4@8VAA;F=E(&EN(&5Q=6ET>0T*("`@(&1U<FEN
M9R!A('!E<FEO9"!F<F]M('1R86YS86-T:6]N<R!A;F0@;W1H97(@979E;G1S
M(&%N9"!C:7)C=6US=&%N8V5S(&9R;VT@;F]N;W=N97(@<V]U<F-E<RX@3F5T
M#0H@("`@:6YC;VUE("AL;W-S*28C,38P.V%N9"!O=&AE<B!C;VUP<F5H96YS
M:79E(&EN8V]M92`H;&]S<RDL(&EN8VQU9&EN9R!F;W)E:6=N(&-U<G)E;F-Y
M('1R86YS;&%T:6]N#0H@("`@861J=7-T;65N=',L(&%R92!R97!O<G1E9"P@
M;F5T(&]F(&%N>2!R96QA=&5D('1A>"!E9F9E8W0L('1O(&%R<FEV92!A="!C
M;VUP<F5H96YS:79E(&EN8V]M92`H;&]S<RDN#0H@("`@3F\@=&%X97,@=V5R
M92!R96-O<F1E9"!O;B!I=&5M<R!O9B!O=&AE<B!C;VUP<F5H96YS:79E(&EN
M8V]M92X-"B`@("`\+V1I=CX-"B`@("`\9&EV(&%L:6=N/3-$8V5N=&5R/@T*
M("`@(#QT86)L92!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(&QE9G0G(&-E;&QS<&%C:6YG/3-$,"!B;W)D97(],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#$P,"4^#0H@("`@/"$M+2!"96=I;B!486)L92!(
M96%D("TM/@T*("`@(#QT<B!V86QI9VX],T1B;W1T;VT^#0H@("`@/'1D('=I
M9'1H/3-$,S`E/B8C,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$,R4^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!W:61T:#TS1#DE/B8C,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$
M,24^)B,Q-C`[/"]T9#X-"B`@("`\=&0@=VED=&@],T0S)3XF(S$V,#L\+W1D
M/@T*("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@/'1D('=I
M9'1H/3-$.24^)B,Q-C`[/"]T9#X-"B`@("`\=&0@=VED=&@],T0Q)3XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS1#,E/B8C,38P.SPO=&0^#0H@("`@
M/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`\=&0@=VED=&@],T0Y
M)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^
M#0H@("`@/'1D('=I9'1H/3-$,R4^)B,Q-C`[/"]T9#X-"B`@("`\=&0@=VED
M=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS1#DE/B8C,38P
M.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@=VED=&@],T0S)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS1#$E
M/B8C,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$.24^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@(#PO='(^#0H@
M("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(^/&(^4&5R:6]D(&9R;VT\
M+V(^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@
M(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G('9A;&EG;CTS1&)O='1O
M;3X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQB/D%U9W5S="`Q,RP@,3DY
M-CPO8CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#PO='(^#0H@
M("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L
M<W!A;CTS1#8^/&(^5&AR964@36]N=&AS($5N9&5D/"]B/CPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$-CX\
M8CY3:7@@36]N=&AS($5N9&5D/"]B/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\8CXH:6YC97!T:6]N
M*2!T;SPO8CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#PO='(^
M#0H@("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@
M8V]L<W!A;CTS1#8@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED
M(",P,#`P,#`G/CQB/DIU;F4@,S`L/"]B/CPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$-B!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P,"<^/&(^2G5N92`S,"P\
M+V(^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R
M(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI
M9"`C,#`P,#`P)SX\8CY*=6YE(#,P+#PO8CX\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#PO='(^#0H@("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P="<@=F%L:6=N/3-$8F]T=&]M/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/C(P,3`\+V(^/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X]
M,T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P
M)SX\8CXR,#$Q/"]B/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1&-E;G1E<B!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`Q<'@@<V]L:60@(S`P,#`P,"<^/&(^,C`Q,#PO8CX\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!N
M;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/C(P
M,3$\+V(^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N
M=&5R(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S
M;VQI9"`C,#`P,#`P)SX\8CXR,#$Q/"]B/CPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/"]T<CX-"B`@("`\(2TM($5N9"!486)L92!(96%D("TM
M/@T*("`@(#PA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`@("`\='(@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@(#QT9#X-"B`@("`\9&EV('-T>6QE/3-$)VUA
M<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SXF(S$V,#L-"B`@
M("`\+V1I=CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!A
M;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,3@^)FYB<W`[)#`P,#PO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/"]T<CX-"B`@("`\='(@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0Z("-C8V5E9F8G/@T*("`@
M(#QT9#X-"B`@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E
M>'0M:6YD96YT.BTQ-7!X)SY.970@;&]S<PT*("`@(#PO9&EV/CPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1&QE9G0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI9VX],T1R:6=H
M=#XH,RPY,S,\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`^*3PO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!A;&EG;CTS1&QE9G0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI9VX],T1R
M:6=H=#XH,RPU-3(\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`^*3PO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1&QE9G0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI9VX]
M,T1R:6=H=#XH.2PP-#`\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`^
M*3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!A;&EG;CTS1&QE9G0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI
M9VX],T1R:6=H=#XH."PQ-#`\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R
M87`^*3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1&QE9G0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M86QI9VX],T1R:6=H=#XH,C0V+#0T-CPO=&0^#0H@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<#XI/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT<B!V86QI9VX],T1B
M;W1T;VT^#0H@("`@/'1D/@T*("`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/E1R86YS;&%T:6]N(&%D:G5S
M=&UE;G0-"B`@("`\+V1I=CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1L969T/B8C,38P.SPO
M=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^*#$Y/"]T9#X-"B`@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P/BD\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG;CTS1')I9VAT/C$S
M.3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG
M:'0^-"PP,#$\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1L
M969T/B8C,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^*#(L.#(V
M/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P/BD\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!A
M;&EG;CTS1')I9VAT/C4L.34R/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\+W1R/@T*("`@(#QT<B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M8F%C:V=R;W5N9#H@(V-C965F9B<^#0H@("`@/'1D/@T*("`@(#QD:78@<W1Y
M;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/E5N
M<F5A;&EZ960@9F]R96EG;@T*("`@(&5X8VAA;F=E("AL;W-S*28C,38P.V=A
M:6X-"B`@("!O;B!I;G1E<F-O;7!A;GD@;&]A;G,-"B`@("`\+V1I=CX\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!A;&EG;CTS1')I9VAT/CD\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1L969T/B8C,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N
M/3-$<FEG:'0^*#$P.#PO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<#XI
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P(&%L:6=N/3-$;&5F=#XF(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG
M;CTS1')I9VAT/B@S+#DW.3PO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<#XI/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@86QI9VX],T1R:6=H=#XR+#@S-#PO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&QE9G0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@86QI9VX],T1R:6=H=#XH-2PY,3,\+W1D/@T*("`@(#QT9"!N;W=R
M87`],T1N;W=R87`^*3PO=&0^#0H@("`@/"]T<CX-"B`@("`\='(@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q<'@G/@T*("`@(#QT9#X-"B`@("`\9&EV('-T>6QE
M/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SXF(S$V
M,#L-"B`@("`\+V1I=CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H
M="!S='EL93TS1"=B;W)D97(M=&]P.B`Q<'@@<V]L:60@(S`P,#`P,"<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L
M:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,7!X('-O;&ED(",P
M,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS
M<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#%P
M>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N
M;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D
M97(M=&]P.B`Q<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$<FEG:'0@<W1Y
M;&4],T0G8F]R9&5R+71O<#H@,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/"]T<CX-"B`@("`\='(@
M=F%L:6=N/3-$8F]T=&]M/@T*("`@(#QT9#X-"B`@("`\9&EV('-T>6QE/3-$
M)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY#;VUP<F5H
M96YS:79E(&QO<W,-"B`@("`\+V1I=CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1L969T/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^*#,L.30S/"]T9#X-
M"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P/BD\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1L969T
M/B8C,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^*#,L-3(Q/"]T
M9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P/BD\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1L
M969T/B8C,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^*#DL,#$X
M/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P/BD\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX]
M,T1L969T/B8C,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^*#@L
M,3,R/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P/BD\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1L969T/B8C,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^
M*#(T-BPT,#<\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`^*3PO=&0^
M#0H@("`@/"]T<CX-"B`@("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q<'@G
M/@T*("`@(#QT9#X-"B`@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U
M<'@[('1E>'0M:6YD96YT.BTQ-7!X)SXF(S$V,#L-"B`@("`\+V1I=CX\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M
M=&]P.B`S<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z(#-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$
M<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,W!X(&1O=6)L92`C,#`P,#`P
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS
M1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`S<'@@9&]U
M8FQE(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT
M;W`Z(#-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#PA+2T@16YD(%1A8FQE($)O
M9'D@+2T^#0H@("`@/"]T86)L93X-"B`@("`\+V1I=CX-"B`@("`\+V1I=CX-
M"B`@/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R
M.38Q,#0Q.5]E93<Q7S0X.3A?8CDQ85\W.&1A-F9C-C4P93@-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,CDV,3`T,3E?964W,5\T.#DX7V(Y,6%?
M-SAD839F8S8U,&4X+U=O<FMS:&5E=',O4VAE970P."YH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M13)(/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D9A:7(@5F%L=64@365A<W5R
M96UE;G1S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@
M,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^1F%I<B!686QU92!-96%S=7)E;65N=',@6T%B<W1R86-T73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&04E2
M(%9!3%5%($U%05-54D5-14Y44SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^#0H@("`@/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O
M1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW
M,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@
M+2T^#0H@("`@/"$M+2!"96=I;B!";&]C:R!486=G960@3F]T92`S("T@=7,M
M9V%A<#I&86ER5F%L=65$:7-C;&]S=7)E<U1E>'1";&]C:RTM/@T*("`@(#QD
M:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+%1I
M;65S+'-E<FEF.R!M87)G:6XM;&5F=#H@,&EN.R`G/@T*("`@(#QD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O
M<#H@,3!P="<^/&(^,RX@1D%)4B!604Q512!-14%355)%345.5%,\+V(^#0H@
M("`@/"]D:78^#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@
M-"4G/D%S(&1E9FEN960@:6X@05-#(#@R,"P@9F%I<B!V86QU92!I<R!B87-E
M9"!O;B!T:&4@<')I8V4@=&AA="!W;W5L9"!B92!R96-E:79E9"!T;R!S96QL
M(&%N#0H@("`@87-S970@;W(@<&%I9"!T;R!T<F%N<V9E<B!A(&QI86)I;&ET
M>2!I;B!A;B!O<F1E<FQY('1R86YS86-T:6]N(&)E='=E96X@;6%R:V5T('!A
M<G1I8VEP86YT<R!A="!T:&4-"B`@("!M96%S=7)E;65N="!D871E+B!);B!O
M<F1E<B!T;R!I;F-R96%S92!C;VYS:7-T96YC>2!A;F0@8V]M<&%R86)I;&ET
M>2!I;B!F86ER('9A;'5E(&UE87-U<F5M96YT<RP-"B`@("!!4T,@.#(P(&5S
M=&%B;&ES:&5S(&$@9F%I<B!V86QU92!H:65R87)C:'D@=&AA="!P<FEO<FET
M:7IE<R!O8G-E<G9A8FQE(&%N9"!U;F]B<V5R=F%B;&4@:6YP=71S('5S960-
M"B`@("!T;R!M96%S=7)E(&9A:7(@=F%L=64@:6YT;R!T:')E92!B<F]A9"!L
M979E;',L('=H:6-H(&%R92!D97-C<FEB960@8F5L;W<Z#0H@("`@/"]D:78^
M#0H@("`@/&1I=B!S='EL93TS1"=M87)G:6XM=&]P.B`Q,'!T)SX-"B`@("`\
M=&%B;&4@=VED=&@],T0Q,#`E(&)O<F1E<CTS1#`@8V5L;'!A9&1I;F<],T0P
M(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(&QE9G0G/@T*("`@(#QT<B!V86QI9VX],T1T;W`@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!C;VQO<CH@(S`P,#`P,#L@8F%C:V=R;W5N
M9#H@=')A;G-P87)E;G0G/@T*("`@(#QT9"!W:61T:#TS1#0E('-T>6QE/3-$
M)V)A8VMG<F]U;F0Z('1R86YS<&%R96YT)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!W:61T:#TS1#,E(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&QE9G0^/&(^
M)B,X,C(V.SPO8CX\+W1D/@T*("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO
M=&0^#0H@("`@/'1D/DQE=F5L(#$Z(%%U;W1E9"!P<FEC97,@*'5N861J=7-T
M960I)B,Q-C`[:6X@86-T:79E(&UA<FME=',@=&AA="!A<F4@86-C97-S:6)L
M92!A="!T:&4-"B`@("!M96%S=7)E;65N="!D871E(&9O<B!A<W-E=',@;W(@
M;&EA8FEL:71I97,N(%1H92!F86ER('9A;'5E(&AI97)A<F-H>2!G:79E<R!T
M:&4@:&EG:&5S=`T*("`@('!R:6]R:71Y('1O($QE=F5L(#$@:6YP=71S+CPO
M=&0^#0H@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`@(#PO9&EV/@T*("`@
M(#QD:78@<W1Y;&4],T0G;6%R9VEN+71O<#H@,3!P="<^#0H@("`@/'1A8FQE
M('=I9'1H/3-$,3`P)2!B;W)D97(],T0P(&-E;&QP861D:6YG/3-$,"!C96QL
M<W!A8VEN9STS1#`@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)SX-"B`@("`\='(@=F%L:6=N/3-$=&]P('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@8V]L;W(Z(",P,#`P,#`[(&)A8VMG<F]U;F0Z('1R
M86YS<&%R96YT)SX-"B`@("`\=&0@=VED=&@],T0T)2!S='EL93TS1"=B86-K
M9W)O=6YD.B!T<F%N<W!A<F5N="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@=VED
M=&@],T0S)2!N;W=R87`],T1N;W=R87`@86QI9VX],T1L969T/CQB/B8C.#(R
M-CL\+V(^/"]T9#X-"B`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*
M("`@(#QT9#Y,979E;"`R.B!);G!U=',@;W1H97(@=&AA;B!Q=6]T960@<')I
M8V5S('=I=&AI;B!,979E;"`Q('1H870@87)E(&]B<V5R=F%B;&4@9F]R('1H
M90T*("`@(&%S<V5T(&]R(&QI86)I;&ET>2P@96ET:&5R(&1I<F5C=&QY(&]R
M(&EN9&ER96-T;'DN/"]T9#X-"B`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M("`@/"]D:78^#0H@("`@/&1I=B!S='EL93TS1"=M87)G:6XM=&]P.B`Q,'!T
M)SX-"B`@("`\=&%B;&4@=VED=&@],T0Q,#`E(&)O<F1E<CTS1#`@8V5L;'!A
M9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*("`@(#QT<B!V86QI9VX],T1T
M;W`@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!C;VQO<CH@(S`P,#`P,#L@
M8F%C:V=R;W5N9#H@=')A;G-P87)E;G0G/@T*("`@(#QT9"!W:61T:#TS1#0E
M('-T>6QE/3-$)V)A8VMG<F]U;F0Z('1R86YS<&%R96YT)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!W:61T:#TS1#,E(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1&QE9G0^/&(^)B,X,C(V.SPO8CX\+W1D/@T*("`@(#QT9"!W:61T:#TS1#$E
M/B8C,38P.SPO=&0^#0H@("`@/'1D/DQE=F5L(#,Z(%5N;V)S97)V86)L92!I
M;G!U=',@=&AA="!A<F4@=7-E9"!W:&5N(&QI='1L92!O<B!N;R!M87)K970@
M9&%T82!I<R!A=F%I;&%B;&4N#0H@("`@5&AE(&9A:7(@=F%L=64@:&EE<F%R
M8VAY(&=I=F5S('1H92!L;W=E<W0@<')I;W)I='D@=&\@3&5V96P@,R!I;G!U
M=',N/"]T9#X-"B`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@("`@/"]D:78^
M#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@-"4G/DEN(&1E
M=&5R;6EN:6YG(&9A:7(@=F%L=64L('1H92!#;VUP86YY('5T:6QI>F5S('9A
M;'5A=&EO;B!T96-H;FEQ=65S('1H870@;6%X:6UI>F4@=&AE('5S92!O9@T*
M("`@(&]B<V5R=F%B;&4@:6YP=71S(&%N9"!M:6YI;6EZ92!T:&4@=7-E(&]F
M('5N;V)S97)V86)L92!I;G!U=',@=&\@=&AE(&5X=&5N="!P;W-S:6)L92!A
M<R!W96QL(&%S#0H@("`@8V]N<VED97)S(&-O=6YT97)P87)T>2!C<F5D:70@
M<FES:R!I;B!I=',@87-S97-S;65N="!O9B!F86ER('9A;'5E+B!&:6YA;F-I
M86P@87-S971S(&%N9`T*("`@(&QI86)I;&ET:65S(&-A<G)I960@870@9F%I
M<B!V86QU92!O;B!A(')E8W5R<FEN9R!B87-I<R!A<R!O9B!$96-E;6)E<B8C
M,38P.S,Q+"`R,#$P(&%R92!C;&%S<VEF:65D(&EN#0H@("`@=&AE('1A8FQE
M(&)E;&]W(&EN(&]N92!O9B!T:&4@=&AR964@8V%T96=O<FEE<R!D97-C<FEB
M960@86)O=F4Z#0H@("`@/"]D:78^#0H@("`@/&1I=B!A;&EG;CTS1&-E;G1E
M<CX-"B`@("`\=&%B;&4@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!L969T)R!C96QL<W!A8VEN9STS1#`@8F]R9&5R/3-$,"!C96QL
M<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*("`@(#PA+2T@0F5G:6X@5&%B
M;&4@2&5A9"`M+3X-"B`@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@(#QT
M9"!W:61T:#TS1#0T)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS1#,E
M/B8C,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@=VED=&@],T0Y)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T
M:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$,R4^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!W:61T:#TS1#DE/B8C,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$,24^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@=VED=&@],T0S)3XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@/'1D('=I9'1H
M/3-$.24^)B,Q-C`[/"]T9#X-"B`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!W:61T:#TS1#,E/B8C,38P.SPO=&0^#0H@("`@/'1D
M('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`\=&0@=VED=&@],T0Y)3XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@
M("`@/"]T<CX-"B`@("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)R!V
M86QI9VX],T1B;W1T;VT^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1&-E;G1E<B!C;VQS<&%N/3-$,CX\8CY,979E;"`Q/"]B/CPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\
M8CY,979E;"`R/"]B/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\8CY,979E;"`S/"]B/CPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$
M,CX\8CY4;W1A;#PO8CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#PO='(^#0H@("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C
M96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X
M('-O;&ED(",P,#`P,#`G/CQB/B9N8G-P.R0P,#`\+V(^/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\8CXF
M;F)S<#LD,#`P/"]B/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1&-E;G1E<B!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`Q<'@@<V]L:60@(S`P,#`P,"<^/&(^)FYB<W`[)#`P,#PO8CX\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G
M/CQB/B9N8G-P.R0P,#`\+V(^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\+W1R/@T*("`@(#PA+2T@16YD(%1A8FQE($AE860@+2T^#0H@("`@
M/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*("`@(#QT<B!V86QI9VX],T1B
M;W1T;VT^/"$M+2!";&%N:R!3<&%C92`M+3X-"B`@("`\=&0^#0H@("`@/&1I
M=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P
M>"<^)B,Q-C`[#0H@("`@/"]D:78^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\+W1R/@T*("`@(#QT<B!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G8F%C:V=R;W5N9#H@(V-C965F9B<^#0H@("`@/'1D/@T*("`@(#QD:78@
M<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G
M/D-A<V@@97%U:79A;&5N=',-"B`@("`\+V1I=CX\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG
M;CTS1')I9VAT/C(Y+#`V-CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&%L:6=N/3-$<FEG:'0^)B,X,C$R.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^)B,X,C$R.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^,CDL,#8V/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT<CX-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT<B!V86QI
M9VX],T1B;W1T;VT^#0H@("`@/'1D/@T*("`@(#QD:78@<W1Y;&4],T0G;6%R
M9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/E=A<G)A;G1S#0H@
M("`@/"]D:78^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI9VX],T1R:6=H=#XF(S@R,3([/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI9VX],T1R:6=H=#XF
M(S@R,3([/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI9VX]
M,T1R:6=H=#XV.#`\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!A
M;&EG;CTS1')I9VAT/C8X,#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/"]T<CX-"B`@("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q<'@G/@T*
M("`@(#QT9#X-"B`@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[
M('1E>'0M:6YD96YT.BTQ-7!X)SXF(S$V,#L-"B`@("`\+V1I=CX\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P
M.B`Q<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G
M8F]R9&5R+71O<#H@,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI
M9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`Q<'@@<V]L:60@(S`P
M,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M+W1R/@T*("`@(#QT<B!V86QI9VX],T1B;W1T;VT^/"$M+2!";&%N:R!3<&%C
M92`M+3X-"B`@("`\=&0^#0H@("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F
M=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^)B,Q-C`[#0H@("`@/"]D:78^
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT
M<B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F%C:V=R;W5N9#H@(V-C965F
M9B<^#0H@("`@/'1D/@T*("`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z
M,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/E1O=&%L#0H@("`@/"]D:78^/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@86QI9VX],T1R:6=H=#XR.2PP-C8\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!A;&EG;CTS1')I9VAT/B8C.#(Q,CL\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG;CTS1')I9VAT/C8X,#PO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^
M,CDL-S0V/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*
M("`@(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#%P>"<^#0H@("`@/'1D/@T*
M("`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E
M;G0Z+3$U<'@G/B8C,38P.PT*("`@(#PO9&EV/CPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$
M,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#-P>"!D;W5B
M;&4@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M(&-O;'-P86X],T0R(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O
M<#H@,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R
M87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS
M1"=B;W)D97(M=&]P.B`S<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I
M9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#-P>"!D;W5B;&4@(S`P,#`P,"<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*
M("`@(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^#0H@("`@/"]T86)L93X-"B`@
M("`\+V1I=CX-"B`@("`\(2TM($9O;&EO("TM/@T*("`@(#PA+2T@+T9O;&EO
M("TM/@T*("`@(#PO9&EV/@T*("`@(#PA+2T@4$%'14)214%+("TM/@T*("`@
M(#QD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG
M+%1I;65S+'-E<FEF.R!M87)G:6XM;&5F=#H@,&EN.R`G/@T*("`@(#QD:78@
M86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN
M+71O<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY&:6YA;F-I86P@87-S971S
M(&%N9"!L:6%B:6QI=&EE<R!C87)R:65D(&%T(&9A:7(@=F%L=64@;VX@82!R
M96-U<G)I;F<@8F%S:7,@87,@;V8@2G5N928C,38P.S,P+`T*("`@(#(P,3$@
M87)E(&-L87-S:69I960@:6X@=&AE('1A8FQE(&)E;&]W(&EN(&]N92!O9B!T
M:&4@=&AR964@8V%T96=O<FEE<R!D97-C<FEB960@86)O=F4Z#0H@("`@/"]D
M:78^#0H@("`@/&1I=B!A;&EG;CTS1&-E;G1E<CX-"B`@("`\=&%B;&4@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)R!C96QL
M<W!A8VEN9STS1#`@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@]
M,T0Q,#`E/@T*("`@(#PA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`@("`\
M='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@(#QT9"!W:61T:#TS1#0T)3XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS1#,E/B8C,38P.SPO=&0^#0H@("`@
M/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`\=&0@=VED=&@],T0Y
M)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^
M#0H@("`@/'1D('=I9'1H/3-$,R4^)B,Q-C`[/"]T9#X-"B`@("`\=&0@=VED
M=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS1#DE/B8C,38P
M.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@=VED=&@],T0S)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS1#$E
M/B8C,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$.24^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T
M:#TS1#,E/B8C,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@=VED=&@],T0Y)3XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@/"]T<CX-"B`@("`\='(@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)R!V86QI9VX],T1B;W1T;VT^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$
M,CX\8CY,979E;"`Q/"]B/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\8CY,979E;"`R/"]B/CPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N
M/3-$,CX\8CY,979E;"`S/"]B/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\8CY4;W1A;#PO8CX\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#PO='(^#0H@("`@/'1R('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB
M/B9N8G-P.R0P,#`\+V(^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L
M:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\8CXF;F)S<#LD,#`P/"]B/CPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N
M/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P
M,"<^/&(^)FYB<W`[)#`P,#PO8CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/B9N8G-P.R0P,#`\+V(^
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT
M<CX-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#PA+2T@
M16YD(%1A8FQE($AE860@+2T^#0H@("`@/"$M+2!"96=I;B!486)L92!";V1Y
M("TM/@T*("`@(#QT<B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F%C:V=R
M;W5N9#H@(V-C965F9B<^#0H@("`@/'1D/@T*("`@(#QD:78@<W1Y;&4],T0G
M;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/D-A<V@@97%U
M:79A;&5N=',-"B`@("`\+V1I=CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG;CTS1')I9VAT
M/C$W+#,S,SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N
M/3-$<FEG:'0^)B,X,C$R.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&%L:6=N/3-$<FEG:'0^)B,X,C$R.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^,3<L,S,S/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT<CX-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT<B!V86QI9VX],T1B;W1T
M;VT^#0H@("`@/'1D/@T*("`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z
M,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/E=A<G)A;G1S#0H@("`@/"]D:78^
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@86QI9VX],T1R:6=H=#XF(S@R,3([/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI9VX],T1R:6=H=#XF(S@R,3([/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI9VX],T1R:6=H=#XT
M-S<\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG;CTS1')I
M9VAT/C0W-SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/"]T<CX-
M"B`@("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q<'@G/@T*("`@(#QT9#X-
M"B`@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD
M96YT.BTQ-7!X)SXF(S$V,#L-"B`@("`\+V1I=CX\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS
M1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`Q<'@@<V]L
M:60@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M(&-O;'-P86X],T0R(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O
M<#H@,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z(#%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H
M="!S='EL93TS1"=B;W)D97(M=&]P.B`Q<'@@<V]L:60@(S`P,#`P,"<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@
M(#QT<CX-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT
M<B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F%C:V=R;W5N9#H@(V-C965F
M9B<^#0H@("`@/'1D/@T*("`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z
M,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/E1O=&%L#0H@("`@/"]D:78^/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@86QI9VX],T1R:6=H=#XQ-RPS,S,\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!A;&EG;CTS1')I9VAT/B8C.#(Q,CL\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG;CTS1')I9VAT/C0W-SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^
M,3<L.#$P/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*
M("`@(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#%P>"<^#0H@("`@/'1D/@T*
M("`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E
M;G0Z+3$U<'@G/B8C,38P.PT*("`@(#PO9&EV/CPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$
M,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#-P>"!D;W5B
M;&4@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M(&-O;'-P86X],T0R(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O
M<#H@,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R
M87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS
M1"=B;W)D97(M=&]P.B`S<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I
M9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#-P>"!D;W5B;&4@(S`P,#`P,"<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*
M("`@(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^#0H@("`@/"]T86)L93X-"B`@
M("`\+V1I=CX-"B`@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/CQB/CQI/E=A<G)A;G1S
M($QI86)I;&ET>3PO:3X\+V(^#0H@("`@/"]D:78^#0H@("`@/&1I=B!A;&EG
M;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P
M.B`Q,'!T.R!T97AT+6EN9&5N=#H@-"4G/E1H92!#;VUP86YY(&ES<W5E9"!W
M87)R86YT<R!T;R!P=7)C:&%S92!S:&%R97,@;V8@8V]M;6]N('-T;V-K('5N
M9&5R('1H92!R96=I<W1E<F5D(&1I<F5C=`T*("`@(&9I;F%N8VEN9R!C;VUP
M;&5T960@:6X@1F5B<G5A<GDF(S$V,#LR,#`W+B!4:&5S92!W87)R86YT<R!A
M<F4@8F5I;F<@86-C;W5N=&5D(&9O<B!A<R!A(&QI86)I;&ET>2!I;@T*("`@
M(&%C8V]R9&%N8V4@=VET:"!!4T,@.#$U+"`F(S@R,C`[/&D^1&5R:79A=&EV
M97,@86YD($AE9&=I;F<F(S@R,C$[(#PO:3XH)B,X,C(P.T%30R`X,34F(S@R
M,C$[*2X@070@=&AE(&1A=&4@;V8@=&AE('1R86YS86-T:6]N+`T*("`@('1H
M92!F86ER('9A;'5E(&]F('1H92!W87)R86YT<R!O9B`F;F)S<#LD-BXX)B,Q
M-C`[;6EL;&EO;B!W87,@9&5T97)M:6YE9"!U=&EL:7II;F<@=&AE($)L86-K
M+5-C:&]L97,@;W!T:6]N#0H@("`@<')I8VEN9R!M;V1E;"!U=&EL:7II;F<@
M=&AE(&9O;&QO=VEN9R!A<W-U;7!T:6]N<SH@<FES:R!F<F5E(&EN=&5R97-T
M(')A=&4@)B,X,C$R.R`T+C8X)2P@97AP96-T960-"B`@("!V;VQA=&EL:71Y
M("8C.#(Q,CL@.#4E+"!E>'!E8W1E9"!D:79I9&5N9"!Y:65L9"`F(S@R,3([
M(#`E+"!A;F0@82!C;VYT<F%C='5A;"!L:69E(&]F(#<F(S$V,#MY96%R<RX@
M5&AE(&9A:7(@=F%L=64-"B`@("!O9B!T:&4@=V%R<F%N="!I<R!B96EN9R!R
M92UM96%S=7)E9"!E86-H(')E<&]R=&EN9R!P97)I;V0L('=I=&@@82!D97)I
M=F%T:79E(&=A:6X@;W(@;&]S<PT*("`@(')E8V]G;FEZ960@:6X@=&AE(&-O
M;G-O;&ED871E9"!S=&%T96UE;G0@;V8@;W!E<F%T:6]N<RX@4W5C:"!G86EN
M<R!O<B!L;W-S97,@=VEL;"!C;VYT:6YU92!T;R!B90T*("`@(')E<&]R=&5D
M('5N=&EL('1H92!W87)R86YT<R!A<F4@97AE<F-I<V5D(&]R(&5X<&ER960N
M(%1H92!#;VUP86YY('5S960@=&AE($)L86-K+5-C:&]L97,-"B`@("!O<'1I
M;VXM<')I8VEN9R!M;V1E;"!W:71H('1H92!F;VQL;W=I;F<@87-S=6UP=&EO
M;G,@=&\@=F%L=64@=&AE('=A<G)A;G1S.@T*("`@(#PO9&EV/@T*("`@(#QD
M:78@86QI9VX],T1C96YT97(^#0H@("`@/'1A8FQE('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<@8V5L;'-P86-I;F<],T0P
M(&)O<F1E<CTS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-"B`@
M("`\(2TM($)E9VEN(%1A8FQE($AE860@+2T^#0H@("`@/'1R('9A;&EG;CTS
M1&)O='1O;3X-"B`@("`\=&0@=VED=&@],T0W,B4^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@=VED=&@],T0S)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS
M1#$E/B8C,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$.24^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W
M:61T:#TS1#,E/B8C,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$,24^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@=VED=&@],T0Y)3XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@/"]T<CX-"B`@("`\
M='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)R!V86QI9VX],T1B;W1T;VT^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N
M/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P
M,"<^/&(^1&5C96UB97(@,S$L/"]B/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P,"<^/&(^2G5N92`S,"P\+V(^
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT
M<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G('9A;&EG;CTS1&)O='1O;3X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X]
M,T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P
M)SX\8CXR,#$P/"]B/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1&-E;G1E<B!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`Q<'@@<V]L:60@(S`P,#`P,"<^/&(^,C`Q,3PO8CX\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#PO='(^#0H@("`@/"$M+2!%;F0@5&%B;&4@
M2&5A9"`M+3X-"B`@("`\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@("`@
M/'1R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD.B`C8V-E
M969F)SX-"B`@("`\=&0^#0H@("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F
M=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^17AE<F-I<V4@<')I8V4-"B`@
M("`\+V1I=CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!A
M;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG
M:'0^."XT-#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-
M"B`@("`\=&0@86QI9VX],T1R:6=H=#XX+C0T/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT<B!V86QI9VX],T1B;W1T;VT^
M#0H@("`@/'1D/@T*("`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P
M>#L@=&5X="UI;F1E;G0Z+3$U<'@G/D5X<&5C=&5D('1E<FT-"B`@("`\+V1I
M=CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N
M/3-$,B!A;&EG;CTS1')I9VAT/C,N,3,@67)S+CPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P
M86X],T0R(&%L:6=N/3-$<FEG:'0^,BXV,R!9<G,N/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT<B!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G8F%C:V=R;W5N9#H@(V-C965F9B<^#0H@("`@/'1D/@T*
M("`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E
M;G0Z+3$U<'@G/E)I<VL@9G)E92!I;G1E<F5S="!R871E#0H@("`@/"]D:78^
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P(&%L:6=N/3-$;&5F=#XF(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG
M;CTS1')I9VAT/C$N,#(\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`^
M)3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!A;&EG;CTS1&QE9G0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI
M9VX],T1R:6=H=#XP+C8X/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M/B4\+W1D/@T*("`@(#PO='(^#0H@("`@/'1R('9A;&EG;CTS1&)O='1O;3X-
M"B`@("`\=&0^#0H@("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X
M.R!T97AT+6EN9&5N=#HM,35P>"<^17AP96-T960@=F]L871I;&ET>0T*("`@
M(#PO9&EV/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&QE9G0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@86QI9VX],T1R:6=H=#XQ,C$\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N
M;W=R87`^)3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&QE9G0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@86QI9VX],T1R:6=H=#XQ,3@\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N
M;W=R87`^)3PO=&0^#0H@("`@/"]T<CX-"B`@("`\='(@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0Z("-C8V5E9F8G/@T*("`@(#QT9#X-
M"B`@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD
M96YT.BTQ-7!X)SY%>'!E8W1E9"!D:79I9&5N9"!Y:65L9"!O=F5R(&5X<&5C
M=&5D('1E<FT-"B`@("`\+V1I=CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG;CTS1')I9VAT
M/B8C.#(Q,CL\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG
M;CTS1')I9VAT/B8C.#(Q,CL\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#PO='(^#0H@("`@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X-"B`@("`\
M+W1A8FQE/@T*("`@(#PO9&EV/@T*("`@(#QD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P=#L@=&5X
M="UI;F1E;G0Z(#0E)SY$=7)I;F<@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!*
M=6YE)B,Q-C`[,S`L(#(P,3`@86YD(#(P,3$L('1H92!#;VUP86YY(')E8V]G
M;FEZ960@=&AE(&-H86YG90T*("`@(&EN('1H92!V86QU92!O9B!W87)R86YT
M<R!O9B!A<'!R;WAI;6%T96QY("9N8G-P.R0P+C,F(S$V,#MM:6QL:6]N(&%N
M9"`F;F)S<#LD,"XQ)B,Q-C`[;6EL;&EO;BP@<F5S<&5C=&EV96QY+"!A<R!A
M(&=A:6X@;VX-"B`@("!T:&4@8V]N<V]L:61A=&5D('-T871E;65N="!O9B!O
M<&5R871I;VYS+B!$=7)I;F<@=&AE('-I>"!M;VYT:',@96YD960@2G5N928C
M,38P.S,P+"`R,#$P+"!T:&4@0V]M<&%N>0T*("`@(')E8V]G;FEZ960@=&AE
M("9N8G-P.R0P+C4F(S$V,#MM:6QL:6]N(&EN8W)E87-E(&EN('1H92!V86QU
M92!O9B!W87)R86YT<R!A<R!A(&QO<W,@;VX@=&AE(&-O;G-O;&ED871E9`T*
M("`@('-T871E;65N="!O9B!O<&5R871I;VYS+B!$=7)I;F<@=&AE('-I>"!M
M;VYT:',@96YD960@2G5N928C,38P.S,P+"`R,#$Q+"!T:&4@0V]M<&%N>2!R
M96-O9VYI>F5D('1H90T*("`@("9N8G-P.R0P+C(F(S$V,#MM:6QL:6]N(&1E
M8W)E87-E(&EN('1H92!V86QU92!O9B!W87)R86YT<R!A<R!A(&=A:6X@;VX@
M=&AE(&-O;G-O;&ED871E9"!S=&%T96UE;G0@;V8-"B`@("!O<&5R871I;VYS
M+B!4:&4@9F]L;&]W:6YG('1A8FQE(')E8V]N8VEL97,@=&AE(&)E9VEN;FEN
M9R!A;F0@96YD:6YG(&)A;&%N8V4@;V8@3&5V96P@,R!I;G!U=',@9F]R#0H@
M("`@=&AE('-I>"!M;VYT:',@96YD960@2G5N928C,38P.S,P+"`R,#$Q.@T*
M("`@(#PO9&EV/@T*("`@(#QD:78@86QI9VX],T1C96YT97(^#0H@("`@/'1A
M8FQE('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F
M="<@8V5L;'-P86-I;F<],T0P(&)O<F1E<CTS1#`@8V5L;'!A9&1I;F<],T0P
M('=I9'1H/3-$,3`P)3X-"B`@("`\(2TM($)E9VEN(%1A8FQE($AE860@+2T^
M#0H@("`@/'1R('9A;&EG;CTS1&)O='1O;3X-"B`@("`\=&0@=VED=&@],T0X
M-B4^)B,Q-C`[/"]T9#X-"B`@("`\=&0@=VED=&@],T0S)3XF(S$V,#L\+W1D
M/@T*("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@/'1D('=I
M9'1H/3-$.24^)B,Q-C`[/"]T9#X-"B`@("`\=&0@=VED=&@],T0Q)3XF(S$V
M,#L\+W1D/@T*("`@(#PO='(^#0H@("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P="<@=F%L:6=N/3-$8F]T=&]M/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/DQE=F5L(#,\+V(^/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT<B!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G('9A;&EG;CTS1&)O='1O;3X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R
M/CQB/B9N8G-P.R0P,#`\+V(^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\+W1R/@T*("`@(#PA+2T@16YD(%1A8FQE($AE860@+2T^#0H@("`@
M/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*("`@(#QT<B!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G8F%C:V=R;W5N9#H@(V-C965F9B<^#0H@("`@/'1D
M/@T*("`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI
M;F1E;G0Z+3$U<'@G/D)A;&%N8V4@87,@;V8@1&5C96UB97(F(S$V,#LS,2P@
M,C`Q,`T*("`@(#PO9&EV/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^-C@P
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT
M<B!V86QI9VX],T1B;W1T;VT^#0H@("`@/'1D/@T*("`@(#QD:78@<W1Y;&4]
M,T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/D=A:6X@
M9G)O;2!C:&%N9V4@:6X@=F%L=6%T:6]N(&]F('=A<G)A;G1S(&QI86)I;&ET
M>2!R97!O<G1E9"!I;B!E87)N:6YG<PT*("`@(#PO9&EV/CPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1&QE9G0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI9VX],T1R:6=H=#XH
M,C`S/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P/BD\+W1D/@T*("`@
M(#PO='(^#0H@("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,7!X)SX-"B`@
M("`\=&0^#0H@("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T
M97AT+6EN9&5N=#HM,35P>"<^)B,Q-C`[#0H@("`@/"]D:78^/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O
M;'-P86X],T0R(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@
M,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/"]T<CX-"B`@("`\='(@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)V)A8VMG<F]U;F0Z("-C8V5E9F8G/@T*("`@(#QT9#X-"B`@("`\
M9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ
M-7!X)SY"86QA;F-E(&%S(&]F($IU;F4F(S$V,#LS,"P@,C`Q,0T*("`@(#PO
M9&EV/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^-#<W/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT<B!S='EL93TS1"=F
M;VYT+7-I>F4Z(#%P>"<^#0H@("`@/'1D/@T*("`@(#QD:78@<W1Y;&4],T0G
M;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/B8C,38P.PT*
M("`@(#PO9&EV/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z(#-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#PA
M+2T@16YD(%1A8FQE($)O9'D@+2T^#0H@("`@/"]T86)L93X-"B`@("`\+V1I
M=CX-"B`@("`\(2TM($9O;&EO("TM/@T*("`@(#PA+2T@+T9O;&EO("TM/@T*
M("`@(#PO9&EV/@T*("`@(#PA+2T@4$%'14)214%+("TM/@T*("`@(#QD:78@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+%1I;65S
M+'-E<FEF.R!M87)G:6XM;&5F=#H@,&EN.R`G/@T*("`@(#PO9&EV/@T*("`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S(Y-C$P
M-#$Y7V5E-S%?-#@Y.%]B.3%A7S<X9&$V9F,V-3!E.`T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B\R.38Q,#0Q.5]E93<Q7S0X.3A?8CDQ85\W.&1A
M-F9C-C4P93@O5V]R:W-H965T<R]3:&5E=#`Y+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,D@^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^4')E<&%I9"!%>'!E;G-E<R!A;F0@
M3W1H97(@0W5R<F5N="!!<W-E=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^2G5N+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0<F5P86ED($5X<&5N<V5S(&%N9"!/
M=&AE<B!#=7)R96YT($%S<V5T<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!215!!240@15A014Y315,@
M04Y$($]42$52($-54E)%3E0@05-31513/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X-"B`@("`\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O
M5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O
M=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN
M9'1D(B`M+3X-"B`@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#0@
M+2!C>6-C.E!R97!A:61%>'!E;G-E<T%N9$]T:&5R0W5R<F5N=$%S<V5T<U1E
M>'1";&]C:RTM/@T*("`@(#QD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4
M:6UE<R!.97<@4F]M86XG+%1I;65S+'-E<FEF.R!M87)G:6XM;&5F=#H@,&EN
M.R`G/@T*("`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^/&(^-"X@4%)%4$%)1"!%6%!%
M3E-%4R!!3D0@3U1(15(@0U524D5.5"!!4U-%5%,\+V(^#0H@("`@/"]D:78^
M#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@-"4G/E!R97!A
M:60@97AP96YS97,@86YD(&]T:&5R(&-U<G)E;G0@87-S971S(&-O;G-I<W0@
M;V8@=&AE(&9O;&QO=VEN9SH-"B`@("`\+V1I=CX-"B`@("`\9&EV(&%L:6=N
M/3-$8V5N=&5R/@T*("`@(#QT86)L92!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&QE9G0G(&-E;&QS<&%C:6YG/3-$,"!B;W)D97(]
M,T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^#0H@("`@/"$M+2!"
M96=I;B!486)L92!(96%D("TM/@T*("`@(#QT<B!V86QI9VX],T1B;W1T;VT^
M#0H@("`@/'1D('=I9'1H/3-$-S(E/B8C,38P.SPO=&0^#0H@("`@/'1D('=I
M9'1H/3-$,R4^)B,Q-C`[/"]T9#X-"B`@("`\=&0@=VED=&@],T0Q)3XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS1#DE/B8C,38P.SPO=&0^#0H@("`@
M/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`\=&0@=VED=&@],T0S
M)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^
M#0H@("`@/'1D('=I9'1H/3-$.24^)B,Q-C`[/"]T9#X-"B`@("`\=&0@=VED
M=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@(#PO='(^#0H@("`@/'1R('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P="<@=F%L:6=N/3-$8F]T=&]M/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!N
M;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(^/&(^
M1&5C96UB97(@,S$L/"]B/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\8CY*=6YE(#,P+#PO8CX\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#PO='(^#0H@("`@/'1R('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB
M/C(P,3`\+V(^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M8V5N=&5R(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P
M>"!S;VQI9"`C,#`P,#`P)SX\8CXR,#$Q/"]B/CPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/"]T<CX-"B`@("`\='(@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T)R!V86QI9VX],T1B;W1T;VT^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$-CX\8CXH)FYB<W`[)#`P
M,',I/"]B/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/"]T<CX-
M"B`@("`\(2TM($5N9"!486)L92!(96%D("TM/@T*("`@(#PA+2T@0F5G:6X@
M5&%B;&4@0F]D>2`M+3X-"B`@("`\='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)V)A8VMG<F]U;F0Z("-C8V5E9F8G/@T*("`@(#QT9#X-"B`@("`\9&EV
M('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X
M)SY297-E87)C:"!A;F0@9&5V96QO<&UE;G0@=&%X(&-R961I="!R96-E:79A
M8FQE#0H@("`@/"]D:78^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI9VX],T1R:6=H=#XV-C`\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG;CTS1')I9VAT
M/CDY.#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/"]T<CX-"B`@
M("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@(#QT9#X-"B`@("`\9&EV('-T
M>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY0
M<F5P87EM96YT<PT*("`@(#PO9&EV/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG
M:'0^,S$W/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI9VX]
M,T1R:6=H=#XT-S8\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#PO
M='(^#0H@("`@/'1R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O
M=6YD.B`C8V-E969F)SX-"B`@("`\=&0^#0H@("`@/&1I=B!S='EL93TS1"=M
M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^3W1H97(@8W5R
M<F5N="!A<W-E=',-"B`@("`\+V1I=CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG;CTS1')I
M9VAT/C0P-3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N
M/3-$<FEG:'0^,C$T/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M+W1R/@T*("`@(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#%P>"<^#0H@("`@
M/'1D/@T*("`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X
M="UI;F1E;G0Z+3$U<'@G/B8C,38P.PT*("`@(#PO9&EV/CPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS
M<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#%P
M>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N
M;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D
M97(M=&]P.B`Q<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT<B!V86QI9VX],T1B
M;W1T;VT^#0H@("`@/'1D/@T*("`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/E1O=&%L('!R97!A:60@97AP
M96YS97,@86YD(&]T:&5R(&-U<G)E;G0@87-S971S#0H@("`@/"]D:78^/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@86QI9VX],T1R:6=H=#XQ+#,X,CPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^,2PV.#@\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#PO='(^#0H@("`@/'1R('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,7!X)SX-"B`@("`\=&0^#0H@("`@/&1I=B!S='EL93TS
M1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^)B,Q-C`[
M#0H@("`@/"]D:78^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$<FEG:'0@
M<W1Y;&4],T0G8F]R9&5R+71O<#H@,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI
M9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`S<'@@9&]U8FQE(",P
M,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/"]T<CX-"B`@("`\(2TM($5N9"!486)L92!";V1Y("TM/@T*("`@(#PO=&%B
M;&4^#0H@("`@/"]D:78^#0H@("`@/"]D:78^#0H@(#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,CDV,3`T,3E?964W,5\T.#DX
M7V(Y,6%?-SAD839F8S8U,&4X#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S(Y-C$P-#$Y7V5E-S%?-#@Y.%]B.3%A7S<X9&$V9F,V-3!E."]7;W)K
M<VAE971S+U-H965T,3`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4R2#X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY!8V-R=65D($QI86)I;&ET:65S(&%N9"!/=&AE<B!#=7)R
M96YT($QI86)I;&ET:65S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIU;BX@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^06-C<G5E9"!,:6%B:6QI=&EE<R!A;F0@3W1H
M97(@0W5R<F5N="!,:6%B:6QI=&EE<R!;06)S=')A8W1=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%#0U)5140@3$E!0DE,
M251)15,@04Y$($]42$52($-54E)%3E0@3$E!0DE,251)15,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/@T*("`@(#PA+2U$3T-465!%(&AT;6P@
M4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%
M3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R
M86YS:71I;VYA;"YD=&0B("TM/@T*("`@(#PA+2T@0F5G:6X@0FQO8VL@5&%G
M9V5D($YO=&4@-2`M('5S+6=A87`Z06-C;W5N='-087EA8FQE06-C<G5E9$QI
M86)I;&ET:65S06YD3W1H97),:6%B:6QI=&EE<T1I<V-L;W-U<F5#=7)R96YT
M5&5X=$)L;V-K+2T^#0H@("`@/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)U1I;65S($YE=R!2;VUA;B<L5&EM97,L<V5R:68[(&UA<F=I;BUL969T.B`P
M:6X[("<^#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SX\8CXU+B!!0T-2545$($Q)
M04))3$E42453($%.1"!/5$A%4B!#55)214Y4($Q)04))3$E42453/"]B/@T*
M("`@(#PO9&EV/@T*("`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P=#L@=&5X="UI;F1E;G0Z
M(#0E)SY!8V-R=65D(&%N9"!O=&AE<B!C=7)R96YT(&QI86)I;&ET:65S(&-O
M;G-I<W1E9"!O9B!T:&4@9F]L;&]W:6YG.@T*("`@(#PO9&EV/@T*("`@(#QD
M:78@86QI9VX],T1C96YT97(^#0H@("`@/'1A8FQE('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<@8V5L;'-P86-I;F<],T0P
M(&)O<F1E<CTS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-"B`@
M("`\(2TM($)E9VEN(%1A8FQE($AE860@+2T^#0H@("`@/'1R('9A;&EG;CTS
M1&)O='1O;3X-"B`@("`\=&0@=VED=&@],T0W,B4^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@=VED=&@],T0S)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS
M1#$E/B8C,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$.24^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W
M:61T:#TS1#,E/B8C,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$,24^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@=VED=&@],T0Y)3XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@/"]T<CX-"B`@("`\
M='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)R!V86QI9VX],T1B;W1T;VT^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N
M/3-$,CX\8CY$96-E;6)E<B`S,2P\+V(^/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQB/DIU;F4@,S`L
M/"]B/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/"]T<CX-"B`@
M("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)R!V86QI9VX],T1B;W1T
M;VT^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS
M<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P
M,#`P,"<^/&(^,C`Q,#PO8CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/C(P,3$\+V(^/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT<B!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0G('9A;&EG;CTS1&)O='1O;3X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0V/CQB/B@F
M;F)S<#LD,#`P/"]B/G,I/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\+W1R/@T*("`@(#PA+2T@16YD(%1A8FQE($AE860@+2T^#0H@("`@/"$M
M+2!"96=I;B!486)L92!";V1Y("TM/@T*("`@(#QT<B!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G8F%C:V=R;W5N9#H@(V-C965F9B<^#0H@("`@/'1D/@T*
M("`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E
M;G0Z+3$U<'@G/D%C8W)U960@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT#0H@
M("`@/"]D:78^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI9VX],T1R:6=H=#XR+#<Y,SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^,RPS
M-#,\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#PO='(^#0H@("`@
M/'1R('9A;&EG;CTS1&)O='1O;3X-"B`@("`\=&0^#0H@("`@/&1I=B!S='EL
M93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^3W1H
M97(@8W5R<F5N="!L:6%B:6QI=&EE<PT*("`@(#PO9&EV/CPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M(&%L:6=N/3-$<FEG:'0^,2PS,SD\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!A;&EG;CTS1')I9VAT/C$L,3$V/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT<B!S='EL93TS1"=F;VYT+7-I
M>F4Z(#%P>"<^#0H@("`@/'1D/@T*("`@(#QD:78@<W1Y;&4],T0G;6%R9VEN
M+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/B8C,38P.PT*("`@(#PO
M9&EV/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z(#%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H
M="!S='EL93TS1"=B;W)D97(M=&]P.B`Q<'@@<V]L:60@(S`P,#`P,"<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@
M(#QT<B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F%C:V=R;W5N9#H@(V-C
M965F9B<^#0H@("`@/'1D/@T*("`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/B8C,38P.PT*("`@(#PO9&EV
M/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^-"PQ,S(\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG;CTS1')I9VAT/C0L-#4Y/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT<B!S='EL
M93TS1"=F;VYT+7-I>F4Z(#%P>"<^#0H@("`@/'1D/@T*("`@(#QD:78@<W1Y
M;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/B8C
M,38P.PT*("`@(#PO9&EV/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I
M9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#-P>"!D;W5B;&4@(S`P,#`P,"<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R
M(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,W!X(&1O=6)L
M92`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#PO='(^#0H@("`@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X-"B`@("`\
M+W1A8FQE/@T*("`@(#PO9&EV/@T*("`@(#PO9&EV/@T*("`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S(Y-C$P-#$Y7V5E-S%?
M-#@Y.%]B.3%A7S<X9&$V9F,V-3!E.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B\R.38Q,#0Q.5]E93<Q7S0X.3A?8CDQ85\W.&1A-F9C-C4P93@O
M5V]R:W-H965T<R]3:&5E=#$Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,D@^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^4W1O8VL@0F%S960@0V]M<&5N<V%T:6]N/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1O
M8VL@0F%S960@0V]M<&5N<V%T:6]N(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4U1/0TL@0D%3140@0T]-
M4$5.4T%424]./"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X-"B`@
M("`\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@
M,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X
M:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X-"B`@("`\
M(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#8@+2!U<RUG86%P.D1I<V-L
M;W-U<F5/9D-O;7!E;G-A=&EO;E)E;&%T961#;W-T<U-H87)E0F%S961087EM
M96YT<U1E>'1";&]C:RTM/@T*("`@(#QD:78@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=4:6UE<R!.97<@4F]M86XG+%1I;65S+'-E<FEF.R!M87)G:6XM;&5F
M=#H@,&EN.R`G/@T*("`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^/&(^-BX@4U1/0TL@
M0D%3140@0T]-4$5.4T%424]./"]B/@T*("`@(#PO9&EV/@T*("`@(#QD:78@
M86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN
M+71O<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#@E)SY3=&]C:R!B87-E9"!C;VUP
M96YS871I;VX@:&%S(&)E96X@<F5P;W)T960@=VET:&EN(&5X<&5N<V4@;&EN
M92!I=&5M<R!O;B!T:&4@8V]N<V]L:61A=&5D#0H@("`@<W1A=&5M96YT(&]F
M(&]P97)A=&EO;G,@9F]R('1H92!T:')E92!M;VYT:',@96YD960@2G5N928C
M,38P.S,P+"`R,#$P(&%N9"`R,#$Q(&%S('-H;W=N(&EN('1H92!F;VQL;W=I
M;F<-"B`@("!T86)L93H-"B`@("`\+V1I=CX-"B`@("`\9&EV(&%L:6=N/3-$
M8V5N=&5R/@T*("`@(#QT86)L92!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M('1E>'0M86QI9VXZ(&QE9G0G(&-E;&QS<&%C:6YG/3-$,"!B;W)D97(],T0P
M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^#0H@("`@/"$M+2!"96=I
M;B!486)L92!(96%D("TM/@T*("`@(#QT<B!V86QI9VX],T1B;W1T;VT^#0H@
M("`@/'1D('=I9'1H/3-$-#0E/B8C,38P.SPO=&0^#0H@("`@/'1D('=I9'1H
M/3-$,R4^)B,Q-C`[/"]T9#X-"B`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!W:61T:#TS1#DE/B8C,38P.SPO=&0^#0H@("`@/'1D
M('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`\=&0@=VED=&@],T0S)3XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@
M("`@/'1D('=I9'1H/3-$.24^)B,Q-C`[/"]T9#X-"B`@("`\=&0@=VED=&@]
M,T0Q)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS1#,E/B8C,38P.SPO
M=&0^#0H@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M=VED=&@],T0Y)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS1#$E/B8C
M,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$,R4^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS
M1#DE/B8C,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T
M9#X-"B`@("`\+W1R/@T*("`@(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0G('9A;&EG;CTS1&)O='1O;3X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L
M:6=N/3-$8V5N=&5R(&-O;'-P86X],T0V/CQB/D9O<B!T:&4@=&AR964@;6]N
M=&AS/"]B/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E
M;G1E<B!C;VQS<&%N/3-$-CX\8CY&;W(@=&AE('-I>"!M;VYT:',\+V(^/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT<B!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G('9A;&EG;CTS1&)O='1O;3X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0V
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\
M8CYE;F1E9"!*=6YE(#,P+#PO8CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#8@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/F5N9&5D($IU;F4@,S`L
M/"]B/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/"]T<CX-"B`@
M("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)R!V86QI9VX],T1B;W1T
M;VT^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS
M<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P
M,#`P,"<^/&(^,C`Q,#PO8CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/C(P,3$\+V(^/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\
M8CXR,#$P/"]B/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1&-E;G1E<B!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q
M<'@@<V]L:60@(S`P,#`P,"<^/&(^,C`Q,3PO8CX\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#PO='(^#0H@("`@/'1R('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P="<@=F%L:6=N/3-$8F]T=&]M/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@,'!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$
M-CX\8CXH)FYB<W`[)#`P,',I/"]B/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`P<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#PA+2T@16YD(%1A
M8FQE($AE860@+2T^#0H@("`@/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*
M("`@(#QT<B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F%C:V=R;W5N9#H@
M(V-C965F9B<^#0H@("`@/'1D/@T*("`@(#QD:78@<W1Y;&4],T0G;6%R9VEN
M+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/E)E<V5A<F-H(&%N9"!D
M979E;&]P;65N=`T*("`@(#PO9&EV/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG
M:'0^.3,\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG;CTS
M1')I9VAT/C0Q/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI
M9VX],T1R:6=H=#XQ-C4\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!A;&EG;CTS1')I9VAT/CDP/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\+W1R/@T*("`@(#QT<B!V86QI9VX],T1B;W1T;VT^#0H@("`@/'1D
M/@T*("`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI
M;F1E;G0Z+3$U<'@G/D=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E#0H@("`@
M/"]D:78^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@86QI9VX],T1R:6=H=#XS-S0\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG;CTS1')I9VAT/C$V-#PO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^-C(Q
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI9VX],T1R:6=H
M=#XS-C4\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#PO='(^#0H@
M("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,7!X)SX-"B`@("`\=&0^#0H@
M("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N
M=#HM,35P>"<^)B,Q-C`[#0H@("`@/"]D:78^/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R
M(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,7!X('-O;&ED
M(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C
M;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M(#%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B
M;W)D97(M=&]P.B`Q<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$<FEG:'0@
M<W1Y;&4],T0G8F]R9&5R+71O<#H@,7!X('-O;&ED(",P,#`P,#`G/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/"]T<CX-"B`@("`\
M='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0Z("-C8V5E
M9F8G/@T*("`@(#QT9#X-"B`@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T
M.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY3=&]C:RUB87-E9"!C;VUP96YS
M871I;VX@8V]S=',@8F5F;W)E(&EN8V]M92!T87AE<PT*("`@(#PO9&EV/CPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^-#8W/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@86QI9VX],T1R:6=H=#XR,#4\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG;CTS1')I9VAT/C<X-CPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^-#4U/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT<B!S
M='EL93TS1"=F;VYT+7-I>F4Z(#%P>"<^#0H@("`@/'1D/@T*("`@(#QD:78@
M<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G
M/B8C,38P.PT*("`@(#PO9&EV/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS
M1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#-P>"!D;W5B;&4@(S`P,#`P
M,"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X]
M,T0R(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,W!X(&1O
M=6)L92`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M
M=&]P.B`S<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z(#-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#PA+2T@
M16YD(%1A8FQE($)O9'D@+2T^#0H@("`@/"]T86)L93X-"B`@("`\+V1I=CX-
M"B`@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD96YT.B`X)2<^56YD97(@
M=&AE(#(P,#8@4&QA;BP@-2PR,#`L,#`P('-H87)E<R!O9B!T:&4@0V]M<&%N
M>28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!H879E(&)E96X@<F5S97)V960N(%1H
M90T*("`@(&%W87)D<R!G<F%N=&5D('5N9&5R('1H92`R,#`V(%!L86X@:&%V
M92!A(&UA>&EM=6T@;6%T=7)I='D@;V8@,3`F(S$V,#MY96%R<R!A;F0@9V5N
M97)A;&QY('9E<W0@;W9E<B!A#0H@("`@9F]U<BUY96%R('!E<FEO9"!F<F]M
M('1H92!D871E(&]F(&=R86YT+@T*("`@(#PO9&EV/@T*("`@(#PA+2T@1F]L
M:6\@+2T^#0H@("`@/"$M+2`O1F]L:6\@+2T^#0H@("`@/"]D:78^#0H@("`@
M/"$M+2!004=%0E)%04L@+2T^#0H@("`@/&1I=B!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L5&EM97,L<V5R:68[(&UA<F=I;BUL
M969T.B`P:6X[("<^#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN9&5N
M=#H@."4G/D$@<W5M;6%R>2!O9B!A8W1I=FET>2!F;W(@=&AE(&]P=&EO;G,@
M=6YD97(@=&AE($-O;7!A;GDF(S@R,3<[<R`R,#`V(%!L86X@9F]R('1H92!S
M:7@@;6]N=&AS(&5N9&5D#0H@("`@2G5N928C,38P.S,P+"`R,#$Q(&ES(&%S
M(&9O;&QO=W,Z#0H@("`@/"]D:78^#0H@("`@/&1I=B!A;&EG;CTS1&-E;G1E
M<CX-"B`@("`\=&%B;&4@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!L969T)R!C96QL<W!A8VEN9STS1#`@8F]R9&5R/3-$,"!C96QL
M<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*("`@(#PA+2T@0F5G:6X@5&%B
M;&4@2&5A9"`M+3X-"B`@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@(#QT
M9"!W:61T:#TS1#0T)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS1#,E
M/B8C,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@=VED=&@],T0Y)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T
M:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$,R4^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!W:61T:#TS1#DE/B8C,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$,24^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@=VED=&@],T0S)3XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@/'1D('=I9'1H
M/3-$.24^)B,Q-C`[/"]T9#X-"B`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!W:61T:#TS1#,E/B8C,38P.SPO=&0^#0H@("`@/'1D
M('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`\=&0@=VED=&@],T0Y)3XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@
M("`@/"]T<CX-"B`@("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)R!V
M86QI9VX],T1B;W1T;VT^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS
M<&%N/3-$,CX\8CY796EG:'1E9"`\8G(@+SX-"B`@("!!=F5R86=E/"]B/CPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS
M<&%N/3-$,CXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#PO='(^#0H@("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@
M8V]L<W!A;CTS1#(^/&(^5V5I9VAT960\+V(^/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQB/E)E;6%I
M;FEN9SPO8CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C
M96YT97(@8V]L<W!A;CTS1#(^/&(^06=G<F5G871E/"]B/CPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/"]T<CX-"B`@("`\='(@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T)R!V86QI9VX],T1B;W1T;VT^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\8CY!=F5R86=E/"]B
M/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C
M;VQS<&%N/3-$,CX\8CY#;VYT<F%C='5A;#PO8CX\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(^/&(^26YT
M<FEN<VEC/"]B/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/"]T
M<CX-"B`@("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)R!V86QI9VX]
M,T1B;W1T;VT^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E
M<B!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L
M:60@(S`P,#`P,"<^/&(^3W!T:6]N<SPO8CX\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/D5X97)C:7-E
M(%!R:6-E/"]B/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1&-E;G1E<B!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q
M<'@@<V]L:60@(S`P,#`P,"<^/&(^5&5R;2`H>65A<G,I/"]B/CPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$
M,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P,"<^
M/&(^5F%L=64\+V(^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M+W1R/@T*("`@(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G('9A;&EG
M;CTS1&)O='1O;3X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N
M=&5R(&-O;'-P86X],T0Q,#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(^/&(^*&EN("9N8G-P
M.R0P,#!S*3PO8CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#PO
M='(^#0H@("`@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X-"B`@("`\(2TM($)E
M9VEN(%1A8FQE($)O9'D@+2T^#0H@("`@/'1R('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=B86-K9W)O=6YD.B`C8V-E969F)SX-"B`@("`\=&0^#0H@("`@
M/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM
M,35P>"<^3W!T:6]N<R!O=71S=&%N9&EN9R!A="!$96-E;6)E<B8C,38P.S,Q
M+"`R,#$P#0H@("`@/"]D:78^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI9VX],T1R:6=H=#XS
M+#0X.2PY,S(\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^
M#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^,RXY-CPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^-RXR,CPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^.3,X/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT<B!V86QI
M9VX],T1B;W1T;VT^#0H@("`@/'1D/@T*("`@(#QD:78@<W1Y;&4],T0G;6%R
M9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/D=R86YT960-"B`@
M("`\+V1I=CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG;CTS1')I9VAT/C$Y.2PU,#`\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@/'1D(&%L
M:6=N/3-$<FEG:'0^,2XU,CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/"]T<CX-"B`@
M("`\='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0Z("-C
M8V5E9F8G/@T*("`@(#QT9#X-"B`@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL
M969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY%>&5R8VES960-"B`@("`\
M+V1I=CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1L969T/B8C,38P.SPO=&0^#0H@("`@/'1D
M(&%L:6=N/3-$<FEG:'0^*#8L-C,X/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P/BD\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!A
M;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG
M:'0^,"XT,3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/"]T<CX-"B`@("`\='(@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@(#QT9#X-"B`@("`\9&EV('-T>6QE/3-$)VUA
M<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY%>'!I<F5D#0H@
M("`@/"]D:78^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI9VX],T1R:6=H=#XF(S@R,3([/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT<B!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G8F%C:V=R;W5N9#H@(V-C965F9B<^#0H@("`@/'1D/@T*("`@(#QD
M:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U
M<'@G/D-A;F-E;&QE9"`O(&9O<F9E:71E9`T*("`@(#PO9&EV/CPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1&QE9G0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI9VX],T1R:6=H
M=#XH,3,Y+#(V-3PO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<#XI/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI9VX],T1L969T
M/B9N8G-P.R0\+W1D/@T*("`@(#QT9"!A;&EG;CTS1')I9VAT/C8N,S(\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#PO='(^#0H@("`@/'1R('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,7!X)SX-"B`@("`\=&0^#0H@("`@/&1I=B!S='EL93TS1"=M87)G
M:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^)B,Q-C`[#0H@("`@
M/"]D:78^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$<FEG:'0@<W1Y;&4]
M,T0G8F]R9&5R+71O<#H@,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/"]T<CX-"B`@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M(#QT9#X-"B`@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E
M>'0M:6YD96YT.BTQ-7!X)SY/<'1I;VYS(&]U='-T86YD:6YG(&%T($IU;F4F
M(S$V,#LS,"P@,C`Q,0T*("`@(#PO9&EV/CPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$
M<FEG:'0^,RPU-#,L-3(Y/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI9VX],T1L969T/B9N8G-P
M.R0\+W1D/@T*("`@(#QT9"!A;&EG;CTS1')I9VAT/C,N-S0\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG;CTS1')I9VAT/C8N.34\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG;CTS1')I9VAT/C@R
M.#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/"]T<CX-"B`@("`\
M='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q<'@G/@T*("`@(#QT9#X-"B`@("`\
M9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ
M-7!X)SXF(S$V,#L-"B`@("`\+V1I=CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI
M9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`S<'@@9&]U8FQE(",P
M,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/"]T<CX-"B`@("`\='(@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0Z("-C8V5E9F8G/@T*
M("`@(#QT9#X-"B`@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[
M('1E>'0M:6YD96YT.BTQ-7!X)SY5;G9E<W1E9"!A="!*=6YE)B,Q-C`[,S`L
M(#(P,3$-"B`@("`\+V1I=CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG;CTS1')I9VAT/CDV
M."PP,C0\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@
M("`@/'1D(&%L:6=N/3-$<FEG:'0^,2XX,SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^."XW-3PO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^,34S/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT<B!S='EL93TS
M1"=F;VYT+7-I>F4Z(#%P>"<^#0H@("`@/'1D/@T*("`@(#QD:78@<W1Y;&4]
M,T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/B8C,38P
M.PT*("`@(#PO9&EV/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT<B!V86QI9VX],T1B;W1T
M;VT^#0H@("`@/'1D/@T*("`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z
M,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/E9E<W1E9"!A;F0@97AE<F-I<V%B
M;&4@870@2G5N928C,38P.S,P+"`R,#$Q#0H@("`@/"]D:78^/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@86QI9VX],T1R:6=H=#XR+#4W-2PU,#4\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG;CTS
M1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^-"XT
M-3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG
M:'0^-BXR-SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N
M/3-$<FEG:'0^-C<U/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M+W1R/@T*("`@(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#%P>"<^#0H@("`@
M/'1D/@T*("`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X
M="UI;F1E;G0Z+3$U<'@G/B8C,38P.PT*("`@(#PO9&EV/CPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS
M<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#-P
M>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*
M("`@(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^#0H@("`@/"]T86)L93X-"B`@
M("`\+V1I=CX-"B`@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD96YT.B`X
M)2<^05-#(#<Q."!R97%U:7)E<R!C;VUP96YS871I;VX@97AP96YS92!A<W-O
M8VEA=&5D('=I=&@@<VAA<F4M8F%S960@87=A<F1S('1O(&)E(')E8V]G;FEZ
M960@;W9E<@T*("`@('1H92!R97%U:7-I=&4@<V5R=FEC92!P97)I;V0L('=H
M:6-H(&9O<B!T:&4@0V]M<&%N>2!I<R!T:&4@<&5R:6]D(&)E='=E96X@=&AE
M(&=R86YT(&1A=&4@86YD('1H90T*("`@(&1A=&4@=&AE(&%W87)D('9E<W1S
M(&]R(&)E8V]M97,@97AE<F-I<V%B;&4N($UO<W0@;V8@=&AE(&%W87)D<R!G
M<F%N=&5D(&)Y('1H92!#;VUP86YY("AA;F0@<W1I;&P-"B`@("!O=71S=&%N
M9&EN9RDL('9E<W0@<F%T86)L>2!O=F5R(&9O=7(@>65A<G,L('=I=&@@,2\T
M(&]F('1H92!A=V%R9"!V97-T:6YG(&]N92!Y96%R(&9R;VT@=&AE(&1A=&4@
M;V8-"B`@("!G<F%N="!A;F0@,2\T."!O9B!T:&4@87=A<F0@=F5S=&EN9R!E
M86-H(&UO;G1H('1H97)E869T97(N($AO=V5V97(L(&-E<G1A:6X@87=A<F1S
M(&UA9&4@=&\-"B`@("!E>&5C=71I=F4@;V9F:6-E<G,@=F5S="!O=F5R('1H
M<F5E('1O(&9I=F4@>65A<G,L(&1E<&5N9&EN9R!O;B!T:&4@=&5R;7,@;V8@
M=&AE:7(@96UP;&]Y;65N="!W:71H#0H@("`@=&AE($-O;7!A;GDN($EN(&%D
M9&ET:6]N+"!R96-E;G0@87=A<F1S(&UA9&4@=&\@;W1H97(@96UP;&]Y965S
M('9E<W0@<F%T86)L>2!O=F5R(&9O=7(@>65A<G,L('=I=&@-"B`@("`Q+S0X
M(&]F('1H92!A=V%R9"!V97-T:6YG(&5A8V@@;6]N=&@N#0H@("`@/"]D:78^
M#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@."4G/D5F9F5C
M=&EV92!*86YU87)Y)B,Q-C`[,2P@,C`P-BP@=&AE($-O;7!A;GD@96QE8W1E
M9"!T;R!R96-O9VYI>F4@86QL('-H87)E+6)A<V5D(&%W87)D<R!I<W-U960-
M"B`@("!A9G1E<B!T:&4@861O<'1I;VX@;V8@05-#(#<Q."!U;F1E<B!T:&4@
M<W1R86EG:'0M;&EN92!A='1R:6)U=&EO;B!M971H;V0N($%30R`W,3@@<F5Q
M=6ER97,-"B`@("!F;W)F96ET=7)E<R!T;R!B92!E<W1I;6%T960@870@=&AE
M('1I;64@;V8@9W)A;G0@86YD(')E=FES960L(&EF(&YE8V5S<V%R>2P@:6X@
M<W5B<V5Q=65N="!P97)I;V1S#0H@("`@:68@86-T=6%L(&9O<F9E:71U<F5S
M(&1I9F9E<B!F<F]M('1H;W-E(&5S=&EM871E<RX@5&AI<R!A;F%L>7-I<R!I
M<R!E=F%L=6%T960@<75A<G1E<FQY(&%N9"!T:&4-"B`@("!F;W)F96ET=7)E
M(')A=&4@861J=7-T960@87,@;F5C97-S87)Y+B!5;'1I;6%T96QY+"!T:&4@
M86-T=6%L(&5X<&5N<V4@<F5C;V=N:7IE9"!O=F5R('1H92!V97-T:6YG#0H@
M("`@<&5R:6]D(&ES(&)A<V5D(&]N(&]N;'D@=&AO<V4@<VAA<F5S('1H870@
M=F5S="X-"B`@("`\+V1I=CX-"B`@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E>'0M
M:6YD96YT.B`X)2<^5&AE($-O;7!A;GD@=7-E9"!T:&4@0FQA8VLM4V-H;VQE
M<R!O<'1I;VXM<')I8VEN9R!M;V1E;"!W:71H('1H92!F;VQL;W=I;F<@87-S
M=6UP=&EO;G,@9F]R#0H@("`@<W1O8VL@;W!T:6]N(&=R86YT<R!T;R!E;7!L
M;WEE97,@86YD(&1I<F5C=&]R<R!F;W(@=&AE('-I>"!M;VYT:',@96YD960@
M2G5N928C,38P.S,P+"`R,#$P(&%N9"`R,#$Q.@T*("`@(#PO9&EV/@T*("`@
M(#QD:78@86QI9VX],T1C96YT97(^#0H@("`@/'1A8FQE('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<@8V5L;'-P86-I;F<]
M,T0P(&)O<F1E<CTS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-
M"B`@("`\(2TM($)E9VEN(%1A8FQE($AE860@+2T^#0H@("`@/'1R('9A;&EG
M;CTS1&)O='1O;3X-"B`@("`\=&0@=VED=&@],T0W,B4^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@=VED=&@],T0S)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T
M:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$.24^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!W:61T:#TS1#,E/B8C,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$,24^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@=VED=&@],T0Y)3XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@/"]T<CX-"B`@
M("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)R!V86QI9VX],T1B;W1T
M;VT^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS
M<&%N/3-$-CX\8CY&;W(@=&AE('-I>"!M;VYT:',\+V(^/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT<B!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0G('9A;&EG;CTS1&)O='1O;3X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0V('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\8CYE;F1E9"!*
M=6YE(#,P+#PO8CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#PO
M='(^#0H@("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT
M97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O
M;&ED(",P,#`P,#`G/CQB/C(P,3`\+V(^/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\8CXR,#$Q/"]B/CPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/"]T<CX-"B`@("`\(2TM
M($5N9"!486)L92!(96%D("TM/@T*("`@(#PA+2T@0F5G:6X@5&%B;&4@0F]D
M>2`M+3X-"B`@("`\='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG
M<F]U;F0Z("-C8V5E9F8G/@T*("`@(#QT9#X-"B`@("`\9&EV('-T>6QE/3-$
M)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY%>'!E8W1E
M9"!T97)M#0H@("`@/"]D:78^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@8V]L<W!A;CTS1#,@86QI9VX],T1C96YT97(^-2`F(S@R,3$[
M(#99<G,\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS
M<&%N/3-$,R!A;&EG;CTS1&-E;G1E<CXU("8C.#(Q,3L@-EER<SPO=&0^#0H@
M("`@/"]T<CX-"B`@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@(#QT9#X-
M"B`@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD
M96YT.BTQ-7!X)SY2:7-K(&9R964@:6YT97)E<W0@<F%T90T*("`@(#PO9&EV
M/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CXR+C,W("8C.#(Q
M,3L@,BXY-B4\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/C$N-#<@)B,X,C$Q
M.R`R+C(Y)3PO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\
M+W1D/@T*("`@(#PO='(^#0H@("`@/'1R('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=B86-K9W)O=6YD.B`C8V-E969F)SX-"B`@("`\=&0^#0H@("`@/&1I
M=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P
M>"<^17AP96-T960@=F]L871I;&ET>0T*("`@(#PO9&EV/CPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CXY,"`F(S@R,3$[(#$P,"4\+W1D/@T*
M("`@(#QT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M8V5N=&5R(&-O;'-P86X],T0R/CDS("8C.#(Q,3L@.3DE/"]T9#X-"B`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H@("`@/"]T<CX-"B`@
M("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@(#QT9#X-"B`@("`\9&EV('-T
M>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY%
M>'!E8W1E9"!D:79I9&5N9"!Y:65L9"!O=F5R(&5X<&5C=&5D('1E<FT-"B`@
M("`\+V1I=CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!N
M;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(^)B,X
M,C$R.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E
M<B!C;VQS<&%N/3-$,CXF(S@R,3([/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\+W1R/@T*("`@(#QT<B!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G8F%C:V=R;W5N9#H@(V-C965F9B<^#0H@("`@/'1D/@T*("`@(#QD:78@
M<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G
M/E)E<W5L=&EN9R!W96EG:'1E9"!A=F5R86=E(&=R86YT(&9A:7(-"B`@("!V
M86QU90T*("`@(#PO9&EV/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N
M/3-$,CXF;F)S<#LD,2XX,#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CXF;F)S<#LD,2XQ-3PO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/"]T<CX-"B`@("`\(2TM($5N9"!4
M86)L92!";V1Y("TM/@T*("`@(#PO=&%B;&4^#0H@("`@/"]D:78^#0H@("`@
M/"$M+2!&;VQI;R`M+3X-"B`@("`\(2TM("]&;VQI;R`M+3X-"B`@("`\+V1I
M=CX-"B`@("`\(2TM(%!!1T5"4D5!2R`M+3X-"B`@("`\9&EV('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RQ4:6UE<RQS97)I9CL@
M;6%R9VEN+6QE9G0Z(#!I;CL@)SX-"B`@("`\9&EV(&%L:6=N/3-$;&5F="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E
M>'0M:6YD96YT.B`T)2<^5&AE<F4@=V5R92`Q.3DL-3`P(&]P=&EO;G,@9W)A
M;G1E9"!D=7)I;F<@=&AE('-I>"!M;VYT:',@96YD960@2G5N928C,38P.S,P
M+"`R,#$Q+B!&;W(@9W)A;G1S(&UA9&4-"B`@("!D=7)I;F<@=&AE('-I>"!M
M;VYT:',@96YD960@2G5N928C,38P.S,P+"`R,#$P(&%N9"!*=6YE)B,Q-C`[
M,S`L(#(P,3$L('1H92!E>'!E8W1E9"!T97)M(&%S<W5M<'1I;VX@=V%S#0H@
M("`@97-T:6UA=&5D('5S:6YG('!A<W0@:&ES=&]R>2!O9B!E87)L>2!E>&5R
M8VES92!B96AA=FEO<B!A;F0@97-T:6UA=&5D(&5X<&5C=&%T:6]N<R!O9B!F
M=71U<F4-"B`@("!E>&5R8VES92!B96AA=FEO<BX@4W1A<G1I;F<@=VET:"!T
M:&4@1&5C96UB97(F(S$V,#LR,#$P(&%N;G5A;"!G<F%N=',@=&\@=&AE($-O
M;7!A;GDF(S@R,3<[<R!E;7!L;WEE97,L('1H90T*("`@($-O;7!A;GD@<F5L
M:65D(&5X8VQU<VEV96QY(&]N(&ET<R!H:7-T;W)I8V%L('9O;&%T:6QI='D@
M87,@86X@:6YP=70@=&\@=&AE(&]P=&EO;B!P<FEC:6YG(&UO9&5L(&%S#0H@
M("`@=&AE($-O;7!A;GDF(S@R,3<[<R!M86YA9V5M96YT(&)E;&EE=F5S('1H
M870@=&AI<PT*("`@(')A=&4@=VEL;"!B92!R97!R97-E;G1A=&EV92!O9B!F
M=71U<F4@=F]L871I;&ET>2!O=F5R('1H92!E>'!E8W1E9"!T97)M(&]F('1H
M92!O<'1I;VYS+B!0<FEO<@T*("`@('1O($1E8V5M8F5R)B,Q-C`[,C`Q,"P@
M8F5C875S92!T:&4@0V]M<&%N>2!H860@8F5E;B!P=6)L:6-L>2!T<F%D960@
M9F]R(&$@;&EM:71E9"!P97)I;V0L('1H92!E>'!E8W1E9`T*("`@('9O;&%T
M:6QI='D@87-S=6UP=&EO;B!W87,@8F%S960@;VX@=&AE(&AI<W1O<FEC86P@
M=F]L871I;&ET>2!O9B!P965R(&-O;7!A;FEE<R!O=F5R('1H92!E>'!E8W1E
M9`T*("`@('1E<FT@;V8@=&AE(&]P=&EO;B!A=V%R9',N#0H@("`@/"]D:78^
M#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@-"4G/D5S=&EM
M871E<R!O9B!P<F4M=F5S=&EN9R!O<'1I;VX@9F]R9F5I='5R97,@87)E(&)A
M<V5D(&]N('1H92!#;VUP86YY)B,X,C$W.W,@97AP97)I96YC92X@1F]R#0H@
M("`@;W5T<W1A;F1I;F<@;W!T:6]N<RP@=&AE($-O;7!A;GD@=7-E<R!A(&9O
M<F9E:71U<F4@<F%T92!O9B`P("8C.#(Q,CL@-3`E(&1E<&5N9&EN9R!O;B!W
M:&5N(&%N9"!T;R!W:&]M#0H@("`@=&AE(&]P=&EO;G,@87)E(&=R86YT960N
M(%1H92!#;VUP86YY(&%D:G5S=',@:71S(&5S=&EM871E(&]F(&9O<F9E:71U
M<F5S(&]V97(@=&AE(')E<75I<VET92!S97)V:6-E#0H@("`@<&5R:6]D(&)A
M<V5D(&]N('1H92!E>'1E;G0@=&\@=VAI8V@@86-T=6%L(&9O<F9E:71U<F5S
M(&1I9F9E<BP@;W(@87)E(&5X<&5C=&5D('1O(&1I9F9E<BP@9G)O;2!S=6-H
M#0H@("`@97-T:6UA=&5S+B!#:&%N9V5S(&EN(&5S=&EM871E9"!F;W)F96ET
M=7)E<R!A<F4@<F5C;V=N:7IE9"!T:')O=6=H(&$@8W5M=6QA=&EV92!A9&IU
M<W1M96YT(&EN('1H90T*("`@('!E<FEO9"!O9B!C:&%N9V4@86YD(&UA>2!I
M;7!A8W0@=&AE(&%M;W5N="!O9B!C;VUP96YS871I;VX@97AP96YS92!T;R!B
M92!R96-O9VYI>F5D(&EN(&9U='5R90T*("`@('!E<FEO9',N#0H@("`@/"]D
M:78^#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@-"4G/E1H
M92!W96EG:'1E9"!A=F5R86=E(')I<VLM9G)E92!I;G1E<F5S="!R871E(')E
M<')E<V5N=',@:6YT97)E<W0@<F%T92!F;W(@=')E87-U<GD@8V]N<W1A;G0-
M"B`@("!M871U<FET:65S('!U8FQI<VAE9"!B>2!T:&4@1F5D97)A;"!297-E
M<G9E($)O87)D+B!)9B!T:&4@=&5R;2!O9B!A=F%I;&%B;&4@=')E87-U<GD@
M8V]N<W1A;G0-"B`@("!M871U<FET>2!I;G-T<G5M96YT<R!I<R!N;W0@97%U
M86P@=&\@=&AE(&5X<&5C=&5D('1E<FT@;V8@86X@96UP;&]Y964@;W!T:6]N
M+"!#>6-L86-E;"!U<V5S('1H90T*("`@('=E:6=H=&5D(&%V97)A9V4@;V8@
M=&AE('1W;R!&961E<F%L(%)E<V5R=F4@<V5C=7)I=&EE<R!C;&]S97-T('1O
M('1H92!E>'!E8W1E9"!T97)M(&]F('1H92!E;7!L;WEE90T*("`@(&]P=&EO
M;BX-"B`@("`\+V1I=CX-"B`@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD
M96YT.B`T)2<^1'5R:6YG('1H92!S:7@@;6]N=&AS(&5N9&5D($IU;F4F(S$V
M,#LS,"P@,C`Q,2P@-BPV,S@@<W1O8VL@;W!T:6]N<R!W97)E(&5X97)C:7-E
M9"!R97-U;'1I;F<@:6X-"B`@("!A<'!R;WAI;6%T96QY("9N8G-P.R0S+#`P
M,"!O9B!C87-H('!R;V-E961S('1O('1H92!#;VUP86YY+B!$=7)I;F<@=&AE
M('-I>"!M;VYT:',@96YD960@2G5N928C,38P.S,P+"`R,#$P+`T*("`@('1H
M97)E('=E<F4@,3(T+#(W-R!S=&]C:R!O<'1I;VYS(&5X97)C:7-E9"!F;W(@
M<')O8V5E9',@;V8@87!P<F]X:6UA=&5L>2`F;F)S<#LD,"XQ)B,Q-C`[;6EL
M;&EO;BX@07,@=&AE#0H@("`@0V]M<&%N>2!P<F5S96YT;'D@:&%S('1A>"!L
M;W-S(&-A<G)Y(&9O<G=A<F1S(&9R;VT@<')I;W(@<&5R:6]D<R!A;F0@97AP
M96-T<R!T;R!I;F-U<B!T87@@;&]S<V5S(&EN#0H@("`@,C`Q,2P@=&AE($-O
M;7!A;GD@:7,@;F]T(&%B;&4@=&\@8F5N969I="!F<F]M('1H92!D961U8W1I
M;VX@9F]R(&5X97)C:7-E9"!S=&]C:R!O<'1I;VYS(&EN('1H90T*("`@(&-U
M<G)E;G0@<F5P;W)T:6YG('!E<FEO9"X-"B`@("`\+V1I=CX-"B`@("`\9&EV
M(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I
M;BUT;W`Z(#$P<'0G/CQI/E)E<W1R:6-T960@4W1O8VL\+VD^#0H@("`@/"]D
M:78^#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@-"4G/DEN
M($YO=F5M8F5R)B,Q-C`[,C`P."P@=&AE($-O;7!A;GD@:7-S=65D(')E<W1R
M:6-T960@8V]M;6]N('-T;V-K('1O(&%N(&5M<&QO>65E('-U8FIE8W0@=&\@
M8V5R=&%I;@T*("`@(&9O<F9E:71U<F4@<')O=FES:6]N<RX@4W!E8VEF:6-A
M;&QY+"!O;F4@<75A<G1E<B!O9B!T:&4@87=A<F0@=F5S=&5D(&]N92!Y96%R
M(&9R;VT@=&AE(&1A=&4@;V8-"B`@("!G<F%N="!A;F0@,2\T."!O9B!T:&4@
M87=A<F0@969F96-T:79E;'D@=F5S=',@96%C:"!M;VYT:"!T:&5R96%F=&5R
M+B!4:&ES(')E<W1R:6-T960@<W1O8VL@9W)A;G0-"B`@("!I<R!A8V-O=6YT
M960@9F]R(&%T(&9A:7(@=F%L=64@870@=&AE(&1A=&4@;V8@9W)A;G0@86YD
M(&%N(&5X<&5N<V4@:7,@<F5C;V=N:7IE9"!D=7)I;F<@=&AE('9E<W1I;F<-
M"B`@("!T97)M+B!3=6UM87)I>F5D(&EN9F]R;6%T:6]N(&9O<B!T:&4@<F5S
M=')I8W1E9"!S=&]C:R!G<F%N="!F;W(@=&AE('-I>"!M;VYT:',@96YD960@
M2G5N928C,38P.S,P+"`R,#$Q#0H@("`@:7,@87,@9F]L;&]W<SH-"B`@("`\
M+V1I=CX-"B`@("`\9&EV(&%L:6=N/3-$8V5N=&5R/@T*("`@(#QT86)L92!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G(&-E
M;&QS<&%C:6YG/3-$,"!B;W)D97(],T0P(&-E;&QP861D:6YG/3-$,"!W:61T
M:#TS1#$P,"4^#0H@("`@/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*("`@
M(#QT<B!V86QI9VX],T1B;W1T;VT^#0H@("`@/'1D('=I9'1H/3-$-S(E/B8C
M,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$,R4^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS
M1#DE/B8C,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@=VED=&@],T0S)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W
M:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$.24^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@
M(#PO='(^#0H@("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@
M8V]L<W!A;CTS1#(^/&(^5V5I9VAT960@079E<F%G92!'<F%N=#PO8CX\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#PO='(^#0H@("`@/'1R('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB
M/E)E<W1R:6-T960@4W1O8VL\+V(^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\8CY$871E(%9A;'5E(%!E
M<B!3:&%R93PO8CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#PO
M='(^#0H@("`@/'1R/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#PO='(^
M#0H@("`@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X-"B`@("`\(2TM($)E9VEN
M(%1A8FQE($)O9'D@+2T^#0H@("`@/'1R('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=B86-K9W)O=6YD.B`C8V-E969F)SX-"B`@("`\=&0^#0H@("`@/&1I
M=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P
M>"<^3F]N+79E<W1E9"!A="!$96-E;6)E<B8C,38P.S,Q+"`R,#$P#0H@("`@
M/"]D:78^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@86QI9VX],T1R:6=H=#XR,RPY-30\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@/'1D(&%L:6=N
M/3-$<FEG:'0^,"XT-#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/"]T<CX-"B`@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@(#QT9#X-"B`@
M("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT
M.BTQ-7!X)SY697-T960-"B`@("`\+V1I=CX\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1L969T
M/B8C,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^*#8L,C4R/"]T
M9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P/BD\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^
M#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^,"XT-#PO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/"]T<CX-"B`@("`\='(@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)V)A8VMG<F]U;F0Z("-C8V5E9F8G/@T*("`@(#QT9#X-"B`@
M("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT
M.BTQ-7!X)SY.;VXM=F5S=&5D(&%T($IU;F4F(S$V,#LS,"P@,C`Q,0T*("`@
M(#PO9&EV/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^,3<L-S`R/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@86QI9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@(#QT9"!A;&EG
M;CTS1')I9VAT/C`N-#0\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#PO='(^#0H@("`@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X-"B`@("`\+W1A
M8FQE/@T*("`@(#PO9&EV/@T*("`@(#PA+2T@1F]L:6\@+2T^#0H@("`@/"$M
M+2`O1F]L:6\@+2T^#0H@("`@/"]D:78^#0H@("`@/"$M+2!004=%0E)%04L@
M+2T^#0H@("`@/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE
M=R!2;VUA;B<L5&EM97,L<V5R:68[(&UA<F=I;BUL969T.B`P:6X[("<^#0H@
M("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!M87)G:6XM=&]P.B`Q,'!T)SX\:3Y297-T<FEC=&5D(%-T;V-K(%5N:71S
M/"]I/@T*("`@(#PO9&EV/@T*("`@(#QD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P=#L@=&5X="UI
M;F1E;G0Z(#0E)SY297-T<FEC=&5D('-T;V-K('5N:71S('=E<F4@:7-S=65D
M('1O('-E;FEO<B!E>&5C=71I=F5S(&]F('1H92!#;VUP86YY(&EN($YO=F5M
M8F5R)B,Q-C`[,C`P."P@=VAI8V@-"B`@("!E;G1I=&QE('1H92!H;VQD97)S
M('1O(')E8V5I=F4@82!S<&5C:69I960@;G5M8F5R(&]F('-H87)E<R!O9B!T
M:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!O=F5R('1H90T*("`@
M(&9O=7(@>65A<B!V97-T:6YG('1E<FTN($$@<F5S=')I8W1E9"!S=&]C:R!U
M;FET(&=R86YT(&ES(&%C8V]U;G1E9"!F;W(@870@9F%I<B!V86QU92!A="!T
M:&4@9&%T90T*("`@(&]F(&=R86YT('=H:6-H(&ES(&5Q=6EV86QE;G0@=&\@
M=&AE(&UA<FME="!P<FEC92!O9B!A('-H87)E(&]F('1H92!#;VUP86YY)B,X
M,C$W.W,@8V]M;6]N('-T;V-K+"!A;F0@86X-"B`@("!E>'!E;G-E(&ES(')E
M8V]G;FEZ960@9'5R:6YG('1H92!V97-T:6YG('1E<FTN(%1H97)E('=E<F4@
M;F\@<F5S=')I8W1E9"!S=&]C:R!U;FET(&=R86YT<R!P<FEO<B!T;PT*("`@
M($YO=F5M8F5R)B,Q-C`[,C`P."X@4W5M;6%R:7IE9"!I;F9O<FUA=&EO;B!F
M;W(@<F5S=')I8W1E9"!S=&]C:R!G<F%N=',@9F]R('1H92!S:7@@;6]N=&AS
M(&5N9&5D($IU;F4F(S$V,#LS,"P-"B`@("`R,#$Q(&ES(&%S(&9O;&QO=W,Z
M#0H@("`@/"]D:78^#0H@("`@/&1I=B!A;&EG;CTS1&-E;G1E<CX-"B`@("`\
M=&%B;&4@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L
M969T)R!C96QL<W!A8VEN9STS1#`@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS
M1#`@=VED=&@],T0Q,#`E/@T*("`@(#PA+2T@0F5G:6X@5&%B;&4@2&5A9"`M
M+3X-"B`@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@(#QT9"!W:61T:#TS
M1#<R)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS1#,E/B8C,38P.SPO
M=&0^#0H@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M=VED=&@],T0Y)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS1#$E/B8C
M,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$,R4^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS
M1#DE/B8C,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T
M9#X-"B`@("`\+W1R/@T*("`@(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0G('9A;&EG;CTS1&)O='1O;3X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M8V5N=&5R(&-O;'-P86X],T0R/CQB/E=E:6=H=&5D($%V97)A9V4@1W)A;G0\
M+V(^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@
M(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G('9A;&EG;CTS1&)O='1O
M;3X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P
M86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P
M,#`P)SX\8CY297-T<FEC=&5D(%-T;V-K(%5N:71S/"]B/CPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,B!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P,"<^/&(^
M1&%T92!686QU92!097(@4VAA<F4\+V(^/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT<CX-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\+W1R/@T*("`@(#PA+2T@16YD(%1A8FQE($AE860@+2T^#0H@
M("`@/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*("`@(#QT<B!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G8F%C:V=R;W5N9#H@(V-C965F9B<^#0H@("`@
M/'1D/@T*("`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X
M="UI;F1E;G0Z+3$U<'@G/DYO;BUV97-T960@870@1&5C96UB97(F(S$V,#LS
M,2P@,C`Q,`T*("`@(#PO9&EV/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^
M,S4L.3,Q/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@86QI9VX],T1L969T/B9N8G-P.R0\+W1D/@T*
M("`@(#QT9"!A;&EG;CTS1')I9VAT/C`N-#0\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#PO='(^#0H@("`@/'1R('9A;&EG;CTS1&)O='1O;3X-
M"B`@("`\=&0^#0H@("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X
M.R!T97AT+6EN9&5N=#HM,35P>"<^5F5S=&5D#0H@("`@/"]D:78^/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M(&%L:6=N/3-$;&5F=#XF(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG;CTS1')I
M9VAT/B@Y+#,W.#PO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<#XI/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI9VX],T1L969T
M/B9N8G-P.R0\+W1D/@T*("`@(#QT9"!A;&EG;CTS1')I9VAT/C`N-#0\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#PO='(^#0H@("`@/'1R('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD.B`C8V-E969F)SX-
M"B`@("`\=&0^#0H@("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X
M.R!T97AT+6EN9&5N=#HM,35P>"<^3F]N+79E<W1E9"!A="!*=6YE)B,Q-C`[
M,S`L(#(P,3$-"B`@("`\+V1I=CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG;CTS1')I9VAT
M/C(V+#4U,SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-
M"B`@("`\=&0@86QI9VX],T1R:6=H=#XP+C0T/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#PA+2T@16YD(%1A8FQE($)O9'D@
M+2T^#0H@("`@/"]T86)L93X-"B`@("`\+V1I=CX-"B`@("`\+V1I=CX-"B`@
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R.38Q
M,#0Q.5]E93<Q7S0X.3A?8CDQ85\W.&1A-F9C-C4P93@-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO,CDV,3`T,3E?964W,5\T.#DX7V(Y,6%?-SAD
M839F8S8U,&4X+U=O<FMS:&5E=',O4VAE970Q,BYH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13)(
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;6UI=&UE;G1S(&%N9"!#;VYT
M:6YG96YC:65S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU
M;BX@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#3TU-251-14Y44R!!3D0@0T].5$E.1T5.0TE%4SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^#0H@("`@/"$M+41/0U194$4@:'1M;"!0
M54),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.
M(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A
M;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`@/"$M+2!"96=I;B!";&]C:R!486=G
M960@3F]T92`W("T@=7,M9V%A<#I#;VUM:71M96YT<T%N9$-O;G1I;F=E;F-I
M97-$:7-C;&]S=7)E5&5X=$)L;V-K+2T^#0H@("`@/&1I=B!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L5&EM97,L<V5R:68[(&UA
M<F=I;BUL969T.B`P:6X[("<^#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SX\8CXW
M+B!#3TU-251-14Y44R!!3D0@0T].5$E.1T5.0TE%4SPO8CX-"B`@("`\+V1I
M=CX-"B`@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/CQB/CQI/DQI8V5N<VEN9R!!9W)E
M96UE;G1S/"]I/CPO8CX-"B`@("`\+V1I=CX-"B`@("`\9&EV(&%L:6=N/3-$
M;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P
M<'0[('1E>'0M:6YD96YT.B`X)2<^5&AE($-O;7!A;GD@:&%S(&5N=&5R960@
M:6YT;R!L:6-E;G-I;F<@86=R965M96YT<R!W:71H(&%C861E;6EC(&%N9"!R
M97-E87)C:"!O<F=A;FEZ871I;VYS+@T*("`@(%5N9&5R('1H92!T97)M<R!O
M9B!T:&5S92!A9W)E96UE;G1S+"!T:&4@0V]M<&%N>2!H87,@<F5C96EV960@
M;&EC96YS97,@=&\@=&5C:&YO;&]G>2!A;F0@<&%T96YT#0H@("`@87!P;&EC
M871I;VYS+B!4:&4@0V]M<&%N>2!I<R!R97%U:7)E9"!T;R!P87D@<F]Y86QT
M:65S(&]N(&9U='5R92!S86QE<R!O9B!P<F]D=6-T(&5M<&QO>6EN9R!T:&4-
M"B`@("!T96-H;F]L;V=Y(&]R(&9A;&QI;F<@=6YD97(@8VQA:6US(&]F('!A
M=&5N="!A<'!L:6-A=&EO;G,N#0H@("`@/"]D:78^#0H@("`@/&1I=B!A;&EG
M;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P
M.B`Q,'!T.R!T97AT+6EN9&5N=#H@."4G/E!U<G-U86YT('1O('1H92!$86EI
M8VAI(%-A;FMY;R!L:6-E;G-E('5N9&5R('=H:6-H('1H92!#;VUP86YY(&QI
M8V5N<V5S(&-E<G1A:6X@<&%T96YT(')I9VAT<PT*("`@(&9O<B!S87!A8VET
M86)I;F4L(&ET<R!L96%D(&1R=6<@8V%N9&ED871E+"!T:&4@0V]M<&%N>2!I
M<R!U;F1E<B!A;B!O8FQI9V%T:6]N('1O('5S92!R96%S;VYA8FQE#0H@("`@
M96YD96%V;W)S('1O(&1E=F5L;W`@82!P<F]D=6-T(&%N9"!O8G1A:6X@<F5G
M=6QA=&]R>2!A<'!R;W9A;"!T;R!S96QL(&$@<')O9'5C="!A;F0@:&%S(&%G
M<F5E9"!T;PT*("`@('!A>2!$86EI8VAI(%-A;FMY;R!A;B!U<"UF<F]N="!F
M964L(')E:6UB=7)S96UE;G0@9F]R($1A:6EC:&D@4V%N:WEO)B,X,C$W.W,@
M96YU;65R871E9"!E>'!E;G-E<RP-"B`@("!M:6QE<W1O;F4@<&%Y;65N=',@
M86YD(')O>6%L=&EE<R!O;B!A(&-O=6YT<GDM8GDM8V]U;G1R>2!B87-I<RX@
M56YD97(@=&AI<R!A9W)E96UE;G0L(&%G9W)E9V%T90T*("`@(&UI;&5S=&]N
M92!P87EM96YT<R!T;W1A;&EN9R`F;F)S<#LD,3$N-R8C,38P.VUI;&QI;VX@
M8V]U;&0@8F4@<&%Y86)L92!S=6)J96-T('1O(&%C:&EE=F5M96YT(&]F(&%L
M;"!T:&4-"B`@("!S<&5C:69I8R!C;VYT<F%C='5A;"!M:6QE<W1O;F5S(&%N
M9"!T:&4@0V]M<&%N>28C.#(Q-SMS(&1E8VES:6]N('1O(&-O;G1I;G5E('=I
M=&@@=&AE<V4@<')O:F5C=',N(%1H90T*("`@('5P+69R;VYT(&9E92!A;F0@
M8V5R=&%I;B!P87-T(')E:6UB=7)S96UE;G1S(&AA=F4@8F5E;B!P86ED(&%N
M9"P@87,@82!R97-U;'0@;V8@=&AE(%-%04U,15-3('1R:6%L#0H@("`@96YT
M97)I;F<@4&AA<V4@,R!D=7)I;F<@=&AE(&9I<G-T('%U87)T97(@;V8@,C`Q
M,2P@)FYB<W`[)#$N-B8C,38P.VUI;&QI;VX@=V%S('!A:60@:6X@2G5L>28C
M,38P.S(P,3$N($9O;&QO=VEN9PT*("`@('1H97-E(&UI;&5S=&]N92!P87EM
M96YT<RP@82!F=7)T:&5R("9N8G-P.R0Y+C,F(S$V,#MM:6QL:6]N(&EN(&%G
M9W)E9V%T92!M:6QE<W1O;F4@<&%Y;65N=',@8V]U;&0@8F4@<&%Y86)L92X-
M"B`@("!2;WEA;'1I97,@87)E('!A>6%B;&4@:6X@96%C:"!C;W5N=')Y(&9O
M<B!T:&4@=&5R;2!O9B!P871E;G0@<')O=&5C=&EO;B!I;B!T:&4@8V]U;G1R
M>2!O<B!F;W(@=&5N#0H@("`@>65A<G,@9F]L;&]W:6YG('1H92!F:7)S="!C
M;VUM97)C:6%L('-A;&4@;V8@;&EC96YS960@<')O9'5C=',@:6X@=&AE(&-O
M=6YT<GDL('=H:6-H979E<B!I<R!L871E<BX-"B`@("!2;WEA;'1I97,@87)E
M('!A>6%B;&4@;VX@;F5T('-A;&5S+B!.970@<V%L97,@87)E(&1E9FEN960@
M87,@=&AE(&=R;W-S(&%M;W5N="!I;G9O:6-E9"!B>2!T:&4-"B`@("!#;VUP
M86YY(&]R(&ET<R!A9F9I;&EA=&5S(&]R(&QI8V5N<V5E<RP@;&5S<R!D:7-C
M;W5N=',L(&-R961I=',L('1A>&5S+"!S:&EP<&EN9R!A;F0@8F%D(&1E8G0-
M"B`@("!L;W-S97,N(%1H92!A9W)E96UE;G0@97AT96YD<R!F<F]M(&ET<R!C
M;VUM96YC96UE;G0@9&%T92!T;R!T:&4@9&%T92!O;B!W:&EC:"!N;R!F=7)T
M:&5R(&%M;W5N=',-"B`@("!A<F4@;W=E9"!U;F1E<B!I="X@268@=&AE($-O
M;7!A;GD@=VES:&5S('1O(&%P<&]I;G0@82!T:&ER9"!P87)T>2!T;R!D979E
M;&]P(&]R(&-O;6UE<F-I86QI>F4@80T*("`@('-A<&%C:71A8FEN92UB87-E
M9"!P<F]D=6-T(&EN($IA<&%N+"!W:71H:6X@8V5R=&%I;B!L:6UI=&%T:6]N
M<RP@1&%I:6-H:2!386YK>6\@;75S="!B92!N;W1I9FEE9`T*("`@(&%N9"!G
M:79E;B!A(')I9VAT(&]F(&9I<G-T(')E9G5S86P@=&\@9&5V96QO<"!A;F0O
M;W(@8V]M;65R8VEA;&EZ92!I;B!*87!A;BX@26X@9V5N97)A;"P@=&AE#0H@
M("`@;&EC96YS92!M87D@8F4@=&5R;6EN871E9"!B>2!T:&4@0V]M<&%N>2!F
M;W(@=&5C:&YI8V%L+"!S8VEE;G1I9FEC+"!E9F9I8V%C>2P@<V%F971Y+"!O
M<B!C;VUM97)C:6%L#0H@("`@<F5A<V]N<R!O;B!S:7@@;6]N=&AS(&YO=&EC
M92P@;W(@='=E;'9E(&UO;G1H<RP@:68@869T97(@82!L875N8V@@;V8@82!S
M87!A8VET86)I;F4M8F%S960@<')O9'5C="P-"B`@("!O<B!B>2!E:71H97(@
M<&%R='D@9F]R(&UA=&5R:6%L(&1E9F%U;'0N($5F9F5C=&EV92!*=6QY)B,Q
M-C`[,3$L(#(P,3$L('1H92!L:6-E;G-E(&%G<F5E;65N="!W87,@86UE;F1E
M9`T*("`@('1O(&ER<F5V;V-A8FQY('=A:79E(&$@=&5R;6EN871I;VX@<FEG
M:'0@1&%I:6-H:2!386YK>6\@<&]S<V5S<V5D('5N9&5R(&$@<')O=FES:6]N
M(&]F('1H90T*("`@(&%G<F5E;65N="!T:&%T(')E<75I<F5D('1H92!#;VUP
M86YY('1O(&]B=&%I;B!R96=U;&%T;W)Y(&%P<')O=F%L('1O('-E;&P@<V%P
M86-I=&%B:6YE(&EN(&%T(&QE87-T#0H@("`@;VYE(&-O=6YT<GD@8GD@4V5P
M=&5M8F5R)B,Q-C`[,C`Q,2P@86YD(')E;&5A<V5S('1H92!#;VUP86YY(&9R
M;VT@86QL(&-L86EM<R!A;F0@;&EA8FEL:71Y(&]F(&%N>2!K:6YD#0H@("`@
M87)I<VEN9R!U;F1E<B!S=6-H('!R;W9I<VEO;BX@5&AE(&%M96YD;65N="!F
M=7)T:&5R('!R;W9I9&5S('1H870@=&AE(')O>6%L='D@9'5E(&9R;VT@=&AE
M($-O;7!A;GD-"B`@("!T;R!$86EI8VAI(%-A;FMY;R!O;B!F=71U<F4@;F5T
M('-A;&5S(&]F('-A<&%C:71A8FEN92!B92!I;F-R96%S960@8GD@82!P97)C
M96YT86=E(&)E='=E96X@,2XR-24-"B`@("!A;F0@,2XU,"4@9&5P96YD:6YG
M(&]N('1H92!L979E;"!O9B!N970@<V%L97,@;V8@<V%P86-I=&%B:6YE(')E
M86QI>F5D+@T*("`@(#PO9&EV/@T*("`@(#PA+2T@1F]L:6\@+2T^#0H@("`@
M/"$M+2`O1F]L:6\@+2T^#0H@("`@/"]D:78^#0H@("`@/"$M+2!004=%0E)%
M04L@+2T^#0H@("`@/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S
M($YE=R!2;VUA;B<L5&EM97,L<V5R:68[(&UA<F=I;BUL969T.B`P:6X[("<^
M#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SX\8CX\:3Y'=6%R86YT964\+VD^/"]B
M/@T*("`@(#PO9&EV/@T*("`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P=#L@=&5X="UI;F1E
M;G0Z(#@E)SY/;B!*=6QY)B,Q-C`[,C@L(#(P,#4@86YD(&%S(&%M96YD960@
M;VX@36%R8V@F(S$V,#LR-RP@,C`P-BP@0WEC;&%C96P@1W)O=7`@<&QC("@F
M(S@R,C`[1W)O=7`F(S@R,C$[*2!S:6=N960@80T*("`@(&-O;G9E<G1I8FQE
M($QO86X@3F]T92!);G-T<G5M96YT(&-O;G-T:71U=&EN9R!C;VYV97)T:6)L
M92!U;G-E8W5R960@;&]A;B!N;W1E<R`H=&AE("8C.#(R,#M,;V%N)B,X,C(Q
M.RD@86YD#0H@("`@96YT97)E9"!I;G1O(&$@1F%C:6QI='D@06=R965M96YT
M("@F(S@R,C`[06=R965M96YT)B,X,C(Q.RD@=VET:"!38V]T=&ES:"!%;G1E
M<G!R:7-E("@F(S@R,C`[4T4F(S@R,C$[*2P@87,@;&5N9&5R+"!W:&5R96)Y
M#0H@("`@4T4@<W5B<V-R:6)E9"!F;W(@)B,Q-C,[-28C,38P.VUI;&QI;VXL
M(&]R(&%P<')O>&EM871E;'D@)FYB<W`[)#DF(S$V,#MM:6QL:6]N(&%T('1H
M92!T:6UE+"!O9B!T:&4@8V]N=F5R=&EB;&4@;&]A;@T*("`@(&YO=&5S+B!4
M:&4@;&]A;B!W87,@<W5B<V5Q=65N=&QY(&-O;G9E<G1E9"!I;G1O(#$L,C,Q
M+#4R-R!P<F5F97)R960@1"!S:&%R97,@;V8@=&AE($=R;W5P(&EN#0H@("`@
M<V%T:7-F86-T:6]N(&]F(&%L;"!A;6]U;G1S(&]W960@8GD@1W)O=7`@=6YD
M97(@=&AE(&-O;G9E<G1I8FQE(&QO86X@;F]T97,N(%1H92!N=6UB97(@;V8@
M<')E9F5R<F5D#0H@("`@1"!S:&%R97,@=&AA="!312!R96-E:79E9"!W87,@
M8V%L8W5L871E9"!B>2!D:79I9&EN9R!T:&4@<')I;F-I<&%L(&%M;W5N="!O
M=71S=&%N9&EN9R!U;F1E<B!T:&4-"B`@("!L;V%N(&YO=&4@8GD@)B,Q-C,[
M-"XP-BX@5&AE('!R969E<G)E9"!$('-H87)E<R!W97)E(&5X8VAA;F=E9"!F
M;W(@<VAA<F5S(&EN(%AC>71E(%1H97)A<&EE<RP@26YC+B!O;@T*("`@($UA
M<F-H)B,Q-C`[,C<L(#(P,#8@87,@<&%R="!O9B!T:&4@=')A;G-A8W1I;VX@
M8F5T=V5E;B!88WET92!A;F0@0WEC;&%C96P@3&EM:71E9"X@2&]W979E<BP@
M4V-O='1I<V@-"B`@("!%;G1E<G!R:7-E(')E=&%I;F5D('1H92!A8FEL:71Y
M(&ET(&AA9"!U;F1E<B!T:&4@06=R965M96YT('1O(')E8V5I=F4@82!C87-H
M('!A>6UE;G0@<VAO=6QD('1H90T*("`@(')E<V5A<F-H(&]P97)A=&EO;G,@
M:6X@4V-O=&QA;F0@8F4@<VEG;FEF:6-A;G1L>2!R961U8V5D+B!4:&4@0V]M
M<&%N>2!H860@9W5A<F%N=&5E9"!A<'!R;WAI;6%T96QY#0H@("`@)B,Q-C,[
M-28C,38P.VUI;&QI;VXL('1H92!A;6]U;G0@<&]T96YT:6%L;'D@9'5E('1O
M(%-%+"!W:&EC:"!W:6QL(&)E(&-A;&-U;&%T960@87,@82!M87AI;75M(&]F
M("8C,38S.S4F(S$V,#MM:6QL:6]N#0H@("`@;&5S<R!T:&4@;6%R:V5T('9A
M;'5E(&]F('1H92!S:&%R97,@:&5L9"!B>2!312!A="!T:&4@=&EM92!O9B!A
M;GD@<VEG;FEF:6-A;G0@<F5D=6-T:6]N(&EN(')E<V5A<F-H#0H@("`@9F%C
M:6QI=&EE<RX-"B`@("`\+V1I=CX-"B`@("`\9&EV(&%L:6=N/3-$;&5F="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E
M>'0M:6YD96YT.B`X)2<^3VX@2G5N928C,38P.S(R+"`R,#`Y+"!T:&4@0V]M
M<&%N>2!A;65N9&5D('1H92!!9W)E96UE;G0@=VET:"!312`H=&AE("8C.#(R
M,#M!;65N9&UE;G0F(S@R,C$[*2P@:6X@;W)D97(@=&\-"B`@("!A;&QO=R!T
M:&4@0V]M<&%N>2!T;R!I;7!L96UE;G0@82!R961U8W1I;VX@;V8@=&AE($-O
M;7!A;GDF(S@R,3<[<R!R97-E87)C:"!O<&5R871I;VYS(&QO8V%T960@:6X@
M4V-O=&QA;F0-"B`@("!I;B!E>&-H86YG92!F;W(@=&AE('!A<G1I97,F(S@R
M,3<[(&%G<F5E;65N="!T;R!M;V1I9GD@=&AE('!A>6UE;G0@=&5R;7,@;V8@
M=&AE($%G<F5E;65N="!I;B!T:&4-"B`@("!P<FEN8VEP86P@86UO=6YT(&]F
M("8C,38S.S4F(S$V,#MM:6QL:6]N("AA<'!R;WAI;6%T96QY("9N8G-P.R0X
M+C`F(S$V,#MM:6QL:6]N(&%T($1E8V5M8F5R)B,Q-C`[,S$L(#(P,#DI+"!W
M:&EC:"!312!H860-"B`@("!P<F5V:6]U<VQY(&5N=&5R960@:6YT;R!W:71H
M('1H92!#;VUP86YY+B!4:&4@06=R965M96YT('!R;W9I9&5D(&9O<B!R97!A
M>6UE;G0@;V8@)B,Q-C,[-28C,38P.VUI;&QI;VX@:6X@=&AE#0H@("`@979E
M;G0@=&AE($-O;7!A;GD@<VEG;FEF:6-A;G1L>2!R961U8V5D(&ET<R!38V]T
M=&ES:"!R97-E87)C:"!O<&5R871I;VYS+B!0=7)S=6%N="!T;R!T:&4@=&5R
M;7,@;V8-"B`@("!T:&4@06UE;F1M96YT+"!I;B!A<W-O8VEA=&EO;B!W:71H
M($-Y8VQA8V5L)B,X,C$W.W,@;6%T97)I86P@<F5D=6-T:6]N(&EN('-T869F
M(&%T(&ET<R!38V]T=&ES:"!R97-E87)C:`T*("`@(&9A8VEL:71Y+"!T:&4@
M<&%R=&EE<R!A9W)E960@=&\@82!M;V1I9FEE9"!P87EM96YT(&]F("8C,38S
M.S$F(S$V,#MM:6QL:6]N("AA<'!R;WAI;6%T96QY("9N8G-P.R0Q+C<F(S$V
M,#MM:6QL:6]N(&%T#0H@("`@2G5N928C,38P.S(R+"`R,#`Y*2!P87EA8FQE
M(&EN('1W;R!E<75A;"!T<F%N8VAE<RX@3VX@2G5L>28C,38P.S$L(#(P,#DL
M('1H92!F:7)S="!I;G-T86QL;65N="!O9B`F(S$V,SLP+C4-"B`@("!M:6QL
M:6]N("AA<'!R;WAI;6%T96QY("9N8G-P.R0P+C@F(S$V,#MM:6QL:6]N*2!W
M87,@<&%I9"!A;F0@=&AE(')E;6%I;FEN9R!A;6]U;G0@;V8@)B,Q-C,[,"XU
M)B,Q-C`[;6EL;&EO;@T*("`@("AA<'!R;WAI;6%T96QY("9N8G-P.R0P+C@F
M(S$V,#MM:6QL:6]N*2!W87,@<&%I9"!O;B!*86YU87)Y)B,Q-C`[-BP@,C`Q
M,"X@26X@861D:71I;VXL('-H;W5L9"!A(&9U<G1H97(@<F5D=6-T:6]N#0H@
M("`@8F5L;W<@8W5R<F5N="!M:6YI;75M('-T869F(&QE=F5L<R!B92!E9F9E
M8W1U871E9"!B969O<F4@2G5L>28C,38P.S(P,30@=VET:&]U="!3128C.#(Q
M-SMS('!R:6]R(&-O;G-E;G0L('1H90T*("`@($-O;7!A;GD@=VEL;"!G=6%R
M86YT964@87!P<F]X:6UA=&5L>2`F(S$V,SLT)B,Q-C`[;6EL;&EO;BP@=&AE
M(&%M;W5N="!P;W1E;G1I86QL>2!D=64@=&\@4T4L('=H:6-H('=I;&P@8F4-
M"B`@("!C86QC=6QA=&5D(&%S(&$@;6%X:6UU;2!O9B`F(S$V,SLT)B,Q-C`[
M;6EL;&EO;B!L97-S('1H92!M87)K970@=F%L=64@;V8@=&AE('-H87)E<R!H
M96QD(&)Y(%-%(&%T('1H92!T:6UE(&]F#0H@("`@86YY(&9U<G1H97(@<F5D
M=6-T:6]N(&EN(')E<V5A<F-H(&9A8VEL:71I97,N#0H@("`@/"]D:78^#0H@
M("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@."4G/E1H:7,@87)R
M86YG96UE;G0@:7,@86-C;W5N=&5D(&9O<B!A<R!A(&QI86)I;&ET>2!A;F0@
M:7,@;65A<W5R960@870@9F%I<B!V86QU92X@0VAA;F=E<R!I;@T*("`@(&9A
M:7(@=F%L=64@87)E(')E8V]G;FEZ960@:6X@96%R;FEN9W,N($1U92!T;R!T
M:&4@;F%T=7)E(&]F('1H92!A<W-O8VEA=&5D(&-O;G1I;F=E;F-Y(&%N9"!T
M:&4-"B`@("!L:6ME;&EH;V]D(&]F(&]C8W5R<F5N8V4L('1H92!#;VUP86YY
M(&AA<R!C;VYC;'5D960@=&AE(&9A:7(@=F%L=64@;V8@=&AI<R!L:6%B:6QI
M='D@:7,@:6UM871E<FEA;`T*("`@(&%S(&]F($1E8V5M8F5R)B,Q-C`[,S$L
M(#(P,3`@86YD($IU;F4F(S$V,#LS,"P@,C`Q,2X-"B`@("`\+V1I=CX-"B`@
M("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&UA<F=I;BUT;W`Z(#$P<'0G/CQB/CQI/DQE9V%L('!R;V-E961I;F=S/"]I
M/CPO8CX-"B`@("`\+V1I=CX-"B`@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E>'0M
M:6YD96YT.B`T)2<^3VX@07!R:6PF(S$V,#LR-RP@,C`Q,"P@=&AE($-O;7!A
M;GD@=V%S('-E<G9E9"!W:71H(&$@8V]M<&QA:6YT(&9I;&5D(&)Y($-E;&=E
M;F4@0V]R<&]R871I;VX@:6X@=&AE#0H@("`@56YI=&5D(%-T871E<R!$:7-T
M<FEC="!#;W5R="!F;W(@=&AE($1I<W1R:6-T(&]F($1E;&%W87)E('-E96MI
M;F<@82!D96-L87)A=&]R>2!J=61G;65N="!T:&%T(&9O=7(-"B`@("!O9B!I
M=',@;W=N('!A=&5N=',L(&-L86EM:6YG('1H92!U<V4@;V8@<F]M:61E<'-I
M;B!I;FIE8W1I;VX@:6X@5"UC96QL(&QY;7!H;VUA<RP@87)E(&EN=F%L:60@
M86YD#0H@("`@;F]T(&EN9G)I;F=E9"!B>2!#96QG96YE)B,X,C$W.W,@<')O
M9'5C=',L(&)U="!D:7)E8W1L>2!I;G9O;'9E('1H92!U<V4@86YD(&%D;6EN
M:7-T<F%T:6]N(&]F($-E;&=E;F4F(S@R,3<[<PT*("`@($E35$]$05@\<W5P
M('-T>6QE/3-$)V9O;G0M<VEZ93H@.#4E.R!V97)T:6-A;"UA;&EG;CH@=&5X
M="UT;W`G/B8C,3<T.SPO<W5P/B`H<F]M:61E<'-I;B!F;W(@:6YJ96-T:6]N
M*2!P<F]D=6-T+B!/;B!*=6YE)B,Q-C`[,3<L(#(P,3`L('1H92!#;VUP86YY
M(&9I;&5D(&ET<R!A;G-W97(@86YD#0H@("`@8V]U;G1E<F-L86EM<R!T;R!T
M:&4@9&5C;&%R871O<GD@:G5D9VUE;G0@8V]M<&QA:6YT+B!4:&4@0V]M<&%N
M>2!F:6QE9"!C;W5N=&5R8VQA:6US(&-H87)G:6YG#0H@("`@0V5L9V5N92!W
M:71H(&EN9G)I;F=E;65N="!O9B!E86-H(&]F('1H92!#;VUP86YY)B,X,C$W
M.W,@9F]U<B!P871E;G1S(&%N9"!S965K:6YG(&1A;6%G97,@9F]R($-E;&=E
M;F4F(S@R,3<[<PT*("`@(&EN9G)I;F=E;65N="!A<R!W96QL(&%S(&EN:G5N
M8W1I=F4@<F5L:65F+B!4:&4@9F]U<B!P871E;G1S(&1I<F5C=&QY(&EN=F]L
M=F4@=&AE('5S92!A;F0-"B`@("!A9&UI;FES=')A=&EO;B!O9B!#96QG96YE
M)B,X,C$W.W,@25-43T1!6#QS=7`@<W1Y;&4],T0G9F]N="US:7IE.B`X-24[
M('9E<G1I8V%L+6%L:6=N.B!T97AT+71O<"<^)B,Q-S0[/"]S=7`^("AR;VUI
M9&5P<VEN(&9O<B!I;FIE8W1I;VXI('!R;V1U8W0N#0H@("`@/"]D:78^#0H@
M("`@/"]D:78^#0H@(#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?,CDV,3`T,3E?964W,5\T.#DX7V(Y,6%?-SAD839F8S8U,&4X
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S(Y-C$P-#$Y7V5E-S%?
M-#@Y.%]B.3%A7S<X9&$V9F,V-3!E."]7;W)K<VAE971S+U-H965T,3,N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$4R2#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:VAO
M;&1E<G,G($5Q=6ET>3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y*=6XN(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4U1/0TM(3TQ$15)3)R!%455)5%D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/@T*("`@(#PA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O
M+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N
M=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B
M("TM/@T*("`@(#PA+2T@0F5G:6X@0FQO8VL@5&%G9V5D($YO=&4@."`M('5S
M+6=A87`Z4W1O8VMH;VQD97)S17%U:71Y3F]T941I<V-L;W-U<F5497AT0FQO
M8VLM+3X-"B`@("`\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@
M3F5W(%)O;6%N)RQ4:6UE<RQS97)I9CL@;6%R9VEN+6QE9G0Z(#!I;CL@)SX-
M"B`@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/CQB/C@N(%-43T-+2$],1$524R8C.#(Q
M-SL@15%52519/"]B/@T*("`@(#PO9&EV/@T*("`@(#QD:78@86QI9VX],T1L
M969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P
M="<^/&(^/&D^4')E9F5R<F5D(%-T;V-K/"]I/CPO8CX-"B`@("`\+V1I=CX-
M"B`@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD96YT.B`T)2<^07,@;V8@
M2G5N928C,38P.S,P+"`R,#$Q+"!T:&5R92!W97)E(#$L,C$S+#$T,B!S:&%R
M97,@;V8@4')E9F5R<F5D(%-T;V-K(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@
M870-"B`@("!A;B!I<W-U92!P<FEC92!O9B`F;F)S<#LD,3`N,#`@<&5R('-H
M87)E+B!$:79I9&5N9',@;VX@=&AE(%!R969E<G)E9"!3=&]C:R!A<F4@8W5M
M=6QA=&EV92!F<F]M('1H92!D871E#0H@("`@;V8@;W)I9VEN86P@:7-S=6%N
M8V4@870@=&AE(&%N;G5A;"!R871E(&]F(#8E(&]F('1H92!L:7%U:61A=&EO
M;B!P<F5F97)E;F-E(&]F('1H92!0<F5F97)R960@4W1O8VLL#0H@("`@<&%Y
M86)L92!Q=6%R=&5R;'D@;VX-"B`@("!T:&4@9FER<W0@9&%Y(&]F($9E8G)U
M87)Y+"!-87DL($%U9W5S="!A;F0@3F]V96UB97(L(&-O;6UE;F-I;F<@1F5B
M<G5A<GDF(S$V,#LQ+"`R,#`U+B!!;GD-"B`@("!D:79I9&5N9',@;75S="!B
M92!D96-L87)E9"!B>2!T:&4@0V]M<&%N>28C.#(Q-SMS($)O87)D(&]F($1I
M<F5C=&]R<R!A;F0@;75S="!C;VUE(&9R;VT@9G5N9',@=&AA="!A<F4-"B`@
M("!L96=A;&QY(&%V86EL86)L92!F;W(@9&EV:61E;F0@<&%Y;65N=',N(%1H
M92!0<F5F97)R960@4W1O8VL@:&%S(&$@;&EQ=6ED871I;VX@<')E9F5R96YC
M92!O9B`F;F)S<#LD,3`-"B`@("!P97(@<VAA<F4L('!L=7,@86-C<G5E9"!A
M;F0@=6YP86ED(&1I=FED96YD<RX-"B`@("`\+V1I=CX-"B`@("`\(2TM($9O
M;&EO("TM/@T*("`@(#PA+2T@+T9O;&EO("TM/@T*("`@(#PO9&EV/@T*("`@
M(#PA+2T@4$%'14)214%+("TM/@T*("`@(#QD:78@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+%1I;65S+'-E<FEF.R!M87)G:6XM
M;&5F=#H@,&EN.R`G/@T*("`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P=#L@=&5X="UI;F1E
M;G0Z(#0E)SY4:&4@4')E9F5R<F5D(%-T;V-K(&ES(&-O;G9E<G1I8FQE(&%T
M('1H92!O<'1I;VX@;V8@=&AE(&AO;&1E<B!A="!A;GD@=&EM92!I;G1O('1H
M92!#;VUP86YY)B,X,C$W.W,-"B`@("!S:&%R97,@;V8@8V]M;6]N('-T;V-K
M(&%T(&$@8V]N=F5R<VEO;B!R871E(&]F(&%P<')O>&EM871E;'D@,"XT,C4U
M,R!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&9O<@T*("`@(&5A8V@@<VAA<F4@
M;V8@4')E9F5R<F5D(%-T;V-K(&)A<V5D(&]N(&$@<')I8V4@;V8@)FYB<W`[
M)#(S+C4P+B!$=7)I;F<@,C`Q,"P@.#,S+#8W,2!S:&%R97,@;V8@4')E9F5R
M<F5D#0H@("`@4W1O8VL@=V5R92!C;VYV97)T960@:6YT;R`Q+#8U-2PU.3D@
M<VAA<F5S(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K+"!W
M:&EC:"!I<R!D97-C<FEB960@:6X-"B`@("!M;W)E(&1E=&%I;"!B96QO=RX@
M4VEN8V4@:6YC97!T:6]N('1H<F]U9V@@2G5N928C,38P.S,P+"`R,#$Q+"!H
M;VQD97)S(&AA=F4@=F]L=6YT87)I;'D@8V]N=F5R=&5D#0H@("`@,2PW-S8L
M.#4X('-H87)E<R!O9B!0<F5F97)R960@4W1O8VL@:6YT;R!C;VUM;VX@<W1O
M8VLN(%1H92!#;VUP86YY(&AA<R!R97-E<G9E9"`U,38L,C(X('-H87)E<R!O
M9@T*("`@(&-O;6UO;B!S=&]C:R!F;W(@:7-S=6%N8V4@=7!O;B!C;VYV97)S
M:6]N(&]F('1H92!R96UA:6YI;F<@<VAA<F5S(&]F(%!R969E<G)E9"!3=&]C
M:R!O=71S=&%N9&EN9R!A=`T*("`@($IU;F4F(S$V,#LS,"P@,C`Q,2X@5&AE
M(&-O;G9E<G1E9"!S:&%R97,@;V8@4')E9F5R<F5D(%-T;V-K(&AA=F4@8F5E
M;B!R971I<F5D(&%N9"!C86YC96QE9"!A;F0@<VAA;&P-"B`@("!U<&]N(&-A
M;F-E;&QA=&EO;B!B92!R97-T;W)E9"!T;R!T:&4@<W1A='5S(&]F(&%U=&AO
M<FEZ960@8G5T('5N:7-S=65D('-H87)E<R!O9B!P<F5F97)R960@<W1O8VLL
M#0H@("`@<W5B:F5C="!T;R!R96ES<W5A;F-E(&)Y('1H92!";V%R9"!O9B!$
M:7)E8W1O<G,@87,@<VAA<F5S(&]F(%!R969E<G)E9"!3=&]C:R!O9B!O;F4@
M;W(@;6]R92!S97)I97,N#0H@("`@/"]D:78^#0H@("`@/&1I=B!A;&EG;CTS
M1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q
M,'!T.R!T97AT+6EN9&5N=#H@-"4G/E1H92!#;VUP86YY(&UA>2!A=71O;6%T
M:6-A;&QY(&-O;G9E<G0@=&AE(%!R969E<G)E9"!3=&]C:R!I;G1O(&-O;6UO
M;B!S=&]C:R!I9B!T:&4@8VQO<VEN9PT*("`@('!R:6-E(&]F('1H92!#;VUP
M86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K(&AA<R!E>&-E961E9"`F;F)S<#LD
M,S4N,C4L('=H:6-H(&ES(#$U,"4@;V8@=&AE(&-O;G9E<G-I;VX@<')I8V4@
M;V8-"B`@("!T:&4@4')E9F5R<F5D(%-T;V-K+"!F;W(@870@;&5A<W0@,C`@
M=')A9&EN9R!D87ES(&1U<FEN9R!A;GD@,S`M9&%Y('1R861I;F<@<&5R:6]D
M+"!E;F1I;F<@=VET:&EN#0H@("`@9FEV92!T<F%D:6YG(&1A>7,@<')I;W(@
M=&\@;F]T:6-E(&]F(&%U=&]M871I8R!C;VYV97)S:6]N+@T*("`@(#PO9&EV
M/@T*("`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+71O<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY4:&4@
M0V5R=&EF:6-A=&4@;V8@1&5S:6=N871I;VYS(&=O=F5R;FEN9R!T:&4@4')E
M9F5R<F5D(%-T;V-K('!R;W9I9&5S('1H870@:68@=&AE($-O;7!A;GD-"B`@
M("!F86EL<R!T;R!P87D@9&EV:61E;F1S(&]N(&ET<R!0<F5F97)R960@4W1O
M8VL@9F]R('-I>"!Q=6%R=&5R;'D@<&5R:6]D<RP@:&]L9&5R<R!O9B!0<F5F
M97)R960@4W1O8VL-"B`@("!A<F4@96YT:71L960@=&\@;F]M:6YA=&4@86YD
M(&5L96-T('1W;R!D:7)E8W1O<G,@=&\@=&AE($-O;7!A;GDF(S@R,3<[<R!"
M;V%R9"!O9B!$:7)E8W1O<G,N(%1H:7,@<FEG:'0-"B`@("!A8V-R=65D('1O
M('1H92!H;VQD97)S(&]F(%!R969E<G)E9"!3=&]C:R!A<R!O9B!!=6=U<W0F
M(S$V,#LR+"`R,#$P(&%N9"!T=V\@9&ER96-T;W)S('=E<F4@;F]M:6YA=&5D
M(&%N9`T*("`@(&5L96-T960@870@=&AE(&%N;G5A;"!M965T:6YG(&AE;&0@
M;VX@36%Y)B,Q-C`[,C0L(#(P,3$N#0H@("`@/"]D:78^#0H@("`@/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM
M=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@-"4G/E1H92!0<F5F97)R960@4W1O
M8VL@:&%S(&YO(&UA='5R:71Y(&1A=&4@86YD(&YO('9O=&EN9R!R:6=H=',@
M<')I;W(@=&\@8V]N=F5R<VEO;B!I;G1O(&-O;6UO;@T*("`@('-T;V-K+"!E
M>&-E<'0@=6YD97(@;&EM:71E9"!C:7)C=6US=&%N8V5S+@T*("`@(#PO9&EV
M/@T*("`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+71O<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY&<F]M
M($YO=F5M8F5R)B,Q-C`[-BP@,C`P-RP@=&AE($-O;7!A;GD@;6%Y+"!A="!I
M=',@;W!T:6]N+"!R961E96T@=&AE(%!R969E<G)E9"!3=&]C:R!I;B!W:&]L
M92!O<@T*("`@(&EN('!A<G0L(&]U="!O9B!F=6YD<R!L96=A;&QY(&%V86EL
M86)L92!A="!T:&4@<F5D96UP=&EO;B!P<FEC97,@<&5R('-H87)E('-T871E
M9"!B96QO=RP@<&QU<R!A;@T*("`@(&%M;W5N="!E<75A;"!T;R!A8V-R=65D
M(&%N9"!U;G!A:60@9&EV:61E;F1S('5P('1O('1H92!D871E(&]F(')E9&5M
M<'1I;VXZ#0H@("`@/"]D:78^#0H@("`@/&1I=B!A;&EG;CTS1&-E;G1E<CX-
M"B`@("`\=&%B;&4@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)R!C96QL<W!A8VEN9STS1#`@8F]R9&5R/3-$,"!C96QL<&%D
M9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*("`@(#PA+2T@0F5G:6X@5&%B;&4@
M2&5A9"`M+3X-"B`@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@(#QT9"!W
M:61T:#TS1#@V)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS1#,E/B8C
M,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@=VED=&@],T0Y)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS
M1#$E/B8C,38P.SPO=&0^#0H@("`@/"]T<CX-"B`@("`\(2TM($5N9"!486)L
M92!(96%D("TM/@T*("`@(#PA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`@
M("`\='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0Z("-C
M8V5E9F8G/@T*("`@(#QT9#X-"B`@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL
M969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY996%R(&9R;VT@3F]V96UB
M97(F(S$V,#LQ+"`R,#$P('1O($]C=&]B97(F(S$V,#LS,2P@,C`Q,0T*("`@
M(#PO9&EV/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&%L
M:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`\=&0@86QI9VX],T1R:6=H
M=#XQ,"XR-#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/"]T<CX-
M"B`@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@(#QT9#X-"B`@("`\9&EV
M('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X
M)SY996%R(&9R;VT@3F]V96UB97(F(S$V,#LQ+"`R,#$Q('1O($]C=&]B97(F
M(S$V,#LS,2P@,C`Q,@T*("`@(#PO9&EV/CPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@
M("`\=&0@86QI9VX],T1R:6=H=#XQ,"XQ.#PO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/"]T<CX-"B`@("`\='(@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)V)A8VMG<F]U;F0Z("-C8V5E9F8G/@T*("`@(#QT9#X-"B`@("`\
M9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ
M-7!X)SY996%R(&9R;VT@3F]V96UB97(F(S$V,#LQ+"`R,#$R('1O($]C=&]B
M97(F(S$V,#LS,2P@,C`Q,PT*("`@(#PO9&EV/CPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-
M"B`@("`\=&0@86QI9VX],T1R:6=H=#XQ,"XQ,CPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/"]T<CX-"B`@("`\='(@=F%L:6=N/3-$8F]T=&]M
M/@T*("`@(#QT9#X-"B`@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U
M<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY996%R(&9R;VT@3F]V96UB97(F(S$V
M,#LQ+"`R,#$S('1O($]C=&]B97(F(S$V,#LS,2P@,C`Q-`T*("`@(#PO9&EV
M/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$
M;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`\=&0@86QI9VX],T1R:6=H=#XQ,"XP
M-CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/"]T<CX-"B`@("`\
M='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0Z("-C8V5E
M9F8G/@T*("`@(#QT9#X-"B`@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T
M.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY.;W9E;6)E<B8C,38P.S$L(#(P
M,30@86YD('1H97)E869T97(-"B`@("`\+V1I=CX\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^
M#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^,3`N,#`\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#PO='(^#0H@("`@/"$M+2!%;F0@5&%B;&4@0F]D
M>2`M+3X-"B`@("`\+W1A8FQE/@T*("`@(#PO9&EV/@T*("`@(#QD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O
M<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY4:&4@4')E9F5R<F5D(%-T;V-K
M(&ES(&5X8VAA;F=E86)L92P@:6X@=VAO;&4@8G5T(&YO="!I;B!P87)T+"!A
M="!T:&4@;W!T:6]N(&]F('1H92!#;VUP86YY(&]N#0H@("`@86YY(&1I=FED
M96YD('!A>6UE;G0@9&%T92!B96=I;FYI;F<@;VX@3F]V96UB97(F(S$V,#LQ
M+"`R,#`U("AT:&4@)B,X,C(P.T5X8VAA;F=E($1A=&4F(S@R,C$[*2!F;W(@
M=&AE($-O;7!A;GDF(S@R,3<[<R`V)0T*("`@($-O;G9E<G1I8FQE(%-U8F]R
M9&EN871E9"!$96)E;G1U<F5S("@F(S@R,C`[1&5B96YT=7)E<R8C.#(R,3LI
M(&%T('1H92!R871E(&]F("9N8G-P.R0Q,"!P<FEN8VEP86P@86UO=6YT(&]F
M#0H@("`@1&5B96YT=7)E<R!F;W(@96%C:"!S:&%R92!O9B!0<F5F97)R960@
M4W1O8VLN(%1H92!$96)E;G1U<F5S+"!I9B!I<W-U960L('=I;&P@;6%T=7)E
M(#(U)B,Q-C`[>65A<G,@869T97(-"B`@("!T:&4@17AC:&%N9V4@1&%T92!A
M;F0@:&%V92!T97)M<R!S=6)S=&%N=&EA;&QY('-I;6EL87(@=&\@=&AO<V4@
M;V8@=&AE(%!R969E<G)E9"!3=&]C:RX-"B`@("`\+V1I=CX-"B`@("`\(2TM
M($9O;&EO("TM/@T*("`@(#PA+2T@+T9O;&EO("TM/@T*("`@(#PO9&EV/@T*
M("`@(#PA+2T@4$%'14)214%+("TM/@T*("`@(#QD:78@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+%1I;65S+'-E<FEF.R!M87)G
M:6XM;&5F=#H@,&EN.R`G/@T*("`@(#QD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^/&D^0V]N
M=F5R<VEO;B!O9B!#;VYV97)T:6)L92!0<F5F97)R960@4W1O8VL\+VD^#0H@
M("`@/"]D:78^#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@
M."4G/D1U<FEN9R!T:&4@9FER<W0@86YD('-E8V]N9"!Q=6%R=&5R<R!O9B`R
M,#$P+"!#>6-L86-E;"!E;G1E<F5D(&EN=&\@86=R965M96YT<R!T;R!E>&-H
M86YG90T*("`@('-H87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(%!R969E
M<G)E9"!3=&]C:R!I;G1O('-H87)E<R!O9B!C;VUM;VX@<W1O8VLN(%1H97)E
M('=E<F4@;F\@<W5C:"!C;VYV97)S:6]N<PT*("`@(&9O<B!T:&4@<VEX(&UO
M;G1H<R!E;F1E9"!*=6YE)B,Q-C`[,S`L(#(P,3$N(%1H92!T86)L92!B96QO
M=R!P<F]V:61E<R!D971A:6QS(&]F('1H92!A9V=R96=A=&4-"B`@("!A8W1I
M=FET:65S(&EN(#(P,3`Z#0H@("`@/"]D:78^#0H@("`@/&1I=B!A;&EG;CTS
M1&-E;G1E<CX-"B`@("`\=&%B;&4@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!T97AT+6%L:6=N.B!L969T)R!C96QL<W!A8VEN9STS1#`@8F]R9&5R/3-$
M,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*("`@(#PA+2T@0F5G
M:6X@5&%B;&4@2&5A9"`M+3X-"B`@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@(#QT9"!W:61T:#TS1#<R)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T
M:#TS1#,E/B8C,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@=VED=&@],T0Y)3XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$,R4^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!W:61T:#TS1#DE/B8C,38P.SPO=&0^#0H@("`@/'1D('=I9'1H
M/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT<B!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0G('9A;&EG;CTS1&)O='1O;3X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQB/D9O
M<B!T:&4@=&AR964\+V(^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L
M:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQB/D9O<B!T:&4@<VEX/"]B/CPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/"]T<CX-"B`@("`\='(@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)R!V86QI9VX],T1B;W1T;VT^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$
M,CX\8CYM;VYT:',@96YD960\+V(^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQB/FUO;G1H<R!E;F1E
M9#PO8CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#PO='(^#0H@
M("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L
M<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED(",P
M,#`P,#`G/CQB/DIU;F4@,S`L(#(P,3`\+V(^/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\8CY*=6YE(#,P
M+"`R,#$P/"]B/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/"]T
M<CX-"B`@("`\(2TM($5N9"!486)L92!(96%D("TM/@T*("`@(#PA+2T@0F5G
M:6X@5&%B;&4@0F]D>2`M+3X-"B`@("`\='(@=F%L:6=N/3-$8F]T=&]M/CPA
M+2T@0FQA;FL@4W!A8V4@+2T^#0H@("`@/'1D/@T*("`@(#QD:78@<W1Y;&4]
M,T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/B8C,38P
M.PT*("`@(#PO9&EV/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/"]T<CX-"B`@("`\='(@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)V)A8VMG<F]U;F0Z("-C8V5E9F8G/@T*("`@(#QT9#X-"B`@("`\
M9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ
M-7!X)SY0<F5F97)R960@<VAA<F5S(&5X8VAA;F=E9`T*("`@(#PO9&EV/CPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^-S$P+#(W,3PO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^.#,S+#8W,3PO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/"]T<CX-"B`@("`\='(@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q<'@G/@T*("`@(#QT9#X-"B`@("`\9&EV('-T
M>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SXF
M(S$V,#L-"B`@("`\+V1I=CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R
M:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`S<'@@9&]U8FQE(",P,#`P,#`G
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$
M,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#-P>"!D;W5B
M;&4@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\+W1R/@T*("`@(#QT<B!V86QI9VX],T1B;W1T;VT^/"$M+2!";&%N
M:R!3<&%C92`M+3X-"B`@("`\=&0^#0H@("`@/&1I=B!S='EL93TS1"=M87)G
M:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^)B,Q-C`[#0H@("`@
M/"]D:78^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\+W1R/@T*("`@(#QT<B!V86QI9VX],T1B;W1T;VT^#0H@("`@/'1D
M/@T*("`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI
M;F1E;G0Z+3$U<'@G/D-O;6UO;B!S:&%R97,@:7-S=65D.@T*("`@(#PO9&EV
M/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/"]T<CX-"B`@("`\='(@=F%L:6=N/3-$8F]T=&]M/CPA+2T@0FQA;FL@4W!A
M8V4@+2T^#0H@("`@/'1D/@T*("`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/B8C,38P.PT*("`@(#PO9&EV
M/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/"]T<CX-"B`@("`\='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG
M<F]U;F0Z("-C8V5E9F8G/@T*("`@(#QT9#X-"B`@("`\9&EV('-T>6QE/3-$
M)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY!="!S=&%T
M960@8V]N=F5R=&EB;&4@;W!T:6]N#0H@("`@/"]D:78^/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M86QI9VX],T1R:6=H=#XS,#(L,C0R/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@86QI9VX],T1R:6=H=#XS-30L-S4R/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT<B!V86QI9VX],T1B;W1T
M;VT^/"$M+2!";&%N:R!3<&%C92`M+3X-"B`@("`\=&0^#0H@("`@/&1I=B!S
M='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^
M)B,Q-C`[#0H@("`@/"]D:78^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT<B!V86QI9VX],T1B;W1T
M;VT^#0H@("`@/'1D/@T*("`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z
M,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/DEN8W)E;65N=&%L('-H87)E<R!I
M<W-U960@=6YD97(@86X@:6YD=6-E;65N="!O9F9E<@T*("`@(#PO9&EV/CPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^,2PQ,3,L.38Q/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI9VX],T1R:6=H=#XQ+#,P,"PX-#<\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#PO='(^#0H@("`@/'1R
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,7!X)SX-"B`@("`\=&0^#0H@("`@/&1I
M=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P
M>"<^)B,Q-C`[#0H@("`@/"]D:78^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N
M/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,7!X('-O;&ED(",P,#`P
M,#`G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N
M/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#%P>"!S
M;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#PO='(^#0H@("`@/'1R('9A;&EG;CTS1&)O='1O;3X\(2TM($)L
M86YK(%-P86-E("TM/@T*("`@(#QT9#X-"B`@("`\9&EV('-T>6QE/3-$)VUA
M<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SXF(S$V,#L-"B`@
M("`\+V1I=CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#PO='(^#0H@("`@/'1R('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=B86-K9W)O=6YD.B`C8V-E969F)SX-"B`@("`\=&0^#0H@("`@/&1I=B!S
M='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^
M5&]T86P@8V]M;6]N('-H87)E<R!I<W-U960-"B`@("`\+V1I=CX\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!A;&EG;CTS1')I9VAT/C$L-#$V+#(P,SPO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^,2PV-34L-3DY/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT<B!S='EL
M93TS1"=F;VYT+7-I>F4Z(#%P>"<^#0H@("`@/'1D/@T*("`@(#QD:78@<W1Y
M;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/B8C
M,38P.PT*("`@(#PO9&EV/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I
M9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#-P>"!D;W5B;&4@(S`P,#`P,"<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R
M(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,W!X(&1O=6)L
M92`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#PO='(^#0H@("`@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X-"B`@("`\
M+W1A8FQE/@T*("`@(#PO9&EV/@T*("`@(#QD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P=#L@=&5X
M="UI;F1E;G0Z(#@E)SY!4T,@,C8P+"!%251&(%1O<&EC($0M-#(L("8C.#(R
M,#L\:3Y4:&4@169F96-T(&]F('1H92!#86QC=6QA=&EO;B!O9B!%87)N:6YG
M<R!P97(@4VAA<F4@9F]R('1H90T*("`@(%)E9&5M<'1I;VX@;W(@26YD=6-E
M9"!#;VYV97)S:6]N(&]F(%!R969E<G)E9"!3=&]C:R8C.#(R,3L@/"]I/B@F
M(S@R,C`[05-#(#(V,"8C.#(R,3LI(')E<75I<F5S('1H870@:68@8V]N=F5R
M=&EB;&4-"B`@("!P<F5F97)R960@<W1O8VL@:7,@8V]N=F5R=&5D('1O(&]T
M:&5R('-E8W5R:71I97,@<'5R<W5A;G0@=&\@86X@:6YD=6-E;65N="!O9F9E
M<BP@=&AE($-O;7!A;GD-"B`@("!S:&]U;&0@<F5C;W)D('1H92!E>&-E<W,@
M;V8@*#$I)B,Q-C`[=&AE(&9A:7(@=F%L=64@;V8@86QL('-E8W5R:71I97,@
M86YD(&]T:&5R(&-O;G-I9&5R871I;VX-"B`@("!T<F%N<V9E<G)E9"!T;R!T
M:&4@:&]L9&5R<R!O9B!T:&4@8V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K
M(&%N9"`H,BDF(S$V,#MT:&4@9F%I<B!V86QU92!O9B!S96-U<FET:65S#0H@
M("`@:7-S=6%B;&4@=&\@=&AE(&]R:6=I;F%L(&-O;G9E<G-I;VX@=&5R;7,@
M87,@86X@:6YC<F5A<V4@=&\@;F5T(&QO<W,@=&\@87)R:79E(&%T(&$@;F5T
M(&QO<W,-"B`@("!A='1R:6)U=&%B;&4@=&\@8V]M;6]N('-H87)E:&]L9&5R
M<RX@5&AE('-T;V-K:&]L9&5R(')E8V5I=F5D(&UO<F4@<VAA<F5S(&]F('1H
M92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N#0H@("`@<W1O8VL@=&AA;B!W;W5L
M9"!H879E(&)E96X@9&5L:79E<F5D('!U<G-U86YT('1O('1H92!O<FEG:6YA
M;"!C;VYV97)S:6]N('1E<FUS(&]F('1H92!0<F5F97)R960-"B`@("!3=&]C
M:RP@<'5R<W5A;G0@=&\@82!S:&]R="!T97)M(&EN9'5C96UE;G0@;V9F97(N
M(%1H92!E>&-E<W,@;V8@=&AE(&9A:7(@=F%L=64@;V8@=&AE(&-O;6UO;B!S
M=&]C:PT*("`@('1R86YS9F5R<F5D('1O('1H92!S=&]C:VAO;&1E<B!O=F5R
M('1H92!C87)R>6EN9R!A;6]U;G0@;V8@=&AE('!R969E<G)E9"!S=&]C:R!I
M;B!T:&4@0V]M<&%N>28C.#(Q-SMS#0H@("`@8F%L86YC92!S:&5E="!A="!T
M:&4@=&EM92!O9B!T:&4@=')A;G-F97(@=V%S(&-O;G-I9&5R960@=&\@8F4@
M86X@861D:71I;VYA;"!R971U<FX@=&\@=&AE(&AO;&1E<@T*("`@(&]F('1H
M92!0<F5F97)R960@4W1O8VLN(%-P96-I9FEC86QL>2P@=&AE($-O;7!A;GD@
M<F5C;W)D960@9&5E;65D(&1I=FED96YD<R!R96QA=&5D('1O('1H90T*("`@
M(&%D9&ET:6]N86P@<VAA<F5S(&ES<W5E9"!U;F1E<B!T:&4@97AC:&%N9V4@
M=')A;G-A8W1I;VYS(&]F(&%P<')O>&EM871E;'D@)FYB<W`[)#(N-28C,38P
M.VUI;&QI;VX@86YD("9N8G-P.R0R+CD-"B`@("!M:6QL:6]N(&9O<B!T:&4@
M=&AR964@86YD('-I>"!M;VYT:',@96YD960@2G5N928C,38P.S,P+"`R,#$P
M+"!R97-P96-T:79E;'DN#0H@("`@/"]D:78^#0H@("`@/&1I=B!A;&EG;CTS
M1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q
M,'!T)SX\8CX\:3Y#;VUM;VX@4W1O8VL\+VD^/"]B/@T*("`@(#PO9&EV/@T*
M("`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@;6%R9VEN+71O<#H@,3!P="<^/&D^3V-T;V)E<B8C,38P.S(P,3`@4')I
M=F%T92!0;&%C96UE;G0\+VD^#0H@("`@/"]D:78^#0H@("`@/&1I=B!A;&EG
M;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P
M.B`Q,'!T.R!T97AT+6EN9&5N=#H@-"4G/D]N($]C=&]B97(F(S$V,#LW+"`R
M,#$P+"!T:&4@0V]M<&%N>2!C;VUP;&5T960@82!P<FEV871E('!L86-E;65N
M="!P=7)S=6%N="!T;R!W:&EC:"!I="!S;VQD#0H@("`@87!P<F]X:6UA=&5L
M>2`F;F)S<#LD,34N,B8C,38P.VUI;&QI;VX@;V8@:71S('5N:71S('1O('-E
M=F5R86P@:6YS=&ET=71I;VYA;"!I;G9E<W1O<G,L(&9O<B!N970@<')O8V5E
M9',@;V8-"B`@("!A<'!R;WAI;6%T96QY("9N8G-P.R0Q-"XP)B,Q-C`[;6EL
M;&EO;BX@5&AE('5N:71S(&-O;G-I<W0@;V8@;VYE('-H87)E(&]F(&-O;6UO
M;B!S=&]C:R!A;F0@,"XU(&]F(&$@=V%R<F%N="P-"B`@("!W:71H(&5A8V@@
M=VAO;&4@=V%R<F%N="!R97!R97-E;G1I;F<@=&AE(')I9VAT('1O('!U<F-H
M87-E(&]N92!S:&%R92!O9B!C;VUM;VX@<W1O8VL@870@86X@97AE<F-I<V4-
M"B`@("!P<FEC92!O9B`F;F)S<#LD,2XY,B!P97(@<VAA<F4@9F]R(&$@<&5R
M:6]D(&]F(&9I=F4@>65A<G,N($%S(&]F($IU;F4F(S$V,#LS,"P@,C`Q,2P@
M86QL(&]P=&EO;G,@86YD('=A<G)A;G1S#0H@("`@:7-S=65D('1O('1H92!I
M;G9E<W1O<G,@87)E(&]U='-T86YD:6YG(&%N9"!H879E(&)E96X@8VQA<W-I
M9FEE9"!A<R!E<75I='DN(%1H92!I;G9E<W1O<G,@<'5R8VAA<V5D#0H@("`@
M82!T;W1A;"!O9B`X+#,R,RPQ.3`@=6YI=',@870@82!P<FEC92!O9B`F;F)S
M<#LD,2XX,C8R-2!P97(@=6YI="X@5&AE(&EN=F5S=&]R<R!A;'-O(&AA=F4@
M=&AE(')I9VAT('1O#0H@("`@86-Q=6ER92!U<"!T;R`T+#$V,2PU.34@861D
M:71I;VYA;"!U;FET<R!A="!A('!R:6-E(&]F("9N8G-P.R0Q+C8W('!E<B!U
M;FET("AF;W(@)FYB<W`[)#8N.28C,38P.VUI;&QI;VX@:6X@9W)O<W,-"B`@
M("!P<F]C965D<RD@870@86YY('1I;64@=7`@=&\@;FEN92!M;VYT:',@869T
M97(@8VQO<VEN9R!O<B!B>2!*=6QY)B,Q-C`[-BP@,C`Q,2X@07,@;V8@2G5N
M928C,38P.S,P+"`R,#$Q+"!N;VYE#0H@("`@;V8@=&AE(&%D9&ET:6]N86P@
M=6YI=',@:&%D(&)E96X@97AE<F-I<V5D(&%N9"P@87,@;V8@2G5L>28C,38P
M.S8L(#(P,3$L('1H92!R:6=H="!T;R!A8W%U:7)E('1H90T*("`@(&%D9&ET
M:6]N86P@=6YI=',@;&%P<V5D+B!4:&4@=')A;G-A8W1I;VX@9&%T92!F86ER
M('9A;'5E(&]F('1H92!W87)R86YT<R!A;F0@861D:71I;VYA;"!O<'1I;VYA
M;`T*("`@('5N:71S('=A<R`F;F)S<#LD-2XQ)B,Q-C`[;6EL;&EO;B!A;F0@
M)FYB<W`[)#(N."8C,38P.VUI;&QI;VXL(')E<W!E8W1I=F5L>2X@3F5T('!R
M;V-E961S(&]F(&%P<')O>&EM871E;'D@)FYB<W`[)#$T+C`F(S$V,#MM:6QL
M:6]N#0H@("`@=V5R92!A;&QO8V%T960@8F%S960@;VX@<F5L871I=F4@=')A
M;G-A8W1I;VX@9&%T92!F86ER('9A;'5E<R!I;B!T:&4@9F]L;&]W:6YG(&UA
M;FYE<CH@)FYB<W`[)#@N.28C,38P.VUI;&QI;VX-"B`@("`H)FYB<W`[)#$N
M,#<@<&5R('-H87)E*2P@)FYB<W`[)#,N,R8C,38P.VUI;&QI;VX@*"9N8G-P
M.R0P+C<Y('!E<B!W87)R86YT*2!A;F0@)FYB<W`[)#$N."8C,38P.VUI;&QI
M;VX@*"9N8G-P.R0P+C0S('!E<B!O<'1I;VYA;"!U;FET*2!T;PT*("`@(&-O
M;6UO;B!S:&%R97,L('=A<G)A;G1S(&%N9"!T:&4@861D:71I;VYA;"!O<'1I
M;VYA;"!U;FET<RP@<F5S<&5C=&EV96QY+@T*("`@(#PO9&EV/@T*("`@(#PA
M+2T@1F]L:6\@+2T^#0H@("`@/"$M+2`O1F]L:6\@+2T^#0H@("`@/"]D:78^
M#0H@("`@/"$M+2!004=%0E)%04L@+2T^#0H@("`@/&1I=B!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L5&EM97,L<V5R:68[(&UA
M<F=I;BUL969T.B`P:6X[("<^#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT
M+6EN9&5N=#H@-"4G/DEN(&-O;FYE8W1I;VX@=VET:"!T:&4@3V-T;V)E<B8C
M,38P.S(P,3`@<')I=F%T92!P;&%C96UE;G0L('1H92!#;VUP86YY(&=R86YT
M960@=&\@=&AE(&EN=F5S=&]R<PT*("`@(&-E<G1A:6X@<F5G:7-T<F%T:6]N
M(')I9VAT<R!P=7)S=6%N="!T;R!A(%)E9VES=')A=&EO;B!2:6=H=',@06=R
M965M96YT+"!D871E9"!/8W1O8F5R)B,Q-C`[-RP@,C`Q,"P@:6X-"B`@("!W
M:&EC:"!T:&4@0V]M<&%N>2!A9W)E960L(&%M;VYG(&]T:&5R('1H:6YG<RP@
M=&\@<F5G:7-T97(@86QL(&]F('1H92!S:&%R97,@;V8@8V]M;6]N('-T;V-K
M#0H@("`@86-Q=6ER960@9G)O;2!T:&4@0V]M<&%N>2`H:6YC;'5D:6YG('5P
M;VX@97AE<F-I<V4@;V8@=&AE('=A<G)A;G1S(&%N9"]O<B!T:&4@;W!T:6]N
M<RD@=VET:&EN#0H@("`@=&AI<G1Y(&-A;&5N9&%R(&1A>7,@869T97(@=&AE
M($-O;7!A;GD@8F5C;VUE<R!E;&EG:6)L92!T;R!U<V4@82!R96=I<W1R871I
M;VX@<W1A=&5M96YT(&]N($9O<FT-"B`@("!3+3,L(&%N9"!U<V4@8V]M;65R
M8VEA;&QY(')E87-O;F%B;&4@969F;W)T<R!T;R!H879E('1H92!R96=I<W1R
M871I;VX@<W1A=&5M96YT(&1E8VQA<F5D(&5F9F5C=&EV90T*("`@(&%S('!R
M;VUP=&QY(&%S('!R86-T:6-A8FQE('1H97)E869T97(N(%5P;VX@=&AE($-O
M;7!A;GDF(S@R,3<[<R!F86EL=7)E('1O(&-O;7!L>2!W:71H('1H92!T97)M
M<R!O9B!T:&4-"B`@("!296=I<W1R871I;VX@4FEG:'1S($%G<F5E;65N="!A
M;F0@8V5R=&%I;B!O=&AE<B!C;VYD:71I;VYS+"!T:&4@0V]M<&%N>2!W:6QL
M(&)E(')E<75I<F5D('1O(&UA:V4-"B`@("!P<F\@<F%T82!P87EM96YT<R!T
M;R!E86-H(&EN=F5S=&]R+"!A<R!L:7%U:61A=&5D(&1A;6%G97,L(&EN(&%N
M(&%M;W5N="!E<75A;"!T;R`Q+C4E(&]F('1H90T*("`@(&%G9W)E9V%T92!P
M=7)C:&%S92!P<FEC92!P86ED(&)Y('-U8V@@:6YV97-T;W(N(%1H92!#;VUP
M86YY(&%L<V\@86=R965D('1O(&]T:&5R(&-U<W1O;6%R>0T*("`@(&]B;&EG
M871I;VYS(')E9V%R9&EN9R!R96=I<W1R871I;VXL(&EN8VQU9&EN9R!I;F1E
M;6YI9FEC871I;VX@86YD(&UA:6YT96YA;F-E(&]F('1H92!E9F9E8W1I=F5N
M97-S#0H@("`@;V8@=&AE(')E9VES=')A=&EO;B!S=&%T96UE;G0N(%1H92!#
M;VUP86YY(&ES(&-U<G)E;G1L>2!I;B!C;VUP;&EA;F-E('=I=&@@=&AE(&%P
M<&QI8V%B;&4@=&5R;7,@;V8-"B`@("!T:&4@4F5G:7-T<F%T:6]N(%)I9VAT
M<R!!9W)E96UE;G0L(&%N9"!T:&4@<V5C=7)I=&EE<R!T:&%T('=E<F4@<F5G
M:7-T<F%B;&4@=6YD97(@=&AE('1E<FUS(&]F('1H90T*("`@(%)E9VES=')A
M=&EO;B!2:6=H=',@06=R965M96YT(&%R92!C=7)R96YT;'D@<W5B:F5C="!T
M;R!A;B!E9F9E8W1I=F4@<F5G:7-T<F%T:6]N('-T871E;65N="X-"B`@("`\
M+V1I=CX-"B`@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/CQI/DIA;G5A<GDF(S$V,#LR
M,#$P(%)E9VES=&5R960@1&ER96-T($9I;F%N8VEN9W,\+VD^#0H@("`@/"]D
M:78^#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@-"4G/D]N
M($IA;G5A<GDF(S$V,#LR-2P@,C`Q,"P@=&AE($-O;7!A;GD@8V]M<&QE=&5D
M('1H92!S86QE(&]F(#(L,S4P+#`P,"!U;FET<R!I;B!A("8C.#(R,#MR96=I
M<W1E<F5D#0H@("`@9&ER96-T)B,X,C(Q.R!O9F9E<FEN9R!A="!A('!U<F-H
M87-E('!R:6-E(&]F("9N8G-P.R0R+C4P('!E<B!U;FET('1O(&-E<G1A:6X@
M:6YS=&ET=71I;VYA;"!I;G9E<W1O<G,@;V8@=&AE#0H@("`@0V]M<&%N>2!F
M;W(@9W)O<W,@<')O8V5E9',@;V8@87!P<F]X:6UA=&5L>2`F;F)S<#LD-2XY
M)B,Q-C`[;6EL;&EO;BX@16%C:"!U;FET(&-O;G-I<W1E9"!O9B!O;F4@<VAA
M<F4@;V8@=&AE#0H@("`@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!A
M;F0@;VYE('=A<G)A;G0@=&\@<'5R8VAA<V4@,"XS,"!O9B!O;F4@<VAA<F4@
M;V8@:71S(&-O;6UO;B!S=&]C:RX@5&AE#0H@("`@=V%R<F%N=',@:&%V92!A
M(&9I=F4M>65A<B!T97)M(&9R;VT@=&AE(&1A=&4@;V8@:7-S=6%N8V4L(&%R
M92!E>&5R8VES86)L92!B96=I;FYI;F<@<VEX(&UO;G1H<R!F<F]M#0H@("`@
M=&AE(&1A=&4@;V8@:7-S=6%N8V4@870@86X@97AE<F-I<V4@<')I8V4@;V8@
M)FYB<W`[)#(N.#4@<&5R('-H87)E(&]F(&-O;6UO;B!S=&]C:RX@07,@;V8@
M2G5N928C,38P.S,P+"`R,#$Q+`T*("`@('=A<G)A;G1S(&ES<W5E9"!T;R!T
M:&4@:6YV97-T;W)S(&AA=F4@8F5E;B!C;&%S<VEF:65D(&%S(&5Q=6ET>2X@
M5&AE('1R86YS86-T:6]N(&1A=&4@9F%I<B!V86QU92!O9@T*("`@('1H92!W
M87)R86YT<R!O9B`F;F)S<#LD,2XP)B,Q-C`[;6EL;&EO;B!W87,@9&5T97)M
M:6YE9"!U=&EL:7II;F<@=&AE($)L86-K+5-C:&]L97,@;W!T:6]N('!R:6-I
M;F<@;6]D96P-"B`@("!U=&EL:7II;F<@=&AE(&9O;&QO=VEN9R!A<W-U;7!T
M:6]N<SH@<FES:R!F<F5E(&EN=&5R97-T(')A=&4@)B,X,C$R.R`R+C,Y)2P@
M97AP96-T960@=F]L871I;&ET>2`F(S@R,3([(#DP)2P-"B`@("!E>'!E8W1E
M9"!D:79I9&5N9"!Y:65L9"`F(S@R,3([(#`E+"!A;F0@82!R96UA:6YI;F<@
M8V]N=')A8W1U86P@;&EF92!O9B`U+C`P)B,Q-C`[>65A<G,N($%S(&]F($IU
M;F4F(S$V,#LS,"P@,C`Q,2P-"B`@("!A;&P@=&AE('=A<G)A;G1S(&%R92!O
M=71S=&%N9&EN9RX@3F5T('!R;V-E961S(&]F(&%P<')O>&EM871E;'D@)FYB
M<W`[)#4N-"8C,38P.VUI;&QI;VX@=V5R92!A;&QO8V%T960@8F%S960-"B`@
M("!O;B!R96QA=&EV92!T<F%N<V%C=&EO;B!D871E(&9A:7(@=F%L=65S(&EN
M('1H92!F;VQL;W=I;F<@;6%N;F5R.B`F;F)S<#LD-"XU)B,Q-C`[;6EL;&EO
M;B`H)FYB<W`[)#$N.3,@<&5R('-H87)E*2!T;PT*("`@(&-O;6UO;B!S:&%R
M97,@86YD("9N8G-P.R0P+CDF(S$V,#MM:6QL:6]N("@F;F)S<#LD,2XR.2!P
M97(@=V%R<F%N="D@=&\@=&AE('=A<G)A;G1S+@T*("`@(#PO9&EV/@T*("`@
M(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M;6%R9VEN+71O<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY/;B!*86YU87)Y
M)B,Q-C`[,3,L(#(P,3`L('1H92!#;VUP86YY(&-O;7!L971E9"!T:&4@<V%L
M92!O9B`R+#@U,"PP,#`@=6YI=',@:6X@82`F(S@R,C`[<F5G:7-T97)E9`T*
M("`@(&1I<F5C="8C.#(R,3L@;V9F97)I;F<@=&\@8V5R=&%I;B!I;G-T:71U
M=&EO;F%L(&EN=F5S=&]R<RX@16%C:"!U;FET('=A<R!S;VQD(&%T(&$@<'5R
M8VAA<V4@<')I8V4@;V8-"B`@("`F;F)S<#LD,BXU,2!P97(@=6YI="!A;F0@
M8V]N<VES=',@;V8@;VYE('-H87)E(&]F('1H92!#;VUP86YY)B,X,C$W.W,@
M8V]M;6]N('-T;V-K(&%N9"!O;F4@=V%R<F%N="!T;R!P=7)C:&%S90T*("`@
M(#`N,C4@;V8@;VYE('-H87)E(&]F(&ET<R!C;VUM;VX@<W1O8VL@9F]R(&=R
M;W-S('!R;V-E961S(&]F(&%P<')O>&EM871E;'D@)FYB<W`[)#<N,B8C,38P
M.VUI;&QI;VXN(%1H90T*("`@('=A<G)A;G1S(&AA=F4@82!F:79E+7EE87(@
M=&5R;2!F<F]M('1H92!D871E(&]F(&ES<W5A;F-E+"!A<F4@97AE<F-I<V%B
M;&4@8F5G:6YN:6YG('-I>"!M;VYT:',@9G)O;0T*("`@('1H92!D871E(&]F
M(&ES<W5A;F-E(&%T(&%N(&5X97)C:7-E('!R:6-E(&]F("9N8G-P.R0S+C(V
M('!E<B!S:&%R92!O9B!C;VUM;VX@<W1O8VLN($%S(&]F($IU;F4F(S$V,#LS
M,"P@,C`Q,2P-"B`@("!W87)R86YT<R!I<W-U960@=&\@=&AE(&EN=F5S=&]R
M<R!H879E(&)E96X@8VQA<W-I9FEE9"!A<R!E<75I='DN(%1H92!T<F%N<V%C
M=&EO;B!D871E(&9A:7(@=F%L=64@;V8-"B`@("!T:&4@=V%R<F%N=',@;V8@
M)FYB<W`[)#$N,R8C,38P.VUI;&QI;VX@=V%S(&1E=&5R;6EN960@=71I;&EZ
M:6YG('1H92!";&%C:RU38VAO;&5S(&]P=&EO;B!P<FEC:6YG(&UO9&5L#0H@
M("`@=71I;&EZ:6YG('1H92!F;VQL;W=I;F<@87-S=6UP=&EO;G,Z(')I<VL@
M9G)E92!I;G1E<F5S="!R871E("8C.#(Q,CL@,BXU-24L(&5X<&5C=&5D('9O
M;&%T:6QI='D@)B,X,C$R.R`Y,"4L#0H@("`@97AP96-T960@9&EV:61E;F0@
M>6EE;&0@)B,X,C$R.R`P)2P@86YD(&$@<F5M86EN:6YG(&-O;G1R86-T=6%L
M(&QI9F4@;V8@-2XP,"8C,38P.WEE87)S+B!!<R!O9B!*=6YE)B,Q-C`[,S`L
M(#(P,3$L#0H@("`@86QL('1H92!W87)R86YT<R!A<F4@;W5T<W1A;F1I;F<N
M($YE="!P<F]C965D<R!O9B!A<'!R;WAI;6%T96QY("9N8G-P.R0V+C4F(S$V
M,#MM:6QL:6]N('=E<F4@86QL;V-A=&5D(&)A<V5D#0H@("`@;VX@<F5L871I
M=F4@=')A;G-A8W1I;VX@9&%T92!F86ER('9A;'5E<R!I;B!T:&4@9F]L;&]W
M:6YG(&UA;FYE<CH@)FYB<W`[)#4N-B8C,38P.VUI;&QI;VX@*"9N8G-P.R0Q
M+CDU('!E<B!S:&%R92D@=&\-"B`@("!C;VUM;VX@<VAA<F5S(&%N9"`F;F)S
M<#LD,"XY)B,Q-C`[;6EL;&EO;B`H)FYB<W`[)#$N,S(@<&5R('=A<G)A;G0I
M('1O('1H92!W87)R86YT<RX-"B`@("`\+V1I=CX-"B`@("`\9&EV(&%L:6=N
M/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z
M(#$P<'0G/CQI/DIU;'DF(S$V,#LR,#`Y(%)E9VES=&5R960@1&ER96-T($9I
M;F%N8VEN9SPO:3X-"B`@("`\+V1I=CX-"B`@("`\9&EV(&%L:6=N/3-$;&5F
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[
M('1E>'0M:6YD96YT.B`T)2<^3VX@2G5L>28C,38P.S(Y+"`R,#`Y+"!T:&4@
M0V]M<&%N>2!S;VQD(&ET<R!S96-U<FET:65S('1O('-E;&5C="!I;G-T:71U
M=&EO;F%L(&EN=F5S=&]R<R!C;VYS:7-T:6YG#0H@("`@;V8@-"PP,#`L,#`P
M('5N:71S(&EN(&$@)B,X,C(P.W)E9VES=&5R960@9&ER96-T)B,X,C(Q.R!O
M9F9E<FEN9R!A="!A('!U<F-H87-E('!R:6-E(&]F("9N8G-P.R0P+C@U('!E
M<B!U;FET+B!%86-H#0H@("`@=6YI="!C;VYS:7-T960@;V8@*&DI)B,Q-C`[
M;VYE('-H87)E(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K
M+"`H:6DI)B,Q-C`[;VYE('=A<G)A;G0@=&\@<'5R8VAA<V4@,"XV,C4-"B`@
M("!O9B!O;F4@<VAA<F4@;V8@8V]M;6]N('-T;V-K("AA("8C.#(R,#M397)I
M97,F(S$V,#M)(%=A<G)A;G0F(S@R,C$[*2!A;F0@*&EI:2DF(S$V,#MO;F4@
M=V%R<F%N="!T;R!P=7)C:&%S92`P+C$X,S@X,#4@;V8-"B`@("!O;F4@<VAA
M<F4@;V8@8V]M;6]N('-T;V-K("AA("8C.#(R,#M397)I97,F(S$V,#M)22!7
M87)R86YT)B,X,C(Q.RDN(%1H92!397)I97,F(S$V,#M)(%=A<G)A;G1S(&AA
M9"!A('-E=F5N+6UO;G1H('1E<FT-"B`@("!F<F]M('1H92!D871E(&]F(&ES
M<W5A;F-E+"!W97)E(&5X97)C:7-A8FQE(&)E9VEN;FEN9R!S:7@@;6]N=&AS
M(&9R;VT@=&AE(&1A=&4@;V8@:7-S=6%N8V4@870@86X-"B`@("!E>&5R8VES
M92!P<FEC92!O9B`F;F)S<#LD,2XP,"!P97(@<VAA<F4@;V8@8V]M;6]N('-T
M;V-K+B!$=7)I;F<@=&AE(&9I<G-T('%U87)T97(@;V8@,C`Q,"P@86QL(&]F
M('1H90T*("`@(%-E<FEE<R8C,38P.TD@5V%R<F%N=',@=V5R92!E>&5R8VES
M960@9F]R("9N8G-P.R0R+C4F(S$V,#MM:6QL:6]N+B!4:&4@4V5R:65S)B,Q
M-C`[24D@5V%R<F%N=',@:&%V92!A(&9I=F4M>65A<B!T97)M#0H@("`@9G)O
M;2!T:&4@9&%T92!O9B!I<W-U86YC92P@87)E(&5X97)C:7-A8FQE(&)E9VEN
M;FEN9R!S:7@@;6]N=&AS(&9R;VT@=&AE(&1A=&4@;V8@:7-S=6%N8V4@870@
M86X-"B`@("!E>&5R8VES92!P<FEC92!O9B`F;F)S<#LD,2XP,"!P97(@<VAA
M<F4@;V8@8V]M;6]N('-T;V-K+B!$=7)I;F<@=&AE(&9I<G-T('%U87)T97(@
M;V8@,C`Q,"P-"B`@("`T,RPR-C8@8V]M;6]N('-H87)E<R!W97)E(&ES<W5E
M9"!U<&]N(&5X97)C:7-E(&]F(%-E<FEE<R8C,38P.TE)(%=A<G)A;G1S('=I
M=&@@<')O8V5E9',@;V8@)FYB<W`[)#0S+#(V-BX-"B`@("!4:&5R92!W97)E
M(&YO(&5X97)C:7-E<R!D=7)I;F<@=&AE('-I>"!M;VYT:',@96YD960@2G5N
M928C,38P.S,P+"`R,#$Q+@T*("`@(#PO9&EV/@T*("`@(#PA+2T@1F]L:6\@
M+2T^#0H@("`@/"$M+2`O1F]L:6\@+2T^#0H@("`@/"]D:78^#0H@("`@/"$M
M+2!004=%0E)%04L@+2T^#0H@("`@/&1I=B!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<L5&EM97,L<V5R:68[(&UA<F=I;BUL969T
M.B`P:6X[("<^#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@
M-"4G/E1H92!N970@<')O8V5E9',@=&\@=&AE($-O;7!A;GD@9G)O;2!T:&4@
M<V%L92!O9B!T:&4@=6YI=',L(&%F=&5R(&1E9'5C=&EN9R!F;W(@=&AE('!L
M86-E;65N=`T*("`@(&%G96YT)B,X,C$W.W,@9F5E<R!A;F0@;V9F97)I;F<@
M97AP96YS97,L('=E<F4@87!P<F]X:6UA=&5L>2`F;F)S<#LD,BXY)B,Q-C`[
M;6EL;&EO;BX@07,@;V8@2G5N928C,38P.S,P+"`R,#$Q+"!T:&4-"B`@("!R
M96UA:6YI;F<@4V5R:65S)B,Q-C`[24D@5V%R<F%N=',@;W5T<W1A;F1I;F<@
M86YD(&5X97)C:7-A8FQE(&EN=&\@-CDR+#(U-B!O9B!T:&4@0V]M<&%N>28C
M.#(Q-SMS('-H87)E<R!O9@T*("`@(&-O;6UO;B!S=&]C:R!H879E(&)E96X@
M8VQA<W-I9FEE9"!A<R!E<75I='DN(%1H92!T<F%N<V%C=&EO;B!D871E(&9A
M:7(@=F%L=64@;V8@=&AE(%-E<FEE<R8C,38P.TE)#0H@("`@5V%R<F%N=',@
M;V8@)FYB<W`[)#`N-B8C,38P.VUI;&QI;VX@=V%S(&1E=&5R;6EN960@=71I
M;&EZ:6YG('1H92!";&%C:RU38VAO;&5S(&]P=&EO;B!P<FEC:6YG(&UO9&5L
M('5T:6QI>FEN9PT*("`@('1H92!F;VQL;W=I;F<@87-S=6UP=&EO;G,Z(')I
M<VL@9G)E92!I;G1E<F5S="!R871E("8C.#(Q,CL@,BXV.24L(&5X<&5C=&5D
M('9O;&%T:6QI='D@)B,X,C$R.R`Y,"4L(&5X<&5C=&5D#0H@("`@9&EV:61E
M;F0@>6EE;&0@)B,X,C$R.R`P)2P@86YD(&$@<F5M86EN:6YG(&-O;G1R86-T
M=6%L(&QI9F4@;V8@-2XP,"8C,38P.WEE87)S+@T*("`@(#PO9&EV/@T*("`@
M(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M;6%R9VEN+71O<#H@,3!P="<^/&D^1&5C96UB97(F(S$V,#LR,#`W($-O;6UI
M='1E9"!%<75I='D@1FEN86YC:6YG($9A8VEL:71Y/"]I/@T*("`@(#PO9&EV
M/@T*("`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+71O<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY/;B!$
M96-E;6)E<B8C,38P.S$P+"`R,#`W(&%N9"!A<R!A;65N9&5D(&]N($YO=F5M
M8F5R)B,Q-C`[,C0L(#(P,#DL($-Y8VQA8V5L(&5N=&5R960@:6YT;R!A($-O
M;6UI='1E9`T*("`@($5Q=6ET>2!&:6YA;F-I;F<@1F%C:6QI='DL(&]R($-%
M1D8L('=I=&@@2VEN9W-B<FED9V4L(&EN('=H:6-H($MI;F=S8G)I9&=E(&-O
M;6UI='1E9"!T;R!P=7)C:&%S90T*("`@('1H92!L97-S97(@;V8@-"PP.#0L
M-3DP('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@;W(@)FYB<W`[)#8P)B,Q-C`[
M;6EL;&EO;B!O9B!C;VUM;VX@<W1O8VL@9G)O;2!#>6-L86-E;"!O=F5R(&$-
M"B`@("!T:')E92UY96%R('!E<FEO9"X@5&AE($-%1D8@;&%P<V5D(&]N($1E
M8V5M8F5R)B,Q-C`[,3`L(#(P,3`N#0H@("`@/"]D:78^#0H@("`@/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM
M=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@-"4G/D1U<FEN9R!-87)C:"8C,38P
M.S(P,3`L('1H92!#;VUP86YY('-O;&0@,2PU-C,L,C`X('-H87)E<R!O9B!I
M=',@8V]M;6]N('-T;V-K('1O($MI;F=S8G)I9&=E('5N9&5R#0H@("`@=&AE
M($-%1D8L(&EN(&-O;G-I9&5R871I;VX@;V8@86=G<F5G871E('!R;V-E961S
M(&]F("9N8G-P.R0S+C$F(S$V,#MM:6QL:6]N+B!$=7)I;F<@1&5C96UB97(F
M(S$V,#LR,#`Y(&%N9"!*86YU87)Y#0H@("`@,C`Q,"P@=&AE($-O;7!A;GD@
M<V]L9"!A;B!A9V=R96=A=&4@;V8@,2PU.#,L-C(V('-H87)E<R!O9B!I=',@
M8V]M;6]N('-T;V-K('1O($MI;F=S8G)I9&=E('5N9&5R#0H@("`@=&AE('1E
M<FUS(&]F('1H92!#149&(&EN(&-O;G-I9&5R871I;VX@;V8@86X@86=G<F5G
M871E(&]F("9N8G-P.R0Q+C,F(S$V,#MM:6QL:6]N+"!O9B!W:&EC:"!A<'!R
M;WAI;6%T96QY("9N8G-P.R0Q+C`-"B`@("!M:6QL:6]N('=A<R!R96-E:79E
M9"!I;B`R,#`Y+"!W:71H('1H92!B86QA;F-E(&]F("9N8G-P.R0P+C,F(S$V
M,#MM:6QL:6]N(&EN(')E<W!E8W0@;V8@8V]M;6]N('-H87)E<PT*("`@('-U
M8G-C<FEB960@8G5T('5N:7-S=65D(&%T($1E8V5M8F5R)B,Q-C`[,S$L(#(P
M,#DL(')E8V5I=F5D(&)Y('1H92!#;VUP86YY(&EN($IA;G5A<GDF(S$V,#LR
M,#$P+@T*("`@(#PO9&EV/@T*("`@(#QD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^/&D^0V]M
M;6]N(%-T;V-K(%=A<G)A;G1S/"]I/@T*("`@(#PO9&EV/@T*("`@(#QD:78@
M86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN
M+71O<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY);B!C;VYN96-T:6]N('=I
M=&@@=&AE($-O;7!A;GDF(S@R,3<[<R!&96)R=6%R>28C,38P.S$V+"`R,#`W
M("8C.#(R,#MR96=I<W1E<F5D(&1I<F5C="8C.#(R,3L@;V9F97)I;F<@=&AE
M($-O;7!A;GD-"B`@("!I<W-U960@=&\@:6YV97-T;W)S('=A<G)A;G1S('1O
M('!U<F-H87-E(#$L,#8R+#0Q,B!S:&%R97,@;V8@8V]M;6]N('-T;V-K+B!4
M:&4@=V%R<F%N=',@:7-S=65D('1O#0H@("`@=&AE(&EN=F5S=&]R<R!A<F4@
M8F5I;F<@86-C;W5N=&5D(&9O<B!A<R!A(&QI86)I;&ET>2X@070@=&AE(&1A
M=&4@;V8@=&AE('1R86YS86-T:6]N+"!T:&4@9F%I<@T*("`@('9A;'5E(&]F
M('1H92!W87)R86YT<R!O9B`F;F)S<#LD-BXX)B,Q-C`[;6EL;&EO;B!W87,@
M9&5T97)M:6YE9"!U=&EL:7II;F<@=&AE($)L86-K+5-C:&]L97,@;W!T:6]N
M('!R:6-I;F<-"B`@("!M;V1E;"!U=&EL:7II;F<@=&AE(&9O;&QO=VEN9R!A
M<W-U;7!T:6]N<SH@<FES:R!F<F5E(&EN=&5R97-T(')A=&4@)B,X,C$R.R`T
M+C4X)2P@97AP96-T960@=F]L871I;&ET>2`M#0H@("`@.#4E+"!E>'!E8W1E
M9"!D:79I9&5N9"!Y:65L9"`F(S@R,3([(#`E+"!A;F0@82!R96UA:6YI;F<@
M8V]N=')A8W1U86P@;&EF92!O9B`V+C@X)B,Q-C`[>65A<G,N(%1H92!V86QU
M92!O9B!T:&4-"B`@("!W87)R86YT(&ES(&)E:6YG(&UA<FME9"!T;R!M87)K
M970@96%C:"!R97!O<G1I;F<@<&5R:6]D(&%S(&$@9&5R:79A=&EV92!G86EN
M(&]R(&QO<W,@;VX@=&AE#0H@("`@8V]N<V]L:61A=&5D('-T871E;65N="!O
M9B!O<&5R871I;VYS('5N=&EL(&5X97)C:7-E9"!O<B!E>'!I<F%T:6]N+B!3
M964@)B,X,C(P.TYO=&4@,R`F(S@R,3([($9A:7(@5F%L=64F(S@R,C$[(&9O
M<@T*("`@(&9U<G1H97(@9&5T86EL<RX-"B`@("`\+V1I=CX-"B`@("`\(2TM
M($9O;&EO("TM/@T*("`@(#PA+2T@+T9O;&EO("TM/@T*("`@(#PO9&EV/@T*
M("`@(#PA+2T@4$%'14)214%+("TM/@T*("`@(#QD:78@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+%1I;65S+'-E<FEF.R!M87)G
M:6XM;&5F=#H@,&EN.R`G/@T*("`@(#QD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P=#L@=&5X="UI
M;F1E;G0Z(#0E)SY4:&4@9F]L;&]W:6YG('1A8FQE('-U;6UA<FEZ97,@:6YF
M;W)M871I;VX@86)O=70@=V%R<F%N=',@;W5T<W1A;F1I;F<@870@2G5N928C
M,38P.S,P+"`R,#$Q.@T*("`@(#PO9&EV/@T*("`@(#QD:78@86QI9VX],T1C
M96YT97(^#0H@("`@/'1A8FQE('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M=&5X="UA;&EG;CH@;&5F="<@8V5L;'-P86-I;F<],T0P(&)O<F1E<CTS1#`@
M8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-"B`@("`\(2TM($)E9VEN
M(%1A8FQE($AE860@+2T^#0H@("`@/'1R('9A;&EG;CTS1&)O='1O;3X-"B`@
M("`\=&0@=VED=&@],T0U."4^)B,Q-C`[/"]T9#X-"B`@("`\=&0@=VED=&@]
M,T0S)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO
M=&0^#0H@("`@/'1D('=I9'1H/3-$.24^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS1#,E/B8C
M,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@=VED=&@],T0Y)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W:61T:#TS
M1#$E/B8C,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$,R4^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@(#QT9"!W
M:61T:#TS1#DE/B8C,38P.SPO=&0^#0H@("`@/'1D('=I9'1H/3-$,24^)B,Q
M-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT<B!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0G('9A;&EG;CTS1&)O='1O;3X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M8V5N=&5R(&-O;'-P86X],T0R/CQB/E=E:6=H=&5D/"]B/CPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/"]T<CX-"B`@("`\='(@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T)R!V86QI9VX],T1B;W1T;VT^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\8CY!=F5R86=E/"]B/CPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/"]T<CX-"B`@("`\='(@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T)R!V86QI9VX],T1B;W1T;VT^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\
M8CY%>'!I<F%T:6]N/"]B/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\8CY#;VUM;VX@4VAA<F5S/"]B
M/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C
M;VQS<&%N/3-$,CX\8CY%>&5R8VES93PO8CX\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#PO='(^#0H@("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P="<@=F%L:6=N/3-$8F]T=&]M/@T*("`@(#QT9"!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1L969T('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P
M>"!S;VQI9"`C,#`P,#`P)SX\8CY)<W-U960@:6X@0V]N;F5C=&EO;B!7:71H
M/"]B/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,B!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P,"<^/&(^1&%T93PO
M8CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@
M8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED
M(",P,#`P,#`G/CQB/DES<W5A8FQE/"]B/CPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,B!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P,"<^/&(^4')I8V4\+V(^
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@(#PA
M+2T@16YD(%1A8FQE($AE860@+2T^#0H@("`@/"$M+2!"96=I;B!486)L92!"
M;V1Y("TM/@T*("`@(#QT<B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F%C
M:V=R;W5N9#H@(V-C965F9B<^#0H@("`@/'1D/@T*("`@(#QD:78@<W1Y;&4]
M,T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/D%P<FEL
M)B,Q-C`[,C`P-B!S=&]C:R!I<W-U86YC90T*("`@(#PO9&EV/CPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&%L:6=N/3-$<FEG:'0^,C`Q,SPO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^,BPU-S$L-#(Y/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M86QI9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@(#QT9"!A;&EG;CTS1')I
M9VAT/C<N,#`\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#PO='(^
M#0H@("`@/'1R('9A;&EG;CTS1&)O='1O;3X-"B`@("`\=&0^#0H@("`@/&1I
M=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P
M>"<^1F5B<G5A<GDF(S$V,#LR,#`W('-T;V-K(&ES<W5A;F-E#0H@("`@/"]D
M:78^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@86QI9VX],T1R:6=H=#XR,#$T/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI9VX],T1R:6=H=#XQ+#`V,BPT,3(\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@/'1D
M(&%L:6=N/3-$<FEG:'0^."XT-#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/"]T<CX-"B`@("`\='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)V)A8VMG<F]U;F0Z("-C8V5E9F8G/@T*("`@(#QT9#X-"B`@("`\9&EV('-T
M>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY$
M96-E;6)E<B8C,38P.S(P,#<@0T5&1@T*("`@(#PO9&EV/CPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M(&%L:6=N/3-$<FEG:'0^,C`Q,SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D(&%L:6=N/3-$<FEG:'0^,3`P+#`P,#PO=&0^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N
M/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`\=&0@86QI9VX],T1R:6=H=#XQ
M+C0P/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\+W1R/@T*("`@
M(#QT<B!V86QI9VX],T1B;W1T;VT^#0H@("`@/'1D/@T*("`@(#QD:78@<W1Y
M;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/DIU
M;'DF(S$V,#LR,#`Y(%-E<FEE<R8C,38P.TE)('-T;V-K(&ES<W5A;F-E#0H@
M("`@/"]D:78^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI9VX],T1R:6=H=#XR,#$T/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI9VX],T1R:6=H=#XV.3(L
M,C4V/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@86QI9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@
M(#QT9"!A;&EG;CTS1')I9VAT/C$N,#`\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#PO='(^#0H@("`@/'1R('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=B86-K9W)O=6YD.B`C8V-E969F)SX-"B`@("`\=&0^#0H@("`@/&1I
M=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P
M>"<^2F%N=6%R>28C,38P.S(P,3`@<W1O8VL@:7-S=6%N8V4-"B`@("`\+V1I
M=CX\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!A;&EG;CTS1')I9VAT/C(P,34\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!A;&EG;CTS1')I9VAT/C<Q,BPU,#`\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@/'1D(&%L
M:6=N/3-$<FEG:'0^,RXR-CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/"]T<CX-"B`@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@(#QT9#X-
M"B`@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD
M96YT.BTQ-7!X)SY*86YU87)Y)B,Q-C`[,C`Q,"!S=&]C:R!I<W-U86YC90T*
M("`@(#PO9&EV/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^,C`Q-3PO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$<FEG:'0^-S`U
M+#`P,#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@
M("`\=&0@86QI9VX],T1R:6=H=#XR+C@U/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\+W1R/@T*("`@(#QT<B!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G8F%C:V=R;W5N9#H@(V-C965F9B<^#0H@("`@/'1D/@T*("`@(#QD
M:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U
M<'@G/D]C=&]B97(F(S$V,#LR,#$P('-T;V-K(&ES<W5A;F-E#0H@("`@/"]D
M:78^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@86QI9VX],T1R:6=H=#XR,#$U/"]T9#X-"B`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI9VX],T1R:6=H=#XT+#$V,2PU.34\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@/'1D
M(&%L:6=N/3-$<FEG:'0^,2XY,CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/"]T<CX-"B`@("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q<'@G
M/@T*("`@(#QT9#X-"B`@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U
M<'@[('1E>'0M:6YD96YT.BTQ-7!X)SXF(S$V,#L-"B`@("`\+V1I=CX\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L
M<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`Q
M<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\+W1R/@T*("`@(#QT<B!V86QI9VX],T1B;W1T;VT^/"$M+2!";&%N
M:R!3<&%C92`M+3X-"B`@("`\=&0^#0H@("`@/&1I=B!S='EL93TS1"=M87)G
M:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^)B,Q-C`[#0H@("`@
M/"]D:78^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M+W1R/@T*("`@(#QT<B!V86QI9VX],T1B;W1T;VT^#0H@("`@/'1D/@T*("`@
M(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z
M+3$U<'@G/E1O=&%L#0H@("`@/"]D:78^/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI9VX],T1R:6=H=#XQ
M,"PP,#4L,3DR/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@86QI9VX],T1L969T/B9N8G-P.R0\+W1D
M/@T*("`@(#QT9"!A;&EG;CTS1')I9VAT/C0N,#$\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#PO='(^#0H@("`@/'1R('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,7!X)SX-"B`@("`\=&0^#0H@("`@/&1I=B!S='EL93TS1"=M87)G
M:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^)B,Q-C`[#0H@("`@
M/"]D:78^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R
M9&5R+71O<#H@,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#PO='(^#0H@("`@/"$M+2!%;F0@5&%B;&4@0F]D
M>2`M+3X-"B`@("`\+W1A8FQE/@T*("`@(#PO9&EV/@T*("`@(#QD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O
M<#H@,3!P="<^/&(^/&D^17AE<F-I<V4@;V8@4W1O8VL@3W!T:6]N<SPO:3X\
M+V(^#0H@("`@/"]D:78^#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN
M9&5N=#H@-"4G/D1U<FEN9R!T:&4@<VEX(&UO;G1H<R!E;F1E9"!*=6YE)B,Q
M-C`[,S`L(#(P,3$L('1H97)E('=E<F4@-2PQ,S$@<W1O8VL@;W!T:6]N(&5X
M97)C:7-E<R!T;W1A;&EN9PT*("`@(&%P<')O>&EM871E;'D@)FYB<W`[)#,L
M,#`P+B!$=7)I;F<@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!*=6YE)B,Q-C`[
M,S`L(#(P,3`L('1H97)E('=E<F4@,3(T+#(W-R!S=&]C:R!O<'1I;VX-"B`@
M("!E>&5R8VES97,@=&]T86QI;F<@87!P<F]X:6UA=&5L>2`F;F)S<#LD,"XQ
M)B,Q-C`[;6EL;&EO;BX-"B`@("`\+V1I=CX-"B`@("`\+V1I=CX-"B`@/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R.38Q,#0Q
M.5]E93<Q7S0X.3A?8CDQ85\W.&1A-F9C-C4P93@-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO,CDV,3`T,3E?964W,5\T.#DX7V(Y,6%?-SAD839F
M8S8U,&4X+U=O<FMS:&5E=',O4VAE970Q-"YH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13)(/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-U8G-E<75E;G0@179E;G1S/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5B
M<V5Q=65N="!%=F5N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y354)315%514Y4($5614Y44SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^#0H@("`@/"$M+41/0U194$4@
M:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N
M86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M
M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`@/"$M+2!"96=I;B!";&]C
M:R!486=G960@3F]T92`Y("T@=7,M9V%A<#I3=6)S97%U96YT179E;G1S5&5X
M=$)L;V-K+2T^#0H@("`@/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I
M;65S($YE=R!2;VUA;B<L5&EM97,L<V5R:68[(&UA<F=I;BUL969T.B`P:6X[
M("<^#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SX\8CXY+B!354)315%514Y4($56
M14Y44SPO8CX-"B`@("`\+V1I=CX-"B`@("`\9&EV(&%L:6=N/3-$;&5F="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/CQB
M/CQI/E!R969E<G)E9"!3=&]C:R!$:79I9&5N9#PO:3X\+V(^#0H@("`@/"]D
M:78^#0H@("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@-"4G/D]N
M($IU;'DF(S$V,#LX+"`R,#$Q+"!T:&4@0F]A<F0@;V8@1&ER96-T;W)S(&1E
M8VED960@;F]T('1O(&1E8VQA<F4@=&AE('%U87)T97)L>2!C87-H(&1I=FED
M96YD(&]N#0H@("`@=&AE(%!R969E<G)E9"!3=&]C:R!W:71H(')E<W!E8W0@
M=&\@=&AE('-E8V]N9"!Q=6%R=&5R(&]F(#(P,3$@=&AA="!W;W5L9"!H879E
M(&]T:&5R=VES92!B965N#0H@("`@<&%Y86)L92!O;B!!=6=U<W0F(S$V,#LQ
M+"`R,#$Q+@T*("`@(#PO9&EV/@T*("`@(#QD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P=#L@=&5X
M="UI;F1E;G0Z(#0E)SY4:&4@0F]A<F0@86QS;R!D:60@;F]T(&1E8VQA<F4@
M=&AE('%U87)T97)L>2!C87-H(&1I=FED96YD('=I=&@@<F5S<&5C="!T;R!E
M86-H(&]F('1H92!F;W5R#0H@("`@<75A<G1E<G,@;V8@9FES8V%L('EE87(@
M,C`P.2!A;F0@=&AE(&9I<G-T+"!S96-O;F0@86YD('1H:7)D('%U87)T97)S
M(&]F(#(P,3`N(%1O('1H92!E>'1E;G0@=&AA=`T*("`@(&%N>2!D:79I9&5N
M9',@<&%Y86)L92!O;B!T:&4@4')E9F5R<F5D(%-T;V-K(&%R92!N;W0@<&%I
M9"P@<W5C:"!U;G!A:60@9&EV:61E;F1S(&%R92!A9&1E9"!T;R!T:&4-"B`@
M("!L:7%U:61I='D@<')E9F5R96YC92!O9B!T:&4@4')E9F5R<F5D(%-T;V-K
M+B!!<R!T:&4@0V]M<&%N>2!F86EL960@=&\@<&%Y(&EN(&%N(&%G9W)E9V%T
M92!A;6]U;G0-"B`@("!E<75A;"!T;R!A="!L96%S="!S:7@@<75A<G1E<FQY
M(&1I=FED96YD<R`H=VAE=&AE<B!O<B!N;W0@8V]N<V5C=71I=F4I(&]N('1H
M92!0<F5F97)R960@4W1O8VLL('1H90T*("`@('-I>F4@;V8@=&AE($-O;7!A
M;GDF(S@R,3<[<R!";V%R9"!W87,@:6YC<F5A<V5D(&)Y('1W;R!M96UB97)S
M(&%N9"!T:&4@:&]L9&5R<R!O9B!T:&4@4')E9F5R<F5D(%-T;V-K+`T*("`@
M('9O=&EN9R!S97!A<F%T96QY(&%S(&$@8VQA<W,L('9O=&5D(&]N($UA>28C
M,38P.S(T+"`R,#$Q(&%N9"!E;&5C=&5D('1W;R!D:7)E8W1O<G,@=&\@9FEL
M;"!T:&4@=F%C86YC:65S#0H@("`@8W)E871E9"!T:&5R96)Y+"!W:&EC:"!D
M:7)E8W1O<G-H:7!S('-H86QL('1E<FUI;F%T92!W:&5N('1H92!#;VUP86YY
M('!A>7,@86QL(&%C8W)U960@8G5T('5N<&%I9`T*("`@(&1I=FED96YD<RX-
M"B`@("`\+V1I=CX-"B`@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/CQB/CQI/DQI8V5N
M<V4@06=R965M96YT/"]I/CPO8CX-"B`@("`\+V1I=CX-"B`@("`\9&EV(&%L
M:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT
M;W`Z(#$P<'0[('1E>'0M:6YD96YT.B`T)2<^3VX@2G5L>28C,38P.S$Q+"`R
M,#$Q+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@86X@86UE;F1M96YT('1O
M(&ET<R!L:6-E;G-E(&%G<F5E;65N="!W:71H($1A:6EC:&D-"B`@("!386YK
M>6\@0V]M<&%N>2P@3&EM:71E9"`H)B,X,C(P.T1A:6EC:&D@4V%N:WEO)B,X
M,C(Q.RDL(&1A=&5D(%-E<'1E;6)E<B8C,38P.S$P+"`R,#`S+"!R96QA=&EN
M9R!T;R!C97)T86EN(')I9VAT<PT*("`@('=H:6-H('1H92!#;VUP86YY(&AA
M<R!L:6-E;G-E9"!F<F]M($1A:6EC:&D@4V%N:WEO('=I=&@@<F5G87)D('1O
M('1H92!#;VUP86YY)B,X,C$W.W,@<V%P86-I=&%B:6YE(&1R=6<N#0H@("`@
M169F96-T:79E($IU;'DF(S$V,#LQ,2P@,C`Q,2P@=&AE(&QI8V5N<V4@86=R
M965M96YT('=A<R!A;65N9&5D('1O(&ER<F5V;V-A8FQY('=A:79E(&$@=&5R
M;6EN871I;VX@<FEG:'0-"B`@("!$86EI8VAI(%-A;FMY;R!P;W-S97-S960@
M=6YD97(@82!P<F]V:7-I;VX@;V8@=&AE(&%G<F5E;65N="!T:&%T(')E<75I
M<F5D('1H92!#;VUP86YY('1O(&]B=&%I;@T*("`@(')E9W5L871O<GD@87!P
M<F]V86P@=&\@<V5L;"!S87!A8VET86)I;F4@:6X@870@;&5A<W0@;VYE(&-O
M=6YT<GD@8GD@4V5P=&5M8F5R)B,Q-C`[,C`Q,2P@86YD(')E;&5A<V5S#0H@
M("`@=&AE($-O;7!A;GD@9G)O;2!A;&P@8VQA:6US(&%N9"!L:6%B:6QI='D@
M;V8@86YY(&MI;F0@87)I<VEN9R!U;F1E<B!S=6-H('!R;W9I<VEO;BX@5&AE
M(&%M96YD;65N=`T*("`@(&9U<G1H97(@<')O=FED97,@=&AA="!T:&4@<F]Y
M86QT>2!D=64@9G)O;2!T:&4@0V]M<&%N>2!T;R!$86EI8VAI(%-A;FMY;R!O
M;B!F=71U<F4@;F5T('-A;&5S(&]F#0H@("`@<V%P86-I=&%B:6YE(&)E(&EN
M8W)E87-E9"!B>2!A('!E<F-E;G1A9V4@8F5T=V5E;B`Q+C(U)2!A;F0@,2XU
M,"4@9&5P96YD:6YG(&]N('1H92!L979E;"!O9B!N970-"B`@("!S86QE<R!O
M9B!S87!A8VET86)I;F4@<F5A;&EZ960N#0H@("`@/"]D:78^#0H@("`@/"$M
M+2!&;VQI;R`M+3X-"B`@("`\(2TM("]&;VQI;R`M+3X-"B`@("`\+V1I=CX-
M"B`@("`\(2TM(%!!1T5"4D5!2R`M+3X-"B`@("`\9&EV('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RQ4:6UE<RQS97)I9CL@;6%R
M9VEN+6QE9G0Z(#!I;CL@)SX-"B`@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/CQB/CQI
M/D9I;F%N8VEN9SPO:3X\+V(^#0H@("`@/"]D:78^#0H@("`@/&1I=B!A;&EG
M;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P
M.B`Q,'!T.R!T97AT+6EN9&5N=#H@-"4G/D]N($IU;'DF(S$V,#LW+"`R,#$Q
M('1H92!#;VUP86YY(&-L;W-E9"!A;B!U;F1E<G=R:71T96X@;V9F97)I;F<@
M9F]R(&%N(&%G9W)E9V%T92!O9B`W+#8Q-RPV-#8-"B`@("!U;FET<RP@870@
M86X@;V9F97)I;F<@<')I8V4@;V8@)FYB<W`[)#$N,S8@<&5R('5N:70L(&9O
M<B!G<F]S<R!P<F]C965D<R!O9B!A<'!R;WAI;6%T96QY("9N8G-P.R0Q,"XT
M)B,Q-C`[;6EL;&EO;BX-"B`@("!%86-H('5N:70@8V]N<VES=',@;V8@*&DI
M)B,Q-C`[;VYE('-H87)E(&]F(&-O;6UO;B!S=&]C:R!A;F0@*&EI*28C,38P
M.V$@9FEV92UY96%R('=A<G)A;G0@=&\@<'5R8VAA<V4@,"XU(&]F#0H@("`@
M82!S:&%R92!O9B!C;VUM;VX@<W1O8VL@870@86X@97AE<F-I<V4@<')I8V4@
M;V8@)FYB<W`[)#$N,S8@<&5R('-H87)E+"!E>&5R8VES86)L92!B96=I;FYI
M;F<@<VEX(&UO;G1H<PT*("`@(&%F=&5R('1H92!D871E(&]F(&ES<W5A;F-E
M+B!4:&4@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!A;F0@=V%R<F%N=',@=V5R
M92!I;6UE9&EA=&5L>2!S97!A<F%B;&4@86YD#0H@("`@=V5R92!I<W-U960@
M<V5P87)A=&5L>2!S=6-H('1H870@;F\@=6YI=',@=V5R92!I<W-U960N(%1H
M92!N970@<')O8V5E9',L(&%F=&5R('5N9&5R=W)I=&EN9PT*("`@(&1I<V-O
M=6YT<R!A;F0@8V]M;6ES<VEO;G,@86YD(&]T:&5R(&9E97,@86YD(&5X<&5N
M<V5S('!A>6%B;&4@8GD@=&AE($-O;7!A;GDL('=E<F4@87!P<F]X:6UA=&5L
M>0T*("`@("9N8G-P.R0Y+C,F(S$V,#MM:6QL:6]N+@T*("`@(#PO9&EV/@T*
M("`@(#PO9&EV/@T*("`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7S(Y-C$P-#$Y7V5E-S%?-#@Y.%]B.3%A7S<X9&$V9F,V-3!E
M.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\R.38Q,#0Q.5]E93<Q
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M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`R+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970P,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,#0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`U+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-BYH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,#<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#`X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P.2YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3`N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#$Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970Q,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3,N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$T+FAT;6PB+SX-"CPO
M>&UL/@T*+2TM+2TM/5].97AT4&%R=%\R.38Q,#0Q.5]E93<Q7S0X.3A?8CDQ
285\W.&1A-F9C-C4P93@M+0T*
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
